|
|
|
Scientific Literature, arthritis
-
A SE, Moses PD, George R. Ocular manifestations of Behcet's disease.
Indian Pediatr. 42: 942-945 (2005).
*
-
Aarvak T, Chabaud M, Miossec P, Natvig JB. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells.
J. Immunol. 162: 1246-1251 (1999).
*
-
Abad C, Gomariz RP, Waschek JA. Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP.
Curr. Top. Med. Chem. 6: 151-163 (2006).
-
Abbott JD, Moreland LW. Rheumatoid arthritis: developing pharmacological therapies.
Expert Opin. Investig. Drugs 13: 1007-1018 (2004).
-
Abdel Fattah NS, Hassan HE, Galal ZA, El Okda ES. Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis.
BMC Res. Notes 2: 44 (2009).
*
-
Abdel-Naser MB, Wollina U, El Hefnawi MA, Habib MA, El Okby M. Non-sarcoidal, non-tuberculoid granuloma in common variable immunodeficiency.
J. Drugs Dermatol. 5: 370-372 (2006).
-
Abdelmalek MF, Liu C, Shuster J, Nelson DR, Asal NR. Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease.
Clin. Gastroenterol. Hepatol. 4: 1162-1169 (2006).
-
Abdelmoula LC, Ben M'Barek R, Yahia CB, Tekaya R, Testouri N, Chaabouni L, Zouari R. Update in treatment of psoriatic arthritis.
Tunis. Med. 86: 1036-1041 (2008).
-
Abdelouahab N, Heard CM. Dermal and transcutaneous delivery of the major glycoside constituents of Harpagophytum procumbens (devil's claw) in vitro.
Planta Med. 74: 527-531 (2008).
-
Abdollahi-Roodsaz S, Joosten LA, Helsen MM, Walgreen B, van Lent PL, van den Bersselaar LA, Koenders MI, van den Berg WB. Shift from Toll-like receptor 2 (TLR-2) toward TLR-4 dependency in the erosive stage of chronic streptococcal cell wall arthritis coincident with TLR-4-mediated interleukin-17 production.
Arthritis Rheum. 58: 3753-3764 (2008).
*
-
Abdollahi-Roodsaz S, Joosten LA, Koenders MI, Devesa I, Roelofs MF, Radstake TR, Heuvelmans-Jacobs M, Akira S, Nicklin MJ, Ribeiro-Dias F, van den Berg WB. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis.
J. Clin. Invest. 118: 205-216 (2008).
*
-
Abdollahi-Roodsaz S, Joosten LA, Koenders MI, van den Brand BT, van de Loo FA, van den Berg WB. Local interleukin-1 driven joint pathology is dependent on Toll-like receptor 4 activation.
Am. J. Pathol. 175: 2004-2013 (2009).
*
-
Abdollahi-Roodsaz S, Joosten LA, Roelofs MF, Radstake TR, Matera G, Popa C, van der Meer JW, Netea MG, van den Berg WB. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis.
Arthritis Rheum. 56: 2957-2967 (2007).
*
-
Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CG. Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission.
Arthritis Rheum. 58: 2196-2205 (2008).
*
-
Abdulahad WH, Stegeman CA, van der Geld YM, Doornbos-van der Meer B, Limburg PC, Kallenberg CG. Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission.
Arthritis Rheum. 56: 2080-2091 (2007).
*
-
Abe K, Klaften M, Narita A, Kimura T, Imai K, Kimura M, Rubio-Aliaga I, Wagner S, Jakob T, Hrabe de Angelis M. Genome-wide search for genes that modulate inflammatory arthritis caused by Ali18 mutation in mice.
Mamm. Genome 20: 152-161 (2009).
*
-
Abe M. Complement activation and inflammation.
Rinsho Byori 54: 744-756 (2006).
-
Abe T, Takeuchi T. Rheumatoid arthritis and tumor necrosis factor alpha.
Autoimmunity 34: 291-303 (2001).
-
Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, Nagaya I. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis.
J. Rheumatol. 33: 37-44 (2006).
-
Abe Y, Yoshikawa T, Kamada H, Shibata H, Nomura T, Minowa K, Kayamuro H, Katayama K, Miyoshi H, Mukai Y, Yoshioka Y, Nakagawa S, Tsunoda SI, Tsutsumi Y. Simple and highly sensitive assay system for TNFR2-mediated soluble- and transmembrane-TNF activity.
J. Immunol. Methods 335: 71-78 (2008).
*
-
Abebe F, Mustafa T, Nerland AH, Bjune GA. Cytokine profile during latent and slowly progressive primary tuberculosis: a possible role for interleukin-15 in mediating clinical disease.
Clin. Exp. Immunol. 143: 180-192 (2006).
*
-
Abedin M, Scheurich D, Reimold SC, Reimold AM. Acute coronary syndrome after infliximab infusion.
Cardiol. Rev. 14: 50-52 (2006).
-
Abel B, Kurrer M, Shamshiev A, Marty RR, Eriksson U, Gunthert U, Kopf M. The osteopontin - CD44 pathway is superfluous for the development of autoimmune myocarditis.
Eur. J. Immunol. 36: 494-499 (2006).
*
-
Abeles AM, Marjanovic N, Park J, Attur M, Chan ES, Al-Mussawir H, Dave M, Fisher MC, Stuchin SA, Abramson SB, Pillinger MH. Protein isoprenylation regulates secretion of matrix metalloproteinase 1 from rheumatoid synovial fibroblasts: effects of statins and farnesyl and geranylgeranyl transferase inhibitors.
Arthritis Rheum. 56: 2840-2853 (2007).
*
-
Abeles AM, Pillinger MH. The role of the synovial fibroblast in rheumatoid arthritis - cartilage destruction and the regulation of matrix metalloproteinases.
Bull. Hosp. Jt. Dis. 64: 20-24 (2006).
-
Abhishek A, Butt S, Gadsby K, Zhang W, Deighton CM. Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers.
J. Clin. Rheumatol. 16: 15-18 (2010).
-
Ablassmaier B, Hartmann J. A case of severe gangrenous ischemic colitis following nonsteroidal anti-inflammatory drug intake.
Zentralbl. Chir. 129: 510-512 (2004).
-
Ablin JN, Boguslavski V, Aloush V, Elkayam O, Paran D, Caspi D, George J. Effect of anti-TNFalpha treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis.
Life Sci. 79: 2364-2369 (2006).
*
-
Ablin JN, Goldstein Z, Aloush V, Matz H, Elkayam O, Caspi D, Swartzenberg S, George J, Wohl Y. Normal levels and function of endothelial progenitor cells in patients with psoriatic arthritis.
Rheumatol. Int. 29: 257-262 (2009).
*
-
Abou-Raya A, Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis.
Autoimmun. Rev. 5: 331-337 (2006).
-
Abou-Raya S, Abou-Raya A, Naim A, Abuelkheir H. Chronic inflammatory autoimmune disorders and atherosclerosis.
Ann. N. Y. Acad. Sci. 1107: 56-67 (2007).
*
-
Abourazzak FE, Guggenbuhl P, Perdriger A, Meadeb J, Gando-Cocley N, Chevrant-Breton J, Hajjaj-Hassouni N, Chales G. Cutaneous lupus induced by etanercept in rheumatoid arthritis.
Rev. Med. Interne. 29: 744-747 (2008).
-
Abraham C, Hart J, Locke SM, Baker AL. A case of indometacin-induced acute hepatitis developing into chronic autoimmune hepatitis.
Nat. Clin. Pract. Gastroenterol. Hepatol. 5: 172-176 (2008).
*
-
Abrams B. Long-term sleep apnea as a pathogenic factor for cell-mediated autoimmune disease.
Med. Hypotheses 65: 1024-1027 (2005).
-
Abramson SB, Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage.
Rheumatology (Oxford) 41: 972-980 (2002).
*
-
Abramson SB, Attur M, Yazici Y. Prospects for disease modification in osteoarthritis.
Nat. Clin. Pract. Rheumatol. 2: 304-312 (2006).
*
-
Abramson SB, Yazici Y. Biologics in development for rheumatoid arthritis: relevance to osteoarthritis.
Adv. Drug Deliv. Rev. 58: 212-225 (2006).
*
-
Abreu JR, Dontje W, Krausz S, de Launay D, van Hennik PB, van Stalborch AM, Ten Klooster JP, Sanders ME, Reedquist KA, Hordijk PL, Vervoordeldonk MJ, Tak PP. A Rac1 inhibitory peptide suppresses antibody production and paw swelling in the murine collagen-induced arthritis model of rheumatoid arthritis.
Arthritis Res. Ther. 12: R2 (2010).
*
-
Abreu JR, Grabiec AM, Krausz S, Spijker R, Burakowski T, Maslinski W, Eldering E, Tak PP, Reedquist KA. The presumed hyporesponsive behavior of rheumatoid arthritis T lymphocytes can be attributed to spontaneous ex vivo apoptosis rather than defects in T cell receptor signaling.
J. Immunol. 183: 621-630 (2009).
-
Abunasser J, Forouhar FA, Metersky ML. Etanercept-induced lupus erythematosus presenting as a unilateral pleural effusion.
Chest 134: 850-853 (2008).
*
-
Abuzakouk M, Feighery C, Jackson J. Tumour necrosis factor blocking agents: a new therapeutic modality for inflammatory disorders.
Br. J. Biomed. Sci. 59: 173-179 (2002).
-
Acheson DW. Foodborne infections.
Curr. Opin. Gastroenterol. 15: 538 (1999).
-
Achkar JP, Duerr R. The expanding universe of inflammatory bowel disease genetics.
Curr. Opin. Gastroenterol. 24: 429-434 (2008).
*
-
Ackermann C, Kavanaugh A. Economic burden of psoriatic arthritis.
Pharmacoeconomics 26: 121-129 (2008).
-
Ackermann C, Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease.
Expert Opin. Ther. Targets 11: 1369-1384 (2007).
-
Adachi T, Toishi T, Takashima E, Hara H. Infliximab neutralizes the suppressive effect of TNF-alpha on expression of extracellular-superoxide dismutase in vitro.
Biol. Pharm. Bull. 29: 2095-2098 (2006).
*
-
Adachi Y, Hinoda Y, Takahashi H, Nakagawa N, Sakamoto H, Itoh F, Endo T, Suzuki S, Imai K. Rheumatoid arthritis associated with ulcerative colitis.
J. Gastroenterol. 31: 590-595 (1996).
-
Adachi Y, Yoshio-Hoshino N, Nishimoto N. The blockade of IL-6 signaling in rational drug design.
Curr. Pharm. Des. 14: 1217-1224 (2008).
-
Adak M, Gupta JK. Evaluation of anti-inflammatory activity of Calotropis gigantea (AKANDA) in various biological system.
Nepal. Med. Coll. J. 8: 156-161 (2006).
-
Adam O. Dietary fatty acids and immune reactions in synovial tissue.
Eur. J. Med. Res. 8: 381-387 (2003).
-
Adam O, Beringer C, Kless T, Lemmen C, Adam A, Wiseman M, Adam P, Klimmek R, Forth W. Anti-inflammatory effects of a low arachidonic acid diet and fish oil in patients with rheumatoid arthritis.
Rheumatol. Int. 23: 27-36 (2003).
*
-
Adamczyk M, Brashear RJ, Mattingly PG. Circulating cardiac troponin-I autoantibodies in human plasma and serum.
Ann. N. Y. Acad. Sci. 1173: 67-74 (2009).
*
-
Adamopoulos AB. Inflammatory bowel disease (IBD) and the liver.
Annals of Gastroenterology 19: 146-151 (2006). *
-
Adamopoulos IE, Bowman EP. Immune regulation of bone loss by Th17 cells.
Arthritis Res. Ther. 10: 225 (2008).
*
-
Adamopoulos IE, Chao CC, Geissler R, Laface D, Blumenschein W, Iwakura Y, McClanahan T, Bowman EP. Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors.
Arthritis Res. Ther. 12: R29 (2010).
*
-
Adams AE, Zwicker J, Curiel C, Kadin ME, Falchuk KR, Drews R, Kupper TS. Aggressive cutaneous T-cell lymphomas after TNFalpha blockade.
J. Am. Acad. Dermatol. 51: 660-662 (2004).
-
Adams KM, Yan Z, Stevens AM, Nelson JL. The changing maternal "self" hypothesis: a mechanism for maternal tolerance of the fetus.
Placenta 28: 378-382 (2007).
-
Adamson AS, Collins K, Laurence A, O'Shea JJ. The current STATus of lymphocyte signaling: new roles for old players.
Curr. Opin. Immunol. 21: 161-166 (2009).
-
Adar T, Mizrahi M, Pappo O, Scheiman-Elazary A, Shibolet O. Adalimumab-induced autoimmune hepatitis.
J. Clin. Gastroenterol. 44: e20-e22 (2010).
-
Adarichev VA, Bardos T, Christodoulou S, T Phillips M, Mikecz K, Glant TT. Major histocompatibility complex controls susceptibility and dominant inheritance, but not the severity of the disease in mouse models of rheumatoid arthritis.
Immunogenetics 54: 184-192 (2002).
*
-
Adarichev VA, Vegvari A, Szabo Z, Kis-Toth K, Mikecz K, Glant TT. Congenic strains displaying similar clinical phenotype of arthritis represent different immunologic models of inflammation.
Genes Immun. 9: 591-601 (2008).
*
-
Adarichev VA, Vermes C, Hanyecz A, Ludanyi K, Tunyogi-Csapo M, Finnegan A, Mikecz K, Glant TT. Antigen-induced differential gene expression in lymphocytes and gene expression profile in synovium prior to the onset of arthritis.
Autoimmunity 39: 663-673 (2006).
-
Adarichev VA, Vermes C, Hanyecz A, Mikecz K, Bremer EG, Glant TT. Gene expression profiling in murine autoimmune arthritis during the initiation and progression of joint inflammation.
Arthritis Res. Ther. 7: R196-R207 (2005).
*
-
Adcock I, Evans PC. Resolution of inflammatory responses: a brief introduction.
Biochem. Soc. Trans. 35: 261-262 (2007).
*
-
Addo A, Le J, Li W, Aksentijevich I, Balow J Jr, Lee A, Gregersen PK, Kastner DL, Remmers EF. Analysis of CARD15/NOD2 haplotypes fails to identify common variants associated with rheumatoid arthritis susceptibility.
Scand. J. Rheumatol. 34: 198-203 (2005).
*
-
Adebajo AO, Mitchell C. Patient's ethnicity and use of therapies in rheumatoid arthritis.
J. Rheumatol. 34: 233 (2007).
-
Adisen E, Karaca F, Gurer MA. When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents.
Clin. Exp. Dermatol. 33: 164-166 (2008).
*
-
Adlesic M, Verdrengh M, Bokarewa M, Dahlberg L, Foster SJ, Tarkowski A. Histamine in rheumatoid arthritis.
Scand. J. Immunol. 65: 530-537 (2007).
*
-
Adorini L. Antigen-based immunointervention in human autoimmune diseases.
Trends Biotechnol. 22: 547-549 (2004).
*
-
Adorini L, Penna G. Control of autoimmune diseases by the vitamin D endocrine system.
Nat. Clin. Pract. Rheumatol. 4: 404-412 (2008).
-
Adriaansen J, Fallaux FJ, de Cortie CJ, Vervoordeldonk MJ, Tak PP. Local delivery of beta interferon using an adeno-associated virus type 5 effectively inhibits adjuvant arthritis in rats.
J. Gen. Virol. 88: 1717-1721 (2007).
*
-
Adriaansen J, Khoury M, de Cortie CJ, Fallaux FJ, Bigey P, Scherman D, Gould DJ, Chernajovsky Y, Apparailly F, Jorgensen C, Vervoordeldonk MJ, Tak P. Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent.
Ann. Rheum. Dis. 66: 1143-1150 (2007).
*
-
Adriaansen J, Kuhlman RR, Holten JV, Kaynor C, Vervoordeldonk MJ, Tak PP. Intraarticular interferon-beta gene therapy ameliorates adjuvant arthritis in rats.
Hum. Gene Ther. 17: 985-996 (2006).
-
Adriaansen J, Tas SW, Klarenbeek PL, Bakker AC, Apparailly F, Firestein GS, Jorgensen C, Vervoordeldonk MJ, Tak PP. Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intra-articular gene therapy.
Ann. Rheum. Dis. 64: 1677-1684 (2005).
*
-
Adriaansen J, Vervoordeldonk MJ, Tak PP. Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes.
Rheumatology (Oxford) 45: 656-668 (2006).
*
-
Aeberli D, Leech M, Morand EF. Macrophage migration inhibitory factor and glucocorticoid sensitivity.
Rheumatology (Oxford) 45: 937-943 (2006).
*
-
Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders.
Swiss Med. Wkly. 132: 414-422 (2002).
*
-
Afif H, Benderdour M, Mfuna-Endam L, Martel-Pelletier J, Pelletier JP, Duval N, Fahmi H. Peroxisome proliferator-activated receptor gamma1 expression is diminished in human osteoarthritic cartilage and is down-regulated by interleukin-1beta in articular chondrocytes.
Arthritis Res. Ther. 9: R31 (2007).
*
-
Afonso V, Champy R, Mitrovic D, Collin P, Lomri A. Reactive oxygen species and superoxide dismutases: role in joint diseases.
Joint Bone Spine 74: 324-329 (2007).
*
-
Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease.
Clin. Exp. Immunol. 148: 32-46 (2007).
*
-
Aganna E, Hammond L, Hawkins PN, Aldea A, McKee SA, van Amstel HK, Mischung C, Kusuhara K, Saulsbury FT, Lachmann HJ, Bybee A, McDermott EM, La Regina M, Arostegui JI, Campistol JM, Worthington S, High KP, Molloy MG, Baker N, et al. Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes.
Arthritis Rheum. 48: 2632-2644 (2003).
*
-
Aganna E, Hawkins PN, Ozen S, Pettersson T, Bybee A, McKee SA, Lachmann HJ, Karenko L, Ranki A, Bakkaloglu A, Besbas N, Topaloglu R, Hoffman HM, Hitman GA, Woo P, McDermott MF. Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis.
Genes Immun. 5: 289-293 (2004).
*
-
Aganna E, Martinon F, Hawkins PN, Ross JB, Swan DC, Booth DR, Lachmann HJ, Bybee A, Gaudet R, Woo P, Feighery C, Cotter FE, Thome M, Hitman GA, Tschopp J, McDermott MF. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis.
Arthritis Rheum. 46: 2445-2452 (2002).
*
-
Aganna E, Zeharia A, Hitman GA, Basel-Vanagaite L, Allotey RA, Booth DR, Hawkins PN, Thacker C, Syndercombe-Court D, McDermott MF. An Israeli Arab patient with a de novo TNFRSF1A mutation causing tumor necrosis factor receptor-associated periodic syndrome.
Arthritis Rheum. 46: 245-249 (2002).
*
-
Agarwal A, Singh KP, Jain A. Medical significance and management of staphylococcal biofilm.
FEMS Immunol. Med. Microbiol. Aug 19 [Epub ahead of print] (2009).
*
-
Agarwal S, Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency.
Curr. Allergy Asthma Rep. 9: 347-352 (2009).
-
Agarwal S, Misra R, Aggarwal A. Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases.
J. Rheumatol. 35: 515-519 (2008).
*
-
Agarwal SK, Brenner MB. Role of adhesion molecules in synovial inflammation.
Curr. Opin. Rheumatol. 18: 268-276 (2006).
-
Agarwal SK, Glass RJ, Shadick NA, Coblyn JS, Anderson RJ, Maher NE, Weinblatt ME, Solomon DH. Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
J. Rheumatol. 35: 1737-1744 (2008).
-
Agarwal SK, Reveille JD. The genetics of scleroderma (systemic sclerosis).
Curr. Opin. Rheumatol. Jan 19 [Epub ahead of print] (2010).
-
Aggarwal A, Agarwal S, Misra R. Chemokine and chemokine receptor analysis reveals elevated interferon-inducible protein-10 (IP)-10/CXCL10 levels and increased number of CCR5(+) and CXCR3(+) CD4 T cells in synovial fluid of patients with enthesitis-related arthritis (ERA).
Clin. Exp. Immunol. 148: 515-519 (2007).
*
-
Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword.
Nat. Rev. Immunol. 3: 745-756 (2003).
*
-
Aggarwal BB, Shishodia S. Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning.
Ann. N. Y. Acad. Sci. 1030: 434-441 (2004).
*
-
Aggarwal BB, Shishodia S, Takada Y, Jackson-Bernitsas D, Ahn KS, Sethi G, Ichikawa H. TNF blockade: an inflammatory issue.
Ernst Schering Res. Found. Workshop 56: 161-186 (2006).
-
Aggarwal P, Aggarwal A, Gupta S, Misra R. Osteopenia is common in adult male patients with active juvenile idiopathic arthritis.
J. Rheumatol. 33: 1642-1645 (2006).
-
Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger TA Jr. Anti-U3 RNP autoantibodies in systemic sclerosis.
Arthritis Rheum. 60: 1112-1118 (2009).
*
-
Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17.
J. Biol. Chem. 278: 1910-1914 (2003).
*
-
Agirbasli M, Inanc N, Baykan OA, Direskeneli H. The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders.
Clin. Exp. Rheumatol. 24: 580-583 (2006).
-
Agnholt J, Dahlerup JF, Kaltoft K. The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures.
Cytokine 23: 76-85 (2003).
*
-
Agrawal C, Raghav SK, Gupta B, Das RH, Chaturvedi VP, Goswami K, Das HR. Tumor necrosis factor-alpha microsatellite polymorphism association with rheumatoid arthritis in Indian patients.
Arch. Med. Res. 36: 555-559 (2005).
-
Agrawal H, Jacob N, Carreras E, Bajana S, Putterman C, Turner S, Neas B, Mathian A, Koss MN, Stohl W, Kovats S, Jacob CO. Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease.
J. Immunol. 183: 6021-6029 (2009).
-
Agrawal S, Misra R, Aggarwal A. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA.
Clin. Rheumatol. 26: 201-204 (2007).
*
-
Agrawal S, Srivastava R, Sharma B, Pandya S, Misra R, Aggarwal A. IL1RN*2 allele of IL-1receptor antagonist VNTR polymorphism is associated with susceptibility to anklyosing spondylitis in Indian patients.
Clin. Rheumatol. 27: 573-576 (2008).
*
-
Agrup C. Immune-mediated audiovestibular disorders in the paediatric population: a review.
Int. J. Audiol. 47: 560-565 (2008).
-
Aguillon G JC, Cruzat C A, Contreras-Levicoy J, Dotte G A, Pesce R B, Aravena MO, Salazar A L, Catalan M D, Abello C P, Aguirre D A, Llanos M C, Cuchacovich TM. Emergent therapies for rheumatoid arthritis.
Rev. Med. Chil. 133: 969-976 (2005).
-
Aguillon JC, Contreras J, Dotte A, Cruzat A, Catalan D, Salazar L, Molina MC, Guerrero J, Lopez M, Soto L, Salazar-Onfray F, Cuchacovich M. New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies.
Rev. Med. Chil. 131: 1445-1453 (2003).
-
Aguillon JC, Cruzat A, Aravena O, Salazar L, Llanos C, Cuchacovich M. Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution?
Immunobiology 211: 75-84 (2006).
-
Aguillon JC, Cruzat A, Cuenca J, Cuchacovich M. Tumor necrosis factor alpha genetic polymorphism as a risk factor in disease.
Rev. Med. Chil. 130: 1043-1050 (2002).
-
Aguirre S, Silber AM, Brito ME, Ribone ME, Lagier CM, Marcipar IS. Design, construction, and evaluation of a specific chimeric antigen to diagnose chagasic infection.
J. Clin. Microbiol. 44: 3768-3774 (2006).
*
-
Ahlem C, Auci D, Mangano K, Reading C, Frincke J, Stickney D, Nicoletti F. HE3286: a novel synthetic steroid as an oral treatment for autoimmune disease.
Ann. N. Y. Acad. Sci. 1173: 781-790 (2009).
*
-
Ahlqvist E, Bockermann R, Holmdahl R. Fragmentation of two quantitative trait loci controlling collagen-induced arthritis reveals a new set of interacting subloci.
J. Immunol. 178: 3084-3090 (2007).
*
-
Ahmad K, Rogers S. Two years of experience with etanercept in recalcitrant psoriasis.
Br. J. Dermatol. 156: 1010-1014 (2007).
*
-
Ahmad R, Qureshi HY, El Mabrouk M, Sylvester J, Ahmad M Dr, Zafarullah M. Inhibition of interleukin 1-induced matrix metalloproteinase 13 expression in human chondrocytes by interferon gamma.
Ann. Rheum. Dis. 66: 782-789 (2007).
*
-
Ahmad R, Sylvester J, Zafarullah M. MyD88, IRAK1 and TRAF6 knockdown in human chondrocytes inhibits interleukin-1-induced matrix metalloproteinase-13 gene expression and promoter activity by impairing MAP kinase activation.
Cell. Signal. 19: 2549-2557 (2007).
*
-
Ahmad T, Wallace GR, James T, Neville M, Bunce M, Mulcahy-Hawes K, Armuzzi A, Crawshaw J, Fortune F, Walton R, Stanford MR, Welsh KI, Marshall SE, Jewell DP. Mapping the HLA association in Behcet's disease: a role for tumor necrosis factor polymorphisms?
Arthritis Rheum. 48: 807-813 (2003).
*
-
Ahmad YA, Bruce IN. Genetic epidemiology: systemic lupus erythematosus.
Arthritis Res. 3: 331-336 (2001).
*
-
Ahmadi K, McCruden AB. Macrophage may responses to androgen via its receptor.
Med. Sci. Monit. 12: BR15-BR20 (2005).
*
-
Ahmadi S, Powell FC. Pyoderma gangrenosum: uncommon presentations.
Clin. Dermatol. 23: 612-620 (2005).
-
Ahmadi-Simab K, Schnitzler P. Whipple's disease with normal duodenal histology and ankylosing spondylitis.
Dtsch. Med. Wochenschr. 134: 127-130 (2009).
-
Ahmed MM, Berney SM, Wolf RE, Hearth-Holmes M, Hayat S, Mubashir E, Vanderheyde H, Chang WL, King JW. Prevalence of active hepatitis C virus infection in patients with systemic lupus erythematosus.
Am. J. Med. Sci. 331: 252-256 (2006).
-
Ahmed MM, Mubashir E, Wolf RE, Hayat S, Hall V, Shi R, Berney SM. Impact of treatment with infliximab on anticyclic citrullinated peptide antibody and rheumatoid factor in patients with rheumatoid arthritis.
South. Med. J. 99: 1209-1215 (2006).
-
Ahn BC, Lee SW, Lee J. Intense accumulation of F-18 FDG in colonic wall in adult onset Still disease with pseudomembranous colitis.
Clin. Nucl. Med. 33: 806-808 (2008).
-
Ahn IE, Ju JH, Park SH, Kim HY. Radiologic observation: repair of focal bone erosions after humanized antitumor necrosis factor antibody adalimumab therapy in a patient with rheumatoid arthritis.
Clin. Rheumatol. Oct 7 [Epub ahead of print] (2009).
*
-
Ahn KS, Aggarwal BB. Transcription factor NF-kappaB: a sensor for smoke and stress signals.
Ann. N. Y. Acad. Sci. 1056: 218-233 (2005).
*
-
Ahnfelt-Ronne I, Nielsen OH, Christensen A, Langholz E, Binder V, Riis P. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid.
Gastroenterology 98: 1162-1169 (1990).
-
Ahrens ET, Morel PA. In vivo imaging of autoimmune disease in model systems.
Curr. Top. Dev. Biol. 70C: 215-238 (2005).
-
Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, Shlomchik MJ. Depletion of B cells in murine lupus: efficacy and resistance.
J. Immunol. 179: 3351-3361 (2007).
*
-
Aida Y, Maeno M, Suzuki N, Namba A, Motohashi M, Matsumoto M, Makimura M, Matsumura H. The effect of IL-1beta on the expression of inflammatory cytokines and their receptors in human chondrocytes.
Life Sci. 79: 764-771 (2006).
*
-
Aiello M, Chetta A, Marangio E, Zompatori M, Olivieri D. Pleural involvement in systemic disorders.
Curr. Drug Targets Inflamm. Allergy 3: 441-447 (2004).
-
Aigner E, Schmid I, Osterreicher CH, Zwerina J, Schett G, Strasser M, Niksic F, Hohla F, Ramsauer T, Dorn U, Patsch W, Datz C. Contribution of anti-cyclic citrullinated peptide and rheumatoid factors for the diagnosis of arthropathy in patients with hereditary hemochromatosis.
Ann. Rheum. Dis. 66: 1249-1251 (2007).
*
-
Aimbire F, Albertini R, Pacheco MT, Castro-Faria-Neto HC, Leonardo PS, Iversen VV, Lopes-Martins RA, Bjordal JM. Low-level laser therapy induces dose-dependent reduction of TNFalpha levels in acute inflammation.
Photomed. Laser Surg. 24: 33-37 (2006).
-
Ainola M, Mandelin J, Liljestrom M, Konttinen YT, Salo J. Imbalanced expression of RANKL and osteoprotegerin mRNA in pannus tissue of rheumatoid arthritis.
Clin. Exp. Rheumatol. 26: 240-246 (2008).
-
Ainola M, Valleala H, Nykanen P, Risteli J, Hanemaaijer R, Konttinen YT. Erosive arthritis in a patient with pycnodysostosis: an experiment of nature.
Arthritis Rheum. 58: 3394-3401 (2008).
*
-
Aithal GP. Dangerous liaisons: drug, host and the environment.
J. Hepatol. 46: 995-998 (2007).
*
-
Aittoniemi J, Baer M, Soppi E, Vesikari T, Miettinen A. Mannan binding lectin deficiency and concomitant immunodefects.
Arch. Dis. Child. 78: 245-248 (1998).
*
-
Ajiro J, Narita I, Sato F, Saga D, Hasegawa H, Kuroda T, Nakano M, Gejyo F. SAA1 gene polymorphisms and the risk of AA amyloidosis in Japanese patients with rheumatoid arthritis.
Mod. Rheumatol. 16: 294-299 (2006).
*
-
Ajuebor MN, Carey JA, Swain MG. CCR5 in T cell-mediated liver diseases: what's going on?
J. Immunol. 177: 2039-2045 (2006).
*
-
Akabane H, Miyagawa N, Nii H, Inami Y, Togawa M, Tanaka H, Inagaki N, Nagai H. The effect of a newly synthesized indazole compound, TAS-3-124, on experimental autoimmune disease.
Biol. Pharm. Bull. 27: 1218-1223 (2004).
*
-
Akama H. Antibody to IL-1 or IL-15.
Nippon Rinsho 65: 1227-1230 (2007).
-
Akaogi J, Nozaki T, Satoh M, Yamada H. Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy.
Endocr. Metab. Immune Disord. Drug Targets 6: 383-394 (2006).
-
Akaogi J, Yamada H, Kuroda Y, Nacionales DC, Reeves WH, Satoh M. Prostaglandin E2 receptors EP2 and EP4 are up-regulated in peritoneal macrophages and joints of pristane-treated mice and modulate TNF-alpha and IL-6 production.
J. Leukoc. Biol. 76: 227-236 (2004).
*
-
Akar N, Hasipek M, Ozturk A, Akar E, Tekin M. Serum amyloid A1 -13 T/C alleles in Turkish familial Mediterranean fever patients with and without amyloidosis.
J. Nephrol. 19: 318-321 (2006).
-
Akasaka Y, Abe K, Sato T, Inoue H. Regulation of neurokinin-1 receptor messenger RNA expression in synovial fibroblasts of patients with rheumatoid arthritis.
Neuropeptides 39: 467-474 (2005).
*
-
Akhavani MA, Larsen H, Paleolog E. Circulating endothelial progenitor cells as a link between synovial vascularity and cardiovascular mortality in rheumatoid arthritis.
Scand. J. Rheumatol. 36: 83-90 (2007).
-
Akhmetshina A, Dees C, Busch N, Beer J, Sarter K, Zwerina J, Zimmer A, Distler O, Schett G, Distler JH. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis.
Arthritis Rheum. 60: 1129-1136 (2009).
*
-
Akikusa JD, Schneider R, Harvey EA, Hebert D, Thorner PS, Laxer RM, Silverman ED. Clinical features and outcome of pediatric Wegener's granulomatosis.
Arthritis Rheum. 57: 837-844 (2007).
*
-
Akilesh S, Petkova S, Sproule TJ, Shaffer DJ, Christianson GJ, Roopenian D. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease.
J. Clin. Invest. 113: 1328-1333 (2004).
*
-
Akisu C, Delibas SB, Ozkoc S. Evaluation of three different ELISA kits for the diagnosis of trichinellosis.
Mikrobiyol. Bul. 39: 325-331 (2005).
-
Akkad DA, Jagiello P, Szyld P, Goedde R, Wieczorek S, Gross WL, Epplen JT. Promoter polymorphism rs3087456 in the MHC class II transactivator gene is not associated with susceptibility for selected autoimmune diseases in German patient groups.
Int. J. Immunogenet. 33: 59-61 (2006).
*
-
Akkari R, Burbiel JC, Hockemeyer J, Muller CE. Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs.
Curr. Top. Med. Chem. 6: 1375-1399 (2006).
-
Akkoc N, van der Linden S, Khan MA. Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy.
Best Pract. Res. Clin. Rheumatol. 20: 539-557 (2006).
-
Akkurt MO, Bektaser B, Ocguder A, Oguz T, Solak S. An unusual complication of familial Mediterranean fever: protracted arthritis with bilateral coxarthrosis and intraosseous amyloidosis of femoral head.
Mod. Rheumatol. 15: 358-360 (2005).
-
Akritidis N, Papadopoulos A, Pappas G. Long-term follow-up of patients with adult-onset Still's disease.
Scand. J. Rheumatol. 35: 395-397 (2006).
*
-
Aksentijevich I, D Putnam C, Remmers EF, Mueller JL, Le J, Kolodner RD, Moak Z, Chuang M, Austin F, Goldbach-Mansky R, Hoffman HM, Kastner DL. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model.
Arthritis Rheum. 56: 1273-1285 (2007).
*
-
Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH, Goldbach-Mansky R, Dean J, Athreya B, Reginato AJ, Henrickson M, Pons-Estel B, O'Shea JJ, Kastner DL. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers.
Am. J. Hum. Genet. 69: 301-314 (2001).
*
-
Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, Laxer R, Tedgard U, Cowen EW, Pham TH, Booty M, Estes JD, Sandler NG, Plass N, Stone DL, Turner ML, Hill S, Butman JA, Schneider R, Babyn P, El-Shanti HI, Pope E, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.
N. Engl. J. Med. 360: 2426-2437 (2009).
*
-
Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, Stein L, Russo R, Goldsmith D, Dent P, Rosenberg HF, Austin F, Remmers EF, Balow JE Jr, Rosenzweig S, Komarow H, Shoham NG, Wood G, Jones J, Mangra N, Carrero H, Adams BS, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases.
Arthritis Rheum. 46: 3340-3348 (2002).
*
-
Aksu K, Cagirgan S, Ozsan N, Keser G, Sahin F. Non-Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis.
Rheumatol. Int. Dec 14 [Epub ahead of print] (2009).
*
-
Aksu K, Kitapcioglu G, Keser G, Berdeli A, Karabulut G, Kobak S, Ozmen M, Inal V, Kabasakal Y, Oksel F, Kocanaogullari H, Doganavsargil E. FcgammaRIIa, IIIa and IIIb gene polymorphisms in Behcet's disease: do they have any clinical implications?
Clin. Exp. Rheumatol. 26: S77-S83 (2008).
-
Al-Arfaj A. HLA-DR pattern of rheumatoid arthritis in Saudi Arabia.
Ann. Saudi Med. 21: 92-93 (2001).
-
Al-Awadhi AM, Hasan EA, Sharma PN, Haider MZ, Al-Saeid K. Angiotensin-converting enzyme gene polymorphism in patients with psoriatic arthritis.
Rheumatol. Int. 27: 1119-1123 (2007).
*
-
Al-Awadhi AM, Olusi S, Hasan EA, Abdullah A. Serum concentrations of cardiac troponin-I in patients with rheumatoid arthritis, systemic lupus erythematosus, primary Sjogren's syndrome and Graves' disease.
Singapore Med. J. 48: 847-849 (2007).
*
-
Al-Awadhi AM, Olusi S, Hasan EA, Abdullah A. Frequency of abnormal thyroid function tests in Kuwaiti arabs with autoimmune diseases.
Med. Princ. Pract. 17: 61-65 (2008).
-
Al-Awadi A, Olusi SO, Al-Zaid N, Prabha K. Serum B2-microglobulin concentration correlates with urinary concentrations of type 1 collagen cross-linked N-telopeptides and deoxypyridinoline in rheumatoid arthritis.
Ann. Saudi Med. 18: 113-116 (1998).
-
Al-Heresh AM, Proctor J, Jones SM, Dixey J, Cox B, Welsh K, McHugh N. Tumour necrosis factor-alpha polymorphism and the HLA-Cw*0602 allele in psoriatic arthritis.
Rheumatology (Oxford) 41: 525-530 (2002).
*
-
al-Jarallah KF, Singal DP, Buchanan WW. Immunogenetics of psoriatic arthritis.
Immunol. Invest. 22: 81-86 (1993).
-
Al-Mayouf SM. Familial arthropathy in Saudi Arabian children: demographic, clinical, and biochemical features.
Semin. Arthritis Rheum. 36: 256-261 (2007).
*
-
Al-Mayouf SM, Al-Sonbul A, Al Jumaah S, Al-Hemidan A. Sarcoidosis: a delayed or missed diagnosis in children.
Ann. Saudi Med. 26: 220-223 (2006).
-
Al-Mutairi N, Al-Farag S, Al-Mutairi A, Al-Shiltawy M. Comorbidities associated with psoriasis: an experience from the Middle East.
J. Dermatol. 37: 146-155 (2010).
-
Al-Shukaili AK, Al-Jabri AA. Rheumatoid arthritis, cytokines and hypoxia. What is the link?
Saudi Med. J. 27: 1642-1649 (2006).
-
Al-Swailem R, Al-Rayes H, Sobki S, Arfin M, Tariq M. HLA-DRB1 association in Saudi rheumatoid arthritis patients.
Rheumatol. Int. 26: 1019-1024 (2006).
*
-
Al-Wahadneh AM, Dahabreh MM. Familial mediterranean fever in children: a single centre experience in Jordan.
East. Mediterr. Health J. 12: 818-823 (2006).
-
Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review.
Semin. Arthritis Rheum. 36: 182-188 (2006).
*
-
Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of psoriatic arthritis: a systematic review.
J. Rheumatol. 35: 1354-1358 (2008).
*
-
Alamoudi OS. Sleep-disordered breathing in patients with acquired retrognathia secondary to rheumatoid arthritis.
Med. Sci. Monit. 12: CR530-CR534 (2006).
*
-
Alanara T, Karstila K, Moilanen T, Silvennoinen O, Isomaki P. Expression of IL-10 family cytokines in rheumatoid arthritis: elevated levels of IL-19 in the joints.
Scand. J. Rheumatol. Dec 14 [Epub ahead of print] (2009).
*
-
Alansari A, Gul A, Inanc M, Ordi J, Teh LS, Ollier WE, Gonzalez-Gay MA, Hajeer AH. Fc receptor gamma subunit polymorphisms and systemic lupus erythematosus.
Saudi Med. J. 25: 1445-1448 (2004).
-
Alarcon GS. Psoriatic arthritis, methotrexate, and liver toxicity.
J. Clin. Rheumatol. 7: 213-214 (2001).
-
Alarcon-Riquelme ME. Role of RUNX in autoimmune diseases linking rheumatoid arthritis, psoriasis and lupus.
Arthritis Res. Ther. 6: 169-173 (2004).
*
-
Alarcon-Segovia D, Alarcon-Riquelme ME, Cardiel MH, Caeiro F, Massardo L, Villa AR, Pons-Estel BA. Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort.
Arthritis Rheum. 52: 1138-1147 (2005).
*
-
Alavi A, Axford JS. The pivotal nature of sugars in normal physiology and disease.
Wien. Med. Wochenschr. 156: 19-33 (2006).
-
Alayli G, Kara N, Tander B, Canturk F, Gunes S, Bagci H. Association of transforming growth factor beta1 gene polymorphism with rheumatoid arthritis in a Turkish population.
Joint Bone Spine 76: 20-23 (2009).
*
-
Albani S, Roudier J. Molecular basis for the association between HLA DR4 and rheumatoid arthritis. From the shared epitope hypothesis to a peptidic model of rheumatoid arthritis.
Clin. Biochem. 25: 209-212 (1992).
-
Albers HM, Kurreeman FA, Stoeken-Rijsbergen G, Brinkman DM, Kamphuis SS, van Rossum MA, Girschick HJ, Wouters C, Saurenmann RK, Hoppenreijs E, Slagboom P, Houwing-Duistermaat JJ, Verduijn W, Huizinga TW, Ten Cate R, Toes RE, Schilham MW. Association of the autoimmunity locus 4q27 with juvenile idiopathic arthritis.
Arthritis Rheum. 60: 901-904 (2009).
*
-
Albert D, Clarkin C, Komoroski J, Brensinger CM, Berlin JA. Wegener's granulomatosis: possible role of environmental agents in its pathogenesis.
Arthritis Rheum. 51: 656-664 (2004).
*
-
Albert H, Collin M, Dudziak D, Ravetch JV, Nimmerjahn F. In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner.
Proc. Natl. Acad. Sci. U.S.A. 105: 15005-15009 (2008).
*
-
Albrecht J, Atzeni F, Baldini C, Bombardieri S, Dalakas MC, Demirkesen C, Yazici H, Mat C, Werth VP, Sarzi-Puttini P. Skin involvement and outcome measures in systemic autoimmune diseases.
Clin. Exp. Rheumatol. 24: S52-S59 (2006).
-
Alcantara C, Gomes MJ, Ferreira C. Rituximab therapy in primary Sjogren's syndrome.
Ann. N. Y. Acad. Sci. 1173: 701-705 (2009).
*
-
Alcorta DA, Barnes DA, Dooley MA, Sullivan P, Jonas B, Liu Y, Lionaki S, Reddy CB, Chin H, Dempsey AA, Jennette JC, Falk RJ. Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis.
Kidney Int. 72: 853-864 (2007).
*
-
Alemany-Rodriguez MJ, Aladro Y, Amela-Peris R, Perez-Vieitez MC, Reyes-Yanez MP, Deniz-Naranjo MC, Sanchez-Garcia F. Autoimmune diseases and multiple sclerosis.
Rev. Neurol. 40: 594-597 (2005).
-
Alenius GM. Psoriatic arthritis - new insights give new options for treatment.
Curr. Med. Chem. 14: 359-366 (2007).
-
Alenius GM, Eriksson C, Rantapaa Dahlqvist S. Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis?
Clin. Exp. Rheumatol. 27: 120-123 (2009).
-
Alenius GM, Friberg C, Nilsson S, Wahlstrom J, Dahlqvist SR, Samuelsson L. Analysis of 6 genetic loci for disease susceptibility in psoriatic arthritis.
J. Rheumatol. 31: 2230-2235 (2004).
*
-
Alese OB, Irabor DO. Pyoderma gangrenosum and ulcerative colitis in the tropics.
Rev. Soc. Bras. Med. Trop. 41: 664-667 (2008).
*
-
Alessandri C, Conti F, Conigliaro P, Mancini R, Massaro L, Valesini G. Seronegative autoimmune diseases.
Ann. N. Y. Acad. Sci. 1173: 52-59 (2009).
*
-
Alessandri C, Priori R, Modesti M, Mancini R, Valesini G. The role of anti-cyclic cytrullinate antibodies testing in rheumatoid arthritis.
Clin. Rev. Allergy Immunol. 34: 45-49 (2008).
*
-
Alessandri C, Sorice M, Bombardieri M, Conigliaro P, Longo A, Garofalo T, Manganelli V, Conti F, Esposti ED, Valesini G. Anti-phospholipid reactivity against cardiolipin metabolites occurring during endothelial cell apoptosis.
Arthritis Res. Ther. 8: R180 (2006).
*
-
Aletaha D. Capturing real-life patient care in psoriatic arthritis and its risks: the challenge of analysing registry data.
Arthritis Res. Ther. 11: 112 (2009).
*
-
Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients.
Arthritis Rheum. 56: 3226-3235 (2007).
*
-
Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis.
Clin. Exp. Rheumatol. 23: S100-S108 (2005).
-
Aletaha D, Smolen JS. The definition and measurement of disease modification in inflammatory rheumatic diseases.
Rheum. Dis. Clin. North Am. 32: 9-44 (2006).
-
Aletaha D, Smolen JS. Remission of rheumatoid arthritis: should we care about definitions?
Clin. Exp. Rheumatol. 24: S045-S051 (2006).
*
-
Alexandroff AB, Pauriah M, Camp RD, Lang CC, Struthers AD, Armstrong DJ. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis.
Br. J. Dermatol. 161: 1-7 (2009).
*
-
Alexiou I, Germenis A, Ziogas A, Theodoridou K, Sakkas LI. Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis.
BMC Musculoskelet. Disord. 8: 37 (2007).
*
-
Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNF-a therapies.
J. Cutan. Med. Surg. 9: 296-302 (2005).
*
-
Alexopoulou L, Kranidioti K, Xanthoulea S, Denis M, Kotanidou A, Douni E, Blackshear PJ, Kontoyiannis DL, Kollias G. Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity.
Eur. J. Immunol. 36: 2768-2780 (2006).
*
-
Alfadhli A, McDonald J, Feagan B. Methotrexate for induction of remission in refractory Crohn's disease.
Cochrane Database Syst. Rev. 1: CD003459 (2005).
*
-
Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease.
Cochrane Database Syst. Rev. 1: CD003459 (2003).
*
-
Alfredo CS, Nunes NA, Len CA, Barbosa CM, Terreri MT, Hilario MO. Henoch-Shonlein purpura: recurrence and chronicity.
J. Pediatr. (Rio J.) 83: 177-180 (2007).
-
Ali AA, Moatter T, Baig JA, Iqbal A, Hussain A, Iqbal MP. Polymorphism of HLA-DR and HLA-DQ in rheumatoid arthritis patients and clinical response to methotrexate - a hospital-based study.
J. Pak. Med. Assoc. 56: 452-456 (2006).
-
Ali M, Manolios N. Proteomics in rheumatology: a new direction for old diseases.
Semin. Arthritis Rheum. 35: 67-76 (2005).
*
-
Ali Y, Tom BD, Schentag CT, Farewell VT, Gladman DD. Improved survival in psoriatic arthritis with calendar time.
Arthritis Rheum. 56: 2708-2714 (2007).
*
-
Ali YM, Kuriya B, Orozco C, Cush JJ, Keystone EC. Can tumor necrosis factor inhibitors be safely used in pregnancy?
J. Rheumatol. Dec 14 [Epub ahead of print] (2009).
-
Alizadeh BZ, Valdigem G, Coenen MJ, Zhernakova A, Franke B, Monsuur A, van Riel PL, Barrera P, Radstake TR, Roep BO, Wijmenga C, Koeleman BP. Association analysis of functional variants of the FcgRIIa and FcgRIIIa genes with type 1 diabetes, celiac disease and rheumatoid arthritis.
Hum. Mol. Genet. 16: 2552-2559 (2007).
*
-
Allanore Y, Batteux F, Avouac J, Assous N, Weill B, Kahan A. Levels of circulating endothelial progenitor cells in systemic sclerosis.
Clin. Exp. Rheumatol. 25: 60-66 (2007).
-
Allanore Y, Seror R, Chevrot A, Kahan A, Drape JL. Hand vascular involvement assessed by magnetic resonance angiography in systemic sclerosis.
Arthritis Rheum. 56: 2747-2754 (2007).
*
-
Allcock RJ, Windsor L, Gut IG, Kucharzak R, Sobre L, Lechner D, Garnier JG, Baltic S, Christiansen FT, Price P. High-density SNP genotyping defines 17 distinct haplotypes of the TNF block in the Caucasian population: implications for haplotype tagging.
Hum. Mutat. 24: 517-525 (2004).
-
Allegretti M, Moriconi A, Beccari AR, Di Bitondo R, Bizzarri C, Bertini R, Colotta F. Targeting C5a: recent advances in drug discovery.
Curr. Med. Chem. 12: 217-236 (2005).
-
Allen AS, Satten GA. Genome-wide association analysis of rheumatoid arthritis data via haplotype sharing.
BMC Proc. 3 Suppl. 7: S30 (2009).
*
-
Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, McLaren CE, Bahlo M, Nisselle AE, Vulpe CD, Anderson GJ, Southey MC, Giles GG, English DR, Hopper JL, Olynyk JK, Powell LW, Gertig DM. Iron-overload-related disease in HFE hereditary hemochromatosis.
N. Engl. J. Med. 358: 221-230 (2008).
*
-
Allen RL, Bowness P, McMichael A. The role of HLA-B27 in spondyloarthritis.
Immunogenetics 50: 220-227 (1999).
-
Allen RL, Trowsdale J. Recognition of classical and heavy chain forms of HLA-B27 by leukocyte receptors.
Curr. Mol. Med. 4: 59-65 (2004).
-
Allen-Brady K, Horne BD, Malhotra A, Teerlink C, Camp NJ, Thomas A. Analysis of high-density single-nucleotide polymorphism data: three novel methods that control for linkage disequilibrium between markers in a linkage analysis.
BMC Proc. 1 Suppl. 1: S160 (2007).
*
-
Aloi M, Cucchiara S. Extradigestive manifestations of IBD in pediatrics.
Eur. Rev. Med. Pharmacol. Sci. 13 Suppl. 1: 23-32 (2009).
-
Alonso D, Elgart GW, Schachner LA. Blau syndrome: a new kindred.
J. Am. Acad. Dermatol. 49: 299-302 (2003).
-
Alonso-Ruiz A, Pijoan JI, Ansuategui E, Calabozo M, Urkaregi A, Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.
BMC Musculoskelet. Disord. 9: 52 (2008).
*
-
Aloush V, Ablin JN, Reitblat T, Caspi D, Elkayam O. Fibromyalgia in women with ankylosing spondylitis.
Rheumatol. Int. 27: 865-868 (2007).
*
-
Aloush V, Litinsky I, Caspi D, Elkayam O. Propylthiouracil-induced autoimmune syndromes: two distinct clinical presentations with different course and management.
Semin. Arthritis Rheum. 36: 4-9 (2006).
*
-
Aloysius MM, Kaye PV, Lobo DN. Non-steroidal anti-inflammatory drug (NSAID)-induced colonic strictures and perforation: a case report.
Dig. Liver Dis. 38: 276-278 (2006).
-
Alpers DH. The role of nutritional deficiency in the osteopenia and osteoporosis of gastrointestinal diseases.
Curr. Opin. Gastroenterol. 18: 203-208 (2002).
-
Alpigiani MG, Haupt R, Parodi S, Calcagno A, Poggi E, Lorini R. Coeliac disease in 108 patients with juvenile idiopathic arthritis: a 13-year follow-up study.
Clin. Exp. Rheumatol. 26: 162 (2008).
-
Alsaadi G, Quirynen M, Michiles K, Teughels W, Komarek A, van Steenberghe D. Impact of local and systemic factors on the incidence of failures up to abutment connection with modified surface oral implants.
J. Clin. Periodontol. 35: 51-57 (2008).
-
Alsaeid K, Alawadhi A, Al-Saeed O, Haider MZ. Human leukocyte antigen DRB1*04 is associated with rheumatoid arthritis in Kuwaiti patients.
Joint Bone Spine 73: 62-65 (2006).
*
-
Alsaeid K, Haider MZ, Ayoub EM. Angiotensin converting enzyme gene insertion-deletion polymorphism is associated with juvenile rheumatoid arthritis.
J. Rheumatol. 30: 2705-2709 (2003).
-
Alsaeid K, Haider MZ, Sharma PN, Ayoub EM. The prevalence of human leukocyte antigen (HLA) DR/DQ/DP alleles in Kuwaiti children with oligoarticular juvenile idiopathic arthritis.
Rheumatol. Int. 26: 224-228 (2006).
*
-
Alsaeid KM, Haider MZ, al-Awadhi AM, Srivastva BS, Ayoub EM. Role of human leukocyte antigen DRB1*0307 and DRB1*0308 in susceptibility to juvenile rheumatoid arthritis.
Clin. Exp. Rheumatol. 21: 399-402 (2003).
-
Alsaleh G, Messer L, Semaan N, Boulanger N, Gottenberg JE, Sibilia J, Wachsmann D. BAFF synthesis by rheumatoid synoviocytes is positively controlled by alpha5beta1 integrin stimulation and is negatively regulated by tumor necrosis factor alpha and Toll-like receptor ligands.
Arthritis Rheum. 56: 3202-3214 (2007).
*
-
Alstergren P, Larsson PT, Kopp S. Successful treatment with multiple intra-articular injections of infliximab in a patient with psoriatic arthritis.
Scand. J. Rheumatol. 37: 155-157 (2008).
-
Alter M, Wittmann M, Volker B, Kapp A, Werfel T, Gutzmer R. Successful treatment of pemphigus foliaceus with rituximab: report of 3 cases.
Hautarzt. 60: 743-748 (2009).
-
Althoff CE, Hermann KG, Braun J, Sieper J. Ankylosing spondylitis - current state of imaging including scoring methods.
Z. Rheumatol. 65: 688-699 (2006).
-
Altindag O, Karakoc M, Kocyigit A, Celik H, Soran N. Increased DNA damage and oxidative stress in patients with rheumatoid arthritis.
Clin. Biochem. 40: 167-171 (2007).
*
-
Altobelli E, Maccarone M, Petrocelli R, Marziliano C, Giannetti A, Peris K, Chimenti S. Analysis of health care and actual needs of patients with psoriasis: a survey on the Italian population.
BMC Public Health 7: 59 (2007).
*
-
Altomare G, Ayala F, Berardesca E, Chimenti S, Giannetti A, Girolomoni G, Lotti T, Martini P, Peserico A, Guerra AP, Vena GA. Etanercept provides a more physiological approach in the treatment of psoriasis.
Dermatol. Ther. 21 Suppl. 2: S1-S14 (2008).
-
Altschuler EL, Kast RE. Bupropion for Blau syndrome.
Med. Hypotheses 62: 297-298 (2004).
-
Altuwaijri S, Chuang KH, Lai KP, Lai JJ, Lin HY, Young FM, Bottaro A, Tsai MY, Zeng WP, Chang HC, Yeh S, Chang C. Susceptibility to autoimmunity and B cell resistance to apoptosis in mice lacking androgen receptor in B cells.
Mol. Endocrinol. 23: 444-453 (2009).
*
-
Alvarado-Sanchez B, Hernandez-Castro B, Portales-Perez D, Baranda L, Layseca-Espinosa E, Abud-Mendoza C, Cubillas-Tejeda AC, Gonzalez-Amaro R. Regulatory T cells in patients with systemic lupus erythematosus.
J. Autoimmun. 27: 110-118 (2006).
-
Alvarez I, Collado J, Daura X, Colome N, Rodriguez-Garcia M, Gallart T, Canals F, Jaraquemada D. The rheumatoid arthritis-associated allele HLA-DR10 (DRB1*1001) shares part of its repertoire with HLA-DR1 (DRB1*0101) and HLA-DR4 (DRB*0401).
Arthritis Rheum. 58: 1630-1639 (2008).
*
-
Alvarez Madrid C, Gonzalez Fernandez A, Lisbona Munoz M, Molina Rodriguez MA, Merino Munoz R, Garcia-Consuegra Molina J. Thyroid disorders and childhood rheumatic diseases.
An. Pediatr. (Barc.) 70: 53-56 (2009).
-
Alvarez-Ossorio L, Johannsen M, Russlies M, Kirchner H, Rink L. HLA-dependent heterogeneous T cell response to Mycoplasma arthritidis-derived superantigen (MAS).
Med. Microbiol. Immunol. 185: 245-251 (1997).
-
Alvarez-Rodriguez L, Carrasco E, Lopez-Hoyos M, Mata C, Fernandez-Prieto L, Ruiz-Soto M, Calvo J, Rodriguez-Valverde V, Ruiz T, Blanco R, Corrales A, Martinez-Taboada VM. Interleukin-1RN gene polymorphisms in elderly patients with rheumatic inflammatory chronic conditions: association of IL-1RN*2/2 genotype with polymyalgia rheumatica.
Hum. Immunol. 70: 49-54 (2009).
-
Alvarez-Rodriguez L, Martínez-Taboada VM, Lopez-Hoyos M, Mata C, Fernandez Prieto L, Agudo-Bilbao M, Calvo J, Ruiz Soto M, Rodriguez-Valverde V, Ruiz T, Blanco R, Corrales A, Carrasco-Marín E. Interleukin-12 gene polymorphisim in patients with giant cell arteritis, polymyalgia rheumatica and elderly-onset rheumatoid arthritis.
Clin. Exp. Rheumatol. 27: S14-S18 (2009).
-
Alwawi EA, Mehlis SL, Gordon KB. Treating psoriasis with adalimumab.
Ther. Clin. Risk Manag. 4: 345-351 (2008).
*
-
Amano K. Pulmonary infections in patients with rheumatoid arthritis who have received anti-TNF therapy.
Intern. Med. 45: 991-992 (2006).
*
-
Amano K. Biological agents.
Nippon Rinsho 67: 593-598 (2009).
-
Amat M, Benjamim CF, Williams LM, Prats N, Terricabras E, Beleta J, Kunkel SL, Godessart N. Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo.
Br. J. Pharmacol. 149: 666-575 (2006).
*
-
Ambrose NL, O Connell PG. Anti-TNF alpha therapy does not always protect rheumatoid arthritis patients against developing pericarditis.
Clin. Exp. Rheumatol. 25: 660 (2007).
-
Ambrosio C, Alexandre M, Malcata A. Sternoclavicular joint in psoriatic arthritis.
Acta Reumatol. Port. 34: 138 (2009).
-
Amemori S, Iwakiri R, Endo H, Ootani A, Ogata S, Noda T, Tsunada S, Sakata H, Matsunaga H, Mizuguchi M, Ikeda Y, Fujimoto K. Oral dimethyl sulfoxide for systemic amyloid A amyloidosis complication in chronic inflammatory disease: a retrospective patient chart review.
J. Gastroenterol. 41: 444-449 (2006).
*
-
Amengual O, Atsumi T, Komano Y, Kataoka H, Horita T, Yasuda S, Koike T. A polymorphism in human platelet antigen 6b and risk of thrombocytopenia in patients with systemic lupus erythematosus.
Arthritis Rheum. 56: 2803-2805 (2007).
*
-
Amer R, Bamonte G, Forrester JV. Resolution of juvenile idiopathic arthritis-associated uveitis after development of common variable immunodeficiency.
Eur. J. Ophthalmol. 17: 666-668 (2007).
-
American Academy of Family Physicians. Information from your family doctor. Rheumatoid arthritis: what you should know.
Am. Fam. Physician 72: 1049-1050 (2005).
-
Ameriks MK, Venable JD. Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) delta and gamma.
Curr. Top. Med. Chem. 9: 738-753 (2009).
-
Amezcua-Guerra LM, Hernandez-Martinez B, Pineda C, Bojalil R. Ulcerative colitis during CTLA-4Ig therapy in a patient with rheumatoid arthritis.
Gut 55: 1059-1060 (2006).
*
-
Amezcua-Guerra LM, Prieto P, Bojalil R, Pineda C, Amigo MC. Microscopic polyangiitis associated with primary biliary cirrhosis: a causal or casual association?
J. Rheumatol. 33: 2351-2353 (2006).
-
Amezcua-Guerra LM, Springall R, Marquez-Velasco R, Gomez-Garcia L, Vargas A, Bojalil R. Presence of antibodies against cyclic citrullinated peptides (anti-CCP) in patients with rhupus: a cross-sectional study.
Arthritis Res. Ther. 8: R144 (2006).
*
-
Amherd-Hoekstra A, Naher H, Lorenz HM, Enk AH. Psoriatic arthritis: a review.
J. Dtsch. Dermatol. Ges. Dec 11 [Epub ahead of print] (2009).
-
Amiable N, Tat SK, Lajeunesse D, Duval N, Pelletier JP, Martel-Pelletier J, Boileau C. Proteinase-activated receptor (PAR)-2 activation impacts bone resorptive properties of human osteoarthritic subchondral bone osteoblasts.
Bone 44: 1143-1150 (2009).
*
-
Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases.
Proc. Natl. Acad. Sci. U.S.A. 93: 14014-14019 (1996).
*
-
Amin EA, Welsh WJ. A preliminary in silico lead series of 2-phthalimidinoglutaric acid analogues designed as MMP-3 inhibitors.
J. Chem. Inf. Model. 46: 2104-2109 (2006).
*
-
Amin MA, Mansfield PJ, Pakozdi A, Campbell PL, Ahmed S, Martinez RJ, Koch AE. Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways.
Arthritis Rheum. 56: 1787-1797 (2007).
*
-
Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A. SAPHO syndrome treated with pamidronate: an open-label study of 10 patients.
Rheumatology (Oxford) 43: 658-661 (2004).
*
-
Amital H, Arnson Y, Chodick G, Shalev V. Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate.
Rheumatology (Oxford) 48: 1107-1110 (2009).
-
Amital H, Barak V, Winkler RE, Rubinow A. Impact of treatment with infliximab on serum cytokine profile of patients with rheumatoid and psoriatic arthritis.
Ann. N. Y. Acad. Sci. 1110: 649-660 (2007).
*
-
Amital H, Gershwin EM, Shoenfeld Y. Reshaping the mosaic of autoimmunity.
Semin. Arthritis Rheum. 35: 341-343 (2006).
*
-
Amital H, Govoni M, Maya R, Meroni PL, Ori B, Shoenfeld Y, Tincani A, Trotta F, Sarzi-Puttini P, Atzeni F. Role of infectious agents in systemic rheumatic diseases.
Clin. Exp. Rheumatol. 26: S27-S32 (2008).
-
Amlong CA, Nardelli DT, Peterson SH, Warner TF, Callister SM, Schell RF. Anti-interleukin-15 prevents arthritis in Borrelia-vaccinated and -infected mice.
Clin. Vaccine Immunol. 13: 289-296 (2006).
*
-
Ammon HP. Boswellic acids in chronic inflammatory diseases.
Planta Med. 72: 1100-1116 (2006).
-
Amoroso P, Vergani D, Wojcicka BM, McFarlane IG, Eddleston AL, Tee DE, Williams R. Identification of biliary antigens in circulating immune complexes in primary biliary cirrhosis.
Clin. Exp. Immunol. 42: 95-98 (1980).
*
-
Amos CI, Chen WV, Lee A, Li W, Kern M, Lundsten R, Batliwalla F, Wener M, Remmers E, Kastner DA, Criswell LA, Seldin MF, Gregersen PK. High-density SNP analysis of 642 Caucasian families with rheumatoid arthritis identifies two new linkage regions on 11p12 and 2q33.
Genes Immun. 7: 277-286 (2006).
*
-
Amos CI, Chen WV, Remmers E, Siminovitch KA, Seldin MF, Criswell LA, Lee AT, John S, Shephard ND, Worthington J, Cornelis F, Plenge RM, Begovich AB, Dyer TD, Kastner DL, Gregersen PK. Data for Genetic Analysis Workshop (GAW) 15 Problem 2, genetic causes of rheumatoid arthritis and associated traits.
BMC Proc. 1 Suppl. 1: S3 (2007).
*
-
Amos CI, Chen WV, Seldin MF, Remmers EF, Taylor KE, Criswell LA, Lee AT, Plenge RM, Kastner DL, Gregersen PK. Data for Genetic Analysis Workshop 16 Problem 1, association analysis of rheumatoid arthritis data.
BMC Proc. 3 Suppl. 7: S2 (2009).
*
-
Amoura Z, Dode C, Hue S, Caillat-Zucman S, Bahram S, Delpech M, Grateau G, Wechsler B, Piette JC. Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behcet's disease.
Arthritis Rheum. 52: 608-611 (2005).
*
-
Amria S, Hajiaghamohseni LM, Harbeson C, Zhao D, Goldstein O, Blum JS, Haque A. HLA-DM negatively regulates HLA-DR4-restricted collagen pathogenic peptide presentation and T cell recognition.
Eur. J. Immunol. 38: 1961-1970 (2008).
*
-
Amu S, Stromberg K, Bokarewa M, Tarkowski A, Brisslert M. CD25-expressing B-lymphocytes in rheumatic diseases.
Scand. J. Immunol. 65: 182-191 (2007).
*
-
Amu S, Tarkowski A, Dorner T, Bokarewa M, Brisslert M. The human immunomodulatory CD25(+) B cell population belongs to the memory B cell pool.
Scand. J. Immunol. 66: 77-86 (2007).
*
-
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises.
Mol. Pharm. 4: 807-818 (2007).
*
-
Anandarajah AP, Ory P, Salonen D, Feng C, Wong RL, Ritchlin CT. Effect of adalimumab on joint disease features of patients with psoriatic arthritis detected by magnetic resonance imaging.
Ann. Rheum. Dis. 69: 206-209 (2010).
-
Anandarajah AP, Ritchlin CT. The diagnosis and treatment of early psoriatic arthritis.
Nat. Rev. Rheumatol. 5: 634-641 (2009).
-
Anandarajah AP, Schwarz EM. Anti-RANKL therapy for inflammatory bone disorders: mechanisms and potential clinical applications.
J. Cell. Biochem. 97: 226-232 (2006).
*
-
Ananthakrishna R, Goel R, Padhan P, Mathew J, Danda D. Relapsing polychondritis: case series from South India.
Clin. Rheumatol. 28 Suppl. 1: S7-S10 (2009).
-
Anaya JM, Correa PA, Mantilla RD, Arcos-Burgos M. Rheumatoid arthritis association in Colombian population is restricted to HLA-DRB1*04 QRRAA alleles.
Genes Immun. 3: 56-58 (2002).
*
-
Anaya JM, Correa PA, Mantilla RD, Arcos-Burgos M. TAP, HLA-DQB1, and HLA-DRB1 polymorphism in Colombian patients with primary Sjogren's syndrome.
Semin. Arthritis Rheum. 31: 396-405 (2002).
*
-
Anaya JM, Correa PA, Mantilla RD, Jimenez F, Kuffner T, McNicholl JM. Rheumatoid arthritis in African Colombians from Quibdo.
Semin. Arthritis Rheum. 31: 191-198 (2001).
*
-
Anaya JM, Mantilla RD, Correa PA. Immunogenetics of primary Sjogren's syndrome in Colombians.
Semin. Arthritis Rheum. 34: 735-743 (2005).
*
-
Anaya JM, Tobon GJ, Vega P, Castiblanco J. Autoimmune disease aggregation in families with primary Sjogren's syndrome.
J. Rheumatol. 33: 2227-2234 (2006).
-
Ancuta C, Ancuta E, Iordache C, Ceausu M, Chirieac R. Immunohistochemical study of skeletal muscle in rheumatoid myositis.
Rom. J. Morphol. Embryol. 50: 223-227 (2009).
-
Anders HJ, Zecher D, Pawar RD, Patole PS. Molecular mechanisms of autoimmunity triggered by microbial infection.
Arthritis Res. Ther. 7: 215-224 (2005).
*
-
Anderson AE, Swan DJ, Sayers BL, Harry RA, Patterson AM, von Delwig A, Robinson JH, Isaacs JD, Hilkens CM. LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells.
J. Leukoc. Biol. 85: 243-250 (2009).
*
-
Anderson DW. Cytokines as drug targets.
IDrugs 4: 375-377 (2001).
-
Anderson GM, Nakada MT, DeWitte M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer.
Curr. Opin. Pharmacol. 4: 314-320 (2004).
-
Anderson LA, Gadalla S, Morton LM, Landgren O, Pfeiffer R, Warren JL, Berndt SI, Ricker W, Parsons R, Engels EA. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies.
Int. J. Cancer 125: 398-405 (2009).
*
-
Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions.
Br. J. Cancer 100: 822-828 (2009).
*
-
Anderson P, Phillips K, Stoecklin G, Kedersha N. Post-transcriptional regulation of proinflammatory proteins.
J. Leukoc. Biol. 76: 42-47 (2004).
*
-
Andersson A. Genetic control of disease in an experimental model for Sjogren's syndrome.
Arthritis Res. Ther. 11: 102 (2009).
*
-
Andersson A, Kokkola R, Wefer J, Erlandsson-Harris H, Harris RA. Differential macrophage expression of IL-12 and IL-23 upon innate immune activation defines rat autoimmune susceptibility.
J. Leukoc. Biol. 76: 1118-1124 (2004).
*
-
Andersson AK, Feldmann M, Brennan FM. Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis.
Scand. J. Immunol. 68: 103-111 (2008).
*
-
Andersson AK, Li C, Brennan FM. Recent developments in the immunobiology of rheumatoid arthritis.
Arthritis Res. Ther. 10: 204 (2008).
*
-
Andersson EC, Svendsen P, Svejgaard A, Holmdahl R, Fugger L. A molecule basis for the HLA association in rheumatoid arthritis.
Rev. Immunogenet. 2: 81-87 (2000).
-
Andersson IE, Dzhambazov B, Holmdahl R, Linusson A, Kihlberg J. Probing molecular interactions within class II MHC A(q)/glycopeptide/T-cell receptor complexes associated with collagen-induced arthritis.
J. Med. Chem. 50: 5627-5643 (2007).
*
-
Andersson J, Tran DQ, Pesu M, Davidson TS, Ramsey H, O'Shea JJ, Shevach EM. CD4+FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner.
J. Exp. Med. 205: 1975-1981 (2008).
*
-
Andersson M, Svenungsson E, Khademi M, Lampa J, Brundin L, Wallstrom E. No signs of immunoactivation in the cerebrospinal fluid during treatment with infliximab.
Ann. Rheum. Dis. 65: 1237-1240 (2006).
*
-
Andersson ML, Petersson IF, Karlsson K, Jonsson NE, Mansson B, Heinegard D, Saxne T. Diurnal variation in serum levels of cartilage oligomeric matrix protein (COMP) in individuals with knee osteoarthritis or rheumatoid arthritis.
Ann. Rheum. Dis. 65: 1490-1494 (2006).
*
-
Andersson U, Erlandsson-Harris H. HMGB1 is a potent trigger of arthritis.
J. Intern. Med. 255: 344-350 (2004).
*
-
Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ. HMGB1 as a DNA-binding cytokine.
J. Leukoc. Biol. 72: 1084-1091 (2002).
*
-
Andersson U, Harris HE. The role of HMGB1 in the pathogenesis of rheumatic disease.
Biochim. Biophys. Acta 1799: 141-148 (2010).
*
-
Andersson U, Tracey KJ. HMGB1 in sepsis.
Scand. J. Infect. Dis. 35: 577-584 (2003).
-
Andersson U, Tracey KJ. HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis.
Rheum. Dis. Clin. North Am. 30: 627-637, xi (2004).
-
Andersson UG, Tracey KJ. HMGB1, a pro-inflammatory cytokine of clinical interest: introduction.
J. Intern. Med. 255: 318-319 (2004).
*
-
Andonopoulos AP, Skopouli FN, Dimou GS, Drosos AA, Moutsopoulos HM. Sjogren's syndrome in systemic lupus erythematosus.
J. Rheumatol. 17: 201-204 (1990).
-
Andrade RM, Alarcon GS, Fernandez M, Apte M, Vila LM, Reveille JD. Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort.
Arthritis Rheum. 56: 622-630 (2007).
*
-
Andreakos E. Common and uncommon features of rheumatoid arthritis and chronic obstructive pulmonary disease: clues to a future therapy.
Curr. Drug Targets Immune Endocr. Metabol. Disord. 4: 85-92 (2004).
-
Andreakos E, Foxwell B, Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?
Immunol. Rev. 202: 250-265 (2004).
*
-
Andreakos E, Rauchhaus U, Stavropoulos A, Endert G, Wendisch V, Benahmed AS, Giaglis S, Karras J, Lee S, Gaus H, Bennett CF, Williams RO, Sideras P, Panzner S. Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis.
Arthritis Rheum. 60: 994-1005 (2009).
*
-
Andreakos E, Sacre S, Foxwell BM, Feldmann M. The Toll-like receptor-nuclear factor kappaB pathway in rheumatoid arthritis.
Front. Biosci. 10: 2478-2488 (2005).
-
Andreas K, Haupl T, Lubke C, Ringe J, Morawietz L, Wachtel A, Sittinger M, Kaps C. Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration.
Arthritis Res. Ther. 11: R15 (2009).
*
-
Andreas K, Luebke C, Haeupl T, Dehne T, Morawietz L, Ringe J, Kaps C, Sittinger M. Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study.
Arthritis Res. Ther. 10: R9 (2008).
*
-
Andreev OA, Dupuy AD, Segala M, Sandugu S, Serra DA, Chichester CO, Engelman DM, Reshetnyak YK. Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo.
Proc. Natl. Acad. Sci. U.S.A. 104: 7893-7898 (2007).
*
-
Andren M, Johanneson B, Alarcon-Riquelme ME, Kleinau S. IgG Fc receptor polymorphisms and association with autoimmune disease.
Eur. J. Immunol. 35: 3020-3029 (2005).
*
-
Andreoli L, Malacarne F, Ceribelli A, Kutschera I, Tincani A. Anti-cardiolipin and anti-beta2-glycoprotein I antibodies: performance of new commercial ELISA kits.
Ann. N. Y. Acad. Sci. 1109: 531-537 (2007).
*
-
Andus T, Stange EF, Hoffler D, Keller-Stanislawski B. Suspected cases of severe side effects after infliximab (Remicade) in Germany.
Med. Klin. (Munich) 98: 429-436 (2003).
-
Ang HT, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?
J. Rheumatol. 30: 2315-2318 (2003).
-
Angel K, Provan SA, Gulseth HL, Mowinckel P, Kvien TK, Atar D. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies. A controlled study.
Hypertension Dec 28 [Epub ahead of print] (2009).
-
Angotti C. Arthritis and skin disease.
Skinmed. 4: 293-297 (2005).
-
Angulo JM, Sigal LH, Espinoza LR. Coexistent minocycline-induced systemic lupus erythematosus and autoimmune hepatitis.
Semin. Arthritis Rheum. 28: 187-192 (1998).
*
-
Angyal A, Prechl J, Sarmay G. Possible therapeutic applications of single-chain antibodies in systemic autoimmune diseases.
Expert Opin. Biol. Ther. 7: 691-704 (2007).
-
Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. Type 17 T helper cells - origins, features and possible roles in rheumatic disease.
Nat. Rev. Rheumatol. 5: 325-331 (2009).
-
Annunziato F, Romagnani S. Heterogeneity of human effector CD4+ T cells.
Arthritis Res. Ther. 11: 257 (2009).
-
Anolik JH, Looney RJ, Lund FE, Randall TD, Sanz I. Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets.
Immunol. Res. Apr 7 [Epub ahead of print] (2009).
*
-
Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner EC, Miller CH, Dutcher PO, Hadley JA, Sanz I. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks.
J. Immunol. 180: 688-692 (2008).
*
-
Anshu A, Chee SP. Posterior scleritis and its association with HLA B27 haplotype.
Ophthalmologica 221: 275-278 (2007).
-
Antolín J, Azahara M, Hernandez C, Blanco M, Mao L, Ciguenza R. Tuberculous peritonitis after treatment with adalimumab.
Scand. J. Infect. Dis. 40: 677-678 (2008).
-
Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, Riente L, Ferrannini E. High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis.
Autoimmunity 41: 537-542 (2008).
-
Antonelli A, Ferri C, Galeazzi M, Giannitti C, Manno D, Mieli-Vergani G, Menegatti E, Olivieri I, Puoti M, Palazzi C, Roccatello D, Vergani D, Sarzi-Puttini P, Atzeni F. HCV infection: pathogenesis, clinical manifestations and therapy.
Clin. Exp. Rheumatol. 26: S39-S47 (2008).
-
Antonelli A, Sedie AD, Fallahi P, Ferrari SM, Maccheroni M, Ferrannini E, Bombardieri S, Riente L. High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis.
J. Rheumatol. 33: 2026-2028 (2006).
-
Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Arthritis Rheum. 52: 1227-1236 (2005).
*
-
Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman DD, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen JS. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
J. Rheumatol. 35: 869-876 (2008).
-
Antoniou C, Stefanaki I, Stratigos A, Moustou E, Vergou T, Stavropoulos P, Avgerinou G, Rigopoulos D, Katsambas AD. Infliximab for the treatment of psoriasis in Greece. Four years of clinical experience at a single center.
Br. J. Dermatol. Nov 10 [Epub ahead of print] (2009).
*
-
Antoniou KM, Mamoulaki M, Malagari K, Kritikos HD, Bouros D, Siafakas NM, Boumpas DT. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease.
Clin. Exp. Rheumatol. 25: 23-28 (2007).
-
Antoniu SA. Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting?
Expert Opin. Investig. Drugs 15: 181-184 (2006).
-
Antoniu SA. Treatment options for refractory Wegener's granulomatosis: a role for rituximab?
Curr. Opin. Investig. Drugs 8: 927-932 (2007).
-
Antoniu SA. Golimumab for severe asthma.
Expert Opin. Investig. Drugs 18: 1421-1423 (2009).
-
Antoniv TT, Ivashkiv LB. Dysregulation of interleukin-10-dependent gene expression in rheumatoid arthritis synovial macrophages.
Arthritis Rheum. 54: 2711-2721 (2006).
*
-
Anzilotti C, Merlini G, Pratesi F, Tommasi C, Chimenti D, Migliorini P. Antibodies to viral citrullinated peptide in rheumatoid arthritis.
J. Rheumatol. 33: 647-651 (2006).
-
Anzilotti C, Pratesi F, Tommasi C, Migliorini P. Peptydilarginine deiminase 4 and citrullination in health and disease.
Autoimmun. Rev. Jun 17 [Epub ahead of print] (2009).
-
Anzilotti C, Riente L, Pratesi F, Chimenti D, Sedie AD, Bombardieri S, Migliorini P. IgG, IgA, IgM antibodies to a viral citrullinated peptide in patients affected by rheumatoid arthritis, chronic arthritides and connective tissue disorders.
Rheumatology (Oxford) 46: 1579-1582 (2007).
*
-
Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E, Ostroff GR, Czech MP. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation.
Nature 458: 1180-1184 (2009).
*
-
Apan TZ, Gursel R, Dolgun A. Increased seropositivity of Helicobacter pylori cytotoxin-associated gene-A in Behcet's disease.
Clin. Rheumatol. 26: 885-889 (2007).
*
-
Appel H, Kuon W, Kuhne M, Wu P, Kuhlmann S, Kollnberger S, Thiel A, Bowness P, Sieper J. Use of HLA-B27 tetramers to identify low-frequency antigen-specific T cells in Chlamydia-triggered reactive arthritis.
Arthritis Res. Ther. 6: R521-R534 (2004).
*
-
Appelboom T, Soyfoo MS. Tobacco: from pre-Columbian use to the appearance of rheumatoid arthritis in the old world?
Arthritis Rheum. Jan 28 [Epub ahead of print] (2010).
*
-
Arai A, Kitano A, Sawabe E, Kanegane H, Miyawaki T, Miura O. Relapsing Campylobacter coli bacteremia with reactive arthritis in a patient with X-linked agammaglobulinemia.
Intern. Med. 46: 605-609 (2007).
*
-
Araico A, Terencio MC, Alcaraz MJ, Dominguez JN, Leon C, Ferrandiz ML. Evaluation of the anti-inflammatory and analgesic activity of Me-UCH9, a dual cyclooxygenase-2/5-lipoxygenase inhibitor.
Life Sci. 80: 2108-2117 (2007).
*
-
Arakaki O, Yamamoto Y, Awazawa R, Nonaka K, Taira K, Asato Y, Hagiwara K, Oyama B, Ishii N, Hashimoto T, Uezato H. Case of linear immunoglobulin A bullous dermatosis associated with acquired hemophilia.
J. Dermatol. 35: 437-446 (2008).
-
Araujo EP, De Souza CT, Ueno M, Cintra DE, Bertolo MB, Carvalheira JB, Saad MJ, Velloso LA. Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes.
Endocrinology 148: 5991-5997 (2007).
*
-
Arbour L, Rupps R, Field L, Ross P, Erikson A, Henderson H, Hill W, Yoshida E. Characteristics of primary biliary cirrhosis in British Columbia's First Nations population.
Can. J. Gastroenterol. 19: 305-310 (2005).
*
-
Archer JR. Search for cross-reactivity between HLA B27 and Klebsiella pneumoniae.
Ann. Rheum. Dis. 40: 400-403 (1981).
*
-
Ardigo M, Giuliani A, de Felice C, Mastroianni A, Berardesca E. Efficacy of adalimumab in plaque psoriasis: experience on 28 patients.
J. Drugs Dermatol. 7: 935-939 (2008).
-
Ardoin SP, Pisetsky DS. Developments in the scientific understanding of lupus.
Arthritis Res. Ther. 10: 218 (2008).
*
-
Ardoin SP, Pisetsky DS. The role of cell death in the pathogenesis of autoimmune disease: HMGB1 and microparticles as intercellular mediators of inflammation.
Mod. Rheumatol. 18: 319-326 (2008).
*
-
Arend SM, Breedveld FC, van Dissel JT. TNF-alpha blockade and tuberculosis: better look before you leap.
Neth. J. Med. 61: 111-119 (2003).
*
-
Arend WP. The mode of action of cytokine inhibitors.
J. Rheumatol. Suppl. 65: 16-21 (2002).
-
Aries PM, Witte T, Lamprecht P. Report on the 34th Meeting of the German Clinical Immunology Workgroup, Frankfurt, 03.-04.11.2006.
Z. Rheumatol. 66: 63-64 (2007).
-
Arii K, Kumon Y, Sugahara K, Nakatani K, Ikeda Y, Suehiro T, Hashimoto K. Edaravone inhibits collagen-induced arthritis possibly through suppression of nuclear factor-kappa B.
Mol. Immunol. 45: 463-469 (2008).
*
-
Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor blockade in systemic lupus erythematosus: an open-label study.
Arthritis Rheum. 50: 3161-3169 (2004).
*
-
Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, Steiner G, Smolen JS. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
Rheumatology (Oxford) 48: 1451-1454 (2009).
-
Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus.
Arthritis Res. Ther. 10: 202 (2008).
*
-
Aringer M, Smolen JS. Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus.
Expert Opin. Drug Saf. 7: 411-419 (2008).
-
Aringer M, Steiner G, Graninger WB, Hofler E, Steiner CW, Smolen JS. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus.
Arthritis Rheum. 56: 274-279 (2007).
*
-
Aristodemou P, Stanford M. Therapy insight: the recognition and treatment of retinal manifestations of systemic vasculitis.
Nat. Clin. Pract. Rheumatol. 2: 443-451 (2006).
*
-
Arita K, Shimizu T, Hashimoto H, Hidaka Y, Yamada M, Sato M. Structural basis for histone N-terminal recognition by human peptidylarginine deiminase 4.
Proc. Natl. Acad. Sci. U.S.A. 103: 5291-5396 (2006).
*
-
Ariza-Ariza R, Mestanza-Peralta M, Cardiel MH. Omega-3 fatty acids in rheumatoid arthritis: an overview.
Semin. Arthritis Rheum. 27: 366-370 (1998).
-
Ariza-Ariza R, Navarro-Sarabia F, Hernandez-Cruz B, Rodriguez-Arboleya L, Navarro-Compan V, Toyos J. Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review.
Rheumatology (Oxford) 46: 529-532 (2007).
*
-
Arkfeld DG. The potential utility of B cell-directed biologic therapy in autoimmune diseases.
Rheumatol. Int. 28: 205-215 (2008).
*
-
Arkwright PD, Abinun M, Cant AJ. Autoimmunity in human primary immunodeficiency diseases.
Blood 99: 2694-2702 (2002).
*
-
Arlestig L, Wallberg Jonsson S, Stegmayr B, Rantapaa-Dahlqvist S. Polymorphism of genes related to cardiovascular disease in patients with rheumatoid arthritis.
Clin. Exp. Rheumatol. 25: 866-871 (2007).
-
Armagan O, Ekim A, Dinc A, Oner C. Ankylosing spondylitis in a patient with Turner syndrome: a case report.
Rheumatol. Int. 27: 1177-1180 (2007).
*
-
Armaka M, Apostolaki M, Jacques P, Kontoyiannis DL, Elewaut D, Kollias G. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases.
J. Exp. Med. 205: 331-337 (2008).
*
-
Arman A, Yilmaz B, Coker A, Inanc N, Direskeneli H. Interleukin-1 receptor antagonist (IL-1RN) and interleukin-1B gene polymorphisms in Turkish patients with rheumatoid arthritis.
Clin. Exp. Rheumatol. 24: 643-648 (2006).
-
Arnett FC, Hamilton RG, Reveille JD, Bias WB, Harley JB, Reichlin M. Genetic studies of Ro (SS-A) and La (SS-B) autoantibodies in families with systemic lupus erythematosus and primary Sjogren's syndrome.
Arthritis Rheum. 32: 413-419 (1989).
-
Arnett FC, Howard RF, Tan F, Moulds JM, Bias WB, Durban E, Cameron HD, Paxton G, Hodge TJ, Weathers PE, Reveille JD. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype.
Arthritis Rheum. 39: 1362-1370 (1996).
-
Arnett HA, Viney JL. Considerations for the sensible use of rodent models of inflammatory disease in predicting efficacy of new biological therapeutics in the clinic.
Adv. Drug Deliv. Rev. 59: 1084-1092 (2007).
-
Arnold JN, Dwek RA, Rudd PM, Sim RB. Mannan binding lectin and its interaction with immunoglobulins in health and in disease.
Immunol. Lett. 106: 103-110 (2006).
-
Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins.
Annu. Rev. Immunol. 25: 21-50 (2007).
*
-
Arnson Y, Shoenfeld Y, Amital H. The antiphospholipid syndrome as a neurological disease.
Semin. Arthritis Rheum. Jul 11 [Epub ahead of print] (2009).
*
-
Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity.
J. Autoimmun. Dec 28 [Epub ahead of print] (2009).
-
Arostegui JI, Aldea A, Modesto C, Rua MJ, Arguelles F, Gonzalez-Ensenat MA, Ramos E, Rius J, Plaza S, Vives J, Yague J. Clinical and genetic heterogeneity among Spanish patients with recurrent autoinflammatory syndromes associated with the CIAS1/PYPAF1/NALP3 gene.
Arthritis Rheum. 50: 4045-4050 (2004).
*
-
Arostegui JI, Arnal C, Merino R, Modesto C, Antonia Carballo M, Moreno P, Garcia-Consuegra J, Naranjo A, Ramos E, de Paz P, Rius J, Plaza S, Yague J. NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort.
Arthritis Rheum. 56: 3805-3813 (2007).
*
-
Arostegui JI, Yague J. Hereditary systemic autoinflammatory diseases. Part II: cryopyrin-associated periodic syndromes, pediatric systemic granulomatosis and PAPA syndrome.
Med. Clin. (Barc.) 130: 429-438 (2008).
-
Arrington JL, McMurray DN, Switzer KC, Fan YY, Chapkin RS. Docosahexaenoic acid suppresses function of the CD28 costimulatory membrane receptor in primary murine and Jurkat T cells.
J. Nutr. 131: 1147-1153 (2001).
*
-
Arshadi N, Chang B, Kustra R. Predictive modeling in case-control single-nucleotide polymorphism studies in the presence of population stratification: a case study using Genetic Analysis Workshop 16 Problem 1 dataset.
BMC Proc. 3 Suppl. 7: S60 (2009).
*
-
Artac H, Bozkurt B, Talim B, Reisli I. Sarcoid-like granulomas in common variable immunodeficiency.
Rheumatol. Int. Mar 27 [Epub ahead of print] (2009).
*
-
Artlett CM, O'Hanlon TP, Lopez AM, Song YW, Miller FW, Rider LG. HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals.
Arthritis Rheum. 48: 2567-2572 (2003).
*
-
Arundel C, Lewis JH. Drug-induced liver disease in 2006.
Curr. Opin. Gastroenterol. 23: 244-254 (2007).
-
Arvidson NG, Larsen A, Aaseth J, Larsson A. Short-term effects of the TNFalpha antagonist infliximab on the acute phase reaction and activities of daily life in patients with rheumatoid arthritis.
Scand. J. Clin. Lab. Invest. 67: 337-342 (2007).
*
-
Asada Y, Isomoto H, Shikuwa S, Wen CY, Fukuda E, Miyazato M, Okamoto K, Nakamura T, Nishiyama H, Mizuta Y, Migita K, Ito M, Kohno S. Development of ulcerative colitis during the course of rheumatoid arthritis: association with selective IgA deficiency.
World J. Gastroenterol. 12: 5240-5243 (2006).
*
-
Asagiri M, Hirai T, Kunigami T, Kamano S, Gober HJ, Okamoto K, Nishikawa K, Latz E, Golenbock DT, Aoki K, Ohya K, Imai Y, Morishita Y, Miyazono K, Kato S, Saftig P, Takayanagi H. Cathepsin K-dependent Toll-like receptor 9 signaling revealed in experimental arthritis.
Science 319: 624-627 (2008).
*
-
Asarch A, Barak O, Loo DS, Gottlieb AB. Th17 cells: a new therapeutic target in inflammatory dermatoses.
J. Dermatolog. Treat. 19: 318-326 (2008).
*
-
Asashima N, Fujimoto M, Watanabe R, Nakashima H, Yazawa N, Okochi H, Tamaki K. Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris.
Br. J. Dermatol. 155: 330-336 (2006).
*
-
Aseni P, Di Sandro S, Mihaylov P, Lamperti L, De Carlis LG. Atypical presentation of pioderma gangrenosum complicating ulcerative colitis: rapid disappearance with methylprednisolone.
World J. Gastroenterol. 14: 5471-5473 (2008).
*
-
Ashino T, Arima Y, Shioda S, Iwakura Y, Numazawa S, Yoshida T. Effect of interleukin-6 neutralization on CYP3A11 and metallothionein-1/2 expressions in arthritic mouse liver.
Eur. J. Pharmacol. 558: 199-207 (2007).
*
-
Ashok D, Dubey S, Tomlinson I. C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab.
Clin. Rheumatol. 27: 261-264 (2008).
*
-
Ashok D, Kiely P. Bowel associated dermatosis - arthritis syndrome: a case report.
J. Med. Case Reports 1: 81 (2007).
*
-
Askanase A, Izmirly P, Katholi M, Mumtaz J, Buyon J. Frequency of neuro-psychiatric dysfunction in anti-SSA/SSB exposed children with and without neonatal lupus.
Lupus Dec 14 [Epub ahead of print] (2009).
-
Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, Bertilsson L, Coster L, Jacobsson L, Lindblad S, Lysholm J, Rantapaa-Dahlqvist S, Saxne T, van Vollenhoven R, Klareskog L, Feltelius N. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.
Ann. Rheum. Dis. 68: 648-653 (2009).
-
Askling J, Bongartz T. Malignancy and biologic therapy in rheumatoid arthritis.
Curr. Opin. Rheumatol. 20: 334-339 (2008).
-
Askling J, Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis.
Curr. Opin. Rheumatol. 20: 138-144 (2008).
-
Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Coster L, Geborek P, Jacobsson LT, Lindblad S, Rantapaa-Dahlqvist S, Saxne T, Klareskog L. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Arthritis Rheum. 60: 3180-3189 (2009).
*
-
Aslanidis S, Pyrpasopoulou A, Douma S, Triantafyllou A. Tumor necrosis factor-a antagonist-induced psoriasis: yet another paradox in medicine.
Clin. Rheumatol. 27: 377-380 (2008).
*
-
Asquith DL, McInnes IB. Emerging cytokine targets in rheumatoid arthritis.
Curr. Opin. Rheumatol. 19: 246-251 (2007).
*
-
Asquith DL, Miller AM, Hueber AJ, McKinnon HJ, Sattar N, Graham GJ, McInnes IB. Liver X receptor agonism promotes articular inflammation in murine collagen-induced arthritis.
Arthritis Rheum. 60: 2655-2665 (2009).
*
-
Asquith DL, Miller AM, McInnes IB, Liew FY. Animal models of rheumatoid arthritis.
Eur. J. Immunol. 39: 2040-2044 (2009).
*
-
Assassi S, Del Junco D, Sutter K, McNearney TA, Reveille JD, Karnavas A, Gourh P, Estrada-Y-Martin RM, Fischbach M, Arnett FC, Mayes MD. Clinical and genetic factors predictive of mortality in early systemic sclerosis.
Arthritis Rheum. 61: 1403-1411 (2009).
*
-
Assi LK, Wong SH, Ludwig A, Raza K, Gordon C, Salmon M, Lord JM, Scheel-Toellner D. Tumor necrosis factor alpha activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint.
Arthritis Rheum. 56: 1776-1786 (2007).
*
-
Assmann G, Wagner AD, Monika M, Pfoehler C, Pfreundschuh M, Tilgen W, Roemer K. Single-nucleotide polymorphisms p53 G72C and Mdm2 T309G in patients with psoriasis, psoriatic arthritis, and SAPHO syndrome.
Rheumatol. Int. Sep 25 [Epub ahead of print] (2009).
*
-
Assous N, Gossec L, Dieude P, Meyer O, Dougados M, Kahan A, Allanore Y. Rituximab therapy in rheumatoid arthritis in daily practice.
J. Rheumatol. 35: 31-34 (2008).
-
Assuncao-Miranda I, Bozza MT, Da Poian AT. Pro-inflammatory response resulting from sindbis virus infection of human macrophages: implications for the pathogenesis of viral arthritis.
J. Med. Virol. 82: 164-174 (2009).
*
-
Astorga G, Cubillos A, Masson L, Silva JJ. Active rheumatoid arthritis: effect of dietary supplementation with omega-3 oils. A controlled double-blind trial.
Rev. Med. Chil. 119: 267-272 (1991).
-
Atagunduz P, Appel H, Kuon W, Wu P, Thiel A, Kloetzel PM, Sieper J. HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis.
Arthritis Rheum. 52: 892-901 (2005).
*
-
Atchia II, Kidd CE, Bell RW. Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab.
J. Clin. Rheumatol. 12: 291-293 (2006).
-
Ates A, Karaaslan Y, Aksaray S. Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis.
Clin. Rheumatol. 26: 499-504 (2007).
*
-
Ates A, Kinikli G, Turgay M, Akay G, Tokgoz G. Effects of rheumatoid factor isotypes on disease activity and severity in patients with rheumatoid arthritis: a comparative study.
Clin. Rheumatol. 26: 538-545 (2007).
*
-
Ates A, Kinikli G, Turgay M, Duman M. The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis.
Clin. Rheumatol. 23: 421-425 (2004).
*
-
Ates A, Turkcapar N, Olmez U, Tiryaki O, Duzgun N, Uguz E, Duman M. Serum pro-matrix metalloproteinase-3 as an indicator of disease activity and severity in rheumatoid arthritis: comparison with traditional markers.
Rheumatol. Int. 27: 715-722 (2007).
*
-
Ates O, Dalyan L, Musellim B, Hatemi G, Turker H, Ongen G, Hamuryudan V, Topal-Sarikaya A. NRAMP1 (SLC11A1) gene polymorphisms that correlate with autoimmune versus infectious disease susceptibility in tuberculosis and rheumatoid arthritis.
Int. J. Immunogenet. 36: 15-19 (2009).
*
-
Ates O, Hatemi G, Hamuryudan V, Topal-Sarikaya A. Tumor necrosis factor-alpha and interleukin-10 gene promoter polymorphisms in Turkish rheumatoid arthritis patients.
Clin. Rheumatol. 27: 1243-1248 (2008).
*
-
Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections.
FEMS Microbiol. Rev. 32: 956-973 (2008).
*
-
Atladottir HO, Pedersen MG, Thorsen P, Mortensen PB, Deleuran B, Eaton WW, Parner ET. Association of family history of autoimmune diseases and autism spectrum disorders.
Pediatrics 124: 687-694 (2009).
*
-
Atouf O, Benbouazza K, Brick C, Bzami F, Bennani N, Amine B, Hajja-Hassouni N, Essakali M. HLA polymorphism and early rheumatoid arthritis in the Moroccan population.
Joint Bone Spine 75: 554-558 (2008).
*
-
Atsumi T, Amengual O, Yasuda S, Koike T. Antiprothrombin antibodies-are they worth assaying?
Thromb. Res. 114: 533-538 (2004).
*
-
Atta AM, Carvalho EM, Jeronimo SM, Sousa Atta ML. Serum markers of rheumatoid arthritis in visceral leishmaniasis: rheumatoid factor and anti-cyclic citrullinated peptide antibody.
J. Autoimmun. 28: 55-58 (2007).
-
Atteno M, Peluso R, Costa L, Padula S, Iervolino S, Caso F, Sanduzzi A, Lubrano E, Del Puente A, Scarpa R. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.
Clin. Rheumatol. Jan 12 [Epub ahead of print] (2010).
*
-
Atzeni F, Antivalle M, Pallavicini FB, Caporali R, Bazzani C, Gorla R, Favalli EG, Marchesoni A, Sarzi-Puttini P. Predicting response to anti-TNF treatment in rheumatoid arthritis patients.
Autoimmun. Rev. 8: 431-437 (2009).
-
Atzeni F, Ardizzone S, Bertani L, Antivalle M, Batticciotto A, Sarzi-Puttini P. Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis.
World J. Gastroenterol. 15: 2469-2471 (2009).
*
-
Atzeni F, Bendtzen K, Bobbio-Pallavicini F, Conti F, Cutolo M, Montecucco C, Sulli A, Valesini G, Sarzi-Puttini P. Infections and treatment of patients with rheumatic diseases.
Clin. Exp. Rheumatol. 26: S67-S73 (2008).
-
Atzeni F, Doria A, Carrabba M, Turiel M, Sarzi-Puttini P. Potential target of infliximab in autoimmune and inflammatory diseases.
Autoimmun. Rev. 6: 529-536 (2007).
-
Atzeni F, Doria A, Ghirardello A, Villalta D, Zampieri S, Carrabba M, Sarzi-Puttini P. Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: a prospective long-term follow-up.
Autoimmunity 41: 87-91 (2008).
-
Atzeni F, Doria A, Maurizio T, Sarzi-Puttini P. What is the role of rituximab in the treatment of rheumatoid arthritis?
Autoimmun. Rev. 6: 553-558 (2007).
-
Atzeni F, Sarzi-Puttini P. Early rheumatoid arthritis.
Reumatismo 59: 100-117 (2007).
-
Atzeni F, Sarzi-Puttini P. Anti-cytokine antibodies for rheumatic diseases.
Curr. Opin. Investig. Drugs 10: 1204-1211 (2009).
-
Atzeni F, Sarzi-Puttini P, Deportu S, Cutolo M, Carrabba M, Straub RH. In etanercept-treated psoriatic arthritis patients clinical improvement correlated with an increase of serum cortisol relative to other adrenal hormones.
Clin. Exp. Rheumatol. 26: 103-108 (2008).
-
Atzeni F, Sarzi-Puttini P, Doria A, Iaccarino L, Capsoni F. Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review.
Autoimmun. Rev. 4: 144-152 (2005).
-
Atzeni F, Sarzi-Puttini P, Vena GA. Resistant cases of psoriatic arthritis: how to manage them.
J. Rheumatol. Suppl. 83: 73-75 (2009).
-
Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P. Autoimmunity and anti-TNF-alpha agents.
Ann. N. Y. Acad. Sci. 1051: 559-569 (2005).
*
-
Au-Yeung BB, Deindl S, Hsu LY, Palacios EH, Levin SE, Kuriyan J, Weiss A. The structure, regulation, and function of ZAP-70.
Immunol. Rev. 228: 41-57 (2009).
*
-
Auci D, Kaler L, Subramanian S, Huang Y, Frincke J, Reading C, Offner H. A new orally bioavailable synthetic androstene inhibits collagen-induced arthritis in the mouse: androstene hormones as regulators of regulatory T cells.
Ann. N. Y. Acad. Sci. 1110: 630-640 (2007).
*
-
Auci DL, Mangano K, Destiche D, White SK, Huang Y, Boyle D, Frincke J, Reading CL, Nicoletti F. Oral treatment with HE3286 ameliorates disease in rodent models of rheumatoid arthritis.
Int. J. Mol. Med. 25: 625-633 (2010).
-
Aud D, Peng SL. Mechanisms of disease: transcription factors in inflammatory arthritis.
Nat. Clin. Pract. Rheumatol. 2: 434-442 (2006).
*
-
Audo R, Combe B, Coulet B, Morel J, Hahne M. The pleiotropic effect of TRAIL on tumor-like synovial fibroblasts from rheumatoid arthritis patients is mediated by caspases.
Cell Death Differ. 16: 1227-1237 (2009).
*
-
Audrain MA, Gourbil A, Muller JY, Esnault LM. Anti-lactoferrin autoantibodies: relation between epitopes and iron-binding domain.
J. Autoimmun. 9: 569-574 (1996).
-
Augello A, Tasso R, Negrini SM, Cancedda R, Pennesi G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis.
Arthritis Rheum. 56: 1175-1186 (2007).
*
-
Auger I, Ragni E, Reviron D, Rossi D, Roudier J. Immune response to 70 kD heat shock proteins and rheumatoid arthritis: implication of HLA-DRB1*0401.
Clin. Exp. Rheumatol. 25: 933-934 (2007).
-
Auger I, Roudier C, Guis S, Balandraud N, Roudier J. HLA-DRB1*0404 is strongly associated with anti-calpastatin antibodies in rheumatoid arthritis.
Ann. Rheum. Dis. 66: 1588-1593 (2007).
-
Auger I, Sebbag M, Vincent C, Balandraud N, Guis S, Nogueira L, Svensson B, Cantagrel A, Serre G, Roudier J. Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen.
Arthritis Rheum. 52: 3424-3432 (2005).
*
-
Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany.
Acta Derm. Venereol. 90: 147-151 (2010).
-
Aune TM, Maas K, Moore JH, Olsen NJ. Gene expression profiles in human autoimmune disease.
Curr. Pharm. Des. 9: 1905-1917 (2003).
-
Aune TM, Maas K, Parker J, Moore JH, Olsen NJ. Profiles of gene expression in human autoimmune disease.
Cell. Biochem. Biophys. 40: 81-96 (2004).
-
Avalos P, Camacho FM. Practical management of adalimumab.
Actas. Dermosifiliogr. 99 Suppl. 3: 25-27 (2008).
-
Aversano M, Caiazzo P, Iorio G, Ponticiello L, Lagana B, Leccese F. Improvement of chronic idiopathic urticaria with L-thyroxine: a new TSH role in immune response?
Allergy 60: 489-493 (2005).
*
-
Aviel YB, Tyrrell PN, Schneider R, Dhillon S, Feldman BM, Laxer RM, Saurenmann RK, Spiegel L, Cameron B, Tse SM, Silverman ED. Comparison of patients with juvenile psoriatic arthritis and nonpsoriatic juvenile idiopathic arthritis: how different are they?
J. Rheumatol. 36: 2033-2041 (2009).
-
Avila-Portillo LM, Vargas-Alarcon G, Andrade F, Alarcon-Segovia D, Granados J. Linkage disequilibrium of HLA-DR3 and HLA-DR4 with HLA-B alleles in Mexican patients with rheumatoid arthritis.
Clin. Exp. Rheumatol. 12: 497-502 (1994).
-
Avnir Y, Ulmansky R, Wasserman V, Even-Chen S, Broyer M, Barenholz Y, Naparstek Y. Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: a novel approach to treating autoimmune arthritis.
Arthritis Rheum. 58: 119-129 (2007).
*
-
Avnon LS, Abu-Shakra M, Flusser D, Heimer D, Sion-Vardy N. Pleural effusion associated with rheumatoid arthritis: what cell predominance to anticipate?
Rheumatol. Int. 27: 919-925 (2007).
*
-
Avouac J, Airo P, Dieude P, Caramaschi P, Tiev K, Diot E, Sibilia J, Cappelli S, Granel B, Vacca A, Wipff J, Meyer O, Kahan A, Matucci-Cerinic M, Allanore Y. Associated autoimmune diseases in systemic sclerosis define a subset of patients with milder disease: results from 2 large cohorts of European Caucasian patients.
J. Rheumatol. Jan 28 [Epub ahead of print] (2010).
-
Avouac J, Allanore Y. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.
Expert Opin. Pharmacother. 9: 1121-1128 (2008).
-
Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-CCP (cyclic citrullinated protein) antibodies in rheumatoid arthritis: a systematic literature review.
Ann. Rheum. Dis. 65: 845-851 (2006).
*
-
Avriel A, Zeller L, Flusser D, Abu Shakra M, Halevy S, Sukenik S. Coexistence of psoriatic arthritis and systemic lupus erythematosus.
Isr. Med. Assoc. J. 9: 48-49 (2007).
*
-
Awale M, Mohan CG. Molecular docking guided 3D-QSAR CoMFA analysis of N-4-pyrimidinyl-1H-indazol-4-amine inhibitors of leukocyte-specific protein tyrosine kinase.
J. Mol. Model. 14: 937-947 (2008).
-
Axmann R, Bohm C, Kronke G, Zwerina J, Smolen J, Schett G. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo.
Arthritis Rheum. 60: 2747-2756 (2009).
*
-
Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J, Herrmann M, Smolen J, Schett G. CTLA-4 directly inhibits osteoclast formation.
Ann. Rheum. Dis. 67: 1603-1609 (2008).
-
Ayala F, Ayala F. Clinical aspects and comorbidities of psoriasis.
J. Rheumatol. Suppl. 83: 19-20 (2009).
-
Ayaz NA, Demirkaya E, Bilginer Y, Ozcelik U, Cobanoglu N, Kiper N, Besbas N, Bakkaloglu A, Ozen S. Preventing tuberculosis in children receiving anti-TNF treatment.
Clin. Rheumatol. Jan 19 [Epub ahead of print] (2010).
*
-
Aydin G, Keles I, Atalar E, Orkun S. Extensive erosive arthropathy in a patient with Behcet's disease: case report.
Clin. Rheumatol. 24: 645-647 (2005).
*
-
Aydinli B, Ozturk G, Balik AA, Aslan S, Erdogan F. Spontaneous rupture of the spleen in secondary amyloidosis: a patient with rheumatoid arthritis.
Amyloid 13: 160-163 (2006).
-
Aydog E, Yesilli O, Sever A, Usan H. Dermatitis herpetiformis and rheumatoid arthritis.
Saudi Med. J. 27: 881-884 (2006).
-
Ayer LM, Rubin RL, Dixon GH, Fritzler MJ. Antibodies to HMG proteins in patients with drug-induced autoimmunity.
Arthritis Rheum. 37: 98-103 (1994).
-
Azar D, Martin F. Paediatric uveitis: a Sydney clinic experience.
Clin. Experiment. Ophthalmol. 32: 468-471 (2004).
-
Azevedo PM, Bauer R, Caparbo VD, Silva CA, Bonfa E, Pereira RM. Interleukin-1 receptor antagonist gene (IL1RN) polymorphism possibly associated to severity of rheumatic carditis in a Brazilian cohort.
Cytokine Oct 10 [Epub ahead of print] (2009).
-
Azizan NZ, Gangaram HB, Hussein SH. A novel therapy for the treatment of pyoderma gangrenosum.
Med. J. Malaysia 63: 51-54 (2008).
-
Azuma T, Ishimaru H, Hatta K, Kori Y. Improved response to infliximab after leukocytapheresis in a patent with rheumatoid arthritis.
Mod. Rheumatol. 17: 253-255 (2007).
*
-
Azuma T, Zhu G, Xu H, Rietz AC, Drake CG, Matteson EL, Chen L. Potential role of decoy B7-H4 in the pathogenesis of rheumatoid arthritis: a mouse model informed by clinical data.
PLoS Med. 6: e1000166 (2009).
*
-
B'chir Hamzaoui S, Harmel A, Bouslama K, Abdallah M, Ennafaa M, M'rad S, Ben Dridi M; le groupe tunisien d'etude sur la maladie de Behcet. Behcet's disease in Tunisia. Clinical study of 519 cases.
Rev. Med. Interne. 27: 742-750 (2006).
-
Baba N, Rubio M, Sarfati M. Interplay between CD45RA+ regulatory T cells and TNF-alpha in the regulation of human Th17 differentiation.
Int. Immunol. Feb 24 [Epub ahead of print] (2010).
-
Babic-Naglic D. Early rheumatoid arthritis.
Reumatizam 55: 26-33 (2008).
-
Babyn P, Doria AS. Radiologic investigation of rheumatic diseases.
Pediatr. Clin. North Am. 52: 373-411 (2005).
-
Bacanli A, Sallakci N, Yavuzer U, Alpsoy E, Yegin O. Toll-like receptor 2 Arg753Gln gene polymorphism in Turkish patients with Behcet's disease.
Clin. Exp. Dermatol. 31: 699-701 (2006).
*
-
Baccala R, Smith LR, Vestberg M, Peterson PA, Cole BC, Theofilopoulos AN. Mycoplasma arthritidis mitogen. V beta engaged in mice, rats, and humans, and requirement of HLA-DR alpha for presentation.
Arthritis Rheum. 35: 434-442 (1992).
-
Bacchetta J, Ranchin B, Brunet AS, Bouvier R, Duquesne A, Edery P, Fabien N, Peretti N. Autoimmune hypoparathyroidism in a 12-year-old girl with McKusick cartilage hair hypoplasia.
Pediatr. Nephrol. 24: 2449-2453 (2009).
-
Bache I, Nielsen NM, Rostgaard K, Tommerup N, Frisch M. Autoimmune diseases in a Danish cohort of 4,866 carriers of constitutional structural chromosomal rearrangements.
Arthritis Rheum. 56: 2402-2409 (2007).
*
-
Bacher S, Schmitz ML. The NF-kappa B pathway as a potential target for autoimmune disease therapy.
Curr. Pharm. Des. 10: 2827-2837 (2004).
-
Bachmann C, Lehr D, Janhsen E, Sambach H, Muehlan H, von Gontard A, Bachmann H. Health related quality of life of a tertiary referral center population with urinary incontinence using the DCGM-10 questionnaire.
J. Urol. 182: S2000-S2006 (2009).
-
Bachmeyer C, Rohaut B. Sarcoidosis mimicking rheumatoid arthritis.
Presse. Med. 35: 623-624 (2006).
-
Backdahl L, Guo JP, Jagodic M, Becanovic K, Ding B, Olsson T, Lorentzen JC. Definition of arthritis candidate risk genes by combining rat linkage-mapping results with human case control association data.
Ann. Rheum. Dis. 68: 1925-1932 (2009).
*
-
Backhaus M, Ohrndorf S, Kellner H, Strunk J, Backhaus TM, Hartung W, Sattler H, Albrecht K, Kaufmann J, Becker K, Sorensen H, Meier L, Burmester GR, Schmidt WA. Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project.
Arthritis Rheum. 61: 1194-1201 (2009).
*
-
Badelon I. Eye and spondylarthropathies.
Rev. Prat. 49: 1995-1998 (1999).
-
Badot V, Galant C, Nzeusseu Toukap A, Theate I, Maudoux AL, Van den Eynde BJ, Durez P, Houssiau FA, Lauwerys BR. Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis.
Arthritis Res. Ther. 11: R57 (2009).
*
-
Badsha H, Kong KO, Tak PP. Rheumatoid arthritis in the United Arab Emirates.
Clin. Rheumatol. 27: 739-472 (2008).
*
-
Bae E, Kim WJ, Kang YM, Suk K, Koh EM, Cha HS, Ahn KS, Huh TL, Lee WH. Glucocorticoid-induced tumour necrosis factor receptor-related protein-mediated macrophage stimulation may induce cellular adhesion and cytokine expression in rheumatoid arthritis.
Clin. Exp. Immunol. 148: 410-418 (2007).
*
-
Bae S, Choi J, Hong J, Lee S, Her E, Choi W, Kim S, Choi Y, Kim S. Generation of anti-proteinase 3 monoclonal antibodies and development of immunological methods to detect endogenous proteinase 3.
Hybridoma (Larchmt.) 29: 17-26 (2010).
-
Bae SC, Jung WJ, Lee EJ, Yu R, Sung MK. Effects of antioxidant supplements intervention on the level of plasma inflammatory molecules and disease severity of rheumatoid arthritis patients.
J. Am. Coll. Nutr. 28: 56-62 (2009).
*
-
Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L. Rheumatoid arthritis and malignant lymphomas.
Curr. Opin. Rheumatol. 16: 254-261 (2004).
-
Baecklund E, Backlin C, Iliadou A, Granath F, Ekbom A, Amini RM, Feltelius N, Enblad G, Sundstrom C, Klareskog L, Askling J, Rosenquist R. Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis.
Arthritis Rheum. 54: 3774-3781 (2006).
*
-
Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundstrom C, Klareskog L. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.
Arthritis Rheum. 54: 692-701 (2006).
*
-
Baerwald CG, Panayi GS, Lanchbury JS. Corticotropin releasing hormone promoter region polymorphisms in rheumatoid arthritis.
J. Rheumatol. 24: 215-216 (1997).
-
Baeten D, De Keyser F, Veys EM, Theate Y, Houssiau FA, Durez P. Tumour necrosis factor alpha independent disease mechanisms in rheumatoid arthritis: a histopathological study on the effect of infliximab on rheumatoid nodules.
Ann. Rheum. Dis. 63: 489-493 (2004).
*
-
Baeten D, Kruithof E, Breban M, Tak PP. Spondylarthritis in the absence of B lymphocytes.
Arthritis Rheum. 58: 730-733 (2008).
*
-
Baeten D, Peene I, Union A, Meheus L, Sebbag M, Serre G, Veys EM, De Keyser F. Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies.
Arthritis Rheum. 44: 2255-2262 (2001).
-
Baeten D, Steenbakkers PG, Rijnders AM, Boots AM, Veys EM, De Keyser F. Detection of major histocompatibility complex/human cartilage gp-39 complexes in rheumatoid arthritis synovitis as a specific and independent histologic marker.
Arthritis Rheum. 50: 444-451 (2004).
*
-
Bagnari V, Colina M, Ciancio G, Govoni M, Trotta F. Adult-onset Still's disease.
Rheumatol. Int. Dec 18 [Epub ahead of print] (2009).
*
-
Bagnato G, De Filippis LG, Caliri A, Bruno A, Gambardella N, Muscatello MR, Cambria R, Zoccali R. Comparation of levels of anxiety and depression in patients with autommune and chronic-degenerative rheumatic: preliminary data.
Reumatismo 58: 206-211 (2006).
-
Baharav E, Bar-Yehuda S, Madi L, Silberman D, Rath-Wolfson L, Halpren M, Ochaion A, Weinberger A, Fishman P. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models.
J. Rheumatol. 32: 469-476 (2005).
-
Baharav E, Mor F, Halpern M, Quintana F, Weinberger A. Tropomyosin-induced arthritis in rats.
Clin. Exp. Rheumatol. 25: S86-S92 (2007).
-
Baharav E, Mor F, Halpern M, Weinberger A. Lactobacillus GG bacteria ameliorate arthritis in Lewis rats.
J. Nutr. 134: 1964-1969 (2004).
*
-
Bai S, Kitaura H, Zhao H, Chen J, Muller JM, Schule R, Darnay B, Novack DV, Ross FP, Teitelbaum SL. FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner.
J. Clin. Invest. 115: 2742-2751 (2005).
*
-
Baici A, Muntener K, Willimann A, Zwicky R. Regulation of human cathepsin B by alternative mRNA splicing: homeostasis, fatal errors and cell death.
Biol. Chem. 387: 1017-1021 (2006).
-
Baidoo L, Lichtenstein GR. What next after infliximab?
Am. J. Gastroenterol. 100: 80-83 (2005).
*
-
Baier G, Asadullah K, Zugel U. The immunological synapse: kinases in T cell signalling as potential drug targets.
Immunol. Lett. 105: 3-5 (2006).
-
Baig MA, Aksoy T, McClain D, Fomberstein B. Calciphylaxis in a hemodialysis patient on corticosteroids and etanercept for psoriatic arthritis.
J. Clin. Rheumatol. Feb 2 [Epub ahead of print] (2010).
-
Baig S, Alamgir M. The extrahepatic manifestations of hepatitis B virus.
J. Coll. Physicians Surg. Pak. 18: 451-457 (2008).
-
Baillat D, Leprivier G, Regnier D, Vintonenko N, Begue A, Stehelin D, Aumercier M. Stromelysin-1 expression is activated in vivo by Ets-1 through palindromic head-to-head Ets binding sites present in the promoter.
Oncogene 25: 5764-5776 (2006).
*
-
Baines M, Ebringer A. HLA and disease.
Mol. Aspects Med. 13: 263-378 (1992).
*
-
Bajpai M. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
IDrugs 12: 174-185 (2009).
-
Bajtner E, Nandakumar KS, Engstrom A, Holmdahl R. Chronic development of collagen-induced arthritis is associated with arthritogenic antibodies against specific epitopes on type II collagen.
Arthritis Res. Ther. 7: R1148-R1157 (2005).
*
-
Baka Z, Buzas E, Nagy G. Rheumatoid arthritis and smoking: putting the pieces together.
Arthritis Res. Ther. 11: 238 (2009).
-
Baka Z, Senolt L, Vencovsky J, Mann H, Simon PS, Kittel A, Buzas E, Nagy G. Increased serum concentration of immune cell derived microparticles in polymyositis/dermatomyositis.
Immunol. Lett. Dec 28 [Epub ahead of print] (2009).
-
Baker DE. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody.
Rev. Gastroenterol. Disord. 4: 196-210 (2004).
*
-
Baker KP. BLyS-an essential survival factor for B cells: basic biology, links to pathology and therapeutic target.
Autoimmun. Rev. 3: 368-375 (2004).
-
Bakland G, Nordvag BY, Nossent HC. Efficacy of anti-tumour necrosis factor alpha therapy with etanercept in chronic polyarthritis.
Tidsskr. Nor. Laegeforen. 123: 2561-2564 (2003).
-
Bakland G, Nossent HC, Gran JT. Incidence and prevalence of ankylosing spondylitis in Northern Norway.
Arthritis Rheum. 53: 850-855 (2005).
*
-
Bala SV, Forslind K, Mansson ME. Self-reported outcomes during treatment with tumour necrosis factor alpha inhibitors in patients with rheumatoid arthritis.
Musculoskeletal Care Nov 6 [Epub ahead of print] (2009).
-
Balaban B, Yasar E, Ozgul A, Dincer K, Kalyon TA. Sacroiliitis in familial Mediterranean fever and seronegative spondyloarthropathy: importance of differential diagnosis.
Rheumatol. Int. 25: 641-644 (2005).
*
-
Balada E, Ordi-Ros J, Vilardell-Tarres M. Molecular mechanisms mediated by human endogenous retroviruses (HERVs) in autoimmunity.
Rev. Med. Virol. 19: 273-286 (2009).
-
Balandraud N, Gouret P, Danchin EG, Blanc M, Zinn D, Roudier J, Pontarotti P. A rigorous method for multigenic families' functional annotation: the peptidyl arginine deiminase (PADs) proteins family example.
BMC Genomics 6: 153 (2005).
*
-
Balandraud N, Guis S, Baptiste Meynard J, Auger I, Roudier J, Roudier C. Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase Epstein-Barr virus load in patients with rheumatoid arthritis.
Arthritis Rheum. 57: 762-767 (2007).
*
-
Balandraud N, Roudier J, Roudier C. Epstein-Barr virus and rheumatoid arthritis.
Autoimmun. Rev. 3: 362-367 (2004).
-
Balbir-Gurman A, Guralnik L, Best LA, Vlodavsky E, Yigla M, Menahem Nahir A, Braun-Moscovici Y. Accelerated pulmonary nodulosis and sterile pleural effusion in a patient with psoriatic arthropathy during methotrexate therapy: a case report.
J. Clin. Rheumatol. 15: 29-30 (2009).
-
Balbir-Gurman A, Schapira D, Nahir M. Arthritis related to ileal pouchitis following total proctocolectomy for ulcerative colitis.
Semin. Arthritis Rheum. 30: 242-248 (2001).
*
-
Baldassano VF Jr. Ocular manifestations of rheumatic diseases.
Curr. Opin. Ophthalmol. 9: 85-88 (1998).
-
Baldassarre ME, Altomare MA, Fanelli M, Carbone D, Di Bitonto G, Mautone A, Laforgia N. Does calprotectin represent a regulatory factor in host defense or a drug target in inflammatory disease?
Endocr. Metab. Immune Disord. Drug Targets 7: 1-5 (2007).
-
Baldessarini RJ. Neuropharmacology of S-adenosyl-L-methionine.
Am. J. Med. 83: 95-103 (1987).
-
Balding J, Kane D, Livingstone W, Mynett-Johnson L, Bresnihan B, Smith O, FitzGerald O. Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity.
Arthritis Rheum. 48: 1408-1413 (2003).
*
-
Balducci-Silano PL, Layrisse ZE. HLA-DP and susceptibility to insulin-dependent diabetes mellitus in an ethnically mixed population. Associations with other HLA-alleles.
J. Autoimmun. 8: 425-437 (1995).
-
Baldwin HM, Ito-Ihara T, Isaacs JD, Hilkens CM. TNFalpha blockade impairs dendritic cell survival and function in rheumatoid arthritis.
Ann. Rheum. Dis. Sep 22 [Epub ahead of print] (2009).
-
Baldys-Waligorska A, Kusnierz-Cabala B, Huszno B. A special case of thyroid associated ophthalmopathy in the course of Graves-Basedow disease.
Endokrynol. Pol. 57: 536-540 (2006).
-
Balga R, Wetterwald A, Portenier J, Dolder S, Mueller C, Hofstetter W. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro.
Bone 39: 325-335 (2006).
*
-
Ball R, Shadomy SV, Meyer A, Huber BT, Leffell MS, Zachary A, Belotto M, Hilton E, Bryant-Genevier M, Schriefer ME, Miller FW, Braun MM. HLA type and immune response to Borrelia burgdorferi outer surface protein a in people in whom arthritis developed after Lyme disease vaccination.
Arthritis Rheum. 60: 1179-1186 (2009).
*
-
Ballard DH, Aporntewan C, Lee JY, Lee JS, Wu Z, Zhao H. A pathway analysis applied to Genetic Analysis Workshop 16 genome-wide rheumatoid arthritis data.
BMC Proc. 3 Suppl. 7: S91 (2009).
*
-
Balog A, Gal J, Gyulai Z, Zsilak S, Mandi Y. Tumour necrosis factor-alpha and heat-shock protein 70-2 gene polymorphisms in a family with rheumatoid arthritis.
Acta Microbiol. Immunol. Hung. 51: 263-269 (2004).
-
Balog A, Klausz G, Gal J, Molnar T, Nagy F, Ocsovszky I, Gyulai Z, Mandi Y. Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis.
Pathobiology 71: 274-280 (2004).
-
Balsa A, Pascual-Salcedo D, Martín J. Antibodies to citrullinated peptides in rheumathoid arthritis.
Med. Clin. (Barc.) 128: 668-673 (2007).
-
Bamias G, Siakavellas SI, Stamatelopoulos KS, Chryssochoou E, Papamichael C, Sfikakis PP. Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis.
Clin. Immunol. 129: 249-255 (2008).
-
Ban Y, Taniyama M, Tozaki T, Tomita M, Ban Y. Estrogen receptor alpha dinucleotide repeat polymorphism in Japanese patients with autoimmune thyroid diseases.
BMC Med. Genet. 1: 1 (2000).
*
-
Ban Y, Tozaki T, Taniyama M, Nakano Y, Yoneyama KI, Ban Y, Hirano T. Association studies of the IL-23R gene in autoimmune thyroid disease in the Japanese population.
Autoimmunity 42: 126-130 (2009).
-
Banda NK, Levitt B, Glogowska MJ, Thurman JM, Takahashi K, Stahl GL, Tomlinson S, Arend WP, Holers VM. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice.
J. Immunol. 183: 5928-5937 (2009).
-
Banda NK, Levitt B, Wood AK, Takahashi K, Stahl GL, Holers VM, Arend WP. Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro.
Clin. Exp. Immunol. 159: 100-108 (2010).
*
-
Banda NK, Takahashi K, Wood AK, Holers VM, Arend WP. Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway.
J. Immunol. 179: 4101-4109 (2007).
*
-
Banda NK, Thurman JM, Kraus D, Wood A, Carroll MC, Arend WP, Holers VM. Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis.
J. Immunol. 177: 1904-1912 (2006).
*
-
Bang B, Gniadecki R. Severe exacerbation of psoriatic arthritis during treatment with efalizumab. A case report.
Acta Derm. Venereol. 86: 456-457 (2006).
-
Bang H, Egerer K, Gauliard A, Luthke K, Rudolph PE, Fredenhagen G, Berg W, Feist E, Burmester GR. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis.
Arthritis Rheum. 56: 2503-2511 (2007).
*
-
Bang SY, Lee KH, Cho SK, Lee HS, Lee KW, Bae SC. Smoking increases rheumatoid arthritis susceptibility in individuals carrying the HLA-DRB1 shared epitope, regardless of rheumatoid factor or anti-cyclic citrullinated peptide antibody status.
Arthritis Rheum. 62: 369-377 (2010).
*
-
Bank I, Ben-Horin S, Goldstein I, Koltakov A, Langevitz P, Ehrenfeld M, Rosenthal E, Gur H. The effect of blockade of tumor necrosis factor alpha on VLA-1+T-cells in rheumatoid arthritis patients.
J. Clin. Immunol. 27: 580-588 (2007).
*
-
Bankhurst AD, Nunez SE, Draeger HT, Kettwich SC, Kettwich LG, Sibbitt WL Jr. A randomized controlled trial of the reciprocating procedure device for intraarticular injection of corticosteroid.
J. Rheumatol. 34: 187-192 (2007).
-
Banno T, Gazel A, Blumenberg M. Effects of tumor necrosis factor-alpha (TNFalpha) in epidermal keratinocytes revealed using global transcriptional profiling.
J. Biol. Chem. 279: 32633-32642 (2004).
*
-
Bannwarth B. Drug-induced musculoskeletal disorders.
Drug Saf. 30: 27-46 (2007).
-
Bansback N, Brennan A, Symmons D, Nixon R, Madan J, Harrison M, Watson K. Comment on: modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry: reply.
Rheumatology (Oxford) 47: 1107 (2008).
-
Bansback N, Young A, Brennan A, Dixey J. A prognostic model for functional outcome in early rheumatoid arthritis.
J. Rheumatol. 33: 1503-1510 (2006).
-
Bansi DS, Lo S, Chapman RW, Fleming KA. Absence of antineutrophil cytoplasmic antibodies in relatives of UK patients with primary sclerosing cholangitis and ulcerative colitis.
Eur. J. Gastroenterol. Hepatol. 8: 111-116 (1996).
-
Bar-Yehuda S, Silverman MH, Kerns WD, Ochaion A, Cohen S, Fishman P. The anti-inflammatory effect of A(3) adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis.
Expert Opin. Investig. Drugs 16: 1601-1613 (2007).
-
Baraf HS. Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.
Curr. Pharm. Des. 13: 2228-2236 (2007).
-
Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis.
Arthritis Res. Ther. 10: R104 (2008).
*
-
Barash J, Goldzweig O. Possible role of streptococcal infection in flares of juvenile idiopathic arthritis.
Arthritis Rheum. 57: 877-880 (2007).
*
-
Barcellos LF, Kamdar BB, Ramsay PP, Deloa C, Lincoln RR, Caillier S, Schmidt S, Haines JL, Pericak-Vance MA, Oksenberg JR, Hauser SL. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study.
Lancet Neurol. 5: 924-931 (2006).
-
Bardazzi G, Mannoni A, d'Albasio G, Bonanomi AG, Trallori G, Benucci M, Serni U, Pacini F. Spondyloarthritis in patients with ulcerative colitis.
Ital. J. Gastroenterol. Hepatol. 29: 520-524 (1997).
-
Bardin T. Psoriatic rheumatism.
Rev. Prat. 54: 60-68 (2004).
-
Bardou M, Barkun AN. Preventing the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: from risk factor identification to risk factor intervention.
Joint Bone Spine Dec 17 [Epub ahead of print] (2009).
-
Bardwell PD, Gu J, McCarthy D, Wallace C, Bryant S, Goess C, Mathieu S, Grinnell C, Erickson J, Rosenberg SH, Schwartz AJ, Hugunin M, Tarcsa E, Elmore SW, McRae B, Murtaza A, Wang LC, Ghayur T. The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity.
J. Immunol. 182: 7482-7489 (2009).
-
Baricordi OR, Govoni M, Rizzo R, Trotta F. In rheumatoid arthritis, a polymorphism in the HLA-G gene concurs in the clinical response to methotrexate treatment.
Ann. Rheum. Dis. 66: 1125-1126 (2007).
*
-
Barkham N, Keen HI, Coates LC, O'Connor P, Hensor E, Fraser AD, Cawkwell LS, Bennett A, McGonagle D, Emery P. Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis.
Arthritis Rheum. 60: 946-954 (2009).
*
-
Barksby HE, Lea SR, Preshaw PM, Taylor JJ. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders.
Clin. Exp. Immunol. 149: 217-225 (2007).
*
-
Barksby HE, Milner JM, Patterson AM, Peake NJ, Hui W, Robson T, Lakey R, Middleton J, Cawston TE, Richards CD, Rowan AD. Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degradation in arthritis.
Arthritis Rheum. 54: 3244-3253 (2006).
*
-
Barland P. Antibodies to citrullinated peptides: current role in diagnosis, prognosis, and pathogenesis of rheumatoid arthritis.
New Developments in Rheumatic Diseases 1: 6-9 (2004). *
-
Barnabe CC, Leclercq SA, Fitzgerald AA. The development of inflammatory arthritis and other rheumatic diseases following stem cell transplantation.
Semin. Arthritis Rheum. 39: 55-60 (2009).
*
-
Barnes PJ. Nuclear factor-kappa B.
Int. J. Biochem. Cell Biol. 29: 867-870 (1997).
-
Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases.
Lancet 373: 1905-1917 (2009).
*
-
Barnes T, Moots RJ, Goodacre J. Cytokine medicines in clinical practice: current issues.
Cytokine 32: 62-66 (2005).
-
Barnetche T, Constantin A, Cantagrel A, Cambon-Thomsen A, Gourraud PA. New classification of HLA-DRB1 alleles in rheumatoid arthritis susceptibility: a combined analysis of worldwide samples.
Arthritis Res. Ther. 10: R26 (2008).
*
-
Barnetche T, Constantin A, Gourraud PA, Abbal M, Garnier JG, Cantagrel A, Cambon-Thomsen A. Microsatellite typing of the human leucocyte antigen region: analytical approach and contribution to rheumatoid arthritis immunogenetic studies.
Tissue Antigens 68: 390-398 (2006).
*
-
Barnstein BO, Li G, Wang Z, Kennedy S, Chalfant C, Nakajima H, Bunting KD, Ryan JJ. Stat5 expression is required for IgE-mediated mast cell function.
J. Immunol. 177: 3421-3426 (2006).
*
-
Barone F, Bombardieri M, Manzo A, Blades MC, Morgan PR, Challacombe SJ, Valesini G, Pitzalis C. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjogren's syndrome.
Arthritis Rheum. 52: 1773-1784 (2005).
*
-
Barr C. A nursing guide to infusion therapy with abatacept for the treatment of rheumatoid arthritis.
J. Infus. Nurs. 30: 96-104 (2007).
-
Barra L, Pope JE, Payne M. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
J. Rheumatol. 36: 1421-1428 (2009).
-
Barrera P, Balsa A, Alves H, Westhovens R, Maenaut K, Cornelis F, Fritz P, Bardin T, Ceu Maia M, Lopes-Vaz A, Pascual Salcedo D, de la Concha E, Radstake T, van de Putte LB, Migliorini P, Prudhomme JF, Charron D, Spyropoulou M, Mendes A, Spaepen M, et al. Noninherited maternal antigens do not increase the susceptibility for familial rheumatoid arthritis. European Consortium on Rheumatoid Arthritis Families (ECRAF).
J. Rheumatol. 28: 968-974 (2001).
-
Barrera P, Faure S, Prud'homme JF, Balsa A, Migliorini P, Chimenti D, Radstake TR, van de Putte LB, Pascual-Salcedo D, Westhovens R, Maenaut K, Alves H, Lopes-Vaz A, Stravopoulos C, Spyropoulou M, Fritz P, Bardin T, Charron D, Lepage V, et al. European genetic study on rheumatoid arthritis: is there a linkage of the interleukin-1 (IL-1), IL-10 or IL-4 genes to RA?
Clin. Exp. Rheumatol. 19: 709-714 (2001).
-
Barreto AM, Bigolin MC, Ramos JC, Machado LP, Silva Ldos R, Silveira RB, Boguszewski MC. Growth hormone therapy for children with chronic diseases.
Arq. Bras. Endocrinol. Metabol. 52: 774-782 (2008).
-
Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease.
Nat. Genet. 40: 955-962 (2008).
*
-
Barrett MO, Bal BS. Septic arthritis of the hip in an immune competent adult: the significance of the differential diagnosis.
J. Am. Board Fam. Med. 20: 307-309 (2007).
*
-
Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease.
Inflamm. Bowel Dis. 13: 1424-1429 (2007).
*
-
Barrie III AM, Plevy SE. The interleukin-12 family of cytokines: therapeutic targets for inflammatory disease mediation.
Clin. Appl. Immunol. Rev. 5: 225-240 (2005). *
-
Barsante MM, Cunha TM, Allegretti M, Cattani F, Policani F, Bizzarri C, Tafuri WL, Poole S, Cunha FQ, Bertini R, Teixeira MM. Blockade of the chemokine receptor CXCR2 ameliorates adjuvant-induced arthritis in rats.
Br. J. Pharmacol. 153: 992-1002 (2008).
*
-
Bartalena L, Tanda ML, Medea A, Marcocci C, Pinchera A. Novel approaches to the management of Graves' ophthalmopathy.
Hormones (Athens) 1: 76-90 (2002).
-
Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak P, Wolbink GJ. Clinical response to adalimumab: the relationship with anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.
Ann. Rheum. Dis. 66: 921-926 (2007).
*
-
Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel SO, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study.
Ann. Rheum. Dis. Jul 5 [Epub ahead of print] (2009).
-
Bartelds GM, Wijbrandts CA, Nurmohamed MT, Wolbink GJ, de Vries N, Tak PP, Dijkmans BA, Crusius JB, Vand der Horst-Bruinsma IE. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms.
Arthritis Rheum. 60: 2541-2542 (2009).
*
-
Bartfai T, Waalen J, Buxbaum JN. Adipose tissue as a modulator of clinical inflammation: does obesity reduce the prevalence of rheumatoid arthritis?
J. Rheumatol. 34: 488-492 (2007).
-
Bartke U, Venten I, Kreuter A, Gabbay S, Altmeyer P, Brockmeyer NH. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab.
Br. J. Dermatol. 150: 784-786 (2004).
-
Bartolozzi G, Falcini F, Volpi M, Taccetti G, Tafi L. Arthropathies related to HLA-B27.
Pediatr. Med. Chir. 12: 561-574 (1990).
-
Barton A, Bowes J, Eyre S, Spreckley K, Hinks A, John S, Worthington J. A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population.
Arthritis Rheum. 50: 1117-1121 (2004).
*
-
Barton A, Bowes J, Eyre S, Symmons D, Worthington J, Silman A. Investigation of polymorphisms in the PADI4 gene in determining severity of inflammatory polyarthritis.
Ann. Rheum. Dis. 64: 1311-1315 (2005).
*
-
Barton A, Eyre S, Bowes J, Ho P, John S, Worthington J. Investigation of the SLC22A4 gene (associated with rheumatoid arthritis in a Japanese population) in a United Kingdom population of rheumatoid arthritis patients.
Arthritis Rheum. 52: 752-758 (2005).
*
-
Barton A, Eyre S, Ke X, Hinks A, Bowes J, Flynn E, Martin P; YEAR Consortium; BIRAC Consortium, Wilson AG, Morgan AW, Emery P, Steer S, Hocking LJ, Reid DM, Harrison P, Wordsworth P, Thomson W, Worthington J. Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes.
Hum. Mol. Genet. 18: 2518-2522 (2009).
*
-
Barton A, Eyre S, Myerscough A, Brintnell B, Ward D, Ollier WE, Lorentzen JC, Klareskog L, Silman A, John S, Worthington J; Arthritis Rheumatism Campaign National Repository. High resolution linkage and association mapping identifies a novel rheumatoid arthritis susceptibility locus homologous to one linked to two rat models of inflammatory arthritis.
Hum. Mol. Genet. 10: 1901-1906 (2001).
*
-
Barton A, Jury F, Eyre S, Bowes J, Hinks A, Ward D, Worthington J. Haplotype analysis in simplex families and novel analytic approaches in a case-control cohort reveal no evidence of association of the CTLA-4 gene with rheumatoid arthritis.
Arthritis Rheum. 50: 748-752 (2004).
*
-
Barton A, Lamb R, Symmons D, Silman A, Thomson W, Worthington J, Donn R. Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis.
Genes Immun. 4: 487-491 (2003).
*
-
Barton A, Myerscough A, John S, Gonzalez-Gay M, Ollier W, Worthington J. A single nucleotide polymorphism in exon 1 of cytotoxic T-lymphocyte-associated-4 (CTLA-4) is not associated with rheumatoid arthritis.
Rheumatology (Oxford) 39: 63-66 (2000).
*
-
Barton A, Platt H, Salway F, Symmons D, Barrett E, Bukhari M, Lunt M, Zeggini E, Eyre S, Hinks A, Tellam D, Brintnell B, Ollier W, Worthington J, Silman A. Polymorphisms in the tumour necrosis factor gene are not associated with severity of inflammatory polyarthritis.
Ann. Rheum. Dis. 63: 280-284 (2004).
*
-
Barton A, Platt H, Salway F, Symmons D, Lunt M, Worthington J, Silman A. Polymorphisms in the mannose binding lectin (MBL) gene are not associated with radiographic erosions in rheumatoid or inflammatory polyarthritis.
J. Rheumatol. 31: 442-447 (2004).
*
-
Barton A, Thomson W, Ke X, Eyre S, Hinks A, Bowes J, Gibbons L, Plant D; Wellcome Trust Case Control Consortium, Wilson AG, Marinou I, Morgan A, Emery P; YEAR consortium, Steer S, Hocking L, Reid DM, Wordsworth P, Harrison P, Worthington J. Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility.
Hum. Mol. Genet. 17: 2274-2279 (2008).
*
-
Barton A, Thomson W, Ke X, Eyre S, Hinks A, Bowes J, Plant D, Gibbons LJ; Wellcome Trust Case Control Consortium; YEAR Consortium; BIRAC Consortium. Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13.
Nat. Genet. 40: 1156-1159 (2008).
*
-
Barton AC, Bruce IN, Silman AJ. Genetic studies of psoriatic arthritis: dissecting joints and skin.
J. Rheumatol. 28: 3-5 (2001).
-
Barton JL. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy.
Patient Prefer. Adherence 3: 335-344 (2009).
-
Barton NJ, Stevens DA, Hughes JP, Rossi AG, Chessell IP, Reeve AJ, McQueen DS. Demonstration of a novel technique to quantitatively assess inflammatory mediators and cells in rat knee joints.
J. Inflamm. (Lond.) 4: 13 (2007).
*
-
Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
Health Technol. Assess. 8: 1-104 (2004).
*
-
Barzilai O, Sherer Y, Ram M, Izahaky D, Anaya JM, Shoenfeld Y. Epstein-Barr virus and cytomegalovirus in autoimmune diseases. Are they truly notorious? A preliminary report.
Ann. N. Y. Acad. Sci. 1108: 567-577 (2007).
*
-
Bas S, Neff L, Viatte S, Vuillet M, Spenato U, Guerne PA, Michel M, Tiercy JM, Butrimiene I, Gabay C. Relationship between gamma-interferon and interleukin-17 in Chlamydia trachomatis reactive arthritis.
Clin. Exp. Rheumatol. 27: 885-886 (2009).
-
Basaran Y, Simsek I, Gunal A. Celiac disease with a mixed pattern: a case report.
Cases J. 2: 9330 (2009).
*
-
Basini G, Santini SE, Bussolati S, Grasselli F. Sanguinarine inhibits VEGF-induced Akt phosphorylation.
Ann. N. Y. Acad. Sci. 1095: 371-376 (2007).
*
-
Baslund B, Bendtzen K. Biopharmaceuticals in the treatment of rheumatoid arthritis.
Ugeskr. Laeger. 170: 2108-2110 (2008).
-
Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, Petersen J, Petersen LJ, Beurskens FJ, Schuurman J, van de Winkel JG, Parren PW, Gracie JA, Jongbloed S, Liew FY, McInnes IB. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study.
Arthritis Rheum. 52: 2686-2692 (2005).
*
-
Basu D, Lopez I, Kulkarni A, Sellin JH. Impact of race and ethnicity on inflammatory bowel disease.
Am. J. Gastroenterol. 100: 2254-2261 (2005).
*
-
Basu S, Zhuang H, Torigian DA, Rosenbaum J, Chen W, Alavi A. Functional imaging of inflammatory diseases using nuclear medicine techniques.
Semin. Nucl. Med. 39: 124-145 (2009).
-
Basu SK, Govardhan CP, Jung CW, Margolin AL. Protein crystals for the delivery of biopharmaceuticals.
Expert Opin. Biol. Ther. 4: 301-317 (2004).
-
Bateman J, Cardy CM, Khan SY, Menon A, Obrenovic K, Rowe IF, Erb N. Regional review of patients with psoriatic arthritis in secondary care in the West Midlands: prevalence, disease activity and eligibility for anti-tumour necrosis factor therapy.
Clin. Exp. Rheumatol. 27: 935-939 (2009).
-
Bates JS, Lessard CJ, Leon JM, Nguyen T, Battiest LJ, Rodgers J, Kaufman KM, James JA, Gilkeson GS, Kelly JA, Humphrey MB, Harley JB, Gray-McGuire C, Moser KL, Gaffney PM. Meta-analysis and imputation identifies a 109 kb risk haplotype spanning TNFAIP3 associated with lupus nephritis and hematologic manifestations.
Genes Immun. 10: 470-477 (2009).
-
Bathon JM, Fleischmann RM, Van der Heijde D, Tesser JR, Peloso PM, Chon Y, White B. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis.
J. Rheumatol. 33: 234-243 (2006).
-
Bathon JM, Genovese MC. The Early Rheumatoid Arthritis (ERA) trial comparing the efficacy and safety of etanercept and methotrexate.
Clin. Exp. Rheumatol. 21 (5 Suppl. 31): S195-S197 (2003).
-
Batliwalla FM, Baechler EC, Xiao X, Li W, Balasubramanian S, Khalili H, Damle A, Ortmann WA, Perrone A, Kantor AB, Gulko PS, Kern M, Furie R, Behrens TW, Gregersen PK. Peripheral blood gene expression profiling in rheumatoid arthritis.
Genes Immun. 6: 388-397 (2005).
*
-
Batliwalla FM, Li W, Ritchlin CT, Xiao X, Brenner M, Laragione T, Shao T, Durham R, Kemshetti S, Schwarz E, Coe R, Kern M, Baechler EC, Behrens TW, Gregersen PK, Gulko PS. Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis.
Mol. Med. 11: 21-29 (2005).
*
-
Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, Panoskaltsis-Mortari A, Gregersen PK, Behrens TW, Baechler EC. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study.
Arthritis Rheum. 60: 3098-3107 (2009).
*
-
Bauer K, Yu X, Wernhoff P, Koczan D, Thiesen HJ, Ibrahim SM. Identification of new quantitative trait loci in mice with collagen-induced arthritis.
Arthritis Rheum. 50: 3721-3728 (2004).
*
-
Bauer S, Jendro MC, Wadle A, Kleber S, Stenner F, Dinser R, Reich A, Faccin E, Goedde S, Dinges H, Mueller-Ladner U, Renner C. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes.
Arthritis Res. Ther. 8: R171 (2006).
*
-
Bauerova K, Kucharska J, Mihalova D, Navarova J, Gvozdjakova A, Sumbalova Z. Effect of coenzyme Q(10) supplementation in the rat model of adjuvant arthritis.
Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech. Repub. 149: 501-503 (2005).
-
Bauerova K, Paulovicova E, Mihalova D, Svik K, Ponist S. Study of new ways of supplementary and combinatory therapy of rheumatoid arthritis with immunomodulators. Glucomannan and Imunoglukan(R) in adjuvant arthritis.
Toxicol. Ind. Health 25: 329-335 (2009).
-
Bauerova K, Ponist S, Ondrejickova O, Komendova D, Mihalova D. Association between tissue gamma-glutamyl-transferase and clinical markers of adjuvant arthritis in Lewis rats.
Neuro. Endocrinol. Lett. 27: S172-S175 (2006).
-
Baugh JA, Bucala R. Mechanisms for modulating TNF alpha in immune and inflammatory disease.
Curr. Opin. Drug Discov. Devel. 4: 635-650 (2001).
-
Baugh JA, Chitnis S, Donnelly SC, Monteiro J, Lin X, Plant BJ, Wolfe F, Gregersen PK, Bucala R. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis.
Genes Immun. 3: 170-176 (2002).
*
-
Baughman RP, Iannuzzi M. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy.
BioDrugs 17: 425-431 (2003).
-
Baum H, Staines NA. MHC-derived peptides and the CD4+ T-cell repertoire: implications for autoimmune disease.
Cytokines Cell Mol. Ther. 3: 115-125 (1997).
-
Baumal R, Broder I. Studies into the occurrence of soluble antigen-antibody complexes in disease. III. Rheumatoid arthritis and other human diseases.
Clin. Exp. Immunol. 3: 555-569 (1968).
*
-
Bave U, Nordmark G, Lovgren T, Ronnelid J, Cajander S, Eloranta ML, Alm GV, Ronnblom L. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism.
Arthritis Rheum. 52: 1185-1195 (2005).
*
-
Bayle J, Fitch J, Jacobsen K, Kumar R, Lafyatis R, Lemaire R. Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis.
J. Invest. Dermatol. 128: 871-881 (2008).
*
-
Bayley JP, Baggen JM, van der Pouw-Kraan T, Crusius JB, Huizinga TW, Verweij CL. Association between polymorphisms in the human chemokine receptor genes CCR2 and CX3CR1 and rheumatoid arthritis.
Tissue Antigens 62: 170-174 (2003).
*
-
Bayley JP, Bakker AM, Kaijzel EL, Huizinga TW, Verweij CL. Association of polymorphisms of the tumour necrosis factor receptors I and II and rheumatoid arthritis.
Rheumatology (Oxford) 42: 969-971 (2003).
*
-
Bayley JP, Ottenhoff TH, Verweij CL. Is there a future for TNF promoter polymorphisms?
Genes Immun. 5: 315-329 (2004).
*
-
Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action.
Nat. Clin. Pract. Rheumatol. 3: 262-272 (2007).
*
-
Bayry J, Siberil S, Triebel F, Tough DF, Kaveri SV. Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy.
Drug Discov. Today 12: 548-552 (2007).
-
Bazzani C, Filippini M, Caporali R, Pallavicini FB, Favalli EG, Marchesoni A, Atzeni F, Sarzi-Puttini P, Gorla R. Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: clinical outcomes.
Autoimmun. Rev. 8: 260-265 (2009).
-
Bazzichi L, Ghiadoni L, Rossi A, Bernardini M, Lanza M, De Feo F, Giacomelli C, Mencaroni I, Raimo K, Rossi M, Mazzone AM, Taddei S, Bombardieri S. Osteopontin is associated with increased arterial stiffness in rheumatoid arthritis.
Mol. Med. 15: 402-406 (2009).
*
-
Bazzichi L, Giuliano T, Rossi A, Mazzoni A, Grazzini T, De Feo F, Giacomelli C, Scatena F, Bombardieri S. Partial remission of refractory RA after adacolumn cytapheresis: a case report.
Rheumatol. Int. 28: 295-297 (2008).
*
-
Beardmore VA, Hinton HJ, Eftychi C, Apostolaki M, Armaka M, Darragh J, McIlrath J, Carr JM, Armit LJ, Clacher C, Malone L, Kollias G, Arthur JS. Generation and characterization of p38beta (MAPK11) gene-targeted mice.
Mol. Cell. Biol. 25: 10454-10464 (2005).
*
-
Beauchesne PR, Chung NS, Wasan KM. Cyclosporine A: a review of current oral and intravenous delivery systems.
Drug Dev. Ind. Pharm. 33: 211-220 (2007).
*
-
Becanovic K, Jagodic M, Sheng JR, Dahlman I, Aboul-Enein F, Wallstrom E, Olofsson P, Holmdahl R, Lassmann H, Olsson T. Advanced intercross line mapping of Eae5 reveals Ncf-1 and CLDN4 as candidate genes for experimental autoimmune encephalomyelitis.
J. Immunol. 176: 6055-6064 (2006).
*
-
Becker C, Dornhoff H, Neufert C, Fantini MC, Wirtz S, Huebner S, Nikolaev A, Lehr HA, Murphy AJ, Valenzuela DM, Yancopoulos GD, Galle PR, Karow M, Neurath MF. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis.
J. Immunol. 177: 2760-2764 (2006).
*
-
Becker H, Gaubitz M, Domschke W, Kucharzik T. Joint involvement in chronic inflammatory bowel disease - current diagnostics and treatment options.
Z. Gastroenterol. 44: 497-502 (2006).
-
Becker H, Weber C, Storch S, Federlin K. Relationship between CD5+ B lymphocytes and the activity of systemic autoimmunity.
Clin. Immunol. Immunopathol. 56: 219-225 (1990).
-
Becker KG, Simon RM, Bailey-Wilson JE, Freidlin B, Biddison WE, McFarland HF, Trent JM. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases.
Proc. Natl. Acad. Sci. U.S.A. 95: 9979-9984 (1998).
*
-
Becker ML, Martin TM, Doyle TM, Rose CD. Interstitial pneumonitis in Blau syndrome with documented mutation in CARD15.
Arthritis Rheum. 56: 1292-1294 (2007).
*
-
Becker ML, Rose CD. Blau syndrome and related genetic disorders causing childhood arthritis.
Curr. Rheumatol. Rep. 7: 427-433 (2005).
-
Becker-Merok A, Kalaaji M, Haugbro K, Nikolaisen C, Nilsen K, Rekvig OP, Nossent JC. Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis.
Arthritis Res. Ther. 8: R162 (2006).
*
-
Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time.
Lupus 15: 570-576 (2006).
-
Becvar R, Stork J, Jansa P. New trends in diagnosis and treatment of systemic sclerosis.
Vnitr. Lek. 52: 712-717 (2006).
-
Bedi MK. Successful treatment of long-standing, recalcitrant subcorneal pustular dermatosis with etanercept.
Skinmed. 6: 245-247 (2007).
-
Beech JT, Andreakos E, Ciesielski CJ, Green P, Foxwell BM, Brennan FM. T cell contact-dependent regulation of CC and CXC chemokine production in monocytes through differential involvement of NF-kappaB: implications for rheumatoid arthritis.
Arthritis Res. Ther. 8: R168 (2006).
*
-
Beehler BC, Hei YJ, Chen S, Lupisella JA, Ostrowski J, Starrett JE, Tortolani D, Tramposch KM, Reczek PR. Inhibition of disease progression by a novel retinoid antagonist in animal models of arthritis.
J. Rheumatol. 30: 355-363 (2003).
-
Beeton C, Smith BJ, Sabo JK, Crossley G, Nugent D, Khaytin I, Chi V, Chandy KG, Pennington MW, Norton RS. The D-diastereomer of SHK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation.
J. Biol. Chem. 283: 988-997 (2008).
*
-
Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, Leehealey CJ, S Andrews B, Sankaranarayanan A, Homerick D, Roeck WW, Tehranzadeh J, Stanhope KL, Zimin P, Havel PJ, Griffey S, et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.
Proc. Natl. Acad. Sci. U.S.A. 103: 17414-17419 (2006).
*
-
Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, Ardlie KG, Huang Q, Smith AM, Spoerke JM, Conn MT, Chang M, Chang SY, Saiki RK, Catanese JJ, Leong DU, Garcia VE, McAllister LB, Jeffery DA, Lee AT, Batliwalla F, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis.
Am. J. Hum. Genet. 75: 330-337 (2004).
*
-
Begovich AB, Chang M, Schrodi SJ. Meta-analysis evidence of a differential risk of the FCRL3 -169T-->C polymorphism in white and East Asian rheumatoid arthritis patients.
Arthritis Rheum. 56: 3168-3171 (2007).
*
-
Behera AK, Hildebrand E, Szafranski J, Hung HH, Grodzinsky AJ, Lafyatis R, Koch AE, Kalish R, Perides G, Steere AC, Hu LT. Role of aggrecanase 1 in Lyme arthritis.
Arthritis Rheum. 54: 3319-3329 (2006).
*
-
Behrens EM, Beukelman T, Cron RQ. Juvenile idiopathic arthritis classification criteria: loopholes and diagnosis software.
J. Rheumatol. 34: 234 (2007).
-
Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis.
J. Rheumatol. 34: 1133-1138 (2007).
-
Behrens EM, Finkel TH, Bradfield JP, Kim CE, Linton L, Casalunovo T, Frackelton EC, Santa E, George Otieno F, Glessner JT, Chiavacci RM, Grant SF, Hakonarson H. Association of the TRAF1-C5 locus on chromosome 9 with juvenile idiopathic arthritis.
Arthritis Rheum. 58: 2206-2207 (2008).
*
-
Behrens F, Himsel A, Rehart S, Stanczyk J, Beutel B, Zimmermann SY, Koehl U, Moller B, Gay S, Kaltwasser JP, Pfeilschifter JM, Radeke HH. Imbalance in distribution of functional autologous regulatory T cells in rheumatoid arthritis.
Ann. Rheum. Dis. 66: 1151-1156 (2007).
*
-
Behrens M, Trejo T, Luthra H, Griffiths M, David CS, Taneja V. Mechanism by which HLA-DR4 regulates sex-bias of arthritis in humanized mice.
J. Autoimmun. Jan 8 [Epub ahead of print] (2010).
-
Beleznay Z, Regenass S. Diagnostics of autoimmune diseases.
Ther. Umsch. 65: 529-537 (2008).
-
Belguith-Maalej S, Hadj-Kacem H, Kaddour N, Bahloul Z, Ayadi H. DNase1 exon2 analysis in Tunisian patients with rheumatoid arthritis, systemic lupus erythematosus and Sjogren syndrome and healthy subjects.
Rheumatol. Int. Apr 10 [Epub ahead of print] (2009).
*
-
Belinsky GS, Parke AL, Huang Q, Blanchard K, Jayadev S, Stoll R, Rothe M, Achenie LE, Gupta RR, Wu GY, Rosenberg DW. The contribution of methotrexate exposure and host factors on transcriptional variance in human liver.
Toxicol. Sci. 97: 582-594 (2007).
*
-
Bell DA. Can we rely on anti-citrulline antibody determination for the diagnosis of early rheumatoid arthritis?
J. Rheumatol. 33: 2369-2371 (2006).
-
Bell DA, Hill JA, Cairns E. An intriguing relationship between the immune response to citrullinated vimentin and the HLA shared epitope: Comment on the article by Verpoort et al.
Arthritis Rheum. 58: 3277 (2008).
*
-
Bell JI. The molecular genetics of HLA-related disorders.
Ciba Found. Symp. 130: 197-214 (1987).
-
Bell JT. A two-dimensional genome scan for rheumatoid arthritis susceptibility loci.
BMC Proc. 1 Suppl. 1: S63 (2007).
*
-
Bellinger DL, Lorton D, Brouxhon S, Felten S, Felten DL. The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation.
Adv. Neuroimmunol. 6: 5-27 (1996).
-
Bellisai F, Giannitti C, Donvito A, Galeazzi M. Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection.
Clin. Rheumatol. 26: 1127-1129 (2007).
*
-
Belniak E, Stelmasiak Z, Papuc E. Multiple sclerosis and other autoimmune diseases.
Neurol. Neurochir. Pol. 41: 259-266 (2007).
-
Beltinger J, Froehlich F. Patients with inflammatory bowel disease in specialist gastroenterology practice: a prospective survey.
Schweiz. Rundsch. Med. Prax. 94: 459-465 (2005).
-
Beltran E, Toll A, Pros A, Carbonell J, Pujol RM. Assessment of nailfold capillaroscopy by x 30 digital epiluminescence (dermoscopy) in patients with Raynaud phenomenon.
Br. J. Dermatol. 156: 892-898 (2007).
*
-
Ben Dror L, Barnea E, Beer I, Mann M, Admon A. The HLA-B*2705 peptidome.
Arthritis Rheum. 62: 420-429 (2010).
*
-
Ben-Shoshan M. CTLA-4Ig: uses and future directions.
Recent Pat. Inflamm. Allergy Drug Discov. 3: 132-142 (2009).
-
Benazet JF, Reviron D, Mercier P, Roux H, Roudier J. HLA-DRB1 alleles associated with rheumatoid arthritis in southern France. Absence of extraarticular disease despite expression of the shared epitope.
J. Rheumatol. 22: 607-610 (1995).
-
Bencsath M, Blaskovits A, Borvendeg J. Biomolecular cytokine therapy.
Pathol. Oncol. Res. 9: 24-29 (2003).
*
-
Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients.
Rheumatol. Int. 27: 269-274 (2007).
*
-
Benderdour M, Tardif G, Pelletier JP, Di Battista JA, Reboul P, Ranger P, Martel-Pelletier J. Interleukin 17 (IL-17) induces collagenase-3 production in human osteoarthritic chondrocytes via AP-1 dependent activation: differential activation of AP-1 members by IL-17 and IL-1beta.
J. Rheumatol. 29: 1262-1272 (2002).
*
-
Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Treatment of rheumatoid arthritis (RA) with anti-TNF-alpha antibody (Remicade). Individual monitoring of bioavailability and immunogenicity - secondary publication.
Ugeskr. Laeger. 169: 420-423 (2007).
-
Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
Arthritis Rheum. 54: 3782-3789 (2006).
*
-
Benedek TG. The history of bacteriologic concepts of rheumatic fever and rheumatoid arthritis.
Semin. Arthritis Rheum. 36: 109-123 (2006).
*
-
Benelli R, Lorusso G, Albini A, Noonan DM. Cytokines and chemokines as regulators of angiogenesis in health and disease.
Curr. Pharm. Des. 12: 3101-3115 (2006).
-
Bengmark S. Advanced glycation and lipoxidation end products amplifiers of inflammation: the role of food.
JPEN J. Parenter. Enteral Nutr. 31: 430-440 (2007).
*
-
Benigni A, Caroli C, Longaretti L, Gagliardini E, Zoja C, Galbusera M, Moioli D, Romagnani P, Tincani A, Andreoli L, Remuzzi G. Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus.
Arthritis Rheum. 56: 1569-1578 (2007).
*
-
Benito-Garcia E, Feskanich D, Hu FB, Mandl LA, Karlson EW. Protein, iron and meat consumption and risk of rheumatoid arthritis: a prospective cohort study.
Arthritis Res. Ther. 9: R16 (2007).
*
-
Benjamin M, McGonagle D. Basic concepts of enthesis biology and immunology.
J. Rheumatol. Suppl. 83: 12-13 (2009).
-
Benjamin M, McGonagle D. The enthesis organ concept and its relevance to the spondyloarthropathies.
Adv. Exp. Med. Biol. 649: 57-70 (2009).
-
Bennett AN, McGonagle D, O'Connor P, Hensor EM, Sivera F, Coates LC, Emery P, Marzo-Ortega H. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years.
Arthritis Rheum. 58: 3413-3418 (2008).
*
-
Bennett JC. The role of T lymphocytes in rheumatoid arthritis and other autoimmune diseases.
Arthritis Rheum. 58: S53-S57 (2008).
*
-
Benoist C, Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry?
Nat. Immunol. 2: 797-801 (2001).
*
-
Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease.
Am. J. Ther. 12: 133-141 (2005).
-
Benucci M, Manfredi M, Saviola G, Baiardi P, Campi P. Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-alpha blocking agents in rheumatoid arthritis.
Clin. Exp. Rheumatol. 27: 333-336 (2009).
-
Benucci M, Nenci G, Cappelletti C, Manfredi M. Lupus like syndrome induced by treatment with anti TNFalpha (infliximab): report of three cases.
Recenti Prog. Med. 99: 363-366 (2008).
-
Benucci M, Saviola G, Baiardi P, Cammelli E, Manfredi M. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis.
Clin. Rheumatol. 27: 91-95 (2008).
*
-
Benucci M, Turchini S, Parrochi P, Boccaccini P, Manetti R, Cammelli E, Manfredi M. Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers.
Recenti Prog. Med. 97: 134-139 (2006).
-
Benveniste EN, Qin H. Type I interferons as anti-inflammatory mediators.
Sci. STKE 416: pe70 (2007).
*
-
Berbert AA, Kondo CR, Almendra CL, Matsuo T, Dichi I. Supplementation of fish oil and olive oil in patients with rheumatoid arthritis.
Nutrition 21: 131-136 (2005).
*
-
Berdeli A, Ozyurek AR, Ulger Z, Gurses D, Levent E, Salar K, Gurpinar AR. Association of macrophage migration inhibitory factor gene -173 G/C polymorphism with prognosis in Turkish children with juvenile rheumatoid arthritis.
Rheumatol. Int. 26: 726-731 (2006).
*
-
Berdeli A, Tabel Y, Celik HA, Ozyurek R, Dogrusoz B, Aydin HH. Lack of association between TNFalpha gene polymorphism at position -308 and risk of acute rheumatic fever in Turkish patients.
Scand. J. Rheumatol. 35: 44-47 (2006).
*
-
Berden AE, Kallenberg CG, Savage CO, Yard BA, Abdulahad WH, de Heer E, Bruijn JA, Bajema IM. Cellular immunity in Wegener's granulomatosis: characterizing T lymphocytes.
Arthritis Rheum. 60: 1578-1587 (2009).
*
-
Berdowska I. Cysteine proteases as disease markers.
Clin. Chim. Acta 342: 41-69 (2004).
*
-
Berek C. Do B cells play an important role in the pathogenesis of rheumatoid arthritis?
Z. Rheumatol. 64: 383-388 (2005).
-
Beretta L. Comment on: methotrexate pharmacogenomics in rheumatoid arthritis: introducing false positive report probability.
Rheumatology (Oxford) 48: 1619-1620 (2009).
-
Beretta L, Cappiello F, Moore JH, Barili M, Greene CS, Scorza R. Ability of epistatic interactions of cytokine single-nucleotide polymorphisms to predict susceptibility to disease subsets in systemic sclerosis patients.
Arthritis Rheum. 59: 974-983 (2008).
*
-
Beretta L, Cossu M, Marchini M, Cappiello F, Artoni A, Motta G, Scorza R. A polymorphism in the human serotonin 5-HT2A receptor gene may protect against systemic sclerosis by reducing platelet aggregation.
Arthritis Res. Ther. 10: R103 (2008).
*
-
Beretta L, Scorza R. 5HT2A polymorphism His452Tyr in a German Caucasian systemic sclerosis population - authors' response.
Arthritis Res. Ther. 11: 404 (2009).
-
Berg L, Ronnelid J, Sanjeevi CB, Lampa J, Klareskog L. Interferon-gamma production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1(*)0401 and HLA-DQ8.
Arthritis Res. 2: 75-84 (2000).
*
-
Berg WB. Lessons from animal models of arthritis over the past decade.
Arthritis Res. Ther. 11: 250 (2009).
-
Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ. Primary biliary cirrhosis: report of a focus study group.
Hepatology 40: 1013-1020 (2004).
*
-
Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund H, Van Venrooij WJ, Klareskog L, Dahlqvist SR. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis.
Arthritis Res. Ther. 6: R303-R308 (2004).
*
-
Berglund B, Nordstrom G. Symptoms and functional health status of individuals with Ehlers-Danlos syndrome (EDS).
J. Clin. Rheumatol. 7: 308-314 (2001).
-
Bergman J, Schjott J. Hepatitis caused by Lotus-f3?
Basic Clin. Pharmacol. Toxicol. 104: 414-416 (2009).
*
-
Beri R, Peterlana D, Puccetti A, Simeoni S, Garzotti P, Biasi D, Caramaschi P, Tinazzi E, Lunardi C. HLA-DRB1 alleles and rheumatoid arthritis in northern Italy: lack of correlation with disease severity and extra-articular manifestations.
Recenti Prog. Med. 96: 139-143 (2005).
-
Beris P; Anemia Working Group. Erythropoietin and intravenous iron to save blood in surgery.
Schweiz. Rundsch. Med. Prax. 93: 1905-1910 (2004).
-
Berk DR, Bayliss SJ. Neutrophilic dermatoses in children.
Pediatr. Dermatol. 25: 509-519 (2008).
-
Berkun Y, Atta IA, Rubinow A, Orbach H, Levartovsky D, Aamar S, Arbel O, Dresner-Pollak R, Friedman G, Ben-Yehuda A. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis.
J. Rheumatol. 34: 1664-1669 (2007).
-
Berkun Y, Padeh S. Environmental factors and the geoepidemiology of juvenile idiopathic arthritis.
Autoimmun. Rev. Nov 21 [Epub ahead of print] (2009).
-
Berkun Y, Padeh S, Barash J, Uziel Y, Harel L, Mukamel M, Revel-Vilk S, Kenet G. Antiphospholipid syndrome and recurrent thrombosis in children.
Arthritis Rheum. 55: 850-855 (2006).
*
-
Berliner MN, Giesecke T, Bornhovd KD. Impact of transdermal fentanyl on quality of life in rheumatoid arthritis.
Clin. J. Pain 23: 530-534 (2007).
-
Berlo SE, Guichelaar T, Ten Brink CB, van Kooten PJ, Hauet-Broeren F, Ludanyi K, van Eden W, Broeren CP, Glant TT. Increased arthritis susceptibility in cartilage proteoglycan-specific T cell receptor-transgenic mice.
Arthritis Rheum. 54: 2423-2433 (2006).
*
-
Berlo SE, van Kooten PJ, Ten Brink CB, Hauet-Broere F, Oosterwegel MA, Glant TT, Van Eden W, Broeren CP. Naive transgenic T cells expressing cartilage proteoglycan-specific TCR induce arthritis upon in vivo activation.
J. Autoimmun. 25: 172-180 (2005).
-
Bernard F, Romano A, Granel B. Regulatory T cells and systemic autoimmune diseases: systemic lupus erythematosus, rheumatoid arthritis, primary Sjogren's syndrome.
Rev. Med. Interne. Dec 2 [Epub ahead of print] (2009).
-
Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcon G, Senecal JL, Zummer M, Hanly J, et al. Mortality in systemic lupus erythematosus.
Arthritis Rheum. 54: 2550-2557 (2006).
*
-
Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin P, Gordon C, Barr S, Edworthy S, Bae SC, Petri M, Sibley J, Isenberg D, Rahman A, Steinsson K, Aranow C, Dooley MA, Alarcon GS, Hanly J, Sturfelt G, Nived O, Pope J, et al. Race/ethnicity and cancer occurrence in systemic lupus erythematosus.
Arthritis Rheum. 53: 781-784 (2005).
*
-
Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis.
Rheumatology (Oxford) 46: 1157-1160 (2007).
*
-
Bernatsky S, Lee JL, Rahme E. Non-Hodgkin's lymphoma - meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories.
Rheumatology (Oxford) 46: 690-694 (2007).
*
-
Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy and autoimmunity.
Curr. Opin. Rheumatol. 18: 129-134 (2006).
-
Bernatsky S, Ramsey-Goldman R, Lachance S, Pineau CA, Clarke AE. Lymphoma in a patient with systemic lupus erythematosus.
Nat. Clin. Pract. Rheumatol. 2: 570-574 (2006).
*
-
Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures.
Ann. Rheum. Dis. Jul 23 [Epub ahead of print] (2009).
-
Berner IC, Dudler J. Viral arthritis.
Rev. Med. Suisse. 2: 732-734, 737 (2006).
-
Bernotiene E, Palmer G, Gabay C. The role of leptin in innate and adaptive immune responses.
Arthritis Res. Ther. 8: 217 (2006).
*
-
Bernstein CN. Treatment of the extraintestinal manifestations of inflammatory bowel disease.
Curr. Gastroenterol. Rep. 4: 513-516 (2002).
-
Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in IBD: a population-based study.
Gastroenterology 129: 827-836 (2005).
*
-
Berntson L, Damgard M, Andersson-Gare B, Herlin T, Nielsen S, Nordal E, Rygg M, Zak M, Fasth A. HLA-B27 predicts a more extended disease with increasing age at onset in boys with juvenile idiopathic arthritis.
J. Rheumatol. 35: 2055-2061 (2008).
-
Bertagnolli MM. Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back.
Lancet Oncol. 8: 439-443 (2007).
-
Berthelot C, Cather J, Jones D, Duvic M. Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy.
Clin. Lymphoma Myeloma 6: 329-332 (2006).
-
Berthelot C, Nash J, Duvic M. Coexistent psoriasis and lupus erythematosus treated with alefacept.
Am. J. Clin. Dermatol. 8: 47-50 (2007).
-
Berthelot JM, De Bandt M, Goupille P, Solau-Gervais E, Liote F, Goeb V, Azais I, Martin A, Pallot-Prades B, Maugars Y, Mariette X; on behalf of CRI (Club Rhumatismes et Inflammation). Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature.
Joint Bone Spine 76: 28-34 (2009).
*
-
Berthelot JM, Varin S, Cormier G, Tortellier L, Guillot P, Glemarec J, Maugars Y. 25 mg etanercept once weekly in rheumatoid arthritis and spondylarthropathy.
Joint Bone Spine 74: 144-147 (2007).
*
-
Berthelot P, Carricajo A, Aubert G, Akhavan H, Gazielly D, Lucht F. Outbreak of postoperative shoulder arthritis due to Propionibacterium acnes infection in nondebilitated patients.
Infect. Control Hosp. Epidemiol. 27: 987-990 (2006).
*
-
Bertoli AM, Alarcon GS, Calvo-Alen J, Fernandez M, Vila LM, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort: clinical features, course, and outcome in patients with late-onset disease.
Arthritis Rheum. 54: 1580-1587 (2006).
*
-
Bertoli AM, Fernandez M, McGwin G Jr, Alarcon GS, Tan FK, Reveille JD, Vila LM. Systemic lupus erythematosus in a multiethnic US cohort: XXXVI. Influence of mannose-binding lectin exon 1 polymorphisms in disease manifestations, course, and outcome.
Arthritis Rheum. 54: 1703-1704 (2006).
*
-
Bertoli AM, Strusberg I, Fierro GA, Ramos M, Strusberg AM. Lack of correlation between satisfaction and knowledge in clinical trials participants: a pilot study.
Contemp. Clin. Trials 28: 730-736 (2007).
-
Bertolini A, Ottani A, Sandrini M. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks.
Curr. Med. Chem. 9: 1033-1043 (2002).
-
Bertolini A, Tacchi R, Vergoni AV. Brain effects of melanocortins.
Pharmacol. Res. 59: 13-47 (2009).
*
-
Bertolotto M, Dallegri F, Dapino P, Quercioli A, Pende A, Ottonello L, Montecucco F. Sulphasalazine accelerates apoptosis in neutrophils exposed to immune-complexes (IC): role of caspase pathway.
Clin. Exp. Pharmacol. Physiol. 36: 1132-1135 (2009).
*
-
Bertsias GK, Nakou M, Choulaki C, Raptopoulou A, Papadimitraki E, Goulielmos G, Kritikos H, Sidiropoulos P, Tzardi M, Kardassis D, Mamalaki C, Boumpas DT. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus.
Arthritis Rheum. 60: 207-218 (2009).
*
-
Beslek A, Onen F, Birlik M, Akarsu M, Akar S, Sari I, Gurler O, Akpinar H, Manisali M, Akkoc N. Prevalence of spondyloarthritis in Turkish patients with inflammatory bowel disease.
Rheumatol. Int. 29: 955-957 (2009).
*
-
Bessant R, Duncan R, Ambler G, Swanton J, Isenberg DA, Gordon C, Rahman A. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: a case-control study.
Arthritis Rheum. 55: 892-899 (2006).
*
-
Bessis N, Boissier MC. Gene therapy for patients with rheumatoid arthritis.
Joint Bone Spine 73: 169-176 (2006).
*
-
Bessis N, Boissier MC. Novel pro-inflammatory interleukins: potential therapeutic targets in rheumatoid arthritis.
Joint Bone Spine 68: 477-481 (2001).
-
Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia.
Rheumatology (Oxford) 46: 1005-1008 (2007).
*
-
Beurel E, Michalek SM, Jope RS. Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3).
Trends Immunol. 31: 24-31 (2010).
*
-
Beutler B, Bazzoni F. TNF, apoptosis and autoimmunity: a common thread?
Blood Cells Mol. Dis. 24: 216-230 (1998).
*
-
Beutler BA. The role of tumor necrosis factor in health and disease.
J. Rheumatol. Suppl. 57: 16-21 (1999).
-
Beyeler C, Armstrong M, Bird HA, Idle JR, Daly AK. Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis.
Ann. Rheum. Dis. 55: 66-68 (1996).
*
-
Beyersdorf N, Hanke T, Kerkau T, Hunig T. CD28 superagonists put a break on autoimmunity by preferentially activating CD4(+)CD25(+) regulatory T cells.
Autoimmun. Rev. 5: 40-45 (2006).
-
Bezerra EL, Vilar MJ, da Trindade Neto PB, Inoue Sato EL. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus.
Arthritis Rheum. 52: 3073-3078 (2005).
*
-
Bezerra MC, Carvalho JF, Prokopowitsch AS, Pereira RM. RANK, RANKL and osteoprotegerin in arthritic bone loss.
Braz. J. Med. Biol. Res. 38: 161-170 (2005).
*
-
Bezerra MM, Brain SD, Girao VC, Greenacre S, Keeble J, Rocha FA. Neutrophils-derived peroxynitrite contributes to acute hyperalgesia and cell influx in zymosan arthritis.
Naunyn. Schmiedebergs. Arch. Pharmacol. 374: 265-273 (2007).
-
Bhagwat SS. Kinase inhibitors for the treatment of inflammatory and autoimmune disorders.
Purinergic Signal. 5: 107-115 (2009).
-
Bhambhani V, Abraham J, Sahni M, Harit AK, Khare S, Puliyel JM. Outbreak of Coxsackie B4 arthritis among newborns and staff of a neonatal unit.
Trop. Doct. 37: 188-189 (2007).
-
Bhanji RA, Eystathioy T, Chan EK, Bloch DB, Fritzler MJ. Clinical and serological features of patients with autoantibodies to GW/P bodies.
Clin. Immunol. 125: 247-256 (2007).
*
-
Bhaskaran R, Palmier MO, Bagegni NA, Liang X, Van Doren SR. Solution structure of inhibitor-free human metalloelastase (MMP-12) indicates an internal conformational adjustment.
J. Mol. Biol. 374: 1333-1344 (2007).
*
-
Bhat RM. Management of pyoderma gangrenosum - an update.
Indian J. Dermatol. Venereol. Leprol. 70: 329-335 (2004).
-
Bhatia M. Hydrogen sulfide and substance P in inflammation.
Antioxid. Redox Signal. Oct 5 [Epub ahead of print] (2009).
-
Bhattacharya A, Rahman M, Banu J, Lawrence RA, McGuff HS, Garrett IR, Fischbach M, Fernandes G. Inhibition of osteoporosis in autoimmune disease prone MRL/Mpj-Faslpr mice by n-3 fatty acids.
J. Am. Coll. Nutr. 24: 200-209 (2005).
*
-
Bhattacharya A, Sun D, Rahman M, Fernandes G. Different ratios of eicosapentaenoic and docosahexaenoic omega-3 fatty acids in commercial fish oils differentially alter pro-inflammatory cytokines in peritoneal macrophages from C57BL/6 female mice.
J. Nutr. Biochem. 18: 23-30 (2007).
*
-
Bianchi A, Moulin D, Sebillaud S, Koufany M, Galteau MM, Netter P, Terlain B, Jouzeau JY. Contrasting effects of peroxisome-proliferator-activated receptor (PPAR)gamma agonists on membrane-associated prostaglandin E2 synthase-1 in IL-1beta-stimulated rat chondrocytes.
Arthritis Res. Ther. 7: R1325-R1337 (2005).
*
-
Bica BE, Gomes NM, Fernandes PD, Luiz RR, Koatz VL. Nitric oxide levels and the severity of juvenile idiopathic arthritis.
Rheumatol. Int. 27: 819-825 (2007).
*
-
Bidaguren A, Muller-Thyssen A, Blanco A, Mendicute J, Ubeda M. Retrobulbar optic neuritis associated with infliximab.
Arch. Soc. Esp. Oftalmol. 82: 109-112 (2007).
-
Bienkowska J, Dagin G, Batliwalla F, Allaire N, Roubenoff R, Gregersen P, Carulli J. Convergent random forest predictor: methodology for predicting drug response from genome-scale data applied to anti-TNF response.
Genomics 94: 423-432 (2009).
*
-
Bierbaum S, Sengler C, Gerhold K, Berner R, Heinzmann A. Polymorphisms within interleukin 15 are associated with juvenile idiopathic arthritis.
Clin. Exp. Rheumatol. 24: 219 (2006).
-
Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M. Adalimumab in the therapy of uveitis in childhood.
Br. J. Ophthalmol. 91: 319-324 (2007).
*
-
Bigazzi PE. Autoimmunity and heavy metals.
Lupus 3: 449-453 (1994).
-
Bigbee CL, Gonchoroff DG, Vratsanos G, Nadler SG, Haggerty HG, Flynn JL. Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice.
Arthritis Rheum. 56: 2557-2565 (2007).
*
-
Biggioggero M, Meroni PL. The geoepidemiology of the antiphospholipid antibody syndrome.
Autoimmun. Rev. Nov 19 [Epub ahead of print] (2009).
-
Bikker A, van Woerkom J, Kruize A, Wenting-van Wijk M, de Jager W, Bijlsma J, Lafeber F, van Roon J. Increased expression of Interleukin-7 in labial salivary glands of patients with primary Sjogren's syndrome correlates with increased inflammation.
Arthritis Rheum. Jan 13 [Epub ahead of print] (2010).
*
-
Bilavsky E, Yarden-Bilavsky H, Zevit N, Amir J. Primary meningococcal arthritis in a child: case report and literature review.
Scand. J. Infect. Dis. 38: 396-399 (2006).
*
-
Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, Ellingson S, Newman B, Bauer JW, Peterson EJ, Baechler EC, Reed AM. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis.
Arthritis Rheum. 60: 3436-3446 (2009).
*
-
Billerbeck E, Kang YH, Walker L, Lockstone H, Grafmueller S, Fleming V, Flint J, Willberg CB, Bengsch B, Seigel B, Ramamurthy N, Zitzmann N, Barnes EJ, Thevanayagam J, Bhagwanani A, Leslie A, Oo YH, Kollnberger S, Bowness P, Drognitz O, Adams DH, et al. Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties.
Proc. Natl. Acad. Sci. U.S.A. Jan 28 [Epub ahead of print] (2010).
*
-
Billich A. Drug evaluation: Apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency.
IDrugs 10: 53-59 (2007).
-
Billing E, McKenna S, Staun M, Lindqvist U. Adaptation of the psoriatic arthritis quality of life (PsAQoL) instrument for Sweden.
Scand. J. Rheumatol. Jan 11 [Epub ahead of print] (2010).
*
-
Billings PB, Hoch SO, White PJ, Carson DA, Vaughan JH. Antibodies to the Epstein-Barr virus nuclear antigen and to rheumatoid arthritis nuclear antigen identify the same polypeptide.
Proc. Natl. Acad. Sci. U.S.A. 80: 7104-7108 (1983).
*
-
Bilyy R, Nemesh L, Antonyuk V, Kit Y, Valchuk I, Havryluk A, Chopyak V, Stoika R. Apoptosis-related changes in plasma membrane glycoconjugates of peripheral blood lymphocytes in rheumatoid arthritis.
Autoimmunity 42: 334-336 (2009).
-
Binard A, Alassane S, Devauchelle-Pensec V, Berthelot JM, Jousse-Joulin S, Chales G, Le Henaff C, Thorel JB, Hoang S, Youinou P, Saraux A. Outcome of early monoarthritis: a followup study.
J. Rheumatol. 34: 2351-2357 (2007).
-
Bingham CO. Emerging therapeutics for rheumatoid arthritis.
Bull. N.Y.U. Hosp. Jt. Dis. 66: 210-215 (2008).
*
-
Bingham CO, Ince A, Haraoui B, Keystone EC, Chon Y, Baumgartner S. Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study.
Curr. Med. Res. Opin. 25: 1131-1142 (2009).
*
-
Bingham SJ, Snowden J, McGonagle D, Richards S, Isaacs J, Morgan G, Emery P. Autologous stem cell transplantation for rheumatoid arthritis - interim report of 6 patients.
J. Rheumatol. Suppl. 64: 21-24 (2001).
-
Bingham SJ, Snowden JA, Emery P. Autologous blood stem cell transplantation as therapy for autoimmune diseases.
Ann. Med. 32: 615-521 (2000).
-
Binstadt BA, Hebert JL, Ortiz-Lopez A, Bronson R, Benoist C, Mathis D. The same systemic autoimmune disease provokes arthritis and endocarditis via distinct mechanisms.
Proc. Natl. Acad. Sci. U.S.A. 106: 16758-16763 (2009).
*
-
Binstadt BA, Patel PR, Alencar H, Nigrovic PA, Lee DM, Mahmood U, Weissleder R, Mathis D, Benoist C. Particularities of the vasculature can promote the organ specificity of autoimmune attack.
Nat. Immunol. 7: 284-292 (2006).
*
-
Bircan Z, Usluer H. Protracted febrile myalgia mimicking polyarteritis nodosa.
J. Clin. Rheumatol. 14: 222-225 (2008).
-
Birgisson H, Steingrimsson O, Guethnason T. Kingella kingae ostemyelitis and septic arthritis in paediatric patients. Six cases from the Department of Pediatrics, National University Hospital of Iceland.
Laeknabladid. 86: 516-519 (2000).
-
Birlea S, Birlea M, Cimponeriu D, Apostol P, Cosgarea R, Gavrila L, Tigan S, Costin G, Das PK. Autoimmune diseases and vitamin D receptor Apa-I polymorphism are associated with vitiligo in a small inbred Romanian community.
Acta Derm. Venereol. 86: 209-214 (2006).
*
-
Birlea SA, Costin GE, Norris DA. Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation.
Curr. Drug Targets 9: 345-359 (2008).
-
Birlea SA, Fain PR, Spritz RA. A Romanian population isolate with high frequency of vitiligo and associated autoimmune diseases.
Arch. Dermatol. 144: 310-316 (2008).
*
-
Birlea SA, Gowan K, Fain PR, Spritz RA. Genome-wide association study of generalized vitiligo in an isolated European founder population identifies SMOC2, in close proximity to IDDM8.
J. Invest. Dermatol. Nov 5 [Epub ahead of print] (2009).
*
-
Birmingham DJ, Nagaraja HN, Rovin BH, Spetie L, Zhao Y, Li X, Hackshaw KV, Yu CY, Malarkey WB, Hebert LA. Fluctuation in self-perceived stress and increased risk of flare in patients with lupus nephritis carrying the serotonin receptor 1A -1019 G allele.
Arthritis Rheum. 54: 3291-3299 (2006).
*
-
Birnbaum H, Pike C, Kaufman R, Cifaldi M. Employer model of workplace impacts of anti-TNF therapy for rheumatoid arthritis.
J. Occup. Environ. Med. 51: 1167-1176 (2009).
-
Birnbaum H, Shi L, Pike C, Kaufman R, Sun P, Cifaldi M. Workplace impacts of anti-TNF therapies in rheumatoid arthritis: review of the literature.
Expert Opin. Pharmacother. 10: 255-269 (2009).
-
Birnbaum J, Bartlett JG, Gelber AC. Clostridium difficile: an under-recognized cause of reactive arthritis?
Clin. Rheumatol. 27: 253-255 (2008).
*
-
Biro E, Nieuwland R, Tak PP, Pronk LM, Schaap MC, Sturk A, Hack CE. Activated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals.
Ann. Rheum. Dis. 66: 1085-1092 (2007).
*
-
Biro E, Szekanecz Z, Czirjak L, Danko K, Kiss E, Szabo NA, Szucs G, Zeher M, Bodolay E, Szegedi G, Bako G. Association of systemic and thyroid autoimmune diseases.
Clin. Rheumatol. 25: 240-245 (2006).
*
-
Bissett DL. Glucosamine: an ingredient with skin and other benefits.
J. Cosmet. Dermatol. 5: 309-315 (2006).
-
Bissonnette R. Etanercept for the treatment of psoriasis.
Skin Therapy Lett. 11: 1-4 (2006).
-
Bissonnette R, Ho V, Langley RG. Safety of conventional systemic agents and biologic agents in the treatment of psoriasis.
J. Cutan. Med. Surg. 13 Suppl. 2: S67-S76 (2009).
-
Bister VO, Salmela MT, Karjalainen-Lindsberg ML, Uria J, Lohi J, Puolakkainen P, Lopez-Otin C, Saarialho-Kere U. Differential expression of three matrix metalloproteinases, MMP-19, MMP-26, and MMP-28, in normal and inflamed intestine and colon cancer.
Dig. Dis. Sci. 49: 653-661 (2004).
*
-
Biswas P, Mantelli B, Hasson H, Vecchi A, Saniabadi A, Lazzarin A, Beretta A. In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: implications for treatment of HIV infection and other immune disorders.
Clin. Immunol. 109: 355-358 (2003).
*
-
Biswas PS, Bhagat G, Pernis AB. IRF4 and its regulators: evolving insights into the pathogenesis of inflammatory arthritis?
Immunol. Rev. 233: 79-96 (2010).
-
Bittencourt PL, Farias AQ, Porta G, Cancado EL, Miura I, Pugliese R, Kalil J, Goldberg AC, Carrilho FJ. Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis: effect of age, gender, and genetic background.
J. Clin. Gastroenterol. 42: 300-305 (2008).
-
Bizzaro N. Antibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis.
Clin. Chem. Lab. Med. 45: 150-157 (2007).
*
-
Bjorkbacka H, Lavant EH, Fredrikson GN, Melander O, Berglund G, Carlson JA, Nilsson J. Weak associations between human leucocyte antigen genotype and acute myocardial infarction.
J. Intern. Med. Dec 14 [Epub ahead of print] (2009).
*
-
Black MH, Watanabe RM. A principal-components-based clustering method to identify multiple variants associated with rheumatoid arthritis and arthritis-related autoantibodies.
BMC Proc. 3 Suppl. 7: S129 (2009).
*
-
Blackwell JM, Searle S. Genetic regulation of macrophage activation: understanding the function of Nramp1 (=Ity/Lsh/Bcg).
Immunol. Lett. 65: 73-80 (1999).
-
Blackwell NM, Sembi P, Newson JS, Lawrence T, Gilroy DW, Kabouridis PS. Reduced infiltration and increased apoptosis of leukocytes at sites of inflammation by systemic administration of a membrane-permeable IkappaBalpha repressor.
Arthritis Rheum. 50: 2675-2684 (2004).
*
-
Blagosklonny MV. Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition.
Cell Cycle 5: 2087-2102 (2006).
*
-
Blaho VA, Buczynski MW, Brown CR, Dennis EA. Lipidomic analysis of dynamic eicosanoid responses during the induction and resolution of lyme arthritis.
J. Biol. Chem. 284: 21599-21612 (2009).
*
-
Blair PA, Norena LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, Mauri C. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients.
Immunity Jan 13 [Epub ahead of print] (2010).
-
Blakemore AI, Tarlow JK, Cork MJ, Gordon C, Emery P, Duff GW. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus.
Arthritis Rheum. 37: 1380-1385 (1994).
-
Blanchard F, Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?
Drug Discov. Today. 10: 197-204 (2005).
-
Blanchet MR, Gold M, Maltby S, Bennett J, Petri B, Kubes P, Lee DM, McNagny KM. Loss of CD34 leads to exacerbated autoimmune arthritis through increased vascular permeability.
J. Immunol. Dec 28 [Epub ahead of print] (2009).
-
Blanco P, Pitard V, Viallard JF, Taupin JL, Pellegrin JL, Moreau JF. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus.
Arthritis Rheum. 52: 201-211 (2005).
*
-
Blaney GP, Albert PJ, Proal AD. Vitamin D metabolites as clinical markers in autoimmune and chronic disease.
Ann. N. Y. Acad. Sci. 1173: 384-390 (2009).
*
-
Blankenberg-Sprenkels SH, Fielder M, Feltkamp TE, Tiwana H, Wilson C, Ebringer A. Antibodies to Klebsiella pneumoniae in Dutch patients with ankylosing spondylitis and acute anterior uveitis and to Proteus mirabilis in rheumatoid arthritis.
J. Rheumatol. 25: 743-747 (1998).
-
Blaschke S, Viereck V, Schwarz G, Klinger HM, Guerluek S, Muller GA. Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis.
Scand. J. Rheumatol. Feb 26 [Epub ahead of print] (2009).
*
-
Blass S, Engel JM, Burmester GR. The immunologic homunculus in rheumatoid arthritis. A new viewpoint of immunopathogenesis in rheumatoid arthritis and therapeutic consequences.
Z. Rheumatol. 60: 1-16 (2001).
-
Blau EB. Familial granulomatous arthritis, iritis, and rash.
J. Pediatr. 107: 689-693 (1985).
-
Bleakman D, Alt A, Nisenbaum ES. Glutamate receptors and pain.
Semin. Cell. Dev. Biol. 17: 592-604 (2006).
*
-
Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, Brunner HI, Griffin T, Graham TB, Sherry DD, Passo MH, Ramanan AV, Filipovich A, Grom AA. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis.
Arthritis Rheum. 56: 965-971 (2007).
*
-
Bleich A, Hopf S, Hedrich HJ, van Lith HA, Li F, Sartor RB, Mahler M. Genetic dissection of granulomatous enterocolitis and arthritis in the intramural peptidoglycan-polysaccharide-treated rat model of IBD.
Inflamm. Bowel Dis. 15: 1794-1802 (2009).
*
-
Bliddal H, Terslev L, Qvistgaard E, Konig M, Holm CC, Rogind H, Boesen M, Danneskiold-Samsoe B, Torp-Pedersen S. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis.
Scand. J. Rheumatol. 35: 341-345 (2006).
*
-
Bloch AS. Low carbohydrate diets, pro: time to rethink our current strategies.
Nutr. Clin. Pract. 20: 3-12 (2005).
-
Bloch I, Quintana FJ, Gerber D, Cohen T, Cohen IR, Shai Y. T-cell inactivation and immunosuppressive activity induced by HIV gp41 via novel interacting motif.
FASEB J. 21: 393-401 (2007).
*
-
Blom AM, Nandakumar KS, Holmdahl R. C4b-binding protein (C4BP) inhibits development of experimental arthritis in mice.
Ann. Rheum. Dis. 68: 136-142 (2009).
-
Blom M, Kievit W, Fransen J, Kuper IH, den Broeder AA, De Gendt CM, Jansen TL, Brus HL, van de Laar MA, van Riel PL. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis.
J. Rheumatol. 36: 2171-2177 (2009).
-
Blomberg J. Newly discovered human retroviruses. Association with disease is still undetermined.
Lakartidningen 97: 3597-3599, 3602-3603 (2000).
-
Bloom BJ, Toyoda M, Petrosian A, Jordan S. Anti-endothelial cell antibodies are prevalent in juvenile idiopathic arthritis: implications for clinical disease course and pathogenesis.
Rheumatol. Int. 27: 655-660 (2007).
*
-
Bloquel C, Bessis N, Boissier MC, Scherman D, Bigey P. Gene therapy of collagen-induced arthritis by electrotransfer of human tumor necrosis factor-alpha soluble receptor I variants.
Hum. Gene Ther. 15: 189-201 (2004).
*
-
Bluestone JA. A balanced attack.
The Scientist May, 2007 (http://www.the-scientist.com/2007/05/01/s32/1/ ) (2007).
-
Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application.
Immunity 24: 233-238 (2006).
*
-
Blumenauer B, Judd M, Cranney A, Burls A, Coyle D, Hochberg M, Tugwell P, Wells G. Etanercept for the treatment of rheumatoid arthritis.
Cochrane Database Syst. Rev. 4: CD004525 (2003).
*
-
Blumenauer B, Judd M, Wells G, Burls A, Cranney A, Hochberg M, Tugwell P. Infliximab for the treatment of rheumatoid arthritis.
Cochrane Database Syst. Rev. 3: CD003785 (2002).
*
-
Blundell CD, Mahoney DJ, Cordell MR, Almond A, Kahmann JD, Perczel A, Taylor JD, Campbell ID, Day AJ. Determining the molecular basis for the pH-dependent interaction between the link module of human TSG-6 and hyaluronan.
J. Biol. Chem. 282: 12976-12988 (2007).
*
-
Bobacz K, Sunk IG, Hofstaetter JG, Amoyo L, Toma CD, Akira S, Weichhart T, Saemann M, Smolen JS. Toll-like receptors and chondrocytes: the lipopolysaccharide-induced decrease in cartilage matrix synthesis is dependent on the presence of Toll-like receptor 4 and antagonized by bone morphogenetic protein 7.
Arthritis Rheum. 56: 1880-1893 (2007).
*
-
Bobbio-Pallavicini F, Caporali R, Alpini C, Avalle S, Epis O, Klersy C, Montecucco C. High IgA rheumatoid factor levels are associated with poor clinical response to TNF-alpha inhibitors in rheumatoid arthritis.
Ann. Rheum. Dis. 66: 302-307 (2007).
*
-
Bobbio-Pallavicini F, Caporali R, Alpini C, Moratti R, Montecucco C. Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-alpha treated patients.
Ann. N. Y. Acad. Sci. 1109: 287-295 (2007).
*
-
Bocchino M, Matarese A, Bellofiore B, Giacomelli P, Santoro G, Balato N, Castiglione F, Scarpa R, Perna F, Signoriello G, Galati D, Ponticiello A, Sanduzzi A. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment.
Eur. J. Clin. Microbiol. Infect. Dis. 27: 907-913 (2008).
*
-
Bocci EB, Biscontini D, Olivieri I, Gerli R. Acro-osteolysis of the big toe in a patient with psoriatic arthritis.
J. Rheumatol. 36: 2044 (2009).
-
Bockelmann R, Gollnick H, Bonnekoh B. Anti-cyclic citrullinated peptide antibodies in psoriasis patients without arthritis.
Arthritis Rheum. 54: 1701-1702 (2006).
*
-
Bockermann R, Holmdahl R. Type II collagen without adjuvant induces eosinophilic arthritis.
Eur. J. Immunol. 37: 540-548 (2007).
*
-
Bockermann R, Schubert D, Kamradt T, Holmdahl R. Induction of a B-cell-dependent chronic arthritis with glucose-6-phosphate isomerase.
Arthritis Res. Ther. 7: R1316-R1324 (2005).
*
-
Bodenheimer HC Jr, Schaffner F. State of the art. Primary biliary cirrhosis and the immune system.
Am. J. Gastroenterol. 72: 285-296 (1979).
-
Bodil Roth E, Theander E, Londos E, Sandberg-Wollheim M, Larsson A, Sjoberg K, Stenberg P. Pathogenesis of autoimmune diseases: antibodies against transglutaminase, peptidylarginine deiminase and protein-bound citrulline in primary Sjogren's syndrome, multiple sclerosis and Alzheimer's disease.
Scand. J. Immunol. 67: 626-631 (2008).
*
-
Bodolay E, Derfalvi B, Gergely P, Poor G. When does an autoimmune disease begin? Importance of the early diagnosis.
Orv. Hetil. 148: S25-S30 (2007).
-
Bodur H, Ataman S, Akbulut L, Evcik D, Kavuncu V, Kaya T, Gunaydin R, Kuran B, Kotevoglu N, Bal A, Aydog E, Altay Z, Ugurlu H, Kocabas H, Olmez N, Yazgan P, Gursoy S, Madenci E, Ozel S, Delialioglu SU. Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis.
Clin. Rheumatol. 27: 1119-1125 (2008).
*
-
Bodur H, Seckin U, Eser F, Ergul G, Seckin S. Coexistence of familial Mediterranean fever and psoriasis in a patient with seronegative spondyloarthropathy.
Rheumatol. Int. 29: 107-110 (2008).
*
-
Boehm I. Drug treatment-induced downregulation of antiphospholipid antibodies in PAPS.
Clin. Rheumatol. 28: 1347-1348 (2009).
-
Boehncke WH. Treatment recommendations for psoriatic arthritis.
Z. Rheumatol. 68: 842-844 (2009).
-
Boehncke WH, Adebajo A, Cauli A, Nash P, Salvarani C, Kavanaugh AF. Initiative for quality in psoriasis and psoriatic arthritis.
J. Rheumatol. 35: 1431-1433 (2008).
-
Boehncke WH, Boehncke S. Cardiovascular morbidity in psoriasis: epidemiology, pathomechanisms, and clinical consequences.
G. Ital. Dermatol. Venereol. 143: 307-313 (2008).
-
Boehncke WH, Boehncke S. Managing comorbidities in psoriasis.
Actas. Dermosifiliogr. 100: S22-S27 (2009).
-
Boehncke WH, Buerger C, Boehncke S. Co-morbidities in psoriasis vulgaris.
Hautarzt. 60: 116-121 (2009).
-
Boelaert K, Newby PR, Simmonds MJ, Holder RL, Carr-Smith JD, Heward JM, Manji N, Allahabadia A, Armitage M, Chatterjee KV, Lazarus JH, Pearce SH, Vaidya B, Gough SC, Franklyn JA. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease.
Am. J. Med. 123: 183.e1-183.e9 (2010).
*
-
Boers M. Abatacept in rheumatoid arthritis: a new branch on the "biologics" tree.
Ann. Intern. Med. 144: 933-935 (2006).
*
-
Boers M. Studying the benefit/risk ratio of glucocorticoids in rheumatoid arthritis.
J. Rheumatol. 34: 661-663 (2007).
-
Boettger MK, Hensellek S, Richter F, Gajda M, Stockigt R, von Banchet GS, Brauer R, Schaible HG. Antinociceptive effects of tumor necrosis factor alpha neutralization in a rat model of antigen-induced arthritis: evidence of a neuronal target.
Arthritis Rheum. 58: 2368-2378 (2008).
*
-
Boffa MJ, Smith A, Chalmers RJ. Comment on: liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy.
Rheumatology (Oxford) 48: 1464 (2009).
-
Bogas M, Afonso Mdo C, Araujo D. Erosive enteropathy in a patient with a polyarthritis.
Acta Reumatol. Port. 31: 349-354 (2006).
-
Bohanec Grabar P, Grabnar I, Rozman B, Logar D, Tomsic M, Suput D, Trdan T, Peterlin Masic L, Mrhar A, Dolzan V. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on A771726 pharmacokinetics in leflunomide treated patients with rheumatoid arthritis.
Drug Metab. Dispos. 37: 2061-2068 (2009).
*
-
Bohanec Grabar P, Logar D, Lestan B, Dolzan V. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism.
Eur. J. Clin. Pharmacol. 64: 1057-1068 (2008).
*
-
Bohanec Grabar P, Logar D, Tomsic M, Rozman B, Dolzan V. Genetic polymorphisms of glutathione S-transferases and disease activity of rheumatoid arthritis.
Clin. Exp. Rheumatol. 27: 229-236 (2009).
-
Bohgaki T, Amasaki Y, Nishimura N, Bohgaki M, Yamashita Y, Nishio M, Sawada KI, Jodo S, Atsumi T, Koike T. Up regulated expression of tumour necrosis factor alpha converting enzyme in peripheral monocytes of patients with early systemic sclerosis.
Ann. Rheum. Dis. 64: 1165-1173 (2005).
*
-
Bohm C, Hayer S, Kilian A, Zaiss MM, Finger S, Hess A, Engelke K, Kollias G, Kronke G, Zwerina J, Schett G, David JP. The alpha-isoform of p38 MAPK specifically regulates arthritic bone loss.
J. Immunol. 183: 5938-5947 (2009).
-
Boiardi L, Casali B, Farnetti E, Pipitone N, Nicoli D, Macchioni P, Cimino L, Bajocchi G, Grazia Catanoso M, Pattacini L, Salvarani C. Interleukin-10 promoter polymorphisms in giant cell arteritis.
Arthritis Rheum. 54: 4011-4017 (2006).
*
-
Boiers U, Lanig H, Sehnert B, Holmdahl R, Burkhardt H. Collagen type II is recognized by a pathogenic antibody through germline encoded structures.
Eur. J. Immunol. 38: 2784-2795 (2008).
*
-
Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME, Massarotti EM, Remold-O'Donnell E, Farndale RW, Ware J, Lee DM. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production.
Science 327: 580-583 (2010).
*
-
Boissier MC, Assier E, Falgarone G, Bessis N. Shifting the imbalance from Th1/Th2 to Th17/Treg: the changing rheumatoid arthritis paradigm.
Joint Bone Spine 75: 373-375 (2008).
*
-
Bokarewa M, Dahlberg L, Tarkowski A. Expression and functional properties of antibodies to tissue inhibitors of metalloproteinases (TIMPs) in rheumatoid arthritis.
Arthritis Res. Ther. 7: R1014-R1022 (2005).
*
-
Bokarewa M, Hultgren O. Is interleukin-18 useful for monitoring rheumatoid arthritis?
Scand. J. Rheumatol. 34: 433-436 (2005).
*
-
Bokarewa M, Lindholm C, Zendjanchi K, Nadali M, Tarkowski A. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
Scand. J. Immunol. 66: 476-483 (2007).
*
-
Bokarewa MI, Jin T, Tarkowski A. Intraarticular release and accumulation of defensins and bactericidal/permeability-increasing protein in patients with rheumatoid arthritis.
J. Rheumatol. 30: 1719-1724 (2003).
-
Boki KA, Drosos AA, Tzioufas AG, Lanchbury JS, Panayi GS, Moutsopoulos HM. Examination of HLA-DR4 as a severity marker for rheumatoid arthritis in Greek patients.
Ann. Rheum. Dis. 52: 517-519 (1993).
*
-
Boki KA, Panayi GS, Vaughan RW, Drosos AA, Moutsopoulos HM, Lanchbury JS. HLA class II sequence polymorphisms and susceptibility to rheumatoid arthritis in Greeks. The HLA-DR beta shared-epitope hypothesis accounts for the disease in only a minority of Greek patients.
Arthritis Rheum. 35: 749-755 (1992).
-
Boland CR. Biology of cancer in ulcerative colitis and consequences for chemoprevention.
Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 82-83. May 7-8 (2004). *
-
Boldizsar F, Tarjanyi O, Nemeth P, Mikecz K, Glant TT. Th1/Th17 polarization and acquisition of an arthritogenic phenotype in arthritis-susceptible BALB/c, but not in MHC-matched, arthritis-resistant DBA/2 mice.
Int. Immunol. 21: 511-522 (2009).
-
Bollag WB. Potential role of sphingosine 1-phosphate in the pathogenesis of rheumatoid arthritis.
J. Lipid Res. 49: 2281-2282 (2008).
*
-
Bolstad AI, Jonsson R. Genetic aspects of Sjogren's syndrome.
Arthritis Res. 4: 353-359 (2002).
*
-
Bolz DD, Weis JJ. Molecular mimicry to Borrelia burgdorferi: pathway to autoimmunity?
Autoimmunity 37: 387-392 (2004).
-
Bombardieri M, Barone F, Pittoni V, Alessandri C, Conigliaro P, Blades MC, Priori R, McInnes IB, Valesini G, Pitzalis C. Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjogren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate.
Arthritis Res. Ther. 6: R447-R456 (2004).
*
-
Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, Oezer U, Kary S, Kupper H, Burmester AG. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
Rheumatology (Oxford) 46: 1191-1199 (2007).
*
-
Boms S, Sehr T, Jappe U, Enk A. First manifestation of psoriasis vulgaris in tumor necrosis factor receptor-associated periodic syndrome during treatment with etanercept.
Hautarzt. 59: 653-655 (2008).
-
Bonaci-Nikolic B, Nikolic MM, Andrejevic S, Zoric S, Bukilica M. Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides.
Arthritis Res. Ther. 7: R1072-R1081 (2005).
*
-
Bondanza A, Zimmermann VS, Dell'Antonio G, Cin ED, Balestrieri G, Tincani A, Amoura Z, Piette JC, Sabbadini MG, Rovere-Querini P, Manfredi AA. Requirement of dying cells and environmental adjuvants for the induction of autoimmunity.
Arthritis Rheum. 50: 1549-1560 (2004).
*
-
Bondeson J, Maini RN. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE).
Int. J. Clin. Pract. 55: 211-216 (2001).
-
Bondeson J, Veress B, Lindroth Y, Lindgren S. Polymyositis associated with asymptomatic primary biliary cirrhosis.
Clin. Exp. Rheumatol. 16: 172-174 (1998).
-
Bondeson J, Wainwright SD, Lauder S, Amos N, Hughes CE. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases and other destructive and inflammatory responses in osteoarthritis.
Arthritis Res. Ther. 8: R187 (2006).
*
-
Bonel HM, Boller C, Saar B, Tanner S, Srivastav S, Villiger PM. Short term changes in magnetic resonance Imaging and disease activity in response to infliximab.
Ann. Rheum. Dis. 69: 120-125 (2010).
-
Bonelli M, Savitskaya A, Steiner CW, Rath E, Smolen JS, Scheinecker C. Phenotypic and functional analysis of CD4+CD25-Foxp3+ T cells in patients with systemic lupus erythematosus.
J. Immunol. 182: 1689-1695 (2009).
-
Bonfiglioli R, Conde RA, Sampaio-Barros PD, Louzada-Junior P, Donadi EA, Bertolo MB. Frequency of HLA-B27 alleles in Brazilian patients with psoriatic arthritis.
Clin. Rheumatol. 27: 709-712 (2008).
*
-
Bongartz T, Cantaert T, Atkins SR, Harle P, Myers JL, Turesson C, Ryu JH, Baeten D, Matteson EL. Citrullination in extra-articular manifestations of rheumatoid arthritis.
Rheumatology (Oxford) 46: 70-75 (2007).
*
-
Bongartz T, Coras B, Vogt T, Scholmerich J, Muller-Ladner U. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study.
Rheumatology (Oxford) 44: 126-129 (2005).
*
-
Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies. A systematic review and individual patient data meta-analysis of randomized controlled trials.
Ann. Rheum. Dis. 68: 1177-1183 (2009).
-
Bongi SM, Porfirio B, Rombola G, Palasciano A, Beneforti E, Bianucci G. Shared-epitope HLA-DRB1 alleles and sex ratio in Italian patients with rheumatoid arthritis.
Joint Bone Spine 71: 24-28 (2004).
-
Bongiorno MR, Pistone G, Doukaki S, Arico M. Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis.
Dermatol. Ther. 21 Suppl. 2: S15-S20 (2008).
-
Boniface K, Blom B, Liu YJ, de Waal Malefyt R. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited.
Immunol. Rev. 226: 132-146 (2008).
*
-
Bonifati C, Berardesca E. Clinical outcome measures of psoriasis.
Reumatismo 59 Suppl. 1: 64-67 (2007).
*
-
Bonkowsky JL, Bohnsack JF, Pennington MJ, Viskochil D, Thompson JA. Leukoencephalopathy, arthritis, colitis, and hypogammaglobulinemia (LACH) in two brothers: a novel syndrome?
Am. J. Med. Genet. 128A: 52-56 (2004).
*
-
Bonnevier JL, Zhang R, Mueller DL. E3 ubiquitin ligases and their control of T cell autoreactivity.
Arthritis Res. Ther. 7: 233-242 (2005).
*
-
Booker MJ, Flint J, Saravana S. Aseptic meningitis in a patient taking etanercept for rheumatoid arthritis: a case report.
Cases J. 1: 364 (2008).
*
-
Bookman AA, Williams KS, Shainhouse JZ. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial.
CMAJ 171: 333-338 (2004).
*
-
Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CG, Limburg PC, Tervaert JW. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study.
Arthritis Rheum. 43: 2025-2033 (2000).
*
-
Boonen A, Vander Cruyssen B, de Vlam K, Steinfeld S, Ribbens C, Lenaerts J, Van den Bosch F, Mielants H, Dewulf L, Vastesaeger N. Spinal radiographic changes in ankylosing spondylitis: association with clinical characteristics and functional outcome.
J. Rheumatol. 36: 1249-1255 (2009).
-
Boot EP, Koning GA, Storm G, Wagenaar-Hilbers JP, van Eden W, Everse LA, Wauben MH. CD134 as target for specific drug delivery to auto-aggressive CD4+ T cells in adjuvant arthritis.
Arthritis Res. Ther. 7: R604-R615 (2005).
*
-
Booth AD, Wallace S, McEniery CM, Yasmin, Brown J, Jayne DR, Wilkinson IB. Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation.
Arthritis Rheum. 50: 581-588 (2004).
*
-
Booth G, Newham P, Barlow R, Raines S, Zheng B, Han S. Gene expression profiles at different stages of collagen-induced arthritis.
Autoimmunity 41: 512-521 (2008).
-
Booth S, Chohan S, Curran JC, Karrison T, Schmitz A, Utset TO. Whole blood viscosity and arterial thrombotic events in patients with systemic lupus erythematosus.
Arthritis Rheum. 57: 845-850 (2007).
*
-
Boots AM, Hubers H, Kouwijzer M, den Hoed-van Zandbrink L, Westrek-Esselink B, van Doorn C, Stenger R, Bos ES, van Lierop MJ, Verheijden GF, Timmers M, van Staveren C. Identification of an altered peptide ligand based on the endogenously presented, rheumatoid arthritis-associated, human cartilage glycoprotein-39 (aa263-275) epitope: an MHC anchor variant peptide for immune modulation.
Arthritis Res. Ther. 9: R71 (2007).
*
-
Booty MG, Chae JJ, Masters SL, Remmers EF, Barham B, Le JM, Barron KS, Holland SM, Kastner DL, Aksentijevich I. Familial Mediterranean fever with a single MEFV mutation: where is the second hit?
Arthritis Rheum. 60: 1851-1861 (2009).
-
Borah BJ, Huang X, Zarotsky V, Globe D. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs.
Curr. Med. Res. Opin. May 8 [Epub ahead of print] (2009).
-
Borba IA. Multiple factors determine the increased prevalence of atherosclerosis in rheumatoid arthritis.
Acta Reumatol. Port. 33: 47-55 (2008).
*
-
Borchardt JK. Focus on small molecule inhibitors for treatment of inflammatory and autoimmune diseases.
Drug News Perspect. 17: 607-614 (2004).
-
Borchers AT, Keen CL, Cheema GS, Gershwin ME. The use of methotrexate in rheumatoid arthritis.
Semin. Arthritis Rheum. 34: 465-483 (2004).
*
-
Borchers AT, Naguwa SM, Keen CL, Gershwin ME. The implications of autoimmunity and pregnancy.
J. Autoimmun. Dec 21 [Epub ahead of print] (2009).
-
Borchers AT, Selmi C, Cheema G, Keen CL, Shoenfeld Y, Gershwin ME. Juvenile idiopathic arthritis.
Autoimmun. Rev. 5: 279-298 (2006).
-
Borea PA, Gessi S, Bar-Yehuda S, Fishman P. A(3) adenosine receptor: pharmacology and role in disease.
Handb. Exp. Pharmacol. 193: 297-327 (2009).
-
Borer JS. Cyclooxygenase inhibition: what should we do to resolve the confusion? An American perspective.
J. Cardiovasc. Pharmacol. 47 Suppl. 1: S87-S91 (2006).
-
Borg AA, Davis MJ, Fowler PD, Shadforth MF, Dawes PT. Rifampicin in early rheumatoid arthritis.
Scand. J. Rheumatol. 22: 39-42 (1993).
-
Borgiani P, Vallo L, D'Apice MR, Giardina E, Pucci S, Capon F, Nistico S, Chimenti S, Pallone F, Novelli G. Exclusion of CARD15/NOD2 as a candidate susceptibility gene to psoriasis in the Italian population.
Eur. J. Dermatol. 12: 540-542 (2002).
*
-
Borman P, Babaoglu S, Gur G, Bingol S, Bodur H. Bone mineral density and bone turnover in patients with psoriatic arthritis.
Clin. Rheumatol. 27: 443-447 (2008).
*
-
Boross P, Verbeek JS. The complex role of Fcgamma receptors in the pathology of arthritis.
Springer Semin. Immunopathol. 28: 339-350 (2006).
*
-
Borowski LC, Lopes RP, Gonzalez TP, Dummer LA, Chies JA, Silveira IG, Keisermann M, Bauer ME. Is steroid resistance related to multidrug resistance-I (MDR-I) in rheumatoid arthritis?
Int. Immunopharmacol. 7: 836-844 (2007).
-
Borras-Blasco J, Gracia-Perez A, Rosique-Robles JD, Castera MD, Abad FJ. Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen.
Expert Opin. Biol. Ther. Jan 8 [Epub ahead of print] (2010).
-
Borras-Blasco J, Gracia-Perez A, Rosique-Robles JD, Nunez-Cornejo C, Castera MD, Abad FJ. Urticaria due to etanercept in a patient with psoriatic arthritis.
South. Med. J. 102: 304-305 (2009).
-
Borras-Blasco J, Nunez-Cornejo C, Gracia-Perez A, Rosique-Robles JD, Castera ME, Viosca E, Abad FJ. Parapharyngeal abscess in a patient receiving etanercept.
Ann. Pharmacother. 41: 341-344 (2007).
-
Borzutzky A, Fried A, Chou J, Bonilla FA, Kim S, Dedeoglu F. NOD2-associated diseases: bridging innate immunity and autoinflammation.
Clin. Immunol. May 23 [Epub ahead of print] (2009).
*
-
Bos JD. Psoriasis, innate immunity, and gene pools.
J. Am. Acad. Dermatol. 56: 468-471 (2007).
-
Bos WE, Thio HB, Neumann HA, van der Fits L, Prens EP. The pathogenesis of inflammatory dermatoses, especially psoriasis.
Ned. Tijdschr. Geneeskd. 150: 179-183 (2006).
-
Bos WH, Bartelds GM, Wolbink GJ, de Koning MH, van de Stadt RJ, van Schaardenburg D, Dijkmans BA, Nurmohamed MT. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
J. Rheumatol. 35: 1972-1977 (2008).
-
Bosch T. Therapeutic apheresis - state of the art in the year 2005.
Ther. Apher. Dial. 9: 459-468 (2005).
*
-
Boschelli DH. Small molecule inhibitors of PKCTheta as potential antiinflammatory therapeutics.
Curr. Top. Med. Chem. 9: 640-654 (2009).
-
Bosco MC, Delfino S, Ferlito F, Puppo M, Gregorio A, Gambini C, Gattorno M, Martini A, Varesio L. The hypoxic synovial environment regulates expression of vascular endothelial growth factor and osteopontin in juvenile idiopathic arthritis.
J. Rheumatol. 36: 1318-1329 (2009).
-
Bosello S, Santoliquido A, Zoli A, Di Campli C, Flore R, Tondi P, Ferraccioli G. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis.
Clin. Rheumatol. 27: 833-839 (2008).
*
-
Botes L, van der Westhuizen FH, Loots du T. Phytochemical contents and antioxidant capacities of two Aloe greatheadii var. davyana extracts.
Molecules 13: 2169-2180 (2008).
-
Botha-Scheepers SA, Watt I, Slagboom E, de Craen AJ, Meulenbelt I, Rosendaal FR, Breedveld FC, Huizinga TW, Kloppenburg M. Innate production of tumor necrosis factor-alpha and interleukin-10 is associated with radiological progression of knee osteoarthritis.
Ann. Rheum. Dis. 67: 1165-1169 (2008).
-
Botsios C, Ostuni P, Sfriso P, Furlan A, Fiocco U, Sgarabotto D, Todesco S. Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects.
Reumatismo 55: 224-235 (2003).
-
Botsios C, Sfriso P, Furlan A, Ostuni P, Biscaro M, Fiocco U, Todesco S, Punzi L. Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis.
Reumatismo 59: 32-37 (2007).
-
Botsios C, Sfriso P, Ostuni PA, Todesco S, Punzi L. Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases.
Rheumatology (Oxford) 46: 1042-1043 (2007).
*
-
Bottcher A, Gaipl US, Furnrohr BG, Herrmann M, Girkontaite I, Kalden JR, Voll RE. Involvement of phosphatidylserine, alphavbeta3, CD14, CD36, and complement C1q in the phagocytosis of primary necrotic lymphocytes by macrophages.
Arthritis Rheum. 54: 927-938 (2006).
*
-
Bottcher Y, Paufler T, Stehr T, Bertschat FL, Paschke R, Koch CA. Thyroid hormone resistance without mutations in thyroid hormone receptor beta.
Med. Sci. Monit. 13: CS67-CS70 (2007).
*
-
Bottiglieri T. S-Adenosyl-L-methionine (SAMe): from the bench to the bedside - molecular basis of a pleiotrophic molecule.
Am. J. Clin. Nutr. 76: 1151S-1157S (2002).
*
-
Bottini N, Vang T, Cucca F, Mustelin T. Role of PTPN22 in type 1 diabetes and other autoimmune diseases.
Semin. Immunol. 18: 207-213 (2006).
*
-
Bottomley WW, Cunliffe WJ. Acute Achilles tendonitis following oral isotretinoin therapy for acne vulgaris.
Clin. Exp. Dermatol. 17: 250-251 (1992).
-
Bouali F, Berrah A, Si Ahmed-Bouali D, Harrieche F, Benhalima M, Hamladji RM, Arrada M. Immunological abnormalities in myelodysplastic syndromes. Prospective study (series of 40 patients).
Rev. Med. Interne. 26: 777-783 (2005).
-
Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation.
Immunol. Rev. 224: 201-214 (2008).
*
-
Bouaziz JD, Yanaba K, Venturi GM, Wang Y, Tisch RM, Poe JC, Tedder TF. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice.
Proc. Natl. Acad. Sci. U.S.A. 104: 20878-20883 (2007).
*
-
Bouchra A, Benbouazza K, Hajjaj-Hassouni N. Guillain-Barre in a patient with ankylosing spondylitis secondary to ulcerative colitis on infliximab therapy.
Clin. Rheumatol. 28 Suppl. 1: S53-S55 (2009).
*
-
Bouis D, Kusumanto Y, Meijer C, Mulder NH, Hospers GA. A review on pro- and anti-angiogenic factors as targets of clinical intervention.
Pharmacol. Res. 53: 89-103 (2006).
*
-
Boulman N, Slobodin G, Rozenbaum M, Rosner I. Calcinosis in rheumatic diseases.
Semin. Arthritis Rheum. 34: 805-812 (2005).
*
-
Boulton JG, Bourne JT. Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis.
Rheumatology (Oxford) 46: 178-179 (2007).
*
-
Bouquillard E, Combe B. A report of 21 cases of rheumatoid arthritis following Chikungunya fever. A mean follow-up of two years.
Joint Bone Spine 76: 654-657 (2009).
*
-
Bourcier ME, Vinik AI. A 41-year-old man with polyarthritis and severe autonomic neuropathy.
Ther. Clin. Risk Manag. 4: 837-842 (2008).
*
-
Bourgault-Rouxel AS, Loughran TP, Zambello R, Epling-Burnette PK, Semenzato G, Donadieu J, Amiot L, Fest T, Lamy T. Clinical spectrum of gammadelta+ T cell LGL leukemia: analysis of 20 cases.
Leuk. Res. 32: 45-48 (2008).
-
Bourikas LA, Papadakis KA. Musculoskeletal manifestations of inflammatory bowel disease.
Inflamm. Bowel Dis. 15: 1915-1924 (2009).
*
-
Bourikas LA, Sidiropoulos PI, Goulielmos GN, Boumpas DT, Kritikos HD. Concomitant onset of Graves disease and rheumatoid arthritis after a serious life event.
J. Clin. Rheumatol. 12: 326-327 (2006).
-
Bourne T, Fossati G, Nesbitt A. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
BioDrugs 22: 331-337 (2008).
-
Bouros D, Pneumatikos I, Tzouvelekis A. Pleural involvement in systemic autoimmune disorders.
Respiration 75: 361-371 (2008).
*
-
Bourrie B, Bribes E, Derocq JM, Vidal H, Casellas P. Sigma receptor ligands: applications in inflammation and oncology.
Curr. Opin. Investig. Drugs 5: 1158-1163 (2004).
-
Boutry N, Carmo CC, Flipo RM, Cotten A. Early rheumatoid arthritis and its differentiation from other joint abnormalities.
Eur. J. Radiol. 71: 217-224 (2009).
-
Bouysset M, Noel E, Tebib JG. Rheumatoid arthritis: a general disease and local diseases.
Rev. Prat. 55: 2121-2133 (2005).
-
Bouyssie D, Gonzalez de Peredo A, Mouton E, Albigot R, Roussel L, Ortega N, Cayrol C, Burlet-Schiltz O, Girard JP, Monsarrat B. Mascot file parsing and quantification (MFPaQ), a new software to parse, validate, and quantify proteomics data generated by ICAT and SILAC mass spectrometric analyses: application to the proteomics study of membrane proteins from primary
Mol. Cell. Proteomics 6: 1621-1637 (2007).
*
-
Bovin LF, Brynskov J, Hegedus L, Jess T, Nielsen CH, Bendtzen K. Gene expression profiling in autoimmune diseases: chronic inflammation or disease specific patterns?
Autoimmunity 40: 191-201 (2007).
-
Bovin LF, Rieneck K, Workman C, Nielsen H, Sorensen SF, Skjodt H, Florescu A, Brunak S, Bendtzen K. Blood cell gene expression profiling in rheumatoid arthritis. Discriminative genes and effect of rheumatoid factor.
Immunol. Lett. 93: 217-226 (2004).
-
Bowcock AM. Understanding the pathogenesis of psoriasis, psoriatic arthritis, and autoimmunity via a fusion of molecular genetics and immunology.
Immunol. Res. 32: 45-56 (2005).
*
-
Bowcock AM, Cookson WO. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis.
Hum. Mol. Genet. 13 Suppl. 1: R43-R55 (2004).
*
-
Bowes J, Barton A. Recent advances in the genetics of RA susceptibility.
Rheumatology (Oxford) 47: 399-402 (2008).
*
-
Bowes JD, Potter C, Gibbons LJ, Hyrich K, Plant D, Morgan AW, Wilson AG, Isaacs JD, Worthington J, Barton A; BRAGGSS. Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients.
Pharmacogenet. Genomics 19: 319-323 (2009).
-
Bowie VL, Snella KA, Gopalachar AS, Bharadwaj P. Listeria meningitis associated with infliximab.
Ann. Pharmacother. 38: 58-61 (2004).
-
Bowman SJ, Booth DA, Platts RG. Measurement of fatigue and discomfort in primary Sjogren's syndrome using a new questionnaire tool.
Rheumatology (Oxford) 43: 758-764 (2004).
*
-
Bowness P. HLA B27 in health and disease: a double-edged sword?
Rheumatology (Oxford) 41: 857-868 (2002).
*
-
Boyce BF, Li P, Yao Z, Zhang Q, Badell IR, Schwarz EM, O'keefe RJ, Xing L. TNFa and pathologic bone resorption.
Keio. J. Med. 54: 127-131 (2005).
*
-
Boyce BF, Schwarz EM, Xing L. Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease.
Curr. Opin. Rheumatol. 18: 427-432 (2006).
-
Boyer JF, Balard P, Authier H, Faucon B, Bernad J, Mazieres B, Davignon JL, Cantagrel A, Pipy B, Constantin A. TNF alpha and adalimumab differentially regulate CD36 expression in human monocytes.
Arthritis Res. Ther. 9: R22 (2007).
*
-
Boyle DL, Jones TL, Hammaker D, Svensson CI, Rosengren S, Albani S, Sorkin L, Firestein GS. Regulation of peripheral inflammation by spinal p38 MAP kinase in rats.
PLoS Med. 3: e338 (2006).
*
-
Boyle DL, Kavanaugh A. The pathobiology of psoriatic synovium.
Curr. Opin. Rheumatol. 20: 404-407 (2008).
-
Boyle K, Egan P, Rakar S, Willson TA, Wicks IP, Metcalf D, Hilton DJ, Nicola NA, Alexander WS, Roberts AW, Robb L. The SOCS box of suppressor of cytokine signaling-3 contributes to the control of G-CSF responsiveness in vivo.
Blood 110: 1466-1474 (2007).
*
-
Boyman O, Conrad C, Tonel G, Gilliet M, Nestle FO. The pathogenic role of tissue-resident immune cells in psoriasis.
Trends Immunol. 28: 51-57 (2007).
*
-
Bracewell C, Isaacs J, Emery P, Ng W. Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis.
Expert Opin. Biol. Ther. 9: 909-919 (2009).
-
Braddock M, Murray C. 10th Anniversary Inflammation and Immune Diseases Drug Discovery and Development Summit 20 - 21 March 2006, New Brunswick, USA.
Expert Opin. Investig. Drugs 15: 721-727 (2006).
-
Bradley DS, Nabozny GH, Cheng S, Zhou P, Griffiths MM, Luthra HS, David CS. HLA-DQB1 polymorphism determines incidence, onset, and severity of collagen-induced arthritis in transgenic mice. Implications in human rheumatoid arthritis.
J. Clin. Invest. 100: 2227-2234 (1997).
*
-
Bradley J. TNF-mediated inflammatory disease.
J. Pathol. 214: 149-160 (2008).
*
-
Bradley JD, Dmitrienko AA, Kivitz AJ, Gluck OS, Weaver AL, Wiesenhutter C, Myers SL, Sides GD. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis.
J. Rheumatol. 32: 417-423 (2005).
-
Bradley JD, Flusser D, Katz BP, Schumacher HR Jr, Brandt KD, Chambers MA, Zonay LJ. A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis.
J. Rheumatol. 21: 905-911 (1994).
-
Bradna P. Gout and diabetes.
Vnitr. Lek. 52: 488-492 (2006).
-
Brahn E, Banquerigo ML, Lee JK, Park EJ, Fogler WE, Plum SM. An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor.
J. Rheumatol. 35: 2119-2128 (2008).
-
Brakenhoff LK, van der Heijde DM, Hommes DW, Huizinga TW, Fidder HH. The joint-gut axis in inflammatory bowel diseases.
Journal of Crohn's and Colitis [In Press] (2009).
-
Bramlage CP, Kaps C, Ungethum U, Bramlage P, Koziolek M, Wessels J, Krenn V, Pruss A, Muller GA, Strutz F, Burmester GR, Haupl T. Modulatory effects of inflammation and therapy on GDF-5 expression in rheumatoid arthritis synovium.
Scand. J. Rheumatol. 37: 401-409 (2008).
*
-
Brand A, Griffiths DJ, Herve C, Mallon E, Venables PJ. Human retrovirus-5 in rheumatic disease.
J. Autoimmun. 13: 149-154 (1999).
-
Brand DD, Kang AH, Rosloniec EF. Immunopathogenesis of collagen arthritis.
Springer Semin. Immunopathol. 25: 3-18 (2003).
*
-
Brand DD, Kang AH, Rosloniec EF. The mouse model of collagen-induced arthritis.
Methods Mol. Med. 102: 295-312 (2004).
-
Brand DD, Latham KA, Rosloniec EF. Collagen-induced arthritis.
Nat. Protoc. 2: 1269-1275 (2007).
*
-
Brandt J, Braun J. Anti-TNF-alpha agents in the treatment of psoriatic arthritis.
Expert Opin. Biol. Ther. 6: 99-107 (2006).
-
Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Rudwaleit M, Sieper J, Braun J. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept.
J. Rheumatol. 31: 531-538 (2004).
-
Brant SR. Exposed: the genetic underpinnings of ulcerative colitis relative to Crohn's disease.
Gastroenterology 136: 396-399 (2009).
*
-
Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Balloum M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES. R406, an orally svailable Syk kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation.
J. Pharmacol. Exp. Ther. 319: 998-1008 (2006).
*
-
Bratcher JM, Korelitz BI. Toxicity of infliximab in the course of treatment of Crohn's disease.
Expert Opin. Drug Saf. 5: 9-16 (2006).
-
Brauer DJ. A method for pattern recognition.
Res. Theory Nurs. Pract. 20: 277-289 (2006).
-
Braun J. Therapy of spondyloarthritides.
Adv. Exp. Med. Biol. 649: 133-147 (2009).
-
Braun J. Epidemiology and prognosis of ankylosing spondylitis.
Radiologe 44: 209-210, 212-216 (2004).
-
Braun J, Baraliakos X. Treatment of ankylosing spondylitis and other spondyloarthritides.
Curr. Opin. Rheumatol. 21: 324-334 (2009).
-
Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
Arthritis Rheum. 57: 639-647 (2007).
*
-
Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors.
Arthritis Rheum. 41: 58-67 (1998).
*
-
Braun J, de Keyser F, Brandt J, Mielants H, Sieper J, Veys E. New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy.
Curr. Opin. Rheumatol. 13: 245-249 (2001).
-
Braun J, Sieper J. Spondylarthritides.
Z. Rheumatol. 65: 613-632 (2006).
-
Braun J, Sieper J. Early diagnosis of spondyloarthritis.
Nat. Clin. Pract. Rheumatol. 2: 536-545 (2006).
*
-
Braun J, Sieper J. Biological therapies in the spondyloarthritides - the current state.
Rheumatology (Oxford) 43: 1072-1084 (2004).
*
-
Braun J, Sieper J. Rheumatologic manifestations of gastrointestinal disorders.
Curr. Opin. Rheumatol. 11: 68-74 (1999).
-
Braun J, Sieper J. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases.
Expert Opin. Biol. Ther. 3: 141-168 (2003).
-
Braun J, van der Heijde D. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides.
Expert Opin. Investig. Drugs 12: 1097-1109 (2003).
-
Braun J, Zochling J, Baraliakos X, Alten RH, Burmester GR, Grasedyck K, Brandt J, Haibel H, Hammer M, Krause A, Mielke F, Tony HP, Ebner W, Gomor B, Hermann J, Zeidler H, Beck E, Baumgaertner M, Sieper J. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomized controlled trial.
Ann. Rheum. Dis. 65: 1147-1153 (2006).
*
-
Braun WE. HLA molecules in autoimmune diseases.
Clin. Biochem. 25: 187-191 (1992).
*
-
Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Isr. Med. Assoc. J. 10: 277-281 (2008).
*
-
Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M, Dain L, Hoffer E, Nahir AM, Balbir-Gurman A. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
J. Rheumatol. 33: 497-500 (2006).
-
Braun-Moscovici Y, Schapira D, Balbir-Gurman A, Sevilia R, Nahir AM. Ticlopidine-induced lupus.
J. Clin. Rheumatol. 7: 102-105 (2001).
-
Braun-Moscovici Y, Toledano K, Markovits D, Rozin A, Nahir AM, Balbir-Gurman A. Vitamin D level: is it related to disease activity in inflammatory joint disease?
Rheumatol. Int. Dec 23 [Epub ahead of print] (2009).
*
-
Bravo Vergel Y, Hawkins NS, Claxton K, Asseburg C, Palmer S, Woolacott N, Bruce IN, Sculpher MJ. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.
Rheumatology (Oxford) 46: 1729-1735 (2007).
*
-
Braybrook C. Are patients with rheumatoid arthritis prone to accelerated atherosclerosis?
Nat. Clin. Pract. Cardiovasc. Med. 3: 296-297 (2006).
-
Breban M, Falgarone G, Blanchard H, Dernis-Labous E, Lamarque D. Animal models of the spondyloarthropathies.
Curr. Rheumatol. Rep. 2: 282-287 (2000).
-
Breban M, Hacquard-Bouder C, Falgarone G. Animal models of HLA-B27-associated diseases.
Curr. Mol. Med. 4: 31-40 (2004).
-
Brechter AB, Persson E, Lundgren I, Lerner UH. Kinin B1 and B2 receptor expression in osteoblasts and fibroblasts is enhanced by interleukin-1 and tumour necrosis factor-alpha. Effects dependent on activation of NF-kappaB and MAP kinases.
Bone 43: 72-83 (2008).
*
-
Breda L, Nozzi M, De Sanctis S, Chiarelli F. Laboratory tests in the diagnosis and follow-up of pediatric rheumatic diseases: an update.
Semin. Arthritis Rheum. Feb 24 [Epub ahead of print] (2009).
*
-
Breedveld FC. Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept.
Ned. Tijdschr. Geneeskd. 149: 2273-2277 (2005).
-
Breedveld FC. Current and future management approaches for rheumatoid arthritis.
Arthritis Res. 4 Suppl. 2: S16-S21 (2002).
*
-
Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR, St Clair EW, Weisman M, Smolen J, Lipsky PE, Maini RN. Infliximab in active early rheumatoid arthritis.
Ann. Rheum. Dis. 63: 149-155 (2004).
*
-
Brenn D, Richter F, Schaible HG. Sensitization of unmyelinated sensory fibers of the joint nerve to mechanical stimuli by interleukin-6 in the rat: an inflammatory mechanism of joint pain.
Arthritis Rheum. 56: 351-359 (2007).
*
-
Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, Symmons D. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
Rheumatology (Oxford) 46: 1345-1354 (2007).
*
-
Brennan F, Beech J. Update on cytokines in rheumatoid arthritis.
Curr. Opin. Rheumatol. 19: 296-301 (2007).
-
Brennan FM, Maini RN, Feldmann M. Cytokine expression in chronic inflammatory disease.
Br. Med. Bull. 51: 368-384 (1995).
-
Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis.
J. Clin. Invest. 118: 3537-3545 (2008).
*
-
Brennan P, Hajeer A, Ong KR, Worthington J, John S, Thomson W, Silman A, Ollier B. Allelic markers close to prolactin are associated with HLA-DRB1 susceptibility alleles among women with rheumatoid arthritis and systemic lupus erythematosus.
Arthritis Rheum. 40: 1383-1386 (1997).
-
Brennan P, Ollier B, Worthington J, Hajeer A, Silman A. Are both genetic and reproductive associations with rheumatoid arthritis linked to prolactin?
Lancet 348: 106-109 (1996).
*
-
Brenner M, Laragione T, Mello A, Gulko PS. Cia25 on rat chromosome 12 regulates severity of autoimmune arthritis induced with pristane and collagen.
Ann. Rheum. Dis. 66: 952-957 (2007).
*
-
Brenner M, Laragione T, Yarlett NC, Gulko PS. Genetic regulation of T regulatory, CD4, and CD8 cell numbers by the arthritis severity loci Cia5a, Cia5d, and the MHC/Cia1 in the rat.
Mol. Med. 13: 277-287 (2007).
*
-
Brenner M, Laragione T, Yarlett NC, Li W, Mello A, Gulko PS. Cia27 is a novel non-MHC arthritis severity locus on rat chromosome 10 syntenic to the rheumatoid arthritis 17q22-q25 locus.
Genes Immun. 7: 335-341 (2006).
*
-
Brenner M, Meng HC, Yarlett NC, Griffiths MM, Remmers EF, Wilder RL, Gulko PS. The non-major histocompatibility complex quantitative trait locus Cia10 contains a major arthritis gene and regulates disease severity, pannus formation, and joint damage.
Arthritis Rheum. 52: 322-332 (2005).
*
-
Brenol CV, Chies JA, Brenol JC, Monticielo OA, Franciscatto P, Birriel F, Neves AG, Xavier RM. Endothelial nitric oxide synthase T-786C polymorphism in rheumatoid arthritis: association with extraarticular manifestations.
Clin. Rheumatol. 28: 201-205 (2009).
-
Brenol CV, Monticielo OA, Xavier RM, Brenol JC. Rheumatoid arthritis and atherosclerosis.
Rev. Assoc. Med. Bras. 53: 465-470 (2007).
-
Brentano F, Kyburz D, Gay S. Toll-like receptors and rheumatoid arthritis.
Methods Mol. Biol. 517: 1-15 (2009).
*
-
Brentano F, Kyburz D, Schorr O, Gay R, Gay S. The role of Toll-like receptor signalling in the pathogenesis of arthritis.
Cell. Immunol. 233: 90-96 (2005).
*
-
Brentano F, Ospelt C, Stanczyk J, Gay RE, Gay S, Kyburz D. Abundant expression of the interleukin (IL)23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: differential expression and Toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis.
Ann. Rheum. Dis. 68: 143-150 (2009).
-
Brentano F, Schorr O, Ospelt C, Stanczyk J, Gay RE, Gay S, Kyburz D. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities.
Arthritis Rheum. 56: 2829-2839 (2007).
*
-
Bresnihan B. Synovial biomarkers in the spondylarthropathies.
Curr. Opin. Rheumatol. 18: 359-363 (2006).
-
Bressan E, De Queiroz Cunha F, Tonussi CR. Contribution of TNFalpha, IL-1beta and CINC-1 for articular incapacitation, edema and cell migration in a model of LPS-induced reactive arthritis.
Cytokine 36: 83-89 (2006).
-
Brewer GJ. Anticopper therapy against cancer and diseases of inflammation and fibrosis.
Drug Discov. Today. 10: 1103-1109 (2005).
-
Breza TS Jr, Magro CM. Lichenoid and granulomatous dermatitis associated with atypical mycobacterium infections.
J. Cutan. Pathol. 33: 512-515 (2006).
*
-
Brezinschek HP, Brickmann K, Yazdani-Biuki B, Dorner T, Graninger WB, Brezinschek RI. Treatment of rheumatoid arthritis in the 21st century: targeting B-lymphocytes.
Wien. Med. Wochenschr. 156: 61-67 (2006).
-
Brezski RJ, Vafa O, Petrone D, Tam SH, Powers G, Ryan MH, Luongo JL, Oberholtzer A, Knight DM, Jordan RE. Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge.
Proc. Natl. Acad. Sci. U.S.A. 106: 17864-17869 (2009).
*
-
Brickman CM, Tsokos GC, Balow JE, Lawley TJ, Santaella M, Hammer CH, Frank MM. Immunoregulatory disorders associated with hereditary angioedema. I. Clinical manifestations of autoimmune disease.
J. Allergy Clin. Immunol. 77: 749-757 (1986).
-
Bridges SL Jr, Jenq G, Moran M, Kuffner T, Whitworth WC, McNicholl J. Single-nucleotide polymorphisms in tumor necrosis factor receptor genes: definition of novel haplotypes and racial/ethnic differences.
Arthritis Rheum. 46: 2045-2050 (2002).
*
-
Briggs D, Stephens C, Vaughan R, Welsh K, Black C. A molecular and serologic analysis of the major histocompatibility complex and complement component C4 in systemic sclerosis.
Arthritis Rheum. 36: 943-954 (1993).
-
Briggs FB, Ramsay PP, Madden E, Norris JM, Holers VM, Mikuls TR, Sokka T, Seldin MF, Gregersen PK, Criswell LA, Barcellos LF. Supervised machine learning and logistic regression identifies novel epistatic risk factors with PTPN22 for rheumatoid arthritis.
Genes Immun. Jan 21 [Epub ahead of print] (2010).
-
Bright JJ. Curcumin and autoimmune disease.
Adv. Exp. Med. Biol. 595: 425-451 (2007).
-
Brik R, Gepstein V, Shahar E, Goldsher D, Berkovitz D. Tumor necrosis factor blockade in the management of children with orphan diseases.
Clin. Rheumatol. 26: 1783-1785 (2007).
*
-
Brik R, Livnat G, Pollack S, Catz R, Nagler R. Salivary gland involvement and oxidative stress in juvenile idiopathic arthritis: novel observation in oligoarticular-type patients.
J. Rheumatol. 33: 2532-2537 (2006).
-
Brik R, Rosen I, Savulescu D, Borovoi I, Gavish M, Nagler R. Salivary antioxidants and metalloproteinases in juvenile idiopathic arthritis.
Mol. Med. Jan 9 [Epub ahead of print] (2010).
*
-
Brinar VV, Petelin Z, Brinar M, Djakovic V, Zadro I, Vranjes D. CNS demyelination in autoimmune diseases.
Clin. Neurol. Neurosurg. 108: 318-326 (2006).
-
Brinckerhoff CE, Sporn MB. Retinoids and rexinoids for the 21st century: a brave new world for arthritis.
J. Rheumatol. 30: 211-213 (2003).
-
Brinkman DM, Jol-van der Zijde CM, Ten Dam MM, Te Boekhorst PA, Ten Cate R, Wulffraat NM, Hintzen RQ, Vossen JM, van Tol MJ. Resetting the adaptive immune system after autologous stem cell transplantation: lessons from responses to vaccines.
J. Clin. Immunol. 27: 647-658 (2007).
*
-
Brintnell W, Bell DA, Hill JA, Jevnikar AM, Sette A, Sidney J, Doege K, Cairns E. The influence of MHC class II molecules containing the rheumatoid arthritis shared epitope on the immune response to aggrecan G1 and its peptides.
Scand. J. Immunol. 65: 444-452 (2007).
*
-
Brintnell W, Zeggini E, Barton A, Thomson W, Eyre S, Hinks A, Silman AJ, Worthington J. Evidence for a novel rheumatoid arthritis susceptibility locus on chromosome 6p.
Arthritis Rheum. 50: 3823-3830 (2004).
*
-
Brinton LA, Buckley LM, Dvorkina O, Lubin JH, Colton T, Murray MC, Hoover R. Risk of connective tissue disorders among breast implant patients.
Am. J. Epidemiol. 160: 619-627 (2004).
*
-
Brinza D, Zelikovsky A. Design and validation of methods searching for risk factors in genotype case-control studies.
J. Comput. Biol. 15: 81-90 (2008).
-
Briot K, Roux C, Gossec L, Charni N, Kolta S, Dougados M, Garnero P. Effects of etanercept on serum biochemical markers of cartilage metabolism in patients with spondyloarthropathy.
J. Rheumatol. 35: 310-314 (2008).
-
Brito-Zeron P, Soria N, Munoz S, Bove A, Akasbi M, Belenguer R, Siso A, Ramos-Casals M. Prevalence and clinical relevance of autoimmune neutropenia in patients with primary Sjogren's syndrome.
Semin. Arthritis Rheum. 38: 389-395 (2009).
*
-
Britto MT, Devellis RF, Hornung RW, Defriese GH, Atherton HD, Slap GB. Health care preferences and priorities of adolescents with chronic illnesses.
Pediatrics 114: 1272-1280 (2004).
*
-
Britto MT, Jimison HB, Munafo JK, Wissman J, Rogers ML, Hersh W. Usability testing finds new problems for novice users of pediatric portals.
J. Am. Med. Inform. Assoc. 16: 660-669 (2009).
-
Brockhausen I. The role of galactosyltransferases in cell surface functions and in the immune system.
Drug News Perspect. 19: 401-409 (2006).
-
Brocq O, Roux CH, Albert C, Breuil V, Aknouche N, Ruitord S, Mousnier A, Euller-Ziegler L. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease.
Joint Bone Spine 74: 148-154 (2007).
*
-
Brodmerkel CM, Vaddi K. Transgenic animals in inflammatory disease models.
Curr. Opin. Biotechnol. 14: 652-658 (2003).
*
-
Brodsky B, Erlanger-Rosengarten A, Proscura E, Shapira E, Wormser U. From topical antidote against skin irritants to a novel counter-irritating and anti-inflammatory peptide.
Toxicol. Appl. Pharmacol. 229: 342-350 (2008).
*
-
Brodszky V, Balint P, Geher P, Hodinka L, Horvath G, Koo E, Pentek M, Polgar A, Sesztak M, Szanto S, Ujfalussy I, Gulacsi L. Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment.
Rheumatol. Int. Apr 19 [Epub ahead of print] (2009).
*
-
Brodszky V, Pentek M, Gulacsi L. Efficacy of adalimumab, etanercept, and infliximab in psoriatic arthritis based on ACR50 response after 24 weeks of treatment.
Scand. J. Rheumatol. 37: 399-400 (2008).
*
-
Broen J, Gourh P, Rueda B, Coenen M, Mayes M, Martin J, Arnett FC, Radstake TR; European Consortium on Systemic Sclerosis Genetics. The FAS -670A>G polymorphism influences susceptibility to systemic sclerosis phenotypes.
Arthritis Rheum. 60: 3815-3820 (2009).
*
-
Broere F, Wieten L, Klein Koerkamp EI, van Roon JA, Guichelaar T, Lafeber FP, van Eden W. Oral or nasal antigen induces regulatory T cells that suppress arthritis and proliferation of arthritogenic T cells in joint draining lymph nodes.
J. Immunol. 181: 899-906 (2008).
*
-
Brogan PA, Malik M, Shah N, Kilday JP, Ramsay A, Shah V, Murch SH, Thomson MA, Walker-Smith JA, Lindley KJ, Milla PJ, Dillon MJ. Systemic vasculitis: a cause of indeterminate intestinal inflammation.
J. Pediatr. Gastroenterol. Nutr. 42: 405-415 (2006).
*
-
Brogan PA, Shah V, Klein N, Dillon MJ. Vbeta-restricted T cell adherence to endothelial cells: a mechanism for superantigen-dependent vascular injury.
Arthritis Rheum. 50: 589-597 (2004).
*
-
Broholm B, Ullman S, Halberg P, Jacobsen S. Deterioration of lung function is associated with presence of IgM rheumatoid factor and smoking in patients with systemic sclerosis.
Clin. Rheumatol. 27: 1053-1056 (2008).
*
-
Bronson PG, Criswell LA, Barcellos LF. The MHC2TA -168A/G polymorphism and risk for rheumatoid arthritis: a meta-analysis of 6,861 patients and 9,270 controls reveals no evidence for association.
Ann. Rheum. Dis. 67: 933-936 (2008).
-
Bronson PG, Komorowski LK, Ramsay PP, May SL, Noble J, Lane JA, Thomson G, Claas FH, Seldin MF, Kelly JA, Harley JB, Moser KL, Gaffney PM, Behrens T, Criswell LA, Barcellos LF. Analysis of maternal-offspring HLA compatibility, parent-of-origin and noninherited effects for HLA-DRB1 in systemic lupus erythematosus.
Arthritis Rheum. Feb 26 [Epub ahead of print] (2010).
-
Brooklyn TN, Williams AM, Dunnill MG, Probert CS. T-cell receptor repertoire in pyoderma gangrenosum: evidence for clonal expansions and trafficking.
Br. J. Dermatol. 157: 960-966 (2007).
*
-
Brooks AJ, Begg EJ, Zhang M, Frampton CM, Barclay ML. Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease.
Ther. Drug Monit. 29: 619-625 (2007).
-
Brooks PM. The burden of musculoskeletal disease - a global perspective.
Clin. Rheumatol. 25: 778-781 (2006).
*
-
Brooks PM. Hematopoietic stem cell transplantation for autoimmune diseases.
J. Rheumatol. Suppl. 48: 19-22 (1997).
-
Brooks WH. Autoimmune disorders result from loss of epigenetic control following chromosome damage.
Med. Hypotheses 64: 590-598 (2005).
-
Brooks WH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y. Epigenetics and autoimmunity.
J. Autoimmun. Jan 4 [Epub ahead of print] (2010).
-
Brophy JM. Cardiovascular effects of cyclooxygenase-2 inhibitors.
Curr. Opin. Gastroenterol. 23: 617-624 (2007).
-
Brophy S, Pavy S, Lewis P, Taylor G, Bradbury L, Robertson D, Lovell C, Calin A. Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors.
J. Rheumatol. 28: 2667-2673 (2001).
-
Broughton SS, Meyerhoff WE, Cohen SB. Immune-mediated inner ear disease: 10-year experience.
Semin. Arthritis Rheum. 34: 544-548 (2004).
*
-
Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery P. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression.
Arthritis Rheum. 54: 3761-3773 (2006).
*
-
Brown C, Gaspar J, Pettit A, Lee R, Gu X, Wang H, Manning C, Voland C, Goldring SR, Goldring MB, Libermann TA, Gravalllese EM, Oettgen P. ESE-1 is a novel transcriptional mediator of angiopoietin-1 expression in the setting of inflammation.
J. Biol. Chem. 279: 12794-12803 (2004).
*
-
Brown DA, Moore J, Johnen H, Smeets TJ, Bauskin AR, Kuffner T, Weedon H, Milliken ST, Tak PP, Smith MD, Breit SN. Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction.
Arthritis Rheum. 56: 753-764 (2007).
*
-
Brown JM, Pfau JC, Pershouse MA, Holian A. Silica, apoptosis, and autoimmunity.
J. Immunotoxicol. 1: 177-187 (2005).
-
Brown KD, Claudio E, Siebenlist U. The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis.
Arthritis Res. Ther. 10: 212 (2008).
*
-
Brown KK, Heitmeyer SA, Hookfin EB, Hsieh L, Buchalova M, Taiwo YO, Janusz MJ. P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis.
J. Inflamm. (Lond.) 5: 22 (2008).
*
-
Brown KS, Nackos E, Morthala S, Jensen LE, Whitehead AS, VON Feldt JM. Independent role of conventional cardiovascular risk factors as predictors of C-reactive protein concentrations in rheumatoid arthritis.
J. Rheumatol. 34: 740-746 (2007).
-
Brown LC, Majumdar SR, Newman SC, Johnson JA. Type 2 diabetes does not increase risk of depression.
CMAJ 175: 42-46 (2006).
*
-
Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders.
Blood 111: 3388-3394 (2008).
*
-
Brown M, Newton J, Harney SM, Wordsworth P. Challenges in mapping non-HLA-DRB1 major histocompatibility genes in rheumatoid arthritis: comment on the article by Vignal et al.
Arthritis Rheum. 60: 2207 (2009).
*
-
Brown MA, Brophy S, Bradbury L, Hamersma J, Timms A, Laval S, Cardon L, Calin A, Wordsworth BP. Identification of major loci controlling clinical manifestations of ankylosing spondylitis.
Arthritis Rheum. 48: 2234-2239 (2003).
*
-
Brown MA, Duncan EL. Genetic studies of osteoporosis.
Expert Rev. Mol. Med. 1: 1-18 (1999).
*
-
Brown MA, Pile KD, Kennedy LG, Campbell D, Andrew L, March R, Shatford JL, Weeks DE, Calin A, Wordsworth BP. A genome-wide screen for susceptibility loci in ankylosing spondylitis.
Arthritis Rheum. 41: 588-595 (1998).
*
-
Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.
Arthritis Rheum. 46: 3151-3158 (2002).
*
-
Brown WM. Anti-CD3 antibody MacroGenics Inc.
Curr. Opin. Investig. Drugs 7: 381-388 (2006).
-
Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment.
Nat. Rev. Drug Discov. 5: 564-576 (2006).
*
-
Brownlie RJ, Lawlor KE, Niederer HA, Cutler AJ, Xiang Z, Clatworthy MR, Floto RA, Greaves DR, Lyons PA, Smith KG. Distinct cell-specific control of autoimmunity and infection by FcgammaRIIb.
J. Exp. Med. 205: 883-895 (2008).
*
-
Brownlie RJ, Myers LK, Wooley PH, Corrigall VM, Bodman-Smith MD, Panayi GS, Thompson SJ. Treatment of murine collagen-induced arthritis by the stress protein BiP via interleukin-4-producing regulatory T cells: a novel function for an ancient protein.
Arthritis Rheum. 54: 854-863 (2006).
*
-
Brucato A, Brambilla G, Moreo A, Alberti A, Munforti C, Ghirardello A, Doria A, Shinar Y, Livneh A, Adler Y, Shoenfeld Y, Mauri F, Palmieri G, Spodick DH. Long-term outcomes in difficult-to-treat patients with recurrent pericarditis.
Am. J. Cardiol. 98: 267-271 (2006).
*
-
Brucato A, Shinar Y, Brambilla G, Robbiolo L, Ferrioli G, Patrosso MC, Zanni D, Penco S, Boiani E, Ghirardello A, Caforio AL, Bergantin A, Tombini V, Moreo A, Ashtamkar L, Doria A, Shoenfeld Y, Livneh A. Idiopathic recurrent acute pericarditis: familial Mediterranean fever mutations and disease evolution in a large cohort of Caucasian patients.
Lupus 14: 670-674 (2005).
-
Bruce IN, Gladman DD. Psoriatic arthritis: recognition and management.
BioDrugs 9: 271-278 (1998).
-
Bruce SP, Boyce EG. Update on abatacept: a selective costimulation modulator for rheumatoid arthritis.
Ann. Pharmacother. 41: 1153-1162 (2007).
-
Bruchfeld A, Qureshi AR, Lindholm B, Barany P, Yang L, Stenvinkel P, Tracey KJ. High mobility group box protein-1 correlates with renal function in chronic kidney disease (CKD).
Mol. Med. 14: 109-115 (2008).
*
-
Bruggraber SF, Leung PS, Amano K, Quan C, Kurth MJ, Nantz MH, Benson GD, Van de Water J, Luketic V, Roche TE, Ansari AA, Coppel RL, Gershwin ME. Autoreactivity to lipoate and a conjugated form of lipoate in primary biliary cirrhosis.
Gastroenterology 125: 1705-1713 (2003).
*
-
Bruhl H, Cihak J, Plachy J, Kunz-Schughart L, Niedermeier M, Denzel A, Rodriguez Gomez M, Talke Y, Luckow B, Stangassinger M, Mack M. Targeting of Gr-1+,CCR2+ monocytes in collagen-induced arthritis.
Arthritis Rheum. 56: 2975-2985 (2007).
*
-
Bruhl H, Cihak J, Schneider MA, Plachy J, Rupp T, Wenzel I, Shakarami M, Milz S, Ellwart JW, Stangassinger M, Schlondorff D, Mack M. Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells.
J. Immunol. 172: 890-898 (2004).
*
-
Brulhart L, Ciurea A, Finckh A, Notter A, Waldburger JM, Kyburz D, Gabay C. Efficacy of B-cell depletion in rheumatoid arthritis patients refractory to anti-tumour necrosis factor (TNF)- a agents: an open label observational study.
Ann. Rheum. Dis. 65: 1255-1257 (2006).
*
-
Brumeanu TD, Bona CA, Casares S. T-cell tolerance and autoimmune diabetes.
Int. Rev. Immunol. 20: 301-331 (2001).
-
Brunner HI, Kim KN, Ballinger SH, Bowyer SL, Griffin TA, Higgins GC, Mier R, Passo MH, Rennebohm R, Schikler K, Lovell DJ. Current medication choices in juvenile rheumatoid arthritis II - update of a survey performed in 1993.
J. Clin. Rheumatol. 7: 295-300 (2001).
-
Brunner J, Kern PM, Gaipl US, Munoz LE, Voll RE, Kalden JR, Wiesenhutter CW, Herrmann M. The low-throughput protein A adsorber: an immune modulatory device. Hypothesis for the mechanism of action in the treatment of rheumatoid arthritis.
Mod. Rheumatol. 15: 9-18 (2005).
-
Brunner J, Sitzmann FC. The diagnostic value of anti-cyclic citrullinated peptide (CCP) antibodies in children with Juvenile Idiopathic Arthritis.
Clin. Exp. Rheumatol. 24: 449-451 (2006).
-
Brunner JK, Sitzmann FC. Anticyclic citrullinated peptide antibodies in juvenile idiopathic arthritis.
Mod. Rheumatol. 16: 372-375 (2006).
*
-
Brunner M, Greinix HT, Redlich K, Knobl P, Smolen J, Leitner G, Derfler K, Graninger W, Kalhs P, Machold K. Autologous blood stem cell transplantation in refractory systemic lupus erythematosus with severe pulmonary impairment: a case report.
Arthritis Rheum. 46: 1580-1584 (2002).
*
-
Bruno MA, Cuello AC. Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade.
Proc. Natl. Acad. Sci. U.S.A. 103: 6735-6740 (2006).
*
-
Bruno O, Brullo C, Arduino N, Schenone S, Ranise A, Bondavalli F, Ottonello L, Dapino P, Dallegri F. Synthesis and biological evaluation of neutrophilic inflammation inhibitors.
Farmaco 59: 223-235 (2004).
-
Bruns L, Frey O, Morawietz L, Landgraf C, Volkmer R, Kamradt T. Immunization with an immunodominant self-peptide derived from glucose-6-phosphate isomerase induces arthritis in DBA/1 mice.
Arthritis Res. Ther. 11: R117 (2009).
*
-
Bruns T, Stallmach A. Drug monitoring in inflammatory bowel disease: helpful or dispensable?
Dig. Dis. 27: 394-403 (2009).
-
Bruyn GA. Thalidomide (Celgene Corp.).
IDrugs 1: 490-500 (1998).
-
Bruzzese V. Diffused suberitrodermic psoriasis induced by infliximab.
Reumatismo 59: 328-331 (2007).
-
Brydges S, Kastner DL. The systemic autoinflammatory diseases: inborn errors of the innate immune system.
Curr. Top. Microbiol. Immunol. 305: 127-160 (2006).
-
Brydges SD, Mueller JL, McGeough MD, Pena CA, Misaghi A, Gandhi C, Putnam CD, Boyle DL, Firestein GS, Horner AA, Soroosh P, Watford WT, O'Shea JJ, Kastner DL, Hoffman HM. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity.
Immunity 30: 875-887 (2009).
*
-
Bryl E, Vallejo AN, Matteson EL, Witkowski JM, Weyand CM, Goronzy JJ. Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis.
Arthritis Rheum. 52: 2996-3003 (2005).
*
-
Brzezinska-Wcislo L, Bergler-Czop B, Lis-Swiety A. Sonozaki syndrome: case report and review of literature.
Rheumatol. Int. Jan 5 [Epub ahead of print] (2010).
*
-
Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. alpha-Melanocyte-stimulating hormone and related tripeptides: biochemistry, anti-inflammatory and protective effects in vitro and in vivo and future perspectives for the treatment of immune-mediated inflammatory diseases.
Endocr. Rev. 29: 581-602 (2008).
*
-
Bucala R, Lolis E. Macrophage migration inhibitory factor: a critical component of autoimmune inflammatory diseases.
Drug News Perspect. 18: 417-426 (2005).
-
Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gomez-Puerta JA, Ramos-Casals M, Font J, Asherson RA. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients.
Arthritis Rheum. 54: 2568-2576 (2006).
*
-
Buch MH, Bingham SJ, Bejarano V, Bryer D, White J, Emery P, Reece R, Quinn M. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
Arthritis Rheum. 57: 448-453 (2007).
*
-
Buch MH, Bingham SJ, Bryer D, Emery P. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders.
Rheumatology (Oxford) 46: 1153-1156 (2007).
*
-
Buch MH, Boyle DL, Rosengren S, Saleem B, Reece RJ, Rhodes LA, Radjenovic A, English A, Tang H, Vratsanos G, O'Connor P, Firestein GS, Emery P. Mode of action of abatacept in rheumatoid arthritis patients having failed TNF blockade: a histological, gene expression and dynamic MRI pilot study.
Ann. Rheum. Dis. 68: 1220-1227 (2009).
-
Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P. True infliximab resistance in rheumatoid arthritis; a role for lymphotoxin-alpha?
Ann. Rheum. Dis. 63: 1344-1346 (2004).
*
-
Buch MH, Marzo-Ortega H, Bingham SJ, Emery P. Long-term treatment of rheumatoid arthritis with tumour necrosis factor alpha blockade: outcome of ceasing and restarting biologicals.
Rheumatology (Oxford) 43: 243-244 (2004).
*
-
Buchbinder R, March L, Lassere M, Briggs AM, Portek I, Reid C, Meehan A, Henderson L, Wengier L, van den Haak R. Effect of treatment with biological agents for arthritis in Australia: the Australian Rheumatology Association Database.
Intern. Med. J. 37: 591-600 (2007).
-
Buchs N, di Giovine FS, Silvestri T, Vannier E, Duff GW, Miossec P. IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: interaction with their plasma levels.
Genes Immun. 2: 222-228 (2001).
*
-
Buckbinder L, Robinson RP. The glucocorticoid receptor: molecular mechanism and new therapeutic opportunities.
Curr. Drug Targets Inflamm. Allergy 1: 127-36 (2002).
-
Budancamanak M, Kanter M, Demirel A, Ocakci A, Uysal H, Karakaya C. Protective effects of thymoquinone and methotrexate on the renal injury in collagen-induced arthritis.
Arch. Toxicol. 80: 768-776 (2006).
*
-
Budzynska R, Zakliczynska H. Methotrexate in the treatment of the patients with rheumatoid arthritis.
Postepy. Hig. Med. Dosw. (Online) 58: 108-117 (2004).
-
Bueso MB, Caballero R, Castro HJ, Barakat A, Bellanti JA. Recurrent infections and joint pain.
Allergy Asthma Proc. 27: 164-171 (2006).
-
Bugatti S, Codullo V, Caporali R, Montecucco C. B cells in rheumatoid arthritis.
Autoimmun. Rev. 7: 137-142 (2007).
-
Buhaescu I, Covic A, Deray G. Treatment of proliferative lupus nephritis - a critical approach.
Semin. Arthritis Rheum. 36: 224-237 (2007).
*
-
Buhaescu I, Yood RA, Izzedine H. Serum procalcitonin in systemic autoimmune diseases - where are we now?
Semin. Arthritis Rheum. Feb 2 [Epub ahead of print] (2010).
*
-
Buisson M, Berthelot JM, Le Goff P, Chastel C, Lamour A, Seigneurin JM, Youinou P. Lack of relationship between the Epstein-Barr virus and the antiperinuclear factor/'perinuclear antigen' system in rheumatoid arthritis.
J. Autoimmun. 7: 485-495 (1994).
-
Buisson-Legendre N, Smith S, March L, Jackson C. Elevation of activated protein C in synovial joints in rheumatoid arthritis and its correlation with matrix metalloproteinase 2.
Arthritis Rheum. 50: 2151-2156 (2004).
*
-
Bukhari M, Thomson W, Naseem H, Bunn D, Silman A, Symmons D, Barton A. The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register.
Arthritis Rheum. 56: 2929-2935 (2007).
*
-
Bukulmez H, Fife M, Tsoras M, Thompson SD, Twine NA, Woo P, Olson JM, Elston RC, Glass DN, Colbert RA. Tapasin gene polymorphism in systemic onset juvenile rheumatoid arthritis: a family-based case-control study.
Arthritis Res. Ther. 7: R285-R290 (2005).
*
-
Bull MJ, Williams AS, Mecklenburgh Z, Calder CJ, Twohig JP, Elford C, Evans BA, Rowley TF, Slebioda TJ, Taraban VY, Al-Shamkhani A, Wang EC. The death receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis.
J. Exp. Med. 205: 2457-2464 (2008).
*
-
Bullano MF, McNeeley BJ, Yu YF, Quimbo R, Burawski LP, Yu EB, Woolley JM. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis.
Manag. Care Interface 19: 47-53 (2006).
-
Buller HA. Problems in diagnosis of IBD in children.
Neth. J. Med. 50: S8-S11 (1997).
-
Bultink IE, Hamann D, Seelen MA, Hart MH, Dijkmans BA, Daha MR, Voskuyl AE. Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus (SLE).
Arthritis Res. Ther. 8: R183 (2006).
*
-
Buning C, Schmidt HH, Molnar T, DE Jong DJ, Fiedler T, Buhner S, Sturm A, Baumgart DC, Nagy F, Lonovics J, Drenth JP, Landt O, Nickel R, Buttner J, Lochs H, Witt H. Heterozygosity for IL23R p.Arg381Gln confers a protective effect not only against Crohn's disease but also ulcerative colitis.
Aliment. Pharmacol. Ther. 26: 1025-1033 (2007).
*
-
Bunte C, Popp-Habeler J, Mischer P, Tuppy H, Haidenthaler A, Knoflach P, Kirchgatterer A. Concomitant manifestation of pyoderma gangrenosum and colorectal carcinoma.
Scand. J. Gastroenterol. 43: 756-758 (2008).
*
-
Burchill MA, Nardelli DT, England DM, DeCoster DJ, Christopherson JA, Callister SM, Schell RF. Inhibition of interleukin-17 prevents the development of arthritis in vaccinated mice challenged with Borrelia burgdorferi.
Infect. Immun. 71: 3437-3442 (2003).
*
-
Burden AD, Javed S, Bailey M, Hodgins M, Connor M, Tillman D. Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p.
J. Invest. Dermatol. 110: 958-960 (1998).
*
-
Burger D, Dayer JM, Palmer G, Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis?
Best Pract. Res. Clin. Rheumatol. 20: 879-896 (2006).
-
Burgos RA, Hancke JL, Bertoglio JC, Aguirre V, Arriagada S, Calvo M, Caceres DD. Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial.
Clin. Rheumatol. 28: 931-946 (2009).
*
-
Burgos-Vargas R. Spondyloarthropathies and psoriatic arthritis in children.
Curr. Opin. Rheumatol. 5: 634-643 (1993).
-
Burgos-Vargas R. A case of childhood-onset ankylosing spondylitis: diagnosis and treatment.
Nat. Clin. Pract. Rheumatol. 5: 52-57 (2009).
-
Burgoyne CH, Field SL, Brown AK, Hensor EM, English A, Bingham SL, Verburg R, Fearon U, Lawson CA, Hamlin JP, Straszynski L, Veale D, Conaghan P, Hull MA, van Laar JM, Tennant A, Emery P, Isaacs JD, Ponchel F. Abnormal T-cell differentiation persists in rheumatoid arthritis patients in clinical remission and predicts relapse.
Ann. Rheum. Dis. 67: 750-757 (2008).
-
Burke AP, Tavora F, Narula N, Tomaszewski JE, Virmani R. Aortitis and ascending aortic aneurysm: description of 52 cases and proposal of a histologic classification.
Hum. Pathol. 39: 514-526 (2008).
-
Burkhardt H, Huffmeier U, Spriewald B, Bohm B, Rau R, Kallert S, Engstrom A, Holmdahl R, Reis A. Association between protein tyrosine phosphatase 22 variant R620W in conjunction with the HLA-DRB1 shared epitope and humoral autoimmunity to an immunodominant epitope of cartilage-specific type II collagen in early rheumatoid arthritis.
Arthritis Rheum. 54: 82-89 (2005).
*
-
Burkhardt H, Sehnert B, Bockermann R, Engstrom A, Kalden JR, Holmdahl R. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis.
Eur. J. Immunol. 35: 1643-1652 (2005).
*
-
Burkhardt J, Petit-Teixeira E, Teixeira VH, Kirsten H, Garnier S, Ruehle S, Oeser C, Wolfram G, Scholz M, Migliorini P, Balsa A, Westhovens R, Barrera P, Alves H, Pascual-Salcedo D, Bombardieri S, Dequeker J, Radstake TR, Van Riel P, van de Putte L, et al. Association of the X-chromosomal genes TIMP1 and IL9R with rheumatoid arthritis.
J. Rheumatol. 36: 2149-2157 (2009).
-
Burleson GR, Burleson FG. Testing human biologicals in animal host resistance models.
J. Immunotoxicol. 5: 23-31 (2008).
-
Burman A, Haworth O, Hardie DL, Amft EN, Siewert C, Jackson DG, Salmon M, Buckley CD. A chemokine-dependent stromal induction mechanism for aberrant lymphocyte accumulation and compromised lymphatic return in rheumatoid arthritis.
J. Immunol. 174: 1693-1700 (2005).
*
-
Burmester GR, Lipsky PE, Dorner T; the Kitasato Meeting Faculty. Kitasato Symposium 2009: new prospects for cytokine inhibition.
Arthritis Res. Ther. 11: 301 (2009).
-
Burmester GR, Mease PJ, Dijkmans BA, Gordon K, Lovell D, Panaccione R, Perez J, Pangan AL. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases.
Ann. Rheum. Dis. 68: 1863-1869 (2009).
*
-
Burnevich EZ, Lopatkina TN. System manifestations of primary biliary cirrhosis.
Klin. Med. (Mosk.) 84: 42-46 (2006).
-
Burr ML, Malaviya AP, Gaston JH, Carmichael AJ, Ostor AJ. Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis.
Rheumatology (Oxford) 47: 738-739 (2008).
*
-
Burr ML, Naseem H, Hinks A, Eyre S, Gibbons L, Bowes J, Consortium B, Consortium Y, Wilson AG, Maxwell J, Morgan AW, Emery P, Steer S, Hocking L, Reid DM, Wordsworth BP, Harrison P, Thomson W, Worthington J, Barton A. PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian population.
Ann. Rheum. Dis. May 25 [Epub ahead of print] (2009).
-
Burrage PS, Huntington JT, Sporn MB, Brinckerhoff CE. Regulation of matrix metalloproteinase gene expression by a retinoid X receptor-specific ligand.
Arthritis Rheum. 56: 892-904 (2007).
*
-
Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis.
Front. Biosci. 11: 529-543 (2006).
-
Burrage PS, Schmucker AC, Ren Y, Sporn MB, Brinckerhoff CE. Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression.
Arthritis Res. Ther. 10: R139 (2008).
*
-
Burroughs AK, Rosenstein IJ, Epstein O, Hamilton-Miller JM, Brumfitt W, Sherlock S. Bacteriuria and primary biliary cirrhosis.
Gut 25: 133-137 (1984).
*
-
Burt RK, Georganas C, Schroeder J, Traynor A, Stefka J, Schuening F, Graziano F, Mineishi S, Brush M, Fishman M, Welles C, Rosen S, Pope R. Autologous hematopoietic stem cell transplantation in refractory rheumatoid arthritis: sustained response in two of four patients.
Arthritis Rheum. 42: 2281-2285 (1999).
*
-
Burt RK, Marmont A, Oyama Y, Slavin S, Arnold R, Hiepe F, Fassas A, Snowden J, Schuening F, Myint H, Patel DD, Collier D, Heslop H, Krance R, Statkute L, Verda L, Traynor A, Kozak T, Hintzen RQ, Rose JW, Voltarelli J, Loh Y, Territo M, Cohen BA, et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens.
Arthritis Rheum. 54: 3750-3760 (2006).
*
-
Burt RK, Traynor AE. SLE - hematopoietic stem cell transplantation for systemic lupus erythematosus.
Arthritis Res. Ther. 5: 207-209 (2003).
*
-
Burt RK, Traynor AE, Pope R, Schroeder J, Cohen B, Karlin KH, Lobeck L, Goolsby C, Rowlings P, Davis FA, Stefoski D, Terry C, Keever-Taylor C, Rosen S, Vesole D, Fishman M, Brush M, Mujias S, Villa M, Burns WH. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation.
Blood 92: 3505-3514 (1998).
*
-
Burton S, Lloyd M. An overview of rheumatoid arthritis.
Nurs. Stand. 20: 46-49 (2006).
-
Bush KA, Farmer KM, Walker JS, Kirkham BW. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein.
Arthritis Rheum. 46: 802-805 (2002).
*
-
Bushell TJ. The emergence of PAR-2 as a novel target for the treatment of inflammation-related CNS disorders.
J. Physiol. 581: 7-16 (2007).
*
-
Buskila D. Hepatitis C-associated rheumatic disorders.
Rheum. Dis. Clin. North Am. 35: 111-123 (2009).
-
Buskila D, Odes LR, Neumann L, Odes HS. Fibromyalgia in inflammatory bowel disease.
J. Rheumatol. 26: 1167-1171 (1999).
-
Busquets-Perez N, Narvaez J, Valverde-Garcia J. Interstitial granulomatous dermatitis with arthritis (Ackerman syndrome).
J. Rheumatol. 33: 1207-1209 (2006).
-
Busso N, Frasnelli M, Feifel R, Cenni B, Steinhoff M, Hamilton J, So A. Evaluation of protease-activated receptor 2 in murine models of arthritis.
Arthritis Rheum. 56: 101-107 (2007).
*
-
Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M, Leo O, So A, De Smedt T. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD.
PLoS ONE 3: e2267 (2008).
*
-
Bussone G, Hachulla E, Sibilia J, Michel M, Godeau B, Guillevin L, Mouthon L. Treatment of systemic autoimmune and inflammatory diseases with rituximab.
Presse. Med. 38: 808-823 (2009).
-
Busteed S, Bennett MW, Molloy C, Houston A, Stone MA, Shanahan F, Molloy MG, O'Connell J. Bcl-x(L) expression in vivo in rheumatoid synovium.
Clin. Rheumatol. 25: 789-793 (2006).
*
-
Butler G, Michaels JC, Al-Waili N, Finkelstein M, Allen M, Petrillo R, Carrey Z, Kolanuvada B, Lee BY, Riera AG, Michaels CC, Urteaga G. Therapeutic effect of hyperbaric oxygen in psoriasis vulgaris: two case reports and a review of the literature.
J. Med. Case Reports 3: 7023 (2009).
*
-
Butler GS, Sim D, Tam E, Devine D, Overall CM. Mannose-binding lectin (MBL) mutants are susceptible to matrix metalloproteinase proteolysis: potential role in human MBL deficiency.
J. Biol. Chem. 277: 17511-17519 (2002).
*
-
Butrimiene I, Ranceva J, Griskevicius A. Potential triggering infections of reactive arthritis.
Scand. J. Rheumatol. 35: 459-462 (2006).
-
Butt C, Gladman D, Rahman P. PPAR-gamma gene polymorphisms and psoriatic arthritis.
J. Rheumatol. 33: 1631-1633 (2006).
*
-
Butt C, Lim S, Greenwood CM, Rahman P. VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis.
BMC Musculoskelet. Disord. 8: 1 (2007).
*
-
Butt C, Peddle L, Greenwood C, Hamilton S, Gladman D, Rahman P. Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case-control study.
Arthritis Res. Ther. 8: R27-R30 (2006).
*
-
Butt C, Rahman P, Siannis F, Farewell VT, Gladman DD. Corneodesmosin polymorphisms in psoriatic arthritis.
Rheumatology (Oxford) 44: 684-685 (2005).
*
-
Butt C, Sun S, Greenwood C, Gladman D, Rahman P. Lack of association of SLC22A4, SLC22A5, SLC9A3R1 and RUNX1 variants in psoriatic arthritis.
Rheumatology (Oxford) 44: 820-821 (2005).
*
-
Butt C, Sun S, Peddle L, Greenwood C, Hamilton S, Gladman D, Rahman P. Association of nuclear factor-kappaB in psoriatic arthritis.
J. Rheumatol. 32: 1742-1744 (2005).
-
Buttgereit F, Saag KG, Cutolo M, da Silva JA, Bijlsma JW. The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis.
Scand. J. Rheumatol. 34: 14-21 (2005).
-
Buttgereit F, Zhou H, Kalak R, Gaber T, Spies CM, Huscher D, Straub RH, Modzelewski J, Dunstan CR, Seibel MJ. Transgenic disruption of glucocorticoid signaling in mature osteoblasts and osteocytes attenuates K/BxN mouse serum-induced arthritis in vivo.
Arthritis Rheum. 60: 1998-2007 (2009).
*
-
Butz DE, Li G, Huebner SM, Cook ME. A mechanistic approach to understanding conjugated linoleic acid's role in inflammation using murine models of rheumatoid arthritis.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 293: R669-R676 (2007).
*
-
Buzas EI, Vegvari A, Murad YM, Finnegan A, Mikecz K, Glant TT. T-cell recognition of differentially tolerated epitopes of cartilage proteoglycan aggrecan in arthritis.
Cell. Immunol. 235: 98-108 (2005).
*
-
Byla P, Andersen MH, Holtet TL, Jacobsen H, Munch M, Gad HH, Thogersen HC, Hartmann R. Selection of a novel and highly specific TNFalpha antagonist: insight from the crystal structure of the antagonist-TNFalpha complex.
J. Biol. Chem. Feb 23 [Epub ahead of print] (2010).
*
-
Caballero-Uribe CV, Acosta-Velez JG, Hernandez-Ruiz EA, Andrade Rodado FM, Penuela-Epalza M. Prevention, diagnosis, and treatment of glucocorticoid induced osteoporosis by rheumatologists in a Latin-American city.
J. Clin. Rheumatol. 14: 153-155 (2008).
-
Cabral DA, Petty RE, Malleson PN, Ensworth S, McCormick AQ, Shroeder ML. Visual prognosis in children with chronic anterior uveitis and arthritis.
J. Rheumatol. 21: 2370-2375 (1994).
-
Cabrera Pivaral CE, Gutierrez Gonzalez TY, Gamez Nava JI, Nava A, Villa Manzano AI, Luce Gonzalez E. Clinical competence for autoimmune and non-autoimmune rheumatic disorders in primary care.
Rev. Alerg. Mex. 56: 18-22 (2009).
-
Caccavo D, Afeltra A, Guido F, Di Monaco C, Ferri GM, Amoroso A, Vaccaro F, Bonomo L. Two spatially distant epitopes of human lactoferrin.
Hybridoma 15: 263-269 (1996).
-
Caccavo D, Afeltra A, Rigon A, Vadacca M, Zobel BB, Zennaro D, Arcarese L, Buzzulini F, Pellegrino NM, Amoroso A. Antibodies to carbonic anhydrase in patients with connective tissue diseases: relationship with lung involvement.
Int. J. Immunopathol. Pharmacol. 21: 659-668 (2008).
-
Cachafeiro-Vilar A, Garcia-Padilla C, Reyes E, Hernandez-Molina G. Polyarticular arthritis secondary to Mycobacterium bovis infection: an unusual clinical presentation.
Joint Bone Spine 74: 107-109 (2007).
*
-
Caetano MC, Ortiz TT, Terreri MT, Sarni RO, Silva SG, Souza FI, Hilario MO. Inadequate dietary intake of children and adolescents with juvenile idiopathic arthritis and systemic lupus erythematosus.
J. Pediatr. (Rio J.) 85: 509-515 (2009).
-
Cagatay Y, Gul A, Cagatay A, Kamali S, Karadeniz A, Inanc M, Ocal L, Aral O, Konice M. Adult-onset Still's disease.
Int. J. Clin. Pract. 63: 1050-1055 (2009).
-
Caggiano TJ, Brazzale A, Ho DM, Kraml CM, Trybulski E, Chadwick CC, Chippari S, Borges-Marcucci L, Eckert A, Keith JC, Kenney T, Harnish DC. Estrogen receptor dependent inhibitors of NF-kappaB transcriptional activation-1 synthesis and biological evaluation of substituted 2-cyanopropanoic acid derivatives: pathway selective inhibitors of NF-kappaB, a potential treatment for rheumatoid
J. Med. Chem. 50: 5245-5248 (2007).
*
-
Cagnard N, Letourneur F, Essabbani A, Devauchelle V, Mistou S, Rapinat A, Decraene C, Fournier C, Chiocchia G. Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes.
Eur. Cytokine Netw. 16: 289-292 (2005).
-
Cahoon Jr WD, Kockler DR. Mycophenolate mofetil treatment of myasthenia gravis.
Ann. Pharmacother. 40: 295-298 (2006).
-
Cai C, La Cava A. Mimicking self-antigens with synthetic peptides in systemic autoimmune rheumatic diseases.
Curr. Clin. Pharmacol. 4: 142-147 (2009).
-
Cai L, Yin JP, Starovasnik MA, Hogue DA, Hillan KJ, Mort JS, Filvaroff EH. Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo.
Cytokine 16: 10-21 (2001).
-
Cai LQ, Wang ZX, Lu WS, Han JW, Sun LD, Du WH, Zhang SM, Zuo XB, Zhang XJ, Yang S. A single-nucleotide polymorphism of the TNFAIP3 gene is associated with systemic lupus erythematosus in Chinese Han population.
Mol. Biol. Rep. Sep 23 [Epub ahead of print] (2009).
*
-
Cai X, Wong YF, Zhou H, Liu ZQ, Xie Y, Jiang ZH, Bian ZX, Xu HX, Liu L. Manipulation of the induction of adjuvant arthritis in Sprague-Dawley rats.
Inflamm. Res. 55: 368-377 (2006).
*
-
Cai X, Wong YF, Zhou H, Xie Y, Liu ZQ, Jiang ZH, Bian ZX, Xu HX, Liu L. The comparative study of Sprague-Dawley and Lewis rats in adjuvant-induced arthritis.
Naunyn. Schmiedebergs. Arch. Pharmacol. 373: 140-147 (2006).
*
-
Cai X, Zhou H, Wong YF, Xie Y, Liu ZQ, Jiang ZH, Bian ZX, Xu HX, Liu L. Suppressive effects of QFGJS, a preparation from an anti-arthritic herbal formula, on rat experimental adjuvant-induced arthritis.
Biochem. Biophys. Res. Commun. 337: 586-594 (2005).
*
-
Cai X, Zhou H, Wong YF, Xie Y, Liu ZQ, Jiang ZH, Bian ZX, Xu HX, Liu L. Suppression of the onset and progression of collagen-induced arthritis in rats by QFGJS, a preparation from an anti-arthritic Chinese herbal formula.
J. Ethnopharmacol. 110: 39-48 (2007).
*
-
Calabuig E, Salavert M. Infectious risk.
Actas Dermosifiliogr. 99 Suppl. 4: 14-22 (2008).
-
Calamia KT, Wilson FC, Icen M, Crowson CS, Gabriel SE, Kremers HM. Epidemiology and clinical characteristics of Behcet's disease in the US: a population-based study.
Arthritis Rheum. 61: 600-604 (2009).
*
-
Calander AM, Starckx S, Opdenakker G, Bergin P, Quiding-Jarbrink M, Tarkowski A. Matrix metalloproteinase-9 (gelatinase B) deficiency leads to increased severity of Staphylococcus aureus-triggered septic arthritis.
Microbes Infect. 8: 1434-1439 (2006).
*
-
Calcagni E, Elenkov I. Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases.
Ann. N. Y. Acad. Sci. 1069: 62-76 (2006).
*
-
Calder PC. n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases.
Am. J. Clin. Nutr. 83: 1505S-1519S (2006).
*
-
Calder PC. n-3 Polyunsaturated fatty acids and cytokine production in health and disease.
Ann. Nutr. Metab. 41: 203-234 (1997).
-
Calder PC. Session 3: Joint Nutrition Society and Irish Nutrition and Dietetic Institute Symposium on 'Nutrition and autoimmune disease'. PUFA, inflammatory processes and rheumatoid arthritis.
Proc. Nutr. Soc. 67: 409-418 (2008).
*
-
Calder PC. n-3 Polyunsaturated fatty acids and inflammation: from molecular biology to the clinic.
Lipids 38: 343-352 (2003).
-
Calder PC. Dietary modification of inflammation with lipids.
Proc. Nutr. Soc. 61: 345-358 (2002).
*
-
Calder PC. Polyunsaturated fatty acids, inflammation, and immunity.
Lipids 36: 1007-1024 (2001).
-
Calder PC, Yaqoob P. Omega-3 polyunsaturated fatty acids and human health outcomes.
Biofactors 35: 266-272 (2009).
-
Calder PC, Yaqoob P. Understanding omega-3 polyunsaturated fatty acids.
Postgrad. Med. 121: 148-157 (2009).
-
Calder PC, Yaqoob P, Thies F, Wallace FA, Miles EA. Fatty acids and lymphocyte functions.
Br. J. Nutr. 87 Suppl. 1: S31-S48 (2002).
*
-
Calich AL, Domiciano DS, Fuller R. Osteoarthritis: can anti-cytokine therapy play a role in treatment?
Clin. Rheumatol. Jan 27 [Epub ahead of print] (2010).
*
-
Calin A, Marder A, Becks E, Burns T. Genetic differences between B27 positive patients with ankylosing spondylitis and B27 positive healthy controls.
Arthritis Rheum. 26: 1460-1464 (1983).
-
Caliskan M, Erdogan D, Gullu H, Yilmaz S, Gursoy Y, Yildirir A, Yucel E, Muderrisoglu H. Impaired coronary microvascular and left ventricular diastolic functions in patients with ankylosing spondylitis.
Atherosclerosis 196: 306-312 (2008).
-
Callan MF. Epstein-Barr virus, arthritis, and the development of lymphoma in arthritis patients.
Curr. Opin. Rheumatol. 16: 399-405 (2004).
-
Callegari PE, Schaible TF, Boscia JA. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
JAMA 296: 2202 (2006).
*
-
Callejas-Rubio JL, Lopez-Perez L, Ortego-Centeno N. Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis.
Ther. Clin. Risk Manag. 4: 1305-1213 (2008).
*
-
Callen JP. Complications and adverse reactions in the use of newer biologic agents.
Semin. Cutan. Med. Surg. 26: 6-14 (2007).
-
Callen JP, Jackson JM. Pyoderma gangrenosum: an update.
Rheum. Dis. Clin. North Am. 33: 787-802 (2007).
-
Callot V, Ochonisky S, Vabres P, Revuz J. Acute arthritis during isotretinoin treatment.
Ann. Dermatol. Venereol. 121: 402-403 (1994).
-
Calvo-Alen J, Alarcon GS, Tew MB, Tan FK, McGwin G Jr, Fessler BJ, Vila LM, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort: XXXIV. Deficient mannose-binding lectin exon 1 polymorphisms are associated with cerebrovascular but not with other arterial thrombotic events.
Arthritis Rheum. 54: 1940-1945 (2006).
*
-
Camargo JF, Correa PA, Castiblanco J, Anaya JM. Interleukin-1beta polymorphisms in Colombian patients with autoimmune rheumatic diseases.
Genes Immun. 5: 609-614 (2004).
*
-
Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
Arthritis Rheum. 54: 723-732 (2006).
*
-
Cammelli D. Extra-articular manifestations of seronegative spondyloarthritis.
Recenti Prog. Med. 97: 280-289 (2006).
-
Camp NJ, Cox A, di Giovine FS, McCabe D, Rich W, Duff GW. Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis.
Genes Immun. 6: 467-471 (2005).
*
-
Campas-Moya C. Golimumab: a novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Drugs Today (Barc.) 46: 13-22 (2010).
-
Campbell AK, Waud JP, Matthews SB. The molecular basis of lactose intolerance.
Sci. Prog. 88: 157-202 (2005).
-
Campbell IK, Kinkel SA, Drake SF, Nieuwenhuijze AV, Hubert FX, Tarlinton DM, Heath WR, Scott HS, Wicks IP. Autoimmune regulator controls T cell help for pathogenetic autoantibody production in collagen-induced arthritis.
Arthritis Rheum. 60: 1683-1693 (2009).
*
-
Campione E, Mazzotta A, Paterno EJ, Diluvio L, Prinz JC, Chimenti S. Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients.
Acta Derm. Venereol. 89: 288-291 (2009).
-
Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Francon B, Martin T, Gretener D, Perrin D, Leroy D, Vitte PA, Hirsch E, Wymann MP, Cirillo R, Schwarz MK, Rommel C. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.
Nat. Med. 11: 936-943 (2005).
*
-
Candia L, Cuellar ML, Marlowe SM, Marquez J, Iglesias A, Espinoza LR. Charcot-like arthropathy: a newly-recognized subset of psoriatic arthritis.
Clin. Exp. Rheumatol. 24: 172-175 (2006).
-
Candia L, Marquez J, Espinoza LR. Autoimmune hepatitis and pregnancy: a rheumatologist's dilemma.
Semin. Arthritis Rheum. 35: 49-56 (2005).
*
-
Candia L, Marquez J, Gonzalez C, Santos AM, Londono J, Valle R, Zabaleta J, Yaqub Z, Espinoza LR. Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis.
J. Clin. Rheumatol. 12: 226-229 (2006).
-
Candia L, Marquez J, Hernandez C, Zea AH, Espinoza LR. Toll-like receptor-2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity?
J. Rheumatol. 34: 374-379 (2007).
-
Canete JD, Celis R, Hernandez MV, Pablos JL, Sanmartí R. Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis.
Ann. Rheum. Dis. Aug 20 [Epub ahead of print] (2009).
-
Canete JD, Celis R, Moll C, Izquierdo E, Marsal S, Sanmarti R, Palacin A, Lora D, de la Cruz J, Pablos JL. Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Ann. Rheum. Dis. 68: 751-756 (2009).
-
Canete JD, Celis R, Noordenbos T, Moll C, Gomez-Puerta JA, Pizcueta P, Palacin A, Tak PP, Sanmarti R, Baeten D. Distinct synovial immunopathology in Behcet disease and psoriatic arthritis.
Arthritis Res. Ther. 11: R17 (2009).
*
-
Canete JD, Santiago B, Cantaert T, Sanmarti R, Palacin A, Celis R, Graell E, Gil-Torregrosa B, Baeten D, Pablos JL. Ectopic lymphoid neogenesis in psoriatic arthritis.
Ann. Rheum. Dis. 66: 720-726 (2007).
*
-
Canete JD, Suarez B, Hernandez MV, Sanmarti R, Rego I, Celis R, Moll C, Pinto JA, Blanco FJ, Lozano F. Influence of variants of Fcgamma receptors IIA and IIIA on the ACR and EULAR responses to anti-TNFalpha therapy in rheumatoid arthritis.
Ann. Rheum. Dis. 68: 1547-1552 (2009).
-
Canhao H, Fonseca JE, Caetano-Lopes J, Saldanha C, Queiroz MV. Assessment of laboratory measurements and -308 TNFalpha gene promoter polymorphisms in normal bone mineral density.
Clin. Rheumatol. 27: 301-307 (2008).
*
-
Canpolat F, Akpinar H, Eskioglu F. Mean platelet volume in psoriasis and psoriatic arthritis.
Clin. Rheumatol. Dec 14 [Epub ahead of print] (2009).
*
-
Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis.
J. Rheumatol. 35: 421-424 (2008).
-
Cantaert T, Brouard S, Thurlings RM, Pallier A, Salinas GF, Braud C, Klarenbeek PL, de Vries N, Zhang Y, Soulillou JP, Tak PP, Baeten D. Alterations of the synovial T cell repertoire in anti-citrullinated protein antibody-positive rheumatoid arthritis.
Arthritis Rheum. 60: 1944-1956 (2009).
*
-
Cantaert T, Coucke P, De Rycke L, Veys EM, De Keyser F, Baeten D. Functional haplotypes of PADI4: relevance for rheumatoid arthritis-specific synovial intracellular citrullinated proteins and anti-citrullinated protein antibodies.
Ann. Rheum. Dis. 64: 1316-1320 (2005).
*
-
Cantaert T, De Rijcke L, Mavragani CP, Wijbrandts CA, Niewold TB, Niers T, Vandooren B, Veys EM, Richel D, Tak PP, Crow MK, Baeten D. Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during TNF alpha blockade.
Ann. Rheum. Dis. 68: 1022-1029 (2009).
-
Cantaert T, De Rycke L, Bongartz T, Matteson EL, Tak PP, Nicholas AP, Baeten D. Citrullinated proteins in rheumatoid arthritis: crucial ... but not sufficient!
Arthritis Rheum. 54: 3381-3389 (2006).
*
-
Cantaert T, Stone MA, Terborg M, Mog R, de Vries N, Wilson AG, Tak PP, Baeten D. A functional polymorphism of TIR-domain-containing adaptor protein is not associated with axial spondyloarthritis.
Ann. Rheum. Dis. 67: 720-722 (2008).
-
Cantaert T, van Baarsen LG, Wijbrandts CA, Thurlings RM, van de Sande MG, Bos C, van der Pouw TK, Verweij CL, Tak PP, Baeten DL. Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis.
Rheumatology (Oxford) 49: 156-166 (2010).
-
Cantagrel A, Navaux F, Loubet-Lescoulie P, Nourhashemi F, Enault G, Abbal M, Constantin A, Laroche M, Mazieres B. Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis.
Arthritis Rheum. 42: 1093-1100 (1999).
*
-
Cantarini L, Lucherini OM, Simonini G, Galeazzi M, Baldari CT, Cimaz R. Systemic-onset juvenile idiopathic arthritis complicated by early onset amyloidosis in a patient carrying a mutation in the MEFV gene.
Rheumatol. Int. Jan 1 [Epub ahead of print] (2010).
*
-
Cantarini L, Tinazzi I, Caramaschi P, Bellisai F, Brogna A, Galeazzi M. Safety and efficacy of etanercept in children with juvenile-onset Behcets disease.
Int. J. Immunopathol. Pharmacol. 22: 551-555 (2009).
-
Canter PH, Wider B, Ernst E. The antioxidant vitamins A, C, E and selenium in the treatment of arthritis: a systematic review of randomized clinical trials.
Rheumatology (Oxford) 46: 1223-1233 (2007).
*
-
Cantini F, Niccoli L, Nannini C, Cassara E, Pasquetti P, Olivieri I, Salvarani C. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs.
Rheumatology (Oxford) 47: 872-876 (2008).
*
-
Cantini F, Niccoli L, Nannini C, Cassara E, Pasquetti P, Olivieri I, Salvarani C. Criteria, frequency, and duration of clinical remission in psoriatic arthritis patients with peripheral involvement requiring second-line drugs.
J. Rheumatol. Suppl. 83: 78-80 (2009).
-
Cantor RM, Yuan J, Napier S, Kono N, Grossman JM, Hahn BH, Tsao BP. Systemic lupus erythematosus genome scan: support for linkage at 1q23, 2q33, 16q12-13, and 17q21-23 and novel evidence at 3p24, 10q23-24, 13q32, and 18q22-23.
Arthritis Rheum. 50: 3203-3210 (2004).
*
-
Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence?
Proc. Soc. Exp. Biol. Med. 223: 230-233 (2000).
*
-
Cantorna MT, Humpal-Winter J, DeLuca HF. In vivo upregulation of interleukin-4 is one mechanism underlying the immunoregulatory effects of 1,25-dihydroxyvitamin D(3).
Arch. Biochem. Biophys. 377: 135-138 (2000).
*
-
Cantorna MT, Mahon BD. D-hormone and the immune system.
J. Rheumatol. Suppl. 76: 11-20 (2005).
*
-
Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence.
Exp. Biol. Med. (Maywood) 229: 1136-1142 (2004).
*
-
Cao Q, Si JM, Gao M, Zhou G, Hu WL, Li JH. Clinical presentation of inflammatory bowel disease: a hospital based retrospective study of 379 patients in eastern China.
Chin. Med. J. (Engl.) 118: 747-752 (2005).
-
Cao Y, Brombacher F, Tunyogi-Csapo M, Glant TT, Finnegan A. Interleukin-4 regulates proteoglycan-induced arthritis by specifically suppressing the innate immune response.
Arthritis Rheum. 56: 861-870 (2007).
*
-
Cao Y, Doodes PD, Glant TT, Finnegan A. IL-27 induces a Th1 immune response and susceptibility to experimental arthritis.
J. Immunol. 180: 922-930 (2008).
*
-
Cao Y, Wang Z, Bu X, Tang S, Mei Z, Liu P. A synthetic peptide derived from A1 module in CRD4 of human TNF receptor-1 inhibits binding and proinflammatory effect of human TNF-alpha.
Inflammation 32: 139-145 (2009).
*
-
Caparbo VF, Prada F, Silva CA, Regio PL, Pereira RM. Serum from children with polyarticular juvenile idiopathic arthritis (pJIA) inhibits differentiation, mineralization and may increase apoptosis of human osteoblasts "in vitro".
Clin. Rheumatol. 28: 71-77 (2009).
-
Caparroz-Assef SM, Bersani-Amado CA, Kelmer-Bracht AM, Bracht A, Ishii-Iwamoto EL. The metabolic changes caused by dexamethasone in the adjuvant-induced arthritic rat.
Mol. Cell. Biochem. 302: 87-98 (2007).
*
-
Capellino S, Montagna P, Villaggio B, Cutolo M. Effects of estrogen peripheral metabolism in rheumatoid arthritis.
Reumatismo 57: 78-82 (2005).
-
Capini C, Jaturanpinyo M, Chang HI, Mutalik S, McNally A, Street S, Steptoe R, O'Sullivan B, Davies N, Thomas R. Antigen-specific suppression of inflammatory arthritis using liposomes.
J. Immunol. 182: 3556-3565 (2009).
-
Caplan L, Russell AS, Wolfe F. Steroids for rheumatoid arthritis: the honeymoon revisited (once again).
J. Rheumatol. 32: 1863-1865 (2005).
-
Capocasale RJ, Makropoulos DA, Achuthanandam R, Stowell N, Quinn J, Rafferty PA, O'Brien J, Emmell E, Bugelski PJ. Myelodysplasia and anemia of chronic disease in human tumor necrosis factor-alpha transgenic mice.
Cytometry A. 73: 148-159 (2008).
-
Caponi L, Petit-Teixeira E, Sebbag M, Bongiorni F, Moscato S, Pratesi F, Pierlot C, Osorio J, Chapuy-Regaud S, Guerrin M, Cornelis F, Serre G, Migliorini P; ECRAF. A family based study shows no association between rheumatoid arthritis and the PADI4 gene in a white French population.
Ann. Rheum. Dis. 64: 587-593 (2005).
*
-
Caporali R, Pallavicini FB, Filippini M, Gorla R, Marchesoni A, Favalli EG, Sarzi-Puttini P, Atzeni F, Montecucco C. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal.
Autoimmun. Rev. 8: 274-280 (2009).
-
Caporali R, Sarzi-Puttini P, Atzeni F, Gorla R, Filippini M, Marchesoni A, Favalli EG, Bobbio-Pallavicini F, Montecucco C. Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry.
Autoimmun. Rev. Dec 28 [Epub ahead of print] (2009).
-
Cappello F, Conway de Macario E, Di Felice V, Zummo G, Macario AJ. Chlamydia trachomatis infection and anti-Hsp60 immunity: the two sides of the coin.
PLoS Pathog. 5: e1000552 (2009).
*
-
Cappello F, Czarnecka AM, Rocca GL, Stefano AD, Zummo G, Macario AJ. Hsp60 and Hsp10 as antitumor molecular agents.
Cancer Biol. Ther. 6: 487-489 (2007).
*
-
Capsoni F, Sarzi-Puttini P, Atzeni F, Minonzio F, Bonara P, Doria A, Carrabba M. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.
Arthritis Res. Ther. 7: R250-R255 (2005).
*
-
Caramaschi P, Bambara LM, Pieropan S, Tinazzi I, Volpe A, Biasi D. Anti-TNFalpha blockers, autoantibodies and autoimmune diseases.
Joint Bone Spine 76: 333-342 (2009).
*
-
Caramaschi P, Biasi D, Colombatti M, Pieropan S, Martinelli N, Carletto A, Volpe A, Pacor LM, Bambara LM. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.
Rheumatol. Int. 26: 209-214 (2006).
*
-
Caramaschi P, Ruzzenente O, Pieropan S, Volpe A, Carletto A, Bambara LM, Biasi D. Determination of ANA specificity using multiplexed fluorescent microsphere immunoassay in patients with ANA positivity at high titres after infliximab treatment: preliminary results.
Rheumatol. Int. 27: 649-654 (2007).
*
-
Caramella C, Avouac J, Sogni P, Puechal X, Kahan A, Allanore Y. Association between rheumatoid arthritis and primary biliary cirrhosis.
Joint Bone Spine 74: 279-281 (2007).
*
-
Caramia G. Omega-3: from cod-liver oil to nutrigenomics.
Minerva Pediatr. 60: 443-455 (2008).
-
Carbone J, Perez-Rojas J, Sarmiento E. Infectious pulmonary complications in patients treated with anti-TNF-alpha monoclonal antibodies and soluble TNF receptor.
Curr. Infect. Dis. Rep. 11: 229-236 (2009).
-
Cardoso CC, Pinto AC, Marques PR, Gayer CR, Afel MI, Coelho MG, Sabino KC. Suppression of T and B cell responses by Pterodon pubescens seeds ethanolic extract.
Pak. J. Biol. Sci. 11: 2308-2313 (2008).
-
Carette S. All patients with rheumatoid arthritis should receive corticosteroids as part of their management.
J. Rheumatol. 34: 656-660 (2007).
-
Carl PL, Temple BR, Cohen PL. Most nuclear systemic autoantigens are extremely disordered proteins: implications for the etiology of systemic autoimmunity.
Arthritis Res. Ther. 7: R1360-R1374 (2005).
*
-
Carlens C, Hergens MP, Grunewald J, Ekbom A, Eklund A, Olgart Hoglund C, Askling J. Smoking, use of moist snuff and risk of chronic inflammatory diseases.
Am. J. Respir. Crit. Care Med. Mar 4 [Epub ahead of print] (2010).
-
Carlisle AC, John AM, Fife-Schaw C, Lloyd M. The self-regulatory model in women with rheumatoid arthritis: relationships between illness representations, coping strategies, and illness outcome.
Br. J. Health Psychol. 10: 571-587 (2005).
-
Carlsen H, Alexander G, Austenaa LM, Ebihara K, Blomhoff R. Molecular imaging of the transcription factor NF-kappaB, a primary regulator of stress response.
Mutat. Res. 551: 199-211 (2004).
-
Carlsen HS, Baekkevold ES, Morton HC, Haraldsen G, Brandtzaeg P. Monocyte-like and mature macrophages produce CXCL13 (B-cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis.
Blood 104: 3021-3027 (2004).
*
-
Carlsen KM, Riis L, Madsen OR. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept.
Clin. Rheumatol. 28: 1001-1003 (2009).
-
Carlsen S, Lu S, Holmdahl R. Arthritis induced with minor cartilage proteins.
Methods Mol. Med. 136: 225-242 (2007).
-
Carlsten C, de Roos AJ, Kaufman JD, Checkoway H, Wener M, Seixas N. Cell markers, cytokines, and immune parameters in cement mason apprentices.
Arthritis Rheum. 57: 147-153 (2007).
*
-
Carlton VE, Hu X, Chokkalingam AP, Schrodi SJ, Brandon R, Alexander HC, Chang M, Catanese JJ, Leong DU, Ardlie KG, Kastner DL, Seldin MF, Criswell LA, Gregersen PK, Beasley E, Thomson G, Amos CI, Begovich AB. PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis.
Am. J. Hum. Genet. 77: 567-581 (2005).
*
-
Carmona L, Descalzo MA, Perez-Pampin E, Ruiz-Montesinos D, Erra A, Cobo Ibanez T, Gomez-Reino JJ, Study Groups EB. All cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with TNF antagonists.
Ann. Rheum. Dis. 66: 880-885 (2007).
*
-
Caro-Oleas JL, Fernandez-Suarez A, Reneses Cesteros S, Porrino C, Nunez-Roldan A, Wichmann Schlipf I. Evaluation of third generation anti-CCP antibodies in the diagnosis of rheumatoid arthritis from undifferentiated polyarthritis after 4 years of follow-up.
Clin. Exp. Rheumatol. 26: 461-463 (2008).
-
Carpenter GH, Proctor GB, Pankhurst CL, O'Donohue J, Scott D, Hunnable MP. Sialochemical markers of salivary gland involvement with Sjogren's syndrome secondary to rheumatoid arthritis and primary biliary cirrhosis.
J. Oral. Pathol. Med. 29: 452-459 (2000).
-
Carr EJ, Niederer HA, Williams J, Harper L, Watts RA, Lyons PA, Smith KG. Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis.
BMC Med. Genet. 10: 121 (2009).
*
-
Carreira PE, Gonzalez-Crespo MR, Ciruelo E, Pablos JL, Santiago B, Gomez-Camara A, Gomez-Reino JJ. Polymorphism of the interleukin-1 receptor antagonist gene: a factor in susceptibility to rheumatoid arthritis in a Spanish population.
Arthritis Rheum. 52: 3015-3019 (2005).
*
-
Carrera C, Mascaro JM Jr, Moreno-Romero JA, Iranzo P, Palou J, Zamora E, Herrero C. Pyoderma vegetans associated with severe psoriatic arthritis: good response to etanercept.
Dermatology 214: 77-81 (2007).
-
Carrick DM, Chulada P, Donn R, Fabris M, McNicholl J, Whitworth W, Blackshear PJ. Genetic variations in ZFP36 and their possible relationship to autoimmune diseases.
J. Autoimmun. 26: 182-196 (2006).
-
Carrier N, Cossette P, Daniel C, de Brum-Fernandes A, Liang P, Menard HA, Boire G. The DERAA HLA-DR alleles in patients with early polyarthritis: protection against severe disease and lack of association with rheumatoid arthritis autoantibodies.
Arthritis Rheum. 60: 698-707 (2009).
*
-
Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, Bouche G, Girard JP. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo.
Proc. Natl. Acad. Sci. U.S.A. 104: 282-287 (2007).
*
-
Carroll L, Frazer IH, Turner M, Marwick T, Thomas R. The receptor for advanced glycation end products glycine 82 serine polymorphism and the risk of cardiovascular events in rheumatoid arthritis.
Arthritis Res. Ther. 9: R39 (2007).
*
-
Carroll L, Hannawi S, Marwick T, Thomas R. Rheumatoid arthritis: links with cardiovascular disease and the receptor for advanced glycation end products.
Wien. Med. Wochenschr. 156: 42-52 (2006).
-
Carroll MB, Holmes R. Dermatomyositis and HIV infection: case report and review of the literature.
Rheumatol. Int. Oct 24 [Epub ahead of print] (2009).
*
-
Carron PN, Yerly S, Ksontini R, Meylan P, Calandra T. Pyoderma gangrenosum: diagnostic and therapeutic challenge.
Rev. Med. Suisse. 4: 1938-1940, 1942-1943 (2008).
-
Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, et al. Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: a report of 57 cases from the Research on Adverse Drug Event and Reports (RADAR) project.
Blood 113: 4834-4840 (2009).
*
-
Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project.
Lancet Oncol. 10: 816-824 (2009).
-
Carter JD, Gerard HC, Hudson AP. Psoriasiform lesions induced by TNF antagonists: a skin-deep medical conundrum.
Ann. Rheum. Dis. 67: 1181-1183 (2008).
-
Carter JD, Valeriano J, Vasey FB. Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship.
J. Rheumatol. 33: 1014-1017 (2006).
-
Carter JD, Valeriano J, Vasey FB. Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthropathy, with special reference to Chlamydia-induced arthritis. A prospective, randomized 9-month comparison.
J. Rheumatol. 31: 1973-1980 (2004).
-
Carter JD, Vasey FB. Psoriatic arthritis: genetics, immunology, and therapies.
J. Clin. Rheumatol. 7: 363-365 (2001).
-
Carter JD, Vasey FB, Kanik KS, Valeriano-Marcet J. Polymyalgia rheumatica and temporal arteritis with sacroiliitis and osteitis pubis.
J. Clin. Rheumatol. 7: 261-264 (2001).
-
Carter PH, Zhao Q. Clinically validated approaches to the treatment of autoimmune diseases.
Expert Opin. Investig. Drugs. Jan 6 [Epub ahead of print] (2010).
-
Carter RH. B cells in health and disease.
Mayo Clin. Proc. 81: 377-384 (2006).
*
-
Carthy D, Ollier W, Papasteriades C, Pappas H, Thomson W. A shared HLA-DRB1 sequence confers RA susceptibility in Greeks.
Eur. J. Immunogenet. 20: 391-398 (1993).
-
Carvalho JF, Blank M, Shoenfeld Y. Vascular endothelial growth factor (VEGF) in autoimmune diseases.
J. Clin. Immunol. 27: 246-256 (2007).
*
-
Cascino I, Paladini F, Belfiore F, Cauli A, Angelini C, Fiorillo MT, Mathieu A, Sorrentino R. Identification of previously unrecognized predisposing factors for ankylosing spondylitis from analysis of HLA-B27 extended haplotypes in Sardinia.
Arthritis Rheum. 56: 2640-2651 (2007).
*
-
Casciola-Rosen L, Miagkov A, Nagaraju K, Askin F, Jacobson L, Rosen A, Drachman DB. Granzyme B: evidence for a role in the origin of myasthenia gravis.
J. Neuroimmunol. 201-202: 33-40 (2008).
-
Casellini C, Citera G, Rosemffet M, Ruggeri S, Saviotti A, Cocco JA. Audiovestibular disorders in patients with ankylosing spondylitis.
J. Clin. Rheumatol. 11: 81-85 (2005).
-
Casimiro L, Barnsley L, Brosseau L, Milne S, Robinson V, Tugwell P, Wells G, Casimiro L. Acupuncture and electroacupuncture for the treatment of rheumatoid arthritis.
Cochrane Database Syst. Rev. 4: CD003788 (2005).
*
-
Caspi D, Anouk M, Golan I, Paran D, Kaufman I, Wigler I, Levartovsky D, Litinsky I, Elkayam O. Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis.
Arthritis Rheum. 55: 53-56 (2006).
*
-
Cassano N, Galluccio A, De Simone C, Loconsole F, Massimino SD, Plumari A, Dattola S, Puglisi Guerra A, Donato L, Cantoresi F, De Pita O, Fenizi G, Altamura V, Congedo M, Pellicano R, Vena GA. Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data.
J. Biol. Regul. Homeost. Agents 22: 233-237 (2008).
-
Cassano N, Loconsole F, Coviello C, Vena GA. Infliximab in recalcitrant severe atopic eczema associated with contact allergy.
Int. J. Immunopathol. Pharmacol. 19: 237-240 (2006).
-
Cassatella MA, da Silva GP, Tinazzi I, Facchetti F, Scapini P, Calzetti F, Tamassia N, Wei P, Nardelli B, Roschke V, Vecchi A, Mantovani A, Bambara LM, Edwards SW, Carletto A. Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis.
J. Immunol. 178: 7325-7333 (2007).
*
-
Cassell S, Kavanaugh A. Psoriatic arthritis: pathogenesis and novel immunomodulatory approaches to treatment.
J. Immune Based Ther. Vaccines 3: 6 (2005).
*
-
Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease. A systematic review.
J. Rheumatol. 33: 1452-1456 (2006).
-
Casserly B, Donat W. Stabilization of lung function and clinical symptoms in a patient with cystic fibrosis (CF) after institution of infliximab: a monoclonal antibody that binds tumor necrosis factor alpha.
Lung 187: 149-152 (2009).
-
Cassidy JT, Walker SE, Soderstrom SJ, Petty RE, Sullivan DB. Diagnostic significance of antibody to native deoxyribonucleic acid in children with juvenile rheumatoid arthritis and other connective tissue diseases.
J. Pediatr. 93: 416-420 (1978).
-
Cassinotti P, Bas S, Siegl G, Vischer TL. Association between human parvovirus B19 infection and arthritis.
Ann. Rheum. Dis. 54: 498-500 (1995).
*
-
Castelo-Soccio L, Van Voorhees AS. Long-term efficacy of biologics in dermatology.
Dermatol. Ther. 22: 22-33 (2009).
-
Castiblanco J, Varela DC, Castano-Rodriguez N, Rojas-Villarraga A, Hincapie ME, Anaya JM. TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus.
Infect. Genet. Evol. 8: 541-544 (2008).
-
Castillero E, Martin AI, Lopez-Menduina M, Villanua MA, Lopez-Calderon A. Eicosapentaenoic acid attenuates arthritis-induced muscle wasting acting on atrogin-1 and on myogenic regulatory factors.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 297: R1322-R1331 (2009).
*
-
Castillo J, Milani C, Mendez-Allwood D. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders.
Expert Opin. Investig. Drugs 18: 491-500 (2009).
-
Castro C, Gourley M. Diagnostic testing and interpretation of tests for autoimmunity.
J. Allergy Clin. Immunol. 125: S238-S247 (2010).
*
-
Castro F, Acevedo E, Ciusani E, Angulo JA, Wollheim FA, Sandberg-Wollheim M. Tumour necrosis factor microsatellites and HLA-DRB1*, HLA-DQA1*, and HLA-DQB1* alleles in Peruvian patients with rheumatoid arthritis.
Ann. Rheum. Dis. 60: 791-795 (2001).
*
-
Castro-Caldas M. Annexin-1: 2nd messanger of the anti-inflammatory actions of glucocorticoids.
Acta Reumatol. Port. 31: 293-302 (2006).
-
Castro-Rueda H, Kavanaugh A. The treatment of psoriatic arthritis and inflammatory spondylitis.
Curr. Pain Headache Rep. 12: 412-417 (2008).
-
Castro-Rueda H, Kavanaugh A. Biologic therapy for early rheumatoid arthritis: the latest evidence.
Curr. Opin. Rheumatol. 20: 314-319 (2008).
*
-
Castro-Santos P, Suarez A, Lopez-Rivas L, Mozo L, Gutierrez C. TNFalpha and IL-10 gene polymorphisms in inflammatory bowel disease. Association of -1082 AA low producer IL-10 genotype with steroid dependency.
Am. J. Gastroenterol. 101: 1039-1047 (2006).
*
-
Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
N. Engl. J. Med. 345: 1809-1817 (2001).
*
-
Caterson B. Notice of retraction: "Pathologic indicators of degradation and inflammation in human osteoarthritic cartilage are abrogated by exposure to n-3 fatty acids" (Arthritis Rheum 2002;46:1544-53).
Arthritis Rheum. 54: 2933 (2006).
*
-
Catsarou-Catsari A, Katsambas A, Theodoropoulos P, Stratigos J. Ophthalmological manifestations in patients with psoriasis.
Acta Derm. Venereol. 64: 557-559 (1984).
-
Cauley JA. Osteoporosis in men: prevalence and investigation.
Clin. Cornerstone 8 Suppl. 3: S20-S25 (2006).
-
Cauli A, Vacca A, Mameli A, Passiu G, Fiorillo MT, Sorrentino R, Mathieu A. A Sardinian patient with ankylosing spondylitis and HLA-B*2709 co-occurring with HLA-B*1403.
Arthritis Rheum. 56: 2807-2809 (2007).
*
-
Cauvi DM, Cauvi G, Pollard KM. Reduced expression of decay-accelerating factor 1 on CD4+ T cells in murine systemic autoimmune disease.
Arthritis Rheum. 56: 1934-1944 (2007).
*
-
Cauwels A, Brouckaert P. Survival of TNF toxicity: dependence on caspases and NO.
Arch. Biochem. Biophys. 462: 132-139 (2007).
*
-
Cauwels A, Bultinck J, Brouckaert P. Dual role of endogenous nitric oxide in tumor necrosis factor shock: induced NO tempers oxidative stress.
Cell. Mol. Life Sci. 62: 1632-1640 (2005).
*
-
Cauza E, Dunky A. Psoriatic arthritis.
Wien. Med. Wochenschr. 156: 587-595 (2006).
-
Cauza E, Hanusch-Enserer U, Etemad M, Koller M, Kostner K, Georg P, Dunky A, Ferenci P. HFE genotyping demonstrates a significant incidence of hemochromatosis in undifferentiated arthritis.
Clin. Exp. Rheumatol. 23: 7-12 (2005).
-
Cavazzana I, Bobbio-Pallavicini F, Bazzani C, Bravi E, Zingarelli S, Ceribelli A, Caporali R, Cattaneo R, Franceschini F, Montecucco C. TNFalpha inhibition in anti-Ro/SSA positive patients with rheumatoid arthritis: clinical and immunological effects.
Reumatismo 58: 275-282 (2006).
-
Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases.
Autoimmun. Rev. 8: 104-106 (2008).
-
Cavazzana I, Ceribelli A, Franceschini F, Cattaneo R. Unusual association between pure red cell aplasia and primary Sjogren's syndrome: a case report.
Clin. Exp. Rheumatol. 25: 309-311 (2007).
-
Cavazzana I, Ceribelli A, Quinzanini M, Scarsi M, Airo P, Cattaneo R, Franceschini F. Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases.
Lupus 17: 727-732 (2008).
*
-
Cavazzana I, Franceschini F, Danieli E, Frassi M, Vianelli M, Gorla R, Airo P, Cattaneo R. Anti-TNFalpha treatment in patients with rheumatoid arthritis and anti-Ro/SSA antibodies.
Reumatismo 57: 267-272 (2005).
-
Cavazzana I, Franceschini F, Quinzanini M, Manera C, Del Papa N, Maglione W, Comina D, Radice A, Sinico RA, Cattaneo R. Anti-Ro/SSA antibodies in rheumatoid arthritis: clinical and immunologic associations.
Clin. Exp. Rheumatol. 24: 59-64 (2006).
-
Cavill D, Waterman SA, Gordon TP. Antibodies raised against the second extracellular loop of the human muscarinic M3 receptor mimic functional autoantibodies in Sjogren's syndrome.
Scand. J. Immunol. 59: 261-266 (2004).
*
-
Cavill I, Auerbach M, Bailie GR, Barrett-Lee P, Beguin Y, Kaltwasser P, Littlewood T, Macdougall IC, Wilson K. Iron and the anaemia of chronic disease: a review and strategic recommendations.
Curr. Med. Res. Opin. 22: 731-737 (2006).
-
Cawston TE, Wilson AJ. Understanding the role of tissue degrading enzymes and their inhibitors in development and disease.
Best Pract. Res. Clin. Rheumatol. 20: 983-1002 (2006).
-
Ceccato F, Gongora V, Zunino A, Roverano S, Paira S. Unusual manifestation of histoplasmosis in connective tissue diseases.
Clin. Rheumatol. 26: 1717-1719 (2007).
*
-
Cecchinato V, Trindade CJ, Laurence A, Heraud JM, Brenchley JM, Ferrari MG, Zaffiri L, Tryniszewska E, Tsai WP, Vaccari M, Washington Parks R, Venzon D, Douek DC, O'Shea JJ, Franchini G. Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques.
Mucosal Immunol. 1: 279-288 (2008).
*
-
Cecil DL, Appleton CT, Polewski MD, Mort JS, Schmidt AM, Bendele A, Beier F, Terkeltaub R. The pattern recognition receptor CD36 is a chondrocyte hypertrophy marker associated with suppression of catabolic responses and promotion of repair responses to inflammatory stimuli.
J. Immunol. 182: 5024-5031 (2009).
-
Cecil DL, Johnson K, Rediske J, Lotz M, Schmidt AM, Terkeltaub R. Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products.
J. Immunol. 175: 8296-8302 (2005).
*
-
Cellini M, Versura P, Leonetti P, Frigato M, Manfredini E, Malavolta N, Campos EC. Ocular surface and intraocular inflammation are related in SS-I and rheumatoid arthritis patients.
Rheumatol. Int. 27: 853-857 (2007).
*
-
Centers for Disease Control and Prevention (CDC). Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation - United States, 2003-2005.
MMWR Morb. Mortal. Wkly. Rep. 55: 1089-1092 (2006).
-
Centers for Disease Control and Prevention (CDC). National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions - United States, 2003.
MMWR Morb. Mortal. Wkly. Rep. 56: 4-7 (2007).
*
-
Centers for Disease Control and Prevention (CDC). Projected state-specific increases in self-reported doctor-diagnosed arthritis and arthritis-attributable activity limitations - United States, 2005-2030.
MMWR Morb. Mortal. Wkly. Rep. 56: 423-425 (2007).
*
-
Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha - California, 2002-2003.
MMWR Morb. Mortal. Wkly. Rep. 53: 683-686 (2004).
-
Centola M, Frank MB, Bolstad AI, Alex P, Szanto A, Zeher M, Hjelmervik TO, Jonsson R, Nakken B, Szegedi G, Szodoray P. Genome-scale assessment of molecular pathology in systemic autoimmune diseases using microarray technology: a potential breakthrough diagnostic and individualized therapy-design tool.
Scand. J. Immunol. 64: 236-242 (2006).
*
-
Cervera R, Asherson RA, Acevedo ML, Gomez-Puerta JA, Espinosa G, De La Red G, Gil V, Ramos-Casals M, Garcia-Carrasco M, Ingelmo M, Font J. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients.
Ann. Rheum. Dis. 63: 1312-1317 (2004).
*
-
Cervera R, Boffa MC, Khamashta M, Hughes G. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe.
Lupus 18: 889-893 (2009).
*
-
Cevik R, Nas K, Gur A, Ayyildiz O, Arica M. Small joint monoarthritis and pyoderma gangrenosum in newly diagnosed ulcerative colitis: an unusual presentation.
J. Clin. Rheumatol. 10: 360-362 (2004).
-
Cha HS, Bae EK, Koh JH, Chai JY, Jeon CH, Ahn KS, Kim J, Koh EM. Tumor necrosis factor-alpha induces vascular endothelial growth factor-C expression in rheumatoid synoviocytes.
J. Rheumatol. 34: 16-19 (2007).
-
Cha S, Choi CB, Han TU, Kang CP, Kang C, Bae SC. Association of anti-cyclic citrullinated peptide antibody levels with PADI4 haplotypes in early rheumatoid arthritis and with shared epitope alleles in very late rheumatoid arthritis.
Arthritis Rheum. 56: 1454-1463 (2007).
*
-
Cha SI, Fessler MB, Cool CD, Schwarz MI, Brown KK. Lymphoid interstitial pneumonia: clinical features, associations, and prognosis.
Eur. Respir. J. 28: 364-369 (2006).
-
Chabane N, Zayed N, Afif H, Mfuna-Endam L, Benderdour M, Boileau C, Martel-Pelletier J, Pelletier JP, Duval N, Fahmi H. Histone deacetylase inhibitors suppress interleukin-1beta-induced nitric oxide and prostaglandin E(2) production in human chondrocytes.
Osteoarthritis Cartilage 16: 1267-1274 (2008).
-
Chabaud M, Lubberts E, Joosten L, van Den Berg W, Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis.
Arthritis Res. 3: 168-177 (2001).
*
-
Chabaud M, Miossec P. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model.
Arthritis Rheum. 44: 1293-1303 (2001).
*
-
Chabaud M, Page G, Miossec P. Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines.
J. Immunol. 167: 6015-6020 (2001).
*
-
Chabchoub G, Petit-Teixeira E, Maalej A, Pierlot C, Bahloul Z, Cornelis F, Ayadi H. Lack of association between signaling lymphocytic activation molecule family member 1 gene and rheumatoid arthritis in the French and Tunisian populations.
Ann. Rheum. Dis. 65: 1538-1539 (2006).
*
-
Chabchoub G, Teixiera EP, Maalej A, Hamad MB, Bahloul Z, Cornelis F, Ayadi H. The R620W polymorphism of the protein tyrosine phosphatase 22 gene in autoimmune thyroid diseases and rheumatoid arthritis in the Tunisian population.
Ann. Hum. Biol. 36: 342-349 (2009).
-
Chabchoub G, Uz E, Maalej A, Mustafa CA, Rebai A, Mnif M, Bahloul Z, Farid NR, Ozcelik T, Ayadi H. Analysis of skewed X-chromosome inactivation in females with rheumatoid arthritis and autoimmune thyroid diseases.
Arthritis Res. Ther. 11: R106 (2009).
*
-
Chaby G, Viseux V, Poulain JF, De Cagny B, Denoeux JP, Lok C. Topical silver sulfadiazine-induced acute renal failure.
Ann. Dermatol. Venereol. 132: 891-893 (2005).
-
Chadha T, Hernandez JE. Infliximab-related lupus and associated valvulitis: a case report and review of the literature.
Arthritis Rheum. 55: 163-166 (2006).
*
-
Chadwick CC, Chippari S, Matelan E, Borges-Marcucci L, Eckert AM, Keith JC Jr, Albert LM, Leathurby Y, Harris HA, Bhat RA, Ashwell M, Trybulski E, Winneker RC, Adelman SJ, Steffan RJ, Harnish DC. Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity.
Proc. Natl. Acad. Sci. U.S.A. 102: 2543-2548 (2005).
*
-
Chae JJ, Aksentijevich I, Kastner DL. Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy.
Br. J. Haematol. 146: 467-478 (2009).
-
Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ, Kastner DL. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production.
Proc. Natl. Acad. Sci. U.S.A. 103: 9982-9987 (2006).
*
-
Chae JJ, Wood G, Richard K, Jaffe H, Colburn NT, Masters SL, Gumucio DL, Shoham NG, Kastner DL. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment.
Blood 112: 1794-1803 (2008).
*
-
Chae SC, Park YR, Shim SC, Lee IK, Chung HT. Eotaxin-3 gene polymorphisms are associated with rheumatoid arthritis in a Korean population.
Hum. Immunol. 66: 314-320 (2005).
-
Chae SC, Park YR, Shim SC, Yoon KS, Chung HT. The polymorphisms of Th1 cell surface gene Tim-3 are associated in a Korean population with rheumatoid arthritis.
Immunol. Lett. 95: 91-95 (2004).
-
Chae SC, Park YR, Song JH, Shim SC, Yoon KS, Chung HT. The polymorphisms of Tim-1 promoter region are associated with rheumatoid arthritis in a Korean population.
Immunogenetics 56: 696-701 (2005).
*
-
Chae SC, Shim SC, Chung HT. Association of TBX21 polymorphisms in a Korean population with rheumatoid arthritis.
Exp. Mol. Med. 41: 33-41 (2009).
*
-
Chagnon P, Schneider R, Hebert J, Fortin PR, Provost S, Belisle C, Gingras M, Bolduc V, Perreault C, Silverman E, Busque L. Identification and characterization of an Xp22.33;Yp11.2 translocation causing a triplication of several genes of the pseudoautosomal region 1 in an XX male patient with severe systemic lupus erythematosus.
Arthritis Rheum. 54: 1270-1278 (2006).
*
-
Chakravarty EF. Viral infection and reactivation in autoimmune disease.
Arthritis Rheum. 58: 2949-2957 (2008).
*
-
Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis.
Arthritis Rheum. 54: 899-907 (2006).
*
-
Chamberlain G, Wright K, Rot A, Ashton B, Middleton J. Murine mesenchymal stem cells exhibit a restricted repertoire of functional chemokine receptors: comparison with human.
PLoS ONE 3: e2934 (2008).
*
-
Chamberlain MA. A family study of Behcet's syndrome.
Ann. Rheum. Dis. 37: 459-465 (1978).
*
-
Chambers C, Koren G, Tutuncu ZN, Johnson D, Jones KL. Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study.
Can. Fam. Physician 53: 409-412 (2007).
-
Chambers MS. Sjogren's syndrome.
ORL Head Neck Nurs. 22: 22-30 (2004).
-
Chambers SA, Isenberg D. Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases.
Lupus 14: 210-214 (2005).
*
-
Chan AY, Liu DT. Methotrexate and chronic uveitis associated with juvenile idiopathic arthritis.
J. Rheumatol. 33: 198 (2006).
-
Chan AY, Westcott JM, Mooney JM, Wakeland EK, Schatzle JD. The role of SAP and the SLAM family in autoimmunity.
Curr. Opin. Immunol. 18: 656-664 (2006).
-
Chan CY, Browning JC, Larsen F, Hsu S. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
Dermatol. Online J. 14: 12 (2008).
*
-
Chan EK, Satoh M, Pauley KM. Contrast in aberrant microRNA expression in systemic lupus erythematosus and rheumatoid arthritis: is microRNA-146 all we need?
Arthritis Rheum. 60: 912-915 (2009).
*
-
Chan FK, Hung LC, Suen BY, Wong VW, Hui AJ, Wu JC, Leung WK, Lee YT, To KF, Chung SC, Sung JJ. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.
Gastroenterology 127: 1038-1043 (2004).
*
-
Chan HL, Lee YS, Hong HS, Kuo TT. Anticentromere antibodies (ACA): clinical distribution and disease specificity.
Clin. Exp. Dermatol. 19: 298-302 (1994).
-
Chan JL, Davis-Reed L, Kimball AB. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy.
J. Drugs Dermatol. 3: 315-318 (2004).
-
Chan JW, Castellanos A. Infliximab and anterior optic neuropathy: case report and review of the literature.
Graefes Arch. Clin. Exp. Ophthalmol. Nov 15 [Epub ahead of print] (2009).
*
-
Chan MT, Owen P, Dunphy J, Cox B, Carmichael C, Korendowych E, McHugh NJ. Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC class II alleles in systemic lupus erythematosus.
J. Rheumatol. 35: 77-83 (2008).
-
Chan SH, Lin YN, Wee GB, Koh WH, Boey ML. HLA class 2 genes in Singaporean Chinese rheumatoid arthritis.
Br. J. Rheumatol. 33: 713-717 (1994).
-
Chan TM. Histologic deterioration and more flares: the case against azathioprine plus methylprednisolone in the treatment of proliferative lupus nephritis.
Arthritis Rheum. 56: 702-704 (2007).
*
-
Chan V, Tett SE. Changes in use of disease-modifying anti-rheumatic drugs in Australia over the period 1992-2004.
Pharmacoepidemiol. Drug Saf. 15: 462-468 (2006).
-
Chanda P, Sucheston L, Zhang A, Brazeau D, Freudenheim JL, Ambrosone C, Ramanathan M. AMBIENCE: a novel approach and efficient algorithm for identifying informative genetic and environment interactions associated with complex phenotypes.
Genetics 180: 1191-1210 (2008).
*
-
Chanda P, Sucheston L, Zhang A, Ramanathan M. The interaction index, a novel information-theoretic metric for prioritizing interacting genetic variations and environmental factors.
Eur. J. Hum. Genet. 17: 1274-1286 (2009).
-
Chandran NS, Greaves M, Gao F, Lim L, Cheng BC. Psoriasis and the eye: prevalence of eye disease in Singaporean Asian patients with psoriasis.
J. Dermatol. 34: 805-810 (2007).
-
Chandran V. Epidemiology of psoriatic arthritis.
J. Rheumatol. 36: 213-215 (2009).
-
Chandran V, Barrett J, Schentag CT, Farewell VT, Gladman DD. Axial psoriatic arthritis: update on a longterm prospective study.
J. Rheumatol. 36: 2744-2750 (2009).
-
Chandran V, Gottlieb A, Cook RJ, Duffin KC, Garg A, Helliwell P, Kavanaugh A, Krueger GG, Langley RG, Lynde C, McHugh N, Mease P, Olivieri I, Rahman P, Rosen CF, Salvarani C, Thaci D, Toloza SM, Wong MY, Zhou QM, Gladman DD. International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis.
Arthritis Rheum. 61: 1235-1242 (2009).
*
-
Chandran V, Pellett F, Gladman DD. Killer cell immunoglobulin-like receptor gene's repertoire in rheumatoid arthritis.
Scand. J. Rheumatol. 36: 409 (2007).
*
-
Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis.
J. Autoimmun. Dec 22 [Epub ahead of print] (2009).
-
Chandran V, Schentag CT. Sensitivity and specificity of the CASPAR criteria for psoriatic arthritis in a family medicine clinic setting.
J. Rheumatol. 35: 2069-2070 (2008).
-
Chandran V, Schentag CT, Brockbank JE, Pellett FJ, Shanmugrajah S, Toloza SM, Rahman P, Gladman DD. Familial aggregation of psoriatic arthritis.
Ann. Rheum. Dis. 68: 664-667 (2009).
-
Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort.
J. Rheumatol. 35: 469-471 (2008).
-
Chandran V, Upadhyaya SK, Haroon N, Aggarwal A, Misra R. Lack of clinical association with antibodies to ribosomal p proteins in Indian patients with systemic lupus erythematosus.
J. Rheumatol. 33: 1987-1989 (2006).
-
Chang BY, Zhao F, He X, Ren H, Braselmann S, Taylor V, Wicks J, Payan DG, Grossbard EB, Pine PR, Bullard DC. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice.
J. Immunol. 183: 2183-2192 (2009).
-
Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial.
Arthritis Rheum. 46: 2924-2927 (2002).
*
-
Chang H, Qin W, Li Y, Zhang J, Lin Z, Lv M, Sun Y, Feng J, Shen B. A novel human scFv fragment against TNF-alpha from de novo design method.
Mol. Immunol. 44: 3789-3796 (2007).
*
-
Chang HK, Bang KT, Lee BH, Kim JH, Bae KW, Kim MJ, Kim SK. Concurrence of Sjogren's syndrome in a patient with Chlamydia-induced reactive arthritis; an unusual finding.
Korean J. Intern. Med. 21: 116-119 (2006).
-
Chang J, Girgis L. Clinical use of anti-TNF-alpha biological agents - a guide for GPs.
Aust. Fam. Physician 36: 1035-1038 (2007).
*
-
Chang JW, Tsai HL, Yang LY. Successful treatment of refractory septic arthritis caused by Salmonella and Staphylococcus aureus with preservation of graft function in a long-term renal transplant recipient by total withdrawal of immunosuppressants.
Clin. Nephrol. 73: 72-75 (2010).
-
Chang M, Rowland CM, Garcia VE, Schrodi SJ, Catanese JJ, van der Helm-van Mil AH, Ardlie KG, Amos CI, Criswell LA, Kastner DL, Gregersen PK, Kurreeman FA, Toes RE, Huizinga TW, Seldin MF, Begovich AB. A large-scale rheumatoid arthritis genetic study identifies association at chromosome 9q33.2.
PLoS Genet. 4: e1000107 (2008).
*
-
Chang WW, Su H, He L, Zhao KF, Wu JL, Xu ZW. Association between transforming growth factor-beta1 T869C polymorphism and rheumatoid arthritis: a meta-analysis.
Rheumatology (Oxford) Jan 4 [Epub ahead of print] (2010).
-
Chang X, Yamada R, Sawada T, Suzuki A, Kochi Y, Yamamoto K. The inhibition of antithrombin by peptidylarginine deiminase 4 may contribute to pathogenesis of rheumatoid arthritis.
Rheumatology (Oxford) 44: 293-298 (2005).
*
-
Chang X, Yamada R, Suzuki A, Kochi Y, Sawada T, Yamamoto K. Citrullination of fibronectin in rheumatoid arthritis synovial tissue.
Rheumatology (Oxford) 44: 1374-1382 (2005).
*
-
Chang X, Yamada R, Suzuki A, Sawada T, Yoshino S, Tokuhiro S, Yamamoto K. Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis.
Rheumatology (Oxford) 44: 40-50 (2005).
*
-
Chang YH, Lin IL, Tsay GJ, Yang SC, Yang TP, Ho KT, Hsu TC, Shiau MY. Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus.
Clin. Biochem. 41: 955-959 (2008).
*
-
Chang YT, Chou CT, Yu CW, Lin MW, Shiao YM, Chen CC, Huang CH, Lee DD, Liu HN, Wang WJ, Tsai SF. Cytokine gene polymorphisms in Chinese patients with psoriasis.
Br. J. Dermatol. 156: 899-905 (2007).
*
-
Changelian PS, Moshinsky D, Kuhn CF, Flanagan ME, Munchhof MJ, Harris TM, Doty JL, Sun J, Kent CR, Magnuson KS, Perregaux DG, Sawyer PS, Kudlacz EM. The specificity of JAK3 kinase inhibitors.
Blood 111: 2155-2157 (2008).
*
-
Channual J, Wu JJ, Dann FJ. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
Dermatol. Ther. 22: 61-73 (2009).
-
Chao SC, Yang CC, Lee JY. Hypersensitivity syndrome and pure red cell aplasia following allopurinol therapy in a patient with chronic kidney disease.
Ann. Pharmacother. 39: 1552-1556 (2005).
-
Chao YC, Cheng TS, Chou CT. Panniculitis: an unusual cutaneous manifestation of rheumatoid arthritis.
J. Clin. Rheumatol. 12: 190-193 (2006).
-
Chaouat D, Belange G, Gompel H. Polymyalgia rheumatica in primary biliary cirrhosis: value of the search for antimitochondrial antibodies in rhizomelic pseudo-polyarthritis and Horton disease.
Rev. Med. Interne. 15: 775-776 (1994).
-
Chaoui Z, Bernoussi A, Belmekki M, Berraho A. Uveitis and chronic intestinal inflammatory diseases: three case studies.
J. Fr. Ophtalmol. 28: 854-856 (2005).
-
Chaouni I, Lefranc MP, d'Angeac AD, Zanin C, Pellet F, Clot J, Combe B, Sany J, Reme T. T cell receptor gamma variable gene locus polymorphism in patients with rheumatoid arthritis.
Arthritis Rheum. 35: 756-760 (1992).
-
Chapman K, Takahashi A, Meulenbelt I, Watson C, Rodriguez-Lopez J, Egli R, Tsezou A, Malizos KN, Kloppenburg M, Shi D, Southam L, van der Breggen R, Donn R, Qin J, Doherty M, Slagboom PE, Wallis G, Kamatani N, Jiang Q, Gonzalez A, Loughlin J, Ikegawa S. A meta-analysis of European and Asian cohorts reveals a global role of a functional SNP in the 5' UTR of GDF5 with osteoarthritis susceptibility.
Hum. Mol. Genet. 17: 1497-1504 (2008).
*
-
Chapman KE, Coutinho A, Gray M, Gilmour JS, Savill JS, Seckl JR. Local amplification of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 and its role in the inflammatory response.
Ann. N. Y. Acad. Sci. 1088: 265-273 (2006).
*
-
Chapman RW. The management of primary sclerosing cholangitis.
Curr. Gastroenterol. Rep. 5: 9-17 (2003).
-
Chapuy-Regaud S, Sebbag M, Baeten D, Clavel C, Foulquier C, De Keyser F, Serre G. Fibrin deimination in synovial tissue is not specific for rheumatoid arthritis but commonly occurs during synovitides.
J. Immunol. 174: 5057-5064 (2005).
*
-
Charalabopoulos K, Mittari E, Peschos D, Golias C, Charalabopoulos A, Tsanou E, Batistatou A. Rare association of chronic lymphocytic thyroiditis with dermatomyositis.
Arch. Med. Res. 37: 563-565 (2006).
-
Charbonneau M, Harper K, Grondin F, Pelmus M, McDonald PP, Dubois CM. Hypoxia-inducible factor mediates hypoxic and tumor necrosis factor alpha-induced increases in tumor necrosis factor-alpha converting enzyme/ADAM17 expression by synovial cells.
J. Biol. Chem. 282: 33714-33724 (2007).
*
-
Charbonnier LM, van Duivenvoorde LM, Apparailly F, Cantos C, Han WG, Noel D, Duperray C, Huizinga TW, Toes RE, Jorgensen C, Louis-Plence P. Immature dendritic cells suppress collagen-induced arthritis by in vivo expansion of CD49b+ regulatory T cells.
J. Immunol. 177: 3806-3813 (2006).
*
-
Charles-Schoeman C, Banquerigo ML, Hama S, Navab M, Park GS, Van Lenten BJ, Wagner AC, Fogelman AM, Brahn E. Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis.
Clin. Immunol. 127: 234-244 (2008).
*
-
Charlier C, Henegar C, Launay O, Pagnoux C, Berezne A, Bienvenu B, Cohen P, Mouthon L, Guillevin L. Risk factors for major infections in Wegener's granulomatosis: analysis of 113 patients.
Ann. Rheum. Dis. 68: 658-663 (2009).
-
Charmley P, Nelson JL, Hansen JA, Branchaud A, Barrington RA, Templin D, Boyer G, Lanier AP, Concannon P. T-cell receptor polymorphisms in Tlingit Indians with rheumatoid arthritis.
Autoimmunity 19: 247-251 (1994).
-
Charmley P, Nepom BS, Concannon P. HLA and T cell receptor beta-chain DNA polymorphisms identify a distinct subset of patients with pauciarticular-onset juvenile rheumatoid arthritis.
Arthritis Rheum. 37: 695-701 (1994).
-
Charniot JC, Genereau T, Mouthon L. Celiprolol-induced lupus-like syndrome.
Acta Cardiol. 61: 661-663 (2006).
-
Charoonpatrapong K, Shah R, Robling AG, Alvarez M, Clapp DW, Chen S, Kopp RP, Pavalko FM, Yu J, Bidwell JP. HMGB1 expression and release by bone cells.
J. Cell Physiol. 207: 480-490 (2006).
*
-
Charpin C, Balandraud N, Guis S, Roudier C, Toussirot E, Rak J, Lambert N, Martin M, Reviron D, Roudier J, Auger I. HLA-DRB1*0404 is strongly associated with high titers of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis.
Clin. Exp. Rheumatol. 26: 627-631 (2008).
-
Charpin C, Guis S, Colson P, Borentain P, Mattei JP, Alcaraz P, Balandraud N, Thomachot B, Roudier J, Gerolami R. Safety of TNF blocking agents in rheumatic patients with serology suggesting past-hepatitis B state: results from a cohort of 21 patients.
Arthritis Res. Ther. 11: R179 (2009).
*
-
Charrier-Hisamuddin L, Laboisse CL, Merlin D. ADAM-15: a metalloprotease that mediates inflammation.
FASEB J. 22: 641-653 (2008).
*
-
Charron DJ. New aspects of HLA: perspectives for rheumatoid arthritis.
Clin. Exp. Rheumatol. 10: 293-296 (1992).
-
Chatfield SM, Brand C, Ebeling PR, Russell DM. Vitamin D deficiency in general medical inpatients in summer and winter.
Intern. Med. J. 37: 377-382 (2007).
*
-
Chatham W. Rheumatic manifestations of systemic disease: sarcoidosis.
Curr. Opin. Rheumatol. 22: 85-90 (2010).
-
Chatzikyriakidou A, Georgiou I, Voulgari PV, Georgiadis AN, Argyriou ES, Drosos AA. Glucocorticoid receptor variants may predispose to rheumatoid arthritis susceptibility.
Scand. J. Rheumatol. 38: 1-5 (2009).
*
-
Chatzikyriakidou A, Georgiou I, Voulgari PV, Papadopoulos CG, Tzavaras T, Drosos AA. Transcription regulatory polymorphism -43T>C in the 5'-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy.
Rheumatol. Int. 27: 1057-1061 (2007).
*
-
Chatzikyriakidou A, Georgiou I, Voulgari PV, Venetsanopoulou AI, Drosos AA. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism.
Rheumatology (Oxford) 46: 1034-1035 (2007).
*
-
Chauhan A, Mikulik Z, Hackshaw KV. Multicentric reticulohistiocytosis with positive anticyclic citrullinated antibodies.
J. Natl. Med. Assoc. 99: 678-680 (2007).
*
-
Chavanas S, Mechin MC, Takahara H, Kawada A, Nachat R, Serre G, Simon M. Comparative analysis of the mouse and human peptidylarginine deiminase gene clusters reveals highly conserved non-coding segments and a new human gene, PADI6.
Gene 330: 19-27 (2004).
*
-
Chaves Y, Duarte G, Ben-Said B, Tebib J, Berard F, Nicolas JF. Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab).
Dermatology 217: 380 (2008).
-
Chavez-Lopez M, Delgado-Villafana J, Gallaga A, Huerta-Yanez G. Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis.
Allergol. Immunopathol. (Madr.) 33: 291-292 (2005).
-
Chavez-Lopez MA, Ramirez-Gonzalez A, Martinez-Guevara MA. Acute hepatitis associated to leflunomide in a patient with rheumatoid arthritis.
Gastroenterol. Hepatol. 30: 430 (2007).
-
Chawla SK, Patel HD, Parrino GR, Soterakis J, Lopresti PA, D'Angelo WA. Allopurinol hepatotoxicity. Case report and literature review.
Arthritis Rheum. 20: 1546-1549 (1977).
-
Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.
Arthritis Rheum. 44: 1313-1319 (2001).
*
-
Chelala C, Duchatelet S, Joffret ML, Bergholdt R, Dubois-Laforgue D, Ghandil P, Pociot F, Caillat-Zucman S, Timsit J, Julier C. PTPN22 R620W functional variant in type 1 diabetes and autoimmunity related traits.
Diabetes 56: 522-526 (2007).
*
-
Chen B, Hu J, Liao L, Sun Z, Han Q, Song Z, Zhao RC. Flk-1(+) mesenchymal stem cells aggravate collagen-induced arthritis by up-regulating interleukin-6.
Clin. Exp. Immunol. Dec 14 [Epub ahead of print] (2009).
*
-
Chen CC, Isomoto H, Narumi Y, Sato K, Oishi Y, Kobayashi T, Yanagihara K, Mizuta Y, Kohno S, Tsukamoto K. Haplotypes of PADI4 susceptible to rheumatoid arthritis are also associated with ulcerative colitis in the Japanese population.
Clin. Immunol. 126: 165-171 (2008).
*
-
Chen CS, Roberton D, Hammerton ME. Juvenile arthritis-associated uveitis: visual outcomes and prognosis.
Can. J. Ophthalmol. 39: 614-620 (2004).
-
Chen D, Wei Y, Li X, Epstein S, Wolosin JM, Asbell P. sPLA2-IIa is an inflammatory mediator when the ocular surface is compromised.
Exp. Eye Res. 88: 880-888 (2009).
*
-
Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL. Functional association of interleukin 18 gene -607 (C/A) promoter polymorphisms with disease course in Chinese patients with adult-onset Still's disease.
J. Rheumatol. 36: 2284-2289 (2009).
-
Chen DY, Chou SJ, Hsieh TY, Chen YH, Chen HH, Hsieh CW, Lan JL. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis.
J. Formos. Med. Assoc. 108: 310-319 (2009).
*
-
Chen DY, Hsieh TY, Chen YM, Hsieh CW, Lan JL, Lin FJ. Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease.
Gerontology 55: 250-258 (2009).
-
Chen DY, Lan JL, Lin FJ, Hsieh TY. Elevated levels of soluble Fas (APO-1, CD95), soluble Fas ligand, and matrix metalloproteinase-3 in sera from patients with active untreated adult onset Still's disease.
Clin. Rheumatol. 26: 393-400 (2007).
*
-
Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway.
Science 296: 1634-1635 (2002).
*
-
Chen G, Li N, Zang YC, Zhang D, He D, Feng G, Ni L, Xu R, Wang L, Shen B, Zhang JZ. Vaccination with selected synovial T cells in rheumatoid arthritis.
Arthritis Rheum. 56: 453-463 (2007).
*
-
Chen G, Ward MF, Sama AE, Wang H. Extracellular HMGB1 as a proinflammatory cytokine.
J. Interferon Cytokine Res. 24: 329-333 (2004).
-
Chen H, Qin J, Wei P, Zhang J, Li Q, Fu L, Li S, Ma C, Cong B. Effects of leukotriene B4 and prostaglandin E2 on the differentiation of murine Foxp3+ T regulatory cells and Th17 cells.
Prostaglandins Leukot. Essent. Fatty Acids 80: 195-200 (2009).
*
-
Chen HC, Kraus VB, Li YJ, Nelson S, Haynes C, Johnson J, Stabler T, Hauser ER, Gregory SG, Kraus WE, Shah SH. Genome-wide linkage analysis of quantitative biomarker traits of osteoarthritis in a large, multigenerational extended family.
Arthritis Rheum. 62: 781-790 (2010).
*
-
Chen HY, Guo JL, Li ZG. Significance of anti-cell membrane-associated DNA (mDNA) antibodies in systemic lupus erythematosus.
Clin. Rheumatol. 27: 183-187 (2008).
*
-
Chen J, Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials.
J. Rheumatol. 33: 722-731 (2006).
-
Chen J, Liu C. Sulfasalazine for ankylosing spondylitis.
Cochrane Database Syst. Rev. 2: CD004800 (2005).
*
-
Chen J, Liu C. Methotrexate for ankylosing spondylitis.
Cochrane Database Syst. Rev. 3: CD004524 (2004).
*
-
Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis.
Cochrane Database Syst. Rev. 4: CD004524 (2006).
*
-
Chen J, Liu X. The role of interferon gamma in regulation of CD4(+) T-cells and its clinical implications.
Cell. Immunol. 254: 85-90 (2009).
*
-
Chen JY, Wang CM, Ma CC, Luo SF, Edberg JC, Kimberly RP, Wu J. Association of a transmembrane polymorphism of Fcgamma receptor IIb (FCGR2B) with systemic lupus erythematosus in Taiwanese patients.
Arthritis Rheum. 54: 3908-3917 (2006).
*
-
Chen JY, Wang CM, Wu JM, Ho HH, Luo SF. Association of rheumatoid factor production with FcgammaRIIIa polymorphism in Taiwanese rheumatoid arthritis.
Clin. Exp. Immunol. 144: 10-16 (2006).
*
-
Chen L, Zhong M, Chen WV, Amos CI, Fan R. A genome-wide association scan for rheumatoid arthritis data by Hotelling's T2 tests.
BMC Proc. 3 Suppl. 7: S6 (2009).
*
-
Chen LN, Wang CH, Zhu P, Fan CM, Wang YH, Li XY. The changes of CD4(+) CD25(high) regulatory T cells in the course of rheumatoid arthritis and their significances.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 23: 331-334 (2007).
-
Chen M, Dittmann A, Kuhn A, Ruzicka T, Mikecz AV. Recruitment of topoisomerase I (Scl-70) to nucleoplasmic proteasomes in response to xenobiotics suggests a role for altered antigen processing in scleroderma.
Arthritis Rheum. 52: 877-884 (2005).
*
-
Chen M, Lam BK, Kanaoka Y, Nigrovic PA, Audoly LP, Austen KF, Lee DM. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis.
J. Exp. Med. 203: 837-842 (2006).
*
-
Chen M, von Mikecz A. Xenobiotic-induced recruitment of autoantigens to nuclear proteasomes suggests a role for altered antigen processing in scleroderma.
Ann. N. Y. Acad. Sci. 1051: 382-389 (2005).
*
-
Chen Q, Li X, He W, Zhang H, Gao A, Cheng Y, Lei J, Li S, Zeng L. The epitope study of alpha-fodrin autoantibody in primary Sjogren's syndrome.
Clin. Exp. Immunol. 149: 497-503 (2007).
*
-
Chen Q, Yang W, Gupta S, Biswas P, Smith P, Bhagat G, Pernis AB. IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor.
Immunity 29: 899-911 (2008).
*
-
Chen R, Fang M, Cai Q, Duan S, Lv K, Cheng N, Ren D, Shen J, He D, He L, Sun S. Tumor necrosis factor alpha -308 polymorphism is associated with rheumatoid arthritis in Han population of Eastern China.
Rheumatol. Int. 28: 121-126 (2007).
*
-
Chen RT, Pless R, Destefano F. Epidemiology of autoimmune reactions induced by vaccination.
J. Autoimmun. 16: 309-318 (2001).
-
Chen WS, Lin KC, Chen CH, Liao HT, Wang HP, Li WY, Lee HT, Tsai CY, Chou CT. Autoantibody and biopsy grading are associated with expression of ICAM-1, MMP-3, and TRAIL in salivary gland mononuclear cells of Chinese patients with Sjogren's syndrome.
J. Rheumatol. 36: 989-996 (2009).
-
Chen WV, Amos CI, Etzel CJ, Shete S, Gregersen PK. Comparison of genome-wide single-nucleotide polymorphism linkage analyses in Caucasian and Hispanic NARAC families.
BMC Proc. 1 Suppl. 1: S97 (2007).
*
-
Chen WY, Chang MS. IL-20 is regulated by hypoxia-inducible factor and up-regulated after experimental ischemic stroke.
J. Immunol. 182: 5003-5012 (2009).
-
Chen X, Bai F, Sokol L, Zhou J, Ren A, Painter JS, Liu J, Sallman DA, Chen YA, Yoder JA, Djeu JY, Loughran TP Jr, Epling-Burnette PK, Wei S. A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia.
Blood 113: 3226-3234 (2009).
*
-
Chen X, Oppenheim JJ. TNF-alpha: an activator of CD4+FoxP3+TNFR2+ regulatory T cells.
Curr. Dir. Autoimmun. 11: 119-134 (2010).
-
Chen X, Oppenheim JJ, Howard OM. Chemokines and chemokine receptors as novel therapeutic targets in rheumatoid arthritis (RA): inhibitory effects of traditional Chinese medicinal components.
Cell. Mol. Immunol. 1: 336-342 (2004).
*
-
Chen Y, Donnelly E, Kobayashi H, Debusk LM, Lin PC. Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction.
Arthritis Rheum. 52: 1585-1594 (2005).
*
-
Chen Y, Khanna S, Goodyear CS, Park YB, Raz E, Thiel S, Gronwall C, Vas J, Boyle DL, Corr M, Kono DH, Silverman GJ. Regulation of dendritic cells and macrophages by an anti-apoptotic cell natural antibody that suppresses TLR responses and inhibits inflammatory arthritis.
J. Immunol. 183: 1346-1359 (2009).
-
Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Health Technol. Assess. 10: 1-248 (2006).
*
-
Chen YJ, Lin CH, Ou TT, Wu CC, Tsai WC, Liu HW, Yen JH. Solute carrier family 11 member A1 gene polymorphisms in reactive arthritis.
J. Clin. Immunol. 27: 46-52 (2007).
*
-
Chen YS, Chou PH, Li SN, Tsai WC, Lin KH, Tsai KB, Yen JH, Liu HW. Parvovirus B19 infection in patients with rheumatoid arthritis in Taiwan.
J. Rheumatol. 33: 887-891 (2006).
-
Chen Z, de Kauwe AL, Keech C, Wijburg O, Simpfendorfer K, Alexander WS, McCluskey J. Humanized transgenic mice expressing HLA DR4-DQ3 haplotype: reconstitution of phenotype and HLA-restricted T-cell responses.
Tissue Antigens 68: 210-219 (2006).
*
-
Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu BM, Tato C, Yoshimura A, Hennighausen L, O'Shea JJ. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells.
Proc. Natl. Acad. Sci. U.S.A. 103: 8137-8142 (2006).
*
-
Chen Z, Laurence A, O'Shea JJ. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation.
Semin. Immunol. 19: 400-408 (2007).
*
-
Chen Z, O'Shea JJ. Th17 cells: a new fate for differentiating helper T cells.
Immunol. Res. 41: 87-102 (2008).
*
-
Chen Z, O'Shea JJ. Regulation of IL-17 production in human lymphocytes.
Cytokine 41: 71-78 (2008).
-
Chen Z, Tato CM, Muul L, Laurence A, O'Shea JJ. Distinct regulation of interleukin-17 in human T helper lymphocytes.
Arthritis Rheum. 56: 2936-2946 (2007).
*
-
Chenevier-Gobeaux C, Lemarechal H, Bonnefont-Rousselot D, Poiraudeau S, Ekindjian OG, Borderie D. Superoxide production and NADPH oxidase expression in human rheumatoid synovial cells: regulation by interleukin-1beta and tumour necrosis factor-alpha.
Inflamm. Res. 55: 483-490 (2006).
*
-
Chenevier-Gobeaux C, Simonneau C, Therond P, Bonnefont-Rousselot D, Poiraudeau S, Ekindjian OG, Borderie D. Implication of cytosolic phospholipase A(2) (cPLA(2)) in the regulation of human synoviocyte NADPH oxidase (Nox2) activity.
Life Sci. 81: 1050-1058 (2007).
*
-
Cheng S, Afif H, Martel-Pelletier J, Benderdour M, Pelletier JP, Hilal G, Haraoui P, Raynauld JP, Choquette D, Fahmi H. Association of polymorphisms in the peroxisome proliferator-activated receptor gamma gene and osteoarthritis of the knee.
Ann. Rheum. Dis. 65: 1394-1397 (2006).
*
-
Cheng VC, Ho PL, Yuen KY. Two probable cases of serious drug interaction between clarithromycin and colchicine.
South Med. J. 98: 811-813 (2005).
-
Cheon H, Rho YH, Choi SJ, Lee YH, Song GG, Sohn J, Won NH, Ji JD. Prostaglandin E2 augments IL-10 signaling and function.
J. Immunol. 177: 1092-1100 (2006).
*
-
Chernajovsky Y. Gene therapy for arthritis - where do we stand?
Arthritis Res. Ther. 7: 227-229 (2005).
*
-
Chernajovsky Y, Gould DJ, Podhajcer OL. Gene therapy for autoimmune diseases: quo vadis?
Nat. Rev. Immunol. 4: 800-811 (2004).
*
-
Cheung YH, Chang NH, Cai YC, Bonventi G, Macleod R, Wither JE. Functional interplay between intrinsic B and T cell defects leads to amplification of autoimmune disease in New Zealand Black chromosome 1 congenic mice.
J. Immunol. 175: 8154-8164 (2005).
*
-
Cheung YH, Loh C, Pau E, Kim J, Wither J. Insights into the genetic basis and immunopathogenesis of systemic lupus erythematosus from the study of mouse models.
Semin. Immunol. 21: 372-382 (2009).
*
-
Chi ZC, Ma SZ. Rheumatologic manifestations of hepatic diseases.
Hepatobiliary Pancreat. Dis. Int. 2: 32-37 (2003).
*
-
Chia WT, Chen YW, Cheng LY, Lee HS, Chang DM, Sytwu HK. MMP-9 mRNA as a therapeutic marker in acute and chronic stages of arthritis induced by type II collagen antibody.
J. Formos. Med. Assoc. 107: 245-252 (2008).
-
Chiang E, Packer CD. Concurrent reactive arthritis, Graves' disease, and warm autoimmune hemolytic anemia: a case report.
Cases J. 2: 6988 (2009).
*
-
Chiang EY, Kolumam GA, Yu X, Francesco M, Ivelja S, Peng I, Gribling P, Shu J, Lee WP, Refino CJ, Balazs M, Paler-Martinez A, Nguyen A, Young J, Barck KH, Carano RA, Ferrando R, Diehl L, Chatterjea D, Grogan JL. Targeted depletion of lymphotoxin-alpha-expressing T(H)1 and T(H)17 cells inhibits autoimmune disease.
Nat. Med. 15: 766-773 (2009).
*
-
Chiang TM, Postlethwaite AE. A cell model system to study regulation of phosphotidylinositol 3-kinase and protein kinase B activity by cytokines/growth factors produced by type I collagen stimulated immune cells from patients with systemic sclerosis.
Biochim. Biophys. Acta 1770: 1181-1186 (2007).
*
-
Chiavaroli C, Moore A. An hypothesis to link the opposing immunological effects induced by the bacterial lysate OM-89 in urinary tract infection and rheumatoid arthritis.
BioDrugs 20: 141-149 (2006).
-
Chiba K. A new orally active anti-rheumatic drug targets IL-15 and IL-17.
Nihon Rinsho Meneki Gakkai Kaishi 30: 375-382 (2007).
-
Chiba K. A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720).
Yakugaku Zasshi 129: 655-665 (2009).
-
Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
Pharmacol. Ther. 108: 308-319 (2005).
*
-
Chikanza IC, Kozaci D, Chernajovsky Y. The molecular and cellular basis of corticosteroid resistance.
J. Endocrinol. 179: 301-310 (2003).
*
-
Chikazawa H, Nishiya K, Matsumori A, Hashimoto K. Immunoglobulin isotypes of anti-myeloperoxidase and anti-lactoferrin antibodies in patients with collagen diseases.
J. Clin. Immunol. 20: 279-286 (2000).
*
-
Chillingworth NL, Morham SG, Donaldson LF. Sex differences in inflammation and inflammatory pain in cyclooxygenase-deficient mice.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 291: R327-334 (2006).
*
-
Chilton F, Collett RA. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis.
Musculoskeletal Care 6: 1-14 (2008).
-
Chimenti MS, Papoutsaki M, Teoli M, Zangrilli A, Perricone R, Chimenti S. Radiologically significant joint improvement in a patient affected by psoriatic arthritis treated with adalimumab.
Clin. Exp. Rheumatol. 27: 1056 (2009).
-
Chin D, Boyle GM, Theile DR, Parsons PG, Coman WB. The human genome and gene expression profiling.
J. Plast. Reconstr. Aesthet. Surg. 59: 902-911 (2006).
-
Chin G, Luxton G, Harvey JM. Infliximab and nephrotic syndrome.
Nephrol. Dial. Transplant. 20: 2824-2826 (2005).
*
-
Chin RK, Zhu M, Christiansen PA, Liu W, Ware C, Peltonen L, Zhang X, Guo L, Han S, Zheng B, Fu YX. Lymphotoxin pathway-directed, autoimmune regulator-independent central tolerance to arthritogenic collagen.
J. Immunol. 177: 290-297 (2006).
*
-
Chinoy H, Platt H, Lamb JA, Betteridge Z, Gunawardena H, Fertig N, Varsani H, Davidson J, Oddis CV, McHugh NJ, Wedderburn LR, Ollier WE, Cooper RG. The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients.
Arthritis Rheum. 58: 3247-3254 (2008).
*
-
Chintalacharuvu SR, Sandusky GE, Burris TP, Burmer GC, Nagpal S. Liver X receptor is a therapeutic target in collagen-induced arthritis.
Arthritis Rheum. 56: 1365-1367 (2007).
*
-
Chiorini JA, Cihakova D, Ouellette CE, Caturegli P. Sjogren syndrome: advances in the pathogenesis from animal models.
J. Autoimmun. 33: 190-196 (2009).
-
Chiou CF, Sherbourne CD, Cornelio I, Lubeck DP, Paulus HE, Dylan M, Chang CH, Weisman MH. Development and validation of the revised Cedars-Sinai health-related quality of life for rheumatoid arthritis instrument.
Arthritis Rheum. 55: 856-863 (2006).
*
-
Chirino YI, Orozco-Lbarra M, Pedraza-Chaverri J. Role of peroxynitrite anion in different diseases.
Rev. Invest. Clin. 58: 350-358 (2006).
-
Chistiakov DA, Chistiakov AP. Is FCRL3 a new general autoimmunity gene?
Hum. Immunol. 68: 375-383 (2007).
-
Chitale S, Moots R. Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis.
Expert Opin. Biol. Ther. 8: 115-122 (2008).
-
Chitkara P, Stojanov S, Kastner DL. The hereditary autoinflammatory syndromes.
Pediatr. Infect. Dis. J. 26: 353-354 (2007).
-
Chiu YC, Lin CY, Chen CP, Huang KC, Tong KM, Tzeng CY, Lee TS, Hsu HC, Tang CH. Peptidoglycan enhances IL-6 production in human synovial fibroblasts via TLR2 receptor, focal adhesion kinase, Akt, and AP-1-dependent pathway.
J. Immunol. 183: 2785-2792 (2009).
-
Chiu YF, Kao HY, Chen YS, Hsu FC, Yang HC. Assessment of gene-covariate interactions by incorporating covariates into association mapping.
BMC Proc. 3 Suppl. 7: S85 (2009).
*
-
Chiu YG, Shao T, Feng C, Mensah KA, Thullen M, Schwarz EM, Ritchlin CT. CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis.
Arthritis Res. Ther. 12: R14 (2010).
*
-
Chizzolini C, Dayer JM, Miossec P. Cytokines in chronic rheumatic diseases: is everything lack of homeostatic balance?
Arthritis Res. Ther. 11: 246 (2009).
-
Chizzolini C, Parel Y, Scheja A, Dayer JM. Polarized subsets of human T-helper cells induce distinct patterns of chemokine production by normal and systemic sclerosis dermal fibroblasts.
Arthritis Res. Ther. 8: R10 (2006).
*
-
Cho ML, Heo YJ, Park MK, Oh HJ, Park JS, Woo YJ, Ju JH, Park SH, Kim HY, Min JK. Grape seed proanthocyanidin extract (GSPE) attenuates collagen-induced arthritis.
Immunol. Lett. 124: 102-110 (2009).
-
Cho ML, Ju JH, Kim HR, Oh HJ, Kang CM, Jhun JY, Lee SY, Park MK, Min JK, Park SH, Lee SH, Kim HY. Toll-like receptor 2 ligand mediates the upregulation of angiogenic factor, vascular endothelial growth factor and interleukin-8/CXCL8 in human rheumatoid synovial fibroblasts.
Immunol. Lett. 108: 121-128 (2007).
-
Cho ML, Ju JH, Kim KW, Moon YM, Lee SY, Min SY, Cho YG, Kim HS, Park KS, Yoon CH, Lee SH, Park SH, Kim HY. Cyclosporine A inhibits IL-15-induced IL-17 production in CD4(+) T cells via down-regulation of PI3K/Akt and NF-kappaB.
Immunol. Lett. 108: 88-96 (2007).
-
Cho ML, Jung YO, Kim KW, Park MK, Oh HJ, Ju JH, Cho YG, Min JK, Kim SI, Park SH, Kim HY. IL-17 induces the production of IL-16 in rheumatoid arthritis.
Exp. Mol. Med. 40: 237-245 (2008).
*
-
Cho ML, Kang JW, Moon YM, Nam HJ, Jhun JY, Heo SB, Jin HT, Min SY, Ju JH, Park KS, Cho YG, Yoon CH, Park SH, Sung YC, Kim HY. STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice.
J. Immunol. 176: 5652-5661 (2006).
*
-
Cho ML, Min SY, Chang SH, Kim KW, Heo SB, Lee SH, Park SH, Cho CS, Kim HY. Transforming growth factor beta 1(TGF-beta1) down-regulates TNFalpha-induced RANTES production in rheumatoid synovial fibroblasts through NF-kappaB-mediated transcriptional repression.
Immunol. Lett. 105: 159-166 (2006).
-
Cho ML, Yoon CH, Hwang SY, Park MK, Min SY, Lee SH, Park SH, Kim HY. Effector function of type II collagen-stimulated T cells from rheumatoid arthritis patients: cross-talk between T cells and synovial fibroblasts.
Arthritis Rheum. 50: 776-784 (2004).
*
-
Cho SG, Min SY, Park MJ, Lee KW, Cho YG, Cho ML, Chang HS, Park SH, Lee JW, Min WS, Kim CC, Kim HY. Immunoregulatory effects of allogeneic mixed chimerism induced by nonmyeloablative bone marrow transplantation on chronic inflammatory arthritis and autoimmunity in interleukin-1 receptor antagonist-deficient mice.
Arthritis Rheum. 54: 1878-1887 (2006).
*
-
Cho SK, Oh IH, Park CK, Bae SC, Sung YK. Etanercept induced organizing pneumonia in a patient with rheumatoid arthritis.
Rheumatol. Int. Jan 9 [Epub ahead of print] (2010).
*
-
Cho SK, Sung YK, Park S, Bae SC. Etanercept treatment in rheumatoid arthritis patients with chronic kidney failure on predialysis.
Rheumatol. Int. Aug 25 [Epub ahead of print] (2009).
*
-
Cho SM, Kim J, Ryu HJ, Kim JJ, Kim HH, Park JH, Kim HT, Kim KH, Cho HY, Oh B, Park C, Kimm K, Jo I, Lee JE, Shin HD, Lee JK. Identification of single nucleotide polymorphisms in the tumor necrosis factor (TNF) and TNF receptor superfamily in the Korean population.
Hum. Immunol. 65: 710-718 (2004).
-
Cho YG, Cho ML, Min SY, Kim HY. Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis.
Autoimmun. Rev. 7: 65-70 (2007).
-
Cho YJ, Han DS, Kim TY, Jang SJ, Jeon YC, Sohn JH, Lee IH, Park KN. Negative conversion of antimitochondrial antibody in primary biliary cirrhosis: a case of autoimmune cholangitis.
J. Korean Med. Sci. 14: 102-106 (1999).
*
-
Chogle AR, Chakravarty A. Cardiovascular events in systemic lupus erythematosus and rheumatoid arthritis: emerging concepts, early diagnosis and management.
J. Assoc. Physicians India 55: 32-40 (2007).
-
Choi CB, Kang CP, Seong SS, Bae SC, Kang C. The -169C/T polymorphism in FCRL3 is not associated with susceptibility to rheumatoid arthritis or systemic lupus erythematosus in a case-control study of Koreans.
Arthritis Rheum. 54: 3838-3841 (2006).
*
-
Choi EM. Oxidative status of DBA/1J mice with type II collagen-induced arthritis.
J. Appl. Toxicol. 27: 472-481 (2007).
*
-
Choi EM. Ligularia fischeri leaf extract prevents the oxidative stress in DBA/1J mice with type II collagen-induced arthritis.
J. Appl. Toxicol. 27: 176-182 (2007).
*
-
Choi HK. Dietary risk factors for rheumatic diseases.
Curr. Opin. Rheumatol. 17: 141-146 (2005).
-
Choi HK, Merkel PA, Tervaert JW, Black RM, McCluskey RT, Niles JL. Alternating antineutrophil cytoplasmic antibody specificity: drug-induced vasculitis in a patient with Wegener's granulomatosis.
Arthritis Rheum. 42: 384-388 (1999).
*
-
Choi HK, Merkel PA, Walker AM, Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies.
Arthritis Rheum. 43: 405-413 (2000).
*
-
Choi HM, Oh DH, Bang JS, Yang HI, Yoo MC, Kim KS. Differential effect of IL-1beta and TNF-alpha on the production of IL-6, IL-8 and PGE(2) in fibroblast-like synoviocytes and THP-1 macrophages.
Rheumatol. Int. Aug 21 [Epub ahead of print] (2009).
*
-
Choi J, Ha KH, Byun MS, Min SY, Park MJ, Park HS, Oh HJ, Ju JH, Kim HY, Jue DM. Treatment with N-tosyl-L-phenylalanine chloromethyl ketone after the onset of collagen-induced arthritis reduces joint erosion and NF-kappaB activation.
Eur. J. Pharmacol. 595: 108-113 (2008).
-
Choi JJ, Yoo SA, Park SJ, Kang YJ, Kim WU, Oh IH, Cho CS. Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-induced arthritis in mice.
Clin. Exp. Immunol. 153: 269-276 (2008).
*
-
Choi JM, Kim SH, Shin JH, Gibson T, Yoon BS, Lee DH, Lee SK, Bothwell AL, Lim JS, Lee SK. Transduction of the cytoplasmic domain of CTLA-4 inhibits TcR-specific activation signals and prevents collagen-induced arthritis.
Proc. Natl. Acad. Sci. U.S.A. 105: 19875-19880 (2008).
*
-
Choi JY, Gao W, Odegard J, Shiah HS, Kashgarian M, McNiff JM, Baker DC, Cheng YC, Craft J. Abrogation of skin disease in LUPUS-prone MRL/FAS(lpr) mice by means of a novel tylophorine analog.
Arthritis Rheum. 54: 3277-3283 (2006).
*
-
Choi KH, Lee EB, Yoo CD, Baek HJ, Kang SW, Shin KC, Lee YJ, Kim HA, Jeon JH, Kim CW, Shin DM, Kim IG, Son YW. Clinical significance of anti-filaggrin antibody recognizing uncitrullinated filaggrin in rheumatoid arthritis.
Exp. Mol. Med. 37: 546-552 (2005).
*
-
Choi SJ, Rho YH, Ji JD, Song GG, Lee YH. Genome scan meta-analysis of rheumatoid arthritis.
Rheumatology (Oxford) 45: 166-170 (2006).
*
-
Choi SW, Ahn JJ, Hwang YT, Koh SH, Cho SD. A case of tuberculous arthritis following the use of etanercept.
Korean J. Intern. Med. 24: 397-401 (2009).
-
Choi SW, Lim MK, Shin DH, Park JJ, Shim SC. Diagnostic performances of anti-cyclic citrullinated peptides antibody and antifilaggrin antibody in korean patients with rheumatoid arthritis.
J. Korean Med. Sci. 20: 473-478 (2005).
*
-
Choi Y, Arron JR, Townsend MJ. Promising bone-related therapeutic targets for rheumatoid arthritis.
Nat. Rev. Rheumatol. 5: 543-548 (2009).
-
Chong BF, Wong HK. Treatment of psoriasis with etanercept in a patient with a history of primary B-cell lymphoma.
Clin. Exp. Dermatol. 34: e11-e13 (2009).
*
-
Chong KT, Ho WF, Koo SH, Thompson P, Lee EJ. Distribution of the FcgammaRIIIa 176 F/V polymorphism amongst healthy Chinese, Malays and Asian Indians in Singapore.
Br. J. Clin. Pharmacol. 63: 328-332 (2007).
*
-
Choo-Kang BS, Hutchison S, Nickdel MB, Bundick RV, Leishman AJ, Brewer JM, McInnes IB, Garside P. TNF-blocking therapies: an alternative mode of action?
Trends Immunol. 26: 518-522 (2005).
*
-
Chopra P, Kanoje V, Semwal A, Ray A. Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases.
Expert Opin. Investig. Drugs 17: 1411-1425 (2008).
-
Chorny A, Gonzalez-Rey E, Fernandez-Martin A, Pozo D, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders.
Proc. Natl. Acad. Sci. U.S.A. 102: 13562-13567 (2005).
*
-
Chorny A, Gonzalez-Rey E, Ganea D, Delgado M. Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo: therapeutic applications in autoimmunity and transplantation.
Ann. N. Y. Acad. Sci. 1070: 190-195 (2006).
*
-
Chorny A, Gonzalez-Rey E, Varela N, Robledo G, Delgado M. Signaling mechanisms of vasoactive intestinal peptide on inflammatory conditions.
Regul. Pept. 137: 67-74 (2006).
-
Choudhuri G, Somani SK, Baba CS, Alexander G. Autoimmune hepatitis in India: profile of an uncommon disease.
BMC Gastroenterol. 5: 27 (2005).
*
-
Chowdary Venigalla RK, Tretter T, Krienke S, Max R, Eckstein V, Blank N, Fiehn C, Dick Ho A, Lorenz HM. Reduced CD4+,CD25- T cell sensitivity to the suppressive function of CD4+,CD25(high),CD127(-/low) regulatory T cells in patients with active systemic lupus erythematosus.
Arthritis Rheum. 58: 2120-2130 (2008).
*
-
Chowdhry IA, Kowal C, Hardin J, Zhou Z, Diamond B. Autoantibodies that bind glomeruli: cross-reactivity with bacterial antigen.
Arthritis Rheum. 52: 2403-2410 (2005).
*
-
Choy E. T cells in psoriatic arthritis.
Curr. Rheumatol. Rep. 9: 437-441 (2007).
-
Choy EH. Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis.
Clin. Exp. Rheumatol. 27: 510-518 (2009).
-
Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, Patel J, Sopwith M, Isenberg DA. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial.
Rheumatology (Oxford) 41: 1133-1137 (2002).
*
-
Choy EH, Smith CM, Farewell V, Walker DJ, Hassell A, Chau L, Scott DL; CARDERA (Combination Anti-Rheumatic Drugs in Early Rheumatoid Arhritis) Trial Group. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis.
Ann. Rheum. Dis. 67: 656-663 (2008).
-
Christensen R, Bliddal H. Is Phytalgic(R) a goldmine for osteoarthritis patients or is there something fishy about this nutraceutical? A summary of findings and risk-of-bias assessment.
Arthritis Res. Ther. 12: 105 (2010).
-
Christensen T, Moller-Larsen A. Human endogenous retroviruses and disease?
Ugeskr. Laeger. 165: 556-561 (2003).
-
Christodoulou C, Choy EH. Joint inflammation and cytokine inhibition in rheumatoid arthritis.
Clin. Exp. Med. 6: 13-19 (2006).
*
-
Christodoulou DK, Katsanos KH, Kitsanou M, Stergiopoulou C, Hatzis J, Tsianos EV. Frequency of extraintestinal manifestations in patients with inflammatory bowel disease in Northwest Greece and review of the literature.
Dig. Liver Dis. 34: 781-786 (2002).
-
Christophers E. Comorbidities in psoriasis.
J. Eur. Acad. Dermatol. Venereol. 20 Suppl. 2: 52-55 (2006). *
-
Christophers E. Comorbidities in psoriasis.
Clin. Dermatol. 25: 529-534 (2007).
-
Christophers E, Barker J, Griffiths C, Dauden E, Milligan G, Molta C, Sato R, Boggs R. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics.
J. Eur. Acad. Dermatol. Venereol. Oct 23 [Epub ahead of print] (2009).
*
-
Chrubasik JE, Roufogalis BD, Wagner H, Chrubasik SA. A comprehensive review on nettle effect and efficacy profiles, Part I: Herba urticae.
Phytomedicine 14: 423-435 (2007).
-
Chrubasik S, Chrubasik C, Kunzel O, Black A. Patient-perceived benefit during one year of treatment with Doloteffin.
Phytomedicine 14: 371-376 (2007).
-
Chu CQ, Swart D, Alcorn D, Tocker J, Elkon KB. Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17.
Arthritis Rheum. 56: 1145-1151 (2007).
*
-
Chu SC, Yang SF, Lue KH, Hsieh YS, Hsiao TY, Lu KH. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
J. Rheumatol. 33: 311-317 (2006).
-
Chuang E, Molitch ME. Prolactin and autoimmune diseases in humans.
Acta Biomed. 78 Suppl. 1: 255-261 (2007).
-
Chubinskaya S, Frank BS, Michalska M, Kumar B, Merrihew CA, Thonar EJ, Lenz ME, Otten L, Rueger DC, Block JA. Osteogenic protein 1 in synovial fluid from patients with rheumatoid arthritis or osteoarthritis: relationship with disease and levels of hyaluronan and antigenic keratan sulfate.
Arthritis Res. Ther. 8: R73 (2006).
*
-
Chun KS, Surh YJ. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.
Biochem. Pharmacol. 68: 1089-1100 (2004).
*
-
Chung CP, Avalos I, Raggi P, Stein CM. Atherosclerosis and inflammation: insights from rheumatoid arthritis.
Clin. Rheumatol. 26: 1228-1233 (2007).
*
-
Chung CP, Oeser A, Avalos I, Gebretsadik T, Shintani A, Raggi P, Sokka T, Pincus T, Stein CM. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis.
Arthritis Res. Ther. 8: R186 (2006).
*
-
Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, Pincus T, Avalos I, Stein CM. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors.
Arthritis Rheum. 52: 3045-3053 (2005).
*
-
Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, Raggi P, Sokka T, Pincus T, Stein CM. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis.
Atherosclerosis 196: 756-763 (2008).
-
Chung EY, Kim SJ, Ma XJ. Regulation of cytokine production during phagocytosis of apoptotic cells.
Cell Res. 16: 154-161 (2006).
*
-
Chung HV, Riley M, Ho JK, Leung B, Jevon GP, Arbour LT, Barker C, Schreiber R, Yoshida EM. Retrospective review of pediatric and adult autoimmune hepatitis in two quaternary care centres in British Columbia: increased prevalence seen in British Columbia's First Nations community.
Can. J. Gastroenterol. 21: 565-568 (2007).
*
-
Chung L, Fiorentino DF, Benbarak MJ, Adler AS, Mariano MM, Paniagua RT, Milano A, Connolly MK, Ratiner BD, Wiskocil RL, Whitfield ML, Chang HY, Robinson WH. Molecular framework for response to imatinib mesylate in systemic sclerosis.
Arthritis Rheum. 60: 584-591 (2009).
*
-
Chung SA, Criswell LA. PTPN22: its role in SLE and autoimmunity.
Autoimmunity 40: 582-590 (2007).
-
Chung SJ, Kim JK, Park MC, Park YB, Lee SK. Reactivation of hepatitis B viral infection in inactive HBsAG carriers following anti-tumor necrosis factor-alpha therapy.
J. Rheumatol. 36: 2416-2420 (2009).
-
Chung TW, Kim SJ, Choi HJ, Kim KJ, Kim MJ, Kim SH, Lee HJ, Ko JH, Lee YC, Suzuki A, Kim CH. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
Glycobiology 19: 229-239 (2009).
-
Chung YM, Liao HT, Lin KC, Lin YC, Chou CT, Chen CH, Tsai CP. Prevalence of spondyloarthritis in 504 Chinese patients with HLA-B27-associated acute anterior uveitis.
Scand. J. Rheumatol. 38: 84-90 (2009).
*
-
Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders.
Nat. Clin. Pract. Rheumatol. 4: 34-42 (2008).
*
-
Churchman SM, Ponchel F. Interleukin-7 in rheumatoid arthritis.
Rheumatology (Oxford) 47: 753-759 (2008).
*
-
Chvojka J, Krouzecky A, Radej J, Sykora R, Karvunidis T, Novak I, Matejovic M. 24-year old male with febricity, multi-organ dysfunction and fast progressing ARDS.
Vnitr. Lek. 55: 991-994 (2009).
-
Cianci R, Giambra V, Mattioli C, Esposito M, Cammarota G, Scibilia G, Magazzù G, Orlando A, Sandri G, Bianchi L, Gasbarrini GB, Pandolfi F, Frezza D. Increased frequency of Ig heavy-chain HS1,2-A enhancer (*)2 allele in dermatitis herpetiformis, plaque psoriasis, and psoriatic arthritis.
J. Invest. Dermatol. 128: 1920-1924 (2008).
*
-
Ciantar M, Adlam DM. Treatment with infliximab: implications in oral surgery? A case report.
Br. J. Oral Maxillofac. Surg. 45: 507-510 (2007).
-
Ciccia F, Bombardieri M, Principato A, Giardina A, Tripodo C, Porcasi R, Peralta S, Franco V, Giardina E, Craxi A, Pitzalis C, Triolo G. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis.
Arthritis Rheum. 60: 955-965 (2009).
*
-
Cimaz R, Cazalis MA, Raynaud C, Gerloni V, Zulian F, Biggioggero M, Martini G, Pontikaki I, Fantini F, Mougin B, Miossec P. IL-1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors.
Ann. Rheum. Dis. 66: 900-904 (2007).
*
-
Cimaz R, Vijay S, Haase C, Coppa GV, Bruni S, Wraith E, Guffon N. Attenuated type I mucopolysaccharidosis in the differential diagnosis of juvenile idiopathic arthritis: a series of 13 patients with Scheie syndrome.
Clin. Exp. Rheumatol. 24: 196-202 (2006).
-
Cimmino MA. Does magnetic resonance represent the gold-standard of imaging for the follow-up of arthritis?
Reumatismo 58: 245-252 (2006).
-
Cimmino MA. Epidemiology of psoriasis and psoriatic arthritis.
Reumatismo 59 Suppl. 1: 19-24 (2007).
*
-
Cimmino MA. Magnetic resonance imaging of the joints: a revolution for the practicing rheumatologist.
Reumatismo 60: 239-241 (2008).
-
Cimmino MA, Parodi M, Zampogna G, Paparo F, Silvestri E, Garlaschi G, Scarpa R. Magnetic resonance imaging of the hand in psoriatic arthritis.
J. Rheumatol. Suppl. 83: 39-41 (2009).
-
Cinek O, Hradsky O, Ahmedov G, Slavcev A, Kolouskova S, Kulich M, Sumnik Z. No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations.
Diabetes Res. Clin. Pract. 76: 297-303 (2007).
-
Cinek O, Vavrincova P, Striz I, Drevinek P, Sedlakova P, Vavrinec J, Slavcev A. Association of single nucleotide polymorphisms within cytokine genes with juvenile idiopathic arthritis in the Czech population.
J. Rheumatol. 31: 1206-1210 (2004).
-
Cingoz O. Ustekinumab.
MAbs. 1: 216-221 (2009).
-
Ciocon DH, Horn EJ, Kimball AB. Quality of life and treatment satisfaction among patients with psoriasis and psoriatic arthritis and patients with psoriasis only : results of the 2005 Spring US National Psoriasis Foundation Survey.
Am. J. Clin. Dermatol. 9: 111-117 (2008).
-
Ciocon DH, Kimball AB. Psoriasis and psoriatic arthritis: separate or one and the same?
Br. J. Dermatol. 157: 850-860 (2007).
*
-
Ciszak L, Pawlak E, Kosmaczewska A, Potoczek S, Frydecka I. Alterations in the expression of signal-transducing CD3 zeta chain in T cells from patients with chronic inflammatory/autoimmune diseases.
Arch. Immunol. Ther. Exp. (Warsz.) 55: 373-386 (2007).
-
Clancy RM, Buyon JP, Ikeda K, Nozawa K, Argyle DA, Friedman DM, Chan EK. Maternal antibody responses to the 52-kd SSA/RO p200 peptide and the development of fetal conduction defects.
Arthritis Rheum. 52: 3079-3086 (2005).
*
-
Clancy RM, Zheng P, O'Mahony M, Izmirly P, Zavadil J, Gardner L, Buyon JP. Role of hypoxia and cAMP in the transdifferentiation of human fetal cardiac fibroblasts: implications for progression to scarring in autoimmune-associated congenital heart block.
Arthritis Rheum. 56: 4120-4131 (2007).
*
-
Clark EA, Ledbetter JA. How does B cell depletion therapy work, and how can it be improved?
Ann. Rheum. Dis. 64 Suppl. 4: iv77-iv80 (2005).
*
-
Clark IA. How TNF was recognized as a key mechanism of disease.
Cytokine Growth Factor Rev. 18: 335-343 (2007).
-
Clark IM, Swingler TE, Young DA. Acetylation in the regulation of metalloproteinase and tissue inhibitor of metalloproteinases gene expression.
Front. Biosci. 12: 528-535 (2007).
-
Clark KL. Nutritional considerations in joint health.
Clin. Sports Med. 26: 101-118 (2007).
-
Clark LN, Lebwohl M. Recent advances in medical dermatology.
Int. J. Dermatol. 46: 1005-1010 (2007).
*
-
Clarke AK, Galbraith RM, Hamilton EB, Williams R. Rheumatic disorders in primary biliary cirrhosis.
Ann. Rheum. Dis. 37: 42-47 (1978).
*
-
Clarke LE, Junkins-Hopkins J, Seykora JT, Adler DJ, Elenitsas R. Methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis presenting in the skin.
J. Am. Acad. Dermatol. 56: 686-690 (2007).
-
Claudepierre P, Bagot M. Psoriatic arthritis.
Ann. Dermatol. Venereol. 135 Suppl. 4: S263-S268 (2008).
-
Claudepierre P, Wendling D, Cohen JD. Anti-TNF alpha in the treatment of psoriatic arthritis.
Presse. Med. 35: 647-655 (2006).
-
Claudio E, Sonder SU, Saret S, Carvalho G, Ramalingam TR, Wynn TA, Chariot A, Garcia-Perganeda A, Leonardi A, Paun A, Chen A, Ren NY, Wang H, Siebenlist U. The adaptor protein CIKS/Act1 is essential for IL-25-mediated allergic airway inflammation.
J. Immunol. 182: 1617-1630 (2009).
-
Clavel G, Bessis N, Lemeiter D, Fardellone P, Mejjad O, Menard JF, Pouplin S, Boumier P, Vittecoq O, Le Loet X, Boissier MC. Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction.
Clin. Immunol. 124: 158-164 (2007).
*
-
Clavel G, Valvason C, Yamaoka K, Lemeiter D, Laroche L, Boissier MC, Bessis N. Relationship between angiogenesis and inflammation in experimental arthritis.
Eur. Cytokine Netw. 17: 202-210 (2006).
-
Clayton A, Ramamurthy S. The impact of physical illness on sexual dysfunction.
Adv. Psychosom. Med. 29: 70-88 (2008).
-
Cleland LG, Caughey GE, James MJ, Proudman SM. Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis.
J. Rheumatol. 33: 1973-1979 (2006).
-
Cleland LG, James MJ, Keen H, Danda D, Caughey G, Proudman SM. Fish oil - an example of an anti-inflammatory food.
Asia Pac. J. Clin. Nutr. 14: S66-S71 (2005).
-
Cleland LG, James MJ, Proudman SM. Fish oil: what the prescriber needs to know.
Arthritis Res. Ther. 8: 202 (2005).
*
-
Cleland LG, James MJ, Proudman SM. Fish oil: what the prescriber needs to know.
Arthritis Res. Ther. 8: 402 (2006).
*
-
Cleland LG, James MJ, Proudman SM. Food inflammation and the anti-inflammatory aspects of food.
Asia Pac. J. Clin. Nutr. 13: S26 (2004).
-
Coaccioli S, Panaccione A, Biondi R, Sabatini C, Landucci P, Del Giorno R, Fantera M, Monno Mondo A, Di Cato L, Paladini A, Fatati G, Puxeddu A. Evaluation of oxidative stress in rheumatoid and psoriatic arthritis and psoriasis.
Clin. Ter. 160: 467-472 (2009).
-
Coakley G, Brooks D, Iqbal M, Kondeatis E, Vaughan R, Loughran TP Jr, Panayi GS, Lanchbury JS. Major histocompatility complex haplotypic associations in Felty's syndrome and large granular lymphocyte syndrome are secondary to allelic association with HLA-DRB1 *0401.
Rheumatology (Oxford) 39: 393-398 (2000).
*
-
Coates LC, Anderson RR, Fitzgerald O, Gottlieb AB, Kelly SG, Lubrano E, McGonagle DG, Olivieri I, Ritchlin CT, Tan AL, De Vlam K, Helliwell PS. Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature review.
J. Rheumatol. 35: 1438-1442 (2008).
-
Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD, Emery P, Marzo-Ortega H. Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience.
Ann. Rheum. Dis. 67: 717-719 (2008).
-
Coates LC, Cook R, Lee KA, Chandran V, Gladman DD. Frequency, predictors and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort.
Arthritis Care Res. (Hoboken) Feb 26 [Epub ahead of print] (2010).
-
Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment.
Ann. Rheum. Dis. 69: 48-53 (2010).
-
Coates LC, Helliwell PS. Classification and categorisation of psoriatic arthritis.
Clin. Rheumatol. 27: 1211-1216 (2008).
*
-
Cobb BA, Kasper DL. Coming of age: carbohydrates and immunity.
Eur. J. Immunol. 35: 352-356 (2005).
*
-
Cobb BL, Lessard CJ, Harley JB, Moser KL. Genes and Sjogren's syndrome.
Rheum. Dis. Clin. North Am. 34: 847-868 (2008).
-
Cobb CS, Ernst E. Systematic review of a marine nutriceutical supplement in clinical trials for arthritis: the effectiveness of the New Zealand green-lipped mussel Perna canaliculus.
Clin. Rheumatol. 25: 275-284 (2006).
*
-
Cobo Ibanez T, Zamora F, Herranz P, Steiner M. Anti-tumour necrosis factor treatment in HIV-positive patients with psoriatic arthritis.
Med. Clin. (Barc.) 133: 682-683 (2009).
-
Codolo G, Amedei A, Steere AC, Papinutto E, Cappon A, Polenghi A, Benagiano M, Paccani SR, Sambri V, Del Prete G, Baldari CT, Zanotti G, Montecucco C, D'Elios MM, de Bernard M. Borrelia burgdorferi NapA-driven Th17 cell inflammation in lyme arthritis.
Arthritis Rheum. 58: 3609-3617 (2008).
*
-
Coelho FM, Pradella-Hallinan M, Alves GR, Bittencourt LR, Pedrazzoli Neto M, Moreira F, Tufik S. A study of T CD4, CD8 and B lymphocytes in narcoleptic patients.
Arq. Neuropsiquiatr. 65: 423-427 (2007).
-
Coenen C, Wegener M, Wedmann B. Severe backache in clinically inactive ulcerative colitis.
Fortschr. Med. 111: 476-478 (1993).
-
Coenen D, Verschueren P, Westhovens R, Bossuyt X. Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis.
Clin. Chem. 53: 498-504 (2007).
*
-
Coenen MJ, Gregersen PK. Rheumatoid arthritis: a view of the current genetic landscape.
Genes Immun. 10: 101-111 (2009).
*
-
Coenen MJ, Toonen EJ, Scheffer H, Radstake TR, Barrera P, Franke B. Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis.
Pharmacogenomics 8: 761-773 (2007).
-
Coenen MJ, Trynka G, Heskamp S, Franke B, van Diemen CC, Smolonska J, van Leeuwen M, Brouwer E, Boezen MH, Postma DS, Platteel M, Zanen P, Lammers JW, Groen HJ, Mali WP, Mulder CJ, Tack GJ, Verbeek WH, Wolters VM, Houwen RH, Mearin ML, van Heel DA, et al. Common and different genetic background for rheumatoid arthritis and coeliac disease.
Hum. Mol. Genet. 18: 4195-4203 (2009).
-
Coffman FD. Chitinase 3-like-1 (CHI3L1): a putative disease marker at the interface of proteomics and glycomics.
Crit. Rev. Clin. Lab. Sci. 45: 531-562 (2008).
-
Cogan E. When thinking to scleroderma?
Rev. Med. Brux. 28: 285-289 (2007).
-
Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study.
Dermatology 216: 152-155 (2008).
-
Cohen G, Courvoisier N, Cohen JD, Zaltni S, Sany J, Combe B. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis.
Clin. Exp. Rheumatol. 23: 795-800 (2005).
-
Cohen G, Gossec L, Dougados M, Cantagrel A, Goupille P, Daures JP, Rincheval N, Combe B. Radiological damage in rheumatoid arthritis patients on sustained remission.
Ann. Rheum. Dis. 66: 358-363 (2007).
*
-
Cohen HD, Das KM. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent.
J. Clin. Gastroenterol. 40 Suppl. 3: S150-S154 (2006).
-
Cohen JD. Successful treatment of psoriatic arthritis with rituximab.
Ann. Rheum. Dis. 67: 1647-1648 (2008).
-
Cohen JD, Bournerias I, Buffard V, Paufler A, Chevalier X, Bagot M, Claudepierre P. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
J. Rheumatol. 34: 380-385 (2007).
-
Cohen JD, Zaltni S, Kaiser MJ, Bozonnat MC, Jorgensen C, Daures JP, Sany J. Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis.
Ann. Rheum. Dis. 63: 209-210 (2004).
*
-
Cohen P. Targeting protein kinases for the development of anti-inflammatory drugs.
Curr. Opin. Cell Biol. 21: 317-324 (2009).
-
Cohen PR. Neutrophilic dermatoses: a review of current treatment options.
Am. J. Clin. Dermatol. 10: 301-312 (2009).
-
Cohen R, Robinson D Jr, Paramore C, Fraeman K, Renahan K, Bala M. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002.
Inflamm. Bowel Dis. 14: 738-743 (2008).
*
-
Cohen SB. Updates from B cell trials: efficacy.
J. Rheumatol. Suppl. 77: 12-17 (2006).
*
-
Cohen SB, Cohen MD, Cush JJ, Fleischmann RM, Mease PJ, Schiff MH, Simon LS, Weaver AL. Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence.
J. Rheumatol. Suppl. 81: 4-30 (2008).
-
Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Arthritis Rheum. 54: 2793-2806 (2006).
*
-
Cohen-Kaminsky S, Jambou F. Prospects for a T-cell receptor vaccination against myasthenia gravis.
Expert Rev. Vaccines 4: 473-492 (2005).
-
Cohran VC, Griffiths M, Heubi JE. Bone mineral density in children exposed to chronic glucocorticoid therapy.
Clin. Pediatr. (Phila.) 47: 469-475 (2008).
-
Colaco CB, Awad J, Festenstein H, Fielder A, Batchelor JR, Alonso A, McCloskey D, Shipley M, Corbett M, Roitt IM. HLA frequency and haplotype analysis in a family study of adult onset rheumatoid arthritis.
Dis. Markers 4: 99-102 (1986).
-
Colak B, Gurlek B, Yegin ZA, Deger SM, Elbek S, Pasaoglu H, Dogan I, Ozturk MA, Unal S, Guz G. The relationship between the MEFV genotype, clinical features, and cytokine-inflammatory activities in patients with familial Mediterranean fever.
Ren. Fail. 30: 187-191 (2008).
-
Colbert RA, Delay ML, Klenk EI, Layh-Schmitt G. From HLA-B27 to spondyloarthritis: a journey through the ER.
Immunol. Rev. 233: 181-202 (2010).
*
-
Colbert RA, Delay ML, Layh-Schmitt G, Sowders DP. HLA-B27 misfolding and spondyloarthropathies.
Prion 3: 15-26 (2009).
-
Colbert RA, Deodhar AA, Fox D, Gravallese EM, Khan MA, McGonagle D, Reveille JD, Schett G, Weisman M, Clegg DO; for the SPARTAN Group. Entheses and bones in spondyloarthritis: 2008 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN).
J. Rheumatol. 36: 1527-1531 (2009).
-
Colbert RA, Deodhar AA, Khan MA, Lories RJ, Maksymowych WP, Reveille JD, Ritchlin CT, Rosenbaum JT, Targan SR, Weisman M, Clegg DO. 2007 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN).
J. Rheumatol. 35: 1398-1402 (2008).
-
Cole A. Patients' groups welcome NICE decisions on arthritis and multiple sclerosis drugs.
BMJ 335: 416-417 (2007).
*
-
Cole BJ, Schumacher HR Jr. Injectable corticosteroids in modern practice.
J. Am. Acad. Orthop. Surg. 13: 37-46 (2005).
-
Cole TJ. Glucocorticoid action and the development of selective glucocorticoid receptor ligands.
Biotechnol. Annu. Rev. 12: 269-300 (2006).
-
Colin EM, Asmawidjaja PS, van Hamburg JP, Mus AM, van Driel M, Hazes JM, van Leeuwen JP, Lubberts E. 1,25-Dihydroxyvitamin D(3) modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis.
Arthritis Rheum. 62: 132-142 (2009).
*
-
Colina M, Govoni M, Orzincolo C, Trotta F. Clinical and radiologic evolution of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single center study of a cohort of 71 subjects.
Arthritis Rheum. 61: 813-821 (2009).
*
-
Colina M, Govoni M, Trotta F. Fatal myocarditis in adult-onset Still disease with diffuse intravascular coagulation.
Rheumatol. Int. 29: 1355-1357 (2009).
*
-
Coll J, Palazon J, Yazbeck H, Gutierrez J, Aubo C, Benito P, Jagiello P, Maldyk H, Marrugat J, Anglada J, et al. Antibodies to human immunodeficiency virus (HIV-1) in autoimmune diseases: primary Sjogren's syndrome, systemic lupus erythematosus, rheumatoid arthritis and autoimmune thyroid diseases.
Clin. Rheumatol. 14: 451-457 (1995).
-
Coll J, Rives A, Grino MC, Setoain J, Vivancos J, Balcells A. Prevalence of Sjogren's syndrome in autoimmune diseases.
Ann. Rheum. Dis. 46: 286-289 (1987).
*
-
Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action.
Arthritis Rheum. 59: 996-1001 (2008).
*
-
Collantes E, Zarco P, Munoz E, Juanola X, Mulero J, Fernandez-Sueiro JL, Torre-Alonso JC, Gratacos J, Gonzalez C, Batlle E, Fernandez P, Linares LF, Brito E, Carmona L. Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) - extended report.
Rheumatology (Oxford) 46: 1309-1315 (2007).
*
-
Collier S, Bolte A, Manolios N. Discrepancy in CD3-transmembrane peptide activity between in vitro and in vivo T-cell inhibition.
Scand. J. Immunol. 64: 388-391 (2006).
*
-
Collins LV, Hajizadeh S, Holme E, Jonsson IM, Tarkowski A. Endogenously oxidized mitochondrial DNA induces in vivo and in vitro inflammatory responses.
J. Leukoc. Biol. 75: 995-1000 (2004).
*
-
Collins-Racie LA, Yang Z, Arai M, Li N, Majumdar MK, Nagpal S, Mounts WM, Dorner AJ, Morris E, Lavallie ER. Global analysis of nuclear receptor expression and dysregulation in human osteoarthritic articular cartilage. Reduced LXR signaling contributes to catabolic metabolism typical of osteoarthritis.
Osteoarthritis Cartilage 17: 939-949 (2009).
-
Colman RW. Regulation of angiogenesis by the kallikrein-kinin system.
Curr. Pharm. Des. 12: 2599-2607 (2006).
-
Colmegna I, Alberts-Grill N. Parvovirus B19: its role in chronic arthritis.
Rheum. Dis. Clin. North Am. 35: 95-110 (2009).
-
Colmegna I, Cuchacovich R, Espinoza LR. HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations.
Clin. Microbiol. Rev. 17: 348-369 (2004).
*
-
Colmegna I, Sainz B Jr, Citera G, Maldonado-Cocco JA, Garry RF, Espinoza LR. Anti-20S proteasome antibodies in psoriatic arthritis.
J. Rheumatol. 35: 674-676 (2008).
-
Colombo E, Latiano A, Palmieri O, Bossa F, Andriulli A, Annese V. Enteropathic spondyloarthropathy: a common genetic background with inflammatory bowel disease?
World J. Gastroenterol. 15: 2456-2462 (2009).
*
-
Colonna L, Dinnall JA, Shivers DK, Frisoni L, Caricchio R, Gallucci S. Abnormal costimulatory phenotype and function of dendritic cells before and after the onset of severe murine lupus.
Arthritis Res. Ther. 8: R49 (2006).
*
-
Comabella M, Altet L, Peris F, Villoslada P, Sanchez A, Montalban X. Genetic analysis of SLC11A1 polymorphisms in multiple sclerosis patients.
Mult. Scler. 10: 618-620 (2004).
*
-
Combe B. Early rheumatoid arthritis: strategies for prevention and management.
Best Pract. Res. Clin. Rheumatol. 21: 27-42 (2007).
-
Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, Pavelka K, Sambrook PN, Smolen JS, Khandker R, Singh A, Wajdula J, Fatenejad S. Efficacy, safety, and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomized two-year study.
Ann. Rheum. Dis. 68: 1146-1152 (2009).
*
-
Combe B, Sany J, Le Quellec A, Clot J, Eliaou JF. Distribution of HLA-DRB1 alleles of patients with polymyalgia rheumatica and giant cell arteritis in a Mediterranean population.
J. Rheumatol. 25: 94-98 (1998).
-
Combe BG, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, Pavelka K, Sambrook PN, Smolen J, Wajdula J, Fatenejad S. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison.
Ann. Rheum. Dis. 65: 1357-1362 (2006).
*
-
Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
J. Rheumatol. 33: 24-30 (2006).
-
Comeau JL, Lin TJ, Macken MB, Li B, Ku CL, von Bernuth H, Casanova JL, Issekutz AC. Staphylococcal pericarditis, and liver and paratracheal abscesses as presentations in two new cases of interleukin-1 receptor associated kinase 4 deficiency.
Pediatr. Infect. Dis. J. 27: 170-174 (2008).
-
Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E, Doria AS, Stephens D, Gilday D, Silverman ED. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus.
Arthritis Rheum. 56: 1966-1973 (2007).
*
-
Comte C, Guillot B, Durand L, Picot E, Dereure O. Interstitial granulomatous dermatitis with arthritis: four cases.
Ann. Dermatol. Venereol. 135: 38-43 (2008).
-
Conaghan PG, Bird P, McQueen F, Peterfy C, Boyesen P, Gandjbakhch F, Duer-Jensen A, Haavardsholm EA, Ejbjerg B, Wiell C, Coates L, Hermann KG, O'Connor P, Lassere M, Freeston JE, Anandarajah A, Genant H, Emery P, Ostergaard M. The OMERACT MRI inflammatory arthritis group: advances and future research priorities.
J. Rheumatol. 36: 1803-1805 (2009).
-
Conaghan PG, Coates LC. Improving recognition of psoriatic arthritis.
Practitioner 253: 15-18, 2-3 (2009).
-
Conen KL, Jeanneret C, Hecker B, Cathomas G, Biedermann BC. Acute occlusive large vessel disease leading to fatal stroke in a patient with systemic lupus erythematosus: arteritis or atherosclerosis?
Arthritis Rheum. 54: 908-913 (2006).
*
-
Cong Y, Yang XG, Lv W, Xue Y. Prediction of novel and selective TNF-alpha converting enzyme (TACE) inhibitors and characterization of correlative molecular descriptors by machine learning approaches.
J. Mol. Graph Model. 28: 236-244 (2009).
*
-
Connell L, McInnes IB. New cytokine targets in inflammatory rheumatic diseases.
Best Pract. Res. Clin. Rheumatol. 20: 865-878 (2006).
-
Connelly M, Schanberg L. Opioid therapy for the treatment of refractory pain in children with juvenile rheumatoid arthritis.
Nat. Clin. Pract. Rheumatol. 2: 636-637 (2006).
*
-
Connolly MK. Sjogren's syndrome.
Semin. Cutan. Med. Surg. 20: 46-52 (2001).
-
Conrad C, Nestle FO. Animal models of psoriasis and psoriatic arthritis: an update.
Curr. Rheumatol. Rep. 8: 342-347 (2006).
-
Consoli A, Devangelio E. Thiazolidinediones and inflammation.
Lupus 14: 794-797 (2005).
-
Constantin A, Dieude P, Lauwers-Cances V, Jamard B, Mazieres B, Cambon-Thomsen A, Cornelis F, Cantagrel A. Tumor necrosis factor receptor II gene polymorphism and severity of rheumatoid arthritis.
Arthritis Rheum. 50: 742-747 (2004).
*
-
Constantin A, Lauwers-Cances V, Navaux F, Abbal M, van Meerwijk J, Mazieres B, Cambon-Thomsen A, Cantagrel A. Collagenase-1 (MMP-1) and HLA-DRB1 gene polymorphisms in rheumatoid arthritis: a prospective longitudinal study.
J. Rheumatol. 29: 15-20 (2002).
*
-
Constantin A, Lauwers-Cances V, Navaux F, Abbal M, van Meerwijk J, Mazieres B, Cambon-Thomsen A, Cantagrel A. Stromelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms: association with severity and progression of rheumatoid arthritis in a prospective study.
Arthritis Rheum. 46: 1754-1762 (2002).
*
-
Constantin A, Navaux F, Lauwers-Cances V, Abbal M, van Meerwijk JP, Mazieres B, Cambon-Thomsen A, Cantagrel A. Interferon gamma gene polymorphism and susceptibility to, and severity of, rheumatoid arthritis.
Lancet 358: 2051-2052 (2001).
*
-
Conte FD, Barja-Fidalgo C, Verri WA Jr, Cunha FQ, Rae GA, Penido C, Henriques MD. Endothelins modulate inflammatory reaction in zymosan-induced arthritis: participation of LTB4, TNF-alpha, and CXCL-1.
J. Leukoc. Biol. 84: 652-660 (2008).
*
-
Conti F, Ceccarelli F, Marocchi E, Magrini L, Romana Spinelli F, Spadaro A, Scrivo R, Valesini G. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
Ann. Rheum. Dis. 66: 1393-1397 (2007).
*
-
Conti F, Ceccarelli F, Priori R, Iagnocco A, Signore A, Valesini G. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha.
Ann. Rheum. Dis. 67: 1787-1790 (2008).
-
Conti F, Rezai S, Valesini G. Vaccination and autoimmune rheumatic diseases.
Autoimmun. Rev. 8: 124-128 (2008).
-
Conti F, Scrivo R, Spinelli FR, Truglia S, Magrini L, Di Franco M, Ceccarelli F, Valesini G. Outcome in patients with rheumatoid arthritis switching TNF-alpha antagonists: a single center, observational study over an 8-year period.
Clin. Exp. Rheumatol. 27: 540-541 (2009).
-
Cook AD, Stockman A, Brand CA, Tait BD, Mackay IR, Muirden KD, Bernard CC, Rowley MJ. Antibodies to type II collagen and HLA disease susceptibility markers in rheumatoid arthritis.
Arthritis Rheum. 42: 2569-2576 (1999).
*
-
Cook RJ, Tolusso D. Second-order estimating equations for the analysis of clustered current status data.
Biostatistics 10: 756-772 (2009).
-
Cooke A. Th17 cells in inflammatory conditions.
Rev. Diabet. Stud. 3: 72-75 (2006).
*
-
Cooke SP, Rigby SP, Griffiths DJ, Venables PJ. Viral studies in rheumatic disease.
Ann. Med. Interne. (Paris) 149: 30-33 (1998).
-
Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases.
J. Autoimmun. 33: 197-207 (2009).
-
Cooper GS, Miller FW, Pandey JP. The role of genetic factors in autoimmune disease: implications for environmental research.
Environ. Health Perspect. 107 Suppl. 5: 693-700 (1999).
-
Cooper GS, Parks CG. Occupational and environmental exposures as risk factors for systemic lupus erythematosus.
Curr. Rheumatol. Rep. 6: 367-374 (2004).
-
Cooper GS, Wither J, McKenzie T, Claudio JO, Bernatsky S, Fortin PR. The prevalence and accuracy of self-reported history of 11 autoimmune diseases.
J. Rheumatol. 35: 2001-2004 (2008).
-
Cooper J, Fluckiger B, Traichl B, Diener PA, Otto P, von Kempis J. Abdominal pain in a patient with ankylosing spondylitis under treatment with infliximab.
J. Clin. Rheumatol. 15: 244-246 (2009).
-
Cooper JD, Walker NM, Healy BC, Smyth DJ, Downes K, Todd JA. Analysis of 55 autoimmune disease and type II diabetes loci: further confirmation of chromosomes 4q27, 12q13.2 and 12q24.13 as type I diabetes loci, and support for a new locus, 12q13.3-q14.1.
Genes Immun. 10: S95-S120 (2009).
-
Cooper T, Savige J, Nassis L, Paspaliaris B, Neeson P, Neil J, Knight KR, Daskalakis M, Doery JC. Clinical associations and characterisation of antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein and azurocidin.
Rheumatol. Int. 19: 129-136 (2000).
*
-
Cope AP. Harmful waste products as novel immune modulators for treating inflammatory arthritis?
PLoS Med. 3: e385 (2006).
*
-
Cope AP. T cells in rheumatoid arthritis.
Arthritis Res. Ther. 10 Suppl. 1: S1 (2008).
*
-
Cope AP, Schulze-Koops H, Aringer M. The central role of T cells in rheumatoid arthritis.
Clin. Exp. Rheumatol. 25: S4-S11 (2007).
-
Coppieters K, Dewint P, Van Beneden K, Jacques P, Seeuws S, Verbruggen G, Deforce D, Elewaut D. NKT cells: manipulable managers of joint inflammation.
Rheumatology (Oxford) 46: 565-571 (2007).
*
-
Copple SS, Martins TB, Masterson C, Joly E, Hill HR. Comparison of three multiplex immunoassays for detection of antibodies to extractable nuclear antibodies using clinically defined sera.
Ann. N. Y. Acad. Sci. 1109: 464-472 (2007).
*
-
Corallini F, Bossi F, Gonelli A, Tripodo C, Castellino G, Mollnes TE, Tedesco F, Rizzi L, Trotta F, Zauli G, Secchiero P. The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis.
Rheumatology (Oxford) 48: 293-298 (2009).
*
-
Cordiali Fei P, Trento E, D'Agosto G, Bordignon V, Mussi A, Ardigo M, Mastroianni A, Vento A, Solivetti F, Berardesca E, Ensoli F. Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-alpha.
J. Autoimmune Dis. 3: 5 (2006).
*
-
Cordiali-Fei P, Ardigo M, Mastroianni A, Giuliani A, D' Agosto G, Bordignon V, Trento E, Vento A, Berardesca E. Serum cytokines and biohumoral immunological characterization of psoriatic patients in long term etanercept treatment.
Int. J. Immunopathol. Pharmacol. 21: 643-650 (2008).
-
Cordiali-Fei P, Trento E, D'Agosto G, Bordignon V, Mussi A, Ardigó M, Mastroianni A, Vento A, Solivetti F, Berardesca E, Ensoli F. Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions.
Ann. N. Y. Acad. Sci. 1110: 578-589 (2007).
*
-
Cordoro KM, Feldman SR. TNF-a inhibitors in dermatology.
Skin Therapy Lett. 12: 4-6 (2007).
*
-
Cornelis F, Faure S, Martinez M, Prud'homme JF, Fritz P, Dib C, Alves H, Barrera P, de Vries N, Balsa A, Pascual-Salcedo D, Maenaut K, Westhovens R, Migliorini P, Tran TH, Delaye A, Prince N, Lefevre C, Thomas G, Poirier M, et al. New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study.
Proc. Natl. Acad. Sci. U.S.A. 95: 10746-10750 (1998).
*
-
Cornelis MC, Bae SC, Kim I, El-Sohemy A. CYP1A2 genotype and rheumatoid arthritis in Koreans.
Rheumatol. Int. Jul 5 [Epub ahead of print] (2009).
*
-
Cornelis S, Kersse K, Festjens N, Lamkanfi M, Vandenabeele P. Inflammatory caspases: targets for novel therapies.
Curr. Pharm. Des. 13: 367-385 (2007).
-
Cornelissen F, Mus AM, Asmawidjaja PS, van Hamburg JP, Tocker J, Lubberts E. Interleukin-23 is critical for full-blown expression of a non-autoimmune destructive arthritis and regulates interleukin-17A and RORgammat in gammadelta T cells.
Arthritis Res. Ther. 11: R194 (2009).
*
-
Cornelissen F, van Hamburg JP, Lubberts E. The IL-12/IL-23 axis and its role in Th17 cell development, pathology and plasticity in arthritis.
Curr. Opin. Investig. Drugs 10: 452-462 (2009).
-
Cornillet A, Camus C, Nimubona S, Gandemer V, Tattevin P, Belleguic C, Chevrier S, Meunier C, Lebert C, Aupee M, Caulet-Maugendre S, Faucheux M, Lelong B, Leray E, Guiguen C, Gangneux JP. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey.
Clin. Infect. Dis. 43: 577-584 (2006).
*
-
Cornish AL, Campbell IK, McKenzie BS, Chatfield S, Wicks IP. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis.
Nat. Rev. Rheumatol. 5: 554-559 (2009).
-
Coroi M, Bontas E, Defranceschi M, Bartos D, Dorobantu M. Ocular manifestations of antiphospholipid (Hughes') syndrome - minor features?
Oftalmologia 51: 16-22 (2007).
-
Corominas H, Figuls R, Riera M, Baiget M. Phenotype of ulcerative colitis, rheumatoid arthritis, and interleukin-10 gene polymorphism.
Rev. Esp. Enferm. Dig. 98: 704-705 (2006).
-
Corporaal S, Bijl M, Kallenberg CG. Familial occurrence of autoimmune diseases and autoantibodies in a Caucasian population of patients with systemic lupus erythematosus.
Clin. Rheumatol. 21: 108-113 (2002).
-
Corr M, Boyle DL, Ronacher L, Flores N, Firestein GS. Synergistic benefit in inflammatory arthritis by targeting I kappaB kinase epsilon and interferon beta.
Ann. Rheum. Dis. 68: 257-263 (2009).
-
Corrao S, Puleo A, Pistone G, Calvo L, Scaglione R, Licata G. No evidence-based practice by biased information from systematic reviews: the case of etanercept and infliximab for the treatment of psoriatic arthritis.
Clin. Exp. Rheumatol. 26: 164-165 (2008).
-
Correa PA, Gomez LM, Anaya JM. Polymorphism of TNF-alpha in autoimmunity and tuberculosis.
Biomedica 24 Supp. 1: 43-51 (2004).
-
Correa PA, Gomez LM, Cadena J, Anaya JM. Autoimmunity and tuberculosis. Opposite association with TNF polymorphism.
J. Rheumatol. 32: 219-224 (2005).
-
Correa PA, Tobon GJ, Citera G, Cadena J, Schneeberger E, Camargo JF, Maldonado-Cocco JA, Anaya JM. Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: relation with clinical features, cytokines and HLA-DRB1.
Biomedica 24: 140-152 (2004).
-
Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence?
Angiogenesis 10: 149-166 (2007).
*
-
Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents.
Semin. Arthritis Rheum. 37: 381-387 (2008).
*
-
Costas J, Perez-Pampin E, Ferreiros-Vidal I, Torres M, Phillips C, Vicario JL, Pablos JL, Carracedo A, Gomez-Reino JJ, Gonzalez A. SUMO4 and MAP3K7IP2 single nucleotide polymorphisms and susceptibility to rheumatoid arthritis.
J. Rheumatol. 33: 1048-1051 (2006).
-
Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, Frances C, Wechsler B, Huong DL, Ghillani P, Musset L, Lechat P, Piette JC. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus.
Arthritis Rheum. 54: 3284-3290 (2006).
*
-
Costello JC, Halverson PB. A new era in rheumatoid arthritis treatment.
WMJ 102: 29-33 (2003).
-
Costello P, FitzGerald O. Disease mechanisms in psoriasis and psoriatic arthritis.
Curr. Rheumatol. Rep. 3: 419-427 (2001).
-
Costenbader KH, Chang SC, De Vivo I, Plenge R, Karlson EW. PTPN22, PADI-4 and CTLA-4 genetic polymorphisms and risk of rheumatoid arthritis in two longitudinal cohort studies: evidence of gene-environment interactions with heavy cigarette smoking.
Arthritis Res. Ther. 10: R52 (2008).
*
-
Costenbader KH, Feskanich D, Benito-Garcia E, Holmes M, Karlson E. Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women.
Ann. Rheum. Dis. 67: 530-535 (2008).
-
Costenbader KH, Feskanich D, Mandl LA, Karlson EW. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women.
Am. J. Med. 119: 503, e1-9 (2006).
*
-
Costenbader KH, Glass R, Cui J, Shadick N. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
JAMA 296: 2201 (2006).
-
Costenbader KH, Karlson EW. Epstein-Barr virus and rheumatoid arthritis: is there a link?
Arthritis Res. Ther. 8: 204 (2006).
*
-
Costenbader KH, Karlson EW. Cigarette smoking and autoimmune disease: what can we learn from epidemiology?
Lupus 15: 737-745 (2006).
*
-
Costenbader KH, Karlson EW, Gall V, Pablo PD, Finckh A, Lynch M, Bermas B, Schur PH, Liang MH. Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus.
Arthritis Rheum. 53: 718-723 (2005).
*
-
Costescu I, Vîlciu A. Clinical observations of a case of anterior uveitis associated with ankylosing spondylitis and psoriatic arthritis. Paraclinical studies.
Oftalmologia 42: 74-77 (1998).
-
Cotch MF, Hoffman GS, Yerg DE, Kaufman GI, Targonski P, Kaslow RA. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources.
Arthritis Rheum. 39: 87-92 (1996).
-
Coto-Segura P, Alvarez V, Soto-Sanchez J, Morales B, Coto E, Santos-Juanes J. Lack of association between angiotensin I-converting enzyme insertion/deletion polymorphism and psoriasis or psoriatic arthritis in Spain.
Int. J. Dermatol. 48: 1320-1323 (2009).
*
-
Couchourel D, Aubry I, Delalandre A, Lavigne M, Martel-Pelletier J, Pelletier JP, Lajeunesse D. Altered mineralization of human osteoarthritic osteoblasts is attributable to abnormal type I collagen production.
Arthritis Rheum. 60: 1438-1450 (2009).
*
-
Couffinhal T, Dufourcq P, Barandon L, Leroux L, Duplaa C. Mouse models to study angiogenesis in the context of cardiovascular diseases.
Front. Biosci. 14: 3310-3325 (2009).
-
Coury F, Annels N, Rivollier A, Olsson S, Santoro A, Speziani C, Azocar O, Flacher M, Djebali S, Tebib J, Brytting M, Egeler RM, Rabourdin-Combe C, Henter JI, Arico M, Delprat C. Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion.
Nat. Med. 14: 81-87 (2008).
*
-
Covic A, Mutica C, Ignat A, Boaru I, Veisa G, Gusbeth-Tatomir P, Enea M, Covic M. Retrospective study of 97 ANCA-positive patients: epidemiological and clinical spectrum.
Rev. Med. Chir. Soc. Med. Nat. Iasi. 108: 305-310 (2004).
-
Covington MB. Omega-3 fatty acids.
Am. Fam. Physician 70: 133-140 (2004).
*
-
Cox AL, Thompson SA, Jones JL, Robertson VH, Hale G, Waldmann H, Compston DA, Coles AJ. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.
Eur. J. Immunol. 35: 3332-3342 (2005).
*
-
Cox LS. How safe are the biologicals in treating asthma and rhinitis?
Allergy Asthma Clin. Immunol. 5: 4 (2009).
*
-
Cox NL, Prowse MV, Maddison MC, Maddison PJ. Treatment of early rheumatoid arthritis with rifampicin.
Ann. Rheum. Dis. 51: 32-34 (1992).
*
-
Crabe S, Guay-Giroux A, Tormo AJ, Duluc D, Lissilaa R, Guilhot F, Mavoungou-Bigouagou U, Lefouili F, Cognet I, Ferlin W, Elson G, Jeannin P, Gauchat JF. The IL-27 p28 subunit binds cytokine-like factor 1 to form a cytokine regulating NK and T cell activities requiring IL-6R for signaling.
J. Immunol. 183: 7692-7702 (2009).
-
Cragnolini JJ, Garcia-Medel N, Lopez de Castro JA. Endogenous processing and presentation of T-cell epitopes from Chlamydia trachomatis with relevance in HLA-B27-associated reactive arthritis.
Mol. Cell. Proteomics 8: 1850-1859 (2009).
*
-
Crane AM, Bradbury L, van Heel DA, McGovern DP, Brophy S, Rubin L, Siminovitch KA, Wordsworth BP, Calin A, Brown MA. Role of NOD2 variants in spondylarthritis.
Arthritis Rheum. 46: 1629-1633 (2002).
*
-
Cranmer LD, Hersh E. The role of the CTLA4 blockade in the treatment of malignant melanoma.
Cancer Invest. 25: 613-631 (2007).
-
Cravo AR, Tavares V, Canas Da Silva J. Anti-TNF alfa therapy in ankylosing spondylitis.
Acta Med. Port. 19: 141-150 (2006).
-
Crestani B. The respiratory system in connective tissue disorders.
Allergy 60: 715-734 (2005).
*
-
Cribier B. Urticaria and hepatitis.
Clin. Rev. Allergy Immunol. 30: 25-30 (2006).
-
Crispin JC, Martinez-Banos D, Alcocer-Varela J. Adult-onset Still disease as the cause of fever of unknown origin.
Medicine (Baltimore) 84: 331-337 (2005).
-
Crispin-Acuna JC, Remes-Troche JM, Uribe M. Abnormal hepatic biochemistries and clinical liver disease in patients with primary Sjogren's syndrome.
Ann. Hepatol. 6: 150-155 (2007).
*
-
Cristea A, Badea T, Bodizs G, Olinic N. Antineutrophil cytoplasmic autoantibodies (ANCA) - markers in diagnosis and monitoring systemic vasculitides.
Rom. J. Intern. Med. 33: 37-46 (1995).
-
Cristofaro P, Opal SM. Role of Toll-like receptors in infection and immunity: clinical implications.
Drugs 66: 15-29 (2006).
-
Criswell LA. Gene discovery in rheumatoid arthritis highlights the CD40/NF-kB signaling pathway in disease pathogenesis.
Immunol. Rev. 233: 55-61 (2010).
*
-
Criswell LA. Familial clustering of disease features: implications for the etiology and investigation of systemic autoimmune disease.
Arthritis Rheum. 50: 1707-1708 (2004).
*
-
Criswell LA, Amos CI. Update on genetic risk factors for systemic lupus erythematosus and rheumatoid arthritis.
Curr. Opin. Rheumatol. 12: 85-90 (2000).
-
Criswell LA, Chen WV, Jawaheer D, Lum RF, Wener MH, Gu X, Gregersen PK, Amos CI. Dissecting the heterogeneity of rheumatoid arthritis through linkage analysis of quantitative traits.
Arthritis Rheum. 56: 58-68 (2007).
*
-
Criswell LA, Gregersen PK. Current understanding of the genetic aetiology of rheumatoid arthritis and likely future developments.
Rheumatology (Oxford) 44 Suppl. 4: iv9-iv13 (2005).
*
-
Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.
Arthritis Rheum. 50: 2750-2756 (2004).
*
-
Criswell LA, Mu H, Such CL, King MC. Inheritance of the shared epitope and long-term outcomes of rheumatoid arthritis among community-based Caucasian females.
Genet. Epidemiol. 15: 61-72 (1998).
-
Criswell LA, Pfeiffer KA, Lum RF, Gonzales B, Novitzke J, Kern M, Moser KL, Begovich AB, Carlton VE, Li W, Lee AT, Ortmann W, Behrens TW, Gregersen PK. Analysis of families in the Multiple Autoimmune Disease Genetics Consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes.
Am. J. Hum. Genet. 76: 561-571 (2005).
*
-
Criswell LA, Saag KG, Mikuls TR, Cerhan JR, Merlino LA, Lum RF, Pfeiffer KA, Woehl B, Seldin MF. Smoking interacts with genetic risk factors in the development of rheumatoid arthritis among older Caucasian women.
Ann. Rheum. Dis. 65: 1163-1167 (2006).
*
-
Crombez L, Marques B, Lenormand JL, Mouz N, Polack B, Trocme C, Toussaint B. High level production of secreted proteins: example of the human tissue inhibitor of metalloproteinases 1.
Biochem. Biophys. Res. Commun. 337: 908-915 (2005).
*
-
Crombie DE, Turer M, Zuasti BB, Wood B, McNaughton D, Nandakumar KS, Holmdahl R, Van Damme MP, Rowley MJ. Destructive effects of murine arthritogenic antibodies to type II collagen on cartilage explants in vitro.
Arthritis Res. Ther. 7: R927-R937 (2005).
*
-
Cronstein BN. Pharmacogenetics in the rheumatic diseases.
Bull. Hosp. Jt. Dis. 64: 16-19 (2006).
-
Cronstein BN. Interleukin-6 - a key mediator of systemic and local symptoms in rheumatoid arthritis.
Bull. N.Y.U. Hosp. Jt. Dis. 65 Suppl. 1: S11-S15 (2007).
*
-
Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment.
Arthritis Res. Ther. 8 Suppl. 1: S3 (2006).
*
-
Crosdale DJ, Poulton KV, Ollier WE, Thomson W, Denning DW. Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis.
J. Infect. Dis. 184: 653-656 (2001).
*
-
Crouzet J, Claudepierre P, Aribi EH, Malbrunot C, Beraneck L, Juan LH, Larget-Piet B. Two cases of discitis due to Propionibacterium acnes.
Rev. Rhum. Engl. Ed. 65: 68-71 (1998).
-
Crowe JP, Molloy MG, Wells I, Thompson BR, Holborow EJ, Hamilton E, Williams R. Increased C1q binding and arthritis in primary biliary cirrhosis.
Gut 21: 418-422 (1980).
*
-
Crowson AN, Mihm MC Jr, Magro CM. Cutaneous vasculitis: a review.
J. Cutan. Pathol. 30: 161-173 (2003).
*
-
Crowson CS, Nicola PJ, Kremers HM, O'Fallon WM, Therneau TM, Jacobsen SJ, Roger VL, Ballman KV, Gabriel SE. How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease?
Arthritis Rheum. 52: 3039-3044 (2005).
*
-
Crowther SD, Rees PJ. Current treatment of asthma - focus on leukotrienes.
Expert Opin. Pharmacother. 1: 1021-1040 (2000).
-
Cruyssen BV, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, Mielants H, De Clerck L, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Keyser F. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity.
Arthritis Res. Ther. 8: R112 (2006).
*
-
Cruz AA, Akaishi PM, Vargas MA, de Paula SA. Association between thyroid autoimmune dysfunction and non-thyroid autoimmune diseases.
Ophthal. Plast. Reconstr. Surg. 23: 104-108 (2007).
-
Csaki C, Matis U, Mobasheri A, Ye H, Shakibaei M. Chondrogenesis, osteogenesis and adipogenesis of canine mesenchymal stem cells: a biochemical, morphological and ultrastructural study.
Histochem. Cell Biol. 128: 507-520 (2007).
-
Csepregi A, Obermayer-Straub P, Kneip S, Kayser A, Loges S, Schmidt E, Nemesanszky E, Szalay F, Manns MP, Strassburg CP. Characterization of a lipoyl domain-independent B-cell autoepitope on the human branched-chain acyltransferase in primary biliary cirrhosis and overlap syndrome with autoimmune hepatitis.
Clin. Dev. Immunol. 10: 173-181 (2003).
*
-
Csernok E, Ahlquist D, Ullrich S, Gross WL. A critical evaluation of commercial immunoassays for antineutrophil cytoplasmic antibodies directed against proteinase 3 and myeloperoxidase in Wegener's granulomatosis and microscopic polyangiitis.
Rheumatology (Oxford) 41: 1313-1317 (2002).
*
-
Csernok E, Schmitt WH, Ernst M, Bainton DF, Gross WL. Membrane surface proteinase 3 expression and intracytoplasmic immunoglobulin on neutrophils from patients with ANCA-associated vasculitides.
Adv. Exp. Med. Biol. 336: 45-50 (1993).
-
Csipo I, Kiss E, Bako E, Szegedi G, Kavai M. Soluble complement receptor 1 (CD35) bound to immune complexes in sera of patients with systemic lupus erythematosus.
Arthritis Rheum. 52: 2950-2951 (2005).
*
-
Csiszar A, Ungvari Z. Synergistic effects of vascular IL-17 and TNFalpha may promote coronary artery disease.
Med. Hypotheses 63: 696-698 (2004).
-
Ctirad A, Lenka B, David P, Zdenek F, Kveta H, Karel E, Jan K. Goeckerman's therapy for psoriasis with special reference to serum pentraxin 3 level.
Int. J. Dermatol. 47: 1011-1014 (2008).
*
-
Cuchacovich M, Ferreira L, Aliste M, Soto L, Cuenca J, Cruzat A, Gatica H, Schiattino I, Perez C, Aguirre A, Salazar-Onfray F, Aguillon J. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis.
Scand. J. Rheumatol. 33: 228-232 (2004).
*
-
Cuchacovich M, Soto L, Edwardes M, Gutierrez M, Llanos C, Pacheco D, Sabugo F, Alamo M, Fuentealba C, Villanueva L, Gatica H, Schiattino I, Salazaro L, Catalan D, Valenzuela O, Salazar-Onfray F, Aguillon JC. Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis.
Scand. J. Rheumatol. 35: 435-440 (2006).
-
Cuchacovich R, Espinoza CG, Virk Z, Espinoza LR. Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha?
J. Clin. Rheumatol. 14: 353-356 (2008).
-
Cuchacovich R, Espinoza LR. Does TNF-alpha blockade play any role in cardiovascular risk among rheumatoid arthritis (RA) patients?
Clin. Rheumatol. 28: 1217-1220 (2009).
-
Cuchacovich R, Justiniano M, Espinoza LR. Churg-Strauss syndrome associated with leukotriene receptor antagonists (LTRA).
Clin. Rheumatol. 26: 1769-1771 (2007).
*
-
Cuchacovich RS, Espinoza LR. Ustekinumab for psoriatic arthritis.
Lancet 373: 605-606 (2009).
*
-
Cuenca J, Cuchacovich M, Perez C, Ferreira L, Aguirre A, Schiattino I, Soto L, Cruzat A, Salazar-Onfray F, Aguillon JC. The -308 polymorphism in the tumour necrosis factor (TNF) gene promoter region and ex vivo lipopolysaccharide-induced TNF expression and cytotoxic activity in Chilean patients with rheumatoid arthritis.
Rheumatology (Oxford) 42: 308-313 (2003).
*
-
Cugno M, Ingegnoli F, Gualtierotti R, Fantini F. Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis.
Curr. Vasc. Pharmacol. Jan 1 [Epub ahead of print] (2010).
-
Cui J, Taylor K, Destefano A, Criswell L, Izmailova E, Alex P, Roubenoff R, Plenge R, Weinblatt M, Shadick N, Karlson E. Genome wide association study of determinants of anti-cyclic citrullinated peptide antibody titer in adults with rheumatoid arthritis.
Mol. Med. 15: 136-143 (2009).
*
-
Cui Y, Xiao Z, Shuxia W, Zhenjun Z, Hengguo Z, Liangyi F, Weicheng G, Li L, Guangfeng Z, Yunzhen S, Guangfu D. Computed tomography guided intra-articular injection of etanercept in the sacroiliac joint is an effective mode of treatment of ankylosing spondylitis.
Scand. J. Rheumatol. Jan 28 [Epub ahead of print] (2010).
*
-
Culligan B. Orbital myositis following streptococcal pharyngitis in a pediatric patient.
Optometry 76: 250-258 (2005).
-
Culver B, Itkin A, Pischel K. Case report and review of minocycline-induced cutaneous polyarteritis nodosa.
Arthritis Rheum. 53: 468-470 (2005).
*
-
Culver EL, Salmon JF, Frith P, Travis SP. Recurrent posterior scleritis and orbital myositis as extra-intestinal manifestations of Crohn's disease: case report and systematic literature review.
Journal of Crohn's and Colitis 2: 337-342 (2008).
-
Culverhouse R, Hinrichs AL, Jin CH, Suarez BK. Gene x gene and gene x environment interactions for complex disorders.
BMC Proc. 1 Suppl. 1: S72 (2007).
*
-
Cummings JR, Herrlinger KR, Travis SP, Gorard DA, McIntyre AS, Jewell DP. Oral methotrexate in ulcerative colitis.
Aliment. Pharmacol. Ther. 21: 385-389 (2005).
*
-
Cummins EP, Comerford KM, Scholz C, Bruning U, Taylor CT. Hypoxic regulation of NF-kappaB signaling.
Methods Enzymol. 435: 479-492 (2007).
-
Cunninghame Graham DS. Genome-wide association studies in systemic lupus erythematosus: a perspective.
Arthritis Res. Ther. 11: 119 (2009).
*
-
Curis E, Nicolis I, Moinard C, Osowska S, Zerrouk N, Benazeth S, Cynober L. Almost all about citrulline in mammals.
Amino Acids 29: 177-205 (2005).
*
-
Curtin K, Wong J, Allen-Brady K, Camp NJ. Meta-genetic association of rheumatoid arthritis and PTPN22 using PedGenie 2.1.
BMC Proc. 1 Suppl. 1: S12 (2007).
*
-
Curtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg J, Kavanaugh A, Reed G, Strand V, Kremer JM. Elevated liver enzyme tests among rheumatoid arthritis and psoriatic arthritis patients treated with methotrexate and/or leflunomide.
Ann. Rheum. Dis. 69: 43-47 (2010).
-
Curtis JR, Kramer JM, Martin C, Saag KG, Patkar N, Shatin D, Burgess M, Xie A, Braun MM. Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists.
Rheumatology (Oxford) 46: 1688-1693 (2007).
*
-
Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, Shatin D, Saag KG. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.
Arthritis Rheum. 56: 1125-1133 (2007).
*
-
Cush JJ. Biological drug use: US perspectives on indications and monitoring.
Ann. Rheum. Dis. 64 Suppl. 4: iv18-iv23 (2005).
*
-
Cutolo M. Sex and rheumatoid arthritis: mouse model versus human disease.
Arthritis Rheum. 56: 1-3 (2007).
*
-
Cutolo M. Vitamin D or hormone D deficiency in autoimmune rheumatic diseases, including undifferentiated connective tissue disease.
Arthritis Res. Ther. 10: 123 (2008).
*
-
Cutolo M, Capellino S, Sulli A, Serioli B, Secchi ME, Villaggio B, Straub RH. Estrogens and autoimmune diseases.
Ann. N. Y. Acad. Sci. 1089: 538-547 (2006).
*
-
Cutolo M, Lahita RG. Estrogens and arthritis.
Rheum. Dis. Clin. North Am. 31: 19-27 (2005).
-
Cutolo M, Otsa K. Review: vitamin D, immunity and lupus.
Lupus 17: 6-10 (2008).
*
-
Cutolo M, Otsa K, Laas K, Yprus M, Lehtme R, Secchi ME, Sulli A, Paolino S, Seriolo B. Circannual vitamin D serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe.
Clin. Exp. Rheumatol. 24: 702-704 (2006).
-
Cutolo M, Otsa K, Uprus M, Paolino S, Seriolo B. Vitamin D in rheumatoid arthritis.
Autoimmun. Rev. 7: 59-64 (2007).
-
Cutolo M, Soldano S, Montagna P, Sulli A, Seriolo B, Villaggio B, Triolo P, Clerico P, Felli L, Brizzolara R. CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production.
Arthritis Res. Ther. 11: R176 (2009).
*
-
Cutolo M, Straub RH. Circadian rhythms in arthritis: hormonal effects on the immune/inflammatory reaction.
Autoimmun. Rev. 7: 223-238 (2008).
-
Cutolo M, Straub RH. Stress as a risk factor in the pathogenesis of rheumatoid arthritis.
Neuroimmunomodulation 13: 277-282 (2006).
-
Cutolo M, Straub RH. Insights into endocrine-immunological disturbances in autoimmunity and their impact on treatment.
Arthritis Res. Ther. 11: 218 (2009).
*
-
Cutolo M, Straub RH, Bijlsma JW. Neuroendocrine-immune interactions in synovitis.
Nat. Clin. Pract. Rheumatol. 3: 627-634 (2007).
*
-
Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Pizzorni C, Paolino S, Seriolo B, Felli L, Straub RH. Anti-TNF and sex hormones.
Ann. N. Y. Acad. Sci. 1069: 391-400 (2006).
*
-
Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Seriolo B, Straub RH. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity.
Lupus 13: 635-638 (2004).
-
Cutolo M, Sulli A, Pizzorni C, Secchi ME, Soldano S, Seriolo B, Straub RH, Otsa K, Maestroni GJ. Circadian rhythms: glucocorticoids and arthritis.
Ann. N. Y. Acad. Sci. 1069: 289-299 (2006).
*
-
Cutolo M, Villaggio B, Otsa K, Aakre O, Sulli A, Seriolo B. Altered circadian rhythms in rheumatoid arthritis patients play a role in the disease's symptoms.
Autoimmun. Rev. 4: 497-502 (2005).
-
Cuzzocrea S. Role of nitric oxide and reactive oxygen species in arthritis.
Curr. Pharm. Des. 12: 3551-3570 (2006).
-
Cuzzocrea S, Saadat F, Di Paola R, Mirshafiey A. Artemether: a new therapeutic strategy in experimental rheumatoid arthritis.
Immunopharmacol. Immunotoxicol. 27: 615-630 (2005).
-
Cvetkovic RS, Scott LJ. Adalimumab: a review of its use in adult patients with rheumatoid arthritis.
BioDrugs 20: 293-311 (2006).
-
Czaja AJ. Autoimmune liver disease and rheumatic manifestations.
Curr. Opin. Rheumatol. 19: 74-80 (2007).
-
Czaja AJ. Autoimmune liver disease.
Curr. Opin. Gastroenterol. 23: 255-262 (2007).
-
D'Acquisto F, Ianaro A. From willow bark to peptides: the ever widening spectrum of NF-kappaB inhibitors.
Curr. Opin. Pharmacol. 6: 387-392 (2006).
-
D'Alfonso S, Barizzone N, Giordano M, Chiocchetti A, Magnani C, Castelli L, Indelicato M, Giacopelli F, Marchini M, Scorza R, Danieli MG, Cappelli M, Migliaresi S, Bigliardo B, Sabbadini MG, Baldissera E, Galeazzi M, Sebastiani GD, Minisola G, Ravazzolo R. Two single-nucleotide polymorphisms in the 5' and 3' ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus.
Arthritis Rheum. 52: 539-547 (2005).
*
-
D'Alfonso S, Rampi M, Bocchio D, Colombo G, Scorza-Smeraldi R, Momigliano-Richardi P. Systemic lupus erythematosus candidate genes in the Italian population: evidence for a significant association with interleukin-10.
Arthritis Rheum. 43: 120-128 (2000).
*
-
D'Amato M, Zucchelli M, Seddighzadeh M, Anedda F, Lindblad S, Kere J, Alfredsson L, Klareskog L, Padyukov L. Analysis of neuropeptide S receptor gene (NPSR1) polymorphism in rheumatoid arthritis.
PLoS One 5: e9315 (2010).
*
-
D'Angelo S, Cutro MS, Lubrano E, Leccese P, Mennillo GA, Ferrara N, Olivieri I. Combination therapy with cyclosporin and etanercept in patients with psoriatic arthritis.
Ann. Rheum. Dis. Aug 9 [Epub ahead of print] (2009).
-
D'Angelo S, Mennillo GA, Cutro MS, Leccese P, Nigro A, Padula A, Olivieri I. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis.
J. Rheumatol. 36: 368-370 (2009).
-
D'Arena G, Taylor RP, Cascavilla N, Lindorfer MA. Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia?
Endocr. Metab. Immune Disord. Drug Targets 8: 62-68 (2008).
-
D'Arienzo A, Manguso F, Scarpa R, Astarita C, D'Armiento FP, Bennato R, Gargano D, Sanges M, Mazzacca G. Ulcerative colitis, seronegative spondyloarthropathies and allergic diseases: the search for a link.
Scand. J. Gastroenterol. 37: 1156-1163 (2002).
*
-
D'Auria F, Rovere-Querini P, Giazzon M, Ajello P, Baldissera E, Manfredi AA, Sabbadini MG. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies.
J. Intern. Med. 255: 409-418 (2004).
*
-
D'Haens GR. Top-down therapy for Crohn's disease: rationale and evidence.
Acta Clin. Belg. 64: 540-546 (2009).
-
D'Haens GR. Top-down therapy for IBD: rationale and requisite evidence.
Nat. Rev. Gastroenterol. Hepatol. 7: 86-92 (2010).
-
D'Inca R, Podswiadek M, Ferronato A, Punzi L, Salvagnini M, Sturniolo GC. Articular manifestations in inflammatory bowel disease patients: a prospective study.
Dig. Liver Dis. 41: 565-569 (2009).
-
D'Osualdo A, Ferlito F, Prigione I, Obici L, Meini A, Zulian F, Pontillo A, Corona F, Barcellona R, Di Duca M, Santamaria G, Traverso F, Picco P, Baldi M, Plebani A, Ravazzolo R, Ceccherini I, Martini A, Gattorno M. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications.
Arthritis Rheum. 54: 998-1008 (2006).
*
-
Da Silva JA, Jacobs JW, Bijlsma JW. Revisiting the toxicity of low-dose glucocorticoids: risks and fears.
Ann. N. Y. Acad. Sci. 1069: 275-288 (2006).
*
-
Daans M, Lories RJ, Luyten FP. Absence of GDF5 does not interfere with LPS Toll-like receptor signaling.
Clin. Exp. Rheumatol. 27: 495-498 (2009).
-
Dagfinrud H, Heiberg MS, Bakland G, Skomsvoll J, Kvien TK. Ankylosing spondylitis - a consensus on diagnosis and treatment.
Tidsskr. Nor. Laegeforen. 127: 3209-3212 (2007).
-
Daha NA, Kurreeman FA, Marques RB, Stoeken-Rijsbergen G, Verduijn W, Huizinga TW, Toes RE. Confirmation of STAT4, IL2/IL21, and CTLA4 polymorphisms in rheumatoid arthritis.
Arthritis Rheum. 60: 1255-1260 (2009).
*
-
Dai H, Li Z, Zhang Y, Lv P, Gao X. Elevated levels of serum antibodies against Saccharomyces cerevisiae mannan in patients with systemic lupus erythematosus.
Lupus 18: 1087-1090 (2009).
*
-
Dai H, Li Z, Zhang Y, Lv P, Gao XM. Elevated levels of serum IgA against Saccharomyces cerevisiae mannan in patients with rheumatoid arthritis.
Cell. Mol. Immunol. 6: 361-366 (2009).
*
-
Dai J, Liu B, Cua DJ, Li Z. Essential roles of IL-12 and dendritic cells but not IL-23 and macrophages in lupus-like diseases initiated by cell surface HSP gp96.
Eur. J. Immunol. 37: 706-715 (2007).
*
-
Dai J, Rabie AB. The use of recombinant adeno-associated virus for skeletal gene therapy.
Orthod. Craniofac. Res. 10: 1-14 (2007).
-
Dai S, Hirayama T, Abbas S, Abu-Amer Y. The IKK inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis.
J. Biol. Chem. 279: 37219-37222 (2004).
*
-
Dai SM, Matsuno H, Nakamura H, Nishioka K, Yudoh K. Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1beta production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis.
Arthritis Rheum. 50: 432-443 (2004).
*
-
Dai SM, Shan ZZ Dr, Xu H, Nishioka K. Cellular targets of interleukin-18 in rheumatoid arthritis.
Ann. Rheum. Dis. 66: 1411-1418 (2007).
*
-
Dai Z, Turtle CJ, Booth GC, Riddell SR, Gooley TA, Stevens AM, Spies T, Groh V. Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus.
J. Exp. Med. 206: 793-805 (2009).
*
-
Dain L, Braun-Moscovici Y, Baum E, Nahir AM, Hoffer E. Modification of neutrophil function by plasma of rheumatoid arthritis patients treated with infliximab.
Clin. Exp. Rheumatol. 24: 38-44 (2006).
-
Dakwar E, Reddy J, Vale FL, Uribe JS. A review of the pathogenesis of ankylosing spondylitis.
Neurosurg. Focus 24: E2 (2008).
-
Dalakos TG, MacSween RN, Whaley K, Dick WC, Boyle JA, Jasani MK, Wilson ME, Buchanan WW, Goudie RB. Conjugal prevalence of rheumatoid arthritis, rheumatoid factor and other autoantibodies in rheumatoid arthritis.
Clin. Exp. Immunol. 3: 761-769 (1968).
*
-
Dalbeth N, Yeoman S, Dockerty JL, Highton J, Robinson E, Tan PL, Herman D, McQueen FM. A randomised placebo controlled trial of delipidated, deglycolipidated Mycobacterium vaccae as immunotherapy for psoriatic arthritis.
Ann. Rheum. Dis. 63: 718-722 (2004).
*
-
Daldrup-Link HE, Steinbach L. MR imaging of pediatric arthritis.
Radiol. Clin. North Am. 47: 939-955 (2009).
-
Daldrup-Link HE, Steinbach L. MR imaging of pediatric arthritis.
Magn. Reson. Imaging Clin. N. Am. 17: 451-467 (2009).
-
Dall'era M, Wofsy D. Systemic lupus erythematosus clinical trials-an interim analysis.
Nat. Rev. Rheumatol. 5: 348-351 (2009).
-
Dalmolin RJ, Zanotto-Filho A, De Oliveira RB, Duarte RF, Pasquali MA, Moreira JC. Retinol and retinoic acid increase MMP-2 activity by different pathways in cultured Sertoli cells.
Free Radic. Res. 41: 1338-1347 (2007).
-
Damjanov N, Vojinovic J. Biologic therapy of rheumatoid arthritis.
Srp. Arh. Celok. Lek. 137: 205-210 (2009).
-
Damjanovska L, Thabet MM, Levarht EW, Stoeken-Rijsbergen G, van der Voort EI, Toes RE, Huizinga TW, van der Helm-van Mil AH. The diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis.
Ann. Rheum. Dis. May 17 [Epub ahead of print] (2009).
-
Dammann HG. Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity.
Z. Gastroenterol. 37: 45-58 (1999).
-
Damore M, Minenna G, D'Amore S. Adverse events in rheumatoid arthritis patient with etanercept therapy: the appearance of osteomalacia.
Recenti Prog. Med. 96: 552-555 (2005).
-
Damsker JM, Okwumabua I, Pushkarsky T, Arora K, Bukrinsky MI, Constant SL. Targeting the chemotactic function of CD147 reduces collagen-induced arthritis.
Immunology 126: 55-62 (2009).
*
-
Danese S, Rutella S. The Janus face of CD4(+)CD25(+) regulatory T cells in cancer and autoimmunity.
Curr. Med. Chem. 14: 649-666 (2007).
-
Daneshtalab N, Lewanczuk RZ, Russell AS, Jamali F. Drug-disease interactions: losartan effect is not downregulated by rheumatoid arthritis.
J. Clin. Pharmacol. 46: 1344-1355 (2006).
*
-
Dang DT, Eriste E, Liepinsh E, Trinh TT, Erlandsson-Harris H, Sillard R, Larsson P. A novel anti-inflammatory compound, artonkin-4'-O-glucoside, from the leaves of Artocarpus tonkinensis suppresses experimentally induced arthritis.
Scand. J. Immunol. 69: 110-118 (2009).
*
-
Danila MI, Hughes LB, Bridges SL. Pharmacogenetics of etanercept in rheumatoid arthritis.
Pharmacogenomics 9: 1011-1015 (2008).
-
Danila MI, Patkar NM, Curtis JR, Saag KG, Teng GG. Biologics and heart failure in rheumatoid arthritis: are we any wiser?
Curr. Opin. Rheumatol. 20: 327-333 (2008).
-
Danis VA, Millington M, Hyland V, Lawford R, Huang Q, Grennan D. Increased frequency of the uncommon allele of a tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus.
Dis. Markers. 12: 127-133 (1995).
-
Danner S, Sordet C, Terzic J, Donato L, Velten M, Fischbach M, Sibilia J. Epidemiology of juvenile idiopathic arthritis in Alsace, France.
J. Rheumatol. 33: 1377-1381 (2006).
-
Danneskiold-Samsoe B, Bartels EM, Dreyer L. Gender differences in autoimmune diseases illustrated by rheumatoid arthritis.
Ugeskr. Laeger. 169: 2440-2442 (2007).
-
Dao K, Cush JJ. Acute polyarthritis.
Best Pract. Res. Clin. Rheumatol. 20: 653-672 (2006).
-
Daoud L, Dhaoui MR, Youssef S, Jaber K, Doss N. Management of severe psoriasis: about 50 cases.
Tunis. Med. 85: 849-856 (2007).
-
Daoussis D, Andonopoulos AP, Liossis SN. Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG Axis.
Semin. Arthritis Rheum. Dec 16 [Epub ahead of print] (2008).
*
-
Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, Yiannopoulos G, Andonopoulos AP. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis.
Arthritis Rheum. 62: 150-158 (2009).
*
-
Dapena Diaz JL, Diaz de Heredia Rubio C, Bastida Vila P, Llort Sales A, Elorza Alvarez I, Olive Oliveras T, Sanchez de Toledo Codina J. Haemophagocytic syndrome: a common pathogenic mechanism of various aetiologies.
An. Pediatr. (Barc.) 71: 110-116 (2009).
-
Darabi K, Jaiswal R, Hostetler S, Bechtel M, Zirwas M. Infectious complications in patients with psoriasis and rheumatoid arthritis treated with antitumor necrosis factor agents and methotrexate.
J. Drugs Dermatol. 8: 175-178 (2009).
-
Daridon C, Burmester GR, Dorner T. Anticytokine therapy impacting on B cells in autoimmune diseases.
Curr. Opin. Rheumatol. 21: 205-210 (2009).
-
Darwech I, Otero J, Alhawagri M, Dai S, Abu-Amer Y. Impediment of NEMO oligomerization inhibits osteoclastogenesis and osteolysis.
J. Cell. Biochem. 108: 1337-1345 (2009).
-
Das Gupta AB, Hossain AK, Islam MH, Dey SR, Khan AL. Role of omega-3 fatty acid supplementation with indomethacin in suppression of disease activity in rheumatoid arthritis.
Bangladesh Med. Res. Counc. Bull. 35: 63-68 (2009).
-
Das P, Abraham R, David C. HLA transgenic mice as models of human autoimmune diseases.
Rev. Immunogenet. 2: 105-114 (2000).
-
Das P, Bradley DS, Geluk A, Griffiths MM, Luthra HS, David CS. An HLA-DRB1*0402 derived peptide (HV3 65-79) prevents collagen-induced arthritis in HLA-DQ8 transgenic mice.
Hum. Immunol. 60: 575-582 (1999).
-
Das UN. Beneficial effect of eicosapentaenoic and docosahexaenoic acids in the management of systemic lupus erythematosus and its relationship to the cytokine network.
Prostaglandins Leukot. Essent. Fatty Acids 51: 207-213 (1994).
-
Daser A, Mitchison H, Mitchison A, Muller B. Non-classical-MHC genetics of immunological disease in man and mouse. The key role of pro-inflammatory cytokine genes.
Cytokine 8: 593-597 (1996).
-
Dasgupta S, Murumkar PR, Giridhar R, Yadav MR. Current perspective of TACE inhibitors: a review.
Bioorg. Med. Chem. 17: 444-459 (2009).
-
Dass S, Vital EM, Emery P. Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis.
Expert Opin. Pharmacother. 7: 2559-2570 (2006).
-
Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab.
Arthritis Rheum. 56: 2715-2718 (2007).
*
-
Dastidar SG, Rajagopal D, Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
Curr. Opin. Investig. Drugs 8: 364-372 (2007).
-
Date Y, Seki N, Kamizono S, Higuchi T, Hirata T, Miyata K, Ohkuni M, Tatsuzawa O, Yokota S, Joo K, Ueda K, Sasazuki T, Kimura A, Itoh K, Kato H. Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5'-flanking region of the TNFalpha gene and HLA genes.
Arthritis Rheum. 42: 2577-2582 (1999).
*
-
Datta D, Ferrell WR, Sturrock RD, Jadhav ST, Sattar N. Inflammatory suppression rapidly attenuates microvascular dysfunction in rheumatoid arthritis.
Atherosclerosis 192: 391-395 (2007).
-
Dauendorffer JN, Rivet J, Allard A, Bachelez H. Sezary syndrome in a patient receiving infliximab for ankylosing spondylitis.
Br. J. Dermatol. 156: 742-743 (2007).
*
-
Davaine A, Saraux A, Prigent S, Kupfer-Bessaguet I, Roswag D, Plantin P, Schoenlaub P, Talarmin F, Zagnoli A, Misery L. Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: a cross-sectional study.
J. Eur. Acad. Dermatol. Venereol. 22: 1471-1477 (2008).
*
-
David CS, Taneja V. Role of major histocompatibility complex genes in murine collagen-induced arthritis: a model for human rheumatoid arthritis.
Am. J. Med. Sci. 327: 180-187 (2004).
-
David JP, Schett G. TNF and bone.
Curr. Dir. Autoimmun. 11: 135-144 (2010).
-
Davidson NJ. The therapeutic potential of anti-cytokine antibodies in the treatment of chronic inflammatory disease.
Expert Opin. Investig. Drugs 7: 1115-1120 (1998).
-
Davidson SI, Wu X, Liu Y, Wei M, Danoy PA, Thomas G, Cai Q, Sun L, Duncan E, Wang N, Yu Q, Xu A, Fu Y, Brown MA, Xu H. Association of ERAP1, but not IL23R, with ankylosing spondylitis in a Han Chinese population.
Arthritis Rheum. 60: 3263-3268 (2009).
*
-
Davies A, Cifaldi MA, Segurado OG, Weisman MH. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
J. Rheumatol. 36: 16-26 (2009).
-
Davies JM. Molecular mimicry: can epitope mimicry induce autoimmune disease?
Immunol. Cell Biol. 75: 113-126 (1997).
*
-
Davies MR, Ribeiro LR, Downey-Jones M, Needham MR, Oakley C, Wardale J. Ligands for retinoic acid receptors are elevated in osteoarthritis and may contribute to pathologic processes in the osteoarthritic joint.
Arthritis Rheum. 60: 1722-1732 (2009).
*
-
Davies NP, Roubin RH, Whitelock JM. Characterization and purification of glycosaminoglycans from crude biological samples.
J. Agric. Food Chem. 56: 343-348 (2008).
*
-
Davis GE Jr, Lowell WE. Solar cycles and their relationship to human disease and adaptability.
Med. Hypotheses 67: 447-461 (2006).
-
Davis J Jr, Webb A, Lund S, Sack K. Results from an open-label extension study of etanercept in ankylosing spondylitis.
Arthritis Rheum. 51: 302-304 (2004).
*
-
Davis JC Jr, Mease PJ. Insights into the pathology and treatment of spondyloarthritis: from the bench to the clinic.
Semin. Arthritis Rheum. 38: 83-100 (2008).
*
-
Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W; Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
Arthritis Rheum. 48: 3230-3236 (2003).
*
-
Davis JM 3rd, Maradit Kremers H, Crowson CS, Nicola PJ, Ballman KV, Therneau TM, Roger VL, Gabriel SE. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study.
Arthritis Rheum. 56: 820-830 (2007).
*
-
Davis JM, Maradit-Kremers H, Gabriel SE. Use of low-dose glucocorticoids and the risk of cardiovascular morbidity and mortality in rheumatoid arthritis: what is the true direction of effect?
J. Rheumatol. 32: 1856-1862 (2005).
-
Davis Jr JC, Dougados M, Braun J, Sieper J, van der Heijde D, van der Linden S. The definition of disease duration in ankylosing spondylitis: reassessing the concept.
Ann. Rheum. Dis. 65: 1518-1520 (2006).
*
-
Davis KA, Finger DR, Shparago NI. Disseminated histoplasmosis mimicking Felty's syndrome.
J. Clin. Rheumatol. 8: 38-43 (2002).
-
Davis L, Chen Y, Sen M. WISP-3 functions as a ligand and promotes superoxide dismutase activity.
Biochem. Biophys. Res. Commun. 342: 259-265 (2006).
*
-
Davis MC, Affleck G, Zautra AJ, Tennen H. Daily interpersonal events in pain patients: applying action theory to chronic illness.
J. Clin. Psychol. 62: 1097-1113 (2006).
*
-
Davis MC, Zautra AJ, Younger J, Motivala SJ, Attrep J, Irwin MR. Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue.
Brain Behav. Immun. 22: 24-32 (2008).
*
-
Dawczynski C, Schubert R, Hein G, Muller A, Eidner T, Vogelsang H, Basu S, Jahreis G. Long-term moderate intervention with n-3 long-chain PUFA-supplemented dairy products: effects on pathophysiological biomarkers in patients with rheumatoid arthritis.
Br. J. Nutr. 101: 1517-1526 (2009).
*
-
Dawkins RL, Kay PH, Christiansen FT. Immunogenetics of rheumatoid arthritis.
Ann. Acad. Med. Singapore 12: 155-163 (1983).
-
Dawkins RL, Leaver A, Cameron PU, Martin E, Kay PH, Christiansen FT. Some disease-associated ancestral haplotypes carry a polymorphism of TNF.
Hum. Immunol. 26: 91-97 (1989).
-
Dawson L, Tobin A, Smith P, Gordon T. Antimuscarinic antibodies in Sjogren's syndrome: where are we, and where are we going?
Arthritis Rheum. 52: 2984-2995 (2005).
*
-
Day TG, Ramanan AV, Hinks A, Lamb R, Packham J, Wise C, Punaro M, Donn RP. Autoinflammatory genes and susceptibility to psoriatic juvenile idiopathic arthritis.
Arthritis Rheum. 58: 2142-2146 (2008).
*
-
Dayangac-Erden D, Karaduman A, Erdem-Yurter H. Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients.
Arch. Dermatol. Res. 299: 487-491 (2007).
*
-
Dayer JM, Chicheportiche R, Juge-Aubry C, Meier C. Adipose tissue has anti-inflammatory properties: focus on IL-1 receptor antagonist (IL-1Ra).
Ann. N. Y. Acad. Sci. 1069: 444-453 (2006).
*
-
Dayer JM, Molnarfi N, Burger D. From cellular receptors to transduction-transcription pathways for cytokines: at which level should the inhibition be targeted in inflammation?
Expert Opin. Biol. Ther. 5 Suppl. 1: S83-S96 (2005).
-
Daysal S, Akcil G, Goker B, Haznedaroglu S, Ercan N, Ozturk MA. Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis.
Arthritis Rheum. 53: 146-147 (2005).
*
-
Daza L, Martin-Jimenez R, De la Torre PX, Hernandez E, Murillo B. Improvement of ACTH response to insulin tolerance test in female patients with rheumatoid arthritis due to tumor necrosis factor inhibition.
Eur. J. Endocrinol. 157: 47-51 (2007).
-
Dazzi F, Horwood NJ. Potential of mesenchymal stem cell therapy.
Curr. Opin. Oncol. 19: 650-655 (2007).
-
Dazzi F, van Laar JM, Cope A, Tyndall A. Cell therapy for autoimmune diseases.
Arthritis Res. Ther. 9: 206 (2007).
*
-
de Abreu DA, Eyles D, Feron F. Vitamin D, a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases.
Psychoneuroendocrinology 34 Suppl. 1: S265-S277 (2009).
-
de Andrade M, Allen AS, Brinza D, Cheng R, Da Y, de Vries AR, Ewhida A, Feng Z, Jung H, Hsieh HJ, Kohler K, Liu Y, Liu-Mares W, Luan J, Marquard V, Nolte IM, Oh S, Platt A, Qin X, Yoo YJ, Yuan A, Tian X, Won S. Summary of contributions to GAW15 Group 13: candidate gene association studies.
Genet. Epidemiol. 31 Suppl. 1: S110-S117 (2007).
-
De Angelis R, Salaffi F, Grassi W. Prevalence of spondyloarthropathies in an Italian population sample: a regional community-based study.
Scand. J. Rheumatol. 36: 14-21 (2007).
*
-
De Bellis A, Bizzarro A, Pivonello R, Lombardi G, Bellastella A. Prolactin and autoimmunity.
Pituitary 8: 25-30 (2005).
*
-
de Benedetti F, Martini A. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis?
Arthritis Rheum. 52: 687-693 (2005).
*
-
De Benedetti F, Ravelli A. Juvenile idiopathic arthritis: will etanercept be an improvement over current therapies?
BioDrugs 14: 93-98 (2000).
-
De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression.
Endocr. Rev. 24: 488-522 (2003).
*
-
de Buys P, Khanna D, Furst DE. Hemopoietic stem cell transplantation in rheumatic diseases-an update.
Autoimmun. Rev. 4: 442-449 (2005).
-
De Felice C, Mazzotta A, Esposito M, Bianchi L, Chimenti S. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life.
J. Dermatolog. Treat. 17: 355-358 (2006).
-
De Filippis D, D'Amico A, Iuvone T. Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation.
J. Neuroendocrinol. 20 Suppl.1: 20-25 (2008).
-
De Filippis L, Caliri A, Anghelone S, Scibilia G, Lo Gullo R, Bagnato G. Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis.
Panminerva Med. 48: 129-135 (2006).
-
de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, Shojania K, Martinka M, Dutz JP. Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions.
Arch. Dermatol. 143: 223-231 (2007).
*
-
De Hertogh G, Geboes K. Crohn's disease and infections: a complex relationship.
MedGenMed. 6: 14 (2004).
*
-
De Jager PL, Richardson A, Vyse TJ, Rioux JD. Genetic variation in Toll-like receptor 9 and susceptibility to systemic lupus erythematosus.
Arthritis Rheum. 54: 1279-1282 (2006).
*
-
De Jager PL, Sawcer S, Waliszewska A, Farwell L, Wild G, Cohen A, Langelier D, Bitton A, Compston A, Hafler DA, Rioux JD. Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis.
Eur. J. Hum. Genet. 14: 317-321 (2006).
*
-
de Jager W, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis; a cross-sectional study.
Ann. Rheum. Dis. 66: 589-598 (2007).
*
-
de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells.
Clin. Diagn. Lab. Immunol. 10: 133-139 (2003).
*
-
de Jager W, Vastert SJ, Beekman JM, Wulffraat NM, Kuis W, Coffer PJ, Prakken BJ. Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis.
Arthritis Rheum. 60: 2782-2793 (2009).
*
-
de Jong H, Lafeber FF, de Jager W, Haverkamp MH, Kuis W, Bijlsma JW, Prakken BJ, Albani S. PAN-DR-Binding Hsp60 self epitopes induce an interleukin-10-mediated immune response in rheumatoid arthritis.
Arthritis Rheum. 60: 1966-1976 (2009).
*
-
de Jongh BM, Westedt ML, de Vries RR, Valkenburg HA, Cats A. Genetic heterogeneity of rheumatoid arthritis.
Dis. Markers 4: 29-33 (1986).
-
De Keyser F, Baeten D, Van den Bosch F, De Vos M, Cuvelier C, Mielants H, Veys E. Gut inflammation and spondyloarthropathies.
Curr. Rheumatol. Rep. 4: 525-532 (2002).
-
De Keyser F, Baeten D, Van den Bosch F, Kruithof E, Verbruggen G, Mielants H, Veys E. Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis.
Drugs 64: 2793-2811 (2004).
-
de Kleer I, Vastert B, Klein M, Teklenburg G, Arkesteijn G, Puga Yung G, Albani S, Kuis W, Wulffraat N, Prakken B. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T-cells and restoring the CD4+CD25+ immune regulatory network.
Blood 107: 1696-1702 (2006).
*
-
de Kruijf P, van Heteren J, Lim HD, Conti PG, van der Lee MM, Bosch L, Ho KK, Auld D, Ohlmeyer M, Smit MJ, Wijkmans JC, Zaman GJ, Smit MJ, Leurs R. Non-peptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptor.
J. Pharmacol. Exp. Ther. 329: 783-790 (2009).
*
-
de la Fontaine L, Schwarz M, Plischke H, Kleindienst N, Gruber R. Lack of association of the CD14/C-159T polymorphism with susceptibility and serological activity parameters of rheumatoid arthritis.
Scand. J. Rheumatol. 35: 20-22 (2006).
*
-
de la Fontaine L, Schwarz MJ, Riedel M, Dehning S, Douhet A, Spellmann I, Kleindienst N, Zill P, Plischke H, Gruber R, Muller N. Investigating disease susceptibility and the negative correlation of schizophrenia and rheumatoid arthritis focusing on MIF and CD14 gene polymorphisms.
Psychiatry Res. 144: 39-47 (2006).
-
de Matos CT, Berg L, Michaelsson J, Fellander-Tsai L, Karre K, Soderstrom K. Activating and inhibitory receptors on synovial fluid natural killer cells of arthritis patients: role of CD94/NKG2A in control of cytokine secretion.
Immunology 122: 291-301 (2007).
*
-
de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behcet's disease: a systematic review and meta-analysis of case-control genetic association studies.
Arthritis Rheum. 61: 1287-1296 (2009).
*
-
De Miguel S, Jover JA, Vadillo C, Judez E, Loza E, Fernandez-Gutierrez B. B cell activation in rheumatoid arthritis patients under infliximab treatment.
Clin. Exp. Rheumatol. 21: 726-732 (2003).
-
de Oliveira SK, de Almeida RG, Fonseca AR, Rodrigues MC, Sztajnbok F, Diniz C. Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center.
Acta Reumatol. Port. 32: 139-150 (2007).
-
de Pablo P, Chapple IL, Buckley CD, Dietrich T. Periodontitis in systemic rheumatic diseases.
Nat. Rev. Rheumatol. 5: 218-224 (2009).
*
-
De Ravin SS, Naumann N, Cowen EW, Friend J, Hilligoss D, Marquesen M, Balow JE, Barron KS, Turner ML, Gallin JI, Malech HL. Chronic granulomatous disease as a risk factor for autoimmune disease.
J. Allergy Clin. Immunol. 122: 1097-1103 (2008).
*
-
de Rham C, Ferrari-Lacraz S, Jendly S, Schneiter G, Dayer JM, Villard J. The pro-inflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors.
Arthritis Res. Ther. 9: R125 (2007).
*
-
de Rie MA, van Kuijk AW, Goedkoop AY, Tak PP. Arthritis psoriatica.
Ned. Tijdschr. Geneeskd. 151: 1716-1722 (2007).
-
De Rosa FG, Shaz D, Campagna AC, Dellaripa PE, Khettry U, Craven DE. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case?
Infect. Control Hosp. Epidemiol. 24: 477-482 (2003).
*
-
De Rosa G, Mignogna C. The histopathology of psoriasis.
Reumatismo 59 Suppl. 1: 46-48 (2007).
*
-
De Rycke L, Kruithof E, Vandooren B, Tak PP, Baeten D. Pathogenesis of spondyloarthritis: insights from synovial membrane studies.
Curr. Rheumatol. Rep. 8: 275-282 (2006).
-
De Rycke L, Nicholas AP, Cantaert T, Kruithof E, Echols JD, Vandekerckhove B, Veys EM, De Keyser F, Baeten D. Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase as pathophysiologically relevant antigenic determinants of rheumatoid arthritis-specific humoral autoimmunity.
Arthritis Rheum. 52: 2323-2330 (2005).
*
-
De Rycke L, Peene I, Hoffman IE, Kruithof E, Union A, Meheus L, Lebeer K, Wyns B, Vincent C, Mielants H, Boullart L, Serre G, Veys EM, De Keyser F. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations.
Ann. Rheum. Dis. 63: 1587-1593 (2004).
*
-
De Sanctis JB, Garmendia JV, Moreno D, Larocca N, Mijares M, Di Giulio C, Salazar-Bookaman M, Wojewodka G, Radzioch D. Pharmacological modulation of Th17.
Recent Pat. Inflamm. Allergy Drug Discov. 3: 149-156 (2009).
-
de Seny D, Fillet M, Meuwis MA, Geurts P, Lutteri L, Ribbens C, Bours V, Wehenkel L, Piette J, Malaise M, Merville MP. Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach.
Arthritis Rheum. 52: 3801-3812 (2005).
*
-
de Seny D, Fillet M, Ribbens C, Maree R, Meuwis MA, Lutteri L, Chapelle JP, Wehenkel L, Louis E, Merville MP, Malaise M. Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis.
Clin. Chem. 54: 1066-1075 (2008).
*
-
De Souza TB, Mentz EF, Brenol CV, Xavier RM, Brenol JC, Chies JA, Simon D. Association between the aggrecan gene and rheumatoid arthritis.
J. Rheumatol. 35: 2325-2328 (2008).
-
De Vita S, Boiocchi M, Sorrentino D, Carbone A, Avellini C, Dolcetti R, Marzotto A, Gloghini A, Bartoli E, Beltrami CA, Ferraccioli G. Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjogren's syndrome.
Arthritis Rheum. 40: 318-331 (1997).
-
De Vita S, Quartuccio L. Treatment of rheumatoid arthritis with rituximab: an update and possible indications.
Autoimmun. Rev. 5: 443-448 (2006).
-
De Vita S, Quartuccio L, Fabris M. Rituximab in mixed cryoglobulinemia: increased experience and perspectives.
Dig. Liver Dis. 39 Suppl. 1: S122-S128 (2007).
-
De Vlam K, Gottlieb AB, Fitzgerald O. Biological biomarkers in psoriatic disease. A review.
J. Rheumatol. 35: 1443-1448 (2008).
-
de Vlam K, Lories RJ. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study.
Rheumatology (Oxford) 45: 321-324 (2006).
*
-
de Vlam K, Lories RJ. Remission in psoriatic arthritis.
Curr. Rheumatol. Rep. 10: 297-302 (2008).
-
De Vos M. Joint involvement associated with inflammatory bowel disease.
Dig. Dis. 27: 511-515 (2009).
-
De Vos M. Joint involvement in inflammatory bowel disease: managing inflammation outside the digestive system.
Expert Rev. Gastroenterol. Hepatol. 4: 81-89 (2010).
-
de Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics.
Adv. Biochem. Eng. Biotechnol. 111: 1-66 (2008).
*
-
de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
Arthritis Rheum. 61: 1484-1490 (2009).
*
-
de Vries N, Prinsen CF, Mensink EB, van Riel PL, van't Hof MA, van de Putte LB. A T cell receptor beta chain variable region polymorphism associated with radiographic progression in rheumatoid arthritis.
Ann. Rheum. Dis. 52: 327-331 (1993).
*
-
de Vries N, Ronningen KS, Tilanus MG, Bouwens-Rombouts A, Segal R, Egeland T, Thorsby E, van de Putte LB, Brautbar C. HLA-DR1 and rheumatoid arthritis in Israeli Jews: sequencing reveals that DRB1*0102 is the predominant HLA-DR1 subtype.
Tissue Antigens 41: 26-30 (1993).
-
de Vries N, Tijssen H, van Riel PL, van de Putte LB. Reshaping the shared epitope hypothesis: HLA-associated risk for rheumatoid arthritis is encoded by amino acid substitutions at positions 67-74 of the HLA-DRB1 molecule.
Arthritis Rheum. 46: 921-928 (2002).
*
-
de Vries RR, Huizinga TW, Toes RE. HLA and RA revisited: citrullinated food for the SE hypothesis, the DR6 effect, and NIMA.
Hum. Immunol. 67: 454-459 (2006).
-
de Vries RR, Huizinga TW, Toes RE. Redefining the HLA and RA association: to be or not to be anti-CCP positive.
J. Autoimmun. 25: S21-S25 (2005).
-
de Vries RR, Nijenhuis LE, Khan MA, Mehra NK. Paradoxical inheritance of HLA-linked susceptibility to rheumatoid arthritis.
Tissue Antigens 26: 286-292 (1985).
-
de Vries-Bouwstra J, Le Cessie S, Allaart C, Breedveld F, Huizinga T. Using predicted disease outcome to provide differentiated treatment of early rheumatoid arthritis.
J. Rheumatol. 33: 1747-1753 (2006).
-
De Vries-Bouwstra JK, Goekoop-Ruiterman YP, Wesoly J, Hulsmans HJ, de Craen AJ, Breedveld FC, Dijkmans BA, Allaart CF, Huizinga TW. Ex vivo interleukin 1 receptor antagonist production on lipopolysaccharide stimulation is associated with rheumatoid arthritis and with joint damage.
Ann. Rheum. Dis. 66: 1033-1037 (2007).
*
-
De Wall SL, Painter C, Stone JD, Bandaranayake R, Wiley DC, Mitchison TJ, Stern LJ, Dedecker BS. Noble metals strip peptides from class II MHC proteins.
Nat. Chem. Biol. 2: 197-201 (2006).
*
-
Decker P, Briand JP, de Murcia G, Pero RW, Isenberg DA, Muller S. Zinc is an essential cofactor for recognition of the DNA binding domain of poly(ADP-ribose) polymerase by antibodies in autoimmune rheumatic and bowel diseases.
Arthritis Rheum. 41: 918-926 (1998).
*
-
Degreef I, De Smet L. Vanishing finger in psoriatic arthritis: a case report.
Clin. Rheumatol. 26: 1391-1392 (2007).
*
-
Deighton C, Criswell LA. Recent advances in the genetics of rheumatoid arthritis.
Curr. Rheumatol. Rep. 8: 394-400 (2006).
-
Deighton C, Hyrich K. Why do the French get much greater access to anti-TNF than the British? Vive la difference? Pas necessairement.
Rheumatology (Oxford) 47: 1600-1602 (2008).
*
-
Deighton CM, Cavanagh G, Rigby AS, Lloyd HL, Walker DJ. Both inherited HLA-haplotypes are important in the predisposition to rheumatoid arthritis.
Br. J. Rheumatol. 32: 893-898 (1993).
-
Deighton CM, Fay A, Walker DJ. Rheumatoid arthritis in thyroid disease positive and negative same-sexed sibships.
Br. J. Rheumatol. 31: 13-17 (1992).
-
Deighton CM, George E, Kiely PD, Ledingham J, Luqmani RA, Scott DG. Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again).
Rheumatology (Oxford) 45: 649-652 (2006).
*
-
Deighton CM, Kelly PJ, Walker DJ. Linkage of rheumatoid arthritis with HLA.
Ann. Rheum. Dis. 52: 638-642 (1993).
*
-
Dejaco C, Duftner C, Klotz W, Schirmer M, Herold M. Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-alpha treatment response in rheumatoid arthritis.
Rheumatol. Int. Jun 9 [Epub ahead of print] (2009).
*
-
Dejaco C, Duftner C, Wipfler E, Schirmer M. A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation.
Wien. Med. Wochenschr. 159: 70-75 (2009).
-
Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis.
Arthritis Res. Ther. 8: R119 (2006).
*
-
Dejardin E. The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development.
Biochem. Pharmacol. 72: 1161-1179 (2006).
*
-
Dejica DI, Manea EM. Costimulatory molecule CD154 in systemic lupus erythematosus and rheumatoid arthritis. Therapeutic perspectives.
Roum. Arch. Microbiol. Immunol. 65: 66-74 (2006).
-
Dekker L, Armbrust W, Rademaker CM, Prakken B, Kuis W, Wulffraat NM. Safety of anti-TNFalpha therapy in children with juvenile idiopathic arthritis.
Clin. Exp. Rheumatol. 22: 252-258 (2004).
-
Dekker-Saeys BJ, Meuwissen SG, Van Den Berg-Loonen EM, De Haas WH, Agenant D, Tytgat GN. Ankylosing spondylitis and inflammatory bowel disease. II. Prevalence of peripheral arthritis, sacroiliitis, and ankylosing spondylitis in patients suffering from inflammatory bowel disease.
Ann. Rheum. Dis. 37: 33-35 (1978).
*
-
Dekker-Saeys BJ, Meuwissen SG, Van Den Berg-Loonen EM, De Haas WH, Meijers KA, Tytgat GN. Ankylosing spondylitis and inflammatory bowel disease. III. Clinical characteristics and results of histocompatibility typing (HLA B27) in 50 patients with both ankylosing spondylitis and inflammatory bowel disease.
Ann. Rheum. Dis. 37: 36-41 (1978).
*
-
del Rincon I, Battafarano DF, Arroyo RA, Murphy FT, Escalante A. Heterogeneity between men and women in the influence of the HLA-DRB1 shared epitope on the clinical expression of rheumatoid arthritis.
Arthritis Rheum. 46: 1480-1488 (2002).
*
-
del Rincon I, Escalante A. HLA-DRB1 alleles associated with susceptibility or resistance to rheumatoid arthritis, articular deformities, and disability in Mexican Americans.
Arthritis Rheum. 42: 1329-1338 (1999).
*
-
Del Val Del Amo N, Ibanez Bosch R, Fito Manteca C, Gutierrez Polo R, Loza Cortina E. Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness.
Clin. Exp. Rheumatol. 24: 281-286 (2006).
-
Delaleu N, Immervoll H, Cornelius J, Jonsson R. Biomarker profiles in serum and saliva of experimental Sjogren's syndrome - associations with specific autoimmune manifestations.
Arthritis Res. Ther. 10: R22 (2008).
*
-
Delaleu N, Jonsson R. Altered fractalkine cleavage results in an organ-specific 17 kDa fractalkine fragment in salivary glands of NOD mice.
Arthritis Res. Ther. 10: 114 (2008).
*
-
Delavallee L, Le Buanec H, Bessis N, Assier E, Denys A, Bizzini B, Zagury D, Boissier MC. Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha.
Ann. Rheum. Dis. 67: 1332-1338 (2008).
-
Delavallee L, Semerano L, Assier E, Vogel G, Vuagniaux G, Laborie M, Zagury D, Bessis N, Boissier MC. Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long term study in a transgenic model of arthritis.
Arthritis Res. Ther. 11: R195 (2009).
*
-
Delay ML, Turner MJ, Klenk EI, Smith JA, Sowders DP, Colbert RA. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats.
Arthritis Rheum. 60: 2633-2643 (2009).
*
-
Deleuran B, Abraham DJ. Possible implication of the effector CD4(+) T-cell subpopulation T(H)17 in the pathogenesis of systemic scleroderma.
Nat. Clin. Pract. Rheumatol. 3: 682-683 (2007).
*
-
Delgado M, Abad C, Martinez C, Juarranz MG, Arranz A, Gomariz RP, Leceta J. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases.
J. Mol. Med. 80: 16-24 (2002).
*
-
Delgado M, Abad C, Martinez C, Juarranz MG, Leceta J, Ganea D, Gomariz RP. PACAP in immunity and inflammation.
Ann. N. Y. Acad. Sci. 992: 141-157 (2003).
*
-
Delgado M, Robledo G, Rueda B, Varela N, O'Valle F, Hernandez-Cortes P, Caro M, Orozco G, Gonzalez-Rey E, Martin J. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells.
Arthritis Rheum. 58: 1010-1019 (2008).
*
-
Delgado M, Toscano MG, Benabdellah K, Cobo M, O'Valle F, Gonzalez-Rey E, Marti N F. In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis.
Arthritis Rheum. 58: 1026-1037 (2008).
*
-
Delgado-Vega AM, Anaya JM. Meta-analysis of HLA-DRB1 polymorphism in Latin American patients with rheumatoid arthritis.
Autoimmun. Rev. 6: 402-408 (2007).
-
Delgado-Vega AM, Castiblanco J, Gomez LM, Diaz-Gallo LM, Rojas-Villarraga A, Anaya JM. BCL2 antagonist killer 1 (BAK1) polymorphisms influence the risk of developing autoimmune rheumatic diseases in women.
Ann. Rheum. Dis. Mar 11 [Epub ahead of print] (2009).
-
Delgado-Vega AM, Martin J, Granados J, Anaya JM. Genetic epidemiology of rheumatoid arthritis: what to expect from Latin America?
Biomedica 26: 562-584 (2006).
-
Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology.
FASEB J. 15: 2579-2585 (2001).
*
-
DeLuca HF, Zierold C. Mechanisms and functions of vitamin D.
Nutr. Rev. 56: S4-S10 (1998).
-
Delunardo F, Conti F, Margutti P, Alessandri C, Priori R, Siracusano A, Rigano R, Profumo E, Valesini G, Sorice M, Ortona E. Identification and characterization of the carboxy-terminal region of Sip-1, a novel autoantigen in Behcet's disease.
Arthritis Res. Ther. 8: R71 (2006).
*
-
Demetter P, De Vos M, Van Huysse JA, Baeten D, Ferdinande L, Peeters H, Mielants H, Veys EM, De Keyser F, Cuvelier CA. Colon mucosa of both spondyloarthritis and Crohn's disease patients is enriched with macrophages expressing the scavenger receptor CD163.
Ann. Rheum. Dis. 64: 321-324 (2005).
*
-
Demirtas-Ertan G, Rowshani AT, Ten Berge IJ. Azathioprine-induced shock in a patient suffering from undifferentiated erosive oligoarthritis.
Neth. J. Med. 64: 124-126 (2006).
*
-
Dempfle A, Hein R, Beckmann L, Scherag A, Nguyen TT, Schafer H, Chang-Claude J. Comparison of the power of haplotype-based versus single- and multilocus association methods for gene x environment (gene x sex) interactions and application to gene x smoking and gene x sex interactions in rheumatoid arthritis.
BMC Proc. 1 Suppl. 1: S73 (2007).
*
-
den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, de Waal-Malefijt M, van den Hoogen FH. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study.
J. Rheumatol. 34: 689-695 (2007).
-
Dendle C, Woolley IJ, Korman TM. Rat-bite fever septic arthritis: illustrative case and literature review.
Eur. J. Clin. Microbiol. Infect. Dis. 25: 791-797 (2006).
*
-
Deng A, Harvey V, Sina B, Strobel D, Badros A, Junkins-Hopkins JM, Samuels A, Oghilikhan M, Gaspari A. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
Arch. Dermatol. 142: 198-202 (2006).
*
-
Deng GM. Tumor necrosis factor receptor pre-ligand assembly domain is an important therapeutic target in inflammatory arthritis.
BioDrugs 21: 23-29 (2007).
-
Deng GM, Zheng L, Ka-Ming Chan F, Lenardo M. Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors.
Nat. Med. 11: 1066-1072 (2005).
*
-
Denissen NH, Peters JG, Masereeuw R, Barrera P. Can sulfasalazine therapy induce or exacerbate Wegener's granulomatosis?
Scand. J. Rheumatol. 37: 72-74 (2008).
*
-
Denkinger CM, Metz C, Fingerle-Rowson G, Denkinger MD, Forsthuber T. Macrophage migration inhibitory factor and its role in autoimmune diseases.
Arch. Immunol. Ther. Exp. (Warsz.) 52: 389-400 (2004).
-
Denson LA. Growth hormone therapy in children and adolescents: pharmacokinetic/pharmacodynamic considerations and emerging indications.
Expert Opin. Drug Metab. Toxicol. 4: 1569-1580 (2008).
-
Dentener MA, Wouters EF. Tumor necrosis factor inhibitors for rheumatoid arthritis.
N. Engl. J. Med. 355: 2047-2048 (2006).
-
Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, Hoogen F, Herrick A, Mayes MD, Veale D, Haas J, Ledbetter S, Korn JH, Black CM, Seibold JR; Cat-192 Study Group. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.
Arthritis Rheum. 56: 323-333 (2007).
*
-
Dequeker J, Decock T, Walravens M, Van de Putte I. A systematic survey of the HLA B27 prevalence in inflammatory rheumatic diseases.
J. Rheumatol. 5: 452-459 (1978).
-
Derijk RH, Schaaf MJ, Turner G, Datson NA, Vreugdenhil E, Cidlowski J, de Kloet ER, Emery P, Sternberg EM, Detera-Wadleigh SD. A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor beta-isoform mRNA is associated with rheumatoid arthritis.
J. Rheumatol. 28: 2383-2388 (2001).
-
Dernis E, Lavie F, Salliot C, Flipo RM, Saraux A, Maillefert JF, Paul C, Goupille P, Cantagrel A, Claudepierre P, Gaudin P, Tebib J, Wendling D, Schaeverbeke T, Le Loet X, Combe B. Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: development of recommendations for clinical practice based on data from the literature and experts opinion.
Joint Bone Spine 76: 524-531 (2009).
*
-
Dervieux T, Wessels JA, van der Straaten T, Penrod N, Moore JH, Guchelaar HJ, Kremer JM. Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis.
Pharmacogenet. Genomics Oct 24 [Epub ahead of print] (2009).
-
Desai HG, Gupte PA. Increasing incidence of Crohn's disease in India: is it related to improved sanitation?
Indian J. Gastroenterol. 24: 23-24 (2005).
*
-
Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy.
Best Pract. Res. Clin. Rheumatol. 20: 757-790 (2006).
-
Desai SN, White DM, O'Shea KM, Brown ML, Cywin CL, Spero DM, Panzenbeck MJ. An orally active reversible inhibitor of cathepsin S inhibits human trans vivo delayed-type hypersensitivity.
Eur. J. Pharmacol. 538: 168-174 (2006).
*
-
Deshmukh H, Kim-Howard X, Nath SK. Replication of recently identified associated single-nucleotide polymorphisms from six autoimmune diseases in Genetic Analysis Workshop 16 rheumatoid arthritis data.
BMC Proc. 3 Suppl. 7: S31 (2009).
*
-
Deshmukh US, Ohyama Y, Bagavant H, Guo X, Gaskin F, Fu SM. Inflammatory stimuli accelerate Sjogren's syndrome-like disease in (NZB x NZW)F(1) mice.
Arthritis Rheum. 58: 1318-1323 (2008).
*
-
Desmetz C, Lin YL, Mettling C, Portales P, Noel D, Clot J, Jorgensen C, Corbeau P. Cell surface CCR5 density determines the intensity of T cell migration towards rheumatoid arthritis synoviocytes.
Clin. Immunol. 123: 148-154 (2007).
*
-
Dessein PH, Joffe BI. Suppression of circulating interleukin-6 concentrations is associated with decreased endothelial activation in rheumatoid arthritis.
Clin. Exp. Rheumatol. 24: 161-167 (2006).
-
Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis.
Arthritis Rheum. 54: 2765-2775 (2006).
*
-
Dessein PH, Norton GR, Woodiwiss AJ, Joffe BI, Wolfe F. Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis.
J. Rheumatol. 34: 943-951 (2007).
-
Dessein PH, Tobias M, Veller MG. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis.
J. Rheumatol. 33: 2425-2432 (2006).
-
Dessein PH, Woodiwiss AJ, Joffe BI, Norton GR. Aminotransferases are associated with insulin resistance and atherosclerosis in rheumatoid arthritis.
BMC Cardiovasc. Disord. 7: 31 (2007).
*
-
Deutsch L. Evaluation of the effect of neptune krill oil on chronic inflammation and arthritic symptoms.
J. Am. Coll. Nutr. 26: 39-48 (2007).
*
-
Devauchelle V, Essabbani A, De Pinieux G, Germain S, Tourneur L, Mistou S, Margottin-Goguet F, Anract P, Migaud H, Le Nen D, Lequerre T, Saraux A, Dougados M, Breban M, Fournier C, Chiocchia G. Characterization and functional consequences of underexpression of clusterin in rheumatoid arthritis.
J. Immunol. 177: 6471-6479 (2006).
*
-
Devauchelle V, Marion S, Cagnard N, Mistou S, Falgarone G, Breban M, Letourneur F, Pitaval A, Alibert O, Lucchesi C, Anract P, Hamadouche M, Ayral X, Dougados M, Gidrol X, Fournier C, Chiocchia G. DNA microarray allows molecular profiling of rheumatoid arthritis and identification of pathophysiological targets.
Genes Immun. 5: 597-608 (2004).
*
-
Devesa I, Ferrandiz ML, Terencio MC, Joosten LA, van den Berg WB, Alcaraz MJ. Influence of heme oxygenase 1 modulation on the progression of murine collagen-induced arthritis.
Arthritis Rheum. 52: 3230-3238 (2005).
*
-
Devraj JP, Shankarkumar U, Ghosh K. Increased frequency of HLA-B7 among B27-negative seronegative spondarthritis patients from Mumbai, western India.
Br. J. Biomed. Sci. 66: 25-27 (2009).
-
Dewint P, Hoffman IE, Rogge S, Joos R, Union A, Dehoorne J, Delanghe J, Veys EM, De Keyser F, Elewaut D. Effect of age on prevalence of anticitrullinated protein/peptide antibodies in polyarticular juvenile idiopathic arthritis.
Rheumatology (Oxford) 45: 204-208 (2006).
*
-
Dharmapatni AA, Smith MD, Findlay DM, Holding CJ, Evdokiou A, Ahern MJ, Weedon HM, Chen P, Screaton GR, Xu XN, Haynes DR. Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium.
Arthritis Res. Ther. 11: R13 (2009).
*
-
Dhaun N, Kluth DC. TWEAK: a novel biomarker for lupus nephritis?
Arthritis Res. Ther. 11: 133 (2009).
-
Dhillon S, Lyseng-Williamson KA, Scott LJ. Etanercept: a review of its use in the management of rheumatoid arthritis.
Drugs 67: 1211-1241 (2007).
-
Dhimolea E. Canakinumab.
MAbs. Jan 15 [Epub ahead of print] (2010).
-
DI Comite G, Marinosci A, DI Matteo P, Manfredi A, Rovere-Querini P, Baldissera E, Aiello P, Corti A, Sabbadini MG. Neuroendocrine modulation induced by selective blockade of TNF-alpha in rheumatoid arthritis.
Ann. N. Y. Acad. Sci. 1069: 428-437 (2006).
*
-
Di Comite G, Rossi CM, Marinosci A, Lolmede K, Baldissera E, Aiello P, Mueller RB, Herrmann M, Voll RE, Rovere-Querini P, Sabbadini MG, Corti A, Manfredi AA. Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-alpha-elicited endothelial activation.
J. Leukoc. Biol. 85: 81-87 (2009).
*
-
Di Gangi M, Foti R, Leonardi R, Leonetti C, Castellino P. Recurrent new-onset uveitis in a patient with rheumatoid arthritis during anti-TNFalpha treatment.
Reumatismo 59: 169-172 (2007).
-
Di Girolamo N, Indoh I, Jackson N, Wakefield D, McNeil HP, Yan W, Geczy C, Arm JP, Tedla N. Human mast cell-derived gelatinase B (matrix metalloproteinase-9) is regulated by inflammatory cytokines: role in cell migration.
J. Immunol. 177: 2638-2650 (2006).
*
-
di Meglio P, Ianaro A, Ghosh S. Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation.
Arthritis Rheum. 52: 951-958 (2005).
*
-
Di Poi E, Perin A, Morassi MP, Del Frate M, Ferraccioli GF, De Vita S. Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab.
Clin. Exp. Rheumatol. 25: 85-87 (2007).
-
DI Renzo L, Saraceno R, Schipani C, Chimenti S, DE Lorenzo A. Why 3 mg/kg instead of 5 mg/kg of infliximab should work in psoriatic arthritis?
J. Dermatol. 36: 666-668 (2009).
-
Diaco M, Ancarini F, Montalto M, Verrechia E, Evoli A, Servidei S, Gasbarrini G, Manna R. Association of myasthenia gravis and antisynthetase syndrome: a case report.
Int. J. Immunopathol. Pharmacol. 17: 395-400 (2004).
-
Diallo M, Kane A, Sy N, Ndiaye B. Pyoderma gangrenosum in Dakar: about 14 cases.
Dakar Med. 50: 52-55 (2005).
-
Diallo S, Ndongo S, Leye A, Pouye A, Ka MM, Diop TM. Tuberculosis and systemic diseases: study of 8 Senegalese cases.
Med. Trop. (Mars.) 69: 307-308 (2009).
-
Diamond B. Autoimmunity.
Immunol. Rev. 204: 5-8 (2005).
*
-
Dias Gonzalez F, Pedreira Magalhaes F, Pontes Vilas Boas Freitas A, Castro Lima Filho H, Santiago MB. Lipodermatosclerosis in patients with diffuse connective tissue diseases.
Eur. J. Intern. Med. 17: 288-289 (2006).
-
Diatchenko L, Romanov S, Malinina I, Clarke J, Tchivilev I, Li X, Makarov SS. Identification of novel mediators of NF-kappaB through genome-wide survey of monocyte adherence-induced genes.
J. Leukoc. Biol. 78: 1366-1377 (2005).
*
-
Diaz FJ, Davalos MM, Roman VR, Bustios SC, Zumaeta VE. Hepatotoxicity and pancreatitis associated with gold salts: case report.
Rev. Gastroenterol. Peru 24: 353-356 (2004).
-
Diaz-Gonzalez F, Alten RH, Bensen WG, Brown JP, Sibley JT, Dougados M, Bombardiere S, Durez P, de Miguel G, Ortiz P, Staab A, Sigmund R, Salin L, Leledy C, Polmar SH. Clinical trial of a leukotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis.
Ann. Rheum. Dis. 66: 628-632 (2007).
*
-
Diaz-Jouanen E, Abud-Mendoza C, Garza-Elizondo MA, Medrano-Ramirez G, Burgos-Vargas R, Orozco-Alcala JJ, Pacheco-Tena CF, Pineda C, Pozos-Espíndola JC, Ramos-Niembro F, Robles-San-Roman M, Santana-Sahagun JE. Guidelines in RA treatment: concepts on safety and recommendations using anti-TNF-alpha inhibitors.
Rev. Invest. Clin. 61: 252-266 (2009).
-
Diaz-Lopez C, Geli C, Corominas H, Malat N, Diaz-Torner C, Llobet JM, De La Serna AR, Laiz A, Moreno M, Vazquez G. Are there clinical or serological differences between male and female patients with primary Sjogren's syndrome?
J. Rheumatol. 31: 1352-1355 (2004).
*
-
Díaz-Pena R, Blanco-Gelaz MA, Lopez-Larrea C. KIR genes and their role in spondyloarthropathies.
Adv. Exp. Med. Biol. 649: 286-299 (2009).
-
Díaz-Pena R, Blanco-Gelaz MA, Njobvu P, Lopez-Vazquez A, Suarez-Alvarez B, Lopez-Larrea C. Influence of HLA-B*5703 and HLA-B*1403 on susceptibility to spondyloarthropathies in the Zambian population.
J. Rheumatol. 35: 2236-2240 (2008).
*
-
Diaz-Torne C, Narvaez J, Lama ED, Diez-García M, Narvaez JA, Bernad B, Llatjos R, Nolla JM, Valverde J. Inflammatory pseudotumor of the liver associated with rheumatoid arthritis.
Arthritis Rheum. 57: 1102-1106 (2007).
*
-
Dichamp I, Bourgeois A, Dirand C, Herbein G, Wendling D. Increased nuclear factor-kappaB activation in peripheral blood monocytes of patients with rheumatoid arthritis is mediated primarily by tumor necrosis factor-alpha.
J. Rheumatol. 34: 1976-1983 (2007).
-
Dideberg V, Kristjansdottir G, Milani L, Libioulle C, Sigurdsson S, Louis E, Wiman AC, Vermeire S, Rutgeerts P, Belaiche J, Franchimont D, Van Gossum A, Bours V, Syvanen AC. An insertion-deletion polymorphism in the interferon regulatory factor 5 (IRF5) gene confers risk of inflammatory bowel diseases.
Hum. Mol. Genet. 16: 3008-3016 (2007).
*
-
Diedrichs-Mohring M, Wildner G. Immunostimulatory and immunomodulatory peptides derived from the alpha1 domain of HLA-B27 in experimental autoimmune diseases in Lewis rats.
Immunobiology 209: 711-717 (2005).
-
Dieguez-Gonzalez R, Calaza M, Perez-Pampin E, de la Serna AR, Fernandez-Gutierrez B, Castaneda S, Largo R, Joven B, Narvaez J, Navarro F, Marenco JL, Vicario JL, Blanco FJ, Fernandez-Lopez JC, Caliz R, Collado-Escobar MD, Carreno L, Lopez-Longo J, et al. Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis.
Arthritis Rheum. 58: 1264-1274 (2008).
*
-
Dieker J, Muller S. Epigenetic histone code and autoimmunity.
Clin. Rev. Allergy Immunol. Aug 7 [Epub ahead of print] (2009).
*
-
Dieker JW, Fransen JH, van Bavel CC, Briand JP, Jacobs CW, Muller S, Berden JH, van der Vlag J. Apoptosis-induced acetylation of histones is pathogenic in systemic lupus erythematosus.
Arthritis Rheum. 56: 1921-1933 (2007).
*
-
Dieker JW, Van Bavel CC, Riemekasten G, Berden JH, Van der Vlag J. The binding of lupus-derived autoantibodies to the C-terminal peptide (83-119) of the major SmD1 autoantigen can be mediated by dsDNA and nucleosomes.
Ann. Rheum. Dis. 65: 1525-1528 (2006).
*
-
Diel R, Hauer B, Loddenkemper R, Manger B, Kruger K. Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases.
Z. Rheumatol. 68: 411-416 (2009).
-
Diep JT, Kerr LD, Barton C, Emre S. Musculoskeletal manifestations in liver transplantation recipients.
J. Clin. Rheumatol. 14: 257-260 (2008).
-
Dieude P. Genetic aspects of rheumatoid arthritis.
Rev. Prat. 55: 2143-2145 (2005).
-
Dieude P. Rheumatic diseases: environment and genetics.
Joint Bone Spine 76: 602-607 (2009).
*
-
Dieude P, Cornelis F. Genetic basis of rheumatoid arthritis.
Joint Bone Spine 72: 520-526 (2005).
*
-
Dieude P, Garnier S, Michou L, Petit-Teixeira E, Glikmans E, Pierlot C, Lasbleiz S, Bardin T, Prum B, Cornelis F; European Consortium on Rheumatoid Arthritis Families. Rheumatoid arthritis seropositive for the rheumatoid factor is linked to the protein tyrosine phosphatase nonreceptor 22-620W allele.
Arthritis Res. Ther. 7: R1200-R1207 (2005).
*
-
Dieude P, Goossens M, Cornelis F, Bardin T, Tchernitchko DO. The TNFRSF1A R92Q mutation is frequent in rheumatoid arthritis but shows no evidence for association or linkage with the disease.
Ann. Rheum. Dis. 66: 1113-1115 (2007).
*
-
Dieude P, Guedj M, Wipff J, Avouac J, Fajardy I, Diot E, Granel B, Sibilia J, Cabane J, Mouthon L, Cracowski JL, Carpentier PH, Hachulla E, Meyer O, Kahan A, Boileau C, Allanore Y. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis.
Arthritis Rheum. 60: 225-233 (2009).
*
-
Dieude P, Guedj M, Wipff J, Avouac J, Hachulla E, Diot E, Granel B, Sibilia J, Cabane J, Meyer O, Mouthon L, Kahan A, Boileau C, Allanore Y. The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis.
Arthritis Rheum. 58: 2183-2188 (2008).
*
-
Dieude P, Guedj M, Wipff J, Ruiz B, Hachulla E, Diot E, Granel B, Sibilia J, Tiev K, Mouthon L, Cracowski JL, Carpentier PH, Amoura Z, Fajardy I, Avouac J, Meyer O, Kahan A, Boileau C, Allanore Y. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis.
Arthritis Rheum. 60: 2472-2479 (2009).
*
-
Dieude P, Osorio J, Petit-Teixeira E, Moreno S, Garnier S, Cailleau-Moindrault S, Stalens C, Lasbleiz S, Bardin T, Prum B, Cornelis F. A TNFR1 genotype with a protective role in familial rheumatoid arthritis.
Arthritis Rheum. 50: 413-419 (2004).
*
-
Dieude P, Teixeira VH, Pierlot C, Cornelis F, Petit-Teixeira E; ECRAF. Testing for linkage and association with rheumatoid arthritis a PTPN22 promoter polymorphism reported to be associated and linked with type 1 diabetes in the Caucasian population.
Ann. Rheum. Dis. 67: 900-901 (2008).
-
Dijkmans BA, Jansen G. Antimetabolites in the treatment of arthritis: current status of the use of antimetabolites.
Nucleosides Nucleotides Nucleic Acids 23: 1083-1088 (2004).
-
Dijstelbloem HM, Bijl M, Fijnheer R, Scheepers RH, Oost WW, Jansen MD, Sluiter WJ, Limburg PC, Derksen RH, van de Winkel JG, Kallenberg CG. Fcgamma receptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes.
Arthritis Rheum. 43: 2793-2800 (2000).
*
-
Dijstelbloem HM, Scheepers RH, Oost WW, Stegeman CA, van der Pol WL, Sluiter WJ, Kallenberg CG, van de Winkel JG, Tervaert JW. Fcgamma receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse.
Arthritis Rheum. 42: 1823-1827 (1999).
*
-
Dillon CF, Rasch EK, Gu Q, Hirsch R. Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991-94.
J. Rheumatol. 33: 2271-2279 (2006).
-
Dimakou K, Papaioannides D, Latsi P, Katsimboula S, Korantzopoulos P, Orphanidou D. Disseminated tuberculosis complicating anti-TNF-alpha treatment.
Int. J. Clin. Pract. 58: 1052-1055 (2004).
*
-
Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases.
Semin. Nephrol. 27: 98-114 (2007).
-
Dinarello CA. Anti-cytokine therapeutics and infections.
Vaccine 21 Suppl. 2: S24-S34 (2003).
*
-
Dinarello CA. The IL-1 family and inflammatory diseases.
Clin. Exp. Rheumatol. 20 (5 Suppl. 27): S1-S13 (2002).
-
Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation.
Curr. Opin. Pharmacol. 4: 378-385 (2004).
-
Dinarello CA. Anti-cytokine therapy from the bench to the bedside.
Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 84-86 (2005). *
-
Dinarello CA. Interleukin-1 and tumor necrosis factor: effector cytokines in autoimmune diseases.
Semin. Immunol. 4: 133-145 (1992).
-
Dinarello CA, Kim SH. IL-32, a novel cytokine with a possible role in disease.
Ann. Rheum. Dis. 65 Suppl. 3: iii61-iii64 (2006).
*
-
Ding B, Padyukov L, Lundstrom E, Seielstad M, Plenge RM, Oksenberg JR, Gregersen PK, Alfredsson L, Klareskog L. Different patterns of associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in the extended major histocompatibility complex region.
Arthritis Rheum. 60: 30-38 (2009).
*
-
Ding C. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases.
Expert Opin. Biol. Ther. 8: 1805-1814 (2008).
-
Ding C, Jones G. Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline.
Curr. Opin. Investig. Drugs 7: 464-472 (2006).
-
Ding C, Jones G. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases.
Rev. Recent Clin. Trials 1: 193-200 (2006).
-
Ding X, Staudinger JL. The ratio of constitutive androstane receptor to pregnane X receptor determines the activity of guggulsterone against the Cyp2b10 promoter.
J. Pharmacol. Exp. Ther. 314: 120-127 (2005).
*
-
Ding Y, Cong L, Ionita-Laza I, Lo SH, Zheng T. Constructing gene association networks for rheumatoid arthritis using the backward genotype-trait association (BGTA) algorithm.
BMC Proc. 1 Suppl. 1: S13 (2007).
*
-
Dinser R, Braun A, Jendro MC, Engel A. Increased titres of anti-nuclear antibodies do not predict the development of associated disease in the absence of initial suggestive signs and symptoms.
Scand. J. Rheumatol. 36: 448-451 (2007).
-
Distler JH, Huber LC, Gay S, Distler O, Pisetsky DS. Microparticles as mediators of cellular cross-talk in inflammatory disease.
Autoimmunity 39: 683-690 (2006).
-
Distler JH, Jungel A, Kowal-Bielecka O, Michel BA, Gay RE, Sprott H, Matucci-Cerinic M, Chilla M, Reich K, Kalden JR, Muller-Ladner U, Lorenz HM, Gay S, Distler O. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis.
Arthritis Rheum. 52: 856-864 (2005).
*
-
Dixon W, Silman A. Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al.
Arthritis Res. Ther. 8: 111 (2006).
*
-
Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, Symmons DP. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).
Ann. Rheum. Dis. Oct 22 [Epub ahead of print] (2009).
-
Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, Silman AJ; British Society for Rheumatology Biologics Register Control Centre Consortium; British Society for Rheumatology Biologics Register. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.
Arthritis Rheum. 56: 2896-2904 (2007).
*
-
Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Arthritis Rheum. 54: 2368-2376 (2006).
*
-
Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register Control Centre Consortium; British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
Arthritis Rheum. 56: 2905-2912 (2007).
*
-
Dizier MH, Eliaou JF, Babron MC, Combe B, Sany J, Clot J, Clerget-Darpoux F. Investigation of the HLA component involved in rheumatoid arthritis (RA) by using the marker association-segregation chi-square (MASC) method: rejection of the unifying-shared-epitope hypothesis.
Am. J. Hum. Genet. 53: 715-721 (1993).
*
-
Dizier MH, Silman AJ, Ollier W, Grennan DM, Clerget-Darpoux F. Interactive effect of HLA and Gm and genetic heterogeneity tested in 79 rheumatoid arthritis families.
Dis. Markers 9: 27-34 (1991).
-
Djouad F, Fritz V, Apparailly F, Louis-Plence P, Bony C, Sany J, Jorgensen C, Noel D. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis.
Arthritis Rheum. 52: 1595-1603 (2005).
*
-
do Nascimento AP, Dos Santos Trindade Viana V, de Abreu Testagrossa L, Leon EP, Borba EF, Barros RT, Bonfa E. Antibodies to ribosomal P proteins: a potential serologic marker for lupus membranous glomerulonephritis.
Arthritis Rheum. 54: 1568-1572 (2006).
*
-
Doan T, Massarotti E. Rituximab.
Drugs Today (Barc.) 41: 785-797 (2005).
-
Dobec M, Kaeppeli F, Cassinotti P, Satz N. Persistent parvovirus B19 infection and arthralgia in a patient mistakenly treated for Lyme disease.
J. Clin. Virol. 43: 226-229 (2008).
-
Dode C, Andre M, Bienvenu T, Hausfater P, Pecheux C, Bienvenu J, Lecron JC, Reinert P, Cattan D, Piette JC, Szajnert MF, Delpech M, Grateau G; French Heraditary Recurrent Inflammatory Disorder Study Group. The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome.
Arthritis Rheum. 46: 2181-2188 (2002).
*
-
Dodeller F, Schulze-Koops H. The p38 mitogen-activated protein kinase signaling cascade in CD4 T cells.
Arthritis Res. Ther. 8: 205 (2006).
*
-
Doggrell SA. Inflammation, the key to much pathology. Highlights from the 7th World Congress on Inflammation, held August 20-24, 2005, in Melbourne, Australia.
Timely Top. Med. Cardiovasc. Dis. 10: E4 (2006).
-
Doggrell SA. Inflammation, the key to much pathology.
Drug News Perspect. 18: 531-539 (2005).
-
Doggrell SA. Phosphoinositide 3-kinase-gamma as a target in rheumatoid arthritis and systemic lupus.
Expert Opin. Ther. Targets 10: 627-630 (2006).
-
Doggrell SA. Lyprinol - is it a useful anti-inflammatory agent?
Evid. Based Complement. Alternat. Med. Apr 21 [Epub ahead of print] (2009).
*
-
Doherty SD, Van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
J. Am. Acad. Dermatol. 59: 209-217 (2008).
-
Dohn UM, Skjodt H, Hetland ML, Vestergaard A, Moller JM, Knudsen LS, Ejbjerg BJ, Thomsen HS, Ostergaard M. No erosive progression revealed by MRI in rheumatoid arthritis patients treated with etanercept, even in patients with persistent MRI and clinical signs of joint inflammation.
Clin. Rheumatol. 26: 1857-1861(2007).
*
-
Dombrecht EJ, Aerts NE, Schuerwegh AJ, Hagendorens MM, Ebo DG, Van Offel JF, Bridts CH, Stevens WJ, De Clerck LS. Influence of anti-tumor necrosis factor therapy (Adalimumab) on regulatory T cells and dendritic cells in rheumatoid arthritis.
Clin. Exp. Rheumatol. 24: 31-37 (2006).
-
Dombrecht EJ, Van Offel JF, Bridts CH, Ebo DG, Seynhaeve V, Schuerwegh AJ, Stevens WJ, De Clerck LS. Influence of simvastatin on the production of pro-inflammatory cytokines and nitric oxide by activated human chondrocytes.
Clin. Exp. Rheumatol. 25: 534-539 (2007).
-
Domiciano DS, Carvalho JF, Shoenfeld Y. Pathogenic role of anti-endothelial cell antibodies in autoimmune rheumatic diseases.
Lupus 18: 1233-1238 (2009).
-
Dominguez PL, Husni ME, Holt EW, Tyler S, Qureshi AA. Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire.
Arch. Dermatol. Res. 301: 573-579 (2009).
-
Dommasch E, Gelfand JM. Is there truly a risk of lymphoma from biologic therapies?
Dermatol. Ther. 22: 418-430 (2009).
-
Donate F, McCrae K, Shaw DE, Mazar AP. Extracellular tropomyosin: a novel common pathway target for anti-angiogenic therapy.
Curr. Cancer Drug Targets 4: 543-553 (2004).
-
Dong C, Flavell RA. Cell fate decision: T-helper 1 and 2 subsets in immune responses.
Arthritis Res. 2: 179-188 (2000).
*
-
Dong J, Gao Y, Liu Y, Shi J, Feng J, Li Z, Pan H, Xue Y, Liu C, Shen B, Shao N, Yang G. The protective antibodies induced by a novel epitope of human TNF-alpha could suppress the development of collagen-induced arthritis.
PLoS One 5: e8920 (2010).
*
-
Dong L, Ito S, Ishii KJ, Klinman DM. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice.
Arthritis Rheum. 52: 651-658 (2005).
*
-
Donn R, Payne D, Ray D. Glucocorticoid receptor gene polymorphisms and susceptibility to rheumatoid arthritis.
Clin. Endocrinol. (Oxf.) 67: 342-345 (2007).
*
-
Donn RP, Plant D, Jury F, Richards HL, Worthington J, Ray DW, Griffiths CE. Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis.
J. Invest. Dermatol. 123: 484-487 (2004).
*
-
Donn RP, Thomson W, Pepper L, Carthy D, Farhan A, Ryder C, Southwood T, Holt L, Ollier W. Antinuclear antibodies in early onset pauciarticular juvenile chronic arthritis (JCA) are associated with HLA-DQB1*0603: a possible JCA-associated human leucocyte antigen haplotype.
Br. J. Rheumatol. 34: 461-465 (1995).
-
Donnelly S, Roake W, Brown S, Young P, Naik H, Wordsworth P, Isenberg DA, Reid KB, Eggleton P. Impaired recognition of apoptotic neutrophils by the C1q/calreticulin and CD91 pathway in systemic lupus erythematosus.
Arthritis Rheum. 54: 1543-1556 (2006).
*
-
Doodes PD, Cao Y, Hamel KM, Wang Y, Farkas B, Iwakura Y, Finnegan A. Development of proteoglycan-induced arthritis is independent of IL-17.
J. Immunol. 181: 329-337 (2008).
*
-
Doodes PD, Cao Y, Hamel KM, Wang Y, Rodeghero RL, Mikecz K, Glant TT, Iwakura Y, Finnegan A. IFN-gamma regulates the requirement for IL-17 in proteoglycan-induced arthritis.
J. Immunol. Dec 18 [Epub ahead of print] (2009).
-
Doorduyn Y, Van Pelt W, Siezen CL, Van Der Horst F, Van Duynhoven YT, Hoebee B, Janssen R. Novel insight in the association between Salmonellosis or Campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases.
Epidemiol. Infect. 136: 1225-1234 (2008).
-
Doran M. Rheumatoid arthritis and diabetes mellitus: evidence for an association?
J. Rheumatol. 34: 460-462 (2007).
-
Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, Zhou L, Peloso P. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis.
Clin. Exp. Rheumatol. 25: 40-46 (2007).
-
Doria A, Iaccarino L, Arienti S, Ghirardello A, Zampieri S, Rampudda ME, Cutolo M, Tincani A, Todesco S. Th2 immune deviation induced by pregnancy: the two faces of autoimmune rheumatic diseases.
Reprod. Toxicol. 22: 234-241 (2006).
-
Doria A, Iaccarino L, Sarzi-Puttini P, Ghirardello A, Zampieri S, Arienti S, Cutolo M, Todesco S. Estrogens in pregnancy and systemic lupus erythematosus.
Ann. N. Y. Acad. Sci. 1069: 247-256 (2006).
*
-
Doria A, Sarzi-Puttini P, Shoenfeld Y. 2nd Conference on heart, rheumatism and autoimmunity, Pescara, Italy, May 19-20, 2005.
Autoimmun. Rev. 5: 55-63 (2006).
-
Doria AS, Karshafian R, Moineddin R, Mohanta A, Zhong A, Mendes M, Pritzker K, Jong R, Burns P. Contrast-enhanced triggered harmonic sonography for assessment of periarticular hemodynamic changes in experimental arthritis.
Pediatr. Radiol. 36: 1242-1251 (2006).
-
Dorman J, Steenkiste A, O'Leary L, McCarthy B, Lorenzen T, Foley T. Type 1 diabetes in offspring of parents with type 1 diabetes: the tip of an autoimmune iceberg?
Pediatr. Diabetes 1: 17-22 (2000).
-
Dorner AJ, Goldman SJ, Keith Jr JC. Interleukin-11.
BioDrugs 8: 418-429 (1997).
-
Dorner T. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells.
J. Rheumatol. Suppl. 77: 3-11 (2006).
*
-
Dorner T, Burmester GR. New approaches of B-cell-directed therapy: beyond rituximab.
Curr. Opin. Rheumatol. 20: 263-268 (2008).
-
Dorner T, Goldenberg DM. Targeting CD22 as a strategy for treating systemic autoimmune diseases.
Ther. Clin. Risk Manag. 3: 953-959 (2007).
*
-
Dorner T, Haas J, Loddenkemper C, von Baehr V, Salama A. Implant-related inflammatory arthritis.
Nat. Clin. Pract. Rheumatol. 2: 53-56 (2006).
*
-
Dorner T, Isenberg D, Jayne D, Wiendl H, Zillikens D, Burmester G; on behalf of the International Roundtable on B cells as Therapeutic Target for Intervention. Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis.
Autoimmun. Rev. 9: 82-89 (2009).
-
Dorner T, Jacobi AM, Lipsky PE. B cells in autoimmunity.
Arthritis Res. Ther. 11: 247 (2009).
-
Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.
Arthritis Res. Ther. 8: R74 (2006).
*
-
Dorner T, Kinnman N, Tak PP. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers.
Pharmacol. Ther. Jan 21 [Epub ahead of print] (2010).
*
-
Dorner T, Lipsky PE. B-cell targeting: a novel approach to immune intervention today and tomorrow.
Expert Opin. Biol. Ther. 7: 1287-1299 (2007).
-
Dorner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease.
Nat. Rev. Rheumatol. 5: 433-441 (2009).
-
Dorofeyev AE, Vasilenko IV, Rassokhina OA. Joint extraintestinal manifestations in ulcerative colitis.
Dig. Dis. 27: 502-510 (2009).
-
Doron S, Gorbach SL. Probiotics: their role in the treatment and prevention of disease.
Expert Rev. Anti Infect. Ther. 4: 261-275 (2006).
-
Dorr S, Lechtenbohmer N, Rau R, Herborn G, Wagner U, Muller-Myhsok B, Hansmann I, Keyszer G. Association of a specific haplotype across the genes MMP1 and MMP3 with radiographic joint destruction in rheumatoid arthritis.
Arthritis Res. Ther. 6: R199-R207 (2004).
*
-
dos Anjos LM, Pereira IA, d 'Orsi E, Seaman AP, Burlingame RW, Morato EF. A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation anti-cyclic citrullinated peptide (CCP) ELISA for the diagnosis of rheumatoid arthritis.
Clin. Rheumatol. 28: 153-158 (2009).
-
Dostal C, Fojtikova M, Lacinova Z, Cerna M, Moszkorzova L, Zvarova J, Marek J. Prolactine response to stress in patients with systemic lupus erythematodes (SLE), rheumatoid arthritis (RA) and in healthy controls.
Vnitr. Lek. 53: 1265-1268 (2007).
-
Dostal C, Pavelka K, Zvarova J, Hanzlicek P, Olejarova M. Some principles of the development of a clinical database/national register of selected inflammatory rheumatic diseases in the Czech Republic.
Int. J. Med. Inform. 75: 216-223 (2006).
*
-
Dougados M, Hochberg MC. Why is the concept of spondyloarthropathies important?
Best Pract. Res. Clin. Rheumatol. 16: 495-505 (2002).
-
Dougados M, Schmidely N, Le Bars M, Lafosse C, Schiff M, Smolen JS, Aletaha D, van Riel P, Wells G. Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data.
Ann. Rheum. Dis. 68: 484-489 (2009).
*
-
Douglas KM, Ladoyanni E, Treharne GJ, Hale ED, Erb N, Kitas GD. Cutaneous abnormalities in rheumatoid arthritis compared to non-inflammatory rheumatic conditions.
Ann. Rheum. Dis. 65: 1341-1345 (2006).
*
-
Douni E, Armaka M, Kontoyiannis DL, Kollias G. Functional genetic and genomic analysis of modeled arthritis.
Adv. Exp. Med. Biol. 602: 33-42 (2007).
-
Downie-Doyle S, Bayat N, Rischmueller M, Lester S. Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjogren's syndrome.
Arthritis Rheum. 54: 2434-2440 (2006).
*
-
Doyen V, Fournier C, Bautin N, Cortet B, Flipo RM, Wallaert B. Rheumatoid arthritis and cystic fibrosis.
Rev. Mal. Respir. 22: 667-671 (2005).
-
Dozmorov I, Knowlton N, Tang Y, Shields A, Pathipvanich P, Jarvis JN, Centola M. Hypervariable genes - experimental error or hidden dynamics.
Nucleic Acids Res. 32: e147 (2004).
*
-
Dragun D, Distler JH, Riemekasten G, Distler O. Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology.
Arthritis Rheum. 60: 907-911 (2009).
*
-
Drake CG, Kotzin BL. Superantigens: biology, immunology, and potential role in disease.
J. Clin. Immunol. 12: 149-162 (1992).
-
Dreja H, Annenkov A, Chernajovsky Y. Soluble complement receptor 1 (CD35) delivered by retrovirally infected syngeneic cells or by naked DNA injection prevents the progression of collagen-induced arthritis.
Arthritis Rheum. 43: 1698-1709 (2000).
*
-
Drent M, van den Berg R, Haenen GR, van den Berg H, Wouters EF, Bast A. NF-kappaB activation in sarcoidosis.
Sarcoidosis Vasc. Diffuse Lung Dis. 18: 50-56 (2001).
-
Dresch C, Xavier R, Brenol JC, Nardi NB, Chies JA. Analysis of two T-cell receptor BV gene segment polymorphisms in caucasoid Brazilian patients with rheumatoid arthritis.
Immunol. Lett. 90: 77-80 (2003).
-
Drexler SK, Foxwell BM. The role of Toll-like receptors in chronic inflammation.
Int. J. Biochem. Cell Biol. Oct 15 [Epub ahead of print] (2009).
-
Drexler SK, Kong PL, Wales J, Foxwell BM. Cell signalling in macrophages, the principal innate immune effector cells of rheumatoid arthritis.
Arthritis Res. Ther. 10: 216 (2008).
*
-
Dreyer L, Mellemkjaer L, Hetland ML. Cancer in arthritis patients after anti-tumour necrosis factor therapy.
Ugeskr. Laeger. 171: 506-511 (2009).
-
Driessen RJ, de Jong EM, Salemink GW, Burer JH, van de Kerkhof PC, van den Hoogen FH. Analysis of 4-year Dutch reimbursement application data of biological therapies for psoriatic arthritis.
Rheumatology (Oxford) 49: 588-591 (2010).
-
Driessler F, Venstrom K, Sabat R, Asadullah K, Schottelius AJ. Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50.
Clin. Exp. Immunol. 135: 64-73 (2004).
*
-
Drinda S, Franke S, Eidner T, Schmidt C, Ruster C, Bondeva T, Hein G, Wolf G. Decreased RAGE expression in peripheral blood mononuclear cells of patients with rheumatoid arthritis.
Clin. Exp. Rheumatol. 27: 483-490 (2009).
-
Drosos AA, Moutsopoulos HM. Rheumatoid arthritis in Greece: clinical, serological and genetic considerations.
Clin. Exp. Rheumatol. 13 Suppl. 12: S7-S12 (1995).
-
Drosou A, Kirsner RS, Welsh E, Sullivan TP, Kerdel FA. Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses.
J. Cutan. Med. Surg. 7: 382-386 (2003).
*
-
Drotar D, Schwartz L, Palermo TM, Burant C. Factor structure of the child health questionnaire-parent form in pediatric populations.
J. Pediatr. Psychol. 31: 127-138 (2006).
-
Drouin EE, Glickstein L, Kwok WW, Nepom GT, Steere AC. Searching for borrelial T cell epitopes associated with antibiotic-refractory Lyme arthritis.
Mol. Immunol. 45: 2323-2332 (2008).
*
-
Drouin EE, Glickstein L, Kwok WW, Nepom GT, Steere AC. Human homologues of a Borrelia T cell epitope associated with antibiotic-refractory Lyme arthritis.
Mol. Immunol. 45: 180-189 (2008).
*
-
Drover S, Marshall WH, Kwok WW, Nepom GT, Karr RW. Amino acids in the peptide-binding groove influence an antibody-defined, disease-associated HLA-DR epitope.
Scand. J. Immunol. 39: 539-550 (1994).
-
Drozdzik M, Rudas T, Pawlik A, Gornik W, Kurzawski M, Herczynska M. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.
Pharmacogenomics J. 7: 404-407 (2007).
*
-
Drozdzik M, Rudas T, Pawlik A, Kurzawski M, Czerny B, Gornik W, Herczynska M. The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs.
Eur. J. Clin. Pharmacol. 62: 933-937 (2006).
*
-
Drummond M. Pharmacoeconomics: friend or foe?
Ann. Rheum. Dis. 65 Suppl. 3: iii44-iii47 (2006).
*
-
Drummond MF, Barbieri M, Wong JB. Analytic choices in economic models of treatments for rheumatoid arthritis: what makes a difference?
Med. Decis. Making 25: 520-533 (2005).
-
Du AL, Ren HM, Lu CZ, Tu JL, Xu CF, Sun YA. Carbonic anhydrase III is insufficient in muscles of myasthenia gravis patients.
Autoimmunity 42: 209-215 (2009).
-
Du F, Lv L, Fu Q, Dai M, Fan W, Teng J, Chen S, Ye P, Shen N, Huang X, Qian J, Bao C. T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis.
Arthritis Res. Ther. 10: R136 (2008).
*
-
Du F, Wang L, Zhang Y, Jiang W, Sheng H, Cao Q, Wu J, Shen B, Shen T, Zhang JZ, Bao C, Li D, Li N. Role of GADD45beta in the regulation of synovial fluid T cell apoptosis in rheumatoid arthritis.
Clin. Immunol. 128: 238-247 (2008).
*
-
Du L, Kijlstra A, Yang P. Immune response genes in uveitis.
Ocul. Immunol. Inflamm. 17: 249-256 (2009).
-
du Montcel ST, Michou L, Petit-Teixeira E, Osorio J, Lemaire I, Lasbleiz S, Pierlot C, Quillet P, Bardin T, Prum B, Cornelis F, Clerget-Darpoux F. New classification of HLA-DRB1 alleles supports the shared epitope hypothesis of rheumatoid arthritis susceptibility.
Arthritis Rheum. 52: 1063-1068 (2005).
*
-
Duan B, Morel L. Role of B-1a cells in autoimmunity.
Autoimmun. Rev. 5: 403-408 (2006).
-
Duan H, Fleming J, Pritchard DK, Amon LM, Xue J, Arnett HA, Chen G, Breen P, Buckner JH, Molitor JA, Elkon KB, Schwartz SM. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma.
Arthritis Rheum. 58: 1465-1474 (2008).
*
-
Dubaniewicz A, Jamieson SE, Dubaniewicz-Wybieralska M, Fakiola M, Nancy Miller E, Blackwell JM. Association between SLC11A1 (formerly NRAMP1) and the risk of sarcoidosis in Poland.
Eur. J. Hum. Genet. 13: 829-834 (2005).
*
-
Dube SR, Fairweather D, Pearson WS, Felitti VJ, Anda RF, Croft JB. Cumulative childhood stress and autoimmune diseases in adults.
Psychosom. Med. 71: 243-250 (2009).
-
Dubinsky MC, Fleshner PP. Treatment of Crohn's disease of inflammatory, stenotic, and fistulizing phenotypes.
Curr. Treat. Options Gastroenterol. 6: 183-200 (2003).
-
Dubrous P, Gardet V, Hugard L. Value of anti-cyclic citrullinated peptides antibodies in comparison with rheumatoid factor for rheumatoid arthritis diagnosis.
Pathol. Biol. (Paris) 53: 63-67 (2005).
-
Dubucquoi S. Physiological and pathological autoimmunity in neurological disease.
Rev. Neurol. (Paris) 161: 1163-1176 (2005).
-
Ducharme E, Weinberg JM. Etanercept.
Expert Opin. Biol. Ther. 8: 491-502 (2008).
-
Duchatelet S, Caillat-Zucman S, Dubois-Laforgue D, Blanc H, Timsit J, Julier C. FCRL3 -169CT functional polymorphism in type 1 diabetes and autoimmunity traits.
Biomed. Pharmacother. 62: 153-157 (2008).
-
Duchini A, McHutchison JG, Pockros PJ. LKM-positive autoimmune hepatitis in the western United States: a case series.
Am. J. Gastroenterol. 95: 3238-3241 (2000).
*
-
Duchmann R, May E, Ackermann B, Goergen B, Meyer zum Buschenfelde KH, Marker-Hermann E. HLA-B27-restricted cytotoxic T lymphocyte responses to arthritogenic enterobacteria or self-antigens are dominated by closely related TCRBV gene segments. A study in patients with reactive arthritis.
Scand. J. Immunol. 43: 101-108 (1996).
-
Duchmann R, Neurath M, Marker-Hermann E, Meyer Zum Buschenfelde KH. Immune responses towards intestinal bacteria - current concepts and future perspectives.
Z. Gastroenterol. 35: 337-346 (1997).
-
Duclos M, Gossec L, Ruyssen-Witrand A, Salliot C, Luc M, Guignard S, Dougados M. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients.
J. Rheumatol. 33: 2433-2438 (2006).
-
Duclos P. Safety of immunisation and adverse events following vaccination against hepatitis B.
Expert Opin. Drug Saf. 2: 225-231 (2003).
-
Ducoulombier V, Solau E, Coquerelle P, Houvenagel E, Siame JL, Desprez X, Fauquert P, Guyot MH, Delcambre B, Flipo RM. Long-term results of infliximab therapy in rheumatoid arthritis: experience acquired by the North-Pas-de-Calais hospital network.
Joint Bone Spine 74: 56-59 (2007).
*
-
Dudek NL, Maier S, Chen ZJ, Mudd PA, Mannering SI, Jackson DC, Zeng W, Keech CL, Hamlin K, Pan ZJ, Davis-Schwarz K, Workman-Azbill J, Bachmann M, McCluskey J, Farris AD. T cell epitopes of the La/SSB autoantigen in humanized transgenic mice expressing the HLA class II haplotype DRB1*0301/DQB1*0201.
Arthritis Rheum. 56: 3387-3398 (2007).
*
-
Dudich E. MM-093, a recombinant human alpha-fetoprotein for the potential treatment of rheumatoid arthritis and other autoimmune diseases.
Curr. Opin. Mol. Ther. 9: 603-610 (2007).
-
Duek A, Shvidel L, Braester A, Berrebi A. Clinical and immunologic aspects of B chronic lymphocytic leukemia associated with autoimmune disorders.
Isr. Med. Assoc. J. 8: 828-831 (2006).
*
-
Duerr RH. Genome-wide association studies herald a new era of rapid discoveries in inflammatory bowel disease research.
Gastroenterology 132: 2045-2049 (2007).
*
-
Duffin KC, Chandran V, Gladman DD, Krueger GG, Elder JT, Rahman P. Genetics of psoriasis and psoriatic arthritis: update and future direction.
J. Rheumatol. 35: 1449-1453 (2008).
-
Duffin KC, Freeny IC, Schrodi SJ, Wong B, Feng BJ, Soltani-Arabshahi R, Rakkhit T, Goldgar DE, Krueger GG. Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking.
J. Invest. Dermatol. 129: 2777-2783 (2009).
*
-
Duffin KC, Wong B, Horn EJ, Krueger GG. Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis.
J. Am. Acad. Dermatol. 60: 604-608 (2009).
-
Duffy DL. Genetic determinants of diabetes are similarly associated with other immune-mediated diseases.
Curr. Opin. Allergy Clin. Immunol. 7: 468-474 (2007).
-
Duffy J. Arthritis and hepatitis.
Bull. Rheum. Dis. 47: 1-5 (1998).
-
Dugar M, Cox S, Limaye V, Gordon TP, Roberts-Thomson PJ. Diagnostic utility of anti-Ro52 detection in systemic autoimmunity.
Postgrad. Med. J. 86: 79-82 (2010).
-
Duggleby RC, Shaw TN, Jarvis LB, Kaur G, Hill Gaston JS. CD27 expression discriminates between regulatory and non-regulatory cells after expansion of human peripheral blood CD4(+) CD25(+) cells.
Immunology 121: 129-139 (2007).
*
-
Dugoujon JM, Cambon-Thomsen A. Immunoglobulin allotypes (GM and KM) and their interactions with HLA antigens in autoimmune diseases: a review.
Autoimmunity 22: 245-260 (1995).
-
Dulos J, Boots AH. DHEA metabolism in arthritis: a role for the p450 enzyme Cyp7b at the immune-endocrine crossroad.
Ann. N. Y. Acad. Sci. 1069: 401-413 (2006).
*
-
Dulos J, Kaptein A, Kavelaars A, Heijnen C, Boots A. Tumour necrosis factor-alpha stimulates dehydroepiandrosterone metabolism in human fibroblast-like synoviocytes: a role for nuclear factor-kappaB and activator protein-1 in the regulation of expression of cytochrome p450 enzyme 7b.
Arthritis Res. Ther. 7: R1271-R1280 (2005).
*
-
Dulos J, van der Vleuten MA, Kavelaars A, Heijnen CJ, Boots AM. CYP7B expression and activity in fibroblast-like synoviocytes from patients with rheumatoid arthritis: regulation by proinflammatory cytokines.
Arthritis Rheum. 52: 770-778 (2005).
*
-
Dulos J, Verbraak E, Bagchus WM, Boots AM, Kaptein A. Severity of murine collagen-induced arthritis correlates with increased CYP7B activity: enhancement of dehydroepiandrosterone metabolism by interleukin-1beta.
Arthritis Rheum. 50: 3346-3353 (2004).
*
-
Dumolard A, Gaudin P, Juvin R, Bost M, Peoc'h M, Phelip X. SAPHO syndrome or psoriatic arthritis? A familial case study.
Rheumatology (Oxford) 38: 463-467 (1999).
*
-
Dunstan JA, Prescott SL. Does fish oil supplementation in pregnancy reduce the risk of allergic disease in infants?
Curr. Opin. Allergy Clin. Immunol. 5: 215-221 (2005).
-
Duplan V, Foulquier C, Clavel C, Al Badine R, Serre G, Saoudi A, Sebbag M. In the rat, citrullinated autologous fibrinogen is immunogenic but the induced autoimmune response is not arthritogenic.
Clin. Exp. Immunol. 145: 502-512 (2006).
*
-
Duquerroy S, Stura EA, Bressanelli S, Fabiane SM, Vaney MC, Beale D, Hamon M, Casali P, Rey FA, Sutton BJ, Taussig MJ. Crystal structure of a human autoimmune complex between IgM rheumatoid factor RF61 and IgG1 Fc reveals a novel epitope and evidence for affinity maturation.
J. Mol. Biol. 368: 1321-1331 (2007).
*
-
Durai M, Huang MN, Moudgil KD. Self heat-shock protein 65-mediated regulation of autoimmune arthritis.
J. Autoimmun. 33: 208-213 (2009).
-
Durai M, Kim HR, Bala K, Moudgil KD. T cells against the pathogenic and protective epitopes of heat-shock protein 65 are crossreactive and display functional similarity: novel aspect of regulation of autoimmune arthritis.
J. Rheumatol. 34: 2134-2143 (2007).
-
Durand JP, el-Zaatari FA, Krieg AM, Taurog JD. Restriction fragment length polymorphism of T cell receptor alpha and beta chain genes in patients with ankylosing spondylitis.
J. Rheumatol. 15: 1115-1158 (1988).
-
Durie FH, Fava RA, Noelle RJ. Collagen-induced arthritis as a model of rheumatoid arthritis.
Clin. Immunol. Immunopathol. 73: 11-18 (1994).
-
Durox H, Boumediene A, Genet C, Lo Re P, Rogez JP, Weinbreck P, Denes E. Disseminated aspergillosis after intra-articular corticosteroid infiltrations.
Med. Mal. Infect. 37: 609-612 (2007).
-
Durrani K, Foster CS. Psoriatic uveitis: a distinct clinical entity?
Am. J. Ophthalmol. 139: 106-111 (2005).
*
-
Duty JA, Szodoray P, Zheng NY, Koelsch KA, Zhang Q, Swiatkowski M, Mathias M, Garman L, Helms C, Nakken B, Smith K, Farris AD, Wilson PC. Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors.
J. Exp. Med. 206: 139-151 (2009).
*
-
Duzgun N, Sahin M, Genc Y, Tutkak H. Antinucleosome antibodies and systemic lupus erythematosus.
Ann. N. Y. Acad. Sci. 1109: 421-428 (2007).
*
-
Duzova A, Bakkaloglu A. Central nervous system involvement in pediatric rheumatic diseases: current concepts in treatment.
Curr. Pharm. Des. 14: 1295-1301 (2008).
-
Dwarakanath AD, Yu LG, Brookes C, Pryce D, Rhodes JM. 'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis.
Gut 37: 585-588 (1995).
*
-
Dwivedi RC, Dhindsa N, Krokhin OV, Cortens J, Wilkins JA, El-Gabalawy HS. The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients.
Arthritis Res. Ther. 11: R32 (2009).
*
-
Dyjas R, Bulanowski M, Ficek R, Witkowicz J, Chudek J, Wiecek A. Influence of recombinant human erythropoietin (rHuEPO) on plasma levels of selected hormones in females with rheumatoid arthritis.
Pol. Arch. Med. Wewn. 114: 731-737 (2005).
-
Dyszkiewicz A, Janik P, Janik M. Preliminary dielectric studies of knee swelling fluid in the case of arthritis, which is hard to diagnose.
Physiol. Meas. 27: 1345-1359 (2006).
-
Dzhambazov B, Nandakumar KS, Kihlberg J, Fugger L, Holmdahl R, Vestberg M. Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules.
J. Immunol. 176: 1525-1533 (2006).
*
-
Eastell T, Hinks A, Thomson W. SNPs in the FOXP3 gene region show no association with juvenile idiopathic arthritis in a UK Caucasian population.
Rheumatology (Oxford) 46: 1263-1265 (2007).
*
-
Eaton PA, Callen JP. Mycophenolate mofetil as therapy for pyoderma gangrenosum.
Arch. Dermatol. 145: 781-785 (2009).
*
-
Eaton WW, Byrne M, Ewald H, Mors O, Chen CY, Agerbo E, Mortensen PB. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers.
Am. J. Psychiatry 163: 521-528 (2006).
*
-
Eberhardt K, Fex E, Johnson U, Wollheim FA. Associations of HLA-DRB and -DQB genes with two and five year outcome in rheumatoid arthritis.
Ann. Rheum. Dis. 55: 34-39 (1996).
*
-
Ebert EC. Infliximab and the TNFalpha system.
Am. J. Physiol. Gastrointest. Liver Physiol. 296: G612-G620 (2009).
*
-
Ebrahimi AA, Noshad H, Sadreddini S, Hejazi MS, Mohammadzadeh Sadigh Y, Eshraghi Y, Ghojazadeh M. Serum levels of TNF-alpha, TNF-alphaRI, TNF-alphaRII and IL-12 in treated rheumatoid arthritis patients.
Iran J. Immunol. 6: 147-153 (2009).
-
Ebright JR, Ryan LM. Acute erosive reactive arthritis associated with Campylobacter jejuni-induced colitis.
Am. J. Med. 76: 321-323 (1984).
-
Ebringer A. Ankylosing spondylarthritis, HLA B27 and the theory of crossed tolerance.
Rev. Rhum. Mal. Osteoartic. 50: 763-769 (1983).
-
Ebringer A. Ankylosing spondylitis is caused by Klebsiella. Evidence from immunogenetic, microbiologic, and serologic studies.
Rheum. Dis. Clin. North Am. 18: 105-121 (1992).
-
Ebringer A. The relationship between Klebsiella infection and ankylosing spondylitis.
Baillieres Clin. Rheumatol. 3: 321-338 (1989).
-
Ebringer A, Ahmadi K, Fielder M, Rashid T, Tiwana H, Wilson C, Collado A, Tani Y. Molecular mimicry: the geographical distribution of immune responses to Klebsiella in ankylosing spondylitis and its relevance to therapy.
Clin. Rheumatol. 15 Suppl. 1: 57-61 (1996).
-
Ebringer A, Baines M, Ptaszynska T. Spondyloarthritis, uveitis, HLA-B27 and Klebsiella.
Immunol. Rev. 86: 101-116 (1985).
-
Ebringer A, Rashid T. Rheumatoid arthritis is an autoimmune disease triggered by Proteus urinary tract infection.
Clin. Dev. Immunol. 13: 41-48 (2006).
*
-
Ebringer A, Rashid T. Rheumatoid arthritis is caused by Proteus: the molecular mimicry theory and Karl Popper.
Front. Biosci. (Elite Ed.) 1: 577-586 (2009).
-
Ebringer A, Rashid T, Wilson C. Rheumatoid arthritis, Proteus, anti-CCP antibodies and Karl Popper.
Autoimmun. Rev. Nov 3 [Epub ahead of print] (2009).
-
Eck SM, Blackburn JS, Schmucker AC, Burrage PS, Brinckerhoff CE. Matrix metalloproteinase and G protein coupled receptors: co-conspirators in the pathogenesis of autoimmune disease and cancer.
J. Autoimmun. 33: 214-221 (2009).
-
Edberg JC, Langefeld CD, Wu J, Moser KL, Kaufman KM, Kelly J, Bansal V, Brown WM, Salmon JE, Rich SS, Harley JB, Kimberly RP. Genetic linkage and association of Fcgamma receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus.
Arthritis Rheum. 46: 2132-2140 (2002).
*
-
Eder L, Chandran V, Gladman DD. From ankylosis to pencil-in-cup deformity in psoriatic arthritis: a case report.
Clin. Exp. Rheumatol. 27: 661-663 (2009).
-
Eder L, Zisman D, Barzilai M, Laor A, Rahat M, Rozenbaum M, Bitterman H, Feld J, Rimar D, Rosner I. Subclinical atherosclerosis in psoriatic arthritis: a case-control study.
J. Rheumatol. 35: 877-882 (2008).
*
-
Edwards CJ. Immunological therapies for rheumatoid arthritis.
Br. Med. Bull. 73-74: 71-82 (2005).
*
-
Edwards CJ, Cooper C. Early environmental factors and rheumatoid arthritis.
Clin. Exp. Immunol. 143: 1-5 (2006).
*
-
Edwards CJ, Cooper C. Early environmental exposure and the development of lupus.
Lupus 15: 814-819 (2006).
-
Edwards CJ, Feldman JL, Beech J, Shields KM, Stover JA, Trepicchio WL, Larsen G, Foxwell BM, Brennan FM, Feldmann M, Pittman DD. Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritis.
Mol. Med. 13: 40-58 (2007).
*
-
Edwards CK 3rd, Zhou T, Zhang J, Baker TJ, De M, Long RE, Borcherding DR, Bowlin TL, Bluethmann H, Mountz JD. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha.
J. Immunol. 157: 1758-1772 (1996).
-
Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases.
Nat. Rev. Immunol. 6: 394-403 (2006).
*
-
Edwards JC, Cambridge G, Leandro MJ. B cell depletion therapy in rheumatic disease.
Best Pract. Res. Clin. Rheumatol. 20: 915-928 (2006).
-
Edwards JR, Sun SG, Locklin R, Shipman CM, Adamopoulos IE, Athanasou NA, Sabokbar A. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis.
Arthritis Rheum. 54: 1451-1462 (2006).
*
-
Edwards LJ, Constantinescu CS. Platelet activating factor/platelet activating factor receptor pathway as a potential therapeutic target in autoimmune diseases.
Inflamm. Allergy Drug Targets 8: 182-190 (2009).
-
Edwards LJ, Constantinescu CS. Platelet activating factor/platelet activating factor receptor pathway as a potential therapeutic target in autoimmune diseases.
Inflamm. Allergy Drug Targets 8: 182-190 (2009).
-
Edwards MH, Leak AM. Pericardial effusions on anti-TNF therapy for rheumatoid arthritis - a drug side effect or uncontrolled systemic disease?
Rheumatology (Oxford) 48: 316-317 (2009).
*
-
Efthimiou P. Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implications.
Semin. Arthritis Rheum. 36: 168-172 (2006).
*
-
Efthimiou P, Georgy S. Pathogenesis and management of adult-onset Still's disease.
Semin. Arthritis Rheum. 36: 144-152 (2006).
*
-
Efthimiou P, Kontzias A, Ward CM, Ogden NS. Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy?
Nat. Clin. Pract. Rheumatol. 3: 328-335 (2007).
*
-
Efthimiou P, Kukar M. Complementary and alternative medicine use in rheumatoid arthritis: proposed mechanism of action and efficacy of commonly used modalities.
Rheumatol. Int. Oct 30 [Epub ahead of print] (2009).
*
-
Efthimiou P, Markenson JA. Role of biological agents in immune-mediated inflammatory diseases.
South. Med. J. 98: 192-204 (2005).
-
Egan LJ. Mechanism of action of established drugs: cyclosporine, methotrexate and others.
Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 63-64. May 7-8 (2004). *
-
Eggebeen AT, Wasko MC. Aggressive therapy in patients with stable, long-standing rheumatoid arthritis-does it make a difference?
Nat. Clin. Pract. Rheumatol. 2: 530-531 (2006). *
-
Egger SS, Studer IG, Bravo AE, Krahenbuhl S. Minocycline-induced lupus erythematodes.
Schweiz. Rundsch. Med. Prax. 95: 1297-1303 (2006).
-
Eggert M, Zettl UK, Neeck G. Autoantibodies in autoimmune diseases.
Curr. Pharm. Des. Mar 3 [Epub ahead of print] (2010).
-
Egido J, Ruiz-Ortega M. Anti-inflammatory actions of quinapril.
Cardiovasc. Drugs Ther. 21: 211-220 (2007).
-
Egli RJ, Southam L, Wilkins JM, Lorenzen I, Pombo-Suarez M, Gonzalez A, Carr A, Chapman K, Loughlin J. Functional analysis of the osteoarthritis susceptibility-associated GDF5 regulatory polymorphism.
Arthritis Rheum. 60: 2055-2064 (2009).
*
-
Egnatios G, Warthan MM, Pariser R, Hood AF. Pustular psoriasis following treatment of rheumatoid arthritis with TNF-alpha inhibitors.
J. Drugs Dermatol. 7: 975-977 (2008).
-
Eguchi Y, Wakitani S, Imai Y, Naka Y, Hashimoto Y, Nakamura H, Takaoka K. Antitumor necrotic factor agent promotes BMP-2-induced ectopic bone formation.
J. Bone Miner. Metab. Oct 29 [Epub ahead of print] (2009).
*
-
Ehlers M, Ravetch JV. Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance.
Trends Immunol. 28: 74-79 (2007).
*
-
Ehlers S. Why does tumor necrosis factor targeted therapy reactivate tuberculosis?
J. Rheumatol. Suppl. 74: 35-39 (2005).
-
Ehlhardt S, Seifert M, Schneider J, Ojak A, Zang KD, Mehraein Y. Human endogenous retrovirus HERV-K(HML-2) Rec expression and transcriptional activities in normal and rheumatoid arthritis synovia.
J. Rheumatol. 33: 16-23 (2006).
-
Ehrenfeld M. Geoepidemiology: the environment and spondyloarthropathies.
Autoimmun. Rev. Dec 16 [Epub ahead of print] (2009).
-
Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy.
J. Exp. Med. 200: 277-285 (2004).
*
-
Ehrman TM, Barlow DJ, Hylands PJ. In silico search for multi-target anti-inflammatories in Chinese herbs and formulas.
Bioorg. Med. Chem. Feb 8 [Epub ahead of print] (2010).
-
Eike MC, Nordang GB, Karlsen TH, Boberg KM, Vatn MH; IBSEN study group, Dahl-Jorgensen K, Ronningen KS, Joner G, Flato B, Bergquist A, Thorsby E, Forre O, Kvien TK, Undlien DE, Lie BA. The FCRL3 -169T>C polymorphism is associated with rheumatoid arthritis and shows suggestive evidence of involvement with juvenile idiopathic arthritis in a Scandinavian panel of autoimmune diseases.
Ann. Rheum. Dis. 67: 1287-1291 (2008).
-
Eisen A, Arnson Y, Dovrish Z, Hadary R, Amital H. Arrhythmias and conduction defects in rheumatological diseases - a comprehensive review.
Semin. Arthritis Rheum. 39: 145-156 (2009).
*
-
Eisenberg R. Targeting B cells in systemic lupus erythematosus: not just deja vu all over again.
Arthritis Res. Ther. 8: 108 (2006).
*
-
Eisenberg R, Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
Nat. Clin. Pract. Rheumatol. 2: 20-27 (2006).
*
-
Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20. "What do B-cells do?"
Clin. Immunol. 117: 207-213 (2005).
*
-
Eisenmann A, Murr C, Fuchs D, Ledochowski M. Gliadin IgG antibodies and circulating immune complexes.
Scand. J. Gastroenterol. 44: 168-171 (2009).
*
-
Ejaz A, Iftikhar A, Iftikhar N. Patterns of psoriatic arthritis.
J. Coll. Physicians Surg. Pak. 19: 553-556 (2009).
-
Eklow C, Makrygiannakis D, Backdahl L, Padyukov L, Ulfgren AK, Lorentzen JC, Malmstrom V. Cellular distribution of the C-type II lectin dendritic cell immunoreceptor (DCIR) and its expression in the rheumatic joint: identification of a subpopulation of DCIR+ T cells.
Ann. Rheum. Dis. 67: 1742-1749 (2008).
-
Eklund KK. Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy.
Immunol. Rev. 217: 38-52 (2007).
*
-
Ekstrom Smedby K, Vajdic CM, Falster M, Engels EA, Martinez-Maza O, Turner J, Hjalgrim H, Vineis P, Seniori Costantini A, Bracci PM, Holly EA, Willett E, Spinelli JJ, La Vecchia C, Zheng T, Becker N, De Sanjose S, Chiu BC, Dal Maso L, Cocco P, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium.
Blood 111: 4029-4038 (2008).
*
-
El Mabrouk M, Qureshi HY, Li WQ, Sylvester J, Zafarullah M. Interleukin-4 antagonizes oncostatin M and transforming growth factor beta-induced responses in articular chondrocytes.
J. Cell. Biochem. 103: 588-597 (2008).
*
-
El-Gabalawy H. The preclinical stages of RA: lessons from human studies and animal models.
Best Pract. Res. Clin. Rheumatol. 23: 49-58 (2009).
-
El-Gabalawy H. Common denominators of inflammatory joint diseases.
J. Rheumatol. Suppl. 72: 3-6 (2005).
*
-
El-Gabalawy HS, Goldbach-Mansky R, Smith D 2nd, Arayssi T, Bale S, Gulko P, Yarboro C, Wilder RL, Klippel JH, Schumacher HR Jr. Association of HLA alleles and clinical features in patients with synovitis of recent onset.
Arthritis Rheum. 42: 1696-1705 (1999).
*
-
El-Gabalawy HS, Robinson DB, Hart D, Elias B, Markland J, Peschken CA, Smolik I, Montes-Aldana G, Schroeder M, Fritzler MJ, Cheang M, Oen K. Immunogenetic risks of anti-cyclical citrullinated peptide antibodies in a North American native population with rheumatoid arthritis and their first-degree relatives.
J. Rheumatol. 36: 1130-1135 (2009).
-
El-Hag K, Dercken HG, Prenzel R, Holzle E. Drug-induced alveolitis associated with infliximab/azathioprine therapy.
Pneumologie 62: 204-208 (2008).
-
El-Hallak M, Giani T, Yeniay BS, Jacobs KE, Kim S, Sundel RP, Dedeoglu F. Chronic minocycline-induced autoimmunity in children.
J. Pediatr. 153: 314-319 (2008).
*
-
El-Kased RF, Koy C, Deierling T, Lorenz P, Qian Z, Li Y, Thiesen HJ, Glocker MO. Mass spectrometric and peptide chip epitope mapping of rheumatoid arthritis autoantigen RA33.
Eur. J. Mass Spectrom. (Chichester, Eng.) 15: 747-759 (2009).
-
El-Sayed LH, Ghoneim HM, El-Sayed MH, Deimian SR, Adam AN, Abou Rawash SN, Abou Rawash NM, Ursos P. Immunological abnormalities in workers exposed to pollutants at an Egyptian copper company.
Immunopharmacol. Immunotoxicol. 25: 473-490 (2003).
-
El-Sohemy A. Nutrigenetics.
Forum Nutr. 60: 25-30 (2007).
-
Elder JT. Psoriasis clinical registries, genetics, and genomics.
Ann. Rheum. Dis. 64 Suppl. 2: ii106-ii107 (2005).
*
-
Eleftherohorinou H, Wright V, Hoggart C, Hartikainen AL, Jarvelin MR, Balding D, Coin L, Levin M. Pathway analysis of GWAS provides new insights into genetic susceptibility to 3 inflammatory diseases.
PLoS One 4: e8068 (2009).
*
-
Elenkov IJ, Kvetnansky R, Hashiramoto A, Bakalov VK, Link AA, Zachman K, Crane M, Jezova D, Rovensky J, Dimitrov MA, Gold PW, Bonini S, Fleisher T, Chrousos GP, Wilder RL. Low- versus high-baseline epinephrine output shapes opposite innate cytokine profiles: presence of Lewis- and Fischer-like neurohormonal immune phenotypes in humans?
J. Immunol. 181: 1737-1745 (2008).
*
-
Eliakim-Raz N, Shuvy M, Lotan C, Planer D. Psoriasis and dilated cardiomyopathy: coincidence or associated diseases?
Cardiology 111: 202-206 (2008).
-
Elias E. Hepatology highlights.
Hepatology 39: 1467-1468 (2004).
*
-
Elkayam O. Safety and efficacy of vaccination against influenza in patients with rheumatoid arthritis.
Clin. Dev. Immunol. 13: 349-351 (2006).
*
-
Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
Semin. Arthritis Rheum. 33: 283-288 (2004).
*
-
Elkayam O, Levartovsky D, Brautbar C, Yaron M, Burke M, Vardinon N, Caspi D. Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena.
Am. J. Med. 105: 484-487 (1998).
*
-
Elkayam O, Litinsky I, Levartovsky D, Caspi D. The changing face of spondyloarthropathies under TNF alpha blockade.
Open Rheumatol. J. 2: 53-57 (2008).
*
-
Elkayam O, Oumanski M, Yaron M, Caspi D. Watermelon stomach following and preceding systemic sclerosis.
Semin. Arthritis Rheum. 30: 127-131 (2000).
*
-
Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis.
Ann. Rheum. Dis. 61: 623-625 (2002).
*
-
Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes: an overview.
Semin. Arthritis Rheum. 28: 392-397 (1999).
-
Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, Lotze MT. Masquerader: high mobility group box-1 and cancer.
Clin. Cancer Res. 13: 2836-2848 (2007).
*
-
Elliott JI, McVey JH, Higgins CF. The P2X7 receptor is a candidate product of murine and human lupus susceptibility loci: a hypothesis and comparison of murine allelic products.
Arthritis Res. Ther. 7: R468-R475 (2005).
*
-
Elliott M, Benson J, Blank M, Brodmerkel C, Baker D, Sharples KR, Szapary P. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.
Ann. N. Y. Acad. Sci. 1182: 97-110 (2009).
*
-
Ellis BI, Shier CK, Leisen JJ, Kastan DJ, McGoey JW. Acne-associated spondylarthropathy: radiographic features.
Radiology 162: 541-545 (1987).
*
-
Ellis JA, Munro JE, Ponsonby AL. Possible environmental determinants of juvenile idiopathic arthritis.
Rheumatology (Oxford) 49: 411-425 (2010).
-
Ellman MH, Hanauer S, Sitrin M, Cohen R. Crohn's disease arthritis treated with infliximab: an open trial in four patients.
J. Clin. Rheumatol. 7: 67-71 (2001).
-
Elloumi H, Ben Slama A, Arfaoui D, Ghouma M, Sfar S, Ajmi S. Renal amyloidosis complicating Crohn's disease: report of two cases and review of literature.
Tunis. Med. 84: 253-255 (2006).
-
Ells LJ, Lang R, Shield JP, Wilkinson JR, Lidstone JS, Coulton S, Summerbell CD. Obesity and disability - a short review.
Obes. Rev. 7: 341-345 (2006).
-
Ellsworth JL, Hamacher N, Harder B, Bannink K, Bukowski TR, Byrnes-Blake K, Underwood S, Oliver C, Waggie KS, Noriega C, Hebb L, Rixon MW, Lewis KE. Recombinant soluble human FcgammaR1A (CD64A) reduces inflammation in murine collagen-induced arthritis.
J. Immunol. 182: 7272-7279 (2009).
-
Ellsworth JL, Maurer M, Harder B, Hamacher N, Lantry M, Lewis KB, Rene S, Byrnes-Blake K, Underwood S, Waggie KS, Visich J, Lewis KE. Targeting immune complex-mediated hypersensitivity with recombinant soluble human FcgammaRIA (CD64A).
J. Immunol. 180: 580-589 (2008).
*
-
Elmali N, Baysal O, Harma A, Esenkaya I, Mizrak B. Effects of resveratrol in inflammatory arthritis.
Inflammation 30: 1-6 (2007).
*
-
Eloranta ML, Lovgren T, Finke D, Mathsson L, Ronnelid J, Kastner B, Alm GV, Ronnblom L. Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells.
Arthritis Rheum. 60: 2418-2427 (2009).
*
-
Elst EF, Klein M, de Jager W, Kamphuis S, Wedderburn LR, van der Zee R, Albani S, Kuis W, Prakken BJ. Hsp60 in inflamed muscle tissue is the target of regulatory autoreactive T cells in patients with juvenile dermatomyositis.
Arthritis Rheum. 58: 547-555 (2008).
*
-
Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
Arthritis Rheum. 54: 1390-1400 (2006).
*
-
Emery P, Gabay C, Kraan M, Gomez-Reino J. Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis.
Rheumatol. Int. 27: 793-806 (2007).
*
-
Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre Randomised Placebo Controlled Trial.
Ann. Rheum. Dis. 67: 1516-1523 (2008).
-
Emery P, Seto Y. Role of biologics in early arthritis.
Clin. Exp. Rheumatol. 21 (5 Suppl. 31): S191-S194 (2003).
-
Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfa E. Immunogenicity of anti-TNF-alpha agents in autoimmune diseases.
Clin. Rev. Allergy Immunol. Jun 30 [Epub ahead of print] (2009).
*
-
Emily M, Mailund T, Hein J, Schauser L, Schierup MH. Using biological networks to search for interacting loci in genome-wide association studies.
Eur. J. Hum. Genet. 17: 1231-1240 (2009).
-
Emlakcioglu E, Ozcakar L, Kaymak B, Bayraktar Y, Akinci A. Arthritis due to Wilson disease, penicillamine, psoriasis or hepatocellular carcinoma? Blurred focus, sharp boundaries.
Acta Reumatol. Port. 34: 685-686 (2009).
-
Endres M. Statins: potential new indications in inflammatory conditions.
Atheroscler. Suppl. 7: 31-35 (2006).
-
Enevold C, Radstake TR, Coenen MJ, Fransen J, Toonen EJ, Bendtzen K, L C M van Riel P. Multiplex screening of 22 single-nucleotide polymorphisms in 7 Toll-like receptors: an association study in rheumatoid arthritis.
J. Rheumatol. Mar 1 [Epub ahead of print] (2010).
-
Engel SH, Hullar TE, Adkins DR, Thorstad WL, Sunwoo JB. Temporal relationship between antitumor necrosis factor-alpha antibody therapy and recrudescence of head and neck squamous cell carcinoma.
Laryngoscope 118: 450-452 (2008).
-
Englbrecht M, Wang Y, Ronneberger M, Manger B, Vastesaeger N, Veale DJ, Schett G. Measuring joint involvement in polyarticular psoriatic arthritis - an introduction of alternatives.
Arthritis Care Res. (Hoboken) Feb 26 [Epub ahead of print] (2010).
-
Engler J, Paul H, Gamardo J, Rodriguez MA. Acute synovitis, fever and rash possibly caused by metallic debris from a loosened knee prosthesis in a patient with rheumatoid arthritis.
J. Clin. Rheumatol. 7: 257-260 (2001).
-
English PL, Vender R. Occurrence of plantar pustular psoriasis during treatment with infliximab.
J. Cutan. Med. Surg. 13: 40-42 (2009).
-
Enlow RW, Bias WB, Arnett FC. The spondylitis of inflammatory bowel disease. Evidence for a non-HLA linked axial arthropathy.
Arthritis Rheum. 23: 1359-1365 (1980).
-
Ensari C, Ensari A, Tumer N, Ertug E. Clinicopathological and epidemiological analysis of amyloidosis in Turkish patients.
Nephrol. Dial. Transplant. 20: 1721-1725 (2005).
*
-
Enzenauer RJ, West SG. Sarcoidosis in autoimmune disease.
Semin. Arthritis Rheum. 22: 1-17 (1992).
-
Eppinger S, Schmitt J, Meurer M. Reiter disease or reactive arthritis?
Hautarzt. 57: 336-339 (2006).
-
Epstein O, Ajdukiewicz AB, Dick R, Sherlock S. Hypertrophic hepatic osteoarthropathy. Clinical, roentgenologic, biochemical, hormonal and cardiorespiratory studies, and review of the literature.
Am. J. Med. 67: 88-97 (1979).
-
Erbay SK, Stewart C, Hassanein A, Fletcher A, Bhattacharyya I, Cohen D, Wesson SK, Weinstein J, Lyons R, Reeves WH. Cutaneous mastocytosis in a patient with primary Sjogren's syndrome.
J. Rheumatol. 33: 1697-1700 (2006).
-
Erdei A, Isaak A, Torok K, Sandor N, Kremlitzka M, Prechl J, Bajtay Z. Expression and role of CR1 and CR2 on B and T lymphocytes under physiological and autoimmune conditions.
Mol. Immunol. 46: 2767-2773 (2009).
*
-
Erdem H, Pay S, Musabak U, Simsek I, Dinc A, Pekel A, Sengul A. Synovial angiostatic non-ELR CXC chemokines in inflammatory arthritides: does CXCL4 designate chronicity of synovitis?
Rheumatol. Int. 27: 969-973 (2007).
*
-
Erdem H, Pay S, Serdar M, Simsek I, Dinc A, Musabak U, Pekel A, Turan M. Different ELR (+) angiogenic CXC chemokine profiles in synovial fluid of patients with Behcet's disease, familial Mediterranean fever, rheumatoid arthritis, and osteoarthritis.
Rheumatol. Int. 26: 162-167 (2005).
*
-
Erer B, Yilmaz G, Yilmaz FM, Koklu S. Assessment of adenosine deaminase levels in rheumatoid arthritis patients receiving anti-TNF-alpha therapy.
Rheumatol. Int. 29: 651-654 (2009).
*
-
Ergas D, Eilat E, Mendlovic S, Sthoeger ZM. n-3 Fatty acids and the immune system in autoimmunity.
Isr. Med. Assoc. J. 4: 34-38 (2002).
*
-
Erickson AR, Mikuls TR. Switching anti-TNF-alpha agents: what is the evidence?
Curr. Rheumatol. Rep. 9: 416-420 (2007).
-
Eriksson P, Andersson C, Ekerfelt C, Ernerudh J, Skogh T. Relationship between serum levels of IL-18 and IgG1 in patients with primary Sjogren's syndrome, rheumatoid arthritis and healthy controls.
Clin. Exp. Immunol. 137: 617-620 (2004).
*
-
Eriksson P, Andersson C, Ekerfelt C, Ernerudh J, Skogh T. Sjogren's syndrome with myalgia is associated with subnormal secretion of cytokines by peripheral blood mononuclear cells.
J. Rheumatol. 31: 729-735 (2004).
-
Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, Unalp-Arida A, Vilela V, Yazici Y, Lockshin MD. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals.
Arthritis Rheum. 56: 2382-2391 (2007).
*
-
Ernandez T, Mayadas T. Immunoregulatory role of TNFalpha in inflammatory kidney diseases.
Kidney Int. 76: 262-276 (2009).
*
-
Ernestam S, Af Klint E, Catrina AI, Sundberg E, Engstrom M, Klareskog L, Ulfgren AK. Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor.
Arthritis Res. Ther. 8: R18 (2005).
*
-
Ernestam S, Hafstrom I, Werner S, Carlstrom K, Tengstrand B. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
J. Rheumatol. 34: 1451-1458 (2007).
-
Ernst E. Frankincense: systematic review.
BMJ 337: a2813 (2008).
-
Erridge C, Spickett CM. Oxidised phospholipid regulation of Toll-like receptor signalling.
Redox Rep. 12: 76-80 (2007).
-
Ershler WB, Chen K, Reyes EB, Dubois R. Economic burden of patients with anemia in selected diseases.
Value Health 8: 629-638 (2005).
-
Eschbach JW. Iron requirements in erythropoietin therapy.
Best Pract. Res. Clin. Haematol. 18: 347-361 (2005).
-
Esdaile JM, Dwosh IL, Urowitz MB, Smythe HA, Falk J. HLA B27 in rheumatoid factor-negative polyarthritis.
Ann. Intern. Med. 86: 699-702 (1977).
-
Esensten JH, Wofsy D, Bluestone JA. Regulatory T cells as therapeutic targets in rheumatoid arthritis.
Nat. Rev. Rheumatol. 5: 560-565 (2009).
-
Eshkar Sebban L, Ronen D, Levartovsky D, Elkayam O, Caspi D, Aamar S, Amital H, Rubinow A, Golan I, Naor D, Zick Y, Golan I. The involvement of CD44 and its novel ligand galectin-8 in apoptotic regulation of autoimmune inflammation.
J. Immunol. 179: 1225-1235 (2007).
*
-
Eshuis EJ, Bemelman WA, Stokkers PC. Infliximab for the treatment of ulcerative colitis.
Expert Rev. Gastroenterol. Hepatol. 3: 219-229 (2009).
-
Eskandari F, Webster JI, Sternberg EM. Neural immune pathways and their connection to inflammatory diseases.
Arthritis Res. Ther. 5: 251-265 (2003).
*
-
Espinosa G, Cervera R. Antiphospholipid syndrome.
Arthritis Res. Ther. 10: 230 (2008).
*
-
Espinosa G, Mendizabal A, Minguez S, Ramo-Tello C, Capellades J, Olive A, Cervera R. Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients.
Semin. Arthritis Rheum. Nov 18 [Epub ahead of print] (2008).
*
-
Esposito E, Cuzzocrea S. TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma.
Curr. Med. Chem. 16: 3152-3167 (2009).
-
Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S. Treatment of erythrodermic psoriasis with etanercept.
Br. J. Dermatol. 155: 156-159 (2006).
*
-
Essakalli M, Brick C, Bennani N, Benseffaj N, Ouadghiri S, Atouf O. The latest TH17 lymphocyte in the family of T CD4+ lymphocytes.
Pathol. Biol. (Paris) Mar 17 [Epub ahead of print] (2009).
-
Esser AC, Abril A, Fayne S, Doyle JA. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab.
J. Am. Acad. Dermatol. 50: 75S-77S (2004).
-
Estradas J, Pascual-Ramos V, Martinez B, Uribe M, Torre A. Autoimmune hepatitis with giant-cell transformation.
Ann. Hepatol. 8: 68-70 (2009).
*
-
Ettinger R, Kuchen S, Lipsky PE. The role of IL-21 in regulating B-cell function in health and disease.
Immunol. Rev. 223: 60-86 (2008).
*
-
Ettinger R, Kuchen S, Lipsky PE. Interleukin 21 as a target of intervention in autoimmune disease.
Ann. Rheum. Dis. 67 Suppl. 3: iii83-iii86 (2008).
-
Etzel CJ, Chen WV, Shepard N, Jawaheer D, Cornelis F, Seldin MF, Gregersen PK, Amos CI; for the North American Rheumatoid Arthritis Consortium. Genome-wide meta-analysis for rheumatoid arthritis.
Hum. Genet. 119: 634-641 (2006).
*
-
Euler AR, Ament ME. Crohn's disease - a cause of arthritis, oxalate stones and fistulae in cystic fibrosis.
West. J. Med. 125: 315-317 (1976).
-
Eustace N, O'hare B. Use of nonsteroidal anti-inflammatory drugs in infants. A survey of members of the Association of Paediatric Anaesthetists of Great Britain and Ireland.
Paediatr. Anaesth. 17: 464-469 (2007).
-
Evangelou E, Chapman K, Meulenbelt I, Karassa FB, Loughlin J, Carr A, Doherty M, Doherty S, Gomez-Reino JJ, Gonzalez A, Halldorsson BV, Hauksson VB, Hofman A, Hart DJ, Ikegawa S, Ingvarsson T, Jiang Q, Jonsdottir I, Jonsson H, Kerkhof HJ, et al. Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand.
Arthritis Rheum. 60: 1710-1721 (2009).
*
-
Evans CH. Gene therapy: what have we accomplished and where do we go from here?
J. Rheumatol. Suppl. 72: 17-20 (2005).
-
Evans CH, Ghivizzani SC, Gouze E, Rediske JJ, Schwarz EM, Robbins PD. The 3rd International Meeting on Gene Therapy in Rheumatology and Orthopaedics.
Arthritis Res. Ther. 7: 273-278 (2005).
*
-
Evans CH, Ghivizzani SC, Robbins PD. Will arthritis gene therapy become a clinical reality?
Nat. Clin. Pract. Rheumatol. 2: 344-345 (2006).
*
-
Evans CH, Ghivizzani SC, Robbins PD. Gene therapy for arthritis: what next?
Arthritis Rheum. 54: 1714-1729 (2006).
*
-
Evans CH, Robbins PD, Ghivizzani SC, Wasko MC, Tomaino MM, Kang R, Muzzonigro TA, Vogt M, Elder EM, Whiteside TL, Watkins SC, Herndon JH. Gene transfer to human joints: progress toward a gene therapy of arthritis.
Proc. Natl. Acad. Sci. U.S.A. 102: 8698-8703 (2005).
*
-
Evans HG, Gullick NJ, Kelly S, Pitzalis C, Lord GM, Kirkham BW, Taams LS. In vivo activated monocytes from the site of inflammation in humans specifically promote Th17 responses.
Proc. Natl. Acad. Sci. U.S.A. 106: 6232-6237 (2009).
*
-
Evans J, Reuben A, Craft J. PBC 95k, a 95-kilodalton nuclear autoantigen in primary biliary cirrhosis.
Arthritis Rheum. 34: 731-736 (1991).
-
Evans JG, Chavez-Rueda KA, Eddaoudi A, Meyer-Bahlburg A, Rawlings DJ, Ehrenstein MR, Mauri C. Novel suppressive function of transitional 2 B cells in experimental arthritis.
J. Immunol. 178: 7868-7878 (2007).
*
-
Evans TI, Han J, Singh R, Moxley G. The genotypic distribution of shared-epitope DRB1 alleles suggests a recessive mode of inheritance of the rheumatoid arthritis disease-susceptibility gene.
Arthritis Rheum. 38: 1754-1761 (1995).
-
Evensen KJ, Swaak TJ, Nossent JC. Increased ferritin response in adult Still's disease: specificity and relationship to outcome.
Scand. J. Rheumatol. 36: 107-110 (2007).
-
Evereklioglu C. Managing the symptoms of Behcet's disease.
Expert Opin. Pharmacother. 5: 317-328 (2004).
-
Exarchou S, Voulgari P, Markatseli T, Zioga A, Drosos A. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.
Scand. J. Rheumatol. Jul 4 [Epub ahead of print] (2009).
*
-
Eyles JL, Roberts AW, Metcalf D, Wicks IP. Granulocyte colony-stimulating factor and neutrophils-forgotten mediators of inflammatory disease.
Nat. Clin. Pract. Rheumatol. 2: 500-510 (2006).
*
-
Eyre S, Barton A, Shephard N, Hinks A, Brintnell W, MacKay K, Silman A, Ollier W, Wordsworth P, John S, Worthington J. Investigation of susceptibility loci identified in the UK rheumatoid arthritis whole-genome scan in a further series of 217 UK affected sibling pairs.
Arthritis Rheum. 50: 729-735 (2004).
*
-
Eyre S, Bowes J, Potter C, Worthington J, Barton A. Association of the FCRL3 gene with RA: a further example of population specificity?
Arthritis Res. Ther. 8: R117 (2006).
*
-
Eyre S, Bowes J, Spreckley K, Potter C, Ring S, Strachan D, Worthington J, Barton A. Investigation of the MHC2TA gene, associated with rheumatoid arthritis in a Swedish population, in a UK rheumatoid arthritis cohort.
Arthritis Rheum. 54: 3417-3422 (2006).
*
-
Faber C, Morbach H, Singh SK, Girschick HJ. Differential expression patterns of recombination activating genes in individual mature B cells in juvenile idiopathic arthritis.
Ann. Rheum. Dis. 65: 1351-1356 (2006).
*
-
Fabre S, Dupuy AM, Dossat N, Guisset C, Cohen JD, Cristol JP, Daures JP, Jorgensen C. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis.
Clin. Exp. Immunol. 153: 188-195 (2008).
*
-
Fahling M, Steege A, Perlewitz A, Nafz B, Mrowka R, Persson PB, Thiele BJ. Role of nucleolin in posttranscriptional control of MMP-9 expression.
Biochim. Biophys. Acta 1731: 32-40 (2005).
*
-
Fairhurst AM, Wallace PK, Jawad AS, Goulding NJ. Rheumatoid peripheral blood phagocytes are primed for activation but have impaired Fc mediated reactive oxygen species generation.
Arthritis Res. Ther. 9: R29 (2007).
*
-
Falagas ME, Zarkadoulia E, Rafailidis PI. The therapeutic effect of balneotherapy: evaluation of the evidence from randomised controlled trials.
Int. J. Clin. Pract. 63: 1068-1084 (2009).
-
Fall N, Bove KE, Stringer K, Lovell DJ, Brunner HI, Weiss J, Higgins GC, Bowyer SL, Graham TB, Thornton S, Grom AA. Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy.
Arthritis Rheum. 52: 3175-3180 (2005).
*
-
Fallahi GH, Moazzami K, Tabatabaeiyan M, Zamani MM, Asgar-Shirazi M, Najafi M, Motamed F, Farahmand F, Khodad A, Khatami GR, Rezaei N. Clinical characteristics of Iranian pediatric patients with inflammatory bowel disease.
Acta Gastroenterol. Belg. 72: 230-234 (2009).
-
Falta MT, Fontenot AP, Rosloniec EF, Crawford F, Roark CL, Bill J, Marrack P, Kappler J, Kotzin BL. Class II major histocompatibility complex-peptide tetramer staining in relation to functional avidity and T cell receptor diversity in the mouse CD4+ T cell response to a rheumatoid arthritis-associated antigen.
Arthritis Rheum. 52: 1885-1896 (2005).
*
-
Fam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions.
Arthritis Rheum. 44: 231-238 (2001).
*
-
Fam AG, Lewtas J, Stein J, Paton TW. Desensitization to allopurinol in patients with gout and cutaneous reactions.
Am. J. Med. 93: 299-302 (1992).
-
Fan J, Shi D, Dai J, Zhu L, Qin J, Shao Z, Qiu X, Xu Z, Chen D, Jiang Q. Genetic polymorphism of PITX1 in susceptibility to knee osteoarthritis in a Chinese Han population: a case-control study.
Rheumatol. Int. Jan 7 [Epub ahead of print] (2010).
*
-
Fan JH, Gao LB, Pan XM, Li C, Liang WB, Liu J, Li Y, Zhang L. Association between IRF-5 polymorphisms and risk of acute coronary syndrome.
DNA Cell Biol. Sep 24 [Epub ahead of print] (2009).
-
Fan LY, Wang WJ, Wang Q, Zong M, Yang L, Zhang H, Sun LS, Lu TB, Han J. A functional haplotype and expression of the PADI4 gene associated with increased rheumatoid arthritis susceptibility in Chinese.
Tissue Antigens 72: 469-473 (2008).
*
-
Fan PT, Leong KH. The use of biological agents in the treatment of rheumatoid arthritis.
Ann. Acad. Med. Singapore 36: 128-127 (2007).
-
Fan X, Patera AC, Pong-Kennedy A, Deno G, Gonsiorek W, Manfra DJ, Vassileva G, Zeng M, Jackson C, Sullivan L, Sharif-Rodriguez W, Opdenakker G, Van Damme J, Hedrick JA, Lundell D, Lira SA, Hipkin RW. Murine CXCR1 is a functional receptor for GCP-2/CXCL6 and interleukin-8/CXCL8.
J. Biol. Chem. 282: 11658-11666 (2007).
*
-
Fan X, Yang S, Sun LD, Liang YH, Gao M, Zhang KY, Huang W, Zhang X. Comparison of clinical features of HLA-Cw*0602-positive and -negative psoriasis patients in a Han Chinese population.
Acta Derm. Venereol. 87: 335-340 (2007).
*
-
Fanet-Goguet M, Martin S, Fernandez C, Fautrel B, Bourgeois P. Focus on biological agents in rheumatoid arthritis: newer treatments and therapeutic strategies.
Therapie 59: 451-461 (2004).
-
Fang YZ, Yang S, Wu G. Free radicals, antioxidants, and nutrition.
Nutrition 18: 872-879 (2002).
*
-
Fantuzzi F, Del Giglio M, Gisondi P, Girolomoni G. Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis.
Expert Opin. Ther. Targets 12: 1085-1096 (2008).
-
Fantuzzi G. Adiponectin and inflammation: consensus and controversy.
J. Allergy Clin. Immunol. 121: 326-330 (2008).
*
-
Faour WH, Alaaeddine N, Mancini A, He QW, Jovanovic D, Di Battista JA. Early growth response factor-1 mediates prostaglandin E2-dependent transcriptional suppression of cytokine-induced tumor necrosis factor-alpha gene expression in human macrophages and rheumatoid arthritis-affected synovial fibroblasts.
J. Biol. Chem. 280: 9536-9546 (2005).
*
-
Faour WH, He Q, Mancini A, Jovanovic D, Antoniou J, Di Battista JA. Prostaglandin E2 stimulates p53 transactivational activity through specific serine 15 (ser15) phosphorylation in human synovial fibroblasts (HSF): role in suppression of c/EBP/NF-kappa B mediated Erk kinase kinase (MERKK)1-induced MMP-1 expression.
J. Biol. Chem. 281: 19849-19860 (2006).
*
-
Farago B, Magyari L, Safrany E, Csongei V, Jaromi L, Horvatovich K, Sipeky C, Maasz A, Radics J, Gyetvai A, Szekanecz Z, Czirjak L, Melegh B. Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis.
Ann. Rheum. Dis. 67: 248-250 (2008).
-
Farago B, Talian GC, Komlosi K, Nagy G, Berki T, Gyetvai A, Szekanecz Z, Nyarady Z, Kiss CG, Nemeth P, Czirjak L, Melegh B. Protein tyrosine phosphatase gene C1858T allele confers risk for rheumatoid arthritis in Hungarian subjects.
Rheumatol. Int. 29: 793-796 (2009).
*
-
Farahani P, Levine M, Gaebel K, Wang EC, Khalidi N. Community-based evaluation of etanercept in patients with rheumatoid arthritis.
J. Rheumatol. 33: 665-670 (2006).
-
Farber L, Haus U, Spath M, Drechsler S. Physiology and pathophysiology of the 5-HT3 receptor.
Scand. J. Rheumatol. Suppl. 119: 2-8 (2004).
-
Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J, Ouyang J, Kozak T, Moore J, Kotter I, Chesnel V, Marmont A, Gratwohl A, Saccardi R. Autologous hematopoietic stem cell transplantation (HSCT) for autoimmune diseases: an observational study on 12 years of experience from the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Autoimmune Diseases.
Haematologica Sep 22 [Epub ahead of print] (2009).
*
-
Faria AM, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases.
Clin. Dev. Immunol. 13: 143-157 (2006).
*
-
Faria AM, Weiner HL. Oral tolerance.
Immunol. Rev. 206: 232-259 (2005).
*
-
Farmer PK, He X, Schmitz ML, Rubin J, Nanes MS. Inhibitory effect of NF-kappaB on 1,25-dihydroxyvitamin D(3) and retinoid X receptor function.
Am. J. Physiol. Endocrinol. Metab. 279: E213-E220 (2000).
*
-
Farouk HM, Mansour HE, Rahman SA, Mostafa AA, Shamy HA, Zarouk WA. Effect of the human leukocyte antigen HLA-DRB1 and anti-cyclic citrullinated peptide on the outcome of rheumatoid arthritis patients.
Braz. J. Med. Biol. Res. 42: 831-838 (2009).
*
-
Farr M, Kitas GD, Tunn EJ, Bacon PA. Immunodeficiencies associated with sulphasalazine therapy in inflammatory arthritis.
Br. J. Rheumatol. 30: 413-417 (1991).
-
Farragher TM, Goodson NJ, Naseem H, Silman AJ, Thomson W, Symmons D, Barton A. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis.
Arthritis Rheum. 58: 359-369 (2008).
*
-
Farzaneh-Far A, Roman MJ, Lockshin MD, Devereux RB, Paget SA, Crow MK, Davis A, Sammaritano L, Levine DM, Salmon JE. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus.
Arthritis Rheum. 54: 3918-3925 (2006).
*
-
Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, Davis HM, Zhou H. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis.
Eur. J. Clin. Pharmacol. Sep 16 [Epub ahead of print] (2009).
*
-
Fasano A. Surprises from celiac disease.
Sci. Am. 301: 54-61 (2009).
-
Fasth AE, Bjorkstrom NK, Anthoni M, Malmberg KJ, Malmstrom V. Activating NK cell receptors co-stimulate CD4+CD28- T cells in patients with rheumatoid arthritis.
Eur. J. Immunol. Nov 10 [Epub ahead of print] (2009).
*
-
Fathalla BM, Goldsmith DP, Pascasio JM, Baldridge A. Development of autoimmune hepatitis in a child with systemic-onset juvenile idiopathic arthritis during therapy with etanercept.
J. Clin. Rheumatol. 14: 297-298 (2008).
-
Fathalla BM, Miller L, Brady S, Schaller JG. Cutaneous polyarteritis nodosa in children.
J. Am. Acad. Dermatol. 53: 724-728 (2005).
-
Fathi NA, Ezz-Eldin AM, Mosad E, Bakry RM, Hamed HB, Ahmed S, Mahmoud M, Rashed HA, Abdullah F. Diagnostic performance and predictive value of rheumatoid factor, anti- cyclic -citrullinated peptide antibodies and HLA-DRB1 locus genes in rheumatoid arthritis.
Int. Arch. Med. 1: 20 (2008).
*
-
Fauchais AL, Boumediene A, Lalloue F, Gondran G, Loustaud-Ratti V, Vidal E, Jauberteau MO. Brain-derived neurotrophic factor and nerve growth factor correlate with T-cell activation in primary Sjogren's syndrome.
Scand. J. Rheumatol. 38: 50-57 (2009).
-
Faucheron JL, Sani R, Zeid M, Duprez D, Rolachon A. Ileal and right colonic strictures due to prolonged non steroidal anti-inflammatory drug intake.
Gastroenterol. Clin. Biol. 30: 1221-1223 (2006).
-
Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.
Drugs 45: 953-1040 (1993).
-
Faustini F, Zoli A, Ferraccioli GF. Immunologic and genetic links between spondylarthropathies and inflammatory bowel diseases.
Eur. Rev. Med. Pharmacol. Sci. 13 Suppl. 1: 1-9 (2009).
-
Fautrel B, Benhamou M. Chronic inflammatory disorders and reproduction.
Gynecol. Obstet. Fertil. 35: 848-852 (2007).
-
Fautrel B, Flipo RM, Saraux A. Eligibility of rheumatoid arthritis patients for anti-TNF-alpha therapy according to the 2005 recommendations of the French and British Societies for Rheumatology.
Rheumatology (Oxford) 47: 1698-1703 (2008).
*
-
Fautrel B, Guillemin F, Meyer O, de Bandt M, Berthelot JM, Flipo RM, Liote F, Maillefert JF, Wendling D, Saraux A, Combe B, Le Loet X. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
Arthritis Rheum. 61: 425-434 (2009).
*
-
Fearon U, Mullan R, Markham T, Connolly M, Sullivan S, Poole AR, Fitzgerald O, Bresnihan B, Veale DJ. Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures.
Arthritis Rheum. 54: 3152-3162 (2006).
*
-
Federman DG, Kravetz JD, Ruser CB, Judson PH, Kirsner RS. Vogt-Koyanagi-Harada syndrome and ulcerative colitis.
South. Med. J. 97: 169-171 (2004).
-
Federman DG, Shelling M, Prodanovich S, Gunderson CG, Kirsner RS. Psoriasis: an opportunity to identify cardiovascular risk.
Br. J. Dermatol. 160: 1-7 (2009).
*
-
Fedetz M, Ndagire D, Fernandez O, Leyva L, Guerrero M, Arnal C, Lucas M, Izquierdo G, Delgado C, Alcina A, Matesanz F. Multiple sclerosis association study with the TENR-IL2-IL21 region in a Spanish population.
Tissue Antigens 74: 244-247 (2009).
*
-
Feghali-Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies.
Arthritis Rheum. 48: 1956-1963 (2003).
*
-
Feher J, Lengyel G. The effectivity and safety of the biological therapy with adalimumab.
Orv. Hetil. 150: 1215-1222 (2009).
-
Fei Y, Webb R, Cobb BL, Direskeneli H, Saruhan-Direskeneli G, Sawalha AH. Identification of novel genetic susceptibility loci for Behcet's disease using a genome-wide association study.
Arthritis Res. Ther. 11: R66 (2009).
*
-
Feist E, Burmester GR. Citrullinated antigens: just diagnostic tools or pathogenic targets in rheumatoid arthritis?
J. Rheumatol. 33: 2103-2134 (2006).
-
Feist E, Egerer K, Burmester GR. Autoantibody profile in rheumatoid arthritis.
Z. Rheumatol. 66: 212-218 (2007).
-
Feito JG, Pereda CA. Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists.
J. Clin. Rheumatol. 15: 363-365 (2009).
-
Feitsma AL, Toes RE, Begovich AB, Chokkalingam AP, de Vries RR, Huizinga TW, van der Helm-van Mil AH. Risk of progression from undifferentiated arthritis to rheumatoid arthritis: the effect of the PTPN22 1858T-allele in anti-citrullinated peptide antibody positive patients.
Rheumatology (Oxford) 46: 1092-1095 (2007).
*
-
Feitsma AL, van der Voort EI, Franken KL, El Bannoudi H, Elferink BG, Drijfhout JW, Huizinga TW, de Vries RR, Toes RE, Ioan-Facsinay A. Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis.
Arthritis Rheum. 62: 117-125 (2009).
*
-
Feitsma AL, Worthington J, van der Helm-van Mil AH, Plant D, Thomson W, Ursum J, van Schaardenburg D, van der Horst-Bruinsma IE, van Rood JJ, Huizinga TW, Toes RE, de Vries RR. Protective effect of noninherited maternal HLA-DR antigens on rheumatoid arthritis development.
Proc. Natl. Acad. Sci. U.S.A. 104: 19966-19970 (2007).
*
-
Feizy V, Ghobadi A. Atopic dermatitis and systemic autoimmune diseases: a descriptive cross sectional study.
Dermatol. Online J. 12: 3 (2006).
*
-
Feki M, Houman H, Ghannouchi M, Smiti-Khanfir M, Hamzaoui K, Matri LE, Mebazaa A, Kaabachi N. Hyperhomocysteinaemia is associated with uveitis but not with deep venous thrombosis in Behcet's disease.
Clin. Chem. Lab. Med. 42: 1417-1423 (2004).
-
Felaco P, Castellani ML, De Lutiis MA, Felaco M, Pandolfi F, Salini V, De Amicis D, Vecchiet J, Tete S, Ciampoli C, Conti F, Cerulli G, Caraffa A, Antinolfi P, Cuccurullo C, Perrella A, Theoharides TC, Conti P, Toniato E, Kempuraj D, Shaik YB. IL-32: a newly-discovered proinflammatory cytokine.
J. Biol. Regul. Homeost. Agents 23: 141-147 (2009).
-
Feld J, Weiss G, Rosner I, Rozenbaum M, Laor A, Rimar D, Eder L, Bitterman H, Zisman D. Electrocardiographic findings in psoriatic arthritis: a case-controlled study.
J. Rheumatol. 35: 2379-2382 (2008).
-
Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, Li S, Dooley LT, Menter A. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
Br. J. Dermatol. 159: 704-710 (2008).
*
-
Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis.
Nat. Rev. Immunol. 2: 364-371 (2002).
*
-
Feldmann M. Translating molecular insights in autoimmunity into effective therapy.
Annu. Rev. Immunol. 27: 1-27 (2009).
*
-
Feldmann M, Brennan FM, Foxwell BM, Taylor PC, Williams RO, Maini RN. Anti-TNF therapy: where have we got to in 2005?
J. Autoimmun. 25: S26-S28 (2005).
-
Feldmann M, Brennan FM, Paleolog E, Cope A, Taylor P, Williams R, Woody J, Maini RN. Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?
Novartis Found. Symp. 256: 53-69 (2004).
-
Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
Annu. Rev. Immunol. 19: 163-196 (2001).
*
-
Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics.
Immunol. Rev. 223: 7-19 (2008).
*
-
Feldmann M, Pusey CD. Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases.
J. Am. Soc. Nephrol. 17: 1243-1252 (2006).
*
-
Feldmann M, Williams RO, Paleolog E. What have we learnt from targeted anti-TNF therapy?
Ann. Rheum. Dis. 69 Suppl. 1: i97-i99 (2010).
-
Feldstein AC, Elmer PJ, Nichols GA, Herson M. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis.
Osteoporos. Int. 16: 2168-2174 (2005).
*
-
Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis.
Rheumatol. Int. 23: 61-66 (2003).
*
-
Feletar M, Brockbank JE, Schentag CT, Lapp V, Gladman DD. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients.
Ann. Rheum. Dis. 63: 156-161 (2004).
*
-
Felici E, Novarini C, Magni-Manzoni S, Pistorio A, Magnani A, Bozzola E, Buoncompagni A, Martini A, Ravelli A. Course of joint disease in patients with antinuclear antibody-positive juvenile idiopathic arthritis.
J. Rheumatol. 32: 1805-1810 (2005).
-
Felix FH, Leal LK, Fontenele JB. Cloak and dagger: the case for adult onset Still disease and hemophagocytic lymphohistiocytosis.
Rheumatol. Int. 29: 973-974 (2009).
*
-
Felizardo M, Gomes A, Sousa M, Teixeira A, Freitas J, Tavares A, Vaz Patto J, Gomes M. Immunosuppression and tuberculosis.
Rev. Port. Pneumol. 13: S23-S24 (2007).
-
Feng X, Wu H, Grossman JM, Hanvivadhanakul P, Fitzgerald JD, Park GS, Dong X, Chen W, Kim MH, Weng HH, Furst DE, Gorn A, McMahon M, Taylor M, Brahn E, Hahn BH, Tsao BP. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
Arthritis Rheum. 54: 2951-2962 (2006).
*
-
Feng XG, Ye S, Lu Y, Xu XJ, Gu YY, Shen N, Ye P, Cheng FP, Wang AM, Chen SL. Antikinectin autoantibody in Behcet's disease and several other autoimmune connective tissue diseases.
Clin. Exp. Rheumatol. 25: S80-S85 (2007).
-
Ferec C, Youinou P, Le Goff P, Miossec P, Morin JF, Pennec Y, Morin PP, Le Menn G. Significance of antinuclear anti-histone antibodies.
Ann. Med. Interne. (Paris) 135: 427-430 (1984).
-
Ferens-Sieczkowska M, Kossowska B, Gancarz R, Dudzik D, Knas M, Popko J, Zwierz K. Fucosylation in synovial fluid as a novel clinical marker for differentiating joint diseases - a preliminary study.
Clin. Exp. Rheumatol. 25: 92-95 (2007).
-
Ferini-Strambi L. RLS-like symptoms: differential diagnosis by history and clinical assessment.
Sleep Med. 8: S3-S6 (2007).
-
Ferlitsch A, Kummer F, Muller MM, Legenstein E, Haber P, Kohout J. Angiotensin converting enzyme (ACE) - a blood chemistry parameter in the diagnosis of sarcoidosis.
Acta Med. Austriaca 5: 171-174 (1978).
-
Fermor B, Christensen SE, Youn I, Cernanec JM, Davies CM, Weinberg JB. Oxygen, nitric oxide and articular cartilage.
Eur. Cell Mater. 13: 56-65 (2007).
*
-
Fernandes G, Bhattacharya A, Rahman M, Zaman K, Banu J. Effects of n-3 fatty acids on autoimmunity and osteoporosis.
Front. Biosci. 13: 4015-4020 (2008).
-
Fernandes PF, Junior GB, Barros FA, Sousa DC, Franco LM, Patrocinio RM. Behcet's disease and IgA nephropathy: report of this association in a patient from Brazil and literature review.
Invest. Clin. 47: 405-411 (2006).
-
Fernandes TA, Corrente JE, Magalhaes CS. Remission status follow-up in children with juvenile idiopathic arthritis.
J. Pediatr. (Rio J.) 83: 141-148 (2007).
-
Fernandez A, Maddipati S. A priori inference of cross reactivity for drug-targeted kinases.
J. Med. Chem. 49: 3092-3100 (2006).
*
-
Fernandez D, Bonilla E, Mirza N, Niland B, Perl A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus.
Arthritis Rheum. 54: 2983-2988 (2006).
*
-
Fernandez Lison LC, Vazquez Dominguez B, Luis Fernandez J, Moreno Alvarez P, Fruns Gimenez I, Liso Rubio J. Quality of life of patients with rheumatoid arthritis undergoing out-patient treatment with TNF inhibitors.
Farm. Hosp. 32: 178-181 (2008).
-
Fernandez M, Alarcon GS, Apte M, Andrade RM, Vila LM, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor.
Arthritis Rheum. 56: 614-621 (2007).
*
-
Fernandez M, Alarcon GS, Calvo-Alen J, Andrade R, McGwin G Jr, Vila LM, Reveille JD; LUMINA Study Group. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE.
Arthritis Rheum. 57: 576-584 (2007).
*
-
Fernandez P, Guillen MI, Gomar F, Aller E, Molina P, Alcaraz MJ. A novel cyclo-oxygenase-2 inhibitor modulates catabolic and antiinflammatory mediators in osteoarthritis.
Biochem. Pharmacol. 68: 417-421 (2004).
*
-
Fernandez-Blanco L, Perez-Pampin E, Gomez-Reino JJ, Gonzalez A. A CTLA-4 polymorphism associated with susceptibility to systemic lupus erythematosus.
Arthritis Rheum. 50: 328-329 (2004).
*
-
Fernandez-Castro M, Mellor-Pita S, Jesus Citores M, Munoz P, Tutor-Ureta P, Silva L, Antonio Vargas J, Yebra-Bango M, Luis Andreu J. Common variable immunodeficiency in systemic lupus erythematosus.
Semin. Arthritis Rheum. 36: 238-245 (2007).
*
-
Fernandez-Nebro A, Irigoyen MV, Urena I, Belmonte-Lopez MA, Coret V, Jimenez-Nunez FG, Diaz-Cordoves G, Lopez-Lasanta MA, Ponce A, Rodriguez-Perez M, Calero E, Gonzalez-Santos P. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
J. Rheumatol. 34: 2334-2342 (2007).
-
Fernandez-Suarez A, Reneses S, Wichmann I, Criado R, Nunez A. Efficacy of three ELISA measurements of anti-cyclic citrullinated peptide antibodies in the early diagnosis of rheumatoid arthritis.
Clin. Chem. Lab. Med. 43: 1234-1239 (2005).
*
-
Fernandez-Sueiro JL. The challenge and need of defining axial psoriatic arthritis.
J. Rheumatol. 36: 2633-2634 (2009).
-
Fernandez-Sueiro JL, Willisch A, Pertega-Diaz S, Tasende JA, Fernandez-Lopez JC, Villar NO, Galdo F, Blanco FJ. Validity of the bath ankylosing spondylitis disease activity index for the evaluation of disease activity in axial psoriatic arthritis.
Arthritis Care Res. (Hoboken) 62: 78-85 (2010).
-
Fernando MM, Stevens CR, Walsh EC, De Jager PL, Goyette P, Plenge RM, Vyse TJ, Rioux JD. Defining the role of the MHC in autoimmunity: a review and pooled analysis.
PLoS Genet. 4: e1000024 (2008).
*
-
Ferraccioli G. Biologic therapy with anti-TNFalpha in rheumathoid atrhritis.
Reumatismo 57: S17-S21 (2005).
-
Ferraccioli G, Tolusso B. Infections, B cell receptor activation and autoimmunity: different check-point impairments lead to autoimmunity, clonal B cell expansion and fibrosis in different immunological settings.
Autoimmun. Rev. 7: 109-113 (2007).
-
Ferraccioli G, Zoli A, Alivernini S, De Santis M, Verrillo A, Loperfido F. Lupus anticoagulant and ischemic myocardial microangiopathy in rheumatoid arthritis.
Nat. Clin. Pract. Cardiovasc. Med. 3: 339-343 (2006).
*
-
Ferrandi C, Ardissone V, Ferro P, Ruckle T, Zaratin P, Ammannati E, Hauben E, Rommel C, Cirillo R. Phosphoinositide 3-kinase gamma inhibition plays a crucial role in early steps of inflammation by blocking neutrophil recruitment.
J. Pharmacol. Exp. Ther. 322: 923-930 (2007).
*
-
Ferrari-Lacraz S, Zanelli E, Neuberg M, Donskoy E, Kim YS, Zheng XX, Hancock WW, Maslinski W, Li XC, Strom TB, Moll T. Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis.
J. Immunol. 173: 5818-5826 (2004).
*
-
Ferreira AC, Almeida S, Tavares M, Canedo P, Pereira F, Regalo G, Figueiredo C, Trindade E, Seruca R, Carneiro F, Amil J, Machado JC, Tavarela-Veloso F. NOD2/CARD15 and TNFA, but not IL1B and IL1RN, are associated with Crohn's disease.
Inflamm. Bowel Dis. 11: 331-339 (2005).
*
-
Ferreiros-Vidal I, Barros F, Pablos JL, Carracedo A, Gomez-Reino JJ, Gonzalez A. CARD15/NOD2 analysis in rheumatoid arthritis susceptibility.
Rheumatology (Oxford) 42: 1380-1382 (2003).
*
-
Ferreiros-Vidal I, Gomez-Reino JJ, Barros F, Carracedo A, Carreira P, Gonzalez-Escribano F, Liz M, Martin J, Ordi J, Vicario JL, Gonzalez A. Association of PDCD1 with susceptibility to systemic lupus erythematosus: evidence of population-specific effects.
Arthritis Rheum. 50: 2590-2597 (2004).
*
-
Ferrera F, Cava AL, Rizzi M, Hahn BH, Indiveri F, Filaci G. Gene vaccination for the induction of immune tolerance.
Ann. N. Y. Acad. Sci. 1110: 99-111 (2007).
*
-
Ferrera F, Hahn BH, Rizzi M, Anderson M, Fitzgerald J, Millo E, Indiveri F, Shi FD, Filaci G, La Cava A. Protection against renal disease in (NZB x NZW)F(1) lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide.
Arthritis Rheum. 56: 1945-1953 (2007).
*
-
Ferretti M, Gassner R, Wang Z, Perera P, Deschner J, Sowa G, Salter RB, Agarwal S. Biomechanical signals suppress proinflammatory responses in cartilage: early events in experimental antigen-induced arthritis.
J. Immunol. 177: 8757-8766 (2006).
*
-
Ferretti M, Gattorno M, Chiocchetti A, Mesturini R, Orilieri E, Bensi T, Sormani MP, Cappellano G, Cerutti E, Nicola S, Biava A, Bardelli C, Federici S, Ceccherini I, Baldi M, Santoro C, Dianzani I, Martini A, Dianzani U. The 423Q polymorphism of the X-linked inhibitor of apoptosis gene influences monocyte function and is associated with periodic fever.
Arthritis Rheum. 60: 3476-3484 (2009).
*
-
Ferri C. Mixed cryoglobulinemia.
Orphanet J. Rare Dis. 3: 25 (2008).
*
-
Ferri C, Ferraccioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, Triolo G, Valentini G, Valesini G. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.
J. Rheumatol. 35: 1944-1949 (2008).
-
Fert I, Glatigny S, Poulain C, Satumtira N, Dorris ML, Taurog JD, Breban M. Correlation between dendritic cell functional defect and spondylarthritis phenotypes in HLA-B27/human beta(2)-microglobulin-transgenic rat lines.
Arthritis Rheum. 58: 3425-3429 (2008).
*
-
Ferucci ED, Templin DW, Lanier AP. Rheumatoid arthritis in American Indians and Alaska natives: a review of the literature.
Semin. Arthritis Rheum. 34: 662-667 (2005).
*
-
Festen EA, Goyette P, Scott R, Annese V, Zhernakova A, Brant SR, Cho JH, Silverberg MS, Taylor KD, de Jong DJ, Stokkers PC, McGovern D, Palmieri O, Achkar JP, Xavier RJ, Duerr RH, Daly MJ, Wijmenga C, Weersma RK, Rioux JD. Genetic variants in the region harbouring IL2/IL21 associated to ulcerative colitis.
Gut 58: 799-804 (2009).
*
-
Festenstein H, Awad J, Hitman GA, Cutbush S, Groves AV, Cassell P, Ollier W, Sachs JA. New HLA DNA polymorphisms associated with autoimmune diseases.
Nature 322: 64-67 (1986).
*
-
Fetterman JW Jr, Zdanowicz MM. Therapeutic potential of n-3 polyunsaturated fatty acids in disease.
Am. J. Health Syst. Pharm. 66: 1169-1179 (2009).
*
-
Feuchtenberger M, Kleinert S, Tony HP, Kneitz C. Psoriatic arthritis: therapeutic principles.
Clin. Dermatol. 26: 460-463 (2008).
-
Feuchtenberger M, Kneitz C, Roll P, Kleinert S, Tony HP. Sustained remission after combination therapy with rituximab and etanercept in two patients with rheumatoid arthritis after TNF failure: case report.
Open Rheumatol. J. 3: 9-13 (2009).
*
-
Feuchtenberger M, Kneitz C, Tony HP. Cytokines.
Z. Rheumatol. 66: 297-298, 300-303 (2007).
-
Feuchtenberger M, Kneitz C, Tony HP. Treatment of rheumatoid arthritis (RA) with anticytokines.
MMW Fortschr. Med. 148: 44-45, 47 (2006).
-
Feuchtenberger M, Muller S, Roll P, Waschbisch A, Schafer A, Kneitz C, Wiendl H, Tony HP. Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.
Open Rheumatol. J. 2: 81-88 (2008).
*
-
Fialho RN, Martins L, Pinheiro JP, Bettencourt BF, Couto AR, Santos MR, Peixoto MJ, Garrett F, Leal J, Tomas AM, Bruges-Armas J. Role of HLA, KIR and cytokine gene polymorphisms in leptospirosis.
Hum. Immunol. 70: 915-920 (2009).
-
Fida S, Myers MA, Whittingham S, Rowley MJ, Ozaki S, Mackay IR. Autoantibodies to the transcriptional factor SOX13 in primary biliary cirrhosis compared with other diseases.
J. Autoimmun. 19: 251-257 (2002).
*
-
Fiedorczyk M, Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J. Correlations between serum matrix metalloproteinase (MMP-1, MMP-3, MMP-9, MMP-13) concentrations and markers of disease activity in early rheumatoid arthritis.
Przegl. Lek. 62: 1321-1324 (2005).
-
Fiedorczyk M, Klimiuk PA, Sierakowski S, Kita K. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in the pathogenesis of rheumatoid arthritis.
Pol. Merkuriusz. Lek. 20: 228-231 (2006).
-
Fiehn C. Methotrexate in rheumatology.
Z. Rheumatol. 68: 747-756 (2009).
-
Fiehn C, Kessler S. Is the treatment response in elderly patients with rheumatoid arthritis diminished?: results of a prospective study over 3 months.
Z. Rheumatol. 68: 69-74 (2009).
-
Fietta P, Delsante G, Quaini F. Hematologic manifestations of connective autoimmune diseases.
Clin. Exp. Rheumatol. 27: 140-154 (2009).
-
Fife M, Steer S, Fisher S, Newton J, McKay K, Worthington J, Shah C, Polley A, Rosenthal A, Ollier W, Lewis C, Wordsworth P, Lanchbury J. Association of familial and sporadic rheumatoid arthritis with a single corticotropin-releasing hormone genomic region (8q12.3) haplotype.
Arthritis Rheum. 46: 75-82 (2002).
*
-
Fife MS, Fisher SA, John S, Worthington J, Shah CJ, Ollier WE, Panayi GS, Lewis CM, Lanchbury JS. Multipoint linkage analysis of a candidate gene locus in rheumatoid arthritis demonstrates significant evidence of linkage and association with the corticotropin-releasing hormone genomic region.
Arthritis Rheum. 43: 1673-1678 (2000).
*
-
Fife MS, Gathercole L, Ogilvie EM, Stock CJ, Mack LF, Donn RP, Thomson W, Woo P. No evidence for genetic association of interferon regulatory factor 1 in juvenile idiopathic arthritis.
Arthritis Rheum. 56: 972-976 (2007).
*
-
Fife MS, Gutierrez A, Ogilvie EM, Stock CJ, Samuel JM, Thomson W, Mack LF, Lewis CM, Woo P. Novel IL10 gene family associations with systemic juvenile idiopathic arthritis (sJIA).
Arthritis Res. Ther. 8: R148 (2006).
*
-
Fife MS, Ogilvie EM, Kelberman D, Samuel J, Gutierrez A, Humphries SE, Woo P. Novel IL-6 haplotypes and disease association.
Genes Immun. 6: 367-370 (2005).
*
-
Filer A, Raza K, Salmon M, Buckley CD. Targeting stromal cells in chronic inflammation.
Discov. Med. 7: 20-26 (2007).
-
Filer A, Raza K, Salmon M, Buckley CD. The role of chemokines in leucocyte-stromal interactions in rheumatoid arthritis.
Front. Biosci. 13: 2674-2685 (2008).
-
Filer C, Ho P, Smith RL, Griffiths C, Young HS, Worthington J, Bruce IN, Barton A. Investigation of association of the IL12B and IL23R genes with psoriatic arthritis.
Arthritis Rheum. 58: 3705-3709 (2008).
*
-
Filer CE, Ho P, Bruce IN, Worthington J, Barton A. Investigation of association of genes NAT9, SLC9A3R1 and RAPTOR on chromosome 17q25 with psoriatic arthritis.
Ann. Rheum. Dis. 68: 292-293 (2009).
-
Filippini M, Bazzani C, Favalli EG, Marchesoni A, Atzeni F, Sarzi-Puttini P, Pallavicini FB, Caporali R, Gorla R. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study.
Clin. Rev. Allergy Immunol. Jun 23 [Epub ahead of print] (2009).
*
-
Filippucci E, DE Angelis R, Salaffi F, Grassi W. Ultrasound, skin, and joints in psoriatic arthritis.
J. Rheumatol. Suppl. 83: 35-38 (2009).
-
Filippucci E, Gutierrez Riveros M, Georgescu D, Salaffi F, Grassi W. Hyaline cartilage involvement in patients with gout and calcium pyrophosphate deposition disease. An ultrasound study.
Osteoarthritis Cartilage 17: 178-181 (2009).
-
Fillatreau S, Manz RA. Tolls for B cells.
Eur. J. Immunol. 36: 798-801 (2006).
*
-
Filler SG, Yeaman MR, Sheppard DC. Tumor necrosis factor inhibition and invasive fungal infections.
Clin. Infect. Dis. 41 Suppl. 3: S208-S212 (2005).
*
-
Finckh A, Ciurea A, Brulhart L, Kyburz D, Moeller B, Walker UA, Courvoisier D, Dudler J, Gabay C. Which subgroup of rheumatoid arthritis patients benefits from switching to rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agent?
Ann. Rheum. Dis. May 4 [Epub ahead of print] (2009).
-
Finckh A, Ciurea A, Brulhart L, Kyburz D, Moller B, Dehler S, Revaz S, Dudler J, Gabay C; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
Arthritis Rheum. 56: 1417-1423 (2007).
*
-
Finckh A, Cooper GS, Chibnik LB, Costenbader KH, Watts J, Pankey H, Fraser PA, Karlson EW. Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban women.
Arthritis Rheum. 54: 3648-3654 (2006).
*
-
Finckh A, Dehler S, Gabay C. The effectiveness of leflunomide as co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population based study.
Ann. Rheum. Dis. 68: 33-39 (2009).
-
Finckh A, Liang MH. Anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis: bayes clears the haze.
Ann. Intern. Med. 146: 816-817 (2007).
*
-
Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis.
Arthritis Rheum. 55: 864-872 (2006).
*
-
Findlay DM, Chehade M, Tsangari H, Neale S, Hay S, Hopwood B, Panach S, O'Loughlin P, Fazzalari NL. Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males.
Arthritis Res. Ther. 10: R2 (2008).
*
-
Findlay DM, Haynes DR. Mechanisms of bone loss in rheumatoid arthritis.
Mod. Rheumatol. 15: 232-240 (2005).
-
Fineschi S, Goffin L, Rezzonico R, Cozzi F, Dayer JM, Meroni PL, Chizzolini C. Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of Toll-like receptor 4.
Arthritis Rheum. 58: 3913-3923 (2008).
*
-
Finesilver AG. Newer approaches to the treatment of rheumatoid arthritis.
WMJ 102: 34-37 (2003).
-
Fingleton B. Matrix metalloproteinases as valid clinical targets.
Curr. Pharm. Des. 13: 333-346 (2007).
-
Finis K, Sultmann H, Ruschhaupt M, Buness A, Helmchen B, Kuner R, Gross ML, Fink B, Schirmacher P, Poustka A, Berger I. Analysis of pigmented villonodular synovitis with genome-wide complementary DNA microarray and tissue array technology reveals insight into potential novel therapeutic approaches.
Arthritis Rheum. 54: 1009-1019 (2006).
*
-
Fink AM, Cauza E, Hassfeld W, Dunky A, Bayer PM, Jurecka W, Steiner A. Vascular endothelial growth factor in patients with psoriatic arthritis.
Clin. Exp. Rheumatol. 25: 305-308 (2007).
-
Fink B, Egl M, Singer J, Fuerst M, Bubenheim M, Neuen-Jacob E. Morphologic changes in the vastus medialis muscle in patients with osteoarthritis of the knee.
Arthritis Rheum. 56: 3626-3633 (2007).
*
-
Finke D, Randers K, Hoerster R, Hennig H, Zawatzky R, Marion T, Brockmann C, Klempt-Giessing K, Jacobsen K, Kirchner H, Goerg S. Elevated levels of endogenous apoptotic DNA and IFN-alpha in complement C4-deficient mice: implications for induction of systemic lupus erythematosus.
Eur. J. Immunol. 37: 1702-1709 (2007).
*
-
Fiocco U, Sfriso P, Oliviero F, Pagnin E, Scagliori E, Campana C, Cozzi L, Punzi L. Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept.
Autoimmun. Rev. 8: 76-82 (2008).
-
Fiorillo MT, Greco G, Maragno M, Potolicchio I, Monizio A, Dupuis ML, Sorrentino R. The naturally occurring polymorphism Asp116-->His116, differentiating the ankylosing spondylitis-associated HLA-B*2705 from the non-associated HLA-B*2709 subtype, influences peptide-specific CD8 T cell recognition.
Eur. J. Immunol. 28: 2508-2516 (1998).
*
-
Firestein GS. Inhibiting inflammation in rheumatoid arthritis.
N. Engl. J. Med. 354: 80-82 (2006).
*
-
Firestein GS. NF-kappaB: Holy Grail for rheumatoid arthritis?
Arthritis Rheum. 50: 2381-2386 (2004).
*
-
Firestein GS, Corr M. Common mechanisms in immune-mediated inflammatory disease.
J. Rheumatol. Suppl. 73: 8-13 (2005).
*
-
Firneisz G, Zehavi I, Vermes C, Hanyecz A, Frieman JA, Glant TT. Identification and quantification of disease-related gene clusters.
Bioinformatics 19: 1781-1786 (2003).
*
-
Firuzi O, Spadaro A, Spadaro C, Riccieri V, Petrucci R, Marrosu G, Saso L. Protein oxidation markers in the serum and synovial fluid of psoriatic arthritis patients.
J. Clin. Lab. Anal. 22: 210-215 (2008).
-
Fischer S, Lakatos PL, Group TH, Lakatos L, Kovacs A, Molnar T, Altorjay I, Papp M, Szilvasi A, Tulassay Z, Osztovits J, Papp J, Demeter P, Schwab R, Tordai A, Andrikovics H. ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgery in Hungarian patients with inflammatory bowel diseases.
Scand. J. Gastroenterol. 42: 726-733 (2007).
*
-
Fisher BA, Taylor PC. Etanercept plus sulfasalazine: added value in rheumatoid arthritis?
Nat. Clin. Pract. Rheumatol. 3: 70-71 (2007).
*
-
Fisher JR, Ostrov BE. Coexistent lyme disease and parvovirus infection in a child.
J. Clin. Rheumatol. 7: 350-353 (2001).
-
Fisher MA, Eklund SA, James SA, Lin X. Adverse events associated with hepatitis B vaccine in U.S. children less than six years of age, 1993 and 1994.
Ann. Epidemiol. 11: 13-21 (2001).
-
Fisher MC, Cronstein BN. Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity.
J. Rheumatol. 36: 539-545 (2009).
-
Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L, Krishnan JA, Wigley F, Hassoun PM. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension.
Arthritis Rheum. 54: 3043-3050 (2006).
*
-
Fisher SA, Lanchbury JS, Lewis CM. Meta-analysis of four rheumatoid arthritis genome-wide linkage studies: confirmation of a susceptibility locus on chromosome 16.
Arthritis Rheum. 48: 1200-1206 (2003).
*
-
Fishman P, Bar-Yehuda S, Madi L, Rath-Wolfson L, Ochaion A, Cohen S, Baharav E. The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis.
Arthritis Res. Ther. 8: R33 (2006).
*
-
Fitzgerald O, Dougados M. Psoriatic arthritis: one or more diseases?
Best Pract. Res. Clin. Rheumatol. 20: 435-450 (2006).
-
Fitzgerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy.
Arthritis Res. Ther. 11: 214 (2009).
*
-
Fitzpatrick LR, Wang J, Le T. Gliotoxin, an inhibitor of nuclear factor-kappa B, attenuates peptidoglycan-polysaccharide-induced colitis in rats.
Inflamm. Bowel Dis. 8: 159-167 (2002).
*
-
Fjeldstad C, Frederiksen C, Fjeldstad A, Bemben M, Pardo G. Arterial compliance in multiple sclerosis: a pilot study.
Angiology 61: 31-36 (2010).
-
Flamigni F, Stanic' I, Facchini A, Cetrullo S, Tantini B, Borzì RM, Guarnieri C, Caldarera CM. Polyamine biosynthesis as a target to inhibit apoptosis of non-tumoral cells.
Amino Acids 33: 197-202 (2007).
*
-
Flannelly J, Chambers MG, Dudhia J, Hembry RM, Murphy G, Mason RM, Bayliss MT. Metalloproteinase and tissue inhibitor of metalloproteinase expression in the murine STR/ort model of osteoarthritis.
Osteoarthritis Cartilage 10: 722-733 (2002).
-
Flato B, Hoffmann-Vold AM, Reiff A, Forre O, Lien G, Vinje O. Long-term outcome and prognostic factors in enthesitis-related arthritis: a case-control study.
Arthritis Rheum. 54: 3573-3582 (2006).
*
-
Flato B, Lien G, Smerdel-Ramoya A, Vinje O. Juvenile psoriatic arthritis: longterm outcome and differentiation from other subtypes of juvenile idiopathic arthritis.
J. Rheumatol. 36: 642-650 (2009).
-
Flatt PR, Bailey CJ, Green BD. Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.
Front. Biosci. 13: 3648-3660 (2008).
-
Fleischmann R. Primer: establishing a clinical trial unit - regulations and infrastructure.
Nat. Clin. Pract. Rheumatol. 3: 234-239 (2007).
*
-
Fleischmann R, Baumgartner SW, Weisman M, Liu T, White B, Peloso PM. Long-term safety of etanercept in elderly subjects with rheumatic diseases.
Ann. Rheum. Dis. 65: 379-384 (2006).
*
-
Fleischmann R, Iqbal I, Nandeshwar P, Quiceno A. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
Drug Saf. 25: 173-197 (2002).
-
Fleischmann R, Shealy D. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis.
Mol. Intervent. 3: 310-318 (2003).
*
-
Fleischmann R, Stern R, Iqbal I. Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis.
Expert Opin. Biol. Ther. 4: 1333-1344 (2004).
-
Fleischmann R, Vencovsky J, van Vollenhoven R, Borenstein D, Box J, Coteur G, Goel N, Brezinschek HP, Innes A, Strand V. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.
Ann. Rheum. Dis. 68: 805-811 (2009).
*
-
Fleischmann RM. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab.
Semin. Arthritis Rheum. 38: 265-280 (2009).
*
-
Fleischmann RM, Iqbal I, Stern RL. Considerations with the use of biological therapy in the treatment of rheumatoid arthritis.
Expert Opin. Drug Saf. 3: 391-403 (2004).
-
Fleischmann RM, Stern RL, Iqbal I. Treatment of early rheumatoid arthritis.
Mod. Rheumatol. 15: 153-162 (2005).
-
Fleischmann RM, Tesser J, Schiff M, Schechtman J, Burmester GR, Bennett R, Modafferi D, Zhou L, Bell D, Appleton B. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
Ann. Rheum. Dis. 65: 1006-1012 (2006).
*
-
Fleishmann RM. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents.
Clin. Exp. Rheumatol. 20 (5 Suppl. 27): S35-S41 (2002).
-
Fleming RE, Sly WS. Mechanisms of iron accumulation in hereditary hemochromatosis.
Annu. Rev. Physiol. 64: 663-680 (2002).
*
-
Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.
Arthritis Res. Ther. 7: R666-R676 (2005).
*
-
Fleurence R, Spackman E. Cost-effectiveness of biologic agents for treatment of autoimmune disorders: structured review of the literature.
J. Rheumatol. 33: 2124-2131 (2006).
-
Flick MJ, Lajeunesse CM, Talmage KE, Witte DP, Palumbo JS, Pinkerton MD, Thornton S, Degen JL. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alpha(M)beta(2) binding motif.
J. Clin. Invest. 117: 3224-3235 (2007).
*
-
Flierman R, Witteveen HJ, van der Voort EI, Huizinga TW, de Vries RR, Fibbe WE, Toes RE, van Laar JM. Control of systemic B cell-mediated autoimmune disease by nonmyeloablative conditioning and MHC-mismatched allogeneic bone marrow transplantation.
Blood 105: 2991-2994 (2005).
*
-
Flood J, Mihalik C, Fleming RR, Strober BE, Zucker DR, Burgoyne DS. The use of therapeutic interchange for biologic therapies.
Manag. Care 16: 51-62 (2007).
-
Flood S, Parri R, Williams A, Duance V, Mason D. Modulation of interleukin-6 and matrix metalloproteinase 2 expression in human fibroblast-like synoviocytes by functional ionotropic glutamate receptors.
Arthritis Rheum. 56: 2523-2534 (2007).
*
-
Floreani A, Marchiori M, Bonato S, Zucchetto M, Naccarato R, Chiaramonte M. Cognitive assessment in primary biliary cirrhosis: a case-control study.
Am. J. Gastroenterol. 90: 250-253 (1995).
-
Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis.
Proc. Natl. Acad. Sci. U.S.A. 105: 19396-19401 (2008).
*
-
Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, Mageed RA. Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus.
Arthritis Rheum. 56: 291-302 (2007).
*
-
Flytlie HA, Hvid M, Lindgreen E, Kofod-Olsen E, Petersen EL, Jørgensen A, Deleuran M, Vestergaard C, Deleuran B. Expression of MDC/CCL22 and its receptor CCR4 in rheumatoid arthritis, psoriatic arthritis and osteoarthritis.
Cytokine Nov 24 [Epub ahead of print] (2009).
-
Focosi D. Chaperonin 10 for rheumatoid arthritis.
Lancet 368: 1961 (2006).
*
-
Focosi D, Maggi F, Ceccherini-Nelli L, Marchi S, Petrine M. Progressive multifocal leukoencephalopathy in autoimmune disorders.
Gut 58: 605 (2009).
-
Foeldvari I, Kummerle-Deschner J. Autoinflammatory diseases in childhood.
Z. Rheumatol. 68: 726-732 (2009).
-
Foeldvari I, Nielsen S, Kummerle-Deschner J, Espada G, Horneff G, Bica B, Olivieri AN, Wierk A, Saurenmann RK. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.
J. Rheumatol. 34: 1146-1150 (2007).
-
Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease.
Arthritis Rheum. 50: 3762-3771 (2004).
*
-
Foell D, Wittkowski H, Hammerschmidt I, Wulffraat N, Schmeling H, Frosch M, Horneff G, Kuis W, Sorg C, Roth J. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations.
Arthritis Rheum. 50: 1286-1295 (2004).
*
-
Foell D, Wittkowski H, Roth J. Mechanisms of disease: a 'DAMP' view of inflammatory arthritis.
Nat. Clin. Pract. Rheumatol. 3: 382-390 (2007).
*
-
Fojtíkova M, Stolfa J, Novota P, Cejkova P, Dostal C, Cerna M. HLA-Cw*06 class I region rather than MICA is associated with psoriatic arthritis in Czech population.
Rheumatol. Int. 29: 1293-1299 (2009).
*
-
Folkerts G, Kraneveld AD, Nijkamp FP. New endogenous CXC chemokine ligands as potential targets in lung emphysema.
Trends Pharmacol. Sci. 29: 181-185 (2008).
*
-
Fong KY. The genetics of spondyloarthropathies.
Ann. Acad. Med. Singapore 29: 370-375 (2000).
-
Fonollosa A, Segura A, Giralt J, Garcia-Arumi J. Tuberculous uveitis after treatment with etanercept.
Graefes Arch. Clin. Exp. Ophthalmol. 245: 1397-1399 (2007).
-
Fonseca JE, Cavaleiro J, Teles J, Sousa E, Andreozzi VL, Antunes M, Amaral-Turkman MA, Canhao H, Mourao AF, Lopes J, Caetano-Lopes J, Weinmann P, Sobral M, Nero P, Saavedra MJ, Malcata A, Cruz M, Melo R, Brana A, Miranda L, Patto JV, Barcelos A, et al. Contribution for new genetic markers of rheumatoid arthritis activity and severity: sequencing of the tumour necrosis factor alpha gene promoter.
Arthritis Res. Ther. 9: R37 (2007).
*
-
Fonseca JE, Santos MJ, Canhao H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction.
Autoimmun. Rev. 8: 538-542 (2009).
-
Fontalba A, Martinez-Taboada V, Gutierrez O, Pipaon C, Benito N, Balsa A, Blanco R, Fernandez-Luna JL. Deficiency of the NF-kappaB inhibitor caspase activating and recruitment domain 8 in patients with rheumatoid arthritis is associated with disease severity.
J. Immunol. 179: 4867-4873 (2007).
*
-
Fontecchio G, Fioroni MA, Azzarone R, Battistoni C, Cervelli C, Ventura L, Mercurio C, Fornaciari G, Papola F. Genetic predisposition to rheumatoid arthritis in a Tuscan (Italy) ancient human remain.
Int. J. Immunopathol. Pharmacol. 20: 103-109 (2007).
-
Fontecchio G, Ventura L, Azzarone R, Fioroni MA, Fornaciari G, Papola F. HLA-DRB genotyping of an Italian mummy from the 16th century with signs of rheumatoid arthritis.
Ann. Rheum. Dis. 65: 1676-1677 (2006).
*
-
Fonteh PN, Keter FK, Meyer D. HIV therapeutic possibilities of gold compounds.
Biometals Feb 3 [Epub ahead of print] (2010).
-
Foocharoen C, Nanagara R, Salang L, Suwannaroj S, Mahakkanukrauh A. Pregnancy and disease outcome in patients with systemic lupus erythematosus (SLE): a study at Srinagarind Hospital.
J. Med. Assoc. Thai. 92: 167-174 (2009).
-
Forman SB, Higginson R, Garrett AB. Psoriasis and psoriatic arthritis in a patient with HIV: response to mycophenolate mofetil treatment.
J. Drugs Dermatol. 7: 972-973 (2008).
-
Fornaciari G, Salvarani C, Beltrami M, Macchioni P, Stockbrugger RW, Russel MG. Muscoloskeletal manifestations in inflammatory bowel disease.
Can. J. Gastroenterol. 15: 399-403 (2001).
*
-
Forrest CM, Mackay GM, Stoy N, Stone TW, Darlington LG. Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin.
Br. J. Clin. Pharmacol. 64: 517-526 (2007).
*
-
Forsgren S. New data favouring that neurotrophins are of importance in arthritis.
Arthritis Res. Ther. 11: 122 (2009).
*
-
Forsgren S, Grimsholm O, Jonsson M, Alfredson H, Danielson P. New insight into the non-neuronal cholinergic system via studies on chronically painful tendons and inflammatory situations.
Life Sci. 84: 865-870 (2009).
*
-
Forslind K, Hafstrom I, Ahlmen M, Svensson B. Sex: a major predictor of remission in early rheumatoid arthritis?
Ann. Rheum. Dis. 66: 46-52 (2007).
*
-
Forster T, Chapman K, Marcelline L, Mustafa Z, Southam L, Loughlin J. Finer linkage mapping of primary osteoarthritis susceptibility loci on chromosomes 4 and 16 in families with affected women.
Arthritis Rheum. 50: 98-102 (2004).
*
-
Fossati-Jimack L, Cortes-Hernandez J, Norsworthy PJ, Cook HT, Walport MJ, Botto M. Regulation of B cell tolerance by 129-derived chromosome 1 loci in C57BL/6 mice.
Arthritis Rheum. 58: 2131-2141 (2008).
*
-
Foster CS. Diagnosis and treatment of juvenile idiopathic arthritis-associated uveitis.
Curr. Opin. Ophthalmol. 14: 395-398 (2003).
-
Foster W, Carruthers D, Lip GY, Blann AD. Inflammatory cytokines, endothelial markers and adhesion molecules in rheumatoid arthritis: effect of intensive anti-inflammatory treatment.
J. Thromb. Thrombolysis Jul 4 [Epub ahead of print] (2009).
-
Fouache D, Goeb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M, Menard JF, Muraine M, Savoye G, Loet XL, Tharasse C, Vittecoq O. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
Rheumatology (Oxford) 48: 761-764 (2009).
-
Foulquier C, Sebbag M, Clavel C, Chapuy-Regaud S, Al Badine R, Mechin MC, Vincent C, Nachat R, Yamada M, Takahara H, Simon M, Guerrin M, Serre G. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation.
Arthritis Rheum. 56: 3541-3553 (2007).
*
-
Fouque-Aubert A, Jette-Paulin L, Combescure C, Basch A, Tebib J, Gossec L. Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomized placebo-controlled trials.
Ann. Rheum. Dis. Jul 28 [Epub ahead of print] (2009).
-
Fourie AM. Modulation of inflammatory disease by inhibitors of leukotriene A4 hydrolase.
Curr. Opin. Investig. Drugs 10: 1173-1182 (2009).
-
Fournier C. Where do T cells stand in rheumatoid arthritis?
Joint Bone Spine 72: 527-532 (2005).
*
-
Fournier MR, Klein J, Minuk GY, Bernstein CN. Changes in liver biochemistry during methotrexate use for inflammatory bowel disease.
Am. J. Gastroenterol. Feb 16 [Epub ahead of print] (2010).
*
-
Fox RI. Sjogren's syndrome.
Lancet 366: 321-331 (2005).
*
-
Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Kirschbaum BJ. How does leflunomide modulate the immune response in rheumatoid arthritis?
BioDrugs 12: 301-315 (1999).
-
Fox RI, Liu AY. Sjogren's syndrome in dermatology.
Clin. Dermatol. 24: 393-413 (2006).
-
Fox RI, Luppi M, Kang HI, Pisa P. Reactivation of Epstein-Barr virus in Sjogren's syndrome.
Springer Semin. Immunopathol. 13: 217-231 (1991).
-
Fraenkel L, Bogardus ST, Concato J, Felson DT, Wittink DR. Patient preferences for treatment of rheumatoid arthritis.
Ann. Rheum. Dis. 63: 1372-1378 (2004).
*
-
Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narvaez A, Davila-Maldonado L, Atisha-Fregoso Y, Llorente L, Sanchez-Guerrero J. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus.
Arthritis Rheum. 56: 1242-1250 (2007).
*
-
Franchimont N, Lambert C, Huynen P, Ribbens C, Relic B, Chariot A, Bours V, Piette J, Merville MP, Malaise M. Interleukin-6 receptor shedding is enhanced by interleukin-1beta and tumor necrosis factor alpha and is partially mediated by tumor necrosis factor alpha-converting enzyme in osteoblast-like cells.
Arthritis Rheum. 52: 84-93 (2005).
*
-
Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F. B cells and multiple sclerosis.
Lancet Neurol. 7: 852-858 (2008).
-
Franck H; Kommission Osteologie der Deutschen Gesellschaft fur Rheumatologie, Braun J, Buttgereit F, Demary W, Hein G, Kekow J, Schett G, Kern PM. Bone densitometry in inflammatory rheumatic diseases: characteristics of the measurement site and disease-specific factors.
Z. Rheumatol. 68: 845-850 (2009).
-
Francois M, Richette P, Tsagris L, Fitting C, Lemay C, Benallaoua M, Tahiri K, Corvol MT. Activation of the peroxisome proliferator-activated receptor alpha pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes.
Arthritis Rheum. 54: 1233-1245 (2006).
*
-
Frank KM, Hogarth DK, Miller JL, Mandal S, Mease PJ, Samulski RJ, Weisgerber GA, Hart J. Investigation of the cause of death in a gene-therapy trial.
N. Engl. J. Med. 361: 161-169 (2009).
*
-
Frank MB, Itoh K, Fujisaku A, Pontarotti P, Mattei MG, Neas BR. The mapping of the human 52-kD Ro/SSA autoantigen gene to human chromosome 11, and its polymorphisms.
Am. J. Hum. Genet. 52: 183-191 (1993).
*
-
Frank MM, Hester CG. Complement and arthritis: another step in understanding.
Arthritis Res. Ther. 10: 104 (2008).
*
-
Frankel EH, Strober BE, Crowley JJ, Fivenson DP, Woolley JM, Yu EB, Xia HA, Chiou CF, Stevens SR. Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE.
Cutis 79: 322-326 (2007).
-
Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Influence of inflammatory polyarthritis on cancer incidence and survival: results from a community-based prospective study.
Arthritis Rheum. 56: 790-798 (2007).
*
-
Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, van Riel PL. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomized, controlled trials of two TNF inhibitors.
Ann. Rheum. Dis. 65: 1373-1378 (2006).
*
-
Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria.
Clin. Exp. Rheumatol. 23: S93-S99 (2005).
-
Fransen J, van Riel PL. DAS remission cut points.
Clin. Exp. Rheumatol. 24: S029-S032 (2006).
*
-
Fransen JH, Hilbrands LB, Ruben J, Stoffels M, Adema GJ, van der Vlag J, Berden JH. Mouse dendritic cells matured by ingestion of apoptotic blebs induce T cells to produce interleukin-17.
Arthritis Rheum. 60: 2304-2313 (2009).
*
-
Franssila R, Hedman K. Viral causes of arthritis.
Best Pract. Res. Clin. Rheumatol. 20: 1139-1157 (2006).
-
Franz B, Fritzsching B, Riehl A, Oberle N, Klemke CD, Sykora J, Quick S, Stumpf C, Hartmann M, Enk A, Ruzicka T, Krammer PH, Suri-Payer E, Kuhn A. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus.
Arthritis Rheum. 56: 1910-1920 (2007).
*
-
Fraser JR, Engstrom-Laurent A, Nyberg A, Laurent TC. Removal of hyaluronic acid from the circulation in rheumatoid disease and primary biliary cirrhosis.
J. Lab. Clin. Med. 107: 79-85 (1986).
-
Frasnelli ME, Tarussio D, Chobaz-Peclat V, Busso N, So A. TLR2 modulates inflammation in zymosan-induced arthritis in mice.
Arthritis Res. Ther. 7: R370-R379 (2005).
*
-
Fratesi JA, Hogg RC, Young-Newton GS, Patterson AC, Charkhzarin P, Block Thomas K, Sharratt MT, Stark KD. Direct quantitation of omega-3 fatty acid intake of Canadian residents of a long-term care facility.
Appl. Physiol. Nutr. Metab. 34: 1-9 (2009).
*
-
Frediani B, Rossini M, Adami S, Bianchi G, Di Munno O, Sinigaglia L, Antonelli M, Minisola G. Study of vitamin D status of rheumatoid arthritis patients. Rationale and design of a cross-sectional study by the osteoporosis and metabolic bone diseases study group of the Italian Society of Rheumatology (SIR).
Reumatismo 58: 314-318 (2006).
-
Freeman ML, Hawes RH, Vakil N, Camilleri M, Hanauer SB. Best of DDW 2001. Highlights from the 2001 Digestive Disease Week. May 20-23, 2001, Atlanta, GA.
Rev. Gastroenterol. Disord. 1: 100-110 (2001).
*
-
Fregeau DR, Leung PS, Coppel RL, McNeilage LJ, Medsger TA Jr, Gershwin ME. Autoantibodies to mitochondria in systemic sclerosis. Frequency and characterization using recombinant cloned autoantigen.
Arthritis Rheum. 31: 386-392 (1988).
-
Freire de Carvalho J, Pereira RM, Shoenfeld Y. The mosaic of autoimmunity: the role of environmental factors.
Front. Biosci. (Elite Ed.) 1: 501-509 (2009).
-
Frenkel J, Kuis W. Overt and occult rheumatic diseases: the child with chronic fever.
Best Pract. Res. Clin. Rheumatol. 16: 443-469 (2002).
-
Frey B, Gaipl US, Sarter K, Zaiss MM, Stillkrieg W, Rodel F, Schett G, Herrmann M, Fietkau R, Keilholz L. Whole body low dose irradiation improves the course of beginning polyarthritis in human TNF-transgenic mice.
Autoimmunity 42: 346-348 (2009).
-
Frey O, Petrow PK, Gajda M, Siegmund K, Huehn J, Scheffold A, Hamann A, Radbruch A, Brauer R. The role of regulatory T cells in antigen-induced arthritis: aggravation of arthritis after depletion and amelioration after transfer of CD4+CD25+ T cells.
Arthritis Res. Ther. 7: R291-R301 (2005).
*
-
Freysdottir J, Hardardottir I, Gizurarson S, Vikingsson A. Mucosal tolerance to KLH reduces BSA-induced arthritis in rats - an indication of bystander suppression.
J. Clin. Immunol. 27: 284-293 (2007).
*
-
Friberg C, Bjorck K, Nilsson S, Inerot A, Wahlstrom J, Samuelsson L. Analysis of chromosome 5q31-32 and psoriasis: confirmation of a susceptibility locus but no association with SNPs within SLC22A4 and SLC22A5.
J. Invest. Dermatol. 126: 998-1002 (2006).
*
-
Friedman J, Schattner A, Shvidel L, Berrebi A. Characterization of T-cell large granular lymphocyte leukemia associated with Sjogren's syndrome - an important but underrecognized association.
Semin. Arthritis Rheum. 35: 306-311 (2006).
*
-
Frieri M. Identification of masqueraders of autoimmune disease in the office.
Allergy Asthma Proc. 24: 421-429 (2003).
-
Fries JF, Bruce B, Bjorner J, Rose M. More relevant, precise, and efficient items for assessment of physical function and disability: moving beyond the classic instruments.
Ann. Rheum. Dis. 65 Suppl. 3: iii16-iii21 (2006).
*
-
Fries JF, Wolfe F, Apple R, Erlich H, Bugawan T, Holmes T, Bruce B. HLA-DRB1 genotype associations in 793 white patients from a rheumatoid arthritis inception cohort: frequency, severity, and treatment bias.
Arthritis Rheum. 46: 2320-2329 (2002).
*
-
Friese MA, Fugger L. Pathogenic CD8(+) T cells in multiple sclerosis.
Ann. Neurol. 66: 132-141 (2009).
-
Friese MA, Jones EY, Fugger L. MHC II molecules in inflammatory diseases: interplay of qualities and quantities.
Trends Immunol. 26: 559-561 (2005).
*
-
Frini S, Chaabouni L, Ben Hamida A, Kchir M, Zouari R. Arthritis of the hip in spondylarthorpathy: retrospective study about 126 cases.
Tunis. Med. 83: 739-741 (2005).
-
Fritsch DA, Allen TA, Dodd CE, Jewell DE, Sixby KA, Leventhal PS, Brejda J, Hahn KA. A multicenter study of the effect of dietary supplementation with fish oil omega-3 fatty acids on carprofen dosage in dogs with osteoarthritis.
J. Am. Vet. Med. Assoc. 236: 535-539 (2010).
-
Fritsch RD, Shen X, Illei GG, Yarboro CH, Prussin C, Hathcock KS, Hodes RJ, Lipsky PE. Abnormal differentiation of memory T cells in systemic lupus erythematosus.
Arthritis Rheum. 54: 2184-2197 (2006).
*
-
Fritsche K. Fatty acids as modulators of the immune response.
Annu. Rev. Nutr. 26: 45-73 (2006).
*
-
Froehlich F, Fried M, Gonvers JJ, Saraga E, Thorens J, Pecoud A. Association of Crohn's disease and Cogan's syndrome.
Dig. Dis. Sci. 39: 1134-1137 (1994).
-
Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor.
Cytokine 45: 55-57 (2009).
-
Frostegard J. Atherosclerosis in patients with autoimmune disorders.
Arterioscler. Thromb. Vasc. Biol. 25: 1776-1785 (2005).
*
-
Fu HL, Hsu TC, Chang CC, Tsay GJ. Antigenic specificity of anti-neutrophil cytoplasmic antibody.
J. Formos. Med. Assoc. 100: 35-39 (2001).
-
Fu Q, Chen X, Cui H, Guo Y, Chen J, Shen N, Bao C. Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients.
Arthritis Res. Ther. 10: R112 (2008).
*
-
Fu Y, Nathan DM, Li F, Li X, Faustman DL. Defective major histocompatibility complex class I expression on lymphoid cells in autoimmunity.
J. Clin. Invest. 91: 2301-2307 (1993).
*
-
Fuchs BS, Hadi S. Use of etanercept in the treatment of psoriasis and psoriatic arthritis.
Rev. Recent Clin. Trials 1: 259-263 (2006).
-
Fuchs I, Avnon L, Freud T, Abu-Shakra M. Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors.
Clin. Rheumatol. 28: 167-172 (2009).
*
-
Fugger L, Michie SA, Rulifson I, Lock CB, McDevitt GS. Expression of HLA-DR4 and human CD4 transgenes in mice determines the variable region beta-chain T-cell repertoire and mediates an HLA-DR-restricted immune response.
Proc. Natl. Acad. Sci. U.S.A. 91: 6151-6155 (1994).
*
-
Fugger L, Morling N, Ryder LP, Georgsen J, Jakobsen BK, Svejgaard A, Andersen V, Oxholm P, Karup Pedersen F, Friis J, et al. NcoI restriction fragment length polymorphism (RFLP) of the tumor necrosis factor (TNF alpha) region in four autoimmune diseases.
Tissue Antigens 34: 17-22 (1989).
-
Fugger L, Morling N, Ryder LP, Jakobsen BK, Andersen V, Oxholm P, Dalhoff K, Heilmann C, Karup Pedersen F, Friis J, et al. Restriction fragment length polymorphism of two HLA-B-associated transcripts genes in five autoimmune diseases.
Hum. Immunol. 30: 27-31 (1991).
-
Fugger L, Svejgaard A. The HLA-DQ7 and -DQ8 associations in DR4-positive rheumatoid arthritis patients. A combined analysis of data available in the literature.
Tissue Antigens 50: 494-500 (1997).
-
Fujii H, Shao L, Colmegna I, Goronzy JJ, Weyand CM. Telomerase insufficiency in rheumatoid arthritis.
Proc. Natl. Acad. Sci. U.S.A. 106: 4360-4365 (2009).
*
-
Fujikado N, Saijo S, Iwakura Y. Identification of arthritis-related gene clusters by microarray analysis of two independent mouse models for rheumatoid arthritis.
Arthritis Res. Ther. 8: R100 (2006).
*
-
Fujikado N, Saijo S, Yonezawa T, Shimamori K, Ishii A, Sugai S, Kotaki H, Sudo K, Nose M, Iwakura Y. Dcir deficiency causes development of autoimmune diseases in mice due to excess expansion of dendritic cells.
Nat. Med. 14: 176-180 (2008).
*
-
Fujikawa K, Kawakami A, Eguchi K. Etanercept: recombinant human soluble tumor necrosis factor receptor fusion protein.
Nippon Rinsho 65: 1211-1217 (2007).
-
Fujikawa K, Kawakami A, Hayashi T, Iwamoto N, Kawashiri SY, Aramaki T, Ichinose K, Tamai M, Arima K, Kamachi M, Yamasaki S, Nakamura H, Ida H, Origuchi T, Eguchi K. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases.
Mod. Rheumatol. Oct 8 [Epub ahead of print] (2009).
*
-
Fujimaki C, Hayashi H, Tsuboi S, Matsuyama T, Kosuge K, Yamada H, Inoue K, Itoh K. Plasma total homocysteine level and methylenetetrahydrofolate reductase 677C>T genetic polymorphism in Japanese patients with rheumatoid arthritis.
Biomarkers 14: 49-54 (2009).
-
Fujimoto M, Sato S, Ihn H, Kikuchi K, Tamaki K, Takehara K. Autoantibodies to pyruvate dehydrogenase complex in patients with systemic sclerosis. Possible role of anti-E1 alpha antibody as a serologic indicator for development of primary biliary cirrhosis.
Arthritis Rheum. 38: 985-989 (1995).
-
Fujimoto M, Serada S, Mihara M, Uchiyama Y, Yoshida H, Koike N, Ohsugi Y, Nishikawa T, Ripley B, Kimura A, Kishimoto T, Naka T. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
Arthritis Rheum. 58: 3710-3719 (2008).
*
-
Fujimoto M, Serada S, Naka T. Role of IL-6 in the development and pathogenesis of CIA and EAE.
Nihon Rinsho Meneki Gakkai Kaishi 31: 78-84 (2008).
-
Fujimoto N, Mouri N, Iwata K, Ohuchi E, Okada Y, Hayakawa T. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies.
Clin. Chim. Acta 221: 91-103 (1993).
-
Fujio K, Okamoto A, Araki Y, Shoda H, Tahara H, Tsuno NH, Takahashi K, Kitamura T, Yamamoto K. Gene therapy of arthritis with TCR isolated from the inflamed paw.
J. Immunol. 177: 8140-8147 (2006).
*
-
Fujio K, Okamura T, Okamoto A, Yamamoto K. T cell receptor gene therapy for autoimmune diseases.
Ann. N. Y. Acad. Sci. 1110: 222-232 (2007).
*
-
Fujita J, Ohtsuki Y, Yoshinouchi T, Yamadori I, Bandoh S, Tokuda M, Miyawaki H, Kishimoto N, Ishida T. Idiopathic non-specific interstitial pneumonia: as an "autoimmune interstitial pneumonia".
Respir. Med. 99: 234-240 (2005).
-
Fujita M, Hatachi S, Yagita M. Acute Chlamydia pneumoniae infection in the pathogenesis of autoimmune diseases.
Lupus 18: 164-168 (2009).
*
-
Fukasawa H, Kagechika H, Shudo K. Retinoid therapy for autoimmune diseases.
Nihon Rinsho Meneki Gakkai Kaishi 29: 114-126 (2006).
*
-
Fukino K, Kawashima T, Suzuki M, Ueno K. Methylenetetrahydrofolate reductase and reduced folate carrier-1 genotypes and methotrexate serum concentrations in patients with rheumatoid arthritis.
J. Toxicol. Sci. 32: 449-452 (2007).
*
-
Fukuda W, Yamazaki T, Akaogi T, Hayashi H, Kusakabe T, Tsubouchi Y, Kawahito Y, Inoue M, Yoshikawa T. Malnutrition and disease progression in patients with rheumatoid arthritis.
Mod. Rheumatol. 15: 104-107 (2005).
-
Fukunishi S, Yoh K, Kamae S, Yoshiya S. Beta 2-microglobulin amyloid deposit in HLA-B27 transgenic rats.
Mod. Rheumatol. 17: 380-384 (2007).
*
-
Fulci V, Scappucci G, Sebastiani GD, Giannitti C, Franceschini D, Meloni F, Colombo T, Citarella F, Barnaba V, Galeazzi M, Macino G. miR-223 is over-expressed in T-lymphocytes of patients affected by rheumatoid arthritis.
Hum. Immunol. Nov 17 [Epub ahead of print] (2009).
-
Fuleihan RL. The hyper IgM syndrome.
Curr. Allergy Asthma Rep. 1: 445-450 (2001).
-
Fulop T Jr, Larbi A, Dupuis G, Pawelec G. Ageing, autoimmunity and arthritis: perturbations of TCR signal transduction pathways with ageing - a biochemical paradigm for the ageing immune system.
Arthritis Res. Ther. 5: 290-302 (2003).
*
-
Fung E, Smyth DJ, Howson JM, Cooper JD, Walker NM, Stevens H, Wicker LS, Todd JA. Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus.
Genes Immun. 10: 188-191 (2009).
*
-
Funk JL, Frye JB, Oyarzo JN, Kuscuoglu N, Wilson J, McCaffrey G, Stafford G, Chen G, Lantz RC, Jolad SD, Solyom AM, Kiela PR, Timmermann BN. Efficacy and mechanism of action of turmeric supplements in the treatment of experimental arthritis.
Arthritis Rheum. 54: 3452-3464 (2006).
*
-
Funk JL, Oyarzo JN, Frye JB, Chen G, Lantz RC, Jolad SD, Solyom AM, Timmermann BN. Turmeric extracts containing curcuminoids prevent experimental rheumatoid arthritis.
J. Nat. Prod. 69: 351-355 (2006).
*
-
Funkhouser SW, Concannon P, Charmley P, Vredevoe DL, Hood L. Differences in T cell receptor restriction fragment length polymorphisms in patients with rheumatoid arthritis.
Arthritis Rheum. 35: 465-471 (1992).
-
Furfaro N. Diagnostic signs and symptoms of psoriatic arthritis.
Dermatol. Nurs. 2006: S7-S9, S22 (2006).
-
Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham WW, Merrill JT, Weinstein A, McCune WJ, Zhong J, Cai W, Freimuth W, Study Group B. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
Arthritis Res. Ther. 10: R109 (2008).
*
-
Furihata S, Ito T, Kamatani N. Test of association between haplotypes and phenotypes in case-control studies: examination of validity of the application of an algorithm for samples from cohort or clinical trials to case-control samples using simulated and real data.
Genetics 174: 1505-1516 (2006).
*
-
Furlan A, Podswiadek M, Cozzi F, Todesco S. Tenosynovitis of the ankles as onset of sarcoidosis in a patient with ulcerative colitis.
Reumatismo 57: 197-200 (2005).
-
Furlow B. Systemic lupus erythematosus.
Radiol. Technol. 76: 289-296 (2005).
-
Furst DE. Stem cell transplantation for autoimmune disease: progress and problems.
Curr. Opin. Rheumatol. 14: 220-224 (2002).
-
Furst DE. Cerotlizumab pegol - what role does this new TNF inhibitor have in the treatment of RA?
Nat. Clin. Pract. Rheumatol. 5: 134-135 (2009).
-
Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis.
Semin. Arthritis Rheum. Dec 29 [Epub ahead of print] (2008).
*
-
Furst DE. Serum immunoglobulins and risk of infection: how low can you go?
Semin. Arthritis Rheum. 39: 18-29 (2009).
*
-
Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, Weisman M, Wallace D, Crues J, Khanna D, Eckel G, Yeilding N, Callegari P, Visvanathan S, Rojas J, Hegedus R, George L, Mamun K, Gilmer K, Troum O. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the OPPOSITE study.
Ann. Rheum. Dis. 66: 893-899 (2007).
*
-
Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
J. Rheumatol. 30: 2563-2571 (2003).
-
Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection.
Semin. Arthritis Rheum. 36: 159-167 (2006).
*
-
Furukawa K, Ohtani T, Furukawa F, Suzuki Y. Infectious mononucleosis-like syndrome induced by salazosulfapyridine in a patient with rheumatoid arthritis.
Mod. Rheumatol. 17: 492-495 (2007).
*
-
Furuya T, Hakoda M, Ichikawa N, Higami K, Nanke Y, Yago T, Kamatani N, Kotake S. Associations between HLA-DRB1, RANK, RANKL, OPG, and IL-17 genotypes and disease severity phenotypes in Japanese patients with early rheumatoid arthritis.
Clin. Rheumatol. 26: 2137-2141 (2007).
*
-
Furuya T, Hakoda M, Ichikawa N, Higami K, Nanke Y, Yago T, Kobashigawa T, Tokunaga K, Tsuchiya N, Kamatani N, Kotake S. Differential association of HLA-DRB1 alleles in Japanese patients with early rheumatoid arthritis in relationship to autoantibodies to cyclic citrullinated peptide.
Clin. Exp. Rheumatol. 25: 219-224 (2007).
-
Furuya T, Joe B, Salstrom JL, Hashiramoto A, Dobbins DE, Wilder RL, Remmers EF. Polymorphisms of the tumor necrosis factor alpha locus among autoimmune disease susceptible and resistant inbred rat strains.
Genes Immun. 2: 229-232 (2001).
*
-
Furuya T, Kotake S, Inoue E, Nanke Y, Yago T, Kobashigawa T, Ichikawa N, Tanaka E, Momohara S, Nakajima A, Hara M, Tomatsu T, Yamanaka H, Kamatani N. Risk factors associated with incident clinical vertebral and nonvertebral fractures in Japanese women with rheumatoid arthritis: a prospective 54-month observational study.
J. Rheumatol. 34: 303-310 (2007).
-
Furuya T, Matsumoto I, Tsuchiya N, Hakoda M, Ichikawa N, Yago T, Higami K, Nanke Y, Sumida T, Kamatani N, Kotake S. Anti-glucose-6-phosphate isomerase, anti-cyclic citrullinated peptide antibodies and HLA-DRB1 genotypes in Japanese patients with early rheumatoid arthritis.
Clin. Exp. Rheumatol. 26: 918-921 (2008).
-
Furuya T, Salstrom JL, McCall-Vining S, Cannon GW, Joe B, Remmers EF, Griffiths MM, Wilder RL. Genetic dissection of a rat model for rheumatoid arthritis: significant gender influences on autosomal modifier loci.
Hum. Mol. Genet. 9: 2241-2250 (2000).
*
-
Furuya T, Urano T, Ikari K, Kotake S, Inoue S, Hara M, Momohara S, Kamatani N, Yamanaka H. A1330V polymorphism of low-density lipoprotein receptor-related protein 5 gene and self-reported incident fractures in Japanese female patients with rheumatoid arthritis.
Mod. Rheumatol. 19: 140-146 (2009).
*
-
Furuzawa-Carballeda J, Macip-Rodríguez PM, Cabral AR. Osteoarthritis and rheumatoid arthritis pannus have similar qualitative metabolic characteristics and pro-inflammatory cytokine response.
Clin. Exp. Rheumatol. 26: 554-560 (2008).
-
Furuzawa-Carballeda J, Munoz-Chable OA, Barrios-Payan J, Hernandez-Pando R. Effect of polymerized-type I collagen in knee osteoarthritis. I. In vitro study.
Eur. J. Clin. Invest. 39: 591-597 (2009).
-
Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR. Autoimmune inflammation from the Th17 perspective.
Autoimmun. Rev. 6: 169-175 (2007).
*
-
Fuschiotti P, Medsger TA Jr, Morel PA. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis.
Arthritis Rheum. 60: 1119-1128 (2009).
*
-
Fusconi M, Vannini A, Dall'aglio AC, Pappas G, Bianchi FB, Zauli D. Etanercept and infliximab induce the same serological autoimmune modifications in patients with rheumatoid arthritis.
Rheumatol. Int. 28: 47-49 (2007).
*
-
Fusconi M, Vannini A, Dall'aglio AC, Pappas G, Cassani F, Ballardini G, Frisoni M, Grassi A, Bianchi FB, Zauli D. Anti-cyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis.
Aliment. Pharmacol. Ther. 22: 951-955 (2005).
*
-
Fusello AM, Mandik-Nayak L, Shih F, Lewis RE, Allen PM, Shaw AS. The MAPK scaffold kinase suppressor of Ras is involved in ERK activation by stress and proinflammatory cytokines and induction of arthritis.
J. Immunol. 177: 6152-6158 (2006).
*
-
Fussell H, Nesbeth D, Lenart I, Campbell EC, Lynch S, Santos S, Gould K, Powis SJ, Antoniou AN. Novel detection of in vivo HLA-B27 conformations correlates with ankylosing spondylitis association.
Arthritis Rheum. 58: 3419-3424 (2008).
*
-
Gabay C. Interleukin-6 and chronic inflammation.
Arthritis Res. Ther. 8 Suppl. 2: S3 (2006).
*
-
Gabay C. Behcet's syndrome.
Rev. Med. Suisse. 4: 728-730, 732-733 (2008).
-
Gabay C, Krenn V, Bosshard C, Seemayer CA, Chizzolini C, Huard B. Synovial tissues concentrate secreted APRIL.
Arthritis Res. Ther. 11: R144 (2009).
*
-
Gabay C, McInnes IB. The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases.
Arthritis Res. Ther. 11: 230 (2009).
-
Gabhann JN, Higgs R, Brennan K, Thomas W, Damen JE, Ben Larbi N, Krystal G, Jefferies CA. Absence of SHIP-1 results in constitutive phosphorylation of Tank-binding kinase 1 and enhanced TLR3-dependent IFN-beta production.
J. Immunol. Jan 25 [Epub ahead of print] (2010).
-
Gabriel S. Heart disease in rheumatoid arthritis: changing the paradigm of systemic inflammatory disorders.
J. Rheumatol. 34: 220-223 (2007).
-
Gabriel SE, Conn DL, Luthra H. Rifampin therapy in rheumatoid arthritis.
J. Rheumatol. 17: 163-166 (1990).
-
Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.
Arthritis Res. Ther. 11: 229 (2009).
*
-
Gadalla SM, Amr S, Langenberg P, Baumgarten M, Davidson WF, Schairer C, Engels EA, Pfeiffer RM, Goedert JJ. Breast cancer risk in elderly women with systemic autoimmune rheumatic diseases: a population-based case-control study.
Br. J. Cancer 100: 817-821 (2009).
*
-
Gaffen SL. Biology of recently discovered cytokines: interleukin-17 - a unique inflammatory cytokine with roles in bone biology and arthritis.
Arthritis Res. Ther. 6: 240-247 (2004).
*
-
Gaffen SL. The role of interleukin-17 in the pathogenesis of rheumatoid arthritis.
Curr. Rheumatol. Rep. 11: 365-370 (2009).
-
Gaffo A, Saag KG, Curtis JR. Treatment of rheumatoid arthritis.
Am. J. Health Syst. Pharm. 63: 2451-2465 (2006).
*
-
Gagnon F, Hajage D, Plancoulaine S, Tezenas du Montcel S. Modeling of PTPN22 and HLA-DRB1 susceptibility to rheumatoid arthritis.
BMC Proc. 1 Suppl. 1: S14 (2007).
*
-
Gaillard P, Jeanclaude-Etter I, Ardissone V, Arkinstall S, Cambet Y, Camps M, Chabert C, Church D, Cirillo R, Gretener D, Halazy S, Nichols A, Szyndralewiez C, Vitte PA, Gotteland JP. Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase.
J. Med. Chem. 48: 4596-4607 (2005).
*
-
Gajinov Z, Prcic S, Matic M, Duran V, Ivkov-Simic M. Papular-purpuric gloves and socks syndrome - a case report.
Med. Pregl. 59: 380-383 (2006).
-
Gal I, Bajnok E, Szanto S, Sarraj B, Glant TT, Mikecz K. Visualization and in situ analysis of leukocyte trafficking into the ankle joint in a systemic murine model of rheumatoid arthritis.
Arthritis Rheum. 52: 3269-3278 (2005).
*
-
Gal I, Toth L, Szegedi L, Kiss GG. Gastric bleeding in a patient with rheumatoid arthritis complicated by immune thrombocytopenic purpura.
Joint Bone Spine 75: 350-352 (2008).
*
-
Galarraga B, Khan F, Kumar P, Pullar T, Belch JJ. C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis.
Rheumatology (Oxford) 47: 1780-1784 (2008).
*
-
Galarza C, Valencia D, Tobon GJ, Zurita L, Mantilla RD, Pineda-Tamayo R, Rojas-Villarraga A, Rueda JC, Anaya JM. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?
Clin. Rev. Allergy Immunol. 34: 124-128 (2008).
*
-
Galdo FD, Jimenez SA. T cells expressing allograft inflammatory factor 1 display increased chemotaxis and induce a profibrotic phenotype in normal fibroblasts in vitro.
Arthritis Rheum. 56: 3478-3488 (2007).
*
-
Galeazzi M, Gasbarrini G, Ghirardello A, Grandemange S, Hoffman HM, Manna R, Podswiadek M, Punzi L, Sebastiani GD, Touitou I, Doria A. Autoinflammatory syndromes.
Clin. Exp. Rheumatol. 24: S79-S85 (2006).
-
Galeazzi M, Giannitti C, Manganelli S, Benucci M, Scarpato S, Bazzani C, Caporali R, Sebastiani GD. Treatment of rheumatic diseases in patients with HCV and HIV infection.
Autoimmun. Rev. 8: 100-103 (2008).
-
Galeazzi M, Morozzi G, Sebastiani GD, Bellisai F, Marcolongo R, Cervera R, De Ramon Garrido E, Fernandez-Nebro A, Houssiau F, Jedryka-Goral A, Mathieu A, Papasteriades C, Piette JC, Scorza R, Smolen J. Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. European Concerted Action on the Immunogenetics of SLE.
Clin. Exp. Rheumatol. 16: 541-546 (1998).
-
Galeotti L, Adrian K, Berg S, Tarkowski A, Bokarewa M. Circulating survivin indicates severe course of juvenile idiopathic arthritis.
Clin. Exp. Rheumatol. 26: 373-378 (2008).
-
Galhenage SP, Viiala CH, Olynyk JK. Screening for hemochromatosis: patients with liver disease, families, and populations.
Curr. Gastroenterol. Rep. 6: 44-51 (2004).
-
Gallagher MJ, Quinones K, Cervantes-Castaneda RA, Yilmaz T, Foster CS. Biologic response modifier therapy for refractory childhood uveitis.
Br. J. Ophthalmol. 91: 1341-1344 (2007).
*
-
Gallant M, Lories R, Verbanck J. Polymyalgia rheumatica/arteritis temporalis and acquired factor VIII inhibitor.
Clin. Rheumatol. 27 Suppl. 1: 19-21 (2008).
*
-
Galligan CL, Baig E, Bykerk V, Keystone EC, Fish EN. Distinctive gene expression signatures in rheumatoid arthritis synovial tissue fibroblast cells: correlates with disease activity.
Genes Immun. 8: 480-491 (2007).
*
-
Galligan CL, Siebert JC, Siminovitch KA, Keystone EC, Bykerk V, Perez OD, Fish EN. Multiparameter phospho-flow analysis of lymphocytes in early rheumatoid arthritis: implications for diagnosis and monitoring drug therapy.
PLoS One 4: e6703 (2009).
*
-
Galligan CL, Siminovitch KA, Keystone EC, Bykerk V, Perez OD, Fish EN. Fibrocyte activation in rheumatoid arthritis.
Rheumatology (Oxford) Oct 25 [Epub ahead of print] (2009).
-
Galocha B, de Castro JA. Folding of HLA-B27 subtypes is determined by the global effect of polymorphic residues and shows incomplete correspondence to ankylosing spondylitis.
Arthritis Rheum. 58: 401-412 (2008).
*
-
Galon J, Aksentijevich I, McDermott MF, O'Shea JJ, Kastner DL. TNFRSF1A mutations and autoinflammatory syndromes.
Curr. Opin. Immunol. 12: 479-486 (2000).
-
Galvez-Rosas A, Gonzalez-Huerta C, Borgonio-Cuadra VM, Duarte-Salazar C, Lara-Alvarado L, de Los Angeles Soria-Bastida M, Cortes-Gonzalez S, Ramon-Gallegos E, Miranda-Duarte A. A COL2A1 gene polymorphism is related with advanced stages of osteoarthritis of the knee in Mexican Mestizo population.
Rheumatol. Int. Sep 16 [Epub ahead of print] (2009).
*
-
Gamarra RM, McGraw SD, Drelichman VS, Maas LC. Serum sickness-like reactions in patients receiving intravenous infliximab.
J. Emerg. Med. 30: 41-44 (2006).
-
Gambhir D, Lawrence A, Aggarwal A, Misra R, Mandal SK, Naik S. Association of tumor necrosis factor alpha and IL-10 promoter polymorphisms with rheumatoid arthritis in North Indian population.
Rheumatol. Int. Sep 25 [Epub ahead of print] (2009).
*
-
Gamerdinger M, Clement AB, Behl C. Cholesterol-like effects of selective COX inhibitors and fibrates on cellular membranes and amyloid-beta production.
Mol. Pharmacol. 72: 141-151 (2007).
*
-
Gammill HS, Nelson JL. Naturally acquired microchimerism.
Int. J. Dev. Biol. Nov 2 [Epub ahead of print] (2009).
-
Gandjbakhch F, Fajardy I, Ferre B, Dubucquoi S, Flipo RM, Roger N, Solau-Gervais E. A functional haplotype of PADI4 gene in rheumatoid arthritis: positive correlation in a French population.
J. Rheumatol. 36: 881-886 (2009).
-
Ganea D, Gonzalez-Rey E, Delgado M. A novel mechanism for immunosuppression: from neuropeptides to regulatory T cells.
J. Neuroimmune Pharmacol. 1: 400-409 (2006).
-
Ganea E, Trifan M, Laslo AC, Putina G, Cristescu C. Matrix metalloproteinases: useful and deleterious.
Biochem. Soc. Trans. 35: 689-691 (2007).
*
-
Ganesan K, Balachandran C, Manohar BM, Puvanakrishnan R. Comparative studies on the interplay of testosterone, estrogen and progesterone in collagen induced arthritis in rats.
Bone 43: 758-765 (2008).
*
-
Ganesan K, Selvam R, Abhirami R, Raju KV, Manohar BM, Puvanakrishnan R. Gender differences and protective effects of testosterone in collagen induced arthritis in rats.
Rheumatol. Int. 28: 345-353 (2008).
*
-
Ganesan K, Tiwari M, Balachandran C, Manohar BM, Puvanakrishnan R. Estrogen and testosterone attenuate extracellular matrix loss in collagen-Induced arthritis in rats.
Calcif. Tissue Int. 83: 354-364 (2008).
-
Ganguly S. Leukemic phase of follicular lymphoma after treatment with etanercept in a patient with psoriasis.
Am. J. Clin. Dermatol. 10: 125-126 (2009).
-
Gannotti ME, Nahorniak M, Gorton GE 3rd, Sciascia K, Sueltenfuss M, Synder M, Zaniewski A. Can exercise influence low bone mineral density in children with juvenile rheumatoid arthritis?
Pediatr. Phys. Ther. 19: 128-139 (2007).
-
Gao B, Calhoun K, Fang D. The proinflammatory cytokines IL-1beta and TNF-alpha induce the expression of Synoviolin, an E3 ubiquitin ligase, in mouse synovial fibroblasts via the Erk1/2-ETS1 pathway.
Arthritis Res. Ther. 8: R172 (2006).
*
-
Gao IK, Haas-Wohrle A, Mueller KG, Lorenz HM, Fiehn C. Determination of anti-CCP antibodies in patients with suspected rheumatoid arthritis: does it help to predict the diagnosis before referral to a rheumatologist?
Ann. Rheum. Dis. 64: 1516-1517 (2005).
*
-
Gao J, Cha S, Jonsson R, Opalko J, Peck AB. Detection of anti-type 3 muscarinic acetylcholine receptor autoantibodies in the sera of Sjogren's syndrome patients by use of a transfected cell line assay.
Arthritis Rheum. 50: 2615-2621 (2004).
*
-
Gao P, Lu C, Zhang F, Sang P, Yang D, Li X, Kong H, Yin P, Tian J, Lu X, Lu A, Xu G. Integrated GC-MS and LC-MS plasma metabonomics analysis of ankylosing spondylitis.
Analyst 133: 1214-1220 (2008).
*
-
Gao SG, Li KH, Zeng KB, Tu M, Xu M, Lei GH. Elevated osteopontin level of synovial fluid and articular cartilage is associated with disease severity in knee osteoarthritis patients.
Osteoarthritis Cartilage Sep 1 [Epub ahead of print] (2009).
-
Gao X, Gazit E, Livneh A, Stastny P. Rheumatoid arthritis in Israeli Jews: shared sequences in the third hypervariable region of DRB1 alleles are associated with susceptibility.
J. Rheumatol. 18: 801-803 (1991).
-
Gao XJ, Ball EJ, Dombrausky L, Olsen NJ, Pincus T, Khan MA, Wolfe F, Stastny P. Class II human leukocyte antigen genes and T cell receptor polymorphisms in patients with rheumatoid arthritis.
Am. J. Med. 85: 14-16 (1988).
-
Gao XJ, Brautbar C, Gazit E, Segal R, Naparstek Y, Livneh A, Stastny P. A variant of HLA-DR4 determines susceptibility to rheumatoid arthritis in a subset of Israeli Jews.
Arthritis Rheum. 34: 547-551 (1991).
-
Garcia EB, Michaud K, Wolfe F. Gastrointestinal prophylactic therapy among patients with arthritis treated by rheumatology specialists.
J. Rheumatol. 33: 779-784 (2006).
-
García-Carrasco M, Jimenez-Hernandez M, Escarcega RO, Mendoza-Pinto C, Galarza-Maldonado C, Sandoval-Cruz M, Zamudio-Huerta L, Lopez-Colombo A, Cervera R. Use of rituximab in patients with systemic lupus erythematosus: an update.
Autoimmun. Rev. 8: 343-348 (2009).
-
Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, Soto-Vega E, Beltran-Castillo A, Jimenez-Hernandez M, Graillet D, Gonzalez L, Rojas-Rodriguez J, Pineda-Almazana A, Zamudio-Huerta L, Lopez-Colombo A. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.
Lupus Dec 4 [Epub ahead of print] (2009).
-
Garcia-Consuegra Molina J, Tapia Moreno R, Abelairas Gomez J, Peralta Calvo J, Merino Munoz R. Uveitis and juvenile idiopathic arthritis.
An. Esp. Pediatr. 54: 255-259 (2001).
-
Garcia-Gonzalez A, Lotz M, Ochoa JL. Anti-inflammatory activity of superoxide dismutase obtained from Debaryomyces hansenii on type II collagen induced arthritis in rats.
Rev. Invest. Clin. 61: 212-220 (2009).
-
Garcia-Lozano JR, Gonzalez-Escribano MF, Valenzuela A, Garcia A, Nunez-Roldan A. Association of vitamin D receptor genotypes with early onset rheumatoid arthritis.
Eur. J. Immunogenet. 28: 89-93 (2001).
*
-
Garcia-Lozano JR, Torres B, Fernandez O, Orozco G, Alvarez-Marquez A, Garcia A, Gonzalez-Gay MA, Garcia A, Nunez-Roldan A, Martin J, Gon Zalez-Escribano MF. Caspase 7 influences susceptibility to rheumatoid arthritis.
Rheumatology (Oxford) 46: 1243-1247 (2007).
*
-
Garcia-Palacios V, Yeon Chung H, Jin Choi S, Sarmasik A, Kurihara N, Won Lee J, Galson DL, Collins R, Roodman GD. Eosinophil chemotactic factor-L (ECF-L) enhances osteoclast formation by increasing in osteoclast precursors expression of LFA-1 and ICAM-1.
Bone 40: 316-322 (2007).
-
Garcia-Ruiz JC, Amutio E, Ponton J. Invasive fungal infection in immunocompromised patients.
Rev. Iberoam. Micol. 21: 55-62 (2004).
-
Garcia-Vicuna R, Gomez-Gaviro MV, Dominguez-Luis MJ, Pec MK, Gonzalez-Alvaro I, Alvaro-Gracia JM, Diaz-Gonzalez F. CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients.
Arthritis Rheum. 50: 3866-3877 (2004).
*
-
Garg S, Garg K, Altaf M, Magaldi JA. Refractory vertebral sarcoidosis responding to infliximab.
J. Clin. Rheumatol. 14: 238-240 (2008).
-
Garibyan L, Lobito AA, Siegel RM, Call ME, Wucherpfennig KW, Geha RS. Dominant-negative effect of the heterozygous C104R TACI mutation in common variable immunodeficiency (CVID).
J. Clin. Invest. 117: 1550-1557 (2007).
*
-
Garnier S, Dieude P, Michou L, Barbet S, Tan A, Lasbleiz S, Bardin T, Prum B, Cornelis F. IRF5 rs2004640-T allele, the new genetic factor for systemic lupus erythematosus, is not associated with rheumatoid arthritis.
Ann. Rheum. Dis. 66: 828-831 (2007).
*
-
Garred P, Madsen HO, Halberg P, Petersen J, Kronborg G, Svejgaard A, Andersen V, Jacobsen S. Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus.
Arthritis Rheum. 42: 2145-2152 (1999).
*
-
Garred P, Madsen HO, Petersen J, Marquart H, Hansen TM, Freiesleben Sorensen S, Volck B, Svejgaard A, Andersen V. CC chemokine receptor 5 polymorphism in rheumatoid arthritis.
J. Rheumatol. 25: 1462-1465 (1998).
-
Garrett-Sinha LA, John S, Gaffen SL. IL-17 and the Th17 lineage in systemic lupus erythematosus.
Curr. Opin. Rheumatol. 20: 519-525 (2008).
-
Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis.
J. Rheumatol. 33: 2398-2408 (2006).
-
Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence.
Clin. Rheumatol. 27: 67-76 (2008).
*
-
Gaspar MM, Boerman OC, Laverman P, Corvo ML, Storm G, Cruz ME. Enzymosomes with surface-exposed superoxide dismutase: in vivo behaviour and therapeutic activity in a model of adjuvant arthritis.
J. Control. Release 117: 186-195 (2007).
*
-
Gasparyan AY, Sandoo A, Stavropoulos-Kalinoglou A, Kitas GD. Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF-alpha therapy.
Rheumatol. Int. Jan 12 [Epub ahead of print] (2010).
*
-
Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Toms TE, Douglas KM, Kitas GD. The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases.
Curr. Vasc. Pharmacol. Jan 1 [Epub ahead of print] (2010).
-
Gassull MA. The role of nutrition in the treatment of inflammatory bowel disease.
Aliment. Pharmacol. Ther. 20 Suppl. 4: 79-83 (2004).
*
-
Gaston JS. Cytokines in arthritis the 'big numbers' move centre stage.
Rheumatology (Oxford) 47: 8-12 (2008).
*
-
Gaston JS. How much HLA-B27 expression is needed for spondyloarthritis?
J. Rheumatol. 35: 738-740 (2008).
*
-
Gatenby PA, Lucas RM, Engelsen O, Ponsonby AL, Clements M. Antineutrophil cytoplasmic antibody-associated vasculitides: could geographic patterns be explained by ambient ultraviolet radiation?
Arthritis Rheum. 61: 1417-1424 (2009).
*
-
Gatto B. Biologics targeted at TNF: design, production and challenges.
Reumatismo 58: 94-103 (2006).
*
-
Gattorno M, Chicha L, Gregorio A, Ferlito F, Rossi F, Jarrossay D, Lanzavecchia A, Martini A, Manz MG. Distinct expression pattern of IFN-alpha and TNF-alpha in juvenile idiopathic arthritis synovial tissue.
Rheumatology (Oxford) 46: 657-665 (2007).
*
-
Gattorno M, Pelagatti MA, Federici S, Brisca G, Martini A. Clinical presentation of autoinflammatory syndromes in childhood.
Curr. Rheumatol. Rev. 4: 34-45 (2008). *
-
Gatumu MK, Skarstein K, Papandile A, Browning JL, Fava RA, Bolstad AI. Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjogren's syndrome in salivary glands of non-obese diabetic mice.
Arthritis Res. Ther. 11: R24 (2009).
*
-
Gatzka M, Walsh CM. Apoptotic signal transduction and T cell tolerance.
Autoimmunity 40: 442-452 (2007).
-
Gauhar UA, Gaffo AL, Alarcon GS. Pulmonary manifestations of rheumatoid arthritis.
Semin. Respir. Crit. Care Med. 28: 430-440 (2007).
-
Gause A, Schnabel A. Rheumatology 2003-part I: research news concerning pathogenesis, epidemiology, diagnosis, and therapy of chronic inflammatory joint diseases.
Med. Klin. (Munich) 98: 523-533 (2003).
-
Gazi IF, Boumpas DT, Mikhailidis DP, Ganotakis ES. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins.
Clin. Exp. Rheumatol. 25: 102-111 (2007).
-
Gazic M. A familial study of seronegative spondyloarthritis.
Reumatizam 36: 35-40 (1989).
-
Geboes L, Dumoutier L, Kelchtermans H, Schurgers E, Mitera T, Renauld JC, Matthys P. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice.
Arthritis Rheum. 60: 390-395 (2009).
*
-
Geddes R. Minocycline-induced lupus in adolescents: clinical implications for physical therapists.
J. Orthop. Sports Phys. Ther. 37: 65-71 (2007).
-
Geens E, Geusens P, Vanhoof J, Berghs H, Praet J, Esselens G, Lens S, Dufour JP, Vandenberghe M, Van Mullem X, Westhovens R, Verschueren P. Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria.
Rheumatology (Oxford) 48: 546-550 (2009).
-
Geier DA, Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization.
Autoimmunity 38: 295-301 (2005).
-
Geier DA, Geier MR. A one year followup of chronic arthritis following rubella and hepatitis B vaccination based upon analysis of the Vaccine Adverse Events Reporting System (VAERS) database.
Clin. Exp. Rheumatol. 20: 767-771 (2002).
-
Geier MR, Geier DA. A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adverse Event Reporting System (VAERS) database and literature review.
Clin. Exp. Rheumatol. 22: 749-755 (2004).
-
Gelderman KA, Hultqvist M, Holmberg J, Olofsson P, Holmdahl R. T cell surface redox levels determine T cell reactivity and arthritis susceptibility.
Proc. Natl. Acad. Sci. U.S.A. 103: 12831-12836 (2006).
*
-
Gelderman KA, Hultqvist M, Olsson LM, Bauer K, Pizzolla A, Olofsson P, Holmdahl R. Rheumatoid arthritis: the role of reactive oxygen species in disease development and therapeutic strategies.
Antioxid. Redox Signal. 9: 1541-1568 (2007).
-
Gelderman KA, Hultqvist M, Pizzolla A, Zhao M, Nandakumar KS, Mattsson R, Holmdahl R. Macrophages suppress T cell responses and arthritis development in mice by producing reactive oxygen species.
J. Clin. Invest. 117: 3020-3028 (2007).
*
-
Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, Stern RS, Feldman SR, Rolstad T. Epidemiology of psoriatic arthritis in the population of the United States.
J. Am. Acad. Dermatol. 53: 573 (2005).
-
Genaro MS, Cargnelutti DE, Castro DO, Elicabe RJ, Gutierrez JV, Correa SG, de Guzman AM. Yersinia-triggered arthritis in IL-12p40-deficient mice: relevant antigens and local expression of Toll-like receptor mRNA.
Scand. J. Rheumatol. 36: 28-35 (2007).
*
-
Genc H, Duyur Cakit B, Nacir B, Saracoglu M, Kacar M, Erdem HR. The effects of sulfasalazine treatment on enthesal abnormalities of inflammatory rheumatic diseases.
Clin. Rheumatol. 26: 1104-1110 (2007).
*
-
Gendron S, Boisvert M, Chetoui N, Aoudjit F. alpha1beta1 Integrin and interleukin-7 receptor up-regulate the expression of RANKL in human T cells and enhance their osteoclastogenic function.
Immunology 125: 359-369 (2008).
*
-
Generini S, Giacomelli R, Fedi R, Fulminis A, Pignone A, Frieri G, Del Rosso A, Viscido A, Galletti B, Fazzi M, Tonelli F, Matucci Cerinic M. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy in inducing and maintaining remission of musculoskeletal and gut manifestations.
Ann. Rheum. Dis. 63: 1664-1669 (2004).
*
-
Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
Arthritis Rheum. 57: 679-685 (2007).
*
-
Genin E, Babron MC, McDermott MF, Mulcahy B, Waldron-Lynch F, Adams C, Clegg DO, Ward RH, Shanahan F, Molloy MG, O'Gara F, Clerget-Darpoux F. Modelling the major histocompatibility complex susceptibility to RA using the MASC method.
Genet. Epidemiol. 15: 419-430 (1998).
-
Genovese M, Van den Bosch F, Roberson S, Bojin S, Biagini I, Ryan P, Sloan-Lancaster J. LY2439821, a humanized anti-IL-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis.
Arthritis Rheum. Jan 21 [Epub ahead of print] (2010).
*
-
Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
N. Engl. J. Med. 353: 1114-1123 (2005).
*
-
Genovese MC, Breedveld FC, Emery P, Cohen S, Keystone E, Matteson EL, Baptiste Y, Chai A, Burke L, Reiss W, Sweetser M, Shaw TM. Safety of biologic therapies following rituximab treatment in rheumatoid arthritis patients.
Ann. Rheum. Dis. 68: 1894-1897 (2009).
-
Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug
Arthritis Rheum. 58: 2968-2980 (2008).
*
-
Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, Medich J, Sasso EH. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
J. Rheumatol. 34: 1040-1050 (2007).
-
Gensler L, Davis JC Jr. Recognition and treatment of juvenile-onset spondyloarthritis.
Curr. Opin. Rheumatol. 18: 507-611 (2006).
-
Genta MS, Genta RM, Gabay C. Systemic rheumatoid vasculitis: a review.
Semin. Arthritis Rheum. 36: 88-98 (2006).
*
-
George D, Salmeron A. Cot/Tpl-2 protein kinase as a target for the treatment of inflammatory disease.
Curr. Top. Med. Chem. 9: 611-622 (2009).
-
George-Chandy A, Nordstrom I, Nygren E, Jonsson IM, Postigo J, Collins LV, Eriksson K. Th17 development and autoimmune arthritis in the absence of reactive oxygen species.
Eur. J. Immunol. 38: 1118-1126 (2008).
*
-
George-Chandy A, Trysberg E, Eriksson K. Raised intrathecal levels of APRIL and BAFF in patients with SLE; relationship to neuropsychiatric symptoms.
Arthritis Res. Ther. 10: R97 (2008).
*
-
Georgios K, Helias A, Athanassios K, Eleni M, Konstantinos A. Craniofacial surgical management of a patient with systematic juvenile idiopathic arthritis and Crohn's disease.
J. Craniofac. Surg. 20: 948-950 (2009).
-
Geraghty EM, Ristow B, Gordon SM, Aronowitz P. Overwhelming parasitemia with Plasmodium falciparum infection in a patient receiving infliximab therapy for rheumatoid arthritis.
Clin. Infect. Dis. 44: e82-e84 (2007).
*
-
Gerard S, le Goff B, Maugars Y, Berthelot JM. Six-month response to anti-TNF drugs in axial spondylarthropathy according to the fulfillment or not of New-York criteria for ankylosing spondylitis or French recommendations for anti-TNF use. A "real life" retrospective study on 175 patients.
Joint Bone Spine 75: 680-687 (2008).
*
-
Gerdes S, Mrowietz U. Impact of comorbidities on the management of psoriasis.
Curr. Probl. Dermatol. 38: 21-36 (2009).
-
Gergely Jr P, Blazsek A, Weiszhar Z, Pazar B, Poor G. Lack of genetic association of the Toll-like receptor 4 (TLR4) Asp299Gly and Thr399Ile polymorphisms with spondylarthropathies in a Hungarian population.
Rheumatology (Oxford) 45: 1194-1196 (2006).
*
-
Gergely P Jr, Pullmann R, Stancato C, Otvos L Jr, Koncz A, Blazsek A, Poor G, Brown KE, Phillips PE, Perl A. Increased prevalence of transfusion-transmitted virus and cross-reactivity with immunodominant epitopes of the HRES-1/p28 endogenous retroviral autoantigen in patients with systemic lupus erythematosus.
Clin. Immunol. 116: 124-134 (2005).
*
-
Gergely P, Fekete B. New possibilities of treating patients with autoimmune disorders.
Orv. Hetil. 148: S58-S62 (2007).
-
Gerl V, Hostmann B, Johnen C, Waka A, Gerl M, Schumann F, Klein R, Radbruch A, Hiepe F. The intracellular 52-kd Ro/SSA autoantigen in keratinocytes is up-regulated by tumor necrosis factor alpha via tumor necrosis factor receptor I.
Arthritis Rheum. 52: 531-538 (2005).
*
-
Gerli R, Goodson NJ. Cardiovascular involvement in rheumatoid arthritis.
Lupus 14: 679-682 (2005).
-
Gerli R, Lunardi C, Bocci EB, Bobbio-Pallavicini F, Schillaci G, Caporali R, Bistoni O, Pirro M, Pitzalis C, Montecucco C. Anti-tumor necrosis factor-alpha response in rheumatoid arthritis is associated with an increase in serum soluble CD30.
J. Rheumatol. 35: 14-19 (2008).
-
Gerloni V, Pontikaki I, Gattinara M, Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Ann. Rheum. Dis. 67: 1145-1152 (2008).
-
Gerloni V, Pontikaki I, Gattinara M, Fantini F. Biological therapy with TNF-inhibitors in pediatric rheumatology. Review of the literature and personal experience.
Reumatismo 59: 244-261 (2007).
-
Germano V, Picchianti Diamanti A, Baccano G, Natale E, Onetti Muda A, Priori R, Valesini G. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis.
Ann. Rheum. Dis. 64: 1519-1520 (2005).
*
-
Germolec DR, Frawley RP, Evans E. Markers of inflammation.
Methods Mol. Biol. 598: 53-73 (2010).
*
-
Geronikaki AA, Gavalas AM. Antioxidants and inflammatory disease: synthetic and natural antioxidants with anti-inflammatory activity.
Comb. Chem. High Throughput Screen. 9: 425-442 (2006).
-
Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis.
J. Immunol. 138: 3525-3531 (1987).
-
Gershwin ME, Van de Water J, Leung P, Ansari AA, Coppel RL. The pathobiology and the cause of primary biliary cirrhosis.
Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 36-37. September 12 - 13 (2003). *
-
Gershwin ME, Van de WaterJ, Leung P, Ansari AA, Coppel RL. Primary biliary cirrhosis: from induction through destruction.
Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Poppers 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 18. October 15-16 (2003). *
-
Gertsch J. Anti-inflammatory cannabinoids in diet: towards a better understanding of CB(2) receptor action?
Commun. Integr. Biol. 1: 26-28 (2008).
-
Getting SJ. Targeting melanocortin receptors as potential novel therapeutics.
Pharmacol. Ther. 111: 1-15 (2006).
*
-
Getting SJ. Glucocorticoid and melanocortins: special issue.
ScientificWorldJournal 7: 1463-1464 (2007).
-
Getting SJ, Lam CW, Chen AS, Grieco P, Perretti M. Melanocortin 3 receptors control crystal-induced inflammation.
FASEB J. 20: 2234-2241 (2006).
*
-
Geurts J, Arntz OJ, Bennink MB, Joosten LA, van den Berg WB, van de Loo FA. Application of a disease-regulated promoter is a safer mode of local IL-4 gene therapy for arthritis.
Gene Ther. 14: 1632-1638 (2007).
*
-
Geurts P, Fillet M, de Seny D, Meuwis MA, Malaise M, Merville MP, Wehenkel L. Proteomic mass spectra classification using decision tree based ensemble methods.
Bioinformatics 21: 3138-3145 (2005).
*
-
Geyer M, Muller-Ladner U. Actual status of antiinterleukin-1 therapies in rheumatic diseases.
Curr. Opin. Rheumatol. Feb 10 [Epub ahead of print] (2010).
-
Ghezzi P, Cerami A. Tumor necrosis factor as a pharmacological target.
Mol. Biotechnol. 31: 239-244 (2005).
-
Ghezzi P, Cerami A. Tumor necrosis factor as a pharmacological target.
Methods Mol. Med. 98: 1-8 (2004).
-
Ghigo A, Damilano F, Braccini L, Hirsch E. PI3K inhibition in inflammation: toward tailored therapies for specific diseases.
Bioessays 32: 185-196 (2010).
*
-
Ghirardello A, Doria A, Zampieri S, Tarricone E, Tozzoli R, Villalta D, Bizzaro N, Piccoli A, Gambari PF. Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients.
J. Autoimmun. 22: 235-240 (2004).
-
Ghodke Y, Chopra A, Joshi K, Patwardhan B. Are thymidylate synthase and methylene tetrahydrofolate reductase genes linked with methotrexate response (efficacy, toxicity) in Indian (Asian) rheumatoid arthritis patients?
Clin. Rheumatol. 27: 787-789 (2008).
*
-
Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling.
Immunol. Rev. 228: 273-287 (2009).
*
-
Ghoreschi K, Laurence A, O'Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be?
Nat. Immunol. 10: 356-360 (2009).
*
-
Ghoreschi K, Rocken M. Immune deviation strategies in the therapy of psoriasis.
Curr. Drug Targets Inflamm. Allergy 3: 193-198 (2004).
-
Ghosh D, Tsokos GC. Spleen tyrosine kinase: an Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases.
Autoimmunity Dec 14 [Epub ahead of print] (2009).
-
Ghosh S. Maintenance therapy versus episodic therapy with infliximab for Crohns disease.
Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 80-81 (2004).
*
-
Giaginis C, Giagini A, Theocharis S. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands as potential therapeutic agents to treat arthritis.
Pharmacol. Res. 60: 160-169 (2009).
*
-
Giaglis S, Mimidis K, Papadopoulos V, Thomopoulos K, Sidiropoulos P, Rafail S, Nikolopoulou V, Fragouli E, Kartalis G, Tzioufas A, Boumpas D, Ritis K. Increased frequency of mutations in the gene responsible for familial Mediterranean fever (MEFV) in a cohort of patients with ulcerative colitis: evidence for a potential disease-modifying effect?
Dig. Dis. Sci. 51: 687-692 (2006).
*
-
Giagounidis AA, Haase S, Germing U, Heinsch M, Aul C. Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion.
Acta Haematol. 113: 146-149 (2005).
-
Giani T, Simonini G, Lunardi C, Puccetti A, De Martino M, Falcini F. Juvenile psoriatic arthritis and acquired sensorineural hearing loss in a teenager: is there an association?
Clin. Exp. Rheumatol. 24: 344-346 (2006).
-
Giannitti C, Bellisai F, Ferri C, Galeazzi M. Treatment strategies for a patient with rheumatoid arthritis and hepatitis C.
Expert Opin. Pharmacother. 10: 579-587 (2009).
-
Giannitti C, Benucci M, Caporali R, Manganelli S, Bellisai F, Sebastiani GD, Galeazzi M. Efficacy and safety of anti-TNF-alpha therapy combined with cyclosporine A in patients with rheumatoid arthritis and concomitant hepatitis C virus infection.
Int. J. Immunopathol. Pharmacol. 22: 543-546 (2009).
-
Giannoni A, Tani C, Clerico A, Passino C, Tavoni A, d'Ascanio A, Bombardieri S, Emdin M. When the heart is burning: amino-terminal pro-brain natriuretic peptide as an early marker of cardiac involvement in active autoimmune rheumatic disease.
Int. J. Cardiol. Nov 17 [Epub ahead of print] (2009).
-
Giardina AR, Accardo-Palumbo A, Ciccia F, Ferrante A, Principato A, Impastato R, Triolo G. Blocking TNF in vitro with infliximab determines the inhibition of expansion and interferon gamma production of Vgamma9/Vdelta2 T lymphocytes from patients with active rheumatoid arthritis. A role in the susceptibility to tuberculosis?
Reumatismo 61: 21-26 (2009).
*
-
Giardina E, Novelli G, Costanzo A, Nistico S, Bulli C, Sinibaldi C, Sorgi ML, Chimenti S, Pallone F, Taccari E, Borgiani P. Psoriatic arthritis and CARD15 gene polymorphisms: no evidence for association in the Italian population.
J. Invest. Dermatol. 122: 1106-1107 (2004).
*
-
Giardina E, Predazzi I, Sinibaldi C, Peconi C, Amerio P, Costanzo A, Paradisi A, Capizzi R, Paradisi M, Chimenti S, Taccari E, Novelli G. PSORS2 markers are not associated with psoriatic arthritis in the Italian population.
Hum. Hered. 61: 120-122 (2006).
*
-
Gibbons LJ, Hyrich KL. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
BioDrugs 23: 111-124 (2009).
-
Gibbons LJ, Thomson W, Zeggini E, Worthington J, Barton A, Eyre S, Donn R, Hinks A. The type 1 diabetes susceptibility gene SUMO4 at IDDM5 is not associated with susceptibility to rheumatoid arthritis or juvenile idiopathic arthritis.
Rheumatology (Oxford) 44: 1390-1393 (2005).
*
-
Gibert M, Balandraud N, Touinssi M, Mercier P, Roudier J, Reviron D. Functional categorization of HLA-DRB1 alleles in rheumatoid arthritis: the protective effect.
Hum. Immunol. 64: 930-935 (2003).
-
Gibson AW, Li FJ, Wu J, Edberg JC, Su K, Cafardi J, Wiener H, Tiwari H, Kimberly RP, Davis RS. The FCRL3 -169CT promoter single-nucleotide polymorphism, which is associated with systemic lupus erythematosus in a Japanese population, predicts expression of receptor protein on CD19+B cells.
Arthritis Rheum. 60: 3510-3512 (2009).
*
-
Gibson D, Banha J, Penque D, Costa L, Conrads TP, Cahill D, O'Brien J, Rooney M. Diagnostic and prognostic biomarker discovery strategies for autoimmune disorders.
J. Proteomics Dec 5 [Epub ahead of print] (2009).
*
-
Gibson D, Finnegan S, Jordan G, Scaife C, Curry WJ, Brockbank S, McAllister C, Pennington S, Dunn M, Rooney ME. Stratification and monitoring of juvenile idiopathic arthritis patients by synovial proteome analysis.
J. Proteome Res. 8: 5601-5609 (2009).
*
-
Gibson DS, Blelock S, Brockbank S, Curry J, Healy A, McAllister C, Rooney ME. Proteomic analysis of recurrent joint inflammation in juvenile idiopathic arthritis.
J. Proteome Res. 5: 1988-1995 (2006).
*
-
Giembycz MA, Smith SJ. Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?
Curr. Pharm. Des. 12: 3207-3220 (2006).
-
Gil A. Polyunsaturated fatty acids and inflammatory diseases.
Biomed. Pharmacother. 56: 388-396 (2002).
-
Gilaberte Y, Coscojuela C, Vazquez C, Rosello R, Vera J. Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis.
Br. J. Dermatol. 156: 368-371 (2007).
*
-
Giles JT, Allison M, Bingham CO 3rd, Scott WM Jr, Bathon JM. Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis.
Arthritis Rheum. 61: 1248-1256 (2009).
*
-
Giles JT, Bathon JM. Serious infections associated with anticytokine therapies in the rheumatic diseases.
J. Intensive Care Med. 19: 320-334 (2004).
*
-
Giles JT, Fernandes V, Lima JA, Bathon JM. Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis.
Arthritis Res. Ther. 7: 195-207 (2005).
*
-
Giles JT, Post W, Blumenthal RS, Bathon JM. Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis.
Nat. Clin. Pract. Rheumatol. 2: 320-329 (2006).
*
-
Gill H, Majithia V. Successful use of infliximab in the treatment of Reiter's syndrome: a case report and discussion.
Clin. Rheumatol. 27: 121-123 (2008).
*
-
Gill H, Prasad J. Probiotics, immunomodulation, and health benefits.
Adv. Exp. Med. Biol. 606: 423-454 (2008).
-
Gillespie MT. Impact of cytokines and T lymphocytes upon osteoclast differentiation and function.
Arthritis Res. Ther. 9: 103 (2007).
*
-
Gillett CD, Langefeld CD, Williams AH, Ortmann WA, Graham RR, Rodine PR, Selby SA, Gaffney PM, Behrens TW, Moser KL. Fine mapping chromosome 16q12 in a collection of 231 systemic lupus erythematosus sibpair and multiplex families.
Genes Immun. 6: 19-23 (2005).
*
-
Gilliam BE, Wolff AE, Moore TL. Partial C4 deficiency in juvenile idiopathic arthritis patients.
J. Clin. Rheumatol. 13: 256-260 (2007).
-
Gillooly K, Pattoli M, Taylor T, Chen L, Cheng L, Gregor K, Whitney G, Susulic V, Watterson S, Kempson J, Pitts W, Booth-Lute H, Yang G, Davies P, Kukral D, Strnad J, McIntyre K, Darienzo C, Salter-Cid L, Yang Z, Wang-Iverson D, Burke JR. Periodic, partial inhibition of IKKbeta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis.
J. Pharmacol. Exp. Ther. 331: 349-360 (2009).
*
-
Ginanjar E, Sumariyono , Setiati S, Setiyohadi B. Vitamin D and autoimmune disease.
Acta Med. Indones. 39: 133-141 (2007).
-
Gindzienska-Sieskiewicz E, Klimiuk PA, Kisiel DG, Gindzienski A, Sierakowski S. The changes in monosaccharide composition of immunoglobulin G in the course of rheumatoid arthritis.
Clin. Rheumatol. 26: 685-690 (2007).
*
-
Giordano N, Amendola A, Papakostas P, Cipolli F, Agate VM, Battisti E, Marchi B, Nuti R. Immune and autoimmune disorders in HCV chronic liver disease: personal experience and commentary on literature.
New Microbiol. 28: 311-317 (2005).
-
Giquel B, Carmouse S, Denais C, Cherfa A, Chimenti MS, Fert I, Hacquard-Bouder C, Breban M, Andre C. Two HLA-B27 alleles differently associated with spondylarthritis, B*2709 and B*2705, display similar intracellular trafficking and oligomer formation.
Arthritis Rheum. 56: 2232-2242 (2007).
*
-
Girardi E, Holdom MD, Davies AM, Sutton BJ, Beavil AJ. The crystal structure of rabbit IgG-Fc.
Biochem. J. 417: 77-83 (2009).
*
-
Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, Simon M, Senshu T, Masson-Bessiere C, Jolivet-Reynaud C, Jolivet M, Serre G. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues.
J. Immunol. 162: 585-594 (1999).
*
-
Girolomoni G, Gisondi P. Psoriasis and systemic inflammation: underdiagnosed enthesopathy.
J. Eur. Acad. Dermatol. Venereol. 23 Suppl. 1: 3-8 (2009).
-
Girschick HJ, Guilherme L, Inman RD, Latsch K, Rihl M, Sherer Y, Shoenfeld Y, Zeidler H, Arienti S, Doria A. Bacterial triggers and autoimmune rheumatic diseases.
Clin. Exp. Rheumatol. 26: S12-S17 (2008).
-
Gisondi P, Fantuzzi F, Malerba M, Girolomoni G. Folic acid in general medicine and dermatology.
J. Dermatolog. Treat. 18: 138-146 (2007).
-
Gisondi P, Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach.
Autoimmun. Rev. 6: 515-519 (2007).
-
Gisondi P, Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors.
Semin. Thromb. Hemost. 35: 313-324 (2009).
-
Gisondi P, Girolomoni G. Cardiometabolic comorbidities and the approach to patients with psoriasis.
Actas. Dermosifiliogr. 100: S14-S21 (2009).
-
Gjurow D, Grzelewski T, Sobocinska A, Stelmach I. Tumor necrosis factor inhibitors in pediatric asthma.
Recent Pat. Inflamm. Allergy Drug Discov. 3: 143-148 (2009).
-
Gladd DA, Olech E. Antiphospholipid antibodies in rheumatoid arthritis: identifying the dominoes.
Curr. Rheumatol. Rep. 11: 43-51 (2009).
-
Gladman DD. Biologic therapy of psoriatic arthritis.
Reumatismo 59 Suppl. 1: 85-87 (2007).
*
-
Gladman DD. Current concepts in psoriatic arthritis.
Curr. Opin. Rheumatol. 14: 361-366 (2002).
-
Gladman DD. Axial disease in psoriatic arthritis.
Curr. Rheumatol. Rep. 9: 455-460 (2007).
-
Gladman DD. Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis.
Nat. Clin. Pract. Rheumatol. 4: 510-511 (2008).
-
Gladman DD. Psoriatic arthritis.
Dermatol. Ther. 22: 40-55 (2009).
-
Gladman DD. Mortality in psoriatic arthritis.
Clin. Exp. Rheumatol. 26: S62-S65 (2008).
-
Gladman DD. GRAPPA 2007: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis - prologue.
J. Rheumatol. 35: 1420-1422 (2008).
-
Gladman DD. Can we identify psoriatic arthritis early?
Curr. Rheumatol. Rep. 10: 419-421 (2008).
-
Gladman DD. Etanercept for psoriatic arthritis.
BMJ 340: c229 (2010).
-
Gladman DD. Spondyloarthropathies: targeted therapy for psoriatic arthritis.
Nat. Rev. Rheumatol. 5: 241-242 (2009).
-
Gladman DD. Psoriatic arthritis from Wright's era until today.
J. Rheumatol. Suppl. 83: 4-8 (2009).
-
Gladman DD. Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA) 2008.
J. Rheumatol. 37: 446-447 (2010).
-
Gladman DD. Traditional and newer therapeutic options for psoriatic arthritis: an evidence-based review.
Drugs 65: 1223-1238 (2005).
-
Gladman DD. Consensus exercise on domains in psoriatic arthritis.
Ann. Rheum. Dis. 64 Suppl. 2: ii113-ii114 (2005).
*
-
Gladman DD, Ang M, Su L, Tom BD, Schentag CT Phd, Farewell VT. Cardiovascular morbidity in psoriatic arthritis (PsA).
Ann. Rheum. Dis. 68: 1131-1135 (2009).
-
Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome.
Ann. Rheum. Dis. 64 Suppl. 2: ii14-ii17 (2005).
*
-
Gladman DD, Farewell VT. Longitudinal cohort studies.
J. Rheumatol. Suppl. 72: 30-32 (2005).
-
Gladman DD, Farewell VT, Pellett F, Schentag C, Rahman P. HLA is a candidate region for psoriatic arthritis. Evidence for excessive HLA sharing in sibling pairs.
Hum. Immunol. 64: 887-889 (2003).
-
Gladman DD, Landewe R, McHugh NJ, Fitzgerald O, Thaci D, Coates L, Mease PJ, Qureshi AA, Krueger GG, Ritchlin CT, Kavanaugh AF, Garg A. Composite measures in psoriatic arthritis: GRAPPA 2008.
J. Rheumatol. 37: 453-461 (2010).
-
Gladman DD, Mease PD. Towards international guidelines for the management of psoriatic arthritis.
J. Rheumatol. 33: 1228-1230 (2006).
-
Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Adalimumab improves joint- and skin-related functional impairment in patients with psoriatic arthritis: patient- reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).
Ann. Rheum. Dis. 66: 163-168 (2007).
*
-
Gladman DD, Mease PJ, Healy P, Helliwell PS, Fitzgerald O, Cauli A, Lubrano E, Krueger GG, van der Heijde D, Veale DJ, Kavanaugh A, Nash P, Ritchlin C, Taylor W, Strand V. Outcome measures in psoriatic arthritis.
J. Rheumatol. 34: 1159-1166 (2007).
-
Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, Perdok RJ, Sasso EH. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
Arthritis Rheum. 56: 476-488 (2007).
*
-
Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, Gottlieb AB, Krueger GG, Nash P, Ritchlin CT, Taylor W, Adebajo A, Braun J, Cauli A, Carneiro S, Choy E, Dijkmans B, Espinoza L, van der Heijde D, Husni E, Lubrano E, McGonagle D, et al. Consensus on a core set of domains for psoriatic arthritis.
J. Rheumatol. 34: 1167-1170 (2007).
-
Gladman DD, Rahman P, Krueger GG, Mease PJ, Qureshi AA, Dutz JP, Lindqvist U, Carneiro S, Helliwell PS, Ujfalussy I, Gottlieb AB, Behrens F, Stahle M. Clinical and genetic registries in psoriatic disease.
J. Rheumatol. 35: 1458-1463 (2008).
-
Gladman DD, Ritchlin C, Helliwell PS. Psoriatic arthritis clinical registries and genomics.
Ann. Rheum. Dis. 64 Suppl. 2: ii103-ii105 (2005).
*
-
Gladman DD, Strand V, Mease PJ, Antoni C, Nash P, Kavanaugh A. OMERACT 7 psoriatic arthritis workshop: synopsis.
Ann. Rheum. Dis. 64 Suppl. 2: ii115-ii116 (2005).
*
-
Glant TT, Adarichev VA, Nesterovitch AB, Szanto S, Oswald JP, Jacobs JJ, Firneisz G, Zhang J, Finnegan A, Mikecz K. Disease-associated qualitative and quantitative trait loci in proteoglycan-induced arthritis and collagen-induced arthritis.
Am. J. Med. Sci. 327: 188-195 (2004).
-
Glant TT, Szanto S, Vegvari A, Szabo Z, Kis-Toth K, Mikecz K, Adarichev VA. Two loci on chromosome 15 control experimentally induced arthritis through the differential regulation of IL-6 and lymphocyte proliferation.
J. Immunol. 181: 1307-1314 (2008).
*
-
Glas J, Stallhofer J, Ripke S, Wetzke M, Pfennig S, Klein W, Epplen JT, Griga T, Schiemann U, Lacher M, Koletzko S, Folwaczny M, Lohse P, Goke B, Ochsenkuhn T, Muller-Myhsok B, Brand S. Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease.
Am. J. Gastroenterol. 104: 1737-1744 (2009).
*
-
Glaser RL, Goldbach-Mansky R. The spectrum of monogenic autoinflammatory syndromes: understanding disease mechanisms and use of targeted therapies.
Curr. Allergy Asthma Rep. 8: 288-298 (2008).
-
Glass DN. Juvenile idiopathic arthritis and HLA class I and class II interaction and age of onset effects.
Arthritis Rheum. Feb 26 [Epub ahead of print] (2010).
-
Glass GG. Osteoarthritis.
Dis. Mon. 52: 343-362 (2006).
-
Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, Flannery CR, Peluso D, Kanki K, Yang Z, Majumdar MK, Morris EA. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis.
Nature 434: 644-648 (2005).
*
-
Glatigny S, Blaton MA, Mencher SK, Mistou S, Lucas B, Fournier C, Wang LG, Chiocchia G. Treatment of collagen-induced arthritis by Natura-alpha via regulation of Th-1/Th-17 responses.
Eur. J. Immunol. Jan 13 [Epub ahead of print] (2010).
*
-
Glazier RH, Badley EM, Lineker SC, Wilkins AL, Bell MJ. Getting a grip on arthritis: an educational intervention for the diagnosis and treatment of arthritis in primary care.
J. Rheumatol. 32: 137-142 (2005).
-
Gleason BC, Zembowicz A, Granter SR. Non-bullous neutrophilic dermatosis: an uncommon dermatologic manifestation in patients with lupus erythematosus.
J. Cutan. Pathol. 33: 721-725 (2006).
*
-
Glickstein LJ, Coburn JL. Association of macrophage inflammatory response and cell death after in vitro Borrelia burgdorferi infection with arthritis resistance.
Am. J. Trop. Med. Hyg. 75: 964-967 (2006).
-
Gliddon AE, Dore CJ, Black CM, McHugh N, Moots R, Denton CP, Herrick A, Barnes T, Camilleri J, Chakravarty K, Emery P, Griffiths B, Hopkinson ND, Hickling P, Lanyon P, Laversuch C, Lawson T, Mallya R, Nisar M, Rhys-Dillon C, Sheeran T, Maddison PJ. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril.
Arthritis Rheum. 56: 3837-3846 (2007).
*
-
Glinskii AB, Ma J, Ma S, Grant D, Lim CU, Sell S, Glinsky GV. Identification of intergenic trans-regulatory RNAs containing a disease-linked SNP sequence and targeting cell cycle progression/differentiation pathways in multiple common human disorders.
Cell Cycle 8: 3925-3942 (2009).
-
Glinsky GV. An SNP-guided microRNA map of fifteen common human disorders identifies a consensus disease phenocode aiming at principal components of the nuclear import pathway.
Cell Cycle 7: 2570-2583 (2008).
*
-
Glinsky GV. SNP-guided microRNA maps (MirMaps) of 16 common human disorders identify a clinically accessible therapy reversing transcriptional aberrations of nuclear import and inflammasome pathways.
Cell Cycle 7: 3564-3576 (2008).
*
-
Glinsky GV. Disease phenocode analysis identifies SNP-guided microRNA maps (MirMaps) associated with human "master" disease genes.
Cell Cycle 7: 3680-3694 (2008).
*
-
Globe D, Bayliss MS, Harrison DJ. The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups.
Health Qual. Life Outcomes 7: 62 (2009).
*
-
Glocker MO, Guthke R, Kekow J, Thiesen HJ. Rheumatoid arthritis, a complex multifactorial disease: on the way toward individualized medicine.
Med. Res. Rev. 26: 63-87 (2006).
*
-
Glossop JR, Dawes PT, Hassell AB, Mattey DL. Anemia in rheumatoid arthritis: association with polymorphism in the tumor necrosis factor receptor I and II genes.
J. Rheumatol. 32: 1673-1678 (2005).
-
Glossop JR, Dawes PT, Nixon NB, Mattey DL. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis.
Arthritis Res. Ther. 7: R1227-R1234 (2005).
*
-
Glossop JR, Nixon NB, Dawes PT, Hassell AB, Mattey DL. No association of polymorphisms in the tumor necrosis factor receptor I and receptor II genes with disease severity in rheumatoid arthritis.
J. Rheumatol. 30: 1406-1409 (2003).
-
Gluck T, Muller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases.
Clin. Infect. Dis. 46: 1459-1465 (2008).
*
-
Gluszko P. Effects of biologic antirheumatic treatments on bone metabolism in rheumatoid arthritis and ankylosing spondylitis.
Endokrynol. Pol. 60: 115-121 (2009).
-
Glynn F, O'Sullivan P. Vocal fold deposits in macrophagic myofasciitis.
Ear Nose Throat J. 86: 238-239 (2007).
-
Go RC, Alarcon GS, Acton RT, Koopman WJ, Vittor VJ, Barger BO. Analyses of HLA linkage in white families with multiple cases of seropositive rheumatoid arthritis.
Arthritis Rheum. 30: 1115-1123 (1987).
-
Gobelet C, Luthi F, Al-Khodairy AT, Chamberlain MA. Work in inflammatory and degenerative joint diseases.
Disabil. Rehabil. 29: 1331-1339 (2007).
-
Gobezie R, Millett PJ, Sarracino DS, Evans C, Thornhill TS. Proteomics: applications to the study of rheumatoid arthritis and osteoarthritis.
J. Am. Acad. Orthop. Surg. 14: 325-332 (2006).
-
Gockel HR, Lugering A, Heidemann J, Schmidt M, Domschke W, Kucharzik T, Lugering N. Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway.
J. Immunol. 172: 5103-5109 (2004).
*
-
Goeb V, Dieude P, Daveau R, Thomas-L'otellier M, Jouen F, Hau F, Boumier P, Tron F, Gilbert D, Fardellone P, Cornelis F, Le Loet X, Vittecoq O. Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis.
Rheumatology (Oxford) 47: 1208-1212 (2008).
*
-
Goeb V, Dieude P, Vittecoq O, Mejjad O, Menard JF, Thomas M, Gilbert D, Boumier P, Pouplin S, Daragon A, Fardellone P, Tron F, Cornelis F, Le Loet X. Association between the TNFRII 196R allele and diagnosis of rheumatoid arthritis.
Arthritis Res. Ther. 7: R1056-R1062 (2005).
*
-
Goeb V, Smolen J, Emery P, Marzo-Ortega H. Early inflammatory clinics. Experience with early arthritis/back pain clinics.
Clin. Exp. Rheumatol. 27: S74-S79 (2009).
-
Goecke A, Guerrero J. Glucocorticoid receptor beta in acute and chronic inflammatory conditions: clinical implications.
Immunobiology 211: 85-96 (2006).
-
Goedecke V, Crane AM, Jaakkola E, Kaluza W, Laiho K, Weeks DE, Wilson J, Kauppi M, Kaarela K, Tuomilehto J, Wordsworth BP, Brown MA. Interleukin 10 polymorphisms in ankylosing spondylitis.
Genes Immun. 4: 74-76 (2003).
*
-
Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, Kerstens PJ, Grillet BA, de Jager MH, Han KH, Speyer I, van der Lubbe PA, Seys PE, Breedveld FC, Dijkmans BA. Patient preferences for treatment: report from a randomized comparison of treatment strategies in early rheumatoid arthritis (BeSt trial).
Ann. Rheum. Dis. 66: 1227-1232 (2007).
*
-
Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Peeters AJ, de Jonge-Bok JM, Mallee C, de Beus WM, de Sonnaville PB, Ewals JA, Breedveld FC, Dijkmans BA. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial.
Ann. Intern. Med. 146: 406-415 (2007).
*
-
Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "curecumin": from kitchen to clinic.
Biochem. Pharmacol. 75: 787-809 (2008).
*
-
Goel N, Stephens S. Certolizumab pegol.
MAbs. Mar 21 [Epub ahead of print] (2010).
-
Goertz B, Fassbender WJ, Williams JC, Marzeion AM, Bretzel RG, Stracke H, Berliner MN. Vitamin D receptor genotypes are not associated with rheumatoid arthritis or biochemical parameters of bone turnover in German RA patients.
Clin. Exp. Rheumatol. 21: 333-339 (2003).
-
Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF. Exacerbation of ulcerative colitis after rituximab salvage therapy.
Inflamm. Bowel Dis. 13: 1365-1368 (2007).
*
-
Goffe B. Etanercept (Enbrel(R)) - an update.
Skin Therapy Lett. 9: 1-4 (2004).
*
-
Goffe B, Cather JC. Etanercept: an overview.
J. Am. Acad. Dermatol. 49: S105-S111 (2003).
-
Gogalniceanu D, Trandafir V, Chiriac R, Gogalniceanu P. Temporomandibular joint ankylosis. A possible complication in juvenile psoriatic rheumatism.
Rev. Med. Chir. Soc. Med. Nat. Iasi. 109: 652-659 (2005).
-
Goh FG, Piccinini AM, Krausgruber T, Udalova IA, Midwood KS. Transcriptional regulation of the endogenous danger signal tenascin-C: a novel autocrine loop in inflammation.
J. Immunol. Jan 27 [Epub ahead of print] (2010).
-
Goh L, Samanta A. A systematic Medline analysis of therapeutic approaches in ankylosing spondylitis.
Rheumatol. Int. 29: 1123-1135 (2009).
*
-
Goicovich E, Molina C, Perez P, Aguilera S, Fernandez J, Olea N, Alliende C, Leyton C, Romo R, Leyton L, Gonzalez MJ. Enhanced degradation of proteins of the basal lamina and stroma by matrix metalloproteinases from the salivary glands of Sjogren's syndrome patients: correlation with reduced structural integrity of acini and ducts.
Arthritis Rheum. 48: 2573-2584 (2003).
*
-
Goikoetxea U, Eguiluz A, Lobo C, Cosme A, Ojeda E, Bujanda L. Sweet's syndrome and arthritis in a patient with ulcerative colitis.
Gastroenterol. Hepatol. 30: 506-507 (2007).
-
Golan I, Nedvetzki S, Golan I, Eshkar-Sebban L, Levartovsky D, Elkayam O, Caspi D, Aamar S, Amital H, Rubinow A, Naor D. Expression of extra trinucleotide in CD44 variant of rheumatoid arthritis patients allows generation of disease-specific monoclonal antibody.
J. Autoimmun. 28: 99-113 (2007).
-
Gold LS, Ward MH, Dosemeci M, Roos AJ. Systemic autoimmune disease mortality and occupational exposures.
Arthritis Rheum. 56: 3189-3201 (2007).
*
-
Gold SM, Voskuhl RR. Estrogen and testosterone therapies in multiple sclerosis.
Prog. Brain Res. 175: 239-251 (2009).
-
Goldacre MJ, Wotton CJ, Seagroatt V, Yeates D. Immune-related disease before and after vasectomy: an epidemiological database study.
Hum. Reprod. 22: 1273-1278 (2007).
*
-
Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, Kim HJ, Brewer C, Zalewski C, Wiggs E, Hill S, Turner ML, Karp BI, Aksentijevich I, Pucino F, Penzak SR, Haverkamp MH, Stein L, Adams BS, Moore TL, Fuhlbrigge RC, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.
N. Engl. J. Med. 355: 581-592 (2006).
*
-
Goldberg M, Nadiv O, Luknar-Gabor N, Agar G, Beer Y, Katz Y. Synergism between tumor necrosis factor alpha and interleukin-17 to induce IL-23 p19 expression in fibroblast-like synoviocytes.
Mol. Immunol. 46: 1854-1859 (2009).
*
-
Goldberg RJ, Katz J. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain.
Pain 129: 210-223 (2007).
*
-
Goldblatt F, Isenberg DA. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
Handb. Exp. Pharmacol. 181: 163-181 (2008).
-
Goldenberg DM. Epratuzumab in the therapy of oncological and immunological diseases.
Expert Rev. Anticancer Ther. 6: 1341-1353 (2006).
-
Goldfinger S. The inherited autoinflammatory syndrome: a decade of discovery.
Trans. Am. Clin. Climatol. Assoc. 120: 413-418 (2009).
-
Goldin BR, Gorbach SL. Clinical indications for probiotics: an overview.
Clin. Infect. Dis. 46 Suppl. 2: S96-S100 (2008).
*
-
Goldman JA, Xia HA, White B, Paulus H. Evaluation of a modified ACR20 scoring system in patients with rheumatoid arthritis receiving treatment with etanercept.
Ann. Rheum. Dis. 65: 1649-1652 (2006).
*
-
Goldshmid O, Dovorish Z, Zehavi T, Eisen A, Bar-Dayan Y, Amital H. Coexistent pyoderma gangrenosum and tibialis anterior myositis as presenting manifestations of Crohn's disease: case report and review of the literature.
Rheumatol. Int. Oct 22 [Epub ahead of print] (2009).
*
-
Goldsmith DR, Wagstaff AJ. Spotlight on etanercept in plaque psoriasis and psoriatic arthritis.
BioDrugs 19: 401-403 (2005).
-
Goldsmith DR, Wagstaff AJ. Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis.
Am. J. Clin. Dermatol. 6: 121-136 (2005).
-
Goldstein F. Immunosuppressant therapy of inflammatory bowel disease. Pharmacologic and clinical aspects.
J. Clin. Gastroenterol. 9: 654-658 (1987).
-
Goldstein I, Simon AJ, Horin SB, Matzri S, Koltakov A, Langevitz P, Rechavi G, Amariglio N, Bank I. Synovial VLA-1+ T cells display an oligoclonal and partly distinct repertoire in rheumatoid and psoriatic arthritis.
Clin. Immunol. 128: 75-84 (2008).
*
-
Goldstein NS, Sanford WW, Bodzin JH. Crohn's-like complications in patients with ulcerative colitis after total proctocolectomy and ileal pouch-anal anastomosis.
Am. J. Surg. Pathol. 21: 1343-1353 (1997).
-
Goldstein R, Sengar DP. Comparative studies of the major histocompatibility complex in French Canadian and non-French Canadian Caucasians with systemic lupus erythematosus.
Arthritis Rheum. 36: 1121-1127 (1993).
-
Goldstein RS, Bruchfeld A, Yang L, Qureshi AR, Gallowitsch-Puerta M, Patel NB, Huston BJ, Chavan S, Rosas-Ballina M, Gregersen PK, Czura CJ, Sloan RP, Sama AE, Tracey KJ. Cholinergic anti-inflammatory pathway activity and high mobility group box-1 (HMGB 1) serum levels in patients with rheumatoid arthritis.
Mol. Med. 13: 210-215 (2007).
*
-
Gomard-Mennesson E, Fabien N, Cordier JF, Ninet J, Tebib J, Rousset H. Clinical significance of anti-histidyl-tRNA synthetase (Jo1) autoantibodies.
Ann. N. Y. Acad. Sci. 1109: 414-420 (2007).
*
-
Gomariz RP, Juarranz Y, Abad C, Arranz A, Leceta J, Martinez C. VIP-PACAP system in immunity: new insights for multitarget therapy.
Ann. N. Y. Acad. Sci. 1070: 51-74 (2006).
*
-
Gomez J, Prado C, Lopez P, Suarez A, Gutierrez C. Conserved anti-proliferative effect and poor inhibition of TNFalpha secretion by regulatory CD4+CD25+ T cells in patients with systemic lupus erythematosus.
Clin. Immunol. 132: 385-392 (2009).
*
-
Gomez LM, Anaya JM, Gonzalez CI, Pineda-Tamayo R, Otero W, Arango A, Martin J. PTPN22 C1858T polymorphism in Colombian patients with autoimmune diseases.
Genes Immun. 6: 628-631 (2005).
*
-
Gomez LM, Ruiz-Narvaez EA, Pineda-Tamayo R, Rojas-Villarraga A, Anaya JM. TNF microsatellites polymorphism is associated with rheumatoid arthritis. Confirming evidence in north-western Colombians.
Clin. Exp. Rheumatol. 25: 443-448 (2007).
-
Gomez M, Sanz-Gonzalez SM, Nabah YN, Lamana A, Sanchez-Madrid F, Andres V. Atherosclerosis development in apolipoprotein E-null mice deficient for CD69.
Cardiovasc. Res. 81: 197-205 (2009).
-
Gomez-Reino JJ, Carmona L, Angel Descalzo M; Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
Arthritis Rheum. 57: 756-761 (2007).
*
-
Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
Arthritis Rheum. 48: 2122-2127 (2003).
*
-
Gomez-Reino JJ, Carmona L; the BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period.
Arthritis Res. Ther. 8: R29 (2006).
*
-
Gomez-Reino JJ, Pablos JL, Carreira PE, Santiago B, Serrano L, Vicario JL, Balsa A, Figueroa M, de Juan MD. Association of rheumatoid arthritis with a functional chemokine receptor, CCR5.
Arthritis Rheum. 42: 989-992 (1999).
*
-
Gomez-Vaquero C, Fiter J, Enjuanes A, Nogues X, Diez-Perez A, Nolla JM. Influence of the BsmI polymorphism of the vitamin D receptor gene on rheumatoid arthritis clinical activity.
J. Rheumatol. 34: 1823-1826 (2007).
-
Gompels LL, Smith A, Charles PJ, Rogers W, Soon-Shiong J, Mitchell A, Dore C, Taylor PW, Mackworth-Young CG. Single-blind randomized trial of combination antibiotic therapy in rheumatoid arthritis.
J. Rheumatol. 33: 224-227 (2006).
-
Goncalves M, D'Almeida V, Guerra-Shinohara EM, Galdieri LC, Len CA, Hilario MO. Homocysteine and lipid profile in children with juvenile idiopathic arthritis.
Pediatr. Rheumatol. Online J. 5: 2 (2007).
*
-
Gondokaryono SP, Ushio H, Niyonsaba F, Hara M, Takenaka H, Jayawardana ST, Ikeda S, Okumura K, Ogawa H. The extra domain A of fibronectin stimulates murine mast cells via Toll-like receptor 4.
J. Leukoc. Biol. 82: 657-665 (2007).
*
-
Gong R, Liu Z, Li L. Epistatic effect of plasminogen activator inhibitor 1 and beta-fibrinogen genes on risk of glomerular microthrombosis in lupus nephritis: interaction with environmental/clinical factors.
Arthritis Rheum. 56: 1608-1617 (2007).
*
-
Gonnet-Gracia C, Barnetche T, Richez C, Blanco P, Dehais J, Schaeverbeke T. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
Clin. Exp. Rheumatol. 26: 401-407 (2008).
-
Gonski PN, Chan B. Reactive arthritis due to Chlamydia psittaci associated with HLA-B27 genotype.
Med. J. Aust. 190: 649-650 (2009).
-
Gonul M, Gul U, Kilinc C, Cakmak SK, Soylu S, Kilic A. Homocysteine levels in patients with Behcet's disease and patients with recurrent aphthous stomatitis.
Clin. Rheumatol. 28: 1153-1156 (2009).
*
-
Gonzalez A, Nicovani S, Massardo L, Aguirre V, Cervilla V, Lanchbury JS, Jacobelli S. Influence of the HLA-DR beta shared epitope on susceptibility to and clinical expression of rheumatoid arthritis in Chilean patients.
Ann. Rheum. Dis. 56: 191-193 (1997).
*
-
Gonzalez B, Larranaga C, Leon O, Diaz P, Miranda M, Barria M, Gaggero A. Parvovirus B19 may have a role in the pathogenesis of juvenile idiopathic arthritis.
J. Rheumatol. 34: 1336-1340 (2007).
-
Gonzalez J, Tamayo E, Santiuste I, Marquina R, Buelta L, Gonzalez-Gay MA, Izui S, Lopez-Hoyos M, Merino J, Merino R. CD4+CD25+ T cell-dependent inhibition of autoimmunity in transgenic mice overexpressing human Bcl-2 in T lymphocytes.
J. Immunol. 178: 2778-2786 (2007).
*
-
Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells.
Arthritis Rheum. 60: 1006-1019 (2009).
*
-
Gonzalez S, Brautbar C, Martinez-Borra J, Lopez-Vazquez A, Segal R, Blanco-Gelaz MA, Enk CD, Safriman C, Lopez-Larrea C. Polymorphism in MICA rather than HLA-B/C genes is associated with psoriatic arthritis in the Jewish population.
Hum. Immunol. 62: 632-638 (2001).
-
Gonzalez S, Martinez-Borra J, Lopez-Vazquez A, Garcia-Fernandez S, Torre-Alonso JC, Lopez-Larrea C. MICA rather than MICB, TNFA, or HLA-DRB1 is associated with susceptibility to psoriatic arthritis.
J. Rheumatol. 29: 973-978 (2002).
*
-
Gonzalez S, Martinez-Borra J, Torre-Alonso JC, Gonzalez-Roces S, Sanchez del Rio J, Rodriguez Perez A, Brautbar C, Lopez-Larrea C. The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis.
Arthritis Rheum. 42: 1010-1016 (1999).
*
-
Gonzalez S, Rodrigo L, Martinez-Borra J, Lopez-Vazquez A, Fuentes D, Nino P, Cadahia V, Saro C, Dieguez MA, Lopez-Larrea C. TNF-alpha -308A promoter polymorphism is associated with enhanced TNF-alpha production and inflammatory activity in Crohn's patients with fistulizing disease.
Am. J. Gastroenterol. 98: 1101-1016 (2003).
*
-
Gonzalez-Alvaro I, Descalzo MA, Carmona L, Emecar Study Group T. Trends towards improved disease state in rheumatoid arthritis over time: the influence of new therapies and changes in management approach: analysis of the EMECAR cohort.
Arthritis Res. Ther. 10: R138 (2008).
*
-
Gonzalez-Alvaro I, Dominguez-Jimenez C, Ortiz AM, Nunez-Gonzalez V, Roda-Navarro P, Fernandez-Ruiz E, Sancho D, Sanchez-Madrid F. Interleukin-15 and interferon-gamma participate in the cross-talk between natural killer and monocytic cells required for tumour necrosis factor production.
Arthritis Res. Ther. 8: R88 (2006).
*
-
Gonzalez-Alvaro I, Ortiz AM, Tomero EG, Balsa A, Orte J, Laffon A, Garcia-Vicuna R. Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists.
Ann. Rheum. Dis. 66: 1675-1678 (2007).
-
Gonzalez-Alvaro I, Ortiz Garcia AM, Dominguez-Jimenez C, Aragon-Bodi A, Díaz-Sanchez B, Sanchez-Madrid F. Inhibition of TNF and IL-17 production by leflunomide involves the JAK/STAT pathway.
Ann. Rheum. Dis. 68: 1644-1650 (2009).
*
-
Gonzalez-Buitrago JM, Gonzalez C, Hernando M, Carrasco R, Sanchez A, Navajo JA, Papisch W. Antibodies to centromere antigens measured by an automated enzyme immunoassay.
Clin. Chim. Acta 328: 135-138 (2003).
*
-
Gonzalez-Gay MA, Agudo M. Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies.
Med. Clin. (Barc.) Feb 20 [Epub ahead of print] (2010).
-
Gonzalez-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WE. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica.
Semin. Arthritis Rheum. 33: 38-48 (2003).
*
-
Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Llorca J. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis.
Clin. Exp. Rheumatol. 24: 83-86 (2006).
-
Gonzalez-Gay MA, Garcia-Porrua C, Hajeer AH. Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis.
Semin. Arthritis Rheum. 31: 355-360 (2002).
*
-
Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriguez TR, de Matias JM, Martin J, Dessein PH, Llorca J. Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis.
Clin. Exp. Rheumatol. 27: 222-228 (2009).
-
Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, Vazquez-Rodriguez TR, Miranda-Filloy JA, Gonzalez-Juanatey C, de Matias JM, Martin J, Dessein PH, Llorca J. Short-term effect of anti-TNF-alpha therapy on nitric oxide production in patients with severe rheumatoid arthritis.
Clin. Exp. Rheumatol. 27: 452-458 (2009).
-
Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Llorca J. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis.
Clin. Exp. Rheumatol. 24: 373-379 (2006).
-
Gonzalez-Gay MA, Gonzalez-Juanatey C, Llorca J, Ollier WE, Martin J. Contribution of HLA-DRB1 shared epitope alleles and chronic inflammation to the increased incidence of cardiovascular disease in rheumatoid arthritis: comment on the article by Farragher et al.
Arthritis Rheum. 58: 2584 (2008).
*
-
Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, Pineiro A, Garcia-Porrua C, Miranda-Filloy JA, Ollier WE, Martin J, Llorca J. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis.
Arthritis Rheum. 57: 125-132 (2007).
*
-
Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Inflammation and endothelial dysfunction in rheumatoid arthritis.
Clin. Exp. Rheumatol. 24: 115-117 (2006).
-
Gonzalez-Gay MA, Gonzalez-Juanatey C, Miranda-Filloy JA, Garcia-Porrua C, Llorca J, Martin J. Cardiovascular disease in rheumatoid arthritis.
Biomed. Pharmacother. 60: 673-677 (2006).
-
Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Gomez-Acebo I, Miranda-Filloy JA, Paz-Carreira J, Martin J, Llorca J. Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease.
Semin. Arthritis Rheum. 39: 157-162 (2009).
*
-
Gonzalez-Gay MA, Hajeer AH, Dababneh A, Makki R, Garcia-Porrua C, Thomson W, Ollier W. Seronegative rheumatoid arthritis in elderly and polymyalgia rheumatica have similar patterns of HLA association.
J. Rheumatol. 28: 122-125 (2001).
-
Gonzalez-Gay MA, Hajeer AH, Garcia-Porrua C, Dababneh A, Thomson W, Ollier WE, Mattey DL. Patients chosen for treatment with cyclosporine because of severe rheumatoid arthritis are more likely to carry HLA-DRB1 shared epitope alleles, and have earlier disease onset.
J. Rheumatol. 29: 271-275 (2002).
-
Gonzalez-Gay MA, Llorca J, Garcia-Unzueta MT, Gonzalez-Juanatey C, De Matias JM, Martin J, Redelinghuys M, Woodiwiss AJ, Norton GR, Dessein PH. High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis.
Clin. Exp. Rheumatol. 26: 596-603 (2008).
-
Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gonzalez-Juanatey C, Llorca J. Subclinical atherosclerosis in patients with psoriatic arthritis.
J. Rheumatol. 35: 2070 (2008).
-
Gonzalez-Recio O, de Maturana EL, Vega AT, Engelman CD, Broman KW. Detecting single-nucleotide polymorphism by single-nucleotide polymorphism interactions in rheumatoid arthritis using a two-step approach with machine learning and a Bayesian threshold least absolute shrinkage and selection operator (LASSO) model.
BMC Proc. 3 Suppl. 7: S63 (2009).
*
-
Gonzalez-Rey E, Chorny A, Del Moral RG, Varela N, Delgado M. Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responses.
Ann. Rheum. Dis. 66: 582-588 (2007).
*
-
Gonzalez-Rey E, Chorny A, O'valle F, Delgado M. Adrenomedullin protects from experimental arthritis by down-regulating inflammation and Th1 response and inducing regulatory T cells.
Am. J. Pathol. 170: 263-271 (2007).
*
-
Gonzalez-Rey E, Chorny A, Varela N, O'Valle F, Delgado M. Therapeutic effect of urocortin on collagen-induced arthritis by down-regulation of inflammatory and Th1 responses and induction of regulatory T cells.
Arthritis Rheum. 56: 531-543 (2007).
*
-
Gonzalez-Rey E, Delgado M. Cortistatin as a potential multistep therapeutic agent for inflammatory disorders.
Drug News Perspect. 19: 393-399 (2006).
-
Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado M. Therapeutic action of Ghrelin in a mouse model of colitis.
Gastroenterology 130: 1707-1720 (2006).
*
-
Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado M. Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis.
Arthritis Rheum. 54: 864-876 (2006).
*
-
Gonzalez-Rey E, Martinez-Romero R, O'Valle F, Aguilar-Quesada R, Conde C, Delgado M, Oliver FJ. Therapeutic effect of a poly(ADP-ribose) polymerase-1 inhibitor on experimental arthritis by downregulating inflammation and Th1 response.
PLoS ONE 2: e1071 (2007).
*
-
Gonzalez-Rey E, Varela N, Chorny A, Delgado M. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator.
Curr. Pharm. Des. 13: 1113-1139 (2007).
-
Good RA. Progress toward production of immunologic tolerance with no or minimal toxic immunosuppression for prevention of immunodeficiency and autoimmune diseases.
World J. Surg. 24: 797-810 (2000).
*
-
Good RA. Cellular immunology in a historical perspective.
Immunol. Rev. 185: 136-158 (2002).
*
-
Goodall JC, Ellis L, Yeo GS, Gaston JS. Does HLA-B27 influence the monocyte inflammatory response to lipopolysaccharide?
Rheumatology (Oxford) 46: 232-237 (2007).
*
-
Goode S, Tierney G, Deighton C. Life threatening intra-abdominal sepsis in patients on anti-TNF-alpha therapy.
Gut 55: 590-591 (2006).
*
-
Goransson LG, Brun JG, Harboe E, Mellgren SI, Omdal R. Intraepidermal nerve fiber densities in chronic inflammatory autoimmune diseases.
Arch. Neurol. 63: 1410-1413 (2006).
*
-
Gorczynski R, Boudakov I, Khatri I. Peptides of CD200 modulate LPS-induced TNF-alpha induction and mortality in vivo.
J. Surg. Res. 145: 87-96 (2008).
*
-
Gordon DA, Bell DA, Baumal R, Broder I. Studies into the occurrence of soluble antigen-antibody complexes in disease. IV. Correlation between the rheumatoid biologically active factor and the clinical features of rheumatoid arthritis.
Clin. Exp. Immunol. 5: 57-66 (1969).
*
-
Gordon KB, Ruderman EM. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach.
J. Am. Acad. Dermatol. 54: S85-S91 (2006).
-
Gorman C, Leandro M, Isenberg D. B cell depletion in autoimmune disease.
Arthritis Res. Ther. 5 Suppl. 4: S17-S21 (2003).
*
-
Gorman JD. Smoking and rheumatoid arthritis: another reason to just say no.
Arthritis Rheum. 54: 10-13 (2005).
*
-
Gorman JD, David-Vaudey E, Pai M, Lum RF, Criswell LA. Lack of association of the HLA-DRB1 shared epitope with rheumatoid nodules: an individual patient data meta-analysis of 3,272 Caucasian patients with rheumatoid arthritis.
Arthritis Rheum. 50: 753-762 (2004).
*
-
Gorman JD, David-Vaudey E, Pai M, Lum RF, Criswell LA. Particular HLA-DRB1 shared epitope genotypes are strongly associated with rheumatoid vasculitis.
Arthritis Rheum. 50: 3476-3484 (2004).
*
-
Gorman JD, Lum RF, Chen JJ, Suarez-Almazor ME, Thomson G, Criswell LA. Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240 rheumatoid arthritis patients.
Arthritis Rheum. 50: 400-412 (2004).
*
-
Goronzy JJ, Gold KN, Weyand CM. T-cell derived lymphokines as regulators of chronic inflammation: potential targets for immunomodulation?
Am. J. Ther. 3: 109-114 (1996).
-
Goronzy JJ, Henel G, Sawai H, Singh K, Lee EB, Pryshchep S, Weyand CM. Costimulatory pathways in rheumatoid synovitis and T-cell senescence.
Ann. N. Y. Acad. Sci. 1062: 182-194 (2005).
*
-
Goronzy JJ, Weyand CM. T-cell co-stimulatory pathways in autoimmunity.
Arthritis Res. Ther. 10 Suppl. 1: S3 (2008).
*
-
Goronzy JJ, Weyand CM. Developments in the scientific understanding of rheumatoid arthritis.
Arthritis Res. Ther. 11: 249 (2009).
-
Goronzy JJ, Weyand CM. T-cell regulation in rheumatoid arthritis.
Curr. Opin. Rheumatol. 16: 212-217 (2004).
-
Gorska A, Urban M, Pietrewicz E, Gorski S. Composition of linoleic and arachidonic acids in phosphatidylcholine of erythrocytes membrane and IL-6 and TNF-alpha in serum and C-reactive protein concentration in children with juvenile idiopathic arthritis.
Pol. Merkur. Lekarski. 21: 551-553 (2006).
-
Gortz B, Hayer S, Tuerck B, Zwerina J, Smolen JS, Schett G. Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo.
Arthritis Res. Ther. 7: R1140-R1147 (2005).
*
-
Goswami J, Hernandez-Santos N, Zuniga LA, Gaffen SL. A bone-protective role for IL-17 receptor signaling in ovariectomy-induced bone loss.
Eur. J. Immunol. 39: 2831-2839 (2009).
*
-
Goswami R, Mishra SK, Kochupillai N. Prevalence and potential significance of vitamin D deficiency in Asian Indians.
Indian J. Med. Res. 127: 229-238 (2008).
*
-
Goto A, Mukai M, Notoya A, Kohno M. Rheumatoid arthritis complicated with myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis: a case report.
Mod. Rheumatol. 15: 118-122 (2005).
-
Gottenberg JE, Aucouturier F, Goetz J, Sordet C, Jahn I, Busson M, Cayuela JM, Sibilia J, Mariette X. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome.
Ann. Rheum. Dis. 66: 23-27 (2007).
*
-
Gottenberg JE, Busson M, Loiseau P, Cohen-Solal J, Lepage V, Charron D, Sibilia J, Mariette X. In primary Sjogren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response.
Arthritis Rheum. 48: 2240-2245 (2003).
*
-
Gottenberg JE, Busson M, Loiseau P, Dourche M, Cohen-Solal J, Lepage V, Charron D, Miceli C, Sibilia J, Mariette X. Association of transforming growth factor beta1 and tumor necrosis factor alpha polymorphisms with anti-SSB/La antibody secretion in patients with primary Sjogren's syndrome.
Arthritis Rheum. 50: 570-580 (2004).
*
-
Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, Larroche C, Soubrier M, Anaya JM, Sibilia J, Mariette X. Tolerance and short-term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
Ann. Rheum. Dis. 64: 913-920 (2005).
*
-
Gottenberg JE, Loiseau PP, Azarian MM, Chen CC, Cagnard NN, Hachulla EE, Puechal XX, Sibilia JJ, Charron DD, Mariette XX, Miceli-Richard CC. CTLA-4 +49A/G and CT60 gene polymorphisms in primary Sjogren syndrome.
Arthritis Res. Ther. 9: R24 (2007).
*
-
Gottenberg JE, Miceli-Richard C, Ducot B, Goupille P, Combe B, Mariette X. Markers of B lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort.
Arthritis Res. Ther. 11: R114 (2009).
*
-
Gottenberg JE, Mignot S, Nicaise-Rolland P, Cohen-Solal J, Aucouturier F, Goetz J, Labarre C, Meyer O, Sibilia J, Mariette X. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjogren's syndrome.
Ann. Rheum. Dis. 64: 114-117 (2005).
*
-
Gottenberg JE, Sellam J, Ittah M, Lavie F, Proust A, Zouali H, Sordet C, Sibilia J, Kimberly RP, Mariette X, Miceli-Richard C. No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjogren's syndrome.
Arthritis Res. Ther. 8: R30 (2006).
*
-
Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
Lancet 373: 633-640 (2009).
*
-
Gottlieb AB. Alefacept for psoriasis and psoriatic arthritis.
Ann. Rheum. Dis. 64 Suppl. 4: iv58-iv60 (2005).
*
-
Gottlieb AB, Dann F. Comorbidities in patients with psoriasis.
Am. J. Med. 122: 1150.e1-e9 (2009).
-
Gottlieb C, Li Z, Uzel G, Nussenblatt RB, Sen HN. Uveitis in DiGeorge syndrome: a case of autoimmune ocular inflammation in a patient with deletion 22q11.2.
Ophthalmic Genet. 31: 24-29 (2010).
-
Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome.
BMJ 312: 169-172 (1996).
*
-
Gould DJ, Yousaf N, Fatah R, Subang MC, Chernajovsky Y. Gene therapy with an improved doxycycline regulated plasmid encoding a TNFalpha inhibitor in experimental arthritis.
Arthritis Res. Ther. 9: R7 (2007).
*
-
Gould KA, Strecker TE, Hansen KK, Bynote KK, Peterson KA, Shull JD. Genetic mapping of loci controlling diethylstilbestrol-induced thymic atrophy in the Brown Norway rat.
Mamm. Genome 17: 451-464 (2006).
*
-
Goules A, Tzioufas AG, Manousakis MN, Kirou KA, Crow MK, Routsias JG. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases.
J. Autoimmun. 26: 165-171 (2006).
-
Gourh P, Agarwal SK, Divecha D, Assassi S, Paz G, Arora-Singh RK, Reveille JD, Shete S, Mayes MD, Arnett FC, Tan FK. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines.
Arthritis Rheum. 60: 3794-3806 (2009).
*
-
Gourh P, Arnett FC, Assassi S, Tan FK, Huang M, Diekman L, Mayes MD, Reveille JD, Agarwal SK. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations.
Arthritis Res. Ther. 11: R147 (2009).
*
-
Gourh P, Tan FK, Assassi S, Ahn CW, McNearney TA, Fischbach M, Arnett FC, Mayes MD. Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis.
Arthritis Rheum. 54: 3945-3953 (2006).
*
-
Gourraud PA, Boyer JF, Barnetche T, Abbal M, Cambon-Thomsen A, Cantagrel A, Constantin A. A new classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for rheumatoid arthritis structural severity.
Arthritis Rheum. 54: 593-599 (2006).
*
-
Gourraud PA, Dieude P, Boyer JF, Nogueira L, Cambon-Thomsen A, Cornelis F, Mazieres B, Serre G, Cantagrel A, Constantin A. A new classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for autoantibody production in rheumatoid arthritis.
Arthritis Res. Ther. 9: R27 (2007).
*
-
Gouze JN, Evans CH, Ghivizzani SC, Gouze E. Gene therapy for osteoarticular disorders.
Med. Sci. (Paris) 23: 303-310 (2007).
-
Gow PJ, Fleming KA, Chapman RW. Primary sclerosing cholangitis associated with rheumatoid arthritis and HLA DR4: is the association a marker of patients with progressive liver disease?
J. Hepatol. 34: 631-635 (2001).
*
-
Grabar PB, Rozman B, Logar D, Praprotnik S, Dolzan V. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis.
Ann. Rheum. Dis. 68: 1367-1368 (2009).
-
Gracie JA, Koyama N, Murdoch J, Field M, McGarry F, Crilly A, Schobel A, Madhok R, Pons-Kuhnemann J, McInnes IB, Moller B. Disease association of two distinct interleukin-18 promoter polymorphisms in Caucasian rheumatoid arthritis patients.
Genes Immun. 6: 211-216 (2005).
*
-
Grady C, Hampson LA, Wallen GR, Rivera-Goba MV, Carrington KL, Mittleman BB. Exploring the ethics of clinical research in an urban community.
Am. J. Public Health 96: 1996-2001 (2006).
*
-
Graessler J, Graessler A, Unger S, Kopprasch S, Tausche AK, Kuhlisch E, Schroeder HE. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population.
Arthritis Rheum. 54: 292-300 (2005).
*
-
Graham KL, Lee LY, Higgins JP, Steinman L, Utz PJ, Ho PP. Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus.
Arthritis Rheum. 58: 2098-2104 (2008).
*
-
Graham KL, Thibault DL, Steinman JB, Okeke L, Kao PN, Utz PJ. Granzyme B is dispensable for immunologic tolerance to self in a murine model of systemic lupus erythematosus.
Arthritis Rheum. 52: 1684-1693 (2005).
*
-
Graham RR, Cotsapas C, Davies L, Hackett R, Lessard CJ, Leon JM, Burtt NP, Guiducci C, Parkin M, Gates C, Plenge RM, Behrens TW, Wither JE, Rioux JD, Fortin PR, Graham DC, Wong AK, Vyse TJ, Daly MJ, Altshuler D, Moser KL, Gaffney PM. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus.
Nat. Genet. 40: 1059-1061 (2008).
*
-
Graham RR, Langefeld CD, Gaffney PM, Ortmann WA, Selby SA, Baechler EC, Shark KB, Ockenden TC, Rohlf KE, Moser KL, Brown WM, Gabriel SE, Messner RP, King RA, Horak P, Elder JT, Stuart PE, Rich SS, Behrens TW. Genetic linkage and transmission disequilibrium of marker haplotypes at chromosome 1q41 in human systemic lupus erythematosus.
Arthritis Res. 3: 299-305 (2001).
*
-
Grammer AC, Lipsky PE. B cell abnormalities in systemic lupus erythematosus.
Arthritis Res. Ther. 5 Suppl. 4: S22-S27 (2003).
*
-
Gran JT, Husby G. Joint manifestations in gastrointestinal diseases. 1. Pathophysiological aspects, ulcerative colitis and Crohn's disease.
Dig. Dis. 10: 274-294 (1992).
-
Grandbois L, Lomasney LM, Demos TC, Tehrani R. Radiologic case study. Seronegative spondyloarthropathy associated with Crohn's disease.
Orthopedics 28: 1296, 1375-1379 (2005).
-
Granel B, Swiader L, Serratrice J, Disdier P, Weiller PJ. Heat shock proteins or "stress proteins".
Rev. Med. Interne. 21: 421-427 (2000).
-
Granet C, Maslinski W, Miossec P. Increased AP-1 and NF-kappaB activation and recruitment with the combination of the proinflammatory cytokines IL-1beta, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes.
Arthritis Res. Ther. 6: R190-R198 (2004).
*
-
Granet C, Miossec P. Combination of the pro-inflammatory cytokines IL-1, TNF-alpha and IL-17 leads to enhanced expression and additional recruitment of AP-1 family members, Egr-1 and NF-kappaB in osteoblast-like cells.
Cytokine 26: 169-177 (2004).
-
Grant SF, Kristjansdottir H, Steinsson K, Blondal T, Yuryev A, Stefansson K, Gulcher JR. Long PCR detection of the C4A null allele in B8-C4AQ0-C4B1-DR3.
J. Immunol. Methods 244: 41-47 (2000).
*
-
Grant WB. Epidemiology of disease risks in relation to vitamin D insufficiency.
Prog. Biophys. Mol. Biol. 92: 65-79 (2006).
*
-
Grassi A, Corona F, Casellato A, Carnelli V, Bardare M. Prevalence and outcome of juvenile idiopathic arthritis-associated uveitis and relation to articular disease.
J. Rheumatol. 34: 1139-1145 (2007).
-
Grasso G, Fragai M, Rizzarelli E, Spoto G, Yeo KJ. In situ AP/MALDI-MS characterization of anchored matrix metalloproteinases.
J. Mass Spectrom. 41: 1561-1569 (2006).
*
-
Gratacos J, Casado E, Real J, Torre-Alonso JC. Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate.
Ann. Rheum. Dis. 66: 493-497 (2007).
*
-
Gratwohl A, Passweg J, Gerber I, Tyndall A; International Stem Cell Project for Autoimmune Diseases. Stem cell transplantation for autoimmune diseases.
Best Pract. Res. Clin. Haematol. 14: 755-776 (2001).
-
Graudal N. The natural history and prognosis of rheumatoid arthritis: association of radiographic outcome with process variables, joint motion and immune proteins.
Scand. J. Rheumatol. Suppl. 118: 1-38 (2004).
-
Graudal NA, Homann C, Madsen HO, Svejgaard A, Jurik AG, Graudal HK, Garred P. Mannan binding lectin in rheumatoid arthritis. A longitudinal study.
J. Rheumatol. 25: 629-635 (1998).
-
Graudal NA, Madsen HO, Tarp U, Svejgaard A, Jurik G, Graudal HK, Garred P. The association of variant mannose-binding lectin genotypes with radiographic outcome in rheumatoid arthritis.
Arthritis Rheum. 43: 515-521 (2000).
*
-
Gravallese EM. Bone destruction in arthritis.
Ann. Rheum. Dis. 61 Suppl. 2: ii84-ii86 (2002).
*
-
Gravallese EM, Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease.
Am. J. Gastroenterol. 83: 703-709 (1988).
-
Gray M, Miles K, Salter D, Gray D, Savill J. Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells.
Proc. Natl. Acad. Sci. U.S.A. 104: 14080-14085 (2007).
*
-
Gray SG, Dangond F. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis.
Epigenetics 1: 67-75 (2006).
*
-
Gray-McGuire C, Moser KL, Gaffney PM, Kelly J, Yu H, Olson JM, Jedrey CM, Jacobs KB, Kimberly RP, Neas BR, Rich SS, Behrens TW, Harley JB. Genome scan of human systemic lupus erythematosus by regression modeling: evidence of linkage and epistasis at 4p16-15.2.
Am. J. Hum. Genet. 67: 1460-1469 (2000).
*
-
Graziewicz MA, Tarrant TK, Buckley B, Roberts J, Fulton L, Hansen H, Orum H, Kole R, Sazani P. An endogenous TNF-alpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models.
Mol. Ther. 16: 1316-1322 (2008).
*
-
Grcevic D, Jajic Z, Kovacic N, Kresimir I, Velagic V, Grubisic F, Ivcevic S, Marusic A. Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness.
J. Rheumatol. Dec 14 [Epub ahead of print] (2009).
-
Green MR, Kennell AS, Larche MJ, Seifert MH, Isenberg DA, Salaman MR. Natural killer T cells in families of patients with systemic lupus erythematosus: their possible role in regulation of IGG production.
Arthritis Rheum. 56: 303-310 (2007).
*
-
Green N, Hu Y, Janz K, Li HQ, Kaila N, Guler S, Thomason J, Joseph-McCarthy D, Tam SY, Hotchandani R, Wu J, Huang A, Wang Q, Leung L, Pelker J, Marusic S, Hsu S, Telliez JB, Hall JP, Cuozzo JW, Lin LL. Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles.
J. Med. Chem. 50: 4728-4745 (2007).
*
-
Greenberg JD, Fisher MC, Kremer J, Chang H, Rosenstein ED, Kishimoto M, Lee S, Yazici Y, Kavanaugh A, Abramson SB. The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk.
Clin. Exp. Rheumatol. 27: 395-401 (2009).
-
Greenberg JD, Kishimoto M, Strand V, Cohen SB, Olenginski TP, Harrington T, Kafka SP, Reed G, Kremer JM; Consortium of Rheumatology Researchers of North America Investigators. Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort.
Am. J. Med. 121: 532-538 (2008).
*
-
Greenberg JD, Ostrer H. Predicting response to TNF antagonists in rheumatoid arthritis - the promise of pharmacogenetics research using clinical registries.
Bull. N.Y.U. Hosp. Jt. Dis. 65: 139-142 (2007).
*
-
Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, Bishai W, Hochberg M. Association of methotrexate and TNF antagonists with risk of infection outcomes including opportunistic infections in the CORRONA registry.
Ann. Rheum. Dis. Apr 8 [Epub ahead of print] (2009).
-
Greenwood MC, Rathi J, Hakim AJ, Scott DL, Doyle DV. Regression to the mean using the disease activity score in eligibility and response criteria for prescribing TNF-alpha inhibitors in adults with rheumatoid arthritis.
Rheumatology (Oxford) 46: 1165-1167 (2007).
*
-
Greetham D, Ellis CD, Mewar D, Fearon U, Nic An Ultaigh S, Veale DJ, Guesdon F, Wilson AG. Functional characterisation of NF-kappaB inhibitor-like protein 1 (NFkappaBIL1), a candidate susceptibility gene for rheumatoid arthritis.
Hum. Mol. Genet. 16: 3027-3036 (2007).
*
-
Gregersen PK. Genetics of rheumatoid arthritis: confronting complexity.
Arthritis Res. 1: 37-44 (1999).
*
-
Gregersen PK. Gaining insight into PTPN22 and autoimmunity.
Nat. Genet. 37: 1300-1302 (2005).
*
-
Gregersen PK. Pathways to gene identification in rheumatoid arthritis: PTPN22 and beyond.
Immunol. Rev. 204: 74-86 (2005).
*
-
Gregersen PK, Batliwalla F. PTPN22 and rheumatoid arthritis: gratifying replication.
Arthritis Rheum. 52: 1952-1955 (2005).
*
-
Gregersen PK, Amos CI, Lee AT, Lu Y, Remmers EF, Kastner DL, Seldin MF, Criswell LA, Plenge RM, Holers VM, Mikuls TR, Sokka T, Moreland LW, Bridges SL Jr, Xie G, Begovich AB, Siminovitch KA. REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis.
Nat. Genet. 41: 820-823 (2009).
*
-
Gregory B, Ho VC. Cutaneous manifestations of gastrointestinal disorders. Part II.
J. Am. Acad. Dermatol. 26: 371-383 (1992).
-
Greidinger EL, Zang Y, Jaimes K, Hogenmiller S, Nassiri M, Bejarano P, Barber GN, Hoffman RW. A murine model of mixed connective tissue disease induced with U1 small nuclear RNP autoantigen.
Arthritis Rheum. 54: 661-669 (2006).
*
-
Greidinger EL, Zang Y, Martinez L, Jaimes K, Nassiri M, Bejarano P, Barber GN, Hoffman RW. Differential tissue targeting of autoimmunity manifestations by autoantigen-associated Y RNAs.
Arthritis Rheum. 56: 1589-1597 (2007).
*
-
Greiner A, Plischke H, Kellner H, Gruber R. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis.
Ann. N. Y. Acad. Sci. 1050: 295-303 (2005).
*
-
Grennan DM, Dyer P, Dodds W, Read A, Haeney M, Clague R, Harris R. Clinical and immunogenetic studies in multicase rheumatoid families.
Q. J. Med. 53: 479-485 (1984).
-
Grennan DM, Dyer PA, Clague R, Dodds W, Smeaton I, Harris R. Family studies in RA - the importance of HLA-DR4 and of genes for autoimmune thyroid disease.
J. Rheumatol. 10: 584-589 (1983).
-
Grennan DM, Ferguson M, Williamson J, Mavrikakis M, Dick WC, Buchanan WW. Sjogren's syndrome in SLE: part I. The frequency of the clinical and subclinical features of Sjogren's syndrome in patients with SLE.
N. Z. Med. J. 86: 374-376 (1977).
-
Grennan DM, Sanders PA. Rheumatoid arthritis.
Baillieres Clin. Rheumatol. 2: 585-601 (1988).
-
Grennan DM, Sanders PA, Dyer PA, Harris R. HLA haplotype sharing by siblings with rheumatoid arthritis: evidence for genetic heterogeneity.
Ann. Rheum. Dis. 45: 126-129 (1986).
*
-
Grennan DM, Sanders PA, Thomson W, Dyer PA. Rheumatoid arthritis: inheritance and association with other autoimmune diseases.
Dis. Markers 4: 157-162 (1986).
-
Grevers LC, van Lent PL, Koenders MI, Walgreen B, Sloetjes AW, Nimmerjahn F, Sjef Verbeek J, van den Berg WB. Different amplifying mechanisms of interleukin-17 and interferon-gamma in Fcgamma receptor-mediated cartilage destruction in murine immune complex-mediated arthritis.
Arthritis Rheum. 60: 396-407 (2009).
*
-
Grieshaber MC, Mozaffarieh M, Flammer J. What is the link between vascular dysregulation and glaucoma?
Surv. Ophthalmol. 52: S144-S154 (2007).
-
Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis.
Lancet 370: 263-271 (2007).
*
-
Griffiths CE, Iaccarino L, Naldi L, Olivieri I, Pipitone N, Salvarani C, Doria A. Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines.
Clin. Exp. Rheumatol. 24: S72-S78 (2006).
-
Griffiths HR. ROS as signalling molecules in T cells - evidence for abnormal redox signalling in the autoimmune disease, rheumatoid arthritis.
Redox Rep. 10: 273-280 (2005).
-
Griffiths HR. Is the generation of neo-antigenic determinants by free radicals central to the development of autoimmune rheumatoid disease?
Autoimmun. Rev. 7: 544-549 (2008).
-
Griffiths MM, Cannon GW, Corsi T, Reese V, Kunzler K. Collagen-induced arthritis in rats.
Methods Mol. Med. 136: 201-214 (2007).
-
Griffiths MM, Remmers EF. Genetic analysis of collagen-induced arthritis in rats: a polygenic model for rheumatoid arthritis predicts a common framework of cross-species inflammatory/autoimmune disease loci.
Immunol. Rev. 184: 172-183 (2001).
*
-
Griga T, Tromm A, Spranger J, May B. Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease.
Scand. J. Gastroenterol. 33: 504-508 (1998).
*
-
Grijalva CG, Kaltenbach L, Arbogast PG, Mitchel EF Jr, Griffin MR. Initiation of rheumatoid arthritis treatments and the risk of serious infections.
Rheumatology (Oxford) 49: 82-90 (2010).
-
Grimble RF, Tappia PS. Modulation of pro-inflammatory cytokine biology by unsaturated fatty acids.
Z. Ernahrungswiss 37 Suppl. 1: 57-65 (1998).
-
Grimsholm O, Rantapaa-Dahlqvist S, Dalen T, Forsgren S. BDNF in RA: downregulated in plasma following anti-TNF treatment but no correlation with inflammatory parameters.
Clin. Rheumatol. 27: 1289-1297 (2008).
*
-
Grimstein C, Choi YK, Satoh M, Lu Y, Wang X, Campbell-Thompson M, Song S. Combination of alpha-1 antitrypsin and doxycycline suppresses collagen-induced arthritis.
J. Gene Med. 12: 35-44 (2010).
-
Grinblat B, Scheinberg M. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review.
Semin. Arthritis Rheum. 37: 251-255 (2008).
*
-
Grisar JC, Aletaha D, Steiner CW, Kapral T, Steiner S, Saemann M, Schwarzinger I, Buranyi B, Steiner G, Smolen JS. Endothelial progenitor cells in active rheumatoid arthritis: effects of TNF and of glucocorticoid therapy.
Ann. Rheum. Dis. 66: 1284-1288 (2007).
*
-
Grismer LE, Gill SA, Harris MD. Liver biopsy in psoriatic arthritis to detect methotrexate hepatotoxicity.
J. Clin. Rheumatol. 7: 224-227 (2001).
-
Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis.
Proc. Natl. Acad. Sci. U.S.A. 100: 9452-9457 (2003).
*
-
Gronski MA. Novel insights in the regulation of the immune system: a report on the FASEB Summer Research Conference on Autoimmunity (June 14-19, 2003, Saxton's River, Vermont, USA).
Rev. Diabet. Stud. 1: 47-50 (2004).
*
-
Gronthos S, Zannettino AC. The role of the chemokine CXCL12 in osteoclastogenesis.
Trends Endocrinol. Metab. 18: 108-113 (2007).
*
-
Grootenhuis MA, Koopman HM, Verrips EG, Vogels AG, Last BF. Health-related quality of life problems of children aged 8-11 years with a chronic disease.
Dev. Neurorehabil. 10: 27-33 (2007).
-
Grootscholten C, Bajema IM, Florquin S, Steenbergen EJ, Peutz-Kootstra CJ, Goldschmeding R, Bijl M, Hagen EC, Van Houwelingen HC, Derksen RH, Berden JH. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
Arthritis Rheum. 56: 924-937 (2007).
*
-
Gros C, Delesalle F, Gautier S, Delaporte E. Leflunomide-induced skin necrosis.
Ann. Dermatol. Venereol. 135: 205-208 (2008).
-
Grosjean OV. The resistible growth of health care costs.
Acta Chir. Belg. 108: 4-14 (2008).
-
Gross K, Combe C, Kruger K, Schattenkirchner M. Arthritis after hepatitis B vaccination. Report of three cases.
Scand. J. Rheumatol. 24: 50-52 (1995).
-
Grossi O, Caillon J, Arvieux C, Jacqueline C, Bugnon D, Potel G, Hamel A. In vivo efficacy of moxifloxacin in a Staphylococcus aureus rabbit arthritis experimental model: a comparative study with cloxacillin and vancomycin.
Antimicrob. Agents Chemother. 51: 3401-3403 (2007).
*
-
Grover S, Tandon S, Misra R, Aggarwal A. Interleukin-1 receptor antagonist gene polymorphism in patients with rheumatoid arthritis in India.
Indian J. Med. Res. 123: 815-820 (2006).
-
Grubic Z, Peric P, Cecuk-Jelicic E, Zunec R, Curkovic B, Kerhin-Brkljacic V. The distribution of HLA alleles class I and class II among patientes with psoriatic arthritis in Croatia.
Reumatizam 51: 5-11 (2004).
-
Grubic Z, Peric P, Eeeuk-Jelicic E, Zunec R, Stingl K, Curkovic B, Kerhin-Brkljacic V. The MICA-A4 triplet repeats polymorphism in the transmembrane region confers additional risk for development of psoriatic arthritis in the Croatian population.
Eur. J. Immunogenet. 31: 93-98 (2004).
*
-
Gruenwald J, Graubaum HJ, Hansen K, Grube B. Efficacy and tolerability of a combination of Lyprinol and high concentrations of EPA and DHA in inflammatory rheumatoid disorders.
Adv. Ther. 21: 197-201 (2004).
-
Gruenwald J, Petzold E, Busch R, Petzold HP, Graubaum HJ. Effect of glucosamine sulfate with or without omega-3 fatty acids in patients with osteoarthritis.
Adv. Ther. 26: 858-871 (2009).
-
Grulich AE, Vajdic CM. The epidemiology of non-Hodgkin lymphoma.
Pathology 37: 409-419 (2005).
-
Grulich AE, Vajdic CM, Cozen W. Altered immunity as a risk factor for non-Hodgkin lymphoma.
Cancer Epidemiol. Biomarkers Prev. 16: 405-408 (2007).
*
-
Grundemann D, Harlfinger S, Golz S, Geerts A, Lazar A, Berkels R, Jung N, Rubbert A, Schomig E. Discovery of the ergothioneine transporter.
Proc. Natl. Acad. Sci. U.S.A. 102: 5256-5261 (2005).
*
-
Grundmann S, Hoefer IE, Ulusans S, van Royen N, Schirmer SH, Ozaki CK, Bode C, Piek JJ, Buschmann IR. Anti-tumor necrosis factor-alpha therapies attenuate adaptive arteriogenesis in the rabbit.
Am. J. Physiol. Heart Circ. Physiol. 289: H1497-H1505 (2005).
*
-
Grunewald J, Eklund A. Gender specific manifestations of Lofgren's syndrome.
Am. J. Respir. Crit. Care Med. 175: 40-44 (2007).
*
-
Grunewald J, Eklund A. Lofgren's syndrome: human leukocyte antigen strongly influence the disease course.
Am. J. Respir. Crit. Care Med. 179: 307-312 (2009).
*
-
Grunewald RW, Fiedler GM, Stockmann F, Schauer A, Muller GA. Unusual diagnosis in recurrent arthritis, erythema nodosum and arrhythmia.
Dtsch. Med. Wochenschr. 122: 1516-1520 (1997).
-
Grupo de Estudos de Artrite Reumatoide (GEAR) da Sociedade Portuguesa de Reumatologia (SPR). Guidelines for the use of biologic therapies in rheumatoid arthritis - December 2006 update.
Acta Reumatol. Port. 32: 37-41 (2007).
-
Grygorczuk S, Zajkowska J, Kondrusik M, Moniuszko A, Pancewicz S, Pawlak-Zalewska W. Failures of antibiotic treatment in Lyme arthritis.
Przegl. Epidemiol. 62: 581-588 (2008).
-
Grzybowska-Kowalczyk A, Wojtecka-Lukasik E, Maslinska D, Gujski M, Maslinski S. Distribution pattern of histamine H4 receptor in human synovial tissue from patients with rheumatoid arthritis.
Inflamm. Res. 56: S59-S60 (2007).
-
Gu EL, Yao GB. The clinical characteristics of primary biliary cirrhosis in China: a systimatic review.
Zhonghua Gan Zang Bing Za Zhi 17: 861-866 (2009).
-
Gu J, Wei YL, Wei JC, Huang F, Jan MS, Centola M, Frank MB, Yu D. Identification of RGS1 as a candidate biomarker for undifferentiated spondylarthritis by genome-wide expression profiling and real-time polymerase chain reaction.
Arthritis Rheum. 60: 3269-3279 (2009).
*
-
Gu MM, Yuan WT, Yang JQ, Zhang J, Xiong XY, Yao FJ, Lu ZY, Wang ZG, Huang W, Fan LA. A genomewide scan for the susceptibility gene loci to ankylosing spondylitis in Chinese Han population.
Yi Chuan Xue Bao 31: 217-220 (2004).
-
Gudbrandsdottir S, Larsen R, Sorensen LK, Nielsen S, Hansen MB, Svenson M, Bendtzen K, Muller K. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis.
Clin. Exp. Rheumatol. 22: 118-124 (2004).
-
Gudjonsson JE, Elder JT. Psoriasis: epidemiology.
Clin. Dermatol. 25: 535-546 (2007).
-
Guenther L, Gulliver W. Psoriasis comorbidities.
J. Cutan. Med. Surg. 13 Suppl. 2: S77-S87 (2009).
-
Guenther LC. Treatments for scalp psoriasis with emphasis on calcipotriol plus betamethasone dipropionate gel (xamiol(R)).
Skin Therapy Lett. 14: 1-4 (2009).
*
-
Guenther R, Krenn V, Haupl T. Expression analyses for rheumatoid arthritis.
Z. Rheumatol. 67: 17-24 (2008).
-
Guerne PA, Salvi M, Seitz M, Bruhlmann P, Rivier G, Frey D, Mermillod B, Vischer TL, Tiercy JM. Molecular analysis of HLA-DR polymorphism in polymyalgia rheumatica. Swiss Group for Research on HLA in Polymyalgia Rheumatica.
J. Rheumatol. 24: 671-676 (1997).
-
Guerre-Schmidt AR, Pelletier F, Carbonnel F, Humbert P, Aubin F. Dermatosis-arthritis syndrome associated with Crohn's disease in a teenager.
Rev. Med. Interne. 27: 874-877 (2006).
-
Guex-Crosier Y, Zografos L. New therapies in ophthalmology: inhibitors of TNF-alpha.
Rev. Med. Suisse. 1: 140-141 (2005).
-
Guglielmi G, Cascavilla A, Scalzo G, Salaffi F, Grassi W. Imaging of sternocostoclavicular joint in spondyloarthropaties and other rheumatic conditions.
Clin. Exp. Rheumatol. 27: 402-408 (2009).
-
Guglielmi G, Scalzo G, Cascavilla A, Carotti M, Salaffi F, Grassi W. Imaging of the sacroiliac joint involvement in seronegative spondylarthropathies.
Clin. Rheumatol. 28: 1007-1019 (2009).
*
-
Guhl G, García-Diez A. Subcutaneous Sweet syndrome.
Dermatol. Clin. 26: 541-551 (2008).
-
Guichelaar T, Ten Brink CB, van Kooten PJ, Berlo SE, Broeren CP, van Eden W, Broere F. Autoantigen-specific IL-10-transduced T cells suppress chronic arthritis by promoting the endogenous regulatory IL-10 response.
J. Immunol. 180: 1373-1381 (2008).
*
-
Guichelaar T, Ten Brink CB, van Kooten PJ, Berlo SE, Lafeber FP, Broeren CP, van Eden W, Broere F. Cartilage proteoglycan-specific T cells as vectors of immunomodulatory biologicals in chronic proteoglycan-induced arthritis.
Mol. Immunol. 45: 3526-3535 (2008).
*
-
Guignard S, Gossec L, Bandinelli F, Dougados M. Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis.
Clin. Exp. Rheumatol. 26: S23-S29 (2008).
-
Guilherme L, Kalil J. Rheumatic fever and rheumatic heart disease: cellular mechanisms leading autoimmune reactivity and disease.
J. Clin. Immunol. Oct 3 [Epub ahead of print] (2009).
*
-
Guillevin L, Dorner T. Vasculitis: mechanisms involved and clinical manifestations.
Arthritis Res. Ther. 9 Suppl. 2: S9 (2007).
*
-
Guimaraes MR, Nassar PO, Andia DC, Nassar CA, Spolidorio DM, Rossa C Jr, Spolidorio LC. Protective effects of tacrolimus, a calcineurin inhibitor, in experimental periodontitis in rats.
Arch. Oral Biol. 52: 882-888 (2007).
-
Guirado S, Conejo-Mir J, Munoz M, Wite J, Fernandez-Freire L, Ortiz J. Sitosterol xanthomatosis.
J. Eur. Acad. Dermatol. Venereol. 21: 100-103 (2007).
*
-
Guis S, Balandraud N, Bouvenot J, Auger I, Toussirot E, Wendling D, Mattei JP, Nogueira L, Mugnier B, Legeron P, Landt O, Serre G, Roudier J, Roudier C. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis.
Arthritis Rheum. 57: 1426-1430 (2007).
*
-
Gul U, Gonul M, Kaya I, Aslan E. Autoimmune thyroid disorders in patients with psoriasis.
Eur. J. Dermatol. 19: 221-223 (2009).
-
Gul U, Gonul M, Kilic A, Erdem R, Cakmak SK, Gunduz H. Treatment of psoriatic arthritis with etanercept, methotrexate, and cyclosporin A.
Clin. Ther. 28: 251-254 (2006).
*
-
Gulati A, Paige D, Yaqoob M, Proby CM, Cerio R, Harwood CA. Palisaded neutrophilic granulomatous dermatitis associated with systemic lupus erythematosus presenting with the burning rope sign.
J. Am. Acad. Dermatol. 61: 711-714 (2009).
-
Gulfe A, Aletaha D, Saxne T, Geborek P. Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agents.
BMC Musculoskelet. Disord. 10: 41 (2009).
*
-
Gulfe A, Kristensen LE, Saxne T Prof, Jacobsson LT, Petersson IF, Geborek P. Rapid and sustained health utility gain in anti-TNF treated inflammatory arthritis. Observational data during five years in southern Sweden.
Ann. Rheum. Dis. Mar 11 [Epub ahead of print] (2009).
-
Gulko PS. Contribution of genetic studies in rodent models of autoimmune arthritis to understanding and treatment of rheumatoid arthritis.
Genes Immun. 8: 523-531 (2007).
*
-
Gulliver W. Long-term prognosis in patients with psoriasis.
Br. J. Dermatol. 159 Suppl. 2: 2-9 (2008).
-
Gunal EK, Kamali S, Gul A, Ocal L, Konice M, Aral O, Inanc M. Clinical evaluation and comparison of different criteria for classification in Turkish patients with psoriatic arthritis.
Rheumatol. Int. 28: 959-964 (2008).
*
-
Gunal EK, Kamali S, Gul A, Ocal L, Konice M, Aral O, Inanc M. Clinical evaluation and comparison of different criteria for classification in Turkish patients with psoriatic arthritis.
Rheumatol. Int. 29: 365-370 (2009).
*
-
Gunal EK, Sarvan FO, Kamali S, Gul A, Inanc M, Carin M, Konice M, Aral O, Ocal L. Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey.
Joint Bone Spine 75: 299-302 (2008).
*
-
Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WE, Cooper RG, Oddis CV, Ramanan AV, Davidson JE, McHugh NJ; Juvenile Dermatomyositis Research Group, UK and Ireland. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis.
Arthritis Rheum. 60: 1807-1814 (2009).
*
-
Gunaydin R, Kaya T, Atay A, Olmez N, Hur A, Koseoglu M. Serum leptin levels in rheumatoid arthritis and relationship with disease activity.
South Med. J. 99: 1078-1083 (2006).
-
Gunesacar R, Erken E, Ozer HT, Bozkurt B, Dinkci S, Deveci D. Analysis of vascular endothelial growth factor gene 936 C/T polymorphism in patients with familial Mediterranean fever.
Int. J. Immunogenet. 35: 33-36 (2008).
*
-
Gunnarsson I, Kanerud L, Pettersson E, Lundberg I, Lindblad S, Ringertz B. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus.
Br. J. Rheumatol. 36: 1089-1094 (1997).
-
Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
Arthritis Rheum. 56: 1263-1272 (2007).
*
-
Gunther C, Hertl M, Meurer M. Diagnostic use of autoantibodies.
Hautarzt. 58: 1063-1075 (2007).
-
Guo JP, Backdahl L, Marta M, Mathsson L, Ronnelid J, Lorentzen JC. Profound and paradoxical impact on arthritis and autoimmunity of the rat antigen-presenting lectin-like receptor complex.
Arthritis Rheum. 58: 1343-1353 (2008).
*
-
Guo JP, Verdrengh M, Tarkowski A, Lange S, Jennische E, Lorentzen JC, Harris RA. The rat antigen-presenting lectin-like receptor complex influences innate immunity and development of infectious diseases.
Genes Immun. 10: 227-236 (2009).
-
Guo K, Major G, Foster H, Bassendine M, Collier J, Ross D, Griffiths I. Defective repair of O6-methylguanine-DNA in primary Sjogren's syndrome patients predisposed to lymphoma.
Ann. Rheum. Dis. 54: 229-232 (1995).
*
-
Guo L, Deshmukh H, Lu R, Vidal GS, Kelly JA, Kaufman KM, Dominguez N, Klein W, Kim-Howard X, Bruner GR, Scofield RH, Moser KL, Gaffney PM, Dozmorov IM, Gilkeson GS, Wakeland EK, Li QZ, Langefeld CD, Marion MC, Williams AH, Divers J, Alarcón GS, et al. Replication of the BANK1 genetic association with systemic lupus erythematosus in a European-derived population.
Genes Immun. 10: 531-538 (2009).
-
Guo L, Tian J, Marinova E, Zheng B, Han S. Inhibition of clonal expansion by Foxp3 expression as a mechanism of controlled T-cell responses and autoimmune disease.
Eur. J. Immunol. Oct 28 [Epub ahead of print] (2009).
*
-
Guo R, Yamashita M, Zhang Q, Zhou Q, Chen D, Reynolds DG, Awad HA, Yanoso L, Zhao L, Schwarz EM, Zhang YE, Boyce BF, Xing L. Ubiquitin ligase Smurf1 mediates TNF-induced systemic bone loss by promoting proteasomal degradation of BMP signaling proteins.
J. Biol. Chem. 283: 23084-23092 (2008).
*
-
Guo R, Zhou Q, Proulx ST, Wood R, Ji RC, Ritchlin CT, Pytowski B, Zhu Z, Wang YJ, Schwarz EM, Xing L. Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis.
Arthritis Rheum. 60: 2666-2676 (2009).
*
-
Gupta A, Street AC, Macrae FA. Tumour necrosis factor alpha inhibitors: screening for tuberculosis infection in inflammatory bowel disease.
Med. J. Aust. 188: 168-170 (2008).
-
Gupta AD. Sacroiliac joint pathologies in low back pain.
J. Back Musculoskelet. Rehabil. 22: 91-97 (2009).
-
Gupta AK, Cooper EA. Psoriatic nail disease: quality of life and treatment.
J. Cutan. Med. Surg. 13 Suppl. 2: S102-S106 (2009).
-
Gupta AK, Skinner AR. A review of the use of infliximab to manage cutaneous dermatoses.
J. Cutan. Med. Surg. 8: 77-89 (2004).
*
-
Gupta B, Agrawal C, Raghav SK, Das SK, Das RH, Chaturvedi VP, Das HR. Association of mannose-binding lectin gene (MBL2) polymorphisms with rheumatoid arthritis in an Indian cohort of case-control samples.
J. Hum. Genet. 50: 583-591 (2005).
*
-
Gupta B, Raghav SK, Agrawal C, Chaturvedi VP, Das RH, Das HR. Anti-MBL autoantibodies in patients with rheumatoid arthritis: prevalence and clinical significance.
J. Autoimmun. 27: 125-133 (2006).
-
Gupta G, Gelfand JM, Lewis JD. Increased risk of demyelinating diseases in patients with inflammatory bowel disease.
Gastroenterology 129: 819-826 (2005).
*
-
Gupta RC, Dickson ER, McDuffie FC, Baggenstoss AH. Immune complexes in primary biliary cirrhosis. Higher prevalence of circulating immune complexes in patients with associated autoimmune features.
Am. J. Med. 73: 192-198 (1982).
-
Gupta RC, Tan EM. Isolation of circulating immune complexes by conglutinin and separation of antigen from dissociated complexes by immobilized protein A.
Clin. Exp. Immunol. 46: 9-19 (1981).
*
-
Gupta S, Singh RK, Dastidar S, Ray A. Cysteine cathepsin S as an immunomodulatory target: present and future trends.
Expert Opin. Ther. Targets 12: 291-299 (2008).
-
Gupta VA, Hermiston ML, Cassafer G, Daikh DI, Weiss A. B cells drive lymphocyte activation and expansion in mice with the CD45 wedge mutation and Fas deficiency.
J. Exp. Med. 205: 2755-2761 (2008).
*
-
Gurcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases.
Int. Immunopharmacol. 9: 10-25 (2009).
-
Gurley KA, Reimer RJ, Kingsley DM. Biochemical and genetic analysis of ANK in arthritis and bone disease.
Am. J. Hum. Genet. 79: 1017-1029 (2006).
*
-
Guseva IA, Nasonov EL. State-of-the-art immune genetic and immune biological aspects of rheumatoid arthritis.
Vestn. Ross. Akad. Med. Nauk. 6: 7-13 (2008).
-
Gustafsson J, Gunnarsson I, Borjesson O, Pettersson S, Moller S, Fei G, Elvin K, Simard JF, Hansson LO, Lundberg IE, Larsson A, Svenungsson E. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study.
Arthritis Res. Ther. 11: R186 (2009).
*
-
Gutcher I, Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation.
J. Clin. Invest. 117: 1119-1127 (2007).
*
-
Guthrie B, Rouster-Stevens KA, Reynolds SL. Review of medications used in juvenile rheumatoid arthritis.
Pediatr. Emerg. Care 23: 38-46 (2007).
-
Gutierrez M, Filippucci E, De Angelis R, Bertolazzi C, Becciolini A, Ariani A, Grassi W. The ultrasound assessment of the psoriatic arthritis: from joint to skin.
Reumatismo 61: 309-315 (2009).
-
Gutierrez M, Filippucci E, De Angelis R, Filosa G, Kane D, Grassi W. A sonographic spectrum of psoriatic arthritis: "the five targets"
Clin. Rheumatol. Oct 24 [Epub ahead of print] (2009).
*
-
Gutierrez-Canas I, Juarranz Y, Santiago B, Martinez C, Gomariz RP, Pablos JL, Leceta J. Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: implications for rheumatoid arthritis.
Brain Behav. Immun. 22: 312-317 (2008).
-
Gutierrez-Roelens I, Lauwerys BR. Genetic susceptibility to autoimmune disorders: clues from gene association and gene expression studies.
Curr. Mol. Med. 8: 551-861 (2008).
-
Gutierrez-Suarez R, Ruperto N, Gastaldi R, Pistorio A, Felici E, Burgos-Vargas R, Martini A, Ravelli A. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus.
Arthritis Rheum. 54: 2989-2996 (2006).
*
-
Gyetvai A, Szekanecz Z, Soos L, Szabo Z, Fekete A, Kapitany A, Teodorescu M, Sipka S, Szegedi G, Lakos G. New classification of the shared epitope in rheumatoid arthritis: impact on the production of various anti-citrullinated protein antibodies.
Rheumatology (Oxford) 49: 25-33 (2010).
*
-
Gyorgy B, Toth E, Tarcsa E, Falus A, Buzas EI. Citrullination: a posttranslational modification in health and disease.
Int. J. Biochem. Cell Biol. 38: 1662-1677 (2006).
*
-
Ha E, Choe BK, Jung KH, Yoon SH, Park HJ, Park HK, Yim SV, Chung JH, Bae HS, Nam M, Baik HH, Hong SJ. Positive relationship between melatonin receptor type 1B polymorphism and rheumatoid factor in rheumatoid arthritis patients in the Korean population.
J. Pineal Res. 39: 201-205 (2005).
*
-
Haake H, Koneke J, Amann K, Vom Dahl J, Janssen U. Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis.
Med. Klin. (Munich) 102: 852-857 (2007).
-
Haas CS, Amin MA, Ruth JH, Allen BL, Ahmed S, Pakozdi A, Woods JM, Shahrara S, Koch AE. In vivo inhibition of angiogenesis by interleukin-13 gene therapy in a rat model of rheumatoid arthritis.
Arthritis Rheum. 56: 2535-2548 (2007).
*
-
Haas CS, Creighton CJ, Pi X, Maine I, Koch AE, Haines GK 3rd, Ling S, Chinnaiyan AM, Holoshitz J. Identification of genes modulated in rheumatoid arthritis using complementary DNA microarray analysis of lymphoblastoid B cell lines from disease-discordant monozygotic twins.
Arthritis Rheum. 54: 2047-2060 (2006).
*
-
Haas JP, Metzler M, Frank C, Haefner R, Wassmuth R. HLA-DQA1 gene expression profiling in oligoarticular JIA.
Autoimmunity 42: 389-391 (2009).
-
Haavardsholm EA, Boyesen P, Ostergaard M, Schildvold A, Kvien TK. Magnetic resonance imaging findings in 84 early rheumatoid arthritis patients: bone marrow edema predicts erosive progression.
Ann. Rheum. Dis. 67: 794-800 (2008).
-
Haavardsholm EA, Ostergaard M, Hammer HB, Boyesen P, Boonen A, van der Heijde D, Kvien TK. Monitoring anti-TNFalpha treatment in rheumatoid arthritis: responsiveness of magnetic resonance imaging and ultrasonography of the dominant wrist compared to conventional measures of disease activity and structural damage.
Ann. Rheum. Dis. 68: 1572-1579 (2009).
-
Habib HM, Taher TE, Isenberg DA, Mageed RA. Enhanced propensity of T lymphocytes in patients with systemic lupus erythematosus to apoptosis in the presence of tumour necrosis factor alpha.
Scand. J. Rheumatol. 38: 112-120 (2009).
*
-
Hacquard-Bouder C, Chimenti MS, Giquel B, Donnadieu E, Fert I, Schmitt A, Andre C, Breban M. Alteration of antigen-independent immunologic synapse formation between dendritic cells from HLA-B27-transgenic rats and CD4+ T cells: selective impairment of costimulatory molecule engagement by mature HLA-B27.
Arthritis Rheum. 56: 1478-1489 (2007).
*
-
Hadj Kacem H, Kaddour N, Adyel FZ, Bahloul Z, Ayadi H. HLA-DQB1 CAR1/CAR2, TNFa IR2/IR4 and CTLA-4 polymorphisms in Tunisian patients with rheumatoid arthritis and Sjogren's syndrome.
Rheumatology (Oxford) 40: 1370-1374 (2001).
*
-
Hafler JP, Maier LM, Cooper JD, Plagnol V, Hinks A, Simmonds MJ, Stevens HE, Walker NM, Healy B, Howson JM, Maisuria M, Duley S, Coleman G, Gough SC; The International Multiple Sclerosis Genetics Consortium (IMSGC), Worthington J, Kuchroo VK, et al. CD226 Gly307Ser association with multiple autoimmune diseases.
Genes Immun. 10: 5-10 (2009).
*
-
Haga HJ, Peen E. A study of the arthritis pattern in primary Sjogren's syndrome.
Clin. Exp. Rheumatol. 25: 88-91 (2007).
-
Haga N, Masuda K, Takikawa K. Osteochondral destruction in the hand following bee stings: a case report of an infant.
Hand Surg. 11: 143-145 (2006).
-
Hagen AD, Sulit DJ, Sulit AK. Cutaneous psoriasis in a military flight surgeon.
Aviat. Space Environ. Med. 77: 140-144 (2006).
-
Hagen KB, Byfuglien MG, Falzon L, Olsen SU, Smedslund G. Dietary interventions for rheumatoid arthritis.
Cochrane Database Syst. Rev. 1: CD006400 (2009).
-
Hagenow K, Gelderman KA, Hultqvist M, Merky P, Backlund J, Frey O, Kamradt T, Holmdahl R. Ncf1-associated reduced oxidative burst promotes IL-33R+ T cell-mediated adjuvant-free arthritis in mice.
J. Immunol. 183: 874-881 (2009).
-
Hagfors L, Nilsson I, Skoldstam L, Johansson G. Fat intake and composition of fatty acids in serum phospholipids in a randomized, controlled, Mediterranean dietary intervention study on patients with rheumatoid arthritis.
Nutr. Metab. (Lond.) 2: 26 (2005).
*
-
Haggqvist B, Hultman P. Interleukin-10 in murine metal-induced systemic autoimmunity.
Clin. Exp. Immunol. 141: 422-431 (2005).
*
-
Hagiwara K, Sato T, Kobayashi ST, Hasegawa S, Shigihara N, Akiyama O. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis.
J. Rheumatol. 34: 1151-1154 (2007).
-
Hagymasi K, Molnar B, Tulassay Z. Stem cell transplantation in the treatment of gastrointestinal diseases.
Orv. Hetil. 149: 1449-1455 (2008).
-
Hahn BH, Anderson M, Le E, Cava AL. Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients.
Arthritis Rheum. 58: 2488-2497 (2008).
*
-
Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia.
J. Autoimmun. 28: 69-75 (2007).
-
Hahne JC, Fuchs T, Haddouti el M, Okuducu AF, Bories JC, Wernert N. Expression pattern of matrix metalloproteinase and TIMP genes in fibroblasts derived from Ets-1 knock-out mice compared to wild-type mouse fibroblasts.
Int. J. Mol. Med. 18: 153-159 (2006).
*
-
Haidari M, Hajilooi M, Rezazadeh M, Rafiei A, Alavi SA, Keramat F. Polymorphism in the promoter region of the CD14 gene and susceptibility to brucellosis.
Immunol. Invest. 35: 239-245 (2006).
*
-
Haider AS, Cardinale IR, Whynot JA, Krueger JG. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes.
J. Investig. Dermatol. Symp. Proc. 12: 9-15 (2007).
*
-
Hailu A, Knutsen SF, Fraser GE. Associations between meat consumption and the prevalence of degenerative arthritis and soft tissue disorders in the Adventist Health Study, California U.S.A.
J. Nutr. Health Aging 10: 7-14 (2006).
-
Hairfield-Stein M, England C, Paek HJ, Gilbraith KB, Dennis R, Boland E, Kosnik P. Development of self-assembled, tissue-engineered ligament from bone marrow stromal cells.
Tissue Eng. 13: 703-710 (2007).
-
Hajeer AH, Dababneh A, Makki RF, Thomson W, Poulton K, Gonzalez-Gay MA, Garcia-Porrua C, Mattey DL, Ollier WE. Different gene loci within the HLA-DR and TNF regions are independently associated with susceptibility and severity in Spanish rheumatoid arthritis patients.
Tissue Antigens 55: 319-325 (2000).
*
-
Hajeer AH, Issa S, Alaskar A, Abdullah K, Awad M, Tbakhi A, Alabdulkareem A. Neutrophils and lymphoid chimerism after adult living-related liver transplantation from a homozygous donor.
Transplant. Proc. 37: 4386-4388 (2005).
*
-
Hajeer AH, Worthington J, Silman AJ, Ollier WE. Association of tumor necrosis factor microsatellite polymorphisms with HLA-DRB1*04-bearing haplotypes in rheumatoid arthritis patients.
Arthritis Rheum. 39: 1109-1114 (1996).
-
Hajjaj-Hassouni N, Burgos-Vargas R. Ankylosing spondylitis and reactive arthritis in the developing world.
Best Pract. Res. Clin. Rheumatol. 22: 709-723 (2008).
-
Hakala M, Hannonen P, Helve T, Korpela M, Mattila K, Mottonen T, Varis T; Suomalaisen Laakariseuran Duodecimin ja Suomen Reumatologisen Yhdistyksen Asettama Tyoryhma. Rheumatoid arthritis (updated current care guideline).
Duodecim. 125: 2131-2132 (2009).
-
Hakala M, Ilonen J, Reijonen H, Knip M, Koivisto O, Isomaki H. No association between rheumatoid arthritis and insulin dependent diabetes mellitus: an epidemiologic and immunogenetic study.
J. Rheumatol. 19: 856-858 (1992).
-
Hakoda M, Kamatani N, Taniguchi A, Ueda H, Yamanaka H, Terai C, Kashiwazaki S. Generation and molecular characterisation of monoclonal IgG4 rheumatoid factor from a patient with rheumatoid arthritis.
Ann. Rheum. Dis. 56: 74-77 (1997).
*
-
Halabe Bucay A. Treatment of rheumatoid arthritis and other related conditions by provoking a mild infection to be controlled by the immune system itself.
Med. Hypotheses 69: 27-29 (2007).
-
Halayko AJ, Ghavami S. S100A8/A9: a mediator of severe asthma pathogenesis and morbidity?
Can. J. Physiol. Pharmacol. 87: 743-755 (2009).
-
Hale LP, Greer PK, Trinh CT, James CL. Proteinase activity and stability of natural bromelain preparations.
Int. Immunopharmacol. 5: 783-793 (2005).
-
Hale S, Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis.
Cytokine 33: 231-237 (2006).
-
Halili MA, Andrews MR, Sweet MJ, Fairlie DP. Histone deacetylase inhibitors in inflammatory disease.
Curr. Top. Med. Chem. 9: 309-319 (2009).
-
Halin C, Detmar M. Chapter 1. Inflammation, angiogenesis, and lymphangiogenesis.
Methods Enzymol. 445C: 1-25 (2008).
-
Hall FC, Brown MA, Weeks DE, Walsh S, Nicod A, Butcher S, Andrews LJ, Wordsworth BP. A linkage study across the T cell receptor A and T cell receptor B loci in families with rheumatoid arthritis.
Arthritis Rheum. 40: 1798-1802 (1997).
-
Hall MA, McGlinn E, Coakley G, Fisher SA, Boki K, Middleton D, Kaklamani E, Moutsopoulos H, Loughran TP Jr, Ollier WE, Panayi GS, Lanchbury JS. Genetic polymorphism of IL-12 p40 gene in immune-mediated disease.
Genes Immun. 1: 219-224 (2000).
*
-
Hall RJ, Merriman ME, Green RA, Markham VH, Smyth DJ, Heward JM, Jennings CE, Braithwaite AW, Cundy T, Darlow BA, Gow PJ, Harrison AA, Highton J, Hunt PJ, Manning P, Pokorny V, Scott RS, Taylor BJ, Willis JA, Yeoman S, McLean L, Gough SC, Pearce SH, et al. The deleted in colorectal carcinoma (DCC) gene 201 R-->G polymorphism: no evidence for genetic association with autoimmune disease.
Eur. J. Hum. Genet. 11: 840-844 (2003).
*
-
Hall SJ, Hickling P. Failure of etanercept to control extra-articular manifestations of rheumatoid arthritis.
J. Clin. Rheumatol. 13: 54 (2007).
-
Hallett JM, Leitch AE, Riley NA, Duffin R, Haslett C, Rossi AG. Novel pharmacological strategies for driving inflammatory cell apoptosis and enhancing the resolution of inflammation.
Trends Pharmacol. Sci. 29: 250-257 (2008).
*
-
Hallett MB, Williams AS. Stopping the traffic: a route to arthritis therapy.
Eur. J. Immunol. 38: 2650-2653 (2008).
*
-
Halligan CS, Bauch CD, Brey RH, Achenbach SJ, Bamlet WR, McDonald TJ, Matteson EL. Hearing loss in rheumatoid arthritis.
Laryngoscope 116: 2044-2049 (2006).
-
Halpern MT, Cifaldi MA, Kvien TK. Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group.
Ann. Rheum. Dis. 68: 930-937 (2009).
*
-
Halvorsen EH, Haavardsholm EA, Pollmann S, Boonen A, van der Heijde D, Kvien TK, Molberg O. Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents.
Ann. Rheum. Dis. 68: 249-252 (2009).
-
Halvorsen EH, Pollmann S, Gilboe IM, van der Heijde D, Landewe R, Odegard S, Kvien TK, Molberg O. Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity.
Ann. Rheum. Dis. 67: 414-417 (2008).
-
Hamada D, Takata Y, Osabe D, Nomura K, Shinohara S, Egawa H, Nakano S, Shinomiya F, Scafe CR, Reeve VM, Miyamoto T, Moritani M, Kunika K, Inoue H, Yasui N, Itakura M. Association between single-nucleotide polymorphisms in the SEC8L1 gene, which encodes a subunit of the exocyst complex, and rheumatoid arthritis in a Japanese population.
Arthritis Rheum. 52: 1371-1380 (2005).
*
-
Hamaguchi M, Kawahito Y, Omoto A, Tsubouchi Y, Kohno M, Seno T, Kadoya M, Yamamoto A, Ishino H, Matsuyama M, Yoshimura R, Yoshikawa T. Eicosapentaenoic acid suppresses the proliferation of synoviocytes from rheumatoid arthritis.
J. Clin. Biochem. Nutr. 43: 126-128 (2008).
*
-
Hamamoto Y, Tateno H, Ishida T, Muto M. Lack of association between promoter polymorphism of the tumor necrosis factor-alpha gene and psoriatic arthritis in Japanese patients.
J. Invest. Dermatol. 115: 1162-1164 (2000).
*
-
Hamdi H, Mariette X, Godot V, Weldingh K, Hamid AM, Prejean MV, Baron G, Lemann M, Puechal X, Breban M, Berenbaum F, Delchier JC, Flipo RM, Dautzenberg B, Salmon D, Humbert M, Emilie D. Inhibition of anti-tuberculosis T lymphocyte function with tumor necrosis factor antagonists.
Arthritis Res. Ther. 8: R114 (2006).
*
-
Hamdulay SS, Mason JC. Disease-modifying anti-rheumatic drugs - do they reduce cardiac complications of RA ?
Heart 95: 1471-1472 (2009).
-
Hameed K, Bowman S, Kondeatis E, Vaughan R, Gibson T. The association of HLA-DRB genes and the shared epitope with rheumatoid arthritis in Pakistan.
Br. J. Rheumatol. 36: 1184-1188 (1997).
*
-
Hamel K, Doodes P, Cao Y, Wang Y, Martinson J, Dunn R, Kehry MR, Farkas B, Finnegan A. Suppression of proteoglycan-induced arthritis by anti-CD20 B cell depletion therapy is mediated by reduction in autoantibodies and CD4+ T cell reactivity.
J. Immunol. 180: 4994-5003 (2008).
*
-
Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity.
Nat. Rev. Immunol. 8: 533-544 (2008).
*
-
Hamilton ML, Gladman DD, Shore A, Laxer RM, Silverman ED. Juvenile psoriatic arthritis and HLA antigens.
Ann. Rheum. Dis. 49: 694-697 (1990).
*
-
Hamilton TK. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy.
J. Drugs Dermatol. 7: 1089-1093 (2008).
-
Hammaker DR, Boyle DL, Inoue T, Firestein GS. Regulation of the JNK pathway by TGF-beta activated kinase 1 (TAK1) in rheumatoid arthritis synoviocytes.
Arthritis Res. Ther. 9: R57 (2007).
*
-
Hammons AL, Summers CM, Woodside JV, McNulty H, Strain JJ, Young IS, Murray L, Boreham CA, Scott JM, Mitchell LE, Whitehead AS. Folate/homocysteine phenotypes and MTHFR 677C>T genotypes are associated with serum levels of monocyte chemoattractant protein-1.
Clin. Immunol. 133: 132-137 (2009).
*
-
Hamon MA, Nicolas G, Deviere F, Letournel F, Dubas F. Demyelinating neuropathy during anti-TNF alpha treatment with a review of the literature.
Rev. Neurol. (Paris) 163: 1232-1235 (2007).
-
Hampton T. Arthritis clinical trial results revealed.
JAMA 297: 28-29 (2007).
*
-
Hamshere ML, Segurado R, Moskvina V, Nikolov I, Glaser B, Holmans PA. Large-scale linkage analysis of 1302 affected relative pairs with rheumatoid arthritis.
BMC Proc. 1 Suppl. 1: S100 (2007).
*
-
Hamze AB, Wei S, Bahudhanapati H, Kota S, Acharya KR, Brew K. Constraining specificity in the N-domain of tissue inhibitor of metalloproteinases-1; gelatinase-selective inhibitors.
Protein Sci. 16: 1905-1913 (2007).
*
-
Han A, Robinson V, Judd M, Taixiang W, Wells G, Tugwell P. Tai chi for treating rheumatoid arthritis.
Cochrane Database Syst. Rev. 3: CD004849 (2004).
-
Han B, Moore PA, Wu J, Luo H. Overexpression of human decoy receptor 3 in mice results in a systemic lupus erythematosus-like syndrome.
Arthritis Rheum. 56: 3748-3758 (2007).
*
-
Han C, Huang H, Hu M, Wang Q, Gao Y, Liu Y. Time-dependent expression of leukotriene B4 receptors in rat collagen-induced arthritis.
Prostaglandins Other Lipid Mediat. 83: 225-230 (2007).
-
Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and aAnkylosing spondylitis.
J. Rheumatol. 33: 2167-2172 (2006).
-
Han C, Smolen J, Kavanaugh A, van der Heijde D, Braun J, Westhovens R, Zhao N, Rahman MU, Baker D, Bala M. The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases.
Arthritis Res. Ther. 9: R103 (2007).
*
-
Han HJ, Lim MJ, Lee YJ, Lee JH, Yang IS, Taub M. Uric acid inhibits renal proximal tubule cell proliferation via at least two signaling pathways involving PKC, MAPK, cPLA2, and NF-kappaB.
Am. J. Physiol. Renal Physiol. 292: F373-F381 (2007).
*
-
Han KY, Hong BS, Yoon YJ, Yoon CM, Kim YK, Kwon YG, Gho YS. Polyphosphate blocks tumor metastasis via anti-angiogenic activity.
Biochem. J. 406: 49-55 (2007).
*
-
Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease.
Drugs 64: 1767-1777 (2004).
-
Han S, Kim K, Kim H, Kwon J, Lee YH, Lee CK, Song Y, Lee SJ, Ha N, Kim K. Auranofin inhibits overproduction of pro-inflammatory cytokines, cyclooxygenase expression and PGE2 production in macrophages.
Arch. Pharm. Res. 31: 67-74 (2008).
-
Han S, Li Y, Mao Y, Xie Y. Meta-analysis of the association of CTLA-4 exon-1 +49A/G polymorphism with rheumatoid arthritis.
Hum. Genet. 118: 123-132 (2005).
*
-
Han S, Zhang X, Marinova E, Ozen Z, Bheekha-Escura R, Guo L, Wansley D, Booth G, Fu YX, Zheng B. Blockade of lymphotoxin pathway exacerbates autoimmune arthritis by enhancing the Th1 response.
Arthritis Rheum. 52: 3202-3209 (2005).
*
-
Han TU, Bang SY, Kang C, Bae SC. TRAF1 polymorphisms associated with rheumatoid arthritis susceptibility in Asians and in Caucasians.
Arthritis Rheum. 60: 2577-2584 (2009).
*
-
Hanai J. BMP in the kidney : signaling, function and pathophysiological significance.
Clin. Calcium 17: 704-710 (2007).
-
Hanauer SB. New biologicals for inflammatory bowel disease.
Gastroenterology & Hepatology Annual Review Vol. 1, June 2006, p. 67-71 (2006). *
-
Hanauer SB. Review article: safety of infliximab in clinical trials.
Aliment. Pharmacol. Ther. 13 Suppl. 4: 16-22 (1999).
*
-
Hanauer SB. A BALANCING VIEW: lifetime channeling of infliximab for Crohn's disease.
Am. J. Gastroenterol. 100: 1438-1439 (2005).
*
-
Hanauer SB. Assessing the risk of lymphomas in inflammatory bowel disease.
Rev. Gastroenterol. Disord. 3: 50-51 (2003).
*
-
Hanauer SB. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies.
Rev. Gastroenterol. Disord. 4 Suppl. 3: S18-S24 (2004).
*
-
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
Lancet 359: 1541-1549 (2002).
*
-
Handa R. Management of rheumatoid arthritis.
Natl. Med. J. India 17: 143-151 (2004).
-
Handa R. Spondylo-arthropathies.
J. Indian Med. Assoc. 101: 514, 516, 518 (2003).
-
Hanly JG, Fisk JD, McCurdy G, Fougere L, Douglas JA. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis.
J. Rheumatol. 32: 1459-1466 (2005).
-
Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ, Isenberg D, Alarcon GS, Clarke A, Bernatsky S, Merrill JT, Petri M, Dooley MA, Gladman D, Fortin PR, Steinsson K, Bruce I, Manzi S, Khamashta M, Zoma A, Aranow C, Ginzler E, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study.
Arthritis Rheum. 56: 265-273 (2007).
*
-
Hanly JG, Urowitz MB, Siannis F, Farewell V, Gordon C, Bae SC, Isenberg D, Dooley MA, Clarke A, Bernatsky S, Gladman D, Fortin PR, Manzi S, Steinsson K, Bruce IN, Ginzler E, Aranow C, Wallace DJ, Ramsey-Goldman R, van Vollenhoven R, Sturfelt G, et al. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study.
Arthritis Rheum. 58: 843-853 (2008).
*
-
Hanna AN, Waldman WJ, Lott JA, Koesters SC, Hughes AM, Thornton DJ. Increased alkaline phosphatase isoforms in autoimmune diseases.
Clin. Chem. 43: 1357-1364 (1997).
*
-
Hanna B, Holdeman NR, Tang RA, Schiffman JS. Retinal toxicity secondary to plaquenil therapy.
Optometry 79: 90-94 (2008).
-
Hannig G, Bernier SG, Hoyt JG, Doyle B, Clark E, Karp RM, Lorusso J, Westlin WF. Suppression of inflammation and structural damage in experimental arthritis through molecular targeted therapy with PPI-2458.
Arthritis Rheum. 56: 850-860 (2007).
*
-
Hanninen A, Harrison LC. Mucosal tolerance to prevent type 1 diabetes: can the outcome be improved in humans?
Rev. Diabet. Stud. 1: 113-121 (2004).
*
-
Hannu T, Inman R, Granfors K, Leirisalo-Repo M. Reactive arthritis or post-infectious arthritis?
Best Pract. Res. Clin. Rheumatol. 20: 419-433 (2006).
-
Hansen A, Gosemann M, Pruss A, Reiter K, Ruzickova S, Lipsky PE, Dorner T. Abnormalities in peripheral B cell memory of patients with primary Sjogren's syndrome.
Arthritis Rheum. 50: 1897-1908 (2004).
*
-
Hansen A, Lipsky PE, Dorner T. New concepts in the pathogenesis of Sjogren syndrome: many questions, fewer answers.
Curr. Opin. Rheumatol. 15: 563-570 (2003).
-
Hansen A, Lipsky PE, Dorner T. B cells in Sjogren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue.
Arthritis Res. Ther. 9: 218 (2007).
*
-
Hansen A, Lipsky PE, Dorner T. B-cell lymphoproliferation in chronic inflammatory rheumatic diseases.
Nat. Clin. Pract. Rheumatol. 3: 561-569 (2007).
-
Hansen A, Reiter K, Ziprian T, Jacobi A, Hoffmann A, Gosemann M, Scholze J, Lipsky PE, Dorner T. Dysregulation of chemokine receptor expression and function by B cells of patients with primary Sjogren's syndrome.
Arthritis Rheum. 52: 2109-2119 (2005).
*
-
Hansen KE, Cush J, Singhal A, A Cooley D, Cohen S, Patel SR, Genovese M, Sundaramurthy S, Schiff M. The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis.
Arthritis Rheum. 51: 228-232 (2004).
*
-
Hansen SE, Wallenquist A. A case of chronic polyarthritis with debut in 1771: rheumatoid arthritis or Poncet's disease?
Scand. J. Rheumatol. 36: 322-324 (2007).
*
-
Hanson DR, Gottesman II. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis.
BMC Med. Genet. 6: 7 (2005).
*
-
Hansson AS, Johansson AC, Holmdahl R. Critical role of the major histocompatibility complex and IL-10 in matrilin-1-induced relapsing polychondritis in mice.
Arthritis Res. Ther. 6: R484-R491 (2004).
*
-
Hansson M, Djerbi M, Rabbani H, Mellstedt H, Gharibdoost F, Hassan M, Depierre JW, Abedi-Valugerdi M. Exposure to mercuric chloride during the induction phase and after the onset of collagen-induced arthritis enhances immune/autoimmune responses and exacerbates the disease in DBA/1 mice.
Immunology 114: 428-437 (2005).
*
-
Hansson M, Gao Y, Rosen H, Tapper H, Olsson I. Hematopoietic secretory granules as vehicles for the local delivery of cytokines and soluble cytokine receptors at sites of inflammation.
Eur. Cytokine Netw. 15: 167-176 (2004).
-
Hanta I, Ozbek S, Kuleci S, Kocabas A. The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: experience with 192 patients.
Clin. Rheumatol. 27: 1083-1086 (2008).
*
-
Hanta I, Ozbek S, Kuleci S, Sert M, Kocabas A. Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha.
Clin. Rheumatol. 26: 1867-1870 (2007).
*
-
Hantash BM, Chiang D, Kohler S, Fiorentino D. Palisaded neutrophilic and granulomatous dermatitis associated with limited systemic sclerosis.
J. Am. Acad. Dermatol. 58: 661-664 (2008).
-
Hanyecz A, Bardos T, Berlo SE, Buzas E, Nesterovitch AB, Mikecz K, Glant TT. Induction of arthritis in SCID mice by T cells specific for the "shared epitope" sequence in the G3 domain of human cartilage proteoglycan.
Arthritis Rheum. 48: 2959-2973 (2003).
*
-
Hanzlicek P, Zvarova J, Dostal C. Information technology in clinical research in rheumatology domain.
Stud. Health Technol. Inform. 124: 187-192 (2006).
-
Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, Hashimoto H, Yoshino S, Matsui N, Nobunaga M, Nakano S. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study.
Mod. Rheumatol. 17: 1-9 (2007).
*
-
Harada K, Akai Y, Koyama S, Ikenaka Y, Saito Y. A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis.
Clin. Rheumatol. 27: 1063-1066 (2008).
*
-
Harada M, Hashimoto O, Kumemura H, Taniguchi E, Shiratsuchi M, Harada R, Sakamoto M, Yoshida H, Fukuda T, Sakisaka S, Sata M. Bronchiolitis obliterans organizing pneumonia in a patient with primary biliary cirrhosis and rheumatoid arthritis treated with prednisolone.
Hepatol. Res. 23: 301 (2002).
-
Harama D, Koyama K, Mukai M, Shimokawa N, Miyata M, Nakamura Y, Ohnuma Y, Ogawa H, Matsuoka S, Paton AW, Paton JC, Kitamura M, Nakao A. A subcytotoxic dose of subtilase cytotoxin prevents lipopolysaccharide-Induced inflammatory responses, depending on its capacity to induce the unfolded protein response.
J. Immunol. 183: 1368-1374 (2009).
-
Harangi M, Kaminski WE, Fleck M, Orso E, Zeher M, Kiss E, Szekanecz Z, Zilahi E, Marienhagen J, Aslanidis C, Paragh G, Bolstad AI, Jonsson R, Schmitz G. Homozygosity for the 168His variant of the minor histocompatibility antigen HA-1 is associated with reduced risk of primary Sjogren's syndrome.
Eur. J. Immunol. 35: 305-317 (2005).
*
-
Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors.
Semin. Arthritis Rheum. 34: 7-11 (2005).
*
-
Haraoui B. Differentiating the efficacy of tumor necrosis factor inhibitors.
J. Rheumatol. Suppl. 74: 3-7 (2005).
-
Haraoui B. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis.
J. Rheumatol. Suppl. 72: 46-47 (2005).
*
-
Haraoui B, Bykerk V. Etanercept in the treatment of rheumatoid arthritis.
Ther. Clin. Risk Manag. 3: 99-105 (2007).
*
-
Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.
J. Rheumatol. 33: 31-36 (2006).
-
Haraoui B, Keystone E. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents.
Curr. Opin. Rheumatol. 18: 96-100 (2006).
-
Haraoui B, Krelenbaum M. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action.
Semin. Arthritis Rheum. 39: 176-181 (2009).
*
-
Harbuz MS, Richards LJ, Chover-Gonzalez AJ, Marti-Sistac O, Jessop DS. Stress in autoimmune disease models.
Ann. N. Y. Acad. Sci. 1069: 51-61 (2006).
*
-
Hardin DS, Kemp SF, Allen DB. Twenty years of recombinant human growth hormone in children: relevance to pediatric care providers.
Clin. Pediatr. (Phila.) 46: 279-286 (2007).
-
Harding A. Fine-tuning our defenses.
The Scientist May, 2007 (http://www.the-scientist.com/2007/05/01/s56/1/) (2007).
-
Harding G, Mak YT, Evans B, Cheung J, Macdonald D, Hampson G. The effects of dexamethasone and dehydroepiandrosterone (DHEA) on cytokines and receptor expression in a human osteoblastic cell line: potential steroid-sparing role for DHEA.
Cytokine 36: 57-68 (2006).
-
Hardy ML, Coulter I, Morton SC, Favreau J, Venuturupalli S, Chiappelli F, Rossi F, Orshansky G, Jungvig LK, Roth EA, Suttorp MJ, Shekelle P. S-Adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease.
Evid. Rep. Technol. Assess. 64: 1-3 (2003).
-
Harel L, Prais D, Uziel Y, Mukamel M, Hashkes P, Harel G, Amir J, Monselise Y, Press J. Increased prevalence of antithyroid antibodies and subclinical hypothyroidism in children with juvenile idiopathic arthritis.
J. Rheumatol. 33: 164-166 (2006).
-
Harel M, Shoenfeld Y. Predicting and preventing autoimmunity, myth or reality?
Ann. N. Y. Acad. Sci. 1069: 322-345 (2006).
*
-
Harel-Meir M, Sherer Y, Shoenfeld Y. Tobacco smoking and autoimmune rheumatic diseases.
Nat. Clin. Pract. Rheumatol. 3: 707-715 (2007).
*
-
Harigai M. CTLA4-Ig (abatacept).
Nippon Rinsho 65: 1231-1237 (2007).
-
Harigai M. Effect of CTLA4-Ig on radiographic outcome of patients with rheumatoid arthritis.
Clin. Calcium 17: 577-584 (2007).
-
Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, van den Bosch F, Bresnihan B, Breedveld FC, Dinant HJ, Legay F, Gram H, Loetscher P, Schmouder R, Woodworth T, Tak PP. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.
Arthritis Rheum. 54: 2387-2392 (2006).
*
-
Harizi H, Corcuff JB, Gualde N. Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology.
Trends Mol. Med. 14: 461-469 (2008).
*
-
Harjacek M, Ostojic J, Djakovic Rode O. Juvenile spondyloarthropathies associated with Mycoplasma pneumoniae infection.
Clin. Rheumatol. 25: 470-475 (2006).
*
-
Harle P, Hartung W, Lehmann P, Ehrenstein B, Schneider N, Muller H, Muller-Ladner U, Tarner I, Vogt T, Fleck M, Bongartz T. Detection of psoriasis arthritis with the GEPARD patient questionnaire in a dermatologic outpatient setting.
Z. Rheumatol. 69: 157-163 (2010).
-
Harle P, Pongratz G, Albrecht J, Tarner IH, Straub RH. An early sympathetic nervous system influence exacerbates collagen-induced arthritis via CD4+CD25+ cells.
Arthritis Rheum. 58: 2347-2355 (2008).
*
-
Harley JB. IL-7Ralpha and multiple sclerosis risk.
Nat. Genet. 39: 1053-1054 (2007).
*
-
Harloff S, Hartwig D, Kasper K, Wedel T, Muller M, Geerling G. Epitheliotrophic capacity of serum eye drops from healthy donors versus serum from immunosuppressed patients with rheumatoid arthritis.
Klin. Monatsbl. Augenheilkd. 225: 200-206 (2008).
-
Harnett MM, Kean DE, Boitelle A, McGuiness S, Thalhamer T, Steiger CN, Egan C, Al-Riyami L, Alcocer MJ, Houston KM, Gracie JA, McInnes IB, Harnett W. The phosphorycholine moiety of the filarial nematode immunomodulator ES-62 is responsible for its anti-inflammatory action in arthritis.
Ann. Rheum. Dis. 67: 518-523 (2008).
-
Harnett MM, Melendez AJ, Harnett W. The therapeutic potential of the filarial nematode-derived immunodulator, ES-62 in inflammatory disease.
Clin. Exp. Immunol. Dec 1 [Epub ahead of print] (2009).
*
-
Harnett W, Harnett MM. Filarial nematode secreted product es-62 is an anti-inflammatory agent: therapeutic potential of small molecule derivatives and ES-62 peptide mimetics.
Clin. Exp. Pharmacol. Physiol. 33: 511-518 (2006).
-
Harney S, Newton J, Milicic A, Brown MA, Wordsworth BP. Non-inherited maternal HLA alleles are associated with rheumatoid arthritis.
Rheumatology (Oxford) 42: 171-174 (2003).
*
-
Harney SM, Meisel C, Sims AM, Woon PY, Wordsworth BP, Brown MA. Genetic and genomic studies of PADI4 in rheumatoid arthritis.
Rheumatology (Oxford) 44: 869-872 (2005).
*
-
Harney SM, Newton JL, Wordsworth BP. Molecular genetics of rheumatoid arthritis.
Curr. Opin. Pharmacol. 3: 280-285 (2003).
-
Harney SM, Vilarino-Guell C, Adamopoulos IE, Sims AM, Lawrence RW, Cardon LR, Newton JL, Meisel C, Pointon JJ, Darke C, Athanasou N, Wordsworth BP, Brown MA. Fine mapping of the MHC class III region demonstrates association of AIF1 and rheumatoid arthritis.
Rheumatology (Oxford) 47: 1761-1767 (2008).
*
-
Harnish DC. Estrogen receptor ligands in the control of pathogenic inflammation.
Curr. Opin. Investig. Drugs 7: 997-1001 (2006).
-
Haroon M, Bond U, Phelan M. Sinusitis: a possible link with adalimumab.
Clin. Rheumatol. 27: 1189-1190 (2008).
-
Harper L, Radford D, Plant T, Drayson M, Adu D, Savage CO. IgG from myeloperoxidase-antineutrophil cytoplasmic antibody-positive patients stimulates greater activation of primed neutrophils than IgG from proteinase 3-antineutrophil cytosplasmic antibody-positive patients.
Arthritis Rheum. 44: 921-930 (2001).
*
-
Harris CL, Raisch DW, Abhyankar U, Marfatia S, Campbell HM, Sather MR. GI risk factors and use of GI protective agents among patients receiving nonsteroidal antiinflammatory drugs.
Ann. Pharmacother. 40: 1924-1931 (2006).
-
Harris HA. Estrogen receptor-beta: recent lessons from in vivo studies.
Mol. Endocrinol. 21: 1-13 (2007).
*
-
Harris HA. Preclinical characterization of selective estrogen receptor beta agonists: new insights into their therapeutic potential.
Ernst Schering Found. Symp. Proc. 1: 149-161 (2006).
-
Harris HA, Bruner-Tran KL, Zhang X, Osteen KG, Richard Lyttle C. A selective estrogen receptor-beta agonist causes lesion regression in an experimentally induced model of endometriosis.
Hum. Reprod. 20: 936-941 (2005).
-
Harris J, Hope JC, Keane J. Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis.
J. Infect. Dis. 198: 1842-1850 (2008).
*
-
Harris M, Smith B, Veale A. Printed patient education interventions to facilitate shared management of chronic disease: a literature review.
Intern. Med. J. 35: 711-716 (2005).
*
-
Harris ML, Darrah E, Lam GK, Bartlett SJ, Giles JT, Grant AV, Gao P, Scott WW Jr, El-Gabalawy H, Casciola-Rosen L, Barnes KC, Bathon JM, Rosen A. Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis.
Arthritis Rheum. 58: 1958-1967 (2008).
*
-
Harris SJ, Foster JG, Ward SG. PI3K isoforms as drug targets in inflammatory diseases: lessons from pharmacological and genetic strategies.
Curr. Opin. Investig. Drugs 10: 1151-1162 (2009).
-
Harrison B, Thomson W, Symmons D, Ollier B, Wiles N, Payton T, Barrett E, Silman A. The influence of HLA-DRB1 alleles and rheumatoid factor on disease outcome in an inception cohort of patients with early inflammatory arthritis.
Arthritis Rheum. 42: 2174-2183 (1999).
*
-
Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, Symmons DP. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
Ann. Rheum. Dis. 68: 209-215 (2009).
*
-
Harrison MJ, Ravdin LD, Lockshin MD. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus.
Arthritis Rheum. 54: 2515-2522 (2006).
*
-
Harrison P, Pointon JJ, Chapman K, Roddam A, Wordsworth BP. Interleukin-1 promoter region polymorphism role in rheumatoid arthritis: a meta-analysis of IL-1B-511A/G variant reveals association with rheumatoid arthritis.
Rheumatology (Oxford) 47: 1768-1770 (2008).
*
-
Harrison P, Pointon JJ, Farrar C, Brown MA, Wordsworth BP. Effects of PTPN22 C1858T polymorphism on susceptibility and clinical characteristics of British Caucasian rheumatoid arthritis patients.
Rheumatology (Oxford) 45: 1009-1011 (2006).
*
-
Harrison P, Pointon JJ, Farrar C, Harin A, Wordsworth BP. MHC2TA promoter polymorphism (-168*G/A, rs3087456) is not associated with susceptibility to rheumatoid arthritis in British Caucasian rheumatoid arthritis patients.
Rheumatology (Oxford) 46: 409-411 (2007).
*
-
Hart AL, Stagg AJ, Frame M, Graffner H, Glise H, Falk P, Kamm MA. The role of the gut flora in health and disease, and its modification as therapy.
Aliment. Pharmacol. Ther. 16: 1383-1393 (2002).
*
-
Hart PH, Ahern MJ, Smith MD, Finlay-Jones JJ. Regulatory effects of IL-13 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis.
Clin. Exp. Immunol. 99: 331-337 (1995).
*
-
Hartgring SA, Bijlsma JW, Lafeber FP, van Roon JA. Interleukin-7 induced immunopathology in arthritis.
Ann. Rheum. Dis. 65 Suppl. 3: iii69-iii74 (2006).
*
-
Hartmann U, Schmitt S, Reuss-Borst M. Elevated liver enzymes in rheumatoid arthritis: differential diagnostic considerations based on a case report.
Z. Rheumatol. 67: 440-444 (2008).
-
Hartog A, Leenders I, van der Kraan PM, Garssen J. Anti-inflammatory effects of orally ingested lactoferrin and glycine in different zymosan-induced inflammation models: evidence for synergistic activity.
Int. Immunopharmacol. 7: 1784-1792 (2007).
-
Hartung HP. Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis.
Nervenarzt. 80: 1462-1472 (2009).
-
Hartung K, Seelig HP. Laboratory diagnostics of systemic autoimmune diseases: part II. Rheumatoid arthritis and vasculopathies.
Z. Rheumatol. 66: 225-238 (2007).
-
Hartzell TL, Makhni EC, Sampson C. Long-term results of periarterial sympathectomy.
J. Hand. Surg. Am. 34: 1454-1460 (2009).
-
Haruna Y, Morita Y, Komai N, Yada T, Sakuta T, Tomita N, Fox DA, Kashihara N. Endothelial dysfunction in rat adjuvant-induced arthritis: vascular superoxide production by NAD(P)H oxidase and uncoupled endothelial nitric oxide synthase.
Arthritis Rheum. 54: 1847-1855 (2006).
*
-
Harvald B. Genetic epidemiology of Greenland.
Clin. Genet. 36: 364-367 (1989).
-
Hasan U. Tumour necrosis factor inhibitors - what we need to know.
N. Z. Med. J. 119: U2336 (2006).
-
Hasebe A, Pennock ND, Mu HH, Chan FV, Taylor ML, Cole BC. A microbial TLR2 agonist imparts macrophage-activating ability to apolipoprotein A-1.
J. Immunol. 177: 4826-4832 (2006).
*
-
Hasegawa H, Inoue A, Muraoka M, Yamanouchi J, Miyazaki T, Yasukawa M. Therapy for pneumonitis and sialadenitis by accumulation of CCR2-expressing CD4+CD25+ regulatory T cells in MRL/lpr mice.
Arthritis Res. Ther. 9: R15 (2007).
*
-
Hasegawa M. B lymphocyte.
Nihon Rinsho Meneki Gakkai Kaishi 28: 300-308 (2005).
-
Hasegawa M, Nakoshi Y, Iino T, Sudo A, Segawa T, Maeda M, Yoshida T, Uchida A. Thrombin-cleaved osteopontin in synovial fluid of subjects with rheumatoid arthritis.
J. Rheumatol. 36: 240-245 (2009).
-
Hasegawa M, Nakoshi Y, Muraki M, Sudo A, Kinoshita N, Yoshida T, Uchida A. Expression of large tenascin-C splice variants in synovial fluid of patients with rheumatoid arthritis.
J. Orthop. Res. 25: 563-568 (2007).
-
Hashemi M, Moazeni-Roodi AK, Fazaeli A, Sandoughi M, Bardestani GR, Kordi-Tamandani DM, Ghavami S. Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran.
Genet. Mol. Res. 9: 333-339 (2010).
-
Hashii N, Kawasaki N, Itoh S, Nakajima Y, Kawanishi T, Yamaguchi T. Alteration of N-glycosylation in the kidney in a mouse model of systemic lupus erythematosus: relative quantification of N-glycans using an isotope-tagging method.
Immunology 126: 336-345 (2009).
*
-
Hashimoto M, Sakaguchi S. Contribution of Th-1, Th-2, Th-17 or regulatory T cells to connective tissue diseases.
Nippon Rinsho 67: 482-486 (2009).
-
Hashiramoto A, Yamane T, Tsumiyama K, Yoshida K, Komai K, Yamada H, Yamazaki F, Doi M, Okamura H, Shiozawa S. Mammalian clock gene cryptochrome regulates arthritis via proinflammatory cytokine TNF-alpha.
J. Immunol. Dec 30 [Epub ahead of print] (2009).
-
Hashizume F, Hino S, Kakehashi M, Okajima T, Nadano D, Aoki N, Matsuda T. Development and evaluation of transgenic rice seeds accumulating a type II-collagen tolerogenic peptide.
Transgenic Res. 17: 1117-1129 (2008).
*
-
Hashizume M, Yoshida H, Koike N, Suzuki M, Mihara M. Over-produced IL-6 decreases blood lipid levels via up-regulation of VLDLR.
Ann. Rheum. Dis. May 10 [Epub ahead of print] (2009).
-
Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis.
JAMA 294: 1671-1684 (2005).
*
-
Hashkes PJ, Laxer RM. Update on the medical treatment of juvenile idiopathic arthritis.
Curr. Rheumatol. Rep. 8: 450-458 (2006).
-
Hashkes PJ, Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy.
Clin. Exp. Rheumatol. 21: 645-646 (2003).
-
Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases.
Nat. Rev. Drug Discov. 7: 759-770 (2008).
*
-
Hasko G, Szabo C, Nemeth ZH, Deitch EA. Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression.
Immunology 103: 473-478 (2001).
*
-
Hasler P. Biological therapies directed against cells in autoimmune disease.
Springer Semin. Immunopathol. 27: 443-456 (2006).
*
-
Hassan B, Maxwell JR, Hyrich KL; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, Barton A, Worthington J, Isaacs JD, Morgan AW, Wilson AG. Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis.
Rheumatology (Oxford) 49: 43-47 (2010).
-
Hasselberg A, Schon K, Tarkowski A, Lycke N. Role of CTA1R7K-COL-DD as a novel therapeutic mucosal tolerance-inducing vector for treatment of collagen-induced arthritis.
Arthritis Rheum. 60: 1672-1682 (2009).
*
-
Hasselmann DO, Bens G, Tilgen W, Reichrath J. Pyoderma gangrenosum: clinical presentation and outcome in 18 cases and review of the literature.
J. Dtsch. Dermatol. Ges. 5: 560-564 (2007).
-
Hasstedt SJ, Clegg DO, Ingles L, Ward RH. HLA-linked rheumatoid arthritis.
Am. J. Hum. Genet. 55: 738-746 (1994).
*
-
Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, Chiang N, Petasis NA, Levy BD, Serhan CN, Van Dyke TE. RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis.
FASEB J. 20: 401-403 (2006).
*
-
Hata T, Kavanaugh A. Rheumatoid arthritis in dermatology.
Clin. Dermatol. 24: 430-437 (2006).
-
Hatanaka K, Nakamura N, Kojima M, Ando K, Irie S, Bunno M, Nakamine H, Uekusa T. Methotrexate-associated lymphoproliferative disorders mimicking angioimmunoblastic T-cell lymphoma.
Pathol. Res. Pract. Jul 21 [Epub ahead of print] (2009).
-
Hatano T, Fukuda M, Shiotsuki H, Miwa H, Urabe T, Mizuno Y. Chronic inflammatory demyelinating polyneuropathy followed by systemic lupus erythematosus and Sjogren syndrome: a case report.
Rinsho Shinkeigaku 46: 203-209 (2006).
-
Hatemi I, Hatemi G, Celik AF, Melikoglu M, Arzuhal N, Mat C, Ozyazgan Y, Yazici H. Frequency of pathergy phenomenon and other features of Behcet's syndrome among patients with inflammatory bowel disease.
Clin. Exp. Rheumatol. 26: S91-S95 (2008).
-
Hattori T, Von Der Mark K, Kawaki H, Yutani Y, Kubota S, Nakanishi T, Eberspaecher H, De Crombrugghe B, Takigawa M. Downregulation of rheumatoid arthritis-related antigen RA-A47 (HSP47/colligin-2) in chondrocytic cell lines induces apoptosis and cell-surface expression of RA-A47 in association with CD9.
J. Cell. Physiol. 202: 191-204 (2005).
*
-
Hattori Y, Sakaguchi M, Maitani Y. Folate-linked lipid-based nanoparticles deliver a NFkappaB decoy into activated murine macrophage-like RAW264.7 cells.
Biol. Pharm. Bull. 29: 1516-1520 (2006).
*
-
Hauber HP, Zabel P. Lung and autoimmune disease - clinic and diagnostic approach.
Dtsch. Med. Wochenschr. 132: 1633-1638 (2007).
-
Hauber HP, Zabel P. Lung and autoimmune disease - therapy.
Dtsch. Med. Wochenschr. 132: 1703-1706 (2007).
-
Hauff K, Zamzow C, Law WJ, De Melo J, Kennedy K, Los M. Peptide-based approaches to treat asthma, arthritis, other autoimmune diseases and pathologies of the central nervous system.
Arch. Immunol. Ther. Exp. (Warsz.) 53: 308-320 (2005).
-
Haug M, Schepp CP, Kalbacher H, Dannecker GE, Holzer U. 70-kDa heat shock proteins: specific interactions with HLA-DR molecules and their peptide fragments.
Eur. J. Immunol. 37: 1053-1063 (2007).
*
-
Haugen F, Drevon CA. Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin.
Endocrinology 148: 5478-5486 (2007).
*
-
Haupl T, Yahyawi M, Lubke C, Ringe J, Rohrlach T, Burmester GR, Sittinger M, Kaps C. Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs.
J. Biomol. Screen. 12: 328-340 (2007).
-
Havel J, Aboutalebi S, Doughty L, Wirges M. Development of systemic lupus erythematosus in a patient with rheumatoid arthritis following treatment conversion of infliximab to adalimumab.
J. Drugs Dermatol. 7: 796-798 (2008).
-
Havemose-Poulsen A, Sorensen LK, Bendtzen K, Holmstrup P. Polymorphisms within the IL-1 gene cluster: effects on cytokine profiles in peripheral blood and whole blood cell cultures of patients with aggressive periodontitis, juvenile idiopathic arthritis, and rheumatoid arthritis.
J. Periodontol. 78: 475-492 (2007).
-
Hawker GA, Guan J, Croxford R, Coyte PC, Glazier RH, Harvey BJ, Wright JG, Williams JI, Badley EM. A prospective population-based study of the predictors of undergoing total joint arthroplasty.
Arthritis Rheum. 54: 3212-3220 (2006).
*
-
Hawkey CJ, Gitton X, Hoexter G, Richard D, Weinstein WM. Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.
Clin. Gastroenterol. Hepatol. 4: 57-66 (2006).
-
Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra.
Arthritis Rheum. 50: 607-612 (2004).
*
-
Hawrelak JA, Myers SP. The causes of intestinal dysbiosis: a review.
Altern. Med. Rev. 9: 180-197 (2004).
*
-
Hayakawa S, Komine-Aizawa S, Osaka S, Iida T, Hayakawa J, Nishinarita S, Nemoto N. Rembrandt's Maria Bockenolle has a butterfly rash and digital deformities: overlapping syndrome of rheumatoid arthritis and systemic lupus erythematosus.
Med. Hypotheses 68: 906-909 (2007).
-
Hayashi S, Miura Y, Nishiyama T, Mitani M, Tateishi K, Sakai Y, Hashiramoto A, Kurosaka M, Shiozawa S, Doita M. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis.
Arthritis Rheum. 56: 1067-1075 (2007).
*
-
Hayashi T, Gray CS, Chan M, Tawatao RI, Ronacher L, McGargill MA, Datta SK, Carson DA, Corr M. Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7.
Proc. Natl. Acad. Sci. U.S.A. 106: 2764-2769 (2009).
*
-
Hayashi T, Matsumoto I, Muraki Y, Takahashi R, Chino Y, Goto D, Ito S, Tsutsumi A, Sumida T. Clinical characteristics of anti-glucose-6-phosphate isomerase antibody-positive Japanese patients with rheumatoid arthritis.
Mod. Rheumatol. 15: 258-263 (2005).
-
Hayashi T, Sumida T. Targeted therapies including monoclonal antibodies for connective tissue diseases.
Nippon Rinsho 67: 588-592 (2009).
-
Hayashi Y, Hamano H, Haneji N, Ishimaru N, Yanagi K. Biased T cell receptor V beta gene usage during specific stages of the development of autoimmune sialadenitis in the MRL/lpr mouse model of Sjogren's syndrome.
Arthritis Rheum. 38: 1077-1084 (1995).
-
Hayashi Y, Ishimaru N, Arakaki R, Tsukumo S, Fukui H, Kishihara K, Shiota H, Yasutomo K, Hayashi Y. Effective treatment of a mouse model of Sjogren's syndrome with eyedrop administration of anti-CD4 monoclonal antibody.
Arthritis Rheum. 50: 2903-2910 (2004).
*
-
Haydardedeoglu FE, Tutkak H, Kose K, Duzgun N. Genetic susceptibility to rheumatic heart disease and streptococcal pharyngitis: association with HLA-DR alleles.
Tissue Antigens 68: 293-296 (2006).
*
-
Hayem G, Bouchaud-Chabot A, Benali K, Roux S, Palazzo E, Silbermann-Hoffman O, Kahn MF, Meyer O. SAPHO syndrome: a long-term follow-up study of 120 cases.
Semin. Arthritis Rheum. 29: 159-171 (1999).
*
-
Hayer S, Redlich K, Korb A, Hermann S, Smolen J, Schett G. Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis.
Arthritis Rheum. 56: 79-88 (2007).
*
-
Hayman MW, van Beijnen MT, Stamp LK, Spellerberg MB, O'Donnell JL. Soluble human leukocyte antigen: a diagnostic indicator of rheumatoid arthritis?
J. Immunol. Methods 315: 19-26 (2006).
*
-
Haynes DR. Inflammatory cells and bone loss in rheumatoid arthritis.
Arthritis Res. Ther. 9: 104 (2007).
*
-
Haystead TA. The purinome, a complex mix of drug and toxicity targets.
Curr. Top. Med. Chem. 6: 1117-1127 (2006).
-
Hayward K, Wallace CA. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis.
Arthritis Res. Ther. 11: 216 (2009).
*
-
He L, Grammer AC, Wu X, Lipsky PE. TRAF3 forms heterotrimers with TRAF2 and modulates its ability to mediate NF-kB activation.
J. Biol. Chem. 279: 55855-55865 (2004).
*
-
Heale CE, Fahraeus-Van Ree GE, Rahman P, Richardson VJ. Progressive and concordant expression of PKC-{eta} and iNOS phenotypes in monocytes from patients with rheumatoid arthritis: association with disease severity.
J. Histochem. Cytochem. 55: 495-503 (2007).
*
-
Healy AM, Izmailova E, Fitzgerald M, Walker R, Hattersley M, Silva M, Siebert E, Terkelsen J, Picarella D, Pickard MD, Leclair B, Chandra S, Jaffee B. PKC-{theta}-deficient mice are protected from Th1-dependent antigen-induced arthritis.
J. Immunol. 177: 1886-1893 (2006).
*
-
Healy LJ, Collins HL, Thompson SJ. Systemic administration of tolerogenic dendritic cells ameliorates murine inflammatory arthritis.
Open Rheumatol. J. 2: 71-80 (2008).
*
-
Healy PJ, Groves C, Chandramohan M, Helliwell PS. MRI changes in psoriatic dactylitis extent of pathology, relationship to tenderness and correlation with clinical indices.
Rheumatology (Oxford) 47: 92-95 (2008).
*
-
Healy PJ, Helliwell PS. Dactylitis: pathogenesis and clinical considerations.
Curr. Rheumatol. Rep. 8: 338-341 (2006).
-
Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis.
Arthritis Rheum. 59: 686-691 (2008).
*
-
Healy PJ, Helliwell PS. Psoriatic arthritis quality of life instrument: an assessment of sensitivity and response to change.
J. Rheumatol. 35: 1359-1361 (2008).
*
-
Healy PJ, Helliwell PS. Classification of the spondyloarthropathies.
Curr. Opin. Rheumatol. 17: 395-399 (2005).
-
Hecker M, Goertsches RH, Engelmann R, Thiesen HJ, Guthke R. Integrative modeling of transcriptional regulation in response to antirheumatic therapy.
BMC Bioinformatics 10: 262 (2009).
*
-
Hedger SC, Macardle P, Bond MJ, Ahern MJ, Smith MD, Roberts-Thomson PJ. Shared rheumatoid epitope as a risk factor in determining outcome in rheumatoid arthritis.
Aust. N. Z. J. Med. 29: 234-238 (1999).
-
Hedley ML. Gene therapy of chronic inflammatory disease.
Adv. Drug Deliv. Rev. 44: 195-207 (2000).
-
Hee CS, Gun SC, Naidu R, Gupta E, Somnath SD, Radhakrishnan AK. Comparison of single nucleotide polymorphisms in the human interleukin-10 gene promoter between rheumatoid arthritis patients and normal subjects in Malaysia.
Mod. Rheumatol. 17: 429-435 (2007).
*
-
Hee Kim S, Bianco N, Menon R, Lechman ER, Shufesky WJ, Morelli AE, Robbins PD. Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive.
Mol. Ther. 13: 289-300 (2006).
-
Hegen M, Gaestel M, Nickerson-Nutter CL, Lin LL, Telliez JB. MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis.
J. Immunol. 177: 1913-1917 (2006).
*
-
Heiberg MS, Kaufmann C, Rodevand E, Mikkelsen K, Koldingsnes W, Mowinckel P, Kvien TK. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6- month results from a longitudinal, observational, multicenter study.
Ann. Rheum. Dis. 66: 1038-1042 (2007).
*
-
Heiberg MS, Koldingsnes W, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, Kvien TK. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Arthritis Rheum. 59: 234-240 (2008).
*
-
Heidinger M, Kolb H, Krell HW, Jochum M, Ries C. Modulation of autocrine TNF-alpha-stimulated matrix metalloproteinase 9 (MMP-9) expression by mitogen-activated protein kinases in THP-1 monocytic cells.
Biol. Chem. 387: 69-78 (2006).
-
Heijstek MW, Pileggi C, Zonneveld-Huijssoon E, Armbrust W, Hoppenreijs EP, Uiterwaal CS, Kuis W, Wulffraat NM. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis.
Ann. Rheum. Dis. 66: 1384-1387 (2007).
*
-
Heiligenhaus A, Horneff G, Greiner K, Mackensen F, Zierhut M, Foeldvari I, Michels H. Inhibitors of tumour necrosis factor-alpha for the treatment of arthritis and uveitis in childhood.
Klin. Monatsbl. Augenheilkd. 224: 526-531 (2007).
-
Heiligenhaus A, Mingels A, Neudorf U, Ganser G. Juvenile idiopathic arthritis and uveitis: screening and anti-inflammatory therapy.
Klin. Monatsbl. Augenheilkd. 220: 738-753 (2003).
-
Heiligenhaus A, Niewerth M, Mingels A, Ganser G, Thon A, Pleyer U, Greiner K, Minden K. Epidemiology of uveitis in juvenile idiopathic arthritis from a national paediatric rheumatologic and ophthalmologic database.
Klin. Monatsbl. Augenheilkd. 222: 993-1001 (2005).
-
Heinz C, Plentz A, Bauer D, Heiligenhaus A, Modrow S. Prevalence of parvovirus B19-specific antibodies and of viral DNA in patients with endogenous uveitis.
Graefes Arch. Clin. Exp. Ophthalmol. 243: 999-1004 (2005).
-
Heldt C, Listing J, Sozeri O, Blasing F, Frischbutter S, Muller B. Differential expression of HLA class II genes associated with disease susceptibility and progression in rheumatoid arthritis.
Arthritis Rheum. 48: 2779-2787 (2003).
*
-
Helenius LM, Hallikainen D, Helenius I, Meurman JH, Koskimies S, Tervahartiala P, Kivisaari L, Hietanen J, Suuronen R, Lindqvist C, Leirisalo-Repo M. HLA-DRB1* alleles and temporomandibular joint erosion in patients with various rheumatic diseases.
Scand. J. Rheumatol. 33: 24-29 (2004).
-
Helenius LM, Meurman JH, Helenius I, Kari K, Hietanen J, Suuronen R, Hallikainen D, Kautiainen H, Leirisalo-Repo M, Lindqvist C. Oral and salivary parameters in patients with rheumatic diseases.
Acta Odontol. Scand. 63: 284-293 (2005).
-
Helenius LM, Tervahartiala P, Helenius I, Al-Sukhun J, Kivisaari L, Suuronen R, Kautiainen H, Hallikainen D, Lindqvist C, Leirisalo-Repo M. Clinical, radiographic and MRI findings of the temporomandibular joint in patients with different rheumatic diseases.
Int. J. Oral Maxillofac. Surg. 35: 983-989 (2006).
-
Heller A, Koch T, Schmeck J, van Ackern K. Lipid mediators in inflammatory disorders.
Drugs 55: 487-496 (1998).
-
Hellier JP, Eliaou JF, Daures JP, Sany J, Combe B. HLA-DRB1 genes and patients with late onset rheumatoid arthritis.
Ann. Rheum. Dis. 60: 531-533 (2001).
*
-
Helliwell C. Immunology primer. Immunology news: a new type of T cell is discovered (http://www.acnr.co.uk/JF07/ACNR_JF07_immunology.pdf).
ACNR 6: 8-9 (2007). *
-
Helliwell PS. Therapies for dactylitis in psoriatic arthritis. A systematic review.
J. Rheumatol. 33: 1439-1441 (2006).
-
Helliwell PS. GRAPPA - Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Stockholm, May/June 2006.
J. Rheumatol. 34: 214-219 (2007).
-
Helliwell PS. The diagnosis of psoriatic arthritis.
Reumatismo 59 Suppl. 1: 61-63 (2007).
*
-
Helliwell PS. Established psoriatic arthritis: clinical aspects.
J. Rheumatol. Suppl. 83: 21-23 (2009).
-
Helliwell PS, Porter G, Taylor WJ. Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis, than rheumatoid arthritis.
Ann. Rheum. Dis. 66: 113-117 (2007).
*
-
Helliwell PS, Taylor WJ. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs - comparison of drugs and adverse reactions.
J. Rheumatol. 35: 472-476 (2008).
-
Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis.
Ann. Rheum. Dis. 64 Suppl. 2: ii3-ii8 (2005).
*
-
Helms C, Cao L, Krueger JG, Wijsman EM, Chamian F, Gordon D, Heffernan M, Daw JA, Robarge J, Ott J, Kwok PY, Menter A, Bowcock AM. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis.
Nat. Genet. 35: 349-356 (2003).
*
-
Helms S. Celiac disease and gluten-associated diseases.
Altern. Med. Rev. 10: 172-192 (2005).
*
-
Helyes Z. Role of peripheral mu-opioid receptors in arthritis: are they potential targets for therapy?
Arthritis Rheum. 52: 2955-2959 (2005).
*
-
Helyes Z, Pinter E, Sandor K, Elekes K, Banvolgyi A, Keszthelyi D, Szoke E, Toth DM, Sandor Z, Kereskai L, Pozsgai G, Allen JP, Emson PC, Markovics A, Szolcsanyi J. Impaired defense mechanism against inflammation, hyperalgesia, and airway hyperreactivity in somatostatin 4 receptor gene-deleted mice.
Proc. Natl. Acad. Sci. U.S.A. 106: 13088-13093 (2009).
*
-
Hemauer A, Gigler A, Searle K, Beckenlehner K, Raab U, Broliden K, Wolf H, Enders G, Modrow S. Seroprevalence of parvovirus B19 NS1-specific IgG in B19-infected and uninfected individuals and in infected pregnant women.
J. Med. Virol. 60: 48-55 (2000).
-
Hemminki K, Li X, Sundquist J, Sundquist K. Familial associations of rheumatoid arthritis with autoimmune diseases and related conditions.
Arthritis Rheum. 60: 661-668 (2009).
*
-
Hemminki K, Li X, Sundquist J, Sundquist K. Subsequent autoimmune or related disease in asthma patients: clustering of diseases or medical care?
Ann. Epidemiol. Dec 24 [Epub ahead of print] (2009).
-
Hemminki K, Li X, Sundquist J, Sundquist K. Familial association between type 1 diabetes and other autoimmune and related diseases.
Diabetologia 52: 1820-1828 (2009).
*
-
Hemminki K, Li X, Sundquist K, Sundquist J. Shared familial aggregation of susceptibility to autoimmune diseases.
Arthritis Rheum. 60: 2845-2847 (2009).
*
-
Henderson WR Jr. The role of leukotrienes in inflammation.
Ann. Intern. Med. 121: 684-697 (1994).
*
-
Henegar C, Pagnoux C, Puechal X, Zucker JD, Bar-Hen A, Le Guern V, Saba M, Bagneres D, Meyer O, Guillevin L; French Vasculitis Study Group. A paradigm of diagnostic criteria for polyarteritis nodosa: analysis of a series of 949 patients with vasculitides.
Arthritis Rheum. 58: 1528-1538 (2008).
*
-
Henneken M, Dorner T, Burmester GR, Berek C. Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus.
Arthritis Res. Ther. 7: R1001-R1013 (2005).
*
-
Hennigan S, Kavanaugh A. Interleukin-6 inhibitors in the treatment of rheumatoid arthritis.
Ther. Clin. Risk Manag. 4: 767-775 (2008).
*
-
Hennum J, Nace J, Shammash E, Gertner E. Infliximab-associated pneumonitis in rheumatoid arthritis.
J. Rheumatol. 33: 1917-1918 (2006).
-
Heo YJ, Joo YB, Oh HJ, Park MK, Heo YM, Cho ML, Kwok SK, Ju JH, Park KS, Cho SG, Park SH, Kim HY, Min JK. IL-10 suppresses Th17 cells and promotes regulatory T cells in the CD4(+) T cell population of rheumatoid arthritis patients.
Immunol. Lett. Nov 3 [Epub ahead of print] (2009).
-
Herbaut C. Omega-3 and health.
Rev. Med. Brux. 27: S355-S360 (2006).
-
Herfarth H. Therapy of IBD: bottom-up or top-down?
Falk Symposium 154: INFLAMMATORY BOWEL DISEASE - DIAGNOSTIC AND THERAPEUTIC STRATEGIES, Moscow (Russia), June 9 - 10, 2006, pp. 56-57 (2006). *
-
Herfarth H, Obermeier F, Andus T, Rogler G, Nikolaus S, Kuehbacher T, Schreiber S. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease.
Am. J. Gastroenterol. 97: 2688-2690 (2002).
*
-
Herfarth HH, Osterman MT, Isaacs KL, Lewis JD, Sands BE. Efficacy of methotrexate in ulcerative colitis: failure or promise.
Inflamm. Bowel Dis. Feb 23 [Epub ahead of print] (2010).
*
-
Herlin T. Juvenile idiopathic arthritis.
Ugeskr. Laeger. 164: 3941-3946 (2002).
-
Herlin T. Biological therapy treatment of juvenile idiopathic arthritis.
Ugeskr. Laeger. 170: 2105-2108 (2008).
-
Herman S, Kronke G, Schett G. Molecular mechanisms of inflammatory bone damage: emerging targets for therapy.
Trends Mol. Med. 14: 245-253 (2008).
*
-
Hermann E, Fleischer B, Meyer zum Buschenfelde KH. Bacteria-specific cytotoxic CD8+ T cells: a missing link in the pathogenesis of the HLA-B27-associated spondylarthropathies.
Ann. Med. 26: 365-369 (1994).
-
Hermann E, Mayet WJ, Poralla T, Meyer zum Buschenfelde KH. Rheumatologic syndrome in gastrointestinal diseases. Clinical and pathogenetic aspects.
Z. Gastroenterol. 26: 137-144 (1988).
-
Hermann E, Yu DT, Meyer zum Buschenfelde KH, Fleischer B. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis.
Lancet 342: 646-650 (1993).
-
Hermann J, Demel U, Stunzner D, Daghofer E, Tilz G, Graninger W. Clinical interpretation of antineutrophil cytoplasmatic antibodies: parvovirus B19 infection as a pitfall.
Ann. Rheum. Dis. 64: 641-643 (2005).
*
-
Hermann M. Cyclooxygenase-2 and nitric oxide.
J. Cardiovasc. Pharmacol. 47 Suppl. 1: S21-S25 (2006).
-
Hernandez L, Green PH. Extraintestinal manifestationsof celiac disease.
Curr. Gastroenterol. Rep. 8: 383-389 (2006).
-
Hernandez MV, Nogues S, Ruiz-Esquide V, Alsina M, Canete JD, Sanmarti R. Development of alopecia areata after biological therapy with TNF-alpha blockers: description of a case and review of the literature.
Clin. Exp. Rheumatol. 27: 892-893 (2009).
-
Herrera E, Habicheyn S. Infliximab.
Actas Dermosifiliogr. 99 Suppl. 4: 7-13 (2008).
-
Herrero-Beaumont G, Armas JB, Elswood J, Will RK, Calin A. Selective IgA deficiency and spondyloarthropathy: a distinct disease?
Ann. Rheum. Dis. 49: 636-637 (1990).
*
-
Herrlinger KR, Dittmann R, Weitz G, Wehkamp J, Ludwig D, Schwab M, Stange EF, Fellermann K. Serum procalcitonin differentiates inflammatory bowel disease and self- limited colitis.
Inflamm. Bowel Dis. 10: 229-233 (2004).
*
-
Herrlinger KR, Witthoeft T, Raedler A, Bokemeyer B, Krummenerl T, Schulzke JD, Boerner N, Kueppers B, Emmrich J, Mescheder A, Schwertschlag U, Shapiro M, Stange EF. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease.
Am. J. Gastroenterol. 101: 793-797 (2006).
*
-
Hervey PS, Keam SJ. Abatacept.
BioDrugs 20: 53-61 (2006).
-
Heshmat NM, El-Kerdany TH. Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus.
Pediatr. Allergy Immunol. 18: 346-353 (2007).
-
Hetland ML. DANBIO: a nationwide registry of biological therapies in Denmark.
Clin. Exp. Rheumatol. 23: S205-S207 (2005).
-
Hetland ML, Ejbjerg BJ, Horslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, Tarp U, Skjodt H, Pedersen JK, Majgaard O, Svendsen AJ, Ellingsen T, Lindegaard HM, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2 year randomized controlled trial (CIMESTRA).
Ann. Rheum. Dis. 68: 384-390 (2009).
-
Hetland ML, Lindegaard HM, Hansen A, Pødenphant J, Unkerskov J, Ringsdal VS, Ostergaard M, Tarp U. Do changes in prescription practice in patients with rheumatoid arthritis treated with biologics affect treatment response and adherence to therapy? Results from the nationwide Danish Danbio Registry.
Ann. Rheum. Dis. 67: 1023-1026 (2008).
-
Hettema ME, Zhang D, de Leeuw K, Stienstra Y, Smit AJ, Kallenberg CG, Bootsma H. Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors.
Arthritis Res. Ther. 10: R49 (2008).
*
-
Hewagama A, Richardson B. The genetics and epigenetics of autoimmune diseases.
J. Autoimmun. 33: 3-11 (2009).
-
Heward J, Brand O, Barrett J, Carr-Smith J, Franklyn J, Gough S. Association of PTPN22 haplotypes with Graves' disease.
J. Clin. Endocrinol. Metab. 92: 685-690 (2007).
*
-
Heward J, Gough SC. Genetic susceptibility to the development of autoimmune disease.
Clin. Sci. (Lond.) 93: 479-491 (1997).
-
Hewlett S, Cockshott Z, Byron M, Kitchen K, Tipler S, Pope D, Hehir M. Patients' perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored.
Arthritis Rheum. 53: 697-702 (2005).
*
-
Heyman SN, Spectre G, Aamar S, Rubinger D, Pappo O, Ackerman Z. Autoimmune cholangiopathy associated with systemic lupus erythematosus.
Liver 22: 102-106 (2002).
-
Hick J, Feldman SR. Eligibility creep: a cause for placebo group improvement in controlled trials of psoriasis treatments.
J. Am. Acad. Dermatol. 57: 972-976 (2007).
-
Hicks A, Monkarsh SP, Hoffman AF, Goodnow R. Leukotriene B(4) receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments.
Expert Opin. Investig. Drugs 16: 1909-1920 (2007).
-
Hida S, Miura NN, Adachi Y, Ohno N. Effect of Candida albicans cell wall glucan as adjuvant for induction of autoimmune arthritis in mice.
J. Autoimmun. 25: 93-101 (2005).
-
Hida S, Miura NN, Adachi Y, Ohno N. Cell wall beta-glucan derived from Candida albicans acts as a trigger for autoimmune arthritis in SKG mice.
Biol. Pharm. Bull. 30: 1589-1592 (2007).
*
-
Hida S, Miura NN, Adachi Y, Ohno N. Influence of arginine deimination on antigenicity of fibrinogen.
J. Autoimmun. 23: 141-150 (2004).
-
Hida S, Nagi-Miura N, Adachi Y, Ohno N. beta-Glucan derived from zymosan acts as an adjuvant for collagen-induced arthritis.
Microbiol. Immunol. 50: 453-461 (2006).
*
-
Hida S, Nagi-Miura N, Adachi Y, Ohno N. F1 hybrid mice (BALB/cxDBA/1) are resistant to collagen-induced arthritis with beta-glucan as an adjuvant.
Biol. Pharm. Bull. 29: 1300-1303 (2006).
*
-
Hidaka Y, Hagiwara T, Yamada M. Methylation of the guanidino group of arginine residues prevents citrullination by peptidylarginine deiminase IV.
FEBS Lett. 579: 4088-4092 (2005).
*
-
Hider SL, Bruce IN, Silman AJ, Symmons DP. Defining response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis.
J. Rheumatol. 32: 6-10 (2005).
-
Hider SL, Bruce IN, Thomson W. The pharmacogenetics of methotrexate.
Rheumatology (Oxford) 46: 1520-1524 (2007).
*
-
Hider SL, Hoggard P, Khoo S, Back D, Bruce IN. Drug efflux transporters in rheumatoid arthritis: comment on the article by Kremer.
Arthritis Rheum. 52: 670 (2005).
*
-
Hider SL, Tanveer W, Brownfield A, Mattey DL, Packham JC. Depression in RA patients treated with anti-TNF is common and under-recognized in the rheumatology clinic.
Rheumatology (Oxford) 48: 1152-1154 (2009).
-
Higashikawa A, Saito T, Ikeda T, Kamekura S, Kawamura N, Kan A, Oshima Y, Ohba S, Ogata N, Takeshita K, Nakamura K, Chung UI, Kawaguchi H. Identification of the core element responsive to Runt-related transcription factor 2 in the promoter of human type x collagen gene.
Arthritis Rheum. 60: 166-178 (2009).
*
-
Hijova E. Matrix metalloproteinases: their biological functions and clinical implications.
Bratisl. Lek. Listy. 106: 127-132 (2005).
-
Hikami K, Tsuchiya N, Yabe T, Tokunaga K. Variations of human killer cell lectin-like receptors: common occurrence of NKG2-C deletion in the general population.
Genes Immun. 4: 160-167 (2003).
*
-
Hikichi Y, Yoshimura K, Takigawa M. All-trans retinoic acid-induced ADAM28 degrades proteoglycans in human chondrocytes.
Biochem. Biophys. Res. Commun. 386: 294-299 (2009).
*
-
Hilden TJ, Nurmi SM, Fagerholm SC, Gahmberg CG. Interfering with leukocyte integrin activation - a novel concept in the development of anti-inflammatory drugs.
Ann. Med. 38: 503-511 (2006).
-
Hildner KM, Schirmacher P, Atreya I, Dittmayer M, Bartsch B, Galle PR, Wirtz S, Neurath MF. Targeting of the transcription factor STAT4 by antisense phosphorothioate oligonucleotides suppresses collagen-induced arthritis.
J. Immunol. 178: 3427-3436 (2007).
*
-
Hill CL, Gill T, Taylor AW, Daly A, Grande ED, Adams RJ. Psychological factors and quality of life in arthritis: a population-based study.
Clin. Rheumatol. 26: 1049-1054 (2007).
-
Hill JA, Al-Bishri J, Gladman DD, Cairns E, Bell DA. Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis.
J. Rheumatol. 33: 2115-2119 (2006).
-
Hill JA, Bell DA, Brintnell W, Yue D, Wehrli B, Jevnikar AM, Lee DM, Hueber W, Robinson WH, Cairns E. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice.
J. Exp. Med. 205: 967-979 (2008).
*
-
Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule.
J. Immunol. 171: 538-541 (2003).
*
-
Hill RJ, Dabbagh K, Phippard D, Li C, Suttmann RT, Welch M, Papp E, Song KW, Chang KC, Leaffer D, Kim YN, Roberts RT, Zabka TS, Aud D, Dalporto J, Manning AM, Peng SL, Goldstein DM, Wong BR. Pamapimod, a novel p38 MAP kinase inhibitor: preclinical analysis of efficacy and selectivity.
J. Pharmacol. Exp. Ther. 327: 610-619 (2008).
*
-
Hillyer P, Larche MJ, Bowman EP, McClanahan TK, de Waal Malefyt R, Schewitz LP, Giddins G, Feldmann M, Kastelein RA, Brennan FM. Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis.
Rheumatology (Oxford) 48: 1581-1589 (2009).
*
-
Hincapie-Zapata ME, Suarez-Escudero JC, Pineda-Tamayo R, Anaya JM. Quality of life in multiple sclerosis and other chronic autoimmune and non-autoimmune diseases.
Rev. Neurol. 48: 225-230 (2009).
-
Hinks A, Barton A, John S, Bruce I, Hawkins C, Griffiths CE, Donn R, Thomson W, Silman A, Worthington J. Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene.
Arthritis Rheum. 52: 1694-1699 (2005).
*
-
Hinks A, Barton A, John S, Shephard N, Worthington J. Fine mapping of genes within the IDDM8 region in rheumatoid arthritis (RA).
Arthritis Res. Ther. 8: R145 (2006).
*
-
Hinks A, Barton A, Shephard N, Eyre S, Bowes J, Cargill M, Wang E, Ke X, Kennedy GC, John S, Worthington J, Thomson W; British Society of Paediatric and Adolescent Rheumatology Study Group. Identification of a novel susceptibility locus for juvenile idiopathic arthritis by genome-wide association analysis.
Arthritis Rheum. 60: 258-263 (2009).
*
-
Hinks A, Eyre S, Barton A, Thomson W, Worthington J. Investigation of genetic variation across the protein tyrosine phosphatase gene in patients with rheumatoid arthritis in the UK.
Ann. Rheum. Dis. 66: 683-686 (2007).
*
-
Hinks A, Eyre S, Ke X, Barton A, Martin P, Flynn E, Packham J, Worthington J, Thomson W. Overlap of disease susceptibility loci for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA).
Ann. Rheum. Dis. Aug 11 [Epub ahead of print] (2009).
*
-
Hinks A, Eyre S, Ke X, Barton A, Martin P, Flynn E, Packham J, Worthington J; Childhood Arthritis Prospective Study (CAPS), UKRAG Consortium, BSPAR Study Group, Thomson W. Association of the AFF3 gene and IL2/IL21 gene region with juvenile idiopathic arthritis.
Genes Immun. Jan 14 [Epub ahead of print] (2010).
*
-
Hinks A, Ke X, Barton A, Eyre S, Bowes J, Worthington J, Thompson SD, Langefeld CD, Glass DN, Thomson W; UK Rheumatoid Arthritis Genetics Consortium. Association of the IL2RA/CD25 gene with juvenile idiopathic arthritis.
Arthritis Rheum. 60: 251-257 (2009).
*
-
Hinks A, Worthington J, Thomson W. The association of PTPN22 with rheumatoid arthritis and juvenile idiopathic arthritis.
Rheumatology (Oxford) 45: 365-368 (2006).
*
-
Hinz B, Brune K. New insights into physiological and pathophysiological functions of cyclo-oxygenase-2.
Curr. Opin. Anaesthesiol. 13: 585-590 (2000).
-
Hirabayashi T, Murayama T, Shimizu T. Regulatory mechanism and physiological role of cytosolic phospholipase A2.
Biol. Pharm. Bull. 27: 1168-1173 (2004).
*
-
Hiraga Y, Yuhki Y, Itoh K, Tadano K, Takahashi Y, Mukai M. Pharmacokinetics and efficacy of low-dose methotrexate in patients with rheumatoid arthritis.
Mod. Rheumatol. 14: 135-142 (2004).
-
Hirakata M. Autoantibodies and their clinical significance in idiopathic inflammatory myopathies; polymyositis/dermatomyositis and related conditions.
Nihon Rinsho Meneki Gakkai Kaishi 30: 444-454 (2007).
-
Hirakata M, Suwa A, Takada T, Sato S, Nagai S, Genth E, Song YW, Mimori T, Targoff IN. Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase.
Arthritis Rheum. 56: 1295-1303 (2007).
*
-
Hiramitsu T, Yasuda T, Ito H, Shimizu M, Julovi SM, Kakinuma T, Akiyoshi M, Yoshida M, Nakamura T. Intercellular adhesion molecule-1 mediates the inhibitory effects of hyaluronan on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts via down-regulation of NF-kappaB and p38.
Rheumatology (Oxford) 45: 824-832 (2006).
*
-
Hirankarn N, Nakkuntod J, Duangchalermwong P, Deesomchok U, Charoenwongse P. The association of DRB1*04 share epitope alleles and tumor necrosis factor-alpha gene polymorphism (-863) with susceptibility to rheumatoid arthritis in Thai.
Rheumatol. Int. 28: 161-165 (2007).
*
-
Hirankarn N, Tangwattanachuleeporn M, Wongpiyabovorn J, Wongchinsri J, Avihingsanon Y. Association of IL-18 gene polymorphism (-137C) with arthritis manifestations in SLE: combined effect with IFN gamma gene polymorphism (+874A).
Clin. Rheumatol. 28: 219-223 (2009).
*
-
Hirano Y, Kojima T, Kanayama Y, Shioura T, Hayashi M, Kida D, Kaneko A, Eto Y, Ishiguro N. Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis.
Clin. Rheumatol. Jan 13 [Epub ahead of print] (2010).
*
-
Hiraoka A, Kojima N, Yamauchi Y, Ninomiya T, Masumoto T, Michitaka K, Horiike N, Onji M. An autopsy case of primary biliary cirrhosis with severe interstitial pneumonia.
Intern. Med. 40: 1104-1108 (2001).
*
-
Hirayama T, Dai S, Abbas S, Yamanaka Y, Abu-Amer Y. Inhibition of inflammatory bone erosion by constitutively active STAT-6 through blockade of JNK and NF-kappaB activation.
Arthritis Rheum. 52: 2719-2729 (2005).
*
-
Hirohata S. Fully human anti TNF-alpha monoclonal antibodies (adalimumab, golimumab).
Nippon Rinsho 65: 1202-1208 (2007).
-
Hirohata S, Arinuma Y, Takayama M, Yoshio T. Association of cerebrospinal fluid anti-ribosomal P protein antibodies with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus.
Arthritis Res. Ther. 9: R44 (2007).
*
-
Hirohata S, Miura Y, Tomita T, Yoshikawa H, Ochi T, Chiorazzi N. Enhanced expression of mRNA for nuclear factor kappaB1 (p50) in CD34+ cells of the bone marrow in rheumatoid arthritis.
Arthritis Res. Ther. 8: R54 (2006).
*
-
Hiroi A, Ito T, Seo N, Uede K, Yoshimasu T, Ito M, Nakamura K, Ito N, Paus R, Furukawa F. Male New Zealand Black/KN mice: a novel model for autoimmune-induced permanent alopecia?
Br. J. Dermatol. 155: 437-445 (2006).
*
-
Hirose W, Nishikawa K, Hirose M, Nanki T, Sugimoto H. Response of early active rheumatoid arthritis to tumor necrosis factor inhibitors: evaluation by magnetic resonance imaging.
Mod. Rheumatol. 19: 20-26 (2009).
*
-
Hirota K, Hashimoto M, Yoshitomi H, Tanaka S, Nomura T, Yamaguchi T, Iwakura Y, Sakaguchi N, Sakaguchi S. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis.
J. Exp. Med. 204: 41-47 (2007).
*
-
Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N, Yamaguchi T, Nomura T, Ito H, Nakamura T, Sakaguchi N, Sakaguchi S. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model.
J. Exp. Med. 204: 2803-2812 (2007).
*
-
Hirota SA, Beck PL, Macdonald JA. Targeting hypoxia-inducible factor-1 (HIF-1) signaling in therapeutics: implications for the treatment of inflammatory bowel disease.
Recent Pat. Inflamm. Allergy Drug Discov. 3: 1-16 (2009).
-
Hirsh AT, Waxenberg LB, Atchison JW, Gremillion HA, Robinson ME. Evidence for sex differences in the relationships of pain, mood, and disability.
J. Pain 7: 592-601 (2006).
-
Hisamatsu T, Hibi T. Biologics in current therapy for inflammatory bowel disease.
Nihon Rinsho Meneki Gakkai Kaishi 32: 168-179 (2009).
-
Hitchon CA, Alex P, Erdile LB, Frank MB, Dozmorov I, Tang Y, Wong K, Centola M, El-Gabalawy HS. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis.
J. Rheumatol. 31: 2336-2346 (2004).
-
Hitchon CA, Peschken CA. Sm antibodies increase risk of death in systemic lupus erythematosus.
Lupus 16: 186-194 (2007).
*
-
Hizmetli S, Kisa M, Gokalp N, Bakici MZ. Are plasma and synovial fluid leptin levels correlated with disease activity in rheumatoid arthritis?
Rheumatol. Int. 27: 335-338 (2007).
*
-
Hjardem E, Ostergaard M, Podenphant J, Tarp U, Andersen LS, Bing J, Peen E, Lindegaard HM, Ringsdal VS, Rodgaard A, Skot J, Hansen A, Mogensen HH, Unkerskov J, Hetland ML. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?
Ann. Rheum. Dis. 66: 1184-1189 (2007).
*
-
Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects.
Arthritis Rheum. 52: 1534-1544 (2005).
*
-
Hlaing T, Ramteke S, Binymin K. Gold finger: metal jewellery as a disease modifying antirheumatic therapy!
Case Report Med. 2009: 518976 (2009).
*
-
Ho HH, Antoniv TT, Ji JD, Ivashkiv LB. Lipopolysaccharide-induced expression of matrix metalloproteinases in human monocytes is suppressed by IFN-gamma via superinduction of ATF-3 and suppression of AP-1.
J. Immunol. 181: 5089-5097 (2008).
*
-
Ho HH, Yu KH, Chen JY, Lin JL, Wu YJ, Luo SF, Liou LB. Coexisting ankylosing spondylitis and gouty arthritis.
Clin. Rheumatol. 26: 1655-1661 (2007).
*
-
Ho LJ, Lin LC, Hung LF, Wang SJ, Lee CH, Chang DM, Lai JH, Tai TY. Retinoic acid blocks pro-inflammatory cytokine-induced matrix metalloproteinase production by down-regulating JNK-AP-1 signaling in human chondrocytes.
Biochem. Pharmacol. 70: 200-208 (2005).
*
-
Ho P, Barton A, Worthington J. Genetic epidemiology of psoriatic arthritis.
Mod. Rheumatol. 14: 91-100 (2004).
-
Ho P, Bruce IN, Silman A, Symmons D, Newman B, Young H, Griffiths CE, John S, Worthington J, Barton A. Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis.
Arthritis Rheum. 52: 3596-3602 (2005).
*
-
Ho P, Worthington J, Bruce IN, Barton A. Investigation of association of the DLG5 gene with psoriatic arthritis.
Ann. Rheum. Dis. 66: 273-274 (2007).
*
-
Ho PP, Higgins JP, Kidd BA, Tomooka B, Digennaro C, Lee LY, de Vegvar HE, Steinman L, Robinson WH. Tolerizing DNA vaccines for autoimmune arthritis.
Autoimmunity 39: 675-682 (2006).
-
Ho PP, Lee LY, Zhao X, Tomooka BH, Paniagua RT, Sharpe O, Benbarak MJ, Chandra PE, Hueber W, Steinman L, Robinson WH. Autoimmunity against fibrinogen mediates inflammatory arthritis in mice.
J. Immunol. 184: 379-390 (2010).
-
Ho PY, Barton A, Worthington J, Plant D, Griffiths CE, Young HS, Bradburn P, Thomson W, Silman AJ, Bruce IN. Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis.
Ann. Rheum. Dis. 67: 677-682 (2008).
*
-
Ho PY, Barton A, Worthington J, Thomson W, Silman AJ, Bruce IN. HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis.
Ann. Rheum. Dis. 66: 807-811 (2007).
*
-
Hobbs K. Chronic sarcoid arthritis treated with intraarticular etanercept.
Arthritis Rheum. 52: 987-988 (2005).
*
-
Hoberg M, Rudert M, Pap T, Klein G, Gay S, Aicher WK. Attachment to laminin-111 facilitates transforming growth factor beta-induced expression of matrix metalloproteinase-3 in synovial fibroblasts.
Ann. Rheum. Dis. 66: 446-451 (2007).
*
-
Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.
Semin. Arthritis Rheum. 34: 819-836 (2005).
*
-
Hochegger K, Gruber J, Lhotta K. Acute inflammatory syndrome induced by mycophenolate mofetil in a patient following kidney transplantation.
Am. J. Transplant. 6: 852-854 (2006).
*
-
Hochman D, Wolff B. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
JAMA 296: 2203 (2006).
-
Hodanova K, Majewski J, Kublova M, Vyletal P, Kalbacova M, Stiburkova B, Hulkova H, Chagnon YC, Lanouette CM, Marinaki A, Fryns JP, Venkat-Raman G, Kmoch S. Mapping of a new candidate locus for uromodulin-associated kidney disease (UAKD) to chromosome 1q41.
Kidney Int. 68: 1472-1482 (2005).
*
-
Hoes JN, Jacobs JW, Verstappen SM, Bijlsma JW, van der Heijden GJ. Adverse events of low-to-medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis.
Ann. Rheum. Dis. 68: 1833-1838 (2009).
-
Hoeve MA, Savage ND, Boer TD, Langenberg DM, de Waal Malefyt R, Ottenhoff TH, Verreck FA. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells.
Eur. J. Immunol. 36: 661-670 (2006).
*
-
Hof D, Cheung K, de Rooij DJ, van den Hoogen FH, Pruijn GJ, van Venrooij WJ, Raats JM. Autoantibodies specific for apoptotic U1-70K are superior serological markers for mixed connective tissue disease.
Arthritis Res. Ther. 7: R302-R309 (2005).
*
-
Hofer M. Spondylarthropathies in children - are they different from those in adults?
Best Pract. Res. Clin. Rheumatol. 20: 315-328 (2006).
-
Hoff M, Kvien TK, Kalvesten J, Elden A, Haugeberg G. Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study.
Ann. Rheum. Dis. 68: 1171-1176 (2009).
*
-
Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies.
Arthritis Rheum. 41: 1521-1537 (1998).
*
-
Hoffman RW, Gazitt T, Foecking MF, Ortmann RA, Misfeldt M, Jorgenson R, Young SL, Greidinger EL. U1 RNA induces innate immunity signaling.
Arthritis Rheum. 50: 2891-2896 (2004).
*
-
Hoffmann M, Hayer S, Steiner G. Immmunopathogenesis of rheumatoid arthritis; induction of arthritogenic autoimmune responses by proinflammatory stimuli.
Ann. N. Y. Acad. Sci. 1173: 391-400 (2009).
*
-
Hoffmann M, Pohlers D, Koczan D, Thiesen HJ, Woelfl S, Kinne RW. Robust Computational Reconstitution - a new method for the comparative analysis of gene expression in tissues and isolated cell fractions.
BMC Bioinformatics 7: 369 (2006).
*
-
Hofley P, Roarty J, McGinnity G, Griffiths AM, Marcon M, Kraft S, Sherman P. Asymptomatic uveitis in children with chronic inflammatory bowel diseases.
J.
| |
